
    <!DOCTYPE html>
    <html lang="zh-CN">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <title>PubMed DeepReader - 2026-02-14 10:32</title>
        <script src="https://cdn.tailwindcss.com"></script>
        <script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/marked/marked.min.js"></script>
        <style>
            body { height: 100vh; overflow: hidden; }
            .scrollbar-hide::-webkit-scrollbar { display: none; }
            ::-webkit-scrollbar { width: 6px; }
            ::-webkit-scrollbar-thumb { background: #cbd5e1; border-radius: 3px; }
            .prose strong { 
                color: #1e3a8a; font-weight: 800; display: block; 
                margin-top: 1.2em; margin-bottom: 0.4em;
                text-transform: uppercase; font-size: 0.85rem; letter-spacing: 0.05em;
            }
            .prose p { margin-bottom: 0.8em; text-align: justify; line-height: 1.7; }
            .prose p:first-of-type strong { margin-top: 0; }
        </style>
    </head>
    <body class="bg-slate-100 flex flex-col" x-data="app()">
        <header class="bg-white border-b border-gray-200 h-14 flex items-center justify-between px-6 shadow-sm z-10 shrink-0">
            <div class="flex items-center gap-4">
                <div class="font-bold text-xl text-blue-900 tracking-tight">PubMed DeepReader</div>
                <div class="text-xs text-gray-400 mt-1">Updated: 2026-02-14 10:32</div>
            </div>
            <select x-model="currentFeed" @change="selectFeed()" class="bg-gray-50 border border-gray-300 text-gray-900 text-sm rounded-lg p-2 max-w-xs">
                <template x-for="feedName in Object.keys(feeds)" :key="feedName">
                    <option :value="feedName" x-text="feedName"></option>
                </template>
            </select>
        </header>

        <div class="flex flex-1 overflow-hidden">
            <aside class="w-1/3 max-w-md bg-white border-r border-gray-200 flex flex-col overflow-y-auto">
                <template x-for="paper in currentPapers" :key="paper.id">
                    <div @click="currentPaper = paper" 
                         :class="currentPaper.id === paper.id ? 'bg-blue-50 border-l-4 border-blue-600' : 'border-l-4 border-transparent hover:bg-gray-50'"
                         class="p-4 border-b border-gray-100 cursor-pointer transition group">
                        <h3 class="text-sm font-bold text-gray-800 line-clamp-2 leading-snug group-hover:text-blue-700" x-text="paper.title_zh"></h3>
                        <p class="text-xs text-gray-400 mt-1 truncate" x-text="paper.title_en"></p>
                    </div>
                </template>
            </aside>

            <main class="flex-1 bg-slate-50 overflow-y-auto p-6">
                <template x-if="currentPaper">
                    <div class="max-w-6xl mx-auto bg-white rounded-xl shadow-sm p-8 min-h-[90vh]">
                        <div class="border-b border-gray-100 pb-6 mb-6">
                            <h1 class="text-2xl font-bold text-gray-900 mb-2 leading-tight" x-text="currentPaper.title_zh"></h1>
                            <h2 class="text-lg text-gray-500 font-medium mb-4" x-text="currentPaper.title_en"></h2>
                            <div class="flex flex-wrap gap-4 text-xs text-gray-500 bg-gray-50 p-3 rounded-lg border border-gray-100">
                                <span class="flex items-center">ğŸ“… <span class="ml-1" x-text="currentPaper.date"></span></span>
                                <span class="flex items-center">âœï¸ <span class="ml-1" x-text="currentPaper.authors"></span></span>
                                <a :href="currentPaper.link" target="_blank" class="text-blue-600 hover:underline font-bold ml-auto flex items-center">
                                    åŸæ–‡é“¾æ¥ <svg class="w-3 h-3 ml-1" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"></path></svg>
                                </a>
                            </div>
                        </div>

                        <template x-if="currentPaper.keywords_zh">
                            <div class="mb-8 p-4 bg-blue-50/50 rounded-lg border border-blue-100">
                                <span class="text-xs font-bold text-blue-800 uppercase tracking-wide block mb-1">Keywords</span>
                                <div class="text-sm text-gray-700 font-medium">
                                    <span x-text="currentPaper.keywords_zh"></span>
                                    <div class="text-xs text-gray-400 mt-1 font-normal" x-text="currentPaper.keywords_en"></div>
                                </div>
                            </div>
                        </template>

                        <div class="grid grid-cols-1 lg:grid-cols-2 gap-10">
                            <div>
                                <div class="flex items-center mb-4">
                                    <span class="w-1 h-6 bg-blue-600 mr-3 rounded-full"></span>
                                    <h3 class="font-bold text-xl text-gray-900">ä¸­æ–‡æ‘˜è¦</h3>
                                </div>
                                <div class="prose prose-sm prose-slate max-w-none text-gray-800" 
                                     x-html="marked.parse(currentPaper.abstract_zh)"></div>
                            </div>
                            <div>
                                <div class="flex items-center mb-4">
                                    <span class="w-1 h-6 bg-gray-300 mr-3 rounded-full"></span>
                                    <h3 class="font-bold text-gray-400 text-xl">Original Abstract</h3>
                                </div>
                                <div class="prose prose-sm prose-slate max-w-none text-gray-500" 
                                     x-html="marked.parse(currentPaper.abstract_en)"></div>
                            </div>
                        </div>
                    </div>
                </template>
                <template x-if="!currentPaper">
                    <div class="flex flex-col items-center justify-center h-full text-gray-400">
                        <p>è¯·é€‰æ‹©å·¦ä¾§æ–‡ç« å¼€å§‹é˜…è¯»</p>
                    </div>
                </template>
            </main>
        </div>
        <script>
            function app() {
                return {
                    feeds: {"è‚›å‘¨è„“è‚¿": [{"id": "41359092", "title_en": "Systematic review: The management of unhealed wounds and persistent perineal sinuses following proctectomy in inflammatory bowel disease", "title_zh": "ç³»ç»Ÿè¯„ä»·ï¼šç‚ç—‡æ€§è‚ ç—…ç›´è‚ åˆ‡é™¤æœ¯åæœªæ„ˆåˆä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦çš„å¤„ç†", "authors": "A Hart", "abstract_en": "**Introduction:** Unhealed wounds and persistent perineal sinuses (PPS) may occur in as many as one third of patients after proctectomy for Crohn's disease. The management of these conditions remains a significant challenge, particularly in the context of inflammatory bowel disease (IBD), with existing therapies plagued by high failure rates. This systematic review of the literature assessed the efficacy of medical and surgical therapy for PPS closure in IBD. Secondary aims included review of classification systems used for PPS.\n\n**Methods:** A literature search was conducted using Medline, Embase and Cochrane databases on 17 December 2024. The review was registered on PROSPERO (CRD42024622582). Inclusion criteria were adult patients with IBD and PPS or unhealed wounds following proctectomy. We excluded abstract-only publications, case reports, cancer and paediatric cohorts. Two reviewers independently screened abstracts and full texts and extracted data. The primary outcome was clinical healing rate. Secondary outcomes included classification systems used to describe PPS. Risk of bias was assessed.\n\n**Results:** Of 496 records identified, following removal of duplicates, 489 abstracts were screened, and 60 full text articles assessed for eligibility. Of 25 articles included in the final analysis, 23 were case series or retrospective cohort studies, and all were at high risk of bias. No randomised controlled trials were identified. Five articles (including two of the case series) described classification systems for PPS. Interventions included hyperbaric oxygen therapy, Karydakis flap, cleft closure, omentoplasty, skin grafting, gracilis and rectus abdominis flap, platelet-derived growth factor, curettage, lay open and excision of sinuses. Reported healing rates ranged from 30% to 100%. Heterogeneity in the reporting of outcomes, as well as the interventions performed precluded meta-analysis.\n\n**Conclusion:** The published evidence for treatment of PPS in IBD consists of low-quality evidence case series with high risk of bias. There is a need for standardised outcome reporting and high-quality, prospective studies to establish effective treatment algorithms.", "abstract_zh": "**ä»‹ç»ï¼š** å…‹ç½—æ©ç—…ç›´è‚ åˆ‡é™¤æœ¯åï¼Œå¤šè¾¾ä¸‰åˆ†ä¹‹ä¸€çš„æ‚£è€…å¯èƒ½ä¼šå‡ºç°æœªæ„ˆåˆçš„ä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦ (PPS)ã€‚è¿™äº›ç–¾ç—…çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ï¼Œç‰¹åˆ«æ˜¯åœ¨ç‚ç—‡æ€§è‚ ç—…ï¼ˆIBDï¼‰çš„èƒŒæ™¯ä¸‹ï¼Œç°æœ‰çš„æ²»ç–—æ–¹æ³•å—åˆ°é«˜å¤±è´¥ç‡çš„å›°æ‰°ã€‚è¿™é¡¹å¯¹æ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾è¯„ä¼°äº† IBD ä¸­ PPS é—­åˆçš„è¯ç‰©å’Œæ‰‹æœ¯æ²»ç–—çš„ç–—æ•ˆã€‚æ¬¡è¦ç›®æ ‡åŒ…æ‹¬å®¡æŸ¥ç”¨äº PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚\n\n**æ–¹æ³•ï¼š** äº2024å¹´12æœˆ17æ—¥ä½¿ç”¨Medlineã€Embaseå’ŒCochraneæ•°æ®åº“è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚è¯¥ç»¼è¿°å·²åœ¨PROSPEROä¸Šæ³¨å†Œï¼ˆCRD42024622582ï¼‰ã€‚çº³å…¥æ ‡å‡†ä¸ºæ‚£æœ‰ IBD å’Œ PPS çš„æˆå¹´æ‚£è€…æˆ–ç›´è‚ åˆ‡é™¤æœ¯åä¼¤å£æœªæ„ˆåˆçš„æ‚£è€…ã€‚æˆ‘ä»¬æ’é™¤äº†ä»…æ‘˜è¦çš„å‡ºç‰ˆç‰©ã€ç—…ä¾‹æŠ¥å‘Šã€ç™Œç—‡å’Œå„¿ç§‘é˜Ÿåˆ—ã€‚ä¸¤åå®¡ç¨¿äººç‹¬ç«‹ç­›é€‰æ‘˜è¦å’Œå…¨æ–‡å¹¶æå–æ•°æ®ã€‚ä¸»è¦ç»“å±€æ˜¯ä¸´åºŠæ²»æ„ˆç‡ã€‚æ¬¡è¦ç»“æœåŒ…æ‹¬ç”¨äºæè¿° PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚è¯„ä¼°äº†åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨åˆ é™¤é‡å¤é¡¹åï¼Œåœ¨ç¡®å®šçš„ 496 æ¡è®°å½•ä¸­ï¼Œç­›é€‰äº† 489 æ¡æ‘˜è¦ï¼Œå¹¶è¯„ä¼°äº† 60 ç¯‡å…¨æ–‡æ–‡ç« çš„èµ„æ ¼ã€‚æœ€ç»ˆåˆ†æçº³å…¥çš„ 25 ç¯‡æ–‡ç« ä¸­ï¼Œ23 ç¯‡ä¸ºç—…ä¾‹ç³»åˆ—æˆ–å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œä¸”å‡å­˜åœ¨é«˜åå€šé£é™©ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚äº”ç¯‡æ–‡ç« ï¼ˆåŒ…æ‹¬æ¡ˆä¾‹ç³»åˆ—ä¸­çš„ä¸¤ç¯‡ï¼‰æè¿°äº† PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚å¹²é¢„æªæ–½åŒ…æ‹¬é«˜å‹æ°§æ²»ç–—ã€Karydakis çš®ç“£ã€è£‚éš™é—­åˆã€ç½‘è†œæˆå½¢æœ¯ã€æ¤çš®ã€è‚¡è–„è‚Œå’Œè…¹ç›´è‚Œçš®ç“£ã€è¡€å°æ¿è¡ç”Ÿç”Ÿé•¿å› å­ã€åˆ®å®«æœ¯ã€åˆ‡å¼€å’Œåˆ‡é™¤é¼»çª¦ã€‚æ®æŠ¥é“ï¼Œæ²»æ„ˆç‡ä» 30% åˆ° 100% ä¸ç­‰ã€‚ç»“æœæŠ¥å‘Šä»¥åŠæ‰€è¿›è¡Œçš„å¹²é¢„æªæ–½çš„å¼‚è´¨æ€§æ’é™¤äº†èŸèƒåˆ†æã€‚\n\n**ç»“è®ºï¼š** å·²å‘è¡¨çš„ IBD PPS æ²»ç–—è¯æ®ç”±å…·æœ‰é«˜åå€šé£é™©çš„ä½è´¨é‡è¯æ®ç—…ä¾‹ç³»åˆ—ç»„æˆã€‚éœ€è¦æ ‡å‡†åŒ–çš„ç»“æœæŠ¥å‘Šå’Œé«˜è´¨é‡çš„å‰ç»æ€§ç ”ç©¶æ¥å»ºç«‹æœ‰æ•ˆçš„æ²»ç–—ç®—æ³•ã€‚", "keywords_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ã€è‚›å‘¨è„“è‚¿", "keywords_en": "Fistulizing perianal Crohnâ€™s disease, Perianal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/41359092/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 08 Dec 2025"}, {"id": "41219674", "title_en": "Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** While setons are commonly used in the multidisciplinary care of patients with perianal fistulizing Crohn's disease (PFCD), fistula outcomes after their removal are poorly understood. We performed a systematic review with meta-analysis to evaluate fistula outcomes after seton removal in patients with PFCD.\n\n**Methods:** MEDLINE, EMBASE, Web of Science, and Cochrane databases were systematically searched until December 2023. We included studies reporting fistula outcomes after seton removal in PFCD. We used a hierarchy to stratify patients into one of three treatment categories: medical therapy alone, surgical closure, or cell/plasma-based therapy. Fistula outcomes were reported as weighted proportions with 95% confidence intervals (CI).\n\n**Results:** Eighty-two studies (nâ€‰=â€‰2441 patients) were analyzed. Mean/median seton duration varied widely (2 to 70Â weeks). Pooled estimates (95% CI) of fistula outcomes after seton removal for patients treated in the medical therapy alone, surgical closure, or cell/plasma-based therapy categories were, respectively, 64% (54-75), 65% (52-78), and 71% (65-77) for fistula remission; 30% (22-38), 29% (16-42), and 20% (15-25) for recurrence; 15% (8-22), 11% (4-20), and 14% (8-21) for abscess formation; and 26% (18-35), 23% (17-29), and 13% (2-26) for surgical re-intervention. Fistula outcome estimates remained stable in multiple sensitivity analyses. Limited studies directly compared fistula outcomes based on seton duration, yielding inconsistent results.\n\n**Conclusions:** This systematic review provides comprehensive estimates of fistula outcomes after seton removal and demonstrates substantial variability in seton duration. Future research is required to determine the optimal duration of setons.", "abstract_zh": "**èƒŒæ™¯ï¼š** è™½ç„¶æŒ‚çº¿å¸¸ç”¨äºè‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (PFCD) æ‚£è€…çš„å¤šå­¦ç§‘æŠ¤ç†ï¼Œä½†äººä»¬å¯¹æŒ‚çº¿ç§»é™¤åçš„ç˜˜ç®¡ç»“å±€çŸ¥ä¹‹ç”šå°‘ã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥è¯„ä¼° PFCD æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“å±€ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2023 å¹´ 12 æœˆï¼Œæˆ‘ä»¬å¯¹ MEDLINEã€EMBASEã€Web of Science å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚æˆ‘ä»¬çº³å…¥äº†æŠ¥å‘Š PFCD æŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“æœçš„ç ”ç©¶ã€‚æˆ‘ä»¬ä½¿ç”¨å±‚æ¬¡ç»“æ„å°†æ‚£è€…åˆ†ä¸ºä¸‰ç§æ²»ç–—ç±»åˆ«ä¹‹ä¸€ï¼šå•çº¯è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ã€‚ç˜˜ç®¡ç»“æœæŠ¥å‘Šä¸ºå…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„åŠ æƒæ¯”ä¾‹ã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 82 é¡¹ç ”ç©¶ï¼ˆn=2441 åæ‚£è€…ï¼‰ã€‚å¹³å‡/ä¸­ä½æŒ‚çº¿æŒç»­æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼ˆ2 è‡³ 70 å‘¨ï¼‰ã€‚å¯¹äºä»…æ¥å—è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ç±»åˆ«çš„æ‚£è€…ï¼ŒæŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“å±€çš„æ±‡æ€»ä¼°è®¡ (95% CI) ç˜˜ç®¡ç¼“è§£ç‡åˆ†åˆ«ä¸º 64% (54-75)ã€65% (52-78) å’Œ 71% (65-77)ï¼› 30% (22-38)ã€29% (16-42) å’Œ 20% (15-25) å¤å‘ï¼› 15% (8-22)ã€11% (4-20) å’Œ 14% (8-21) è„“è‚¿å½¢æˆï¼› 26% (18-35)ã€23% (17-29) å’Œ 13% (2-26) éœ€è¦å†æ¬¡æ‰‹æœ¯å¹²é¢„ã€‚åœ¨å¤šé¡¹æ•æ„Ÿæ€§åˆ†æä¸­ï¼Œç˜˜ç®¡ç»“æœä¼°è®¡å€¼ä¿æŒç¨³å®šã€‚æœ‰é™çš„ç ”ç©¶æ ¹æ®æŒ‚çº¿æŒç»­æ—¶é—´ç›´æ¥æ¯”è¾ƒç˜˜ç®¡ç»“å±€ï¼Œäº§ç”Ÿä¸ä¸€è‡´çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** è¯¥ç³»ç»Ÿè¯„ä»·æä¾›äº†æŒ‚çº¿ç§»é™¤åç˜˜ç®¡ç»“æœçš„å…¨é¢ä¼°è®¡ï¼Œå¹¶è¯æ˜äº†æŒ‚çº¿æŒç»­æ—¶é—´çš„æ˜¾ç€å·®å¼‚ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥ç¡®å®šæŒ‚çº¿çš„æœ€ä½³æŒç»­æ—¶é—´ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç”Ÿç‰©ç–—æ³•ã€å…‹ç½—æ©ç—…ã€å¼•æµã€é—´å……è´¨å¹²ç»†èƒ", "keywords_en": "Anal fistula, Biologic therapy, Crohnâ€™s disease, Drainage, Mesenchymal stem cells", "link": "https://pubmed.ncbi.nlm.nih.gov/41219674/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Tue, 11 Nov 2025"}, {"id": "41159400", "title_en": "Management of Perianal Sepsis in Neutropenic Patients With Haematological Malignancies-A Systematic Review", "title_zh": "è¡€æ¶²ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡æ‚£è€…è‚›å‘¨è„“æ¯’ç—‡çš„æ²»ç–—â€”â€”ç³»ç»Ÿè¯„ä»·", "authors": "Zi Qin Ng", "abstract_en": "**Introduction:** Despite neutropenia being considered a significant risk factor for acute perianal sepsis, there is a lack of consensus on treatment guidelines for perianal abscess in the immunocompromised patient, specifically in patients with neutropenia secondary to a haematological malignancy. The aim of the article is to review the available literature on. Whether surgical intervention produces better outcomes than a non-surgical approach for perianal sepsis in the immunocompromised patient with a haematological malignancy.\n\n**Methods:** Relevant papers were identified through electronic databases including PubMed, Medline and Scopus. Data were extracted independently by two authors on a Microsoft Excel spreadsheet up to July 2024.\n\n**Results:** A total of eight studies were included in the final analysis (124 cases). Perianal or rectal pain (nâ€‰=â€‰81, 65.3%) was the most reported complaint, followed by fever (nâ€‰=â€‰72, 58.1%), swelling and induration (nâ€‰=â€‰54, 43.5%) and erythema was reported in 26 (21.0%) cases. The most common organisms cultured from blood and anorectum were Escherichia coli and Pseudomonas aeruginosa. A total of 12 deaths (18.8%) were reported out of the 64 patients who underwent conservative management, while 10 (16.7%) deaths were reported out of 60 patients who underwent surgical management. Complete wound healing or good wound granulation was achieved for 35 (54.7%) patients in the conservative group and 35 (58.3%) patients in the surgical group.\n\n**Conclusion:** Our review suggests that conservative management is an acceptable treatment in carefully selected patients without an obvious perianal abscess on cross-sectional radiological imaging.", "abstract_zh": "**ä»‹ç»ï¼š** å°½ç®¡ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡è¢«è®¤ä¸ºæ˜¯æ€¥æ€§è‚›å‘¨è„“æ¯’ç—‡çš„é‡è¦å±é™©å› ç´ ï¼Œä½†å¯¹äºå…ç–«åŠŸèƒ½ä½ä¸‹æ‚£è€…çš„è‚›å‘¨è„“è‚¿çš„æ²»ç–—æŒ‡å—ç¼ºä¹å…±è¯†ï¼Œç‰¹åˆ«æ˜¯ç»§å‘äºè¡€æ¶²æ¶æ€§è‚¿ç˜¤çš„ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡æ‚£è€…ã€‚æœ¬æ–‡çš„ç›®çš„æ˜¯å›é¡¾ç°æœ‰çš„æ–‡çŒ®ã€‚å¯¹äºæ‚£æœ‰è¡€æ¶²ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤çš„å…ç–«åŠŸèƒ½ä½ä¸‹æ‚£è€…çš„è‚›å‘¨è„“æ¯’ç—‡ï¼Œæ‰‹æœ¯å¹²é¢„æ˜¯å¦æ¯”éæ‰‹æœ¯æ–¹æ³•èƒ½äº§ç”Ÿæ›´å¥½çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ç›¸å…³è®ºæ–‡é€šè¿‡ PubMedã€Medline å’Œ Scopus ç­‰ç”µå­æ•°æ®åº“æ‰¾åˆ°ã€‚æˆªè‡³ 2024 å¹´ 7 æœˆï¼Œä¸¤ä½ä½œè€…åœ¨ Microsoft Excel ç”µå­è¡¨æ ¼ä¸Šç‹¬ç«‹æå–æ•°æ®ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆåˆ†æå…±çº³å…¥8é¡¹ç ”ç©¶ï¼ˆ124ä¾‹ï¼‰ã€‚è‚›å‘¨æˆ–ç›´è‚ ç–¼ç—› (nâ€‰=â€‰81, 65.3%) æ˜¯æŠ¥å‘Šæœ€å¤šçš„ä¸»è¯‰ï¼Œå…¶æ¬¡æ˜¯å‘çƒ­ (nâ€‰=â€‰72, 58.1%)ã€è‚¿èƒ€å’Œç¡¬ç»“ (nâ€‰=â€‰54, 43.5%)ï¼Œæœ‰ 26 ä¾‹ (21.0%) æŠ¥å‘Šæœ‰çº¢æ–‘ã€‚ä»è¡€æ¶²å’Œè‚›é—¨ç›´è‚ åŸ¹å…»çš„æœ€å¸¸è§çš„å¾®ç”Ÿç‰©æ˜¯å¤§è‚ æ†èŒå’Œé“œç»¿å‡å•èƒèŒã€‚åœ¨æ¥å—ä¿å®ˆæ²»ç–—çš„ 64 ä¾‹æ‚£è€…ä¸­ï¼Œå…±æœ‰ 12 ä¾‹æ­»äº¡ï¼ˆ18.8%ï¼‰ï¼Œè€Œåœ¨æ¥å—æ‰‹æœ¯æ²»ç–—çš„ 60 ä¾‹æ‚£è€…ä¸­ï¼Œå…±æœ‰ 10 ä¾‹ï¼ˆ16.7%ï¼‰æ­»äº¡ã€‚ä¿å®ˆç»„æœ‰35åï¼ˆ54.7%ï¼‰æ‚£è€…ä¼¤å£å®Œå…¨æ„ˆåˆæˆ–ä¼¤å£è‚‰èŠ½è‰¯å¥½ï¼Œæ‰‹æœ¯ç»„æœ‰35åï¼ˆ58.3%ï¼‰æ‚£è€…ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°è¡¨æ˜ï¼Œå¯¹äºç²¾å¿ƒæŒ‘é€‰çš„æ¨ªæ–­é¢æ”¾å°„å½±åƒå­¦ä¸Šæ²¡æœ‰æ˜æ˜¾è‚›å‘¨è„“è‚¿çš„æ‚£è€…ï¼Œä¿å®ˆæ²»ç–—æ˜¯ä¸€ç§å¯æ¥å—çš„æ²»ç–—æ–¹æ³•ã€‚", "keywords_zh": "è„“è‚¿ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡ã€è‚›é—¨ç›´è‚ ã€å…ç–«åŠŸèƒ½ä½ä¸‹ã€è‚›å‘¨", "keywords_en": "abscess neutropenia, anorectal, immunocompromised, perianal", "link": "https://pubmed.ncbi.nlm.nih.gov/41159400/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Wed, 29 Oct 2025"}, {"id": "40983150", "title_en": "Management of Perianal Abscesses in Infants: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿çš„æ²»ç–—ï¼šAPSA ç»“æœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šçš„ç³»ç»Ÿå®¡æŸ¥", "authors": "American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee", "abstract_en": "**Background:** Management of infant perianal disease, including perianal abscess and fistula-in- ano (FIA), remains controversial. There is lack of consensus regarding the risks and benefits of operative and non-operative approaches.\n\n**Methods:** The American Pediatric Surgical Association Outcomes and Evidence Based Practice Committee created a priori consensus-based questions regarding the various approaches to management of perianal abscess and FIA in infants. A comprehensive search strategy was created, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to identify and review relevant articles and answer the established questions.\n\n**Results:** Over 2460 titles and abstracts were screened to identify 31 manuscripts describing the expected course of perianal disease when managed with nonoperative management (NOM) strategies (such as hygiene, sitz baths, and systemic antibiotics), operative intervention for abscess only (incision and drainage (I&D)) or direct surgical management of the FIA (e.g. upfront fistulotomy). Initial failure of NOM is approximately 37.5 %. Recurrence rate after initial success with NOM or I&D is approximately 21 % and 24 %, respectively. The rate of FIA development is approximately 21 % after NOM and 20 % after I&D. Recurrence after operative management of FIA, regardless of approach, is 7 %. Time to complete resolution varies widely and does not appear to differ based on treatment strategy.\n\n**Conclusions:** Both operative and non-operative approaches can be safely used in the management of perianal abscess and FIA but recurrence is common regardless of approach. Risks and benefits of each approach should be considered on a case-by-case basis.\n\n**Type Of Study:** Systematic Review of level 3-4 studies.\n\n**Level Of Evidence:** Level 4.", "abstract_zh": "**èƒŒæ™¯ï¼š** å©´å„¿è‚›å‘¨ç–¾ç—…çš„æ²»ç–—ï¼ŒåŒ…æ‹¬è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜ï¼ˆFIAï¼‰ï¼Œä»ç„¶å­˜åœ¨äº‰è®®ã€‚å…³äºæ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•çš„é£é™©å’Œç›Šå¤„ç¼ºä¹å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** ç¾å›½å„¿ç§‘å¤–ç§‘åä¼šæˆæœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šé’ˆå¯¹å©´å„¿è‚›å‘¨è„“è‚¿å’Œ FIA çš„å„ç§æ²»ç–—æ–¹æ³•æå‡ºäº†åŸºäºå…ˆéªŒå…±è¯†çš„é—®é¢˜ã€‚åˆ›å»ºäº†å…¨é¢çš„æœç´¢ç­–ç•¥ï¼Œå¹¶ä½¿ç”¨ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—æ¥è¯†åˆ«å’Œå®¡æŸ¥ç›¸å…³æ–‡ç« å¹¶å›ç­”æ—¢å®šé—®é¢˜ã€‚\n\n**ç»“æœï¼š** ç­›é€‰äº† 2460 å¤šä¸ªæ ‡é¢˜å’Œæ‘˜è¦ï¼Œç¡®å®šäº† 31 ç¯‡æ‰‹ç¨¿ï¼Œæè¿°äº†é‡‡ç”¨éæ‰‹æœ¯æ²»ç–— (NOM) ç­–ç•¥ï¼ˆä¾‹å¦‚å«ç”Ÿã€åæµ´å’Œå…¨èº«æŠ—ç”Ÿç´ ï¼‰ã€ä»…é’ˆå¯¹è„“è‚¿è¿›è¡Œæ‰‹æœ¯å¹²é¢„ï¼ˆåˆ‡å¼€å¼•æµ (I&D)ï¼‰æˆ– FIA ç›´æ¥æ‰‹æœ¯æ²»ç–—ï¼ˆä¾‹å¦‚å‰æœŸç˜˜ç®¡åˆ‡å¼€æœ¯ï¼‰æ—¶è‚›å‘¨ç–¾ç—…çš„é¢„æœŸç—…ç¨‹ã€‚ NOM çš„åˆå§‹æ•…éšœçº¦ä¸º 37.5%ã€‚ NOM æˆ– I&D åˆæ¬¡æˆåŠŸåçš„å¤å‘ç‡åˆ†åˆ«çº¦ä¸º 21% å’Œ 24%ã€‚ NOM åçš„ FIA å¼€å‘ç‡çº¦ä¸º 21%ï¼ŒI&D åçš„ FIA å¼€å‘ç‡çº¦ä¸º 20%ã€‚æ— è®ºé‡‡å–ä½•ç§æ–¹æ³•ï¼ŒFIA æ‰‹æœ¯æ²»ç–—åçš„å¤å‘ç‡ä¸º 7%ã€‚å®Œæˆç¼“è§£çš„æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼Œå¹¶ä¸”æ ¹æ®æ²»ç–—ç­–ç•¥ä¼¼ä¹æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•éƒ½å¯ä»¥å®‰å…¨åœ°ç”¨äºè‚›å‘¨è„“è‚¿å’Œ FIA çš„æ²»ç–—ï¼Œä½†æ— è®ºé‡‡ç”¨å“ªç§æ–¹æ³•ï¼Œå¤å‘éƒ½å¾ˆå¸¸è§ã€‚åº”æ ¹æ®å…·ä½“æƒ…å†µè€ƒè™‘æ¯ç§æ–¹æ³•çš„é£é™©å’Œæ”¶ç›Šã€‚\n\n**Type of studyï¼š** 3-4 çº§ç ”ç©¶çš„ç³»ç»Ÿå®¡æŸ¥ã€‚\n\n**Level of evidenceï¼š** 4 çº§ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç˜˜ç®¡åˆ‡å¼€æœ¯ã€å©´å„¿ã€è‚›å‘¨è„“è‚¿ã€ç›´è‚ å‘¨å›´è„“è‚¿", "keywords_en": "Fistula-in-ano, Fistulotomy, Infants, Perianal abscess, Perirectal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/40983150/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 22 Sep 2025"}, {"id": "40740890", "title_en": "Epidemiology, treatment patterns, and associated risk factors in perianal fistulizing Crohn's disease: A systematic literature review", "title_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…çš„æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼å’Œç›¸å…³å±é™©å› ç´ ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Julian PanÃ©s", "abstract_en": "**Background:** Data regarding complex Crohn's perianal fistulas (CPF) epidemiology are limited, and optimal treatment strategies are elusive. An improved understanding of how CPF treatment options are used in the real-world setting and factors associated with CPF development, treatment failure, and reasons for undergoing multiple surgeries may help to inform optimal patient management strategies, reduce treatment burden, and improve outcomes in patients with CPF.\n\n**Aim:** To describe the epidemiology, treatments, outcomes, and associated risk/protective factors for complex CPF.\n\n**Methods:** Electronic databases (MEDLINE, EMBASE, EBM Reviews, EconLit) were searched. Two reviewers independently used populations, interventions, comparators, outcomes, study designs, and time criteria to identify relevant studies. Observational studies published in English from January 1, 2015 to February 17, 2022 with > 50 patients were included, even if complex CPF was not defined. Items of interest included complex CPF definitions, epidemiology, treatment patterns, morbidity, mortality, and risk factors associated with complex CPF development, treatment failure, and undergoing multiple surgeries. Data were reported using descriptive statistics.\n\n**Results:** Overall, 140 studies were included. Complex CPF definitions were heterogeneous and rarely reported (24 studies). Hence, data mostly related to CPF in general. CPF prevalence was variable (range: 1.5%-81.0%). Incidence was wide-ranging and mostly reported cumulatively at 1-year post-Crohn's disease diagnosis (range: 3.5%-50.1%). Overall healing and failure rates after treatment were in the range of 10.5%-80.2% and 3.6%-83.0%, respectively. Abscesses were the most frequently reported morbidity (<i>n =</i> 18). No CPF-related deaths were reported. No consistent risk or protective factors were identified.\n\n**Conclusion:** Epidemiology, treatment patterns, and risk factors for CPF vary, likely due to inconsistent CPF and clinical outcome definitions. Standardization would facilitate comparability, which may inform optimal complex CPF treatment strategies.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ‰å…³å¤æ‚å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ (CPF) æµè¡Œç—…å­¦çš„æ•°æ®æœ‰é™ï¼Œæœ€ä½³æ²»ç–—ç­–ç•¥éš¾ä»¥æ‰æ‘¸ã€‚æ›´å¥½åœ°äº†è§£å¦‚ä½•åœ¨ç°å®ç¯å¢ƒä¸­ä½¿ç”¨ CPF æ²»ç–—æ–¹æ¡ˆï¼Œä»¥åŠä¸ CPF å‘å±•ã€æ²»ç–—å¤±è´¥å’Œæ¥å—å¤šæ¬¡æ‰‹æœ¯çš„åŸå› ç›¸å…³çš„å› ç´ ï¼Œå¯èƒ½æœ‰åŠ©äºä¸º CPF æ‚£è€…æä¾›æœ€ä½³çš„æ‚£è€…ç®¡ç†ç­–ç•¥ã€å‡è½»æ²»ç–—è´Ÿæ‹…å¹¶æ”¹å–„é¢„åã€‚\n\n**Aimï¼š** æè¿°å¤æ‚ CPF çš„æµè¡Œç—…å­¦ã€æ²»ç–—ã€ç»“æœå’Œç›¸å…³é£é™©/ä¿æŠ¤å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº†ç”µå­æ•°æ®åº“ï¼ˆMEDLINEã€EMBASEã€EBM Reviewsã€EconLitï¼‰ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹ä½¿ç”¨äººç¾¤ã€å¹²é¢„æªæ–½ã€æ¯”è¾ƒå™¨ã€ç»“æœã€ç ”ç©¶è®¾è®¡å’Œæ—¶é—´æ ‡å‡†æ¥ç¡®å®šç›¸å…³ç ”ç©¶ã€‚å³ä½¿æœªå®šä¹‰å¤æ‚ CPFï¼Œä¹Ÿçº³å…¥äº† 2015 å¹´ 1 æœˆ 1 æ—¥è‡³ 2022 å¹´ 2 æœˆ 17 æ—¥æœŸé—´ä»¥è‹±æ–‡å‘è¡¨çš„ã€æ¶‰åŠè¶…è¿‡ 50 åæ‚£è€…çš„è§‚å¯Ÿæ€§ç ”ç©¶ã€‚æ„Ÿå…´è¶£çš„é¡¹ç›®åŒ…æ‹¬å¤æ‚çš„ CPF å®šä¹‰ã€æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼ã€å‘ç—…ç‡ã€æ­»äº¡ç‡ä»¥åŠä¸å¤æ‚ CPF å‘å±•ã€æ²»ç–—å¤±è´¥å’Œæ¥å—å¤šæ¬¡æ‰‹æœ¯ç›¸å…³çš„é£é™©å› ç´ ã€‚ä½¿ç”¨æè¿°æ€§ç»Ÿè®¡æŠ¥å‘Šæ•°æ®ã€‚\n\n**ç»“æœï¼š** æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 140 é¡¹ç ”ç©¶ã€‚å¤æ‚çš„ CPF å®šä¹‰å¤šç§å¤šæ ·ä¸”å¾ˆå°‘æŠ¥é“ï¼ˆ24 é¡¹ç ”ç©¶ï¼‰ã€‚å› æ­¤ï¼Œæ•°æ®ä¸»è¦ä¸ä¸€èˆ¬å…¬ç§¯é‡‘ç›¸å…³ã€‚ CPF æ‚£ç—…ç‡å„ä¸ç›¸åŒï¼ˆèŒƒå›´ï¼š1.5%-81.0%ï¼‰ã€‚å‘ç—…ç‡èŒƒå›´å¹¿æ³›ï¼Œå¤§å¤šæ•°æ˜¯åœ¨å…‹ç½—æ©ç—…è¯Šæ–­å 1 å¹´ç´¯ç§¯æŠ¥å‘Šçš„ï¼ˆèŒƒå›´ï¼š3.5%-50.1%ï¼‰ã€‚æ²»ç–—åæ€»ä½“æ²»æ„ˆç‡å’Œå¤±è´¥ç‡åˆ†åˆ«ä¸º10.5%-80.2%å’Œ3.6%-83.0%ã€‚è„“è‚¿æ˜¯æœ€å¸¸æŠ¥å‘Šçš„å‘ç—…ç‡ï¼ˆ<i>n =</i> 18ï¼‰ã€‚æ²¡æœ‰ä¸å…¬ç§¯é‡‘ç›¸å…³çš„æ­»äº¡æŠ¥å‘Šã€‚æ²¡æœ‰å‘ç°ä¸€è‡´çš„é£é™©æˆ–ä¿æŠ¤å› ç´ ã€‚\n\n**ç»“è®ºï¼š** CPF çš„æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼å’Œå±é™©å› ç´ å„ä¸ç›¸åŒï¼Œè¿™å¯èƒ½æ˜¯ç”±äº CPF å’Œä¸´åºŠç»“æœå®šä¹‰ä¸ä¸€è‡´æ‰€è‡´ã€‚æ ‡å‡†åŒ–å°†ä¿ƒè¿›å¯æ¯”æ€§ï¼Œè¿™å¯èƒ½ä¸ºæœ€ä½³çš„å¤æ‚ CPF æ²»ç–—ç­–ç•¥æä¾›ä¿¡æ¯ã€‚", "keywords_zh": "å¤æ‚è‚›å‘¨ç˜˜ã€å…‹ç½—æ©ç—…ã€æµè¡Œç—…å­¦ã€å‘ç—…ç‡ã€å±é™©å› ç´ ã€æ²»ç–—æ¨¡å¼", "keywords_en": "Complex perianal fistula, Crohnâ€™s disease, Epidemiology, Morbidity, Risk factors, Treatment patterns", "link": "https://pubmed.ncbi.nlm.nih.gov/40740890/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 31 Jul 2025"}, {"id": "40585484", "title_en": "Treatment of perianal abscess and anal fistula in infants: a systematic review", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Li Xu", "abstract_en": "**Introduction:** The optimal treatment approach for perianal abscess (PA) and fistula-in-ano (FIA) in infants remains a subject of debate.\n\n**Material And Methods:** A thorough literature search was conducted across multiple databases, including Embase, PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar.\n\n**Results:** A total of eighteen retrospective studies, encompassing 1,770 patients, were analyzed. Of the 702 cases (38.7%) that underwent conservative treatment, 528 cases (75.2%) achieved a cure, while 174 cases (24.8%) were unsuccessful, with 93 experiencing PA recurrence and 81 developing FIA. In contrast, among the 1,068 cases (61.3%) that received surgical interventions, 784 cases (73.4%) were cured, whereas 284 cases (26.6%) were not, with 151 experiencing PA recurrence and 133 developing FIA.\n\n**Conclusion:** The available studies indicate minimal differences in the cure and recurrence rates of PA and FIA between the conservative and surgical treatment groups.\n\n**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/, PROSPERO (CRD42023472249).", "abstract_zh": "**ä»‹ç»ï¼š** å©´å„¿è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰å’Œè‚›ç˜˜ï¼ˆFIAï¼‰çš„æœ€ä½³æ²»ç–—æ–¹æ³•ä»ç„¶æ˜¯ä¸€ä¸ªäº‰è®ºçš„è¯é¢˜ã€‚\n\n**Material and methodsï¼š** å¯¹å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å½»åº•çš„æ–‡çŒ®æ£€ç´¢ï¼ŒåŒ…æ‹¬ Embaseã€PubMedã€Web of Scienceã€Cochrane Libraryã€ClinicalTrials.gov å’Œ Google Scholarã€‚\n\n**ç»“æœï¼š** æ€»å…±åˆ†æäº† 18 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œæ¶µç›– 1,770 åæ‚£è€…ã€‚æ¥å—ä¿å®ˆæ²»ç–—çš„702ä¾‹ï¼ˆ38.7%ï¼‰ä¸­ï¼Œæ²»æ„ˆ528ä¾‹ï¼ˆ75.2%ï¼‰ï¼Œæœªæ²»æ„ˆ174ä¾‹ï¼ˆ24.8%ï¼‰ï¼Œå…¶ä¸­93ä¾‹å‡ºç°PAå¤å‘ï¼Œ81ä¾‹å‡ºç°FIAã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œåœ¨æ¥å—æ‰‹æœ¯å¹²é¢„çš„1,068ä¾‹ï¼ˆ61.3%ï¼‰ä¸­ï¼Œ784ä¾‹ï¼ˆ73.4%ï¼‰æ²»æ„ˆï¼Œ284ä¾‹ï¼ˆ26.6%ï¼‰æœªæ²»æ„ˆï¼Œå…¶ä¸­151ä¾‹å‡ºç°PAå¤å‘ï¼Œ133ä¾‹å‡ºç°FIAã€‚\n\n**ç»“è®ºï¼š** ç°æœ‰ç ”ç©¶è¡¨æ˜ï¼Œä¿å®ˆæ²»ç–—ç»„å’Œæ‰‹æœ¯æ²»ç–—ç»„ä¹‹é—´ PA å’Œ FIA çš„æ²»æ„ˆç‡å’Œå¤å‘ç‡å·®å¼‚å¾ˆå°ã€‚\n\n**Systematic review registrationï¼š** https://www.crd.york.ac.uk/PROSPERO/ï¼ŒPROSPERO (CRD42023472249)ã€‚", "keywords_zh": "ä¿å®ˆæ²»ç–—, è‚›ç˜˜, å©´å„¿, è‚›å‘¨è„“è‚¿, æ‰‹æœ¯æ²»ç–—", "keywords_en": "conservative treatment, fistula-in-ano, infants, perianal abscess, surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40585484/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 30 Jun 2025"}, {"id": "40538531", "title_en": "The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review", "title_zh": "åŒ–è„“æ€§æ±—è…ºç‚ä¸è‚ æ˜“æ¿€ç–¾ç—…ä¹‹é—´çš„ç›¸å…³æ€§ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Ayezel Munoz Gonzalez", "abstract_en": "**Background:** Hidradenitis suppurativa (HS) is an inflammatory skin condition that presents with nodules or abscesses associated with sinus tracts. Inflammatory bowel diseases (IBD) are inflammatory gastrointestinal (GI) conditions presenting with irregular bowel movements. Although HS and IBDs may have similarities in their clinical presentation and pathophysiology, they can differ in their cutaneous manifestations. Both conditions are potentially caused by genetic changes in the human leukocyte antigen (HLA), cause skin inflammation, and are characterized by abscesses in the GI and sinus tracts.\n\n**Objective:** We sought to determine the extent of coincident IBD and HS and the associated risk factors.\n\n**Methods:** The Ovid Medline database was searched for all current literature on the correlations between HS and IBD. Articles were then included and removed according to specific inclusion and exclusion criteria, and a systematic review was performed on the remaining articles.\n\n**Results:** Thirteen papers that met the inclusion and the exclusion criteria were selected, and after data collection, a significant correlation was found between the development of HS and IBD. Most of the articles reviewed stated that the corresponding association was a causal link between the two diseases. Furthermore, there were various risk factors and comorbidities associated with HS and the development of IBD, including smoking, obesity, perianal disease, and genetic predispositions such as HLA-B27 mutations.\n\n**Discussion:** Studies show that there is a potential correlation with HS and IBDs. Additional research should to determine the genetic correlations between HS and IBDs and the underlying pathophysiological mechanism.", "abstract_zh": "**èƒŒæ™¯ï¼š** åŒ–è„“æ€§æ±—è…ºç‚ (HS) æ˜¯ä¸€ç§ç‚ç—‡æ€§çš®è‚¤ç—…ï¼Œè¡¨ç°ä¸ºä¸çª¦é“ç›¸å…³çš„ç»“èŠ‚æˆ–è„“è‚¿ã€‚ç‚ç—‡æ€§è‚ ç—… (IBD) æ˜¯ä¸€ç§ç‚ç—‡æ€§èƒƒè‚ é“ (GI) ç–¾ç—…ï¼Œè¡¨ç°ä¸ºæ’ä¾¿ä¸è§„åˆ™ã€‚å°½ç®¡ HS å’Œ IBD åœ¨ä¸´åºŠè¡¨ç°å’Œç—…ç†ç”Ÿç†å­¦æ–¹é¢å¯èƒ½æœ‰ç›¸ä¼¼ä¹‹å¤„ï¼Œä½†å®ƒä»¬çš„çš®è‚¤è¡¨ç°å¯èƒ½æœ‰æ‰€ä¸åŒã€‚è¿™ä¸¤ç§æƒ…å†µéƒ½å¯èƒ½æ˜¯ç”±äººç±»ç™½ç»†èƒæŠ—åŸï¼ˆHLAï¼‰çš„åŸºå› å˜åŒ–å¼•èµ·çš„ï¼Œä¼šå¼•èµ·çš®è‚¤ç‚ç—‡ï¼Œå¹¶ä»¥èƒƒè‚ é“å’Œçª¦é“è„“è‚¿ä¸ºç‰¹å¾ã€‚\n\n**ç›®çš„ï¼š** æˆ‘ä»¬è¯•å›¾ç¡®å®š IBD å’Œ HS çš„é‡åˆç¨‹åº¦ä»¥åŠç›¸å…³çš„é£é™©å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ Ovid Medline æ•°æ®åº“ä¸­æ£€ç´¢äº†æœ‰å…³ HS å’Œ IBD ä¹‹é—´ç›¸å…³æ€§çš„æ‰€æœ‰å½“å‰æ–‡çŒ®ã€‚ç„¶åæ ¹æ®ç‰¹å®šçš„çº³å…¥å’Œæ’é™¤æ ‡å‡†çº³å…¥å’Œåˆ é™¤æ–‡ç« ï¼Œå¹¶å¯¹å‰©ä½™æ–‡ç« è¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚\n\n**ç»“æœï¼š** ç­›é€‰å‡º13ç¯‡ç¬¦åˆçº³å…¥å’Œæ’é™¤æ ‡å‡†çš„è®ºæ–‡ï¼Œç»è¿‡æ•°æ®æ”¶é›†ï¼Œå‘ç°HSå’ŒIBDçš„å‘å±•ä¹‹é—´å­˜åœ¨æ˜¾ç€ç›¸å…³æ€§ã€‚å¤§å¤šæ•°å®¡æŸ¥çš„æ–‡ç« éƒ½æŒ‡å‡ºï¼Œç›¸åº”çš„å…³è”æ˜¯ä¸¤ç§ç–¾ç—…ä¹‹é—´çš„å› æœå…³ç³»ã€‚æ­¤å¤–ï¼Œå­˜åœ¨ä¸ HS å’Œ IBD å‘å±•ç›¸å…³çš„å„ç§å±é™©å› ç´ å’Œåˆå¹¶ç—‡ï¼ŒåŒ…æ‹¬å¸çƒŸã€è‚¥èƒ–ã€è‚›å‘¨ç–¾ç—…å’Œ HLA-B27 çªå˜ç­‰é—ä¼ å€¾å‘ã€‚\n\n**è®¨è®ºï¼š** ç ”ç©¶è¡¨æ˜ï¼ŒHS å’Œ IBD å­˜åœ¨æ½œåœ¨ç›¸å…³æ€§ã€‚è¿˜åº”å¼€å±•æ›´å¤šç ”ç©¶æ¥ç¡®å®š HS å’Œ IBD ä¹‹é—´çš„é—ä¼ ç›¸å…³æ€§ä»¥åŠæ½œåœ¨çš„ç—…ç†ç”Ÿç†æœºåˆ¶ã€‚", "keywords_zh": "åŒ–è„“æ€§æ±—è…ºç‚ã€è‡ªèº«å…ç–«ã€çš®è‚¤ç§‘ã€èƒƒè‚ ç§‘ã€è‚ æ˜“æ¿€ç—…", "keywords_en": "Hidradenitis suppurativa, autoimmunity, dermatology, gastroenterology, irritable bowel diseases", "link": "https://pubmed.ncbi.nlm.nih.gov/40538531/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Fri, 20 Jun 2025"}, {"id": "40210078", "title_en": "Defining Radiological Healing in Perianal Fistulizing Crohn's Disease: A TOpClass Global Expert Delphi Consensus", "title_zh": "å®šä¹‰è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…çš„æ”¾å°„æ²»ç–—ï¼šé¡¶çº§å…¨çƒä¸“å®¶å¾·å°”è²å…±è¯†", "authors": "TOpClass collaborative authors", "abstract_en": "**Background & Aims:** Perianal fistulising Crohn's disease (pfCD) affects one-fifth of patients with Crohn's disease (CD), significantly affecting their quality of life. Magnetic resonance imaging is the gold standard for evaluating fistula healing in pfCD, but variability in radiological definitions hampers meaningful clinical interpretation and consistent trial design. This study aimed to establish an international consensus on the definition of radiological healing in pfCD.\n\n**Methods:** The study was conducted in 2 phases. Phase 1 involved a systematic review to identify magnetic resonance imaging-based variables and indices used to define healing in pfCD, assessing methodological quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework. Phase 2 utilized a 2-round online Delphi consensus process with 84 international experts, followed by a stakeholder meeting to achieve consensus (agreement threshold >80%). Results were reported as per Accurate Consensus Reporting Document (ACCORD) guidelines.\n\n**Results:** A radiologically healed fistula can be defined by the absence of T2-weighted hyperintensity, a completely fibrotic fistula tract and, when contrast is used, the absence of contrast enhancement on post-contrast T1-weighted images (95% consensus). Radiological improvement of a fistula can be defined (80% consensus) by the presence of a least one essential criterion: an increasingly fibrotic fistula tract, an unequivocal reduction in one or more of the following: T2-weighted hyperintensity, fistula diameter, fistula length, abscess size, or contrast enhancement of the fistula tract.\n\n**Conclusions:** This international Delphi consensus standardizes radiological endpoints in pfCD, improving consistency in clinical and research settings. Future studies will validate this definition and assess how radiological changes predict long-term clinical outcomes and quality of life improvements.", "abstract_zh": "**Background & aimsï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (pfCD) å½±å“äº”åˆ†ä¹‹ä¸€çš„å…‹ç½—æ©ç—… (CD) æ‚£è€…ï¼Œæ˜¾ç€å½±å“ä»–ä»¬çš„ç”Ÿæ´»è´¨é‡ã€‚ç£å…±æŒ¯æˆåƒæ˜¯è¯„ä¼° pfCD ç˜˜ç®¡æ„ˆåˆçš„é»„é‡‘æ ‡å‡†ï¼Œä½†æ”¾å°„å­¦å®šä¹‰çš„å¯å˜æ€§å¦¨ç¢äº†æœ‰æ„ä¹‰çš„ä¸´åºŠè§£é‡Šå’Œä¸€è‡´çš„è¯•éªŒè®¾è®¡ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å°± pfCD æ”¾å°„æ²»ç–—çš„å®šä¹‰å»ºç«‹å›½é™…å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥ç ”ç©¶åˆ†ä¸¤ä¸ªé˜¶æ®µè¿›è¡Œã€‚ç¬¬ä¸€é˜¶æ®µæ¶‰åŠç³»ç»Ÿå®¡æŸ¥ï¼Œä»¥ç¡®å®šç”¨äºå®šä¹‰ pfCD æ„ˆåˆçš„åŸºäºç£å…±æŒ¯æˆåƒçš„å˜é‡å’ŒæŒ‡æ•°ï¼Œä½¿ç”¨åŸºäºå…±è¯†çš„å¥åº·æµ‹é‡ä»ªå™¨é€‰æ‹©æ ‡å‡† (COSMIN) æ¡†æ¶è¯„ä¼°æ–¹æ³•å­¦è´¨é‡ã€‚ç¬¬äºŒé˜¶æ®µé‡‡ç”¨äº†ç”±84ä½å›½é™…ä¸“å®¶å‚ä¸çš„ä¸¤è½®åœ¨çº¿å¾·å°”è²å…±è¯†æµç¨‹ï¼Œéšåå¬å¼€åˆ©ç›Šç›¸å…³è€…ä¼šè®®ä»¥è¾¾æˆå…±è¯†ï¼ˆåŒæ„é˜ˆå€¼>80%ï¼‰ã€‚ç»“æœæŒ‰ç…§å‡†ç¡®å…±è¯†æŠ¥å‘Šæ–‡ä»¶ (ACCORD) æŒ‡å—è¿›è¡ŒæŠ¥å‘Šã€‚\n\n**ç»“æœï¼š** æ”¾å°„å­¦æ„ˆåˆçš„ç˜˜ç®¡å¯ä»¥å®šä¹‰ä¸ºä¸å­˜åœ¨ T2 åŠ æƒé«˜ä¿¡å·ã€å®Œå…¨çº¤ç»´åŒ–çš„ç˜˜ç®¡ï¼Œä»¥åŠä½¿ç”¨é€ å½±å‰‚æ—¶ï¼Œé€ å½±å T1 åŠ æƒå›¾åƒä¸Šä¸å­˜åœ¨é€ å½±å‰‚å¢å¼ºï¼ˆ95% å…±è¯†ï¼‰ã€‚ç˜˜ç®¡çš„æ”¾å°„å­¦æ”¹å–„å¯ä»¥é€šè¿‡è‡³å°‘ä¸€ä¸ªåŸºæœ¬æ ‡å‡†çš„å­˜åœ¨æ¥å®šä¹‰ï¼ˆ80%å…±è¯†ï¼‰ï¼šç˜˜ç®¡çº¤ç»´åŒ–ç¨‹åº¦ä¸æ–­å¢åŠ ï¼Œä»¥ä¸‹ä¸€é¡¹æˆ–å¤šé¡¹æŒ‡æ ‡æ˜ç¡®å‡å°‘ï¼šT2åŠ æƒé«˜ä¿¡å·ã€ç˜˜ç®¡ç›´å¾„ã€ç˜˜ç®¡é•¿åº¦ã€è„“è‚¿å¤§å°æˆ–ç˜˜ç®¡é€ å½±å¢å¼ºã€‚\n\n**ç»“è®ºï¼š** è¿™ä¸€å›½é™…å¾·å°”è²å…±è¯†æ ‡å‡†åŒ–äº† pfCD çš„æ”¾å°„å­¦ç»ˆç‚¹ï¼Œæé«˜äº†ä¸´åºŠå’Œç ”ç©¶ç¯å¢ƒçš„ä¸€è‡´æ€§ã€‚æœªæ¥çš„ç ”ç©¶å°†éªŒè¯è¿™ä¸€å®šä¹‰ï¼Œå¹¶è¯„ä¼°æ”¾å°„å­¦å˜åŒ–å¦‚ä½•é¢„æµ‹é•¿æœŸä¸´åºŠç»“æœå’Œç”Ÿæ´»è´¨é‡çš„æ”¹å–„ã€‚", "keywords_zh": "ç»ˆç‚¹ã€ç˜˜ç®¡ã€æ„ˆåˆã€MRIã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "Endpoints, Fistula, Healing, MRI, Perianal Fistulising Crohnâ€™s Disease", "link": "https://pubmed.ncbi.nlm.nih.gov/40210078/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 10 Apr 2025"}, {"id": "40155532", "title_en": "Early diagnosis of Crohn's disease in patients presenting with a perianal fistula: systematic review and development of a perianal red flags index", "title_zh": "è‚›å‘¨ç˜˜æ‚£è€…å…‹ç½—æ©ç—…çš„æ—©æœŸè¯Šæ–­ï¼šç³»ç»Ÿå›é¡¾å’Œè‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°çš„åˆ¶å®š", "authors": "J D W van der Bilt", "abstract_en": "**Background:** Delay in diagnosing Crohn's disease (CD) in patients presenting with perianal abscess (PAA) and/or fistula (PAF) is common. The aim of this study was to identify red flags suggestive of CD.\n\n**Methods:** A systematic literature review was conducted to identify symptoms associated with CD in patients presenting with PAA/PAF. A questionnaire including those symptoms, supplemented with items from the International Organization for the Study of Inflammatory Bowel Diseases (IO-IBD) red flags index for luminal CD, was administered to all adult patients presenting with a PAF and eventually diagnosed with CD and matched patients (1:3) from the same study period with a cryptoglandular PAF (2012-2023) at a single non-academic teaching hospital. All patients were asked to recall symptoms/signs experienced during their first PAF.\n\n**Results:** The systematic review identified 8 articles reporting on 15 clinical characteristics in patients presenting with PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6), supplemented with 13 items from the IO-IBD red flags index (28 items in total). A total of 25 patients with CD and 75 patients with PAF without CD answered the questionnaire. Univariate analysis identified seven items associated with CD (age, family history,â€‰>â€‰2 perianal interventions, weight loss, abdominal pain, diarrhoea and fatigue), and four items remained significant in multivariate analysis: age (OR 3.4 [1.0-11.5]),â€‰>â€‰2 previous perianal interventions (OR 3.4 [1.0-10.1]), weight loss (OR 14.4 [3.7-55.6]) and abdominal pain (OR 9.8 [1.9-49.8]). Receiver-operating characteristic curve (ROC) analysis showed that a combination of these red flags was associated with good discrimination of CD versus non-CD (AUC 0.83 [0.72-0.94]).\n\n**Conclusions:** The perianal red flags index has a good predictive value for early identification of patients with PAF at risk for underlying CD.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¯¹äºæ‚£æœ‰è‚›å‘¨è„“è‚¿ (PAA) å’Œ/æˆ–ç˜˜ç®¡ (PAF) çš„æ‚£è€…ï¼Œå…‹ç½—æ©ç—… (CD) çš„è¯Šæ–­å»¶è¿Ÿå¾ˆå¸¸è§ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è¯†åˆ«æç¤º CD çš„å±é™©ä¿¡å·ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿæ€§æ–‡çŒ®ç»¼è¿°ï¼Œä»¥ç¡®å®š PAA/PAF æ‚£è€…ä¸­ä¸ CD ç›¸å…³çš„ç—‡çŠ¶ã€‚å¯¹æ‰€æœ‰å‡ºç° PAF å¹¶æœ€ç»ˆè¯Šæ–­ä¸º CD çš„æˆå¹´æ‚£è€…è¿›è¡Œäº†ä¸€ä»½åŒ…å«è¿™äº›ç—‡çŠ¶çš„è°ƒæŸ¥é—®å·ï¼Œå¹¶è¡¥å……äº†å›½é™…ç‚ç—‡æ€§è‚ ç—…ç ”ç©¶ç»„ç»‡ (IO-IBD) ç®¡è…” CD å±é™©ä¿¡å·æŒ‡æ•°çš„é¡¹ç›®ï¼Œå¹¶ä¸æ¥è‡ªåŒä¸€ç ”ç©¶æ—¶æœŸ (2012-2023) åœ¨ä¸€å®¶éå­¦æœ¯æ€§æ•™å­¦åŒ»é™¢çš„éšè…º PAF çš„åŒ¹é…æ‚£è€… (1:3) è¿›è¡Œäº†æ¯”è¾ƒã€‚æ‰€æœ‰æ‚£è€…éƒ½è¢«è¦æ±‚å›å¿†ç¬¬ä¸€æ¬¡ PAF æœŸé—´ç»å†çš„ç—‡çŠ¶/ä½“å¾ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·ç¡®å®šäº† 8 ç¯‡æ–‡ç« ï¼ŒæŠ¥å‘Šäº† PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6) æ‚£è€…çš„ 15 é¡¹ä¸´åºŠç‰¹å¾ï¼Œå¹¶è¡¥å……äº† IO-IBD å±é™©ä¿¡å·æŒ‡æ•°ä¸­çš„ 13 é¡¹ï¼ˆæ€»å…± 28 é¡¹ï¼‰ã€‚å…±æœ‰ 25 åæ‚£æœ‰ CD çš„æ‚£è€…å’Œ 75 åæ²¡æœ‰ CD çš„ PAF æ‚£è€…å›ç­”äº†é—®å·ã€‚å•å˜é‡åˆ†æç¡®å®šäº†ä¸ CD ç›¸å…³çš„ 7 ä¸ªé¡¹ç›®ï¼ˆå¹´é¾„ã€å®¶æ—å²ã€â€‰>â€‰2 æ¬¡è‚›å‘¨å¹²é¢„ã€ä½“é‡å‡è½»ã€è…¹ç—›ã€è…¹æ³»å’Œç–²åŠ³ï¼‰ï¼Œ4 ä¸ªé¡¹ç›®åœ¨å¤šå˜é‡åˆ†æä¸­ä»ç„¶æ˜¾ç€ï¼šå¹´é¾„ (OR 3.4 [1.0-11.5])ã€â€‰>â€‰2 æ¬¡æ—¢å¾€è‚›å‘¨å¹²é¢„ (OR 3.4 [1.0-10.1])ã€ä½“é‡å‡è½» (OR 14.4) [3.7-55.6]ï¼‰å’Œè…¹ç—›ï¼ˆOR 9.8 [1.9-49.8]ï¼‰ã€‚å—è¯•è€…å·¥ä½œç‰¹å¾æ›²çº¿ (ROC) åˆ†æè¡¨æ˜ï¼Œè¿™äº›å±é™©ä¿¡å·çš„ç»„åˆä¸ CD ä¸é CD çš„è‰¯å¥½åŒºåˆ†ç›¸å…³ï¼ˆAUC 0.83 [0.72-0.94]ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°å¯¹äºæ—©æœŸè¯†åˆ«æœ‰æ½œåœ¨ CD é£é™©çš„ PAF æ‚£è€…å…·æœ‰è‰¯å¥½çš„é¢„æµ‹ä»·å€¼ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€å»¶è¿Ÿã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜", "keywords_en": "Crohnâ€™s disease, Delay, Inflammatory bowel disease, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/40155532/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Sat, 29 Mar 2025"}, {"id": "39946821", "title_en": "A systematic review and meta-analysis of the diagnostic test accuracy of diffusion weighted imaging and apparent diffusion coefficient in differentiating active from inactive perianal fistula", "title_zh": "å¯¹å¼¥æ•£åŠ æƒæˆåƒå’Œè¡¨è§‚å¼¥æ•£ç³»æ•°åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "G S Octavius", "abstract_en": "**Introduction:** This systematic review and meta-analysis evaluated the diagnostic accuracy of MRI-based apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) for differentiating active from inactive perianal fistulas.\n\n**Methods:** The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024596604). The review included five databases (MEDLINE, Cochrane Library, PubMed, Science Direct, and Google Scholar). Meta-analyses were performed on studies reporting ADC values and other sequences using STATA software with the \"Midas\" command.\n\n**Results:** Of 21 studies included in the review, 12 were meta-analyzed, encompassing 1007 patients (77.5Â % male) with 1092 fistulas and 321 abscesses. Six studies reported ADC values for active vs. inactive fistulas, with a pooled sensitivity of 83Â % (95%CI 68-92), specificity of 75Â % (95%CI 60-85), and AUC of 0.85 (95%CI 0.81-0.87). Pooled ADC cut-offs ranged from 1.105 to 1.109Â Ã—Â 10â»Â³ mm<sup>2</sup>/s. The T2WIÂ +Â DWI sequence demonstrated the highest diagnostic accuracy, with a pooled sensitivity of 99Â % (95%CI 90-100), specificity of 97Â % (95%CI 79-100), and an AUC of 1.\n\n**Conclusion:** ADC alone is inadequate for reliably distinguishing active from inactive fistulas. T2WI combined with DWI offers superior diagnostic performance, surpassing contrast-enhanced T1WI, and is promising for non-invasive evaluation of perianal fistulas. However, several limitations, such as moderate to high risk of bias and heterogeneity, may bias this conclusion.\n\n**Implications For Practice:** T2WIÂ +Â DWI could become the standard for assessing perianal fistulas, avoiding contrast agents, and benefiting patients contraindicated for Gadolinium-based contrast media. Variability and potential bias across studies warrant further research.", "abstract_zh": "**ä»‹ç»ï¼š** è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æè¯„ä¼°äº†åŸºäº MRI çš„è¡¨è§‚æ‰©æ•£ç³»æ•° (ADC) å’Œæ‰©æ•£åŠ æƒæˆåƒ (DWI) åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥æ–¹æ¡ˆå·²åœ¨å›½é™…ç³»ç»Ÿè¯„ä»·å‰ç»æ€§ç™»è®°å†Œ (PROSPERO) ä¸­æ³¨å†Œ (CRD42024596604)ã€‚è¯¥ç»¼è¿°åŒ…æ‹¬äº”ä¸ªæ•°æ®åº“ï¼ˆMEDLINEã€Cochrane Libraryã€PubMedã€Science Direct å’Œ Google Scholarï¼‰ã€‚ä½¿ç”¨å¸¦æœ‰â€œMidasâ€å‘½ä»¤çš„ STATA è½¯ä»¶å¯¹æŠ¥å‘Š ADC å€¼å’Œå…¶ä»–åºåˆ—çš„ç ”ç©¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** åœ¨è¯¥è¯„ä»·çº³å…¥çš„ 21 é¡¹ç ”ç©¶ä¸­ï¼Œæœ‰ 12 é¡¹è¿›è¡Œäº†èŸèƒåˆ†æï¼Œæ¶‰åŠ 1007 åæ‚£è€…ï¼ˆ77.5% ç”·æ€§ï¼‰ï¼Œæœ‰ 1092 ä¸ªç˜˜ç®¡å’Œ 321 ä¸ªè„“è‚¿ã€‚å…­é¡¹ç ”ç©¶æŠ¥å‘Šäº†æ´»åŠ¨æ€§ç˜˜ç®¡ä¸éæ´»åŠ¨æ€§ç˜˜ç®¡çš„ ADC å€¼ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 83% (95%CI 68-92)ï¼Œç‰¹å¼‚æ€§ä¸º 75% (95%CI 60-85)ï¼ŒAUC ä¸º 0.85 (95%CI 0.81-0.87)ã€‚æ±‡é›†çš„ ADC æˆªæ­¢èŒƒå›´ä¸º 1.105 è‡³ 1.109Â Ã—Â 10â»3 mm<sup>2</sup>/sã€‚ T2WI + DWI åºåˆ—æ˜¾ç¤ºå‡ºæœ€é«˜çš„è¯Šæ–­å‡†ç¡®æ€§ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 99% (95%CI 90-100)ï¼Œç‰¹å¼‚æ€§ä¸º 97% (95%CI 79-100)ï¼ŒAUC ä¸º 1ã€‚\n\n**ç»“è®ºï¼š** å•ç‹¬ä½¿ç”¨ ADC ä¸è¶³ä»¥å¯é åœ°åŒºåˆ†æ´»åŠ¨æ€§ç˜˜ç®¡å’Œéæ´»åŠ¨æ€§ç˜˜ç®¡ã€‚ T2WI ä¸ DWI ç›¸ç»“åˆæä¾›äº†ä¼˜äºå¯¹æ¯”å¢å¼º T1WI çš„è¯Šæ–­æ€§èƒ½ï¼Œå¹¶ä¸”æœ‰æœ›ç”¨äºè‚›å‘¨ç˜˜çš„æ— åˆ›è¯„ä¼°ã€‚ç„¶è€Œï¼Œä¸€äº›é™åˆ¶ï¼Œä¾‹å¦‚ä¸­åº¦è‡³é«˜é£é™©çš„åå€šå’Œå¼‚è´¨æ€§ï¼Œå¯èƒ½ä¼šå¯¼è‡´è¿™ä¸€ç»“è®ºäº§ç”Ÿåå·®ã€‚\n\n**Implications for practiceï¼š** T2WI + DWI å¯ä»¥æˆä¸ºè¯„ä¼°è‚›å‘¨ç˜˜ç®¡ã€é¿å…ä½¿ç”¨é€ å½±å‰‚ä»¥åŠä½¿é’†é€ å½±å‰‚ç¦å¿Œæ‚£è€…å—ç›Šçš„æ ‡å‡†ã€‚ç ”ç©¶ä¹‹é—´çš„å˜å¼‚æ€§å’Œæ½œåœ¨åå·®å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "è¡¨è§‚æ‰©æ•£ç³»æ•°ã€è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§ã€æ‰©æ•£åŠ æƒæˆåƒã€ç£å…±æŒ¯æˆåƒã€è‚›å‘¨ç˜˜", "keywords_en": "Apparent diffusion coefficient, Diagnostic test accuracy, Diffusion weighted imaging, Magnetic resonance imaging, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/39946821/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 13 Feb 2025"}, {"id": "39422801", "title_en": "Perianal Mucinous Adenocarcinoma: A Case Report and a Systematic Review of the Literature", "title_zh": "è‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œï¼šä¸€ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Apostolos P Stamatiadis", "abstract_en": "**Background:** Mucinous adenocarcinoma of anus is an uncommon neoplasm of the gastrointestinal tract. In most of the cases, early diagnosis of this disease is difficult since its symptoms frequently mimic benign inflammatory conditions.\n\n**Methods:** A systematic PubMed and Scopus search was conducted, a propos of a case report.\n\n**Results:** One hundred fifty patients from 93 case reports were included. The mean age of the patients was 60.5Â years (range: 18-81). The majority of them were males (124 out of 150, 82.7%), while the main known risk factor was the history of chronic fistula (109 out of 150, 72.7%). Recurrent perianal sepsis and perianal pain were the principal symptoms at the time of presentation. No symptoms have been reported only in three patients (3 out of 150, 2%). Regarding the prior surgical history of the patients, multiple abscess drainage and perianal fistula's related interventions were present in 62 (41.3%) and 19 (12.7%) patients, respectively. Neoadjuvant chemoradiotherapy was administered in 53 out of 150 patients (35.3%), while the majority of them have been treated with combined treatment of chemotherapy and radiotherapy. APR and its variations were the most applied surgical treatment (68%). Adjuvant chemoradiotherapy was administered almost up to one-third of the included patients (34%). Recurrence of the disease was reported in 41 out of 150 patients (27.3%). Death was reported in 44 out of 150 patients (29.3%).\n\n**Conclusion:** Review of the available published literature suggests that perianal mucinous adenocarcinoma is an extremely rare neoplasia. Î¤here is no consensus as far as the diagnosis and the treatment strategies, due to the rarity of this neoplasm. High degree of clinical suspicion as well as histopathological confirmation is the principal requisites for the diagnosis of mucinous adenocarcinoma, especially in the ground of chronic ulcero-proliferative perianal lesions.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›é—¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§ç½•è§çš„èƒƒè‚ é“è‚¿ç˜¤ã€‚åœ¨å¤§å¤šæ•°æƒ…å†µä¸‹ï¼Œè¿™ç§ç–¾ç—…çš„æ—©æœŸè¯Šæ–­å¾ˆå›°éš¾ï¼Œå› ä¸ºå®ƒçš„ç—‡çŠ¶ç»å¸¸æ¨¡ä»¿è‰¯æ€§ç‚ç—‡ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç—…ä¾‹æŠ¥å‘Šçš„å»ºè®®ï¼Œè¿›è¡Œäº†ç³»ç»Ÿçš„ PubMed å’Œ Scopus æ£€ç´¢ã€‚\n\n**ç»“æœï¼š** çº³å…¥ 93 ä»½ç—…ä¾‹æŠ¥å‘Šä¸­çš„ 150 åæ‚£è€…ã€‚æ‚£è€…çš„å¹³å‡å¹´é¾„ä¸º 60.5 å²ï¼ˆèŒƒå›´ï¼š18-81 å²ï¼‰ã€‚å…¶ä¸­å¤§å¤šæ•°ä¸ºç”·æ€§ï¼ˆ150 äººä¸­çš„ 124 äººï¼Œ82.7%ï¼‰ï¼Œè€Œå·²çŸ¥çš„ä¸»è¦å±é™©å› ç´ æ˜¯æ…¢æ€§ç˜˜ç®¡ç—…å²ï¼ˆ150 äººä¸­çš„ 109 äººï¼Œ72.7%ï¼‰ã€‚å¤å‘æ€§è‚›å‘¨è´¥è¡€ç—‡å’Œè‚›å‘¨ç–¼ç—›æ˜¯å°±è¯Šæ—¶çš„ä¸»è¦ç—‡çŠ¶ã€‚ä»… 3 åæ‚£è€…æ²¡æœ‰æŠ¥å‘Šä»»ä½•ç—‡çŠ¶ï¼ˆ150 åæ‚£è€…ä¸­æœ‰ 3 åï¼Œ2%ï¼‰ã€‚å…³äºæ‚£è€…æ—¢å¾€æ‰‹æœ¯å²ï¼Œåˆ†åˆ«æœ‰62ä¾‹ï¼ˆ41.3%ï¼‰å’Œ19ä¾‹ï¼ˆ12.7%ï¼‰æ‚£è€…æ¥å—è¿‡å¤šå¤„è„“è‚¿å¼•æµå’Œè‚›å‘¨ç˜˜ç›¸å…³å¹²é¢„ã€‚ 150ä¾‹æ‚£è€…ä¸­ï¼Œæœ‰53ä¾‹ï¼ˆ35.3%ï¼‰æ¥å—äº†æ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼Œå…¶ä¸­å¤§å¤šæ•°æ‚£è€…æ¥å—äº†åŒ–ç–—å’Œæ”¾ç–—çš„è”åˆæ²»ç–—ã€‚ APR åŠå…¶å˜ä½“æ˜¯æœ€å¸¸ç”¨çš„æ‰‹æœ¯æ²»ç–—æ–¹æ³• (68%)ã€‚å‡ ä¹ä¸‰åˆ†ä¹‹ä¸€çš„çº³å…¥æ‚£è€…ï¼ˆ34%ï¼‰æ¥å—äº†è¾…åŠ©æ”¾åŒ–ç–—ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 41 åï¼ˆ27.3%ï¼‰æŠ¥å‘Šç–¾ç—…å¤å‘ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 44 åæ­»äº¡ï¼ˆ29.3%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** å¯¹ç°æœ‰å·²å‘è¡¨æ–‡çŒ®çš„å›é¡¾è¡¨æ˜ï¼Œè‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§æå…¶ç½•è§çš„è‚¿ç˜¤ã€‚ç”±äºè¿™ç§è‚¿ç˜¤çš„ç½•è§æ€§ï¼Œåœ¨è¯Šæ–­å’Œæ²»ç–—ç­–ç•¥æ–¹é¢å°šæœªè¾¾æˆå…±è¯†ã€‚é«˜åº¦çš„ä¸´åºŠæ€€ç–‘å’Œç»„ç»‡ç—…ç†å­¦è¯å®æ˜¯è¯Šæ–­ç²˜æ¶²è…ºç™Œçš„ä¸»è¦å¿…è¦æ¡ä»¶ï¼Œç‰¹åˆ«æ˜¯åœ¨æ…¢æ€§æºƒç–¡å¢æ®–æ€§è‚›å‘¨ç—…å˜çš„æƒ…å†µä¸‹ã€‚", "keywords_zh": "è‚›é—¨ã€è‚›é—¨ã€è‚›é—¨å†…è¶…å£°æ£€æŸ¥ã€ç²˜æ¶²æ€§è…ºç™Œã€è‚›å‘¨", "keywords_en": "Anal, Anus, Endoanal ultrasonography, Mucinous adenocarcinoma, Perianal", "link": "https://pubmed.ncbi.nlm.nih.gov/39422801/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Fri, 18 Oct 2024"}, {"id": "39360706", "title_en": "Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis", "title_zh": "Darvadstrocel æ²»ç–—å…‹ç½—æ©ç—…å¤æ‚è‚›å‘¨ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Cristina Alba", "abstract_en": "**Background:** Local injection of darvadstrocel, a suspension of expanded adipose-derived allogenic mesenchymal stem cells, has been used for treatment-refractory perianal fistulas in Crohn's disease (CD).\n\n**Objective:** This study aimed to investigate efficacy and safety of darvadstrocel for complex perianal fistulas in CD.\n\n**Methods:** A systematic search was conducted through April 2024 in relevant databases for observational studies evaluating darvadstrocel. A random-effects meta-analysis model was used to calculate the pooled effect sizes (proportions or incidence rates [IRs]) with 95% confidence intervals (CIs) of effectiveness and safety outcomes. The risk of bias was evaluated using the Joanna Briggs Institute Critical Appraisal Tool. The I<sup>2</sup> value assessed heterogeneity. Sensitivity and subgroup analyses were also conducted.\n\n**Results:** Twelve studies were included with 595 patients. The pooled rate of patients achieving clinical remission, defined as fistula healing, was 68.1% at month 6 (95% CI 63.4-72.7) and 77.2% (95% CI 70.1-83.8) at month 12. Combined remission, defined as clinical remission and absence of collections >2Â cm confirmed by magnetic resonance imaging, was reported in 60.6% and in 69.7% of patients at months 6 and 12, respectively. The rate of patients with treatment failure, defined as no clinical remission at the last follow-up (mean 18.7Â months; SD 9.9), was 34.5%. Failure rate was independent of follow-up time (pÂ =Â 0.85). For effectiveness outcomes, between-study heterogeneity was negligible. Subgroup analysis indicated that none of the covariates modified the treatment effect. Pooled IRs per 100 patient-years of adverse events (AE), serious AEs, perianal abscesses, and reoperations were 19.6, 3.2, 16.9 and 7.1, respectively.\n\n**Conclusion:** Evidence from observational studies supports the efficacy and safety of darvadstrocel for complex perianal fistulas in CD. Studies have reported high fistula healing rates that can be sustained long-term in most patients, with negligible between-study heterogeneity, as well as a favorable safety profile.", "abstract_zh": "**èƒŒæ™¯ï¼š** å±€éƒ¨æ³¨å°„darvadstrocelï¼ˆä¸€ç§æ‰©å¢çš„è„‚è‚ªæ¥æºåŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒæ‚¬æµ®æ¶²ï¼‰å·²ç”¨äºæ²»ç–—å…‹ç½—æ©ç—…ï¼ˆCDï¼‰éš¾æ²»æ€§è‚›å‘¨ç˜˜ã€‚\n\n**ç›®çš„ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨æ¢è®¨ darvadstrocel æ²»ç–— CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2024 å¹´ 4 æœˆï¼Œæˆ‘ä»¬åœ¨ç›¸å…³æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ€§æ£€ç´¢ï¼Œä»¥è¯„ä¼° darvadstrocel çš„è§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†ææ¨¡å‹æ¥è®¡ç®—æ±‡æ€»æ•ˆåº”å¤§å°ï¼ˆæ¯”ä¾‹æˆ–å‘ç”Ÿç‡ [IR]ï¼‰ï¼Œæœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ç»“æœçš„ç½®ä¿¡åŒºé—´ (CI) ä¸º 95%ã€‚ä½¿ç”¨ä¹”å®‰å¨œÂ·å¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€æ‰¹åˆ¤æ€§è¯„ä¼°å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚ I<sup>2</sup> å€¼è¯„ä¼°å¼‚è´¨æ€§ã€‚è¿˜è¿›è¡Œäº†æ•æ„Ÿæ€§å’Œäºšç»„åˆ†æã€‚\n\n**ç»“æœï¼š** 12 é¡¹ç ”ç©¶çº³å…¥äº† 595 åæ‚£è€…ã€‚ç¬¬ 6 ä¸ªæœˆæ—¶è¾¾åˆ°ä¸´åºŠç¼“è§£ï¼ˆå®šä¹‰ä¸ºç˜˜ç®¡æ„ˆåˆï¼‰çš„æ‚£è€…çš„æ±‡æ€»ç‡ä¸º 68.1%ï¼ˆ95% CI 63.4-72.7ï¼‰ï¼Œç¬¬ 12 ä¸ªæœˆæ—¶ä¸º 77.2%ï¼ˆ95% CI 70.1-83.8ï¼‰ã€‚ç»¼åˆç¼“è§£ï¼ˆå®šä¹‰ä¸ºä¸´åºŠç¼“è§£ä¸”ç»ç£å…±æŒ¯æˆåƒè¯å®æ²¡æœ‰ >2 cm çš„ç§¯æ¶²ï¼‰çš„æ‚£è€…æ¯”ä¾‹ä¸º 60.6% å’Œ 69.7%åˆ†åˆ«åœ¨ç¬¬ 6 ä¸ªæœˆå’Œç¬¬ 12 ä¸ªæœˆã€‚æ²»ç–—å¤±è´¥ï¼ˆå®šä¹‰ä¸ºæœ€åä¸€æ¬¡éšè®¿æ—¶æ— ä¸´åºŠç¼“è§£ï¼‰çš„æ‚£è€…æ¯”ä¾‹ï¼ˆå¹³å‡ 18.7 ä¸ªæœˆï¼›SD 9.9ï¼‰ä¸º 34.5%ã€‚å¤±è´¥ç‡ä¸éšè®¿æ—¶é—´æ— å…³ (p = 0.85)ã€‚å¯¹äºæœ‰æ•ˆæ€§ç»“æœï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ã€‚äºšç»„åˆ†æè¡¨æ˜æ²¡æœ‰ä»»ä½•åå˜é‡æ”¹å˜æ²»ç–—æ•ˆæœã€‚æ¯ 100 æ‚£è€…å¹´ä¸è‰¯äº‹ä»¶ (AE)ã€ä¸¥é‡ AEã€è‚›å‘¨è„“è‚¿å’Œå†æ¬¡æ‰‹æœ¯çš„æ±‡æ€» IR åˆ†åˆ«ä¸º 19.6ã€3.2ã€16.9 å’Œ 7.1ã€‚\n\n**ç»“è®ºï¼š** è§‚å¯Ÿæ€§ç ”ç©¶çš„è¯æ®æ”¯æŒ darvadstrocel å¯¹äº CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚ç ”ç©¶è¡¨æ˜ï¼Œå¤§å¤šæ•°æ‚£è€…çš„ç˜˜ç®¡æ„ˆåˆç‡è¾ƒé«˜ï¼Œå¯ä»¥é•¿æœŸç»´æŒï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ï¼Œå¹¶ä¸”å®‰å…¨æ€§è‰¯å¥½ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è„‚è‚ªæ¥æºçš„åŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒã€alofiselã€darvadstrocelã€ç‚ç—‡æ€§è‚ ç—…ã€èŸèƒåˆ†æã€è‚›å‘¨ç˜˜", "keywords_en": "Crohn's disease, adiposeâ€derived allogenic mesenchymal stem cells, alofisel, darvadstrocel, inflammatory bowel disease, metaâ€analysis, perianal fistulas", "link": "https://pubmed.ncbi.nlm.nih.gov/39360706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 03 Oct 2024"}, {"id": "39298676", "title_en": "Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review", "title_zh": "ä½¿ç”¨æŒ‚çº¿å¯¹å¤æ‚å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ç»“æœçš„å½±å“ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Phillip Fleshner", "abstract_en": "**Background:** Optimal treatment strategies for seton use in patients with Crohn's perianal fistulas (CPF) remain elusive. This systematic literature review aimed to summarize clinical, patient-reported, and healthcare resource utilization (HCRU) outcomes associated with seton use for symptomatic relief and treatment of complex CPF.\n\n**Methods:** Electronic databases (MEDLINE, Embase, EBM Reviews, EconLit) were searched. Titles, abstracts, and relevant full texts were screened by 2 reviewers for inclusion using prespecified PICOS-T criteria. Articles published in English between January 1, 1980 and September 6, 2021 were included; animal/in vitro studies and case reports with <5 patients were excluded. Outcomes of interest included rates of complete response/remission and fistula recurrence in patients receiving seton with/without infliximab or biologics. Data were summarized using descriptive statistics.\n\n**Results:** Overall, 56 studies were included (full texts: nâ€…=â€…43; congress abstracts: nâ€…=â€…13). CPF and clinical outcome definitions were heterogeneous. Rates (range) of complete response/remission varied widely (seton: 13%-75%; setonâ€…+â€…infliximab: 23%-100%; setonâ€…+â€…biologics: 23%-59%) as did rates for fistula recurrence (seton: 4%-68%; setonâ€…+â€…infliximab: 0%-50%; setonâ€…+â€…biologics: 0%-17%). Rates of fistula-related reintervention, new fistula or abscess formation, and abscess recurrence were also varied; more consistency was observed regarding the use of patient-reported outcomes. Few studies reported outcomes from pediatric/adolescent patients or HCRU.\n\n**Conclusions:** Optimal use of seton in patients with CPF remains unclear. International standardization of definitions for CPF and related clinical outcomes are required to permit data comparability and identify the most effective treatment strategies involving seton use in CPF.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ï¼ˆCPFï¼‰æ‚£è€…æŒ‚çº¿çš„æœ€ä½³æ²»ç–—ç­–ç•¥ä»ç„¶éš¾ä»¥æ‰æ‘¸ã€‚æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ—¨åœ¨æ€»ç»“ä¸ä½¿ç”¨æŒ‚çº¿ç¼“è§£ç—‡çŠ¶å’Œæ²»ç–—å¤æ‚ CPF ç›¸å…³çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ (HCRU) ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº†ç”µå­æ•°æ®åº“ï¼ˆMEDLINEã€Embaseã€EBM Reviewsã€EconLitï¼‰ã€‚æ ‡é¢˜ã€æ‘˜è¦å’Œç›¸å…³å…¨æ–‡ç”± 2 åå®¡ç¨¿äººç­›é€‰ï¼Œä»¥ä½¿ç”¨é¢„å…ˆæŒ‡å®šçš„ PICOS-T æ ‡å‡†è¿›è¡Œçº³å…¥ã€‚æ”¶å½•äº†1980å¹´1æœˆ1æ—¥è‡³2021å¹´9æœˆ6æ—¥æœŸé—´ä»¥è‹±æ–‡å‘è¡¨çš„æ–‡ç« ï¼›åŠ¨ç‰©/ä½“å¤–ç ”ç©¶å’Œç—…ä¾‹æŠ¥å‘Š<5åæ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æ„Ÿå…´è¶£çš„ç»“æœåŒ…æ‹¬æ¥å—æŒ‚çº¿å¹¶ä½¿ç”¨/ä¸ä½¿ç”¨è‹±å¤«åˆ©æ˜”å•æŠ—æˆ–ç”Ÿç‰©åˆ¶å‰‚çš„æ‚£è€…çš„å®Œå…¨ç¼“è§£/ç¼“è§£ç‡å’Œç˜˜ç®¡å¤å‘ç‡ã€‚ä½¿ç”¨æè¿°æ€§ç»Ÿè®¡æ€»ç»“æ•°æ®ã€‚\n\n**ç»“æœï¼š** æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 56 é¡¹ç ”ç©¶ï¼ˆå…¨æ–‡ï¼šnâ€…=â€…43ï¼›ä¼šè®®æ‘˜è¦ï¼šnâ€…=â€…13ï¼‰ã€‚ CPF å’Œä¸´åºŠç»“æœçš„å®šä¹‰æ˜¯ä¸åŒçš„ã€‚å®Œå…¨ç¼“è§£/ç¼“è§£ç‡ï¼ˆèŒƒå›´ï¼‰å·®å¼‚å¾ˆå¤§ï¼ˆæŒ‚çº¿ï¼š13%-75%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š23%-100%ï¼›æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š23%-59%ï¼‰ï¼Œç˜˜ç®¡å¤å‘ç‡ä¹Ÿæœ‰å¾ˆå¤§å·®å¼‚ï¼ˆæŒ‚çº¿ï¼š4%-68%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼‰ã€‚æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š0%-17%ï¼‰ã€‚ä¸ç˜˜ç®¡ç›¸å…³çš„å†å¹²é¢„ã€æ–°ç˜˜ç®¡æˆ–è„“è‚¿å½¢æˆä»¥åŠè„“è‚¿å¤å‘ç‡ä¹Ÿå„ä¸ç›¸åŒï¼›åœ¨ä½¿ç”¨æ‚£è€…æŠ¥å‘Šçš„ç»“æœæ–¹é¢è§‚å¯Ÿåˆ°æ›´åŠ ä¸€è‡´ã€‚å¾ˆå°‘æœ‰ç ”ç©¶æŠ¥å‘Šå„¿ç§‘/é’å°‘å¹´æ‚£è€…æˆ– HCRU çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** CPF æ‚£è€…æŒ‚çº¿çš„æœ€ä½³ä½¿ç”¨æ–¹å¼ä»ä¸æ¸…æ¥šã€‚éœ€è¦å¯¹ CPF å®šä¹‰å’Œç›¸å…³ä¸´åºŠç»“æœè¿›è¡Œå›½é™…æ ‡å‡†åŒ–ï¼Œä»¥å®ç°æ•°æ®å¯æ¯”æ€§å¹¶ç¡®å®šæ¶‰åŠ CPF æŒ‚çº¿ä½¿ç”¨çš„æœ€æœ‰æ•ˆæ²»ç–—ç­–ç•¥ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è‚›å‘¨ç˜˜ã€æŒ‚çº¿", "keywords_en": "Crohnâ€™s disease, perianal fistula, seton", "link": "https://pubmed.ncbi.nlm.nih.gov/39298676/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 19 Sep 2024"}, {"id": "38813942", "title_en": "Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review", "title_zh": "å£æœè„Šé«“ç°è´¨ç‚ç–«è‹—æ¥ç§è€…ä¸­ä¸ç–«è‹—ç›¸å…³çš„éº»ç—¹æ€§è„Šé«“ç°è´¨ç‚ï¼šä½¿ç”¨ VAERS å’Œç³»ç»Ÿè¯„ä»·è¿›è¡Œä¸æˆæ¯”ä¾‹åˆ†æ", "authors": "Girish Thunga", "abstract_en": "**Background:** Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse event of oral poliovirus vaccines (OPV), particularly affecting immunodeficient individuals.\n\n**Research Design And Methods:** This study aimed to (1) Assess the association between OPV and VAPP using Vaccine Adverse Event Reporting System (VAERS) database (2) Outline patient characteristics and risk factors associated with the occurrence of VAPP in OPV recipients through a systematic review of case reports and case series. A disproportionality analysis was conducted using the data from VAERS, encompassing adverse events reported from 1990 till February 2023. Additionally, we conducted a systematic review of case reports and case series using PubMed, Scopus, and Embase databases.\n\n**Results:** The VAERS data revealed 130 VAPP reports among 1,739,903 OPV linked adverse events, with year 2010 reporting the strongest association. The systematic review of 37 studies highlighted VAPP occurrence within 2â€‰months to 4â€‰years post-vaccination, typically with acute flaccid paralysis. Immunodeficiency and perianal abscess emerged as major risk factors. Out of the 37 included studies, 27 showed consistent causal association of VAPP with OPV using WHO-AEFI causality assessment tool.\n\n**Conclusion:** The study emphasized the seriousness of VAPP and highlights its association with OPV, identifying immunodeficiency as a prominent contributor to VAPP manifestation.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç–«è‹—ç›¸å…³éº»ç—¹æ€§è„Šé«“ç°è´¨ç‚ (VAPP) æ˜¯å£æœè„Šé«“ç°è´¨ç‚ç—…æ¯’ç–«è‹— (OPV) çš„ä¸€ç§ç½•è§ä¸è‰¯äº‹ä»¶ï¼Œå°¤å…¶å½±å“å…ç–«ç¼ºé™·ä¸ªä½“ã€‚\n\n**Research design and methodsï¼š** æœ¬ç ”ç©¶æ—¨åœ¨ (1) ä½¿ç”¨ç–«è‹—ä¸è‰¯äº‹ä»¶æŠ¥å‘Šç³»ç»Ÿ (VAERS) æ•°æ®åº“è¯„ä¼° OPV å’Œ VAPP ä¹‹é—´çš„å…³è” (2) é€šè¿‡å¯¹ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—è¿›è¡Œç³»ç»Ÿå›é¡¾ï¼Œæ¦‚è¿°ä¸ OPV æ¥å—è€…å‘ç”Ÿ VAPP ç›¸å…³çš„æ‚£è€…ç‰¹å¾å’Œå±é™©å› ç´ ã€‚ä½¿ç”¨ VAERS çš„æ•°æ®è¿›è¡Œäº†ä¸æˆæ¯”ä¾‹åˆ†æï¼Œæ¶µç›– 1990 å¹´è‡³ 2023 å¹´ 2 æœˆæŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬ä½¿ç”¨ PubMedã€Scopus å’Œ Embase æ•°æ®åº“å¯¹ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚\n\n**ç»“æœï¼š** VAERS æ•°æ®æ˜¾ç¤ºï¼Œ1,739,903 èµ· OPV ç›¸å…³ä¸è‰¯äº‹ä»¶ä¸­æœ‰ 130 ä»½ VAPP æŠ¥å‘Šï¼Œå…¶ä¸­ 2010 å¹´æŠ¥å‘Šçš„å…³è”æ€§æœ€å¼ºã€‚å¯¹ 37 é¡¹ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾å¼ºè°ƒäº† VAPP åœ¨ç–«è‹—æ¥ç§å 2 ä¸ªæœˆè‡³ 4 å¹´å†…å‘ç”Ÿï¼Œé€šå¸¸ä¼´æœ‰æ€¥æ€§å¼›ç¼“æ€§éº»ç—¹ã€‚å…ç–«ç¼ºé™·å’Œè‚›å‘¨è„“è‚¿æˆä¸ºä¸»è¦å±é™©å› ç´ ã€‚åœ¨çº³å…¥çš„ 37 é¡¹ç ”ç©¶ä¸­ï¼Œ27 é¡¹ä½¿ç”¨ WHO-AEFI å› æœå…³ç³»è¯„ä¼°å·¥å…·æ˜¾ç¤º VAPP ä¸ OPV ä¹‹é—´å­˜åœ¨ä¸€è‡´çš„å› æœå…³ç³»ã€‚\n\n**ç»“è®ºï¼š** è¯¥ç ”ç©¶å¼ºè°ƒäº† VAPP çš„ä¸¥é‡æ€§ï¼Œå¹¶å¼ºè°ƒäº†å…¶ä¸ OPV çš„å…³è”ï¼Œç¡®å®šå…ç–«ç¼ºé™·æ˜¯å¯¼è‡´ VAPP è¡¨ç°çš„ä¸€ä¸ªé‡è¦å› ç´ ã€‚", "keywords_zh": "ç—…ä¾‹æŠ¥å‘Šã€OPVã€VAPPã€å› æœå…³ç³»ã€å…ç–«ç¼ºé™·ã€è„Šé«“ç°è´¨ç‚", "keywords_en": "Case report, OPV, VAPP, causality, immunodeficiency, polio", "link": "https://pubmed.ncbi.nlm.nih.gov/38813942/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 30 May 2024"}, {"id": "38563064", "title_en": "A systematic review and meta-analysis of the use of packing in the management of perianal abscesses", "title_zh": "è‚›å‘¨è„“è‚¿æ²»ç–—ä¸­å¡«å¡ä½¿ç”¨çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Ome Padfield", "abstract_en": "**Background:** Perianal abscesses are common presentations and reasons for emergency general surgery admissions. Management involves incision and drainage of the abscess and packing the cavity with internal wound dressings. This meta-analysis aimed to assess in adults if packing an abscess or leaving it unpacked leads to a significant difference in the outcomes of pain on wound dressing, time to healing, rate of fistulation and abscess recurrence.\n\n**Methods:** Randomised controlled trials (RCTs) with participants aged 18 years or older that compared packing of perianal abscess cavities with no packing between 2002 and 2022 were searched for in December 2022 on OVID Medline and Embase, the CENTRAL register of trials, PubMed and Google Scholar. Risk of bias was assessed using the Cochrane Risk of Bias tool. Random effects meta-analysis was conducted on the data extracted.\n\n**Results:** Three RCTs involving 490 patients were analysed for the outcomes of abscess recurrence and postoperative fistula formation; the data were not adequate to assess pain on dressing and time to healing. For unpacked versus packed, the pooled relative risk of abscess recurrence was 1.57 (95% confidence interval (CI) 0.764, 3.29, <i>p</i>=0.219) and for fistula formation 0.686 (95% CI 0.430, 1.09, <i>p</i>=0.114). These results suggest there is no significant benefit to packing abscess cavities.\n\n**Conclusions:** Analysis of the outcomes suggests there is no significant difference with regards to rates of abscess recurrence or fistula formation between the packed and unpacked groups; however, appropriately powered RCTs are required in this area to provide more primary evidence to inform best practice and clinical management.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨è„“è‚¿æ˜¯æ€¥è¯Šæ™®é€šå¤–ç§‘æ‰‹æœ¯çš„å¸¸è§è¡¨ç°å’ŒåŸå› ã€‚æ²»ç–—åŒ…æ‹¬åˆ‡å¼€è„“è‚¿å¹¶å¼•æµï¼Œå¹¶ç”¨å†…éƒ¨ä¼¤å£æ•·æ–™å¡«å¡ç©ºè…”ã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°æˆäººåŒ…æ‰è„“è‚¿æˆ–ä¸åŒ…æ‰è„“è‚¿æ˜¯å¦ä¼šå¯¼è‡´ä¼¤å£æ•·æ–™ç–¼ç—›ã€æ„ˆåˆæ—¶é—´ã€ç˜˜ç®¡å‘ç”Ÿç‡å’Œè„“è‚¿å¤å‘çš„æ˜¾ç€å·®å¼‚ã€‚\n\n**æ–¹æ³•ï¼š** 2022 å¹´ 12 æœˆï¼Œåœ¨ OVID Medline å’Œ Embaseã€ä¸­å¤®è¯•éªŒæ³¨å†Œåº“ã€PubMed å’Œ Google Scholar ä¸Šæ£€ç´¢äº† 18 å²æˆ–ä»¥ä¸Šå‚ä¸è€…çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œè¿™äº›è¯•éªŒæ¯”è¾ƒäº† 2002 å¹´è‡³ 2022 å¹´æœŸé—´è‚›å‘¨è„“è‚¿è…”å¡«å¡ä¸ä¸å¡«å¡çš„æƒ…å†µã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚å¯¹æå–çš„æ•°æ®è¿›è¡Œéšæœºæ•ˆåº”èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** å¯¹æ¶‰åŠ 490 åæ‚£è€…çš„ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒåˆ†æäº†è„“è‚¿å¤å‘å’Œæœ¯åç˜˜ç®¡å½¢æˆçš„ç»“æœï¼›è¿™äº›æ•°æ®ä¸è¶³ä»¥è¯„ä¼°æ•·æ–™æ—¶çš„ç–¼ç—›å’Œæ„ˆåˆæ—¶é—´ã€‚å¯¹äºæœªå¡«å¡ä¸å¡«å¡çš„æƒ…å†µï¼Œè„“è‚¿å¤å‘çš„æ±‡æ€»ç›¸å¯¹é£é™©ä¸º 1.57ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI) 0.764, 3.29, <i>p</i>=0.219ï¼‰ï¼Œç˜˜ç®¡å½¢æˆçš„æ±‡æ€»ç›¸å¯¹é£é™©ä¸º 0.686ï¼ˆ95% CI 0.430, 1.09ï¼Œ<i>p</i>=0.114ï¼‰ã€‚è¿™äº›ç»“æœè¡¨æ˜ï¼Œå¡«å¡è„“è‚¿ç©ºè…”æ²¡æœ‰æ˜¾ç€çš„å¥½å¤„ã€‚\n\n**ç»“è®ºï¼š** ç»“æœåˆ†æè¡¨æ˜ï¼Œå¡«å¡ç»„å’Œæœªå¡«å¡ç»„ä¹‹é—´è„“è‚¿å¤å‘æˆ–ç˜˜ç®¡å½¢æˆç‡æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼›ç„¶è€Œï¼Œè¯¥é¢†åŸŸéœ€è¦é€‚å½“çš„éšæœºå¯¹ç…§è¯•éªŒæ¥æä¾›æ›´å¤šä¸»è¦è¯æ®ï¼Œä¸ºæœ€ä½³å®è·µå’Œä¸´åºŠç®¡ç†æä¾›ä¿¡æ¯ã€‚", "keywords_zh": "è„“è‚¿å¡«å¡ã€è‚›å‘¨è„“è‚¿ã€å¤å‘", "keywords_en": "Abscess packing, Perianal abscesses, Recurrence", "link": "https://pubmed.ncbi.nlm.nih.gov/38563064/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Tue, 02 Apr 2024"}, {"id": "38428446", "title_en": "Aluminum potassium sulfate and tannic acid (ALTA) sclerotherapy for hemorrhoidal disease: a systematic review and meta-analysis", "title_zh": "ç¡«é…¸é“é’¾å’Œå•å®é…¸ï¼ˆALTAï¼‰ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Kiriakos Ktenidis", "abstract_en": "**Background:** We conducted a systematic review to assess the safety and efficacy of Aluminum potassium sulfate and tannic acid (ALTA) sclerotherapy for the treatment of hemorrhoidal disease.\n\n**Methods:** Our study was conducted in accordance with the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020. Primary endpoints included overall recurrence and type of recurrence while secondary endpoints included postoperative complications, reintervention, presence of rectal ulcer, rectal stricture, defecation abnormalities and perianal abscess. Î‘ regression analysis, where the percentage of patients with grade II, III and IV hemorrhoidal disease was used as a covariate, was also performed.\n\n**Results:** Twelve studies with 4249 patients met all the inclusion criteria and were eventually included. The crude and pooled estimates of the overall recurrence and complications by the end of follow-up were 10% (95% CI, 6.52%-14.08%) and 5.20% (95% CI, 2.59%-8.52%), respectively. Regression analysis displayed no correlation between recurrence and the grade of hemorrhoid disease II, Î²= -0.0012 (95% CI, -0.0074 to 0.0049) (<i>p</i>â€‰=â€‰.64), grade III Î²= -0.0006 (95% CI, -0.0056 to 0.0045) (<i>p</i>â€‰=â€‰.79) and grade IV Î²â€‰=â€‰0.0025 (95% CI, -0.0075 to 0.0124). However, a trend suggestive of increased recurrence was observed in patient populations with a higher proportion of grade IV disease.\n\n**Conclusion:** ALTA sclerotherapy may be a safe and viable alternative for patients with hemorrhoidal disease. Long-term follow-up and high-quality randomized controlled trials will help define the place of ALTA sclerotherapy in the armamentarium of treatment of hemorrhoids.", "abstract_zh": "**èƒŒæ™¯ï¼š** æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¯„ä¼°ç¡«é…¸é“é’¾å’Œå•å®é…¸ (ALTA) ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬çš„ç ”ç©¶æ˜¯æ ¹æ® 2020 å¹´ PRISMA å£°æ˜ï¼ˆç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼‰è¿›è¡Œçš„ã€‚ä¸»è¦ç»ˆç‚¹åŒ…æ‹¬æ€»ä½“å¤å‘å’Œå¤å‘ç±»å‹ï¼Œæ¬¡è¦ç»ˆç‚¹åŒ…æ‹¬æœ¯åå¹¶å‘ç—‡ã€å†æ¬¡å¹²é¢„ã€æ˜¯å¦å­˜åœ¨ç›´è‚ æºƒç–¡ã€ç›´è‚ ç‹­çª„ã€æ’ä¾¿å¼‚å¸¸å’Œè‚›å‘¨è„“è‚¿ã€‚è¿˜è¿›è¡Œäº†Î±å›å½’åˆ†æï¼Œå…¶ä¸­æ‚£æœ‰IIçº§ã€IIIçº§å’ŒIVçº§ç—”ç–®ç–¾ç—…çš„æ‚£è€…çš„ç™¾åˆ†æ¯”è¢«ç”¨ä½œåå˜é‡ã€‚\n\n**ç»“æœï¼š** æ¶‰åŠ 4249 åæ‚£è€…çš„ 12 é¡¹ç ”ç©¶ç¬¦åˆæ‰€æœ‰çº³å…¥æ ‡å‡†å¹¶æœ€ç»ˆè¢«çº³å…¥ã€‚éšè®¿ç»“æŸæ—¶æ€»ä½“å¤å‘å’Œå¹¶å‘ç—‡çš„ç²—ç•¥ä¼°è®¡å’Œæ±‡æ€»ä¼°è®¡åˆ†åˆ«ä¸º 10% (95% CI, 6.52%-14.08%) å’Œ 5.20% (95% CI, 2.59%-8.52%)ã€‚å›å½’åˆ†ææ˜¾ç¤ºå¤å‘ç‡ä¸ç—”ç–®ç–¾ç—…åˆ†çº§ä¹‹é—´æ— ç›¸å…³æ€§ï¼ŒII çº§ï¼ŒÎ²= -0.0012ï¼ˆ95% CIï¼Œ-0.0074 è‡³ 0.0049ï¼‰ï¼ˆ<i>p</i>â€‰=â€‰.64ï¼‰ï¼ŒIII çº§ Î²= -0.0006ï¼ˆ95% CIï¼Œ-0.0056 è‡³ 0.0045ï¼‰ (<i>p</i>â€‰=â€‰.79) å’Œ IV çº§ Î²â€‰=â€‰0.0025 (95% CIï¼Œ-0.0075 è‡³ 0.0124)ã€‚ç„¶è€Œï¼Œåœ¨ IV çº§ç–¾ç—…æ¯”ä¾‹è¾ƒé«˜çš„æ‚£è€…ç¾¤ä½“ä¸­è§‚å¯Ÿåˆ°äº†å¤å‘ç‡å¢åŠ çš„è¶‹åŠ¿ã€‚\n\n**ç»“è®ºï¼š** å¯¹äºç—”ç–®æ‚£è€…æ¥è¯´ï¼ŒALTA ç¡¬åŒ–ç–—æ³•å¯èƒ½æ˜¯ä¸€ç§å®‰å…¨å¯è¡Œçš„æ›¿ä»£æ–¹æ¡ˆã€‚é•¿æœŸéšè®¿å’Œé«˜è´¨é‡éšæœºå¯¹ç…§è¯•éªŒå°†æœ‰åŠ©äºç¡®å®š ALTA ç¡¬åŒ–ç–—æ³•åœ¨ç—”ç–®æ²»ç–—è®¾å¤‡ä¸­çš„åœ°ä½ã€‚", "keywords_zh": "ALTAï¼Œç¡«é…¸é“é’¾ï¼Œç—”ç–®ç–¾ç—…ï¼Œç—”ç–®ï¼Œç¡¬åŒ–ç–—æ³•", "keywords_en": "ALTA, aluminum potassium sulfate, hemorrhoidal disease, hemorrhoids, sclerotherapy", "link": "https://pubmed.ncbi.nlm.nih.gov/38428446/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Fri, 01 Mar 2024"}, {"id": "38223244", "title_en": "Effectiveness and safety of darvadstrocel in patients with complex perianal fistulizing Crohn's disease: a systematic review", "title_zh": "darvadstrocel å¯¹å¤æ‚è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…æ‚£è€…çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Konstantinos H Katsanos", "abstract_en": "**Background:** Managing complex perianal fistulizing Crohn's disease (CD) remains challenging, despite current medical and surgical treatment approaches. Darvadstrocel, a therapy utilizing adipose-derived stem cells, shows promise in promoting tissue regeneration and healing, offering a novel and effective treatment for fistula management.\n\n**Method:** A systematic literature search was conducted on PubMed and Scopus to identify studies involving patients with complex perianal fistulizing CD treated with darvadstrocel.\n\n**Results:** In total, 2 randomized controlled trials (RCT), 5 observational studies with retrospective data collection and 2 observational studies with prospective design were included in the final review. Data from the European ADMIRE-CD RCT demonstrated that darvadstrocel is superior to placebo in terms of clinical and imaging improvement over both the short and long term. These findings align with the prospective studies analyzed in this systematic review. The rate of treatment-emergent adverse events in the ADMIRE-CD trial's RCTs was similar in both the darvadstrocel and control groups, with perianal abscess being the most common adverse event up to 52 weeks after drug administration. Retrospective studies indicated no side-effects beyond 52 weeks.\n\n**Conclusions:** Darvadstrocel appears to be a new, potentially effective and safe treatment option for the management of complex perianal fistulas. However, more randomized clinical trials are needed to evaluate the efficacy and safety profile of the drug.", "abstract_zh": "**èƒŒæ™¯ï¼š** å°½ç®¡ç›®å‰æœ‰è¯ç‰©å’Œæ‰‹æœ¯æ²»ç–—æ–¹æ³•ï¼Œä½†æ²»ç–—å¤æ‚çš„è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (CD) ä»ç„¶å…·æœ‰æŒ‘æˆ˜æ€§ã€‚ Darvadstrocel æ˜¯ä¸€ç§åˆ©ç”¨è„‚è‚ªå¹²ç»†èƒçš„ç–—æ³•ï¼Œåœ¨ä¿ƒè¿›ç»„ç»‡å†ç”Ÿå’Œæ„ˆåˆæ–¹é¢æ˜¾ç¤ºå‡ºå‰æ™¯ï¼Œä¸ºç˜˜ç®¡æ²»ç–—æä¾›äº†ä¸€ç§æ–°é¢–æœ‰æ•ˆçš„æ²»ç–—æ–¹æ³•ã€‚\n\n**Methodï¼š** åœ¨ PubMed å’Œ Scopus ä¸Šè¿›è¡Œäº†ç³»ç»Ÿæ–‡çŒ®æ£€ç´¢ï¼Œä»¥ç¡®å®šæ¶‰åŠæ¥å— darvadstrocel æ²»ç–—çš„å¤æ‚è‚›å‘¨ç˜˜ç®¡æ€§ CD æ‚£è€…çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆè¯„ä»·æ€»å…±çº³å…¥äº† 2 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€5 é¡¹å›é¡¾æ€§æ•°æ®æ”¶é›†è§‚å¯Ÿæ€§ç ”ç©¶å’Œ 2 é¡¹å‰ç»æ€§è®¾è®¡è§‚å¯Ÿæ€§ç ”ç©¶ã€‚æ¥è‡ªæ¬§æ´² ADMIRE-CD RCT çš„æ•°æ®è¡¨æ˜ï¼Œdarvadstrocel åœ¨çŸ­æœŸå’Œé•¿æœŸçš„ä¸´åºŠå’Œå½±åƒå­¦æ”¹å–„æ–¹é¢å‡ä¼˜äºå®‰æ…°å‰‚ã€‚è¿™äº›å‘ç°ä¸æœ¬ç³»ç»Ÿç»¼è¿°ä¸­åˆ†æçš„å‰ç»æ€§ç ”ç©¶ä¸€è‡´ã€‚åœ¨ ADMIRE-CD è¯•éªŒçš„éšæœºå¯¹ç…§è¯•éªŒä¸­ï¼Œdarvadstrocel ç»„å’Œå¯¹ç…§ç»„ä¸­æ²»ç–—å¼•èµ·çš„ä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡ç›¸ä¼¼ï¼Œå…¶ä¸­è‚›å‘¨è„“è‚¿æ˜¯ç»™è¯å 52 å‘¨å†…æœ€å¸¸è§çš„ä¸è‰¯äº‹ä»¶ã€‚å›é¡¾æ€§ç ”ç©¶è¡¨æ˜è¶…è¿‡ 52 å‘¨æ²¡æœ‰å‰¯ä½œç”¨ã€‚\n\n**ç»“è®ºï¼š** Darvadstrocel ä¼¼ä¹æ˜¯æ²»ç–—å¤æ‚è‚›å‘¨ç˜˜çš„ä¸€ç§æ–°çš„ã€æ½œåœ¨æœ‰æ•ˆä¸”å®‰å…¨çš„æ²»ç–—é€‰æ‹©ã€‚ç„¶è€Œï¼Œéœ€è¦æ›´å¤šçš„éšæœºä¸´åºŠè¯•éªŒæ¥è¯„ä¼°è¯¥è¯ç‰©çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§ã€‚", "keywords_zh": "ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…ã€è„‚è‚ªå¹²ç»†èƒã€darvadstrocelã€æ²»ç–—", "keywords_en": "Fistulizing Crohnâ€™s disease, adipose-derived stem-cells, darvadstrocel, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/38223244/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 15 Jan 2024"}, {"id": "37545826", "title_en": "Hidradenitis suppurativa and squamous cell carcinoma: a systematic review of the literature", "title_zh": "åŒ–è„“æ€§æ±—è…ºç‚å’Œé³çŠ¶ç»†èƒç™Œï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Beata Bergler-Czop", "abstract_en": "Hidradenitis suppurativa (HS) is a chronic disease which is often recurrent and occurs as abscesses of the apocrine gland. The most common locations of HS are gluteal/perianal, axillary or inguinal. It is reasonable to assume that squamous cell carcinoma may arise from HS. As researchers in the field of dermatology, HS surgery and conventional surgical oncology, we studied whether there is any correlation between HS and neoplasms. Evidence shows a correlation between HS and squamous cell carcinoma. The aim of the study was to find literature about HS and SCC and analyse potential risk factors. This is a systemic review concerning squamous cell carcinoma and hidradenitis suppurativa.", "abstract_zh": "åŒ–è„“æ€§æ±—è…ºç‚ï¼ˆHSï¼‰æ˜¯ä¸€ç§æ…¢æ€§ç–¾ç—…ï¼Œç»å¸¸å¤å‘ï¼Œå¹¶ä»¥é¡¶æµ†è…ºè„“è‚¿çš„å½¢å¼å‡ºç°ã€‚ HS æœ€å¸¸è§çš„ä½ç½®æ˜¯è‡€è‚Œ/è‚›å‘¨ã€è…‹çªæˆ–è…¹è‚¡æ²Ÿã€‚é³çŠ¶ç»†èƒç™Œå¯èƒ½ç”± HS å¼•èµ·çš„å‡è®¾æ˜¯åˆç†çš„ã€‚ä½œä¸ºçš®è‚¤ç§‘ã€çƒ­å°„ç—…å¤–ç§‘å’Œä¼ ç»Ÿè‚¿ç˜¤å¤–ç§‘é¢†åŸŸçš„ç ”ç©¶äººå‘˜ï¼Œæˆ‘ä»¬ç ”ç©¶äº†çƒ­å°„ç—…å’Œè‚¿ç˜¤ä¹‹é—´æ˜¯å¦å­˜åœ¨ç›¸å…³æ€§ã€‚æœ‰è¯æ®è¡¨æ˜ HS ä¸é³çŠ¶ç»†èƒç™Œä¹‹é—´å­˜åœ¨ç›¸å…³æ€§ã€‚è¯¥ç ”ç©¶çš„ç›®çš„æ˜¯æŸ¥æ‰¾æœ‰å…³ HS å’Œ SCC çš„æ–‡çŒ®å¹¶åˆ†ææ½œåœ¨çš„å±é™©å› ç´ ã€‚è¿™æ˜¯å…³äºé³çŠ¶ç»†èƒç™Œå’ŒåŒ–è„“æ€§æ±—è…ºç‚çš„ç³»ç»Ÿç»¼è¿°ã€‚", "keywords_zh": "åŒ–è„“æ€§æ±—è…ºç‚ï¼Œé³çŠ¶ç»†èƒç™Œï¼Œæ‰‹æœ¯æ²»ç–—", "keywords_en": "hidradenitis suppurativa, squamous cell carcinoma, surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/37545826/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 07 Aug 2023"}, {"id": "37023788", "title_en": "A Systematic Review and Meta-Analysis of Comparing Drainage Alone versus Drainage with Primary Fistula Treatment for the Perianal Abscess in Children", "title_zh": "å•ç‹¬å¼•æµä¸å¼•æµè”åˆç˜˜ç®¡æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Chen Wang", "abstract_en": "This systematic review and meta-analysis of nonrandomized studies (NRSs) aimed to evaluate the clinical efficacy and safety of two types of surgical interventions (respectively drainage alone and drainage with primary fistula treatment) for perianal abscesses (PAs) in children. Studies from 1992 to July 2022 were searched in 10 electronic databases. All relevant NRSs with available data which compared surgical drainage with or without primary fistula treatment were included. Patients with underlying diseases which led to abscess formation were excluded. The Newcastle-Ottawa Scale was used to assess the risk of bias and quality of the included studies. The outcomes were the healing rate, fistula formation rate, fecal incontinence, and wound healing duration. A total of 16 articles with 1,262 patients were considered suitable for the final meta-analysis. Primary fistula treatment was associated with a significantly higher healing rate when compared with incision and drainage alone (odds ratio [OR]: 5.76, 95% confidence interval [CI]: 4.04-8.22). This aggressive procedure for PA resulted in an 86% reduction in the fistula formation rate (OR: 0.14, 95% CI: 0.06-0.32). Limited data showed patients who underwent primary fistula treatment have a minor effect on postoperative fecal incontinence. Primary fistula treatment demonstrates a better clinical efficacy in promoting the healing rate and decreasing the formation of fistulas in PAs in children. The available evidence for a minor impact on anal function after this intervention is less strong.", "abstract_zh": "è¿™é¡¹ééšæœºç ”ç©¶ï¼ˆNRSï¼‰çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°ä¸¤ç§ç±»å‹çš„æ‰‹æœ¯å¹²é¢„ï¼ˆåˆ†åˆ«å•ç‹¬å¼•æµå’Œå¼•æµè”åˆåˆæ¬¡ç˜˜ç®¡æ²»ç–—ï¼‰æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰çš„ä¸´åºŠç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚åœ¨ 10 ä¸ªç”µå­æ•°æ®åº“ä¸­æ£€ç´¢äº† 1992 å¹´è‡³ 2022 å¹´ 7 æœˆçš„ç ”ç©¶ã€‚åŒ…æ‹¬æ‰€æœ‰å…·æœ‰å¯ç”¨æ•°æ®çš„ç›¸å…³ NRSï¼Œè¿™äº› NRS æ¯”è¾ƒäº†æ‰‹æœ¯å¼•æµä¸æˆ–ä¸è¿›è¡Œåˆæ¬¡ç˜˜ç®¡æ²»ç–—çš„æƒ…å†µã€‚æ’é™¤æ‚£æœ‰å¯¼è‡´è„“è‚¿å½¢æˆçš„åŸºç¡€ç–¾ç—…çš„æ‚£è€…ã€‚çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ç”¨äºè¯„ä¼°çº³å…¥ç ”ç©¶çš„åå€šé£é™©å’Œè´¨é‡ã€‚ç»“æœæ˜¯æ„ˆåˆç‡ã€ç˜˜ç®¡å½¢æˆç‡ã€å¤§ä¾¿å¤±ç¦å’Œä¼¤å£æ„ˆåˆæŒç»­æ—¶é—´ã€‚å…±æœ‰ 16 ç¯‡æ–‡ç« ã€1,262 åæ‚£è€…è¢«è®¤ä¸ºé€‚åˆæœ€ç»ˆçš„èŸèƒåˆ†æã€‚ä¸å•ç‹¬åˆ‡å¼€å¼•æµç›¸æ¯”ï¼ŒåŸå‘æ€§ç˜˜ç®¡æ²»ç–—å…·æœ‰æ˜¾ç€æ›´é«˜çš„æ²»æ„ˆç‡ï¼ˆæ¯”å€¼æ¯” [OR]ï¼š5.76ï¼Œ95% ç½®ä¿¡åŒºé—´ [CI]ï¼š4.04-8.22ï¼‰ã€‚è¿™ç§ç§¯æçš„ PA æ‰‹æœ¯ä½¿ç˜˜ç®¡å½¢æˆç‡é™ä½äº† 86%ï¼ˆORï¼š0.14ï¼Œ95% CIï¼š0.06-0.32ï¼‰ã€‚æœ‰é™çš„æ•°æ®æ˜¾ç¤ºï¼Œæ¥å—åŸå‘æ€§ç˜˜ç®¡æ²»ç–—çš„æ‚£è€…å¯¹æœ¯åå¤§ä¾¿å¤±ç¦çš„å½±å“è¾ƒå°ã€‚åŸå‘æ€§ç˜˜ç®¡æ²»ç–—åœ¨ä¿ƒè¿›å„¿ç«¥PAsçš„æ„ˆåˆç‡å’Œå‡å°‘ç˜˜ç®¡å½¢æˆæ–¹é¢æ˜¾ç¤ºå‡ºæ›´å¥½çš„ä¸´åºŠç–—æ•ˆã€‚ç°æœ‰è¯æ®è¡¨æ˜è¿™ç§å¹²é¢„åå¯¹è‚›é—¨åŠŸèƒ½æœ‰è½»å¾®å½±å“ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/37023788/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 06 Apr 2023"}, {"id": "36894443", "title_en": "The Optimal Primary Treatment for Pediatric Perianal Abscess and Anal Fistula: A Systemic Review and Meta-Analysis", "title_zh": "å°å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æœ€ä½³åˆæ­¥æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Hou-Chuan Chen", "abstract_en": "**Background:** Perianal abscesses and anal fistulas are common. The principle of intention-to-treat has not been considered in previous systemic reviews. Thus, the comparison between primary and post-recurrence management was confused, and the recommendation of primary treatment is obscure. The current study aims to identify the optimal initial treatment for pediatric patients.\n\n**Methods:** Using PRISMA guidelines, studies were identified from MEDLINE, EMBASE, PubMed, Cochrane Library, and Google Scholar without any language or study design restriction. The inclusion criteria include original articles or articles with original data, studies of management for a perianal abscess with or without anal fistula, and patient age of <18 years. Patients with local malignancy, Crohn's disease, or other underlying predisposing conditions were excluded. Studies without analyzing recurrence, case series of <5, and irrelevant articles were excluded in the screening stage. Of the 124 screened articles, 14 articles had no full texts or detailed information. Articles written in a language other than English or Mandarin were translated by Google Translation first and confirmed with native speakers. After the eligibility process, studies that compared identified primary managements were then included in the qualitative synthesis.\n\n**Results:** Thirty-one studies involving 2507 pediatric patients met the inclusion criteria. The study design consisted of two prospective case series of 47 patients and retrospective cohort studies. No randomized control trials were identified. Meta-analyses for recurrence after initial management were performed with a random-effects model. Conservative treatment and drainage revealed no difference (Odds ratio [OR], 1.222; 95% Confidential interval [CI]: 0.615-2.427, pÂ =Â 0.567). Conservative management had a higher risk of recurrence than surgery without statistical significance (OR 0.278, 95% CI: 0.109-0.707, pÂ =Â 0.007). Compared with incision/drainage, surgery can prevent recurrence remarkably (OR 4.360, 95% CI: 1.761-10.792, pÂ =Â 0.001). Subgroup analysis of different approaches within conservative treatment and operation was not performed for lacking information.\n\n**Conclusion:** Strong recommendations cannot be made due to the lack of prospective or randomized controlled studies. However, the current study based on real primary management supports initial surgical intervention for pediatric patients with perianal abscesses and anal fistula to prevent recurrence.\n\n**Level Of Evidence:** Type of study: Systemic review; Evidence level: Level II.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜å¾ˆå¸¸è§ã€‚ä»¥å¾€çš„ç³»ç»Ÿè¯„ä»·å¹¶æœªè€ƒè™‘æ„å‘æ²»ç–—åŸåˆ™ã€‚å› æ­¤ï¼Œåˆçº§æ²»ç–—å’Œå¤å‘åæ²»ç–—ä¹‹é—´çš„æ¯”è¾ƒæ˜¯æ··ä¹±çš„ï¼Œåˆçº§æ²»ç–—çš„å»ºè®®ä¹Ÿå«ç³Šä¸æ¸…ã€‚ç›®å‰çš„ç ”ç©¶æ—¨åœ¨ç¡®å®šå„¿ç§‘æ‚£è€…çš„æœ€ä½³åˆå§‹æ²»ç–—ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨ PRISMA æŒ‡å—ï¼Œä» MEDLINEã€EMBASEã€PubMedã€Cochrane å›¾ä¹¦é¦†å’Œ Google Scholar ä¸­è¯†åˆ«ç ”ç©¶ï¼Œæ²¡æœ‰ä»»ä½•è¯­è¨€æˆ–ç ”ç©¶è®¾è®¡é™åˆ¶ã€‚çº³å…¥æ ‡å‡†åŒ…æ‹¬åŸåˆ›æ–‡ç« æˆ–å¸¦æœ‰åŸå§‹æ•°æ®çš„æ–‡ç« ã€ä¼´æˆ–ä¸ä¼´è‚›ç˜˜çš„è‚›å‘¨è„“è‚¿çš„æ²»ç–—ç ”ç©¶ä»¥åŠæ‚£è€…å¹´é¾„<18å²ã€‚æ‚£æœ‰å±€éƒ¨æ¶æ€§è‚¿ç˜¤ã€å…‹ç½—æ©ç—…æˆ–å…¶ä»–æ½œåœ¨è¯±å‘å› ç´ çš„æ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æœªåˆ†æå¤å‘çš„ç ”ç©¶ã€ç—…ä¾‹ç³»åˆ—<5å’Œä¸ç›¸å…³çš„æ–‡ç« åœ¨ç­›é€‰é˜¶æ®µè¢«æ’é™¤ã€‚åœ¨ç­›é€‰çš„ 124 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 14 ç¯‡æ–‡ç« æ²¡æœ‰å…¨æ–‡æˆ–è¯¦ç»†ä¿¡æ¯ã€‚ç”¨è‹±è¯­æˆ–æ™®é€šè¯ä»¥å¤–çš„è¯­è¨€æ’°å†™çš„æ–‡ç« é¦–å…ˆé€šè¿‡è°·æ­Œç¿»è¯‘è¿›è¡Œç¿»è¯‘ï¼Œå¹¶ä¸æ¯è¯­äººå£«ç¡®è®¤ã€‚èµ„æ ¼å®¡æŸ¥ç»“æŸåï¼Œå¯¹å·²ç¡®å®šçš„ä¸»è¦ç®¡ç†æªæ–½è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶éšåè¢«çº³å…¥å®šæ€§ç»¼åˆã€‚\n\n**ç»“æœï¼š** æ¶‰åŠ 2507 åå„¿ç§‘æ‚£è€…çš„ 31 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ç ”ç©¶è®¾è®¡åŒ…æ‹¬ä¸¤ä¸ªåŒ…å« 47 åæ‚£è€…çš„å‰ç»æ€§ç—…ä¾‹ç³»åˆ—å’Œå›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹å¯¹åˆå§‹æ²»ç–—åçš„å¤å‘è¿›è¡ŒèŸèƒåˆ†æã€‚ä¿å®ˆæ²»ç–—å’Œå¼•æµæ˜¾ç¤ºæ²¡æœ‰å·®å¼‚ï¼ˆä¼˜åŠ¿æ¯” [OR]ï¼Œ1.222ï¼›95% ç½®ä¿¡åŒºé—´ [CI]ï¼š0.615-2.427ï¼Œp = 0.567ï¼‰ã€‚ä¿å®ˆæ²»ç–—çš„å¤å‘é£é™©é«˜äºæ‰‹æœ¯ï¼Œä½†æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆOR 0.278ï¼Œ95% CIï¼š0.109-0.707ï¼Œp = 0.007ï¼‰ã€‚ä¸åˆ‡å¼€/å¼•æµç›¸æ¯”ï¼Œæ‰‹æœ¯å¯ä»¥æ˜¾ç€é¢„é˜²å¤å‘ï¼ˆOR 4.360ï¼Œ95% CIï¼š1.761-10.792ï¼Œp = 0.001ï¼‰ã€‚ç”±äºç¼ºä¹ä¿¡æ¯ï¼Œæœªå¯¹ä¿å®ˆæ²»ç–—å’Œæ‰‹æœ¯ä¸­çš„ä¸åŒæ–¹æ³•è¿›è¡Œäºšç»„åˆ†æã€‚\n\n**ç»“è®ºï¼š** ç”±äºç¼ºä¹å‰ç»æ€§æˆ–éšæœºå¯¹ç…§ç ”ç©¶ï¼Œæ— æ³•æå‡ºå¼ºçƒˆå»ºè®®ã€‚ç„¶è€Œï¼Œç›®å‰åŸºäºçœŸå®åˆçº§ç®¡ç†çš„ç ”ç©¶æ”¯æŒå¯¹è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„å„¿ç§‘æ‚£è€…è¿›è¡Œåˆæ­¥æ‰‹æœ¯å¹²é¢„ä»¥é¢„é˜²å¤å‘ã€‚\n\n**Level of evidenceï¼š** ç ”ç©¶ç±»å‹ï¼šç³»ç»Ÿè¯„ä»·ï¼›è¯æ®çº§åˆ«ï¼šIIçº§ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œå„¿ç§‘ï¼Œè‚›å‘¨è„“è‚¿ï¼Œåˆçº§æ²»ç–—", "keywords_en": "Anal fistula, Pediatric, Perianal abscess, Primary management", "link": "https://pubmed.ncbi.nlm.nih.gov/36894443/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 09 Mar 2023"}, {"id": "36794974", "title_en": "Mesenchymal Stem Cells Versus Placebo for Perianal Fistulizing Crohn's Disease: A Systemic Review and Meta-Analysis", "title_zh": "é—´å……è´¨å¹²ç»†èƒä¸å®‰æ…°å‰‚æ²»ç–—è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Minhao Yu", "abstract_en": "**Background:** Mesenchymal stem cells (MSCs)-based therapy for perianal fistulizing Crohn's disease (pfCD) has been extensively studies in the past decade. Its efficacy and safety had been preliminarily confirmed in some phase 2 or phase 3 clinical trials. This meta-analysis is performed to evaluate the efficacy and safety of MSCs-based therapy for pfCD.\n\n**Methods:** Electronic databases (Pubmed, Cochrane Library, Embase) were searched for studies that reported the efficacy and safety of MSCs. And RevMan were used to assess the efficacy and safety.\n\n**Results:** After screening, 5 randomized controlled trials (RCTs) were included in this meta-analysis. RevMan 5.4 for meta-analysis showed that: [Efficacy] Patients had definite remission after MSCs treatment, with an odds ratio (OR) of 2.06 (<i>P</i> < .0001, 95%CI 1.46, 2.89) vs controls. [Safety] The incidence of the most frequently reported TEAEs (treatment-emergent adverse events, TEAEs), perianal abscess and proctalgia, did not significantly increase due to the use of MSCs, with an OR of 1.07 in perianal abscess (<i>P</i> = .87, 95%CI 0.67, 1.72) vs controls, and an OR of 1.10 in proctalgia (<i>P</i> = .47, 95%CI 0.63, 1.92) vs controls.\n\n**Conclusions:** MSCs seem to be an effective and safe therapy for pfCD. MSCs based therapy has the potential to be used in combination with traditional therapies.", "abstract_zh": "**èƒŒæ™¯ï¼š** åœ¨è¿‡å»çš„åå¹´ä¸­ï¼ŒåŸºäºé—´å……è´¨å¹²ç»†èƒï¼ˆMSCï¼‰çš„è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ï¼ˆpfCDï¼‰ç–—æ³•å¾—åˆ°äº†å¹¿æ³›çš„ç ”ç©¶ã€‚å…¶æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§å·²åœ¨ä¸€äº›2æœŸæˆ–3æœŸä¸´åºŠè¯•éªŒä¸­å¾—åˆ°åˆæ­¥è¯å®ã€‚è¿›è¡Œè¿™é¡¹èŸèƒåˆ†ææ˜¯ä¸ºäº†è¯„ä¼°åŸºäº MSC çš„ pfCD ç–—æ³•çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ç”µå­æ•°æ®åº“ï¼ˆPubmedã€Cochrane Libraryã€Embaseï¼‰ä¸­æ£€ç´¢äº†æŠ¥å‘Š MSC åŠŸæ•ˆå’Œå®‰å…¨æ€§çš„ç ”ç©¶ã€‚å¹¶ç”¨RevManè¯„ä¼°ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** ç­›é€‰åï¼Œ5 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT) çº³å…¥æœ¬èŸèƒåˆ†æã€‚ RevMan 5.4èŸèƒåˆ†ææ˜¾ç¤ºï¼šã€ç–—æ•ˆã€‘MSCsæ²»ç–—åæ‚£è€…è·å¾—æ˜ç¡®ç¼“è§£ï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œä¼˜åŠ¿æ¯”ï¼ˆORï¼‰ä¸º2.06ï¼ˆ<i>P</i> < .0001ï¼Œ95%CI 1.46ï¼Œ2.89ï¼‰ã€‚ [å®‰å…¨æ€§] æœ€å¸¸æŠ¥å‘Šçš„ TEAEï¼ˆæ²»ç–—å¼•èµ·çš„ä¸è‰¯äº‹ä»¶ï¼ŒTEAEï¼‰ã€è‚›å‘¨è„“è‚¿å’Œç›´è‚ ç—›çš„å‘ç”Ÿç‡å¹¶æœªå› ä½¿ç”¨ MSC è€Œæ˜¾ç€å¢åŠ ï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œè‚›å‘¨è„“è‚¿çš„ OR ä¸º 1.07ï¼ˆ<i>P</i> = .87, 95%CI 0.67, 1.72ï¼‰ï¼Œç›´è‚ ç—›çš„ OR ä¸º 1.10 (<i>P</i> = .47, 95%CI 0.63, 1.92) ä¸å¯¹ç…§ç»„ç›¸æ¯”ã€‚\n\n**ç»“è®ºï¼š** MSC ä¼¼ä¹æ˜¯æ²»ç–— pfCD çš„æœ‰æ•ˆä¸”å®‰å…¨çš„ç–—æ³•ã€‚åŸºäºé—´å……è´¨å¹²ç»†èƒçš„ç–—æ³•æœ‰å¯èƒ½ä¸ä¼ ç»Ÿç–—æ³•ç»“åˆä½¿ç”¨ã€‚", "keywords_zh": "é—´å……è´¨å¹²ç»†èƒï¼ŒèŸèƒåˆ†æï¼Œè‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "mesenchymal stem cells, meta-analysis, perianal fistulizing Crohnâ€™s disease", "link": "https://pubmed.ncbi.nlm.nih.gov/36794974/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 16 Feb 2023"}, {"id": "34792604", "title_en": "Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts", "title_zh": "è‚›å‘¨å…‹ç½—æ©ç—…çš„æµè¡Œç—…å­¦å’Œè‡ªç„¶å²ï¼šåŸºäºäººç¾¤çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Siddharth Singh", "abstract_en": "**Background And Aims:** Perianal Crohn's disease (pCD) is a potentially severe phenotype of CD. We conducted a systematic review with meta-analysis to estimate cumulative incidence, risk factors, and outcomes of pCD in population-based cohort studies.\n\n**Methods:** Through a systematic literature review through March 1, 2021, we identified population-based inception cohort studies reporting cumulative incidence of perianal disease (primarily abscess and/or fistula) in patients with CD. We estimated the cumulative incidence of pCD at presentation and 1-, 5-, and 10-year follow-up, and risk factors for perianal disease and outcomes including risk of major (bowel resection, proctectomy, ostomy) and minor perianal (incision and drainage, seton placement, etc.) surgery.\n\n**Results:** In 12 population-based studies, prevalence of pCD was 18.7% (95% confidence interval [CI], 12.5%-27.0%) with 1-, 5-, and 10-year risk of perianal disease being 14.3% (95% CI, 7.9%-24.6%), 17.6% (95% CI, 11.3%-26.5%), and 18.9% (95% CI, 15.0%-23.4%), respectively. Approximately 11.5% of patients (95% CI, 6.7%-19.0%) had perianal disease at or before CD diagnosis. Colonic disease location and rectal involvement were associated with higher risk of pCD. Overall, 63.3% of patients (95% CI, 53.3-72.3) required minor perianal surgery and 6.4% of patients (95% CI, 1.8%-20.6%) required major abdominal surgery for pCD. Use of biologic therapy for pCD is common and has steadily increased throughout the years.\n\n**Conclusions:** Approximately 1 in 5 patients with CD develops perianal disease within 10 years of CD diagnosis, including 11.5% who have perianal disease at presentation. Approximately two-thirds of patients require perianal surgery, with a smaller fraction requiring major abdominal surgery.", "abstract_zh": "**Background and aimsï¼š** è‚›å‘¨å…‹ç½—æ©ç—… (pCD) æ˜¯ä¸€ç§æ½œåœ¨çš„ä¸¥é‡å…‹ç½—æ©ç—…è¡¨å‹ã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥ä¼°è®¡åŸºäºäººç¾¤çš„é˜Ÿåˆ—ç ”ç©¶ä¸­ pCD çš„ç´¯ç§¯å‘ç—…ç‡ã€å±é™©å› ç´ å’Œç»“æœã€‚\n\n**æ–¹æ³•ï¼š** é€šè¿‡æˆªè‡³ 2021 å¹´ 3 æœˆ 1 æ—¥çš„ç³»ç»Ÿæ–‡çŒ®å›é¡¾ï¼Œæˆ‘ä»¬ç¡®å®šäº†åŸºäºäººç¾¤çš„åˆå§‹é˜Ÿåˆ—ç ”ç©¶ï¼ŒæŠ¥å‘Šäº† CD æ‚£è€…è‚›å‘¨ç–¾ç—…ï¼ˆä¸»è¦æ˜¯è„“è‚¿å’Œ/æˆ–ç˜˜ç®¡ï¼‰çš„ç´¯ç§¯å‘ç—…ç‡ã€‚æˆ‘ä»¬ä¼°è®¡äº†å°±è¯Šæ—¶ä»¥åŠ 1 å¹´ã€5 å¹´å’Œ 10 å¹´éšè®¿æ—¶çš„ pCD ç´¯ç§¯å‘ç”Ÿç‡ï¼Œä»¥åŠè‚›å‘¨ç–¾ç—…å’Œç»“å±€çš„å±é™©å› ç´ ï¼ŒåŒ…æ‹¬å¤§æ‰‹æœ¯ï¼ˆè‚ åˆ‡é™¤ã€ç›´è‚ åˆ‡é™¤æœ¯ã€é€ å£æœ¯ï¼‰å’Œå°è‚›å‘¨æ‰‹æœ¯ï¼ˆåˆ‡å¼€å¼•æµã€æŒ‚çº¿æ”¾ç½®ç­‰ï¼‰çš„é£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨ 12 é¡¹åŸºäºäººç¾¤çš„ç ”ç©¶ä¸­ï¼ŒpCD çš„æ‚£ç—…ç‡ä¸º 18.7%ï¼ˆ95% ç½®ä¿¡åŒºé—´ [CI]ï¼Œ12.5%-27.0%ï¼‰ï¼Œè‚›å‘¨ç–¾ç—…çš„ 1 å¹´ã€5 å¹´å’Œ 10 å¹´é£é™©åˆ†åˆ«ä¸º 14.3%ï¼ˆ95% CIï¼Œ7.9%-24.6%ï¼‰ã€17.6%ï¼ˆ95% CIï¼Œ11.3%-26.5%ï¼‰å’Œåˆ†åˆ«ä¸º 18.9%ï¼ˆ95% CIï¼Œ15.0%-23.4%ï¼‰ã€‚å¤§çº¦ 11.5% çš„æ‚£è€… (95% CI, 6.7%-19.0%) åœ¨ CD è¯Šæ–­æ—¶æˆ–ä¹‹å‰æ‚£æœ‰è‚›å‘¨ç–¾ç—…ã€‚ç»“è‚ ç–¾ç—…éƒ¨ä½å’Œç›´è‚ å—ç´¯ä¸è¾ƒé«˜çš„ pCD é£é™©ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œ63.3% çš„æ‚£è€… (95% CI, 53.3-72.3) éœ€è¦è¿›è¡Œå°å‹è‚›å‘¨æ‰‹æœ¯ï¼Œ6.4% çš„æ‚£è€… (95% CI, 1.8%-20.6%) éœ€è¦é’ˆå¯¹ pCD è¿›è¡Œè…¹éƒ¨å¤§æ‰‹æœ¯ã€‚ä½¿ç”¨ç”Ÿç‰©ç–—æ³•æ²»ç–— pCD å¾ˆå¸¸è§ï¼Œå¹¶ä¸”å¤šå¹´æ¥ä¸€ç›´åœ¨ç¨³æ­¥å¢åŠ ã€‚\n\n**ç»“è®ºï¼š** å¤§çº¦äº”åˆ†ä¹‹ä¸€çš„ CD æ‚£è€…åœ¨ CD è¯Šæ–­å 10 å¹´å†…å‡ºç°è‚›å‘¨ç–¾ç—…ï¼Œå…¶ä¸­ 11.5% å°±è¯Šæ—¶æ‚£æœ‰è‚›å‘¨ç–¾ç—…ã€‚å¤§çº¦ä¸‰åˆ†ä¹‹äºŒçš„æ‚£è€…éœ€è¦è¿›è¡Œè‚›å‘¨æ‰‹æœ¯ï¼Œä¸€å°éƒ¨åˆ†æ‚£è€…éœ€è¦è¿›è¡Œè…¹éƒ¨å¤§æ‰‹æœ¯ã€‚", "keywords_zh": "è’™ç‰¹åˆ©å°”åˆ†ç±»ï¼ŒæŠ— TNFï¼Œæµè¡Œç—…å­¦ï¼Œç˜˜ç®¡ï¼Œè‡ªç„¶å²", "keywords_en": "Montreal classification, anti-TNF, epidemiology, fistula, natural history", "link": "https://pubmed.ncbi.nlm.nih.gov/34792604/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 18 Nov 2021"}, {"id": "34792583", "title_en": "Strategies to Distinguish Perianal Fistulas Related to Crohn's Disease From Cryptoglandular Disease: Systematic Review With Meta-Analysis", "title_zh": "åŒºåˆ†ä¸å…‹ç½—æ©ç—…ç›¸å…³çš„è‚›å‘¨ç˜˜å’Œéšè…ºç–¾ç—…çš„ç­–ç•¥ï¼šèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** Management of perianal fistulas differs based on fistula type. We aimed to assess the ability of diagnostic strategies to differentiate between Crohn's disease (CD) and cryptoglandular disease (CGD) in patients with perianal fistulas.\n\n**Methods:** We performed a diagnostic accuracy systematic review and meta-analysis. A systematic search of electronic databases was performed from inception through February 2021 for studies assessing a diagnostic test's ability to distinguish fistula types. We calculated weighted summary estimates with 95% confidence intervals for sensitivity and specificity by bivariate analysis, using fixed effects models when data were available from 2 or more studies. The Quality Assessment of Diagnostic Accuracy Studies tool was used to assess study quality.\n\n**Results:** Twenty-one studies were identified and included clinical symptoms (2 studies; n=154), magnetic resonance imaging (MRI) characteristics (3 studies; n=296), ultrasound characteristics (7 studies; n=1003), video capsule endoscopy (2 studies; n=44), fecal calprotectin (1 study; n=56), and various biomarkers (8 studies; n=440). MRI and ultrasound characteristics had the most robust data. Rectal inflammation, multiple-branched fistula tracts, and abscesses on pelvic MRI and the Crohn's ultrasound fistula sign, fistula debris, and bifurcated fistulas on pelvic ultrasonography had high specificity (range, 80%-95% vs 89%-96%) but poor sensitivity (range, 17%-37% vs 31%-63%), respectively. Fourteen of 21 studies had risk of bias on at least 1 of the Quality Assessment of Diagnostic Accuracy Studies domains.\n\n**Conclusions:** Limited high-quality evidence suggest that imaging characteristics may help discriminate CD from CGD in patients with perianal fistulas. Larger, prospective studies are needed to confirm these findings and to evaluate if combining multiple diagnostic tests can improve diagnostic sensitivity.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜çš„æ²»ç–—æ ¹æ®ç˜˜ç®¡ç±»å‹çš„ä¸åŒè€Œæœ‰æ‰€ä¸åŒã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯è¯„ä¼°è¯Šæ–­ç­–ç•¥åŒºåˆ†è‚›å‘¨ç˜˜æ‚£è€…å…‹ç½—æ©ç—…ï¼ˆCDï¼‰å’Œéšè…ºç—…ï¼ˆCGDï¼‰çš„èƒ½åŠ›ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬è¿›è¡Œäº†è¯Šæ–­å‡†ç¡®æ€§ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ä»ä¸€å¼€å§‹åˆ° 2021 å¹´ 2 æœˆï¼Œæˆ‘ä»¬å¯¹ç”µå­æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæœç´¢ï¼Œä»¥è¯„ä¼°è¯Šæ–­æµ‹è¯•åŒºåˆ†ç˜˜ç®¡ç±»å‹çš„èƒ½åŠ›ã€‚å½“æ•°æ®æ¥è‡ª 2 é¡¹æˆ–æ›´å¤šç ”ç©¶æ—¶ï¼Œæˆ‘ä»¬ä½¿ç”¨å›ºå®šæ•ˆåº”æ¨¡å‹ï¼Œé€šè¿‡åŒå˜é‡åˆ†æè®¡ç®—äº†çµæ•åº¦å’Œç‰¹å¼‚æ€§çš„ 95% ç½®ä¿¡åŒºé—´çš„åŠ æƒæ±‡æ€»ä¼°è®¡å€¼ã€‚è¯Šæ–­å‡†ç¡®æ€§ç ”ç©¶è´¨é‡è¯„ä¼°å·¥å…·ç”¨äºè¯„ä¼°ç ”ç©¶è´¨é‡ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº† 21 é¡¹ç ”ç©¶ï¼ŒåŒ…æ‹¬ä¸´åºŠç—‡çŠ¶ï¼ˆ2 é¡¹ç ”ç©¶ï¼›n=154ï¼‰ã€ç£å…±æŒ¯æˆåƒ (MRI) ç‰¹å¾ï¼ˆ3 é¡¹ç ”ç©¶ï¼›n=296ï¼‰ã€è¶…å£°ç‰¹å¾ï¼ˆ7 é¡¹ç ”ç©¶ï¼›n=1003ï¼‰ã€è§†é¢‘èƒ¶å›Šå†…çª¥é•œæ£€æŸ¥ï¼ˆ2 é¡¹ç ”ç©¶ï¼›n=44ï¼‰ã€ç²ªä¾¿é’™å«è›‹ç™½ï¼ˆ1 é¡¹ç ”ç©¶ï¼›n=56ï¼‰å’Œå„ç§ç”Ÿç‰©æ ‡å¿—ç‰©ï¼ˆ8 é¡¹ç ”ç©¶ï¼›n=440ï¼‰ã€‚ MRI å’Œè¶…å£°ç‰¹å¾æ‹¥æœ‰æœ€å¯é çš„æ•°æ®ã€‚ç›†è…” MRI ä¸Šçš„ç›´è‚ ç‚ç—‡ã€å¤šåˆ†æ”¯ç˜˜ç®¡å’Œè„“è‚¿ä»¥åŠç›†è…”è¶…å£°æ£€æŸ¥ä¸Šçš„å…‹ç½—æ©æ°è¶…å£°ç˜˜å¾ã€ç˜˜ç®¡ç¢ç‰‡å’Œåˆ†å‰ç˜˜çš„ç‰¹å¼‚æ€§è¾ƒé«˜ï¼ˆèŒƒå›´ï¼Œ80%-95% vs 89%-96%ï¼‰ï¼Œä½†æ•æ„Ÿæ€§è¾ƒå·®ï¼ˆèŒƒå›´ï¼Œ17%-37% vs 31%-63%ï¼‰ã€‚ 21 é¡¹ç ”ç©¶ä¸­æœ‰ 14 é¡¹åœ¨è‡³å°‘ 1 ä¸ªè¯Šæ–­å‡†ç¡®æ€§ç ”ç©¶è´¨é‡è¯„ä¼°é¢†åŸŸå­˜åœ¨åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** æœ‰é™çš„é«˜è´¨é‡è¯æ®è¡¨æ˜ï¼Œå½±åƒå­¦ç‰¹å¾å¯èƒ½æœ‰åŠ©äºåŒºåˆ†è‚›å‘¨ç˜˜æ‚£è€…çš„ CD å’Œ CGDã€‚éœ€è¦æ›´å¤§è§„æ¨¡çš„å‰ç»æ€§ç ”ç©¶æ¥è¯å®è¿™äº›å‘ç°ï¼Œå¹¶è¯„ä¼°ç»“åˆå¤šç§è¯Šæ–­æµ‹è¯•æ˜¯å¦å¯ä»¥æé«˜è¯Šæ–­æ•æ„Ÿæ€§ã€‚", "keywords_zh": "éšè…ºç–¾ç—…ã€è‚›ç˜˜ã€è‚›å‘¨ç–¾ç—…", "keywords_en": "cryptoglandular disease, fistula-in-ano, perianal disease", "link": "https://pubmed.ncbi.nlm.nih.gov/34792583/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Thu, 18 Nov 2021"}, {"id": "34628909", "title_en": "A systematic review and meta-analysis of incision and seton drainage in the treatment of high perianal abscess", "title_zh": "åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Lihua Zheng", "abstract_en": "**Background:** Surgery is the clinically preferred treatment for high perianal abscesses. Incision and seton drainage improve the cure rate and reduce recurrence. We aimed to systematically evaluate the clinical effect and safety of incision and seton drainage in the treatment of high perianal abscess.\n\n**Methods:** China Knowledge Network (CNKI), WanFang database, VIP database, PubMed, and Cochrane Library were searched and all relevant Chinese and English language documents until July 2021were retrieved. All records that described randomized clinical trials (RCTs) of incision and seton drainage for the treatment of high perianal abscess were eligible. Documents that met the inclusion criteria were evaluated for bias using the Cochrane Collaboration Risk Evaluation Standard, and Revman5.4 software was used to analyze the data.\n\n**Results:** Fourteen RCTs were included. The results of nine studies showed that the clinical cure rate of the incision-seton group was higher than that of the incision-drainage group (P<0.05). Seven studies showed that the wound healing time of the incision-seton group was shorter than that of the incision-drainage group (P<0.05). Four studies showed that the visual analogue scale (VAS) score of the incision-seton group was lower than that of the incision-drainage group (P<0.05). Five studies showed that the Wexner score of the incision-seton group was lower than that of the incision-drainage group (P<0.05). Six studies showed that the formation rate of anal fistula in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Six studies demonstrated that the recurrence rate of abscess in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Seven studies showed that the incidence of adverse events in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Five studies demonstrated that the length of stay in the incision-seton group was shorter than that of the incision-drainage group (P<0.05).\n\n**Discussion:** The choice of surgical methods in clinical research has always been controversial. The incision-seton method can effectively and safely treat high perianal abscess. However, the results of this meta-analysis still leave some gaps in the evidence. More large-sample, high-quality, and multi-center RCTs are needed.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ‰‹æœ¯æ˜¯ä¸´åºŠä¸Šæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„é¦–é€‰æ²»ç–—æ–¹æ³•ã€‚åˆ‡å¼€æŒ‚çº¿å¼•æµæé«˜æ²»æ„ˆç‡ï¼Œå‡å°‘å¤å‘ã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯ç³»ç»Ÿè¯„ä»·åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„ä¸´åºŠæ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢ä¸­å›½çŸ¥ç½‘ï¼ˆCNKIï¼‰ã€ä¸‡æ–¹æ•°æ®åº“ã€ç»´æ™®æ•°æ®åº“ã€PubMedã€Cochraneå›¾ä¹¦é¦†ï¼Œæ£€ç´¢æˆªè‡³2021å¹´7æœˆçš„æ‰€æœ‰ç›¸å…³ä¸­è‹±æ–‡æ–‡çŒ®ã€‚æ‰€æœ‰æè¿°åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„éšæœºä¸´åºŠè¯•éªŒ (RCT) çš„è®°å½•å‡ç¬¦åˆèµ„æ ¼ã€‚ä½¿ç”¨Cochraneåä½œé£é™©è¯„ä¼°æ ‡å‡†å¯¹ç¬¦åˆçº³å…¥æ ‡å‡†çš„æ–‡çŒ®è¿›è¡Œåå€šè¯„ä¼°ï¼Œå¹¶ä½¿ç”¨Revman5.4è½¯ä»¶å¯¹æ•°æ®è¿›è¡Œåˆ†æã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 14 é¡¹éšæœºå¯¹ç…§è¯•éªŒã€‚ 9é¡¹ç ”ç©¶ç»“æœæ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¸´åºŠæ²»æ„ˆç‡é«˜äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 7é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¼¤å£æ„ˆåˆæ—¶é—´çŸ­äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 4é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è§†è§‰æ¨¡æ‹Ÿè¯„åˆ†ï¼ˆVASï¼‰ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 5é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„Wexnerè¯„åˆ†ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 6é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è‚›ç˜˜å½¢æˆç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 6é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è„“è‚¿å¤å‘ç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 7é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 5é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„çš„ä½é™¢æ—¶é—´çŸ­äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚\n\n**è®¨è®ºï¼š** ä¸´åºŠç ”ç©¶ä¸­æ‰‹æœ¯æ–¹å¼çš„é€‰æ‹©ä¸€ç›´å­˜åœ¨äº‰è®®ã€‚åˆ‡å¼€æŒ‚çº¿æ³•å¯ä»¥æœ‰æ•ˆã€å®‰å…¨åœ°æ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿ã€‚ç„¶è€Œï¼Œè¿™é¡¹èŸèƒåˆ†æçš„ç»“æœä»ç„¶åœ¨è¯æ®ä¸Šç•™ä¸‹äº†ä¸€äº›ç©ºç™½ã€‚éœ€è¦æ›´å¤šå¤§æ ·æœ¬ã€é«˜è´¨é‡ã€å¤šä¸­å¿ƒçš„éšæœºå¯¹ç…§è¯•éªŒã€‚", "keywords_zh": "åˆ‡å¼€æŒ‚çº¿æ²»ç–—ï¼Œé«˜ä½è‚›å‘¨è„“è‚¿ï¼Œåˆ‡å¼€å¼•æµæ²»ç–—ï¼ŒMetaåˆ†æ", "keywords_en": "Incision-seton therapy, high perianal abscess, incision-drainage therapy, meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/34628909/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260213212627&v=2.18.0.post22+67771e2", "date": "Mon, 11 Oct 2021"}], "è‚›ç˜˜": [{"id": "41537212", "title_en": "Transanal Opening of the Intersphincteric Space to Treat Anal Fistula: A Systematic Review and Meta-Analysis", "title_zh": "ç»è‚›é—¨å¼€æ”¾æ‹¬çº¦è‚Œé—´é—´éš™æ²»ç–—è‚›ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Zhen-Yi Wang", "abstract_en": "**Aim:** Transanal opening of the intersphincteric space (TROPIS) is a minimally invasive surgical treatment for anal fistula that not only eliminates the source of infection but also protects anal function to the greatest extent. This systematic review and meta-analysis aims to evaluate the efficacy of TROPIS in the treatment of anal fistula.\n\n**Methods:** We searched PubMed, EMBASE, Web of Science, and the Cochrane Library for information on TROPIS surgery for anal fistulas performed between the inception of each database and 1 November 2024. We used the single-arm studies for analysis, with a total of 918 subjects and a follow-up period ranging from 3 months to 36 months. The analysis focused on the cure rate of different types of anal fistula, postoperative bleeding, infection, and adverse reactions.\n\n**Results:** This systematic review included six single-arm studies involving a total of 918 patients with anal fistula who underwent TROPIS surgery, with follow-up durations ranging from 3 to 36 months. Among the included studies, all were classified as high quality (score â‰¥7). This study demonstrated an 80% success rate for the initial operation (95% confidence interval (CI): 0.77-0.83), as well as an 80% success rate specifically for high fistulas (95% CI: 0.77-0.83). The success rate for second operations was 73% (95% CI: 0.47-0.99). For patients with high fistulas who underwent a second procedure, the success rate was 78% (95% CI: 0.40-1.00). The cure rate for anal fistulas accompanied by abscesses was 88%, while the cure rate for anal fistulas without abscesses is the same. For horseshoe fistulas, the cure rate was 87%, whereas it was 88% for non-horseshoe fistulas. The overall cure rate in this study was 88% (95% CI: 0.86-0.90). The rate of intraoperative bleeding was 3%, the postoperative infection rate was 5%, and the overall incidence of adverse reactions was 3%.\n\n**Conclusions:** This study demonstrates that TROPIS holds significant potential in the treatment of anal fistulas, particularly for high fistulas, fistulas with associated abscesses, and horseshoe-shaped fistulas, whilst exhibiting a relatively low incidence of incontinence.", "abstract_zh": "**Aimï¼š** ç»è‚›é—¨æ‹¬çº¦è‚Œé—´å¼€æ”¾æœ¯ï¼ˆTROPISï¼‰æ˜¯è‚›ç˜˜çš„å¾®åˆ›æ‰‹æœ¯æ²»ç–—æ–¹æ³•ï¼Œä¸ä»…æ¶ˆé™¤äº†æ„ŸæŸ“æºï¼Œè¿˜èƒ½æœ€å¤§ç¨‹åº¦åœ°ä¿æŠ¤è‚›é—¨åŠŸèƒ½ã€‚æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼° TROPIS æ²»ç–—è‚›ç˜˜çš„ç–—æ•ˆã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº† PubMedã€EMBASEã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œä»¥è·å–å„æ•°æ®åº“å»ºç«‹ä¹‹æ—¥è‡³ 2024 å¹´ 11 æœˆ 1 æ—¥ä¹‹é—´è¿›è¡Œçš„ TROPIS è‚›ç˜˜æ‰‹æœ¯çš„ä¿¡æ¯ã€‚æˆ‘ä»¬ä½¿ç”¨å•è‡‚ç ”ç©¶è¿›è¡Œåˆ†æï¼Œå…±æœ‰ 918 åå—è¯•è€…ï¼Œéšè®¿æœŸä» 3 ä¸ªæœˆåˆ° 36 ä¸ªæœˆä¸ç­‰ã€‚é‡ç‚¹åˆ†æä¸åŒç±»å‹è‚›ç˜˜çš„æ²»æ„ˆç‡ã€æœ¯åå‡ºè¡€ã€æ„ŸæŸ“ã€ä¸è‰¯ååº”ç­‰ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹ç³»ç»Ÿè¯„ä»·åŒ…æ‹¬å…­é¡¹å•è‡‚ç ”ç©¶ï¼Œå…±æ¶‰åŠ 918 åæ¥å— TROPIS æ‰‹æœ¯çš„è‚›ç˜˜æ‚£è€…ï¼Œéšè®¿æ—¶é—´ä¸º 3 è‡³ 36 ä¸ªæœˆã€‚åœ¨çº³å…¥çš„ç ”ç©¶ä¸­ï¼Œæ‰€æœ‰ç ”ç©¶å‡è¢«è¯„ä¸ºé«˜è´¨é‡ï¼ˆå¾—åˆ†â‰¥7ï¼‰ã€‚è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼Œåˆæ¬¡æ‰‹æœ¯çš„æˆåŠŸç‡ä¸º 80%ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI)ï¼š0.77-0.83ï¼‰ï¼Œç‰¹åˆ«é’ˆå¯¹é«˜ä½ç˜˜ç®¡çš„æˆåŠŸç‡ä¸º 80%ï¼ˆ95% CIï¼š0.77-0.83ï¼‰ã€‚ç¬¬äºŒæ¬¡æ‰‹æœ¯çš„æˆåŠŸç‡ä¸º73%ï¼ˆ95% CIï¼š0.47-0.99ï¼‰ã€‚å¯¹äºæ¥å—ç¬¬äºŒæ¬¡æ‰‹æœ¯çš„é«˜ä½ç˜˜ç®¡æ‚£è€…ï¼ŒæˆåŠŸç‡ä¸º 78%ï¼ˆ95% CIï¼š0.40-1.00ï¼‰ã€‚ä¼´æœ‰è„“è‚¿çš„è‚›ç˜˜æ²»æ„ˆç‡ä¸º88%ï¼Œæ— è„“è‚¿çš„è‚›ç˜˜æ²»æ„ˆç‡ç›¸åŒã€‚é©¬è¹„ç˜˜çš„æ²»æ„ˆç‡ä¸º 87%ï¼Œè€Œéé©¬è¹„ç˜˜çš„æ²»æ„ˆç‡ä¸º 88%ã€‚æœ¬ç ”ç©¶çš„æ€»ä½“æ²»æ„ˆç‡ä¸º88%ï¼ˆ95% CIï¼š0.86-0.90ï¼‰ã€‚æœ¯ä¸­å‡ºè¡€ç‡ä¸º3%ï¼Œæœ¯åæ„ŸæŸ“ç‡ä¸º5%ï¼Œä¸è‰¯ååº”æ€»ä½“å‘ç”Ÿç‡ä¸º3%ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼ŒTROPIS åœ¨æ²»ç–—è‚›ç˜˜æ–¹é¢å…·æœ‰å·¨å¤§æ½œåŠ›ï¼Œç‰¹åˆ«æ˜¯å¯¹äºé«˜ä½ç˜˜ç®¡ã€ä¼´æœ‰è„“è‚¿çš„ç˜˜ç®¡å’Œé©¬è¹„å½¢ç˜˜ç®¡ï¼ŒåŒæ—¶å¤±ç¦å‘ç”Ÿç‡ç›¸å¯¹è¾ƒä½ã€‚", "keywords_zh": "è‚›ç˜˜ï¼ŒèŸèƒåˆ†æï¼Œä¿ç•™æ‹¬çº¦è‚Œæ‰‹æœ¯ï¼Œç»è‚›é—¨æ‹¬çº¦è‚Œé—´éš™å¼€æ”¾", "keywords_en": "anal fistula, meta-analysis, sphincter-preserving procedure, transanal opening of intersphincteric space", "link": "https://pubmed.ncbi.nlm.nih.gov/41537212/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 15 Jan 2026"}, {"id": "41359092", "title_en": "Systematic review: The management of unhealed wounds and persistent perineal sinuses following proctectomy in inflammatory bowel disease", "title_zh": "ç³»ç»Ÿè¯„ä»·ï¼šç‚ç—‡æ€§è‚ ç—…ç›´è‚ åˆ‡é™¤æœ¯åæœªæ„ˆåˆä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦çš„å¤„ç†", "authors": "A Hart", "abstract_en": "**Introduction:** Unhealed wounds and persistent perineal sinuses (PPS) may occur in as many as one third of patients after proctectomy for Crohn's disease. The management of these conditions remains a significant challenge, particularly in the context of inflammatory bowel disease (IBD), with existing therapies plagued by high failure rates. This systematic review of the literature assessed the efficacy of medical and surgical therapy for PPS closure in IBD. Secondary aims included review of classification systems used for PPS.\n\n**Methods:** A literature search was conducted using Medline, Embase and Cochrane databases on 17 December 2024. The review was registered on PROSPERO (CRD42024622582). Inclusion criteria were adult patients with IBD and PPS or unhealed wounds following proctectomy. We excluded abstract-only publications, case reports, cancer and paediatric cohorts. Two reviewers independently screened abstracts and full texts and extracted data. The primary outcome was clinical healing rate. Secondary outcomes included classification systems used to describe PPS. Risk of bias was assessed.\n\n**Results:** Of 496 records identified, following removal of duplicates, 489 abstracts were screened, and 60 full text articles assessed for eligibility. Of 25 articles included in the final analysis, 23 were case series or retrospective cohort studies, and all were at high risk of bias. No randomised controlled trials were identified. Five articles (including two of the case series) described classification systems for PPS. Interventions included hyperbaric oxygen therapy, Karydakis flap, cleft closure, omentoplasty, skin grafting, gracilis and rectus abdominis flap, platelet-derived growth factor, curettage, lay open and excision of sinuses. Reported healing rates ranged from 30% to 100%. Heterogeneity in the reporting of outcomes, as well as the interventions performed precluded meta-analysis.\n\n**Conclusion:** The published evidence for treatment of PPS in IBD consists of low-quality evidence case series with high risk of bias. There is a need for standardised outcome reporting and high-quality, prospective studies to establish effective treatment algorithms.", "abstract_zh": "**ä»‹ç»ï¼š** å…‹ç½—æ©ç—…ç›´è‚ åˆ‡é™¤æœ¯åï¼Œå¤šè¾¾ä¸‰åˆ†ä¹‹ä¸€çš„æ‚£è€…å¯èƒ½ä¼šå‡ºç°æœªæ„ˆåˆçš„ä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦ (PPS)ã€‚è¿™äº›ç–¾ç—…çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ï¼Œç‰¹åˆ«æ˜¯åœ¨ç‚ç—‡æ€§è‚ ç—…ï¼ˆIBDï¼‰çš„èƒŒæ™¯ä¸‹ï¼Œç°æœ‰çš„æ²»ç–—æ–¹æ³•å—åˆ°é«˜å¤±è´¥ç‡çš„å›°æ‰°ã€‚è¿™é¡¹å¯¹æ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾è¯„ä¼°äº† IBD ä¸­ PPS é—­åˆçš„è¯ç‰©å’Œæ‰‹æœ¯æ²»ç–—çš„ç–—æ•ˆã€‚æ¬¡è¦ç›®æ ‡åŒ…æ‹¬å®¡æŸ¥ç”¨äº PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚\n\n**æ–¹æ³•ï¼š** äº2024å¹´12æœˆ17æ—¥ä½¿ç”¨Medlineã€Embaseå’ŒCochraneæ•°æ®åº“è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚è¯¥ç»¼è¿°å·²åœ¨PROSPEROä¸Šæ³¨å†Œï¼ˆCRD42024622582ï¼‰ã€‚çº³å…¥æ ‡å‡†ä¸ºæ‚£æœ‰ IBD å’Œ PPS çš„æˆå¹´æ‚£è€…æˆ–ç›´è‚ åˆ‡é™¤æœ¯åä¼¤å£æœªæ„ˆåˆçš„æ‚£è€…ã€‚æˆ‘ä»¬æ’é™¤äº†ä»…æ‘˜è¦çš„å‡ºç‰ˆç‰©ã€ç—…ä¾‹æŠ¥å‘Šã€ç™Œç—‡å’Œå„¿ç§‘é˜Ÿåˆ—ã€‚ä¸¤åå®¡ç¨¿äººç‹¬ç«‹ç­›é€‰æ‘˜è¦å’Œå…¨æ–‡å¹¶æå–æ•°æ®ã€‚ä¸»è¦ç»“å±€æ˜¯ä¸´åºŠæ²»æ„ˆç‡ã€‚æ¬¡è¦ç»“æœåŒ…æ‹¬ç”¨äºæè¿° PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚è¯„ä¼°äº†åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨åˆ é™¤é‡å¤é¡¹åï¼Œåœ¨ç¡®å®šçš„ 496 æ¡è®°å½•ä¸­ï¼Œç­›é€‰äº† 489 æ¡æ‘˜è¦ï¼Œå¹¶è¯„ä¼°äº† 60 ç¯‡å…¨æ–‡æ–‡ç« çš„èµ„æ ¼ã€‚æœ€ç»ˆåˆ†æçº³å…¥çš„ 25 ç¯‡æ–‡ç« ä¸­ï¼Œ23 ç¯‡ä¸ºç—…ä¾‹ç³»åˆ—æˆ–å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œä¸”å‡å­˜åœ¨é«˜åå€šé£é™©ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚äº”ç¯‡æ–‡ç« ï¼ˆåŒ…æ‹¬æ¡ˆä¾‹ç³»åˆ—ä¸­çš„ä¸¤ç¯‡ï¼‰æè¿°äº† PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚å¹²é¢„æªæ–½åŒ…æ‹¬é«˜å‹æ°§æ²»ç–—ã€Karydakis çš®ç“£ã€è£‚éš™é—­åˆã€ç½‘è†œæˆå½¢æœ¯ã€æ¤çš®ã€è‚¡è–„è‚Œå’Œè…¹ç›´è‚Œçš®ç“£ã€è¡€å°æ¿è¡ç”Ÿç”Ÿé•¿å› å­ã€åˆ®å®«æœ¯ã€åˆ‡å¼€å’Œåˆ‡é™¤é¼»çª¦ã€‚æ®æŠ¥é“ï¼Œæ²»æ„ˆç‡ä» 30% åˆ° 100% ä¸ç­‰ã€‚ç»“æœæŠ¥å‘Šä»¥åŠæ‰€è¿›è¡Œçš„å¹²é¢„æªæ–½çš„å¼‚è´¨æ€§æ’é™¤äº†èŸèƒåˆ†æã€‚\n\n**ç»“è®ºï¼š** å·²å‘è¡¨çš„ IBD PPS æ²»ç–—è¯æ®ç”±å…·æœ‰é«˜åå€šé£é™©çš„ä½è´¨é‡è¯æ®ç—…ä¾‹ç³»åˆ—ç»„æˆã€‚éœ€è¦æ ‡å‡†åŒ–çš„ç»“æœæŠ¥å‘Šå’Œé«˜è´¨é‡çš„å‰ç»æ€§ç ”ç©¶æ¥å»ºç«‹æœ‰æ•ˆçš„æ²»ç–—ç®—æ³•ã€‚", "keywords_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ã€è‚›å‘¨è„“è‚¿", "keywords_en": "Fistulizing perianal Crohnâ€™s disease, Perianal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/41359092/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 08 Dec 2025"}, {"id": "41345764", "title_en": "The diagnostic value of faecal calprotectin levels in patients with perianal fistula: A systematic review", "title_zh": "ç²ªä¾¿é’™å«è›‹ç™½æ°´å¹³å¯¹è‚›å‘¨ç˜˜æ‚£è€…çš„è¯Šæ–­ä»·å€¼ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Dimitrios Chatziisaak", "abstract_en": "**Aim:** Perianal fistula (PAF) is a common condition encountered in surgical and gastroenterological practice. Distinguishing between cryptoglandular disease (CGD) and inflammatory bowel disease (IBD)-related perianal disease is critical to ensure appropriate management. Faecal calprotectin (FC) has emerged as a promising non-invasive biomarker for IBD; however, its role in acute perianal disease is not well established. This systematic review aimed to evaluate the diagnostic accuracy of FC in distinguishing IBD-related perianal disease from CGD.\n\n**Method:** A systematic literature search was conducted in PubMed, Embase and Cochrane databases following PRISMA guidelines. Studies were included if they assessed FC levels in patients with PAF and provided diagnostic accuracy metrics. Data extraction focused on study design, population characteristics, FC cut-off values, sensitivity, specificity and area under the curve (AUC) metrics.\n\n**Results:** Three studies met the inclusion criteria, all reporting significantly higher FC levels in IBD-related PAF compared to CGD-related fistulas. The proposed FC cut-off values varied, ranging from 110â€‰Î¼g/g to 344â€‰Î¼g/g, with corresponding sensitivities between 52% and 81%, as well as specificities between 77% and 93%. The AUC values indicated moderate to high diagnostic accuracy.\n\n**Conclusion:** FC shows potential as a diagnostic tool for differentiating IBD-related perianal disease from CGD. A cut-off of 110-150â€‰Î¼g/g appears most suitable for early screening, whereas a higher threshold may be appropriate for confirmatory diagnosis. Further prospective studies with standardized protocols are necessary to refine these thresholds and validate FC as a clinical decision-making tool.", "abstract_zh": "**Aimï¼š** è‚›å‘¨ç˜˜ï¼ˆPAFï¼‰æ˜¯å¤–ç§‘å’Œèƒƒè‚ ç—…å­¦å®è·µä¸­é‡åˆ°çš„å¸¸è§ç—…ç—‡ã€‚åŒºåˆ†éšè…ºç–¾ç—…ï¼ˆCGDï¼‰å’Œç‚ç—‡æ€§è‚ ç—…ï¼ˆIBDï¼‰ç›¸å…³çš„è‚›å‘¨ç–¾ç—…å¯¹äºç¡®ä¿é€‚å½“çš„æ²»ç–—è‡³å…³é‡è¦ã€‚ç²ªä¾¿é’™å«è›‹ç™½ (FC) å·²æˆä¸ºä¸€ç§æœ‰å‰é€”çš„ IBD éä¾µå…¥æ€§ç”Ÿç‰©æ ‡å¿—ç‰©ï¼›ç„¶è€Œï¼Œå…¶åœ¨æ€¥æ€§è‚›å‘¨ç–¾ç—…ä¸­çš„ä½œç”¨å°šæœªæ˜ç¡®ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼° FC åœ¨åŒºåˆ† IBD ç›¸å…³è‚›å‘¨ç–¾ç—…å’Œ CGD æ–¹é¢çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚\n\n**Methodï¼š** éµå¾ª PRISMA æŒ‡å—ï¼Œåœ¨ PubMedã€Embase å’Œ Cochrane æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿçš„æ–‡çŒ®æ£€ç´¢ã€‚å¦‚æœç ”ç©¶è¯„ä¼°äº† PAF æ‚£è€…çš„ FC æ°´å¹³å¹¶æä¾›äº†è¯Šæ–­å‡†ç¡®æ€§æŒ‡æ ‡ï¼Œåˆ™çº³å…¥ç ”ç©¶ã€‚æ•°æ®æå–ä¾§é‡äºç ”ç©¶è®¾è®¡ã€ç¾¤ä½“ç‰¹å¾ã€FC æˆªæ­¢å€¼ã€æ•æ„Ÿæ€§ã€ç‰¹å¼‚æ€§å’Œæ›²çº¿ä¸‹é¢ç§¯ (AUC) æŒ‡æ ‡ã€‚\n\n**ç»“æœï¼š** ä¸‰é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œæ‰€æœ‰ç ”ç©¶å‡æŠ¥å‘Š IBD ç›¸å…³ PAF çš„ FC æ°´å¹³æ˜¾ç€é«˜äº CGD ç›¸å…³ç˜˜ç®¡ã€‚å»ºè®®çš„ FC æˆªæ­¢å€¼èŒƒå›´ä» 110Î¼g/g åˆ° 344Î¼g/gï¼Œç›¸åº”çš„æ•æ„Ÿæ€§åœ¨ 52% åˆ° 81% ä¹‹é—´ï¼Œç‰¹å¼‚æ€§åœ¨ 77% åˆ° 93% ä¹‹é—´ã€‚ AUC å€¼è¡¨æ˜è¯Šæ–­å‡†ç¡®æ€§ä¸ºä¸­ç­‰åˆ°é«˜ã€‚\n\n**ç»“è®ºï¼š** FC æ˜¾ç¤ºå‡ºä½œä¸ºåŒºåˆ† IBD ç›¸å…³è‚›å‘¨ç–¾ç—…å’Œ CGD çš„è¯Šæ–­å·¥å…·çš„æ½œåŠ›ã€‚ 110-150Î¼g/g çš„ä¸´ç•Œå€¼ä¼¼ä¹æœ€é€‚åˆæ—©æœŸç­›æŸ¥ï¼Œè€Œæ›´é«˜çš„é˜ˆå€¼å¯èƒ½é€‚åˆç¡®è¯Šã€‚æœ‰å¿…è¦ä½¿ç”¨æ ‡å‡†åŒ–æ–¹æ¡ˆè¿›è¡Œè¿›ä¸€æ­¥çš„å‰ç»æ€§ç ”ç©¶ï¼Œä»¥å®Œå–„è¿™äº›é˜ˆå€¼å¹¶éªŒè¯ FC ä½œä¸ºä¸´åºŠå†³ç­–å·¥å…·ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€éšè…ºç–¾ç—…ã€ç²ªä¾¿é’™å«è›‹ç™½ã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜", "keywords_en": "Crohn's disease, cryptoglandular disease, faecal calprotectin, inflammatory bowel disease, perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/41345764/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 04 Dec 2025"}, {"id": "41342583", "title_en": "Letter to the Editor: commentary on \"Transanal opening of intersphincteric space (TROPIS) treatment for high complex anal fistula: a systematic review and meta-analysis\"", "title_zh": "è‡´ç¼–è¾‘çš„ä¿¡ï¼šå¯¹â€œç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ï¼ˆTROPISï¼‰æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€çš„è¯„è®º", "authors": "Jingen Lu", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/41342583/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 04 Dec 2025"}, {"id": "41267606", "title_en": "Efficacy of Adalimumab Biosimilars in Managing Perianal Fistula in Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯æ²»ç–—ä¸­åº¦è‡³é‡åº¦å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„ç–—æ•ˆï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "M R Bakry", "abstract_en": "**Background:** Perianal fistulas represent a severe complication of Crohn's disease (CD), leading to significant morbidity and a decline in patients' quality of life. Adalimumab, a tumor necrosis factor (TNF) inhibitor, has been widely used for managing CD-related fistulas. However, with the introduction of adalimumab biosimilars, their comparative efficacy in fistula closure remains unclear. This systematic review and meta-analysis assessed the effectiveness and safety of adalimumab biosimilars in achieving complete fistula closure in moderate to severe CD.\n\n**Objective:** To evaluate the efficacy of adalimumab biosimilars in achieving complete fistula closure in patients with moderate to severe Crohn's disease, compared to placebo or standard therapies.\n\n**Methods:** A systematic review and meta-analysis were conducted following PRISMA guidelines. Studies published between 2007 and 2024 were retrieved from PubMed, Web of Science, Embase, Google Scholar, and the Cochrane Library. The included studies consisted of randomized controlled trials (RCTs), non-RCTs, case-control studies, and cohort studies that evaluated the efficacy of adalimumab biosimilars in fistula closure. Data extraction and quality assessment were independently performed using the MINORS evaluation tool. Heterogeneity was assessed using Q and IÂ² statistics, and sensitivity analyses were conducted to explore potential sources of heterogeneity. Funnel plots were used to assess publication bias.\n\n**Results:** Ten studies met the inclusion criteria. The analysis demonstrated that adalimumab biosimilars significantly improved the complete fistula closure rate compared to placebo or conventional treatments. The pooled results indicated a moderate to high efficacy, with a statistically significant improvement in clinical remission rates (P < 0.05). Safety analysis revealed that adverse events were comparable between biosimilars and the original adalimumab, with no significant increase in serious adverse reactions. Sensitivity analysis confirmed the robustness of the findings, and publication bias assessment did not indicate significant bias.\n\n**Conclusions:** This meta-analysis supports the efficacy and safety of adalimumab biosimilars in managing perianal fistulas in moderate to severe CD. The findings suggest that adalimumab biosimilars are effective and safe in managing perianal fistulas in Crohn's disease, but further direct comparative studies with originator adalimumab are needed to establish equivalence. Further large-scale RCTs are recommended to confirm these results and establish long-term safety data.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜ç®¡æ˜¯å…‹ç½—æ©ç—… (CD) çš„ä¸¥é‡å¹¶å‘ç—‡ï¼Œä¼šå¯¼è‡´æ‚£è€…å‘ç—…ç‡æ˜¾ç€ä¸‹é™å¹¶å¯¼è‡´ç”Ÿæ´»è´¨é‡ä¸‹é™ã€‚é˜¿è¾¾æœ¨å•æŠ—æ˜¯ä¸€ç§è‚¿ç˜¤åæ­»å› å­ (TNF) æŠ‘åˆ¶å‰‚ï¼Œå·²å¹¿æ³›ç”¨äºæ²»ç–— CD ç›¸å…³ç˜˜ç®¡ã€‚ç„¶è€Œï¼Œéšç€é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯çš„æ¨å‡ºï¼Œå®ƒä»¬åœ¨ç˜˜ç®¡é—­åˆæ–¹é¢çš„æ¯”è¾ƒåŠŸæ•ˆä»ä¸æ¸…æ¥šã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æè¯„ä¼°äº†é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯åœ¨ä¸­åº¦è‡³é‡åº¦ CD ä¸­å®ç°ç˜˜ç®¡å®Œå…¨é—­åˆçš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**ç›®çš„ï¼š** ä¸å®‰æ…°å‰‚æˆ–æ ‡å‡†ç–—æ³•ç›¸æ¯”ï¼Œè¯„ä¼°é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯åœ¨ä¸­åº¦è‡³é‡åº¦å…‹ç½—æ©ç—…æ‚£è€…å®ç°ç˜˜ç®¡å®Œå…¨é—­åˆæ–¹é¢çš„ç–—æ•ˆã€‚\n\n**æ–¹æ³•ï¼š** æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ 2007 å¹´è‡³ 2024 å¹´é—´å‘è¡¨çš„ç ”ç©¶æ˜¯ä» PubMedã€Web of Scienceã€Embaseã€Google Scholar å’Œ Cochrane å›¾ä¹¦é¦†æ£€ç´¢çš„ã€‚çº³å…¥çš„ç ”ç©¶åŒ…æ‹¬éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€é RCTã€ç—…ä¾‹å¯¹ç…§ç ”ç©¶å’Œé˜Ÿåˆ—ç ”ç©¶ï¼Œè¯„ä¼°é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯åœ¨ç˜˜ç®¡é—­åˆä¸­çš„ç–—æ•ˆã€‚ä½¿ç”¨ MINORS è¯„ä¼°å·¥å…·ç‹¬ç«‹è¿›è¡Œæ•°æ®æå–å’Œè´¨é‡è¯„ä¼°ã€‚ä½¿ç”¨ Q å’Œ IÂ² ç»Ÿè®¡æ•°æ®è¯„ä¼°å¼‚è´¨æ€§ï¼Œå¹¶è¿›è¡Œæ•æ„Ÿæ€§åˆ†æä»¥æ¢ç´¢å¼‚è´¨æ€§çš„æ½œåœ¨æ¥æºã€‚æ¼æ–—å›¾ç”¨äºè¯„ä¼°å‘è¡¨åå€šã€‚\n\n**ç»“æœï¼š** åé¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚åˆ†æè¡¨æ˜ï¼Œä¸å®‰æ…°å‰‚æˆ–å¸¸è§„æ²»ç–—ç›¸æ¯”ï¼Œé˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯æ˜¾ç€æé«˜äº†ç˜˜ç®¡å®Œå…¨é—­åˆç‡ã€‚æ±‡æ€»ç»“æœè¡¨æ˜ç–—æ•ˆä¸­ç­‰è‡³è¾ƒé«˜ï¼Œä¸´åºŠç¼“è§£ç‡æœ‰ç»Ÿè®¡å­¦æ˜¾ç€æ”¹å–„ï¼ˆP < 0.05ï¼‰ã€‚å®‰å…¨æ€§åˆ†ææ˜¾ç¤ºï¼Œç”Ÿç‰©ä»¿åˆ¶è¯å’ŒåŸç ”é˜¿è¾¾æœ¨å•æŠ—çš„ä¸è‰¯äº‹ä»¶ç›¸å½“ï¼Œä¸¥é‡ä¸è‰¯ååº”æ²¡æœ‰æ˜¾ç€å¢åŠ ã€‚æ•æ„Ÿæ€§åˆ†æè¯å®äº†ç ”ç©¶ç»“æœçš„ç¨³å¥æ€§ï¼Œå‘è¡¨åå€šè¯„ä¼°å¹¶æœªè¡¨æ˜å­˜åœ¨æ˜¾ç€åå€šã€‚\n\n**ç»“è®ºï¼š** è¯¥èŸèƒåˆ†ææ”¯æŒé˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯æ²»ç–—ä¸­åº¦è‡³é‡åº¦ CD è‚›å‘¨ç˜˜çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œé˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯åœ¨æ²»ç–—å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜æ–¹é¢æœ‰æ•ˆä¸”å®‰å…¨ï¼Œä½†éœ€è¦ä¸åŸç ”è¯é˜¿è¾¾æœ¨å•æŠ—è¿›è¡Œè¿›ä¸€æ­¥çš„ç›´æ¥æ¯”è¾ƒç ”ç©¶ä»¥ç¡®å®šç­‰æ•ˆæ€§ã€‚å»ºè®®è¿›ä¸€æ­¥è¿›è¡Œå¤§è§„æ¨¡éšæœºå¯¹ç…§è¯•éªŒæ¥è¯å®è¿™äº›ç»“æœå¹¶å»ºç«‹é•¿æœŸå®‰å…¨æ€§æ•°æ®ã€‚", "keywords_zh": "é˜¿è¾¾æœ¨å•æŠ—ã€å…‹ç½—æ©ç—…ã€é˜¿è¾¾æœ¨å•æŠ—ç”Ÿç‰©ä»¿åˆ¶è¯ã€æŠ— TNF è¯ç‰©ã€ç”Ÿç‰©ç–—æ³•ã€ç”Ÿç‰©ä»¿åˆ¶è¯ã€ç˜˜ç®¡é—­åˆã€è‚›å‘¨ç˜˜ã€è‚¿ç˜¤åæ­»å› å­æŠ‘åˆ¶å‰‚", "keywords_en": "Adalimumab, Crohnâ€™s disease, adalimumab biosimilars, anti-TNF agents., biologic therapy, biosimilars, fistula closure, perianal fistula, tumor necrosis factor inhibitors", "link": "https://pubmed.ncbi.nlm.nih.gov/41267606/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 21 Nov 2025"}, {"id": "41219674", "title_en": "Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** While setons are commonly used in the multidisciplinary care of patients with perianal fistulizing Crohn's disease (PFCD), fistula outcomes after their removal are poorly understood. We performed a systematic review with meta-analysis to evaluate fistula outcomes after seton removal in patients with PFCD.\n\n**Methods:** MEDLINE, EMBASE, Web of Science, and Cochrane databases were systematically searched until December 2023. We included studies reporting fistula outcomes after seton removal in PFCD. We used a hierarchy to stratify patients into one of three treatment categories: medical therapy alone, surgical closure, or cell/plasma-based therapy. Fistula outcomes were reported as weighted proportions with 95% confidence intervals (CI).\n\n**Results:** Eighty-two studies (nâ€‰=â€‰2441 patients) were analyzed. Mean/median seton duration varied widely (2 to 70Â weeks). Pooled estimates (95% CI) of fistula outcomes after seton removal for patients treated in the medical therapy alone, surgical closure, or cell/plasma-based therapy categories were, respectively, 64% (54-75), 65% (52-78), and 71% (65-77) for fistula remission; 30% (22-38), 29% (16-42), and 20% (15-25) for recurrence; 15% (8-22), 11% (4-20), and 14% (8-21) for abscess formation; and 26% (18-35), 23% (17-29), and 13% (2-26) for surgical re-intervention. Fistula outcome estimates remained stable in multiple sensitivity analyses. Limited studies directly compared fistula outcomes based on seton duration, yielding inconsistent results.\n\n**Conclusions:** This systematic review provides comprehensive estimates of fistula outcomes after seton removal and demonstrates substantial variability in seton duration. Future research is required to determine the optimal duration of setons.", "abstract_zh": "**èƒŒæ™¯ï¼š** è™½ç„¶æŒ‚çº¿å¸¸ç”¨äºè‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (PFCD) æ‚£è€…çš„å¤šå­¦ç§‘æŠ¤ç†ï¼Œä½†äººä»¬å¯¹æŒ‚çº¿ç§»é™¤åçš„ç˜˜ç®¡ç»“å±€çŸ¥ä¹‹ç”šå°‘ã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥è¯„ä¼° PFCD æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“å±€ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2023 å¹´ 12 æœˆï¼Œæˆ‘ä»¬å¯¹ MEDLINEã€EMBASEã€Web of Science å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚æˆ‘ä»¬çº³å…¥äº†æŠ¥å‘Š PFCD æŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“æœçš„ç ”ç©¶ã€‚æˆ‘ä»¬ä½¿ç”¨å±‚æ¬¡ç»“æ„å°†æ‚£è€…åˆ†ä¸ºä¸‰ç§æ²»ç–—ç±»åˆ«ä¹‹ä¸€ï¼šå•çº¯è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ã€‚ç˜˜ç®¡ç»“æœæŠ¥å‘Šä¸ºå…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„åŠ æƒæ¯”ä¾‹ã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 82 é¡¹ç ”ç©¶ï¼ˆn=2441 åæ‚£è€…ï¼‰ã€‚å¹³å‡/ä¸­ä½æŒ‚çº¿æŒç»­æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼ˆ2 è‡³ 70 å‘¨ï¼‰ã€‚å¯¹äºä»…æ¥å—è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ç±»åˆ«çš„æ‚£è€…ï¼ŒæŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“å±€çš„æ±‡æ€»ä¼°è®¡ (95% CI) ç˜˜ç®¡ç¼“è§£ç‡åˆ†åˆ«ä¸º 64% (54-75)ã€65% (52-78) å’Œ 71% (65-77)ï¼› 30% (22-38)ã€29% (16-42) å’Œ 20% (15-25) å¤å‘ï¼› 15% (8-22)ã€11% (4-20) å’Œ 14% (8-21) è„“è‚¿å½¢æˆï¼› 26% (18-35)ã€23% (17-29) å’Œ 13% (2-26) éœ€è¦å†æ¬¡æ‰‹æœ¯å¹²é¢„ã€‚åœ¨å¤šé¡¹æ•æ„Ÿæ€§åˆ†æä¸­ï¼Œç˜˜ç®¡ç»“æœä¼°è®¡å€¼ä¿æŒç¨³å®šã€‚æœ‰é™çš„ç ”ç©¶æ ¹æ®æŒ‚çº¿æŒç»­æ—¶é—´ç›´æ¥æ¯”è¾ƒç˜˜ç®¡ç»“å±€ï¼Œäº§ç”Ÿä¸ä¸€è‡´çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** è¯¥ç³»ç»Ÿè¯„ä»·æä¾›äº†æŒ‚çº¿ç§»é™¤åç˜˜ç®¡ç»“æœçš„å…¨é¢ä¼°è®¡ï¼Œå¹¶è¯æ˜äº†æŒ‚çº¿æŒç»­æ—¶é—´çš„æ˜¾ç€å·®å¼‚ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥ç¡®å®šæŒ‚çº¿çš„æœ€ä½³æŒç»­æ—¶é—´ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç”Ÿç‰©ç–—æ³•ã€å…‹ç½—æ©ç—…ã€å¼•æµã€é—´å……è´¨å¹²ç»†èƒ", "keywords_en": "Anal fistula, Biologic therapy, Crohnâ€™s disease, Drainage, Mesenchymal stem cells", "link": "https://pubmed.ncbi.nlm.nih.gov/41219674/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 11 Nov 2025"}, {"id": "41133388", "title_en": "Letter to the editor: insights into \"Transanal Opening of Intersphincteric Space (TROPIS) treatment for high complex anal fistula: a systematic review and meta-analysis\"", "title_zh": "è‡´ç¼–è¾‘çš„ä¿¡ï¼šå¯¹â€œç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ï¼ˆTROPISï¼‰æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜çš„è§è§£ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€", "authors": "Jing Wang", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/41133388/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 24 Oct 2025"}, {"id": "40983150", "title_en": "Management of Perianal Abscesses in Infants: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿çš„æ²»ç–—ï¼šAPSA ç»“æœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šçš„ç³»ç»Ÿå®¡æŸ¥", "authors": "American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee", "abstract_en": "**Background:** Management of infant perianal disease, including perianal abscess and fistula-in- ano (FIA), remains controversial. There is lack of consensus regarding the risks and benefits of operative and non-operative approaches.\n\n**Methods:** The American Pediatric Surgical Association Outcomes and Evidence Based Practice Committee created a priori consensus-based questions regarding the various approaches to management of perianal abscess and FIA in infants. A comprehensive search strategy was created, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to identify and review relevant articles and answer the established questions.\n\n**Results:** Over 2460 titles and abstracts were screened to identify 31 manuscripts describing the expected course of perianal disease when managed with nonoperative management (NOM) strategies (such as hygiene, sitz baths, and systemic antibiotics), operative intervention for abscess only (incision and drainage (I&D)) or direct surgical management of the FIA (e.g. upfront fistulotomy). Initial failure of NOM is approximately 37.5 %. Recurrence rate after initial success with NOM or I&D is approximately 21 % and 24 %, respectively. The rate of FIA development is approximately 21 % after NOM and 20 % after I&D. Recurrence after operative management of FIA, regardless of approach, is 7 %. Time to complete resolution varies widely and does not appear to differ based on treatment strategy.\n\n**Conclusions:** Both operative and non-operative approaches can be safely used in the management of perianal abscess and FIA but recurrence is common regardless of approach. Risks and benefits of each approach should be considered on a case-by-case basis.\n\n**Type Of Study:** Systematic Review of level 3-4 studies.\n\n**Level Of Evidence:** Level 4.", "abstract_zh": "**èƒŒæ™¯ï¼š** å©´å„¿è‚›å‘¨ç–¾ç—…çš„æ²»ç–—ï¼ŒåŒ…æ‹¬è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜ï¼ˆFIAï¼‰ï¼Œä»ç„¶å­˜åœ¨äº‰è®®ã€‚å…³äºæ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•çš„é£é™©å’Œç›Šå¤„ç¼ºä¹å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** ç¾å›½å„¿ç§‘å¤–ç§‘åä¼šæˆæœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šé’ˆå¯¹å©´å„¿è‚›å‘¨è„“è‚¿å’Œ FIA çš„å„ç§æ²»ç–—æ–¹æ³•æå‡ºäº†åŸºäºå…ˆéªŒå…±è¯†çš„é—®é¢˜ã€‚åˆ›å»ºäº†å…¨é¢çš„æœç´¢ç­–ç•¥ï¼Œå¹¶ä½¿ç”¨ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—æ¥è¯†åˆ«å’Œå®¡æŸ¥ç›¸å…³æ–‡ç« å¹¶å›ç­”æ—¢å®šé—®é¢˜ã€‚\n\n**ç»“æœï¼š** ç­›é€‰äº† 2460 å¤šä¸ªæ ‡é¢˜å’Œæ‘˜è¦ï¼Œç¡®å®šäº† 31 ç¯‡æ‰‹ç¨¿ï¼Œæè¿°äº†é‡‡ç”¨éæ‰‹æœ¯æ²»ç–— (NOM) ç­–ç•¥ï¼ˆä¾‹å¦‚å«ç”Ÿã€åæµ´å’Œå…¨èº«æŠ—ç”Ÿç´ ï¼‰ã€ä»…é’ˆå¯¹è„“è‚¿è¿›è¡Œæ‰‹æœ¯å¹²é¢„ï¼ˆåˆ‡å¼€å¼•æµ (I&D)ï¼‰æˆ– FIA ç›´æ¥æ‰‹æœ¯æ²»ç–—ï¼ˆä¾‹å¦‚å‰æœŸç˜˜ç®¡åˆ‡å¼€æœ¯ï¼‰æ—¶è‚›å‘¨ç–¾ç—…çš„é¢„æœŸç—…ç¨‹ã€‚ NOM çš„åˆå§‹æ•…éšœçº¦ä¸º 37.5%ã€‚ NOM æˆ– I&D åˆæ¬¡æˆåŠŸåçš„å¤å‘ç‡åˆ†åˆ«çº¦ä¸º 21% å’Œ 24%ã€‚ NOM åçš„ FIA å¼€å‘ç‡çº¦ä¸º 21%ï¼ŒI&D åçš„ FIA å¼€å‘ç‡çº¦ä¸º 20%ã€‚æ— è®ºé‡‡å–ä½•ç§æ–¹æ³•ï¼ŒFIA æ‰‹æœ¯æ²»ç–—åçš„å¤å‘ç‡ä¸º 7%ã€‚å®Œæˆç¼“è§£çš„æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼Œå¹¶ä¸”æ ¹æ®æ²»ç–—ç­–ç•¥ä¼¼ä¹æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•éƒ½å¯ä»¥å®‰å…¨åœ°ç”¨äºè‚›å‘¨è„“è‚¿å’Œ FIA çš„æ²»ç–—ï¼Œä½†æ— è®ºé‡‡ç”¨å“ªç§æ–¹æ³•ï¼Œå¤å‘éƒ½å¾ˆå¸¸è§ã€‚åº”æ ¹æ®å…·ä½“æƒ…å†µè€ƒè™‘æ¯ç§æ–¹æ³•çš„é£é™©å’Œæ”¶ç›Šã€‚\n\n**Type of studyï¼š** 3-4 çº§ç ”ç©¶çš„ç³»ç»Ÿå®¡æŸ¥ã€‚\n\n**Level of evidenceï¼š** 4 çº§ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç˜˜ç®¡åˆ‡å¼€æœ¯ã€å©´å„¿ã€è‚›å‘¨è„“è‚¿ã€ç›´è‚ å‘¨å›´è„“è‚¿", "keywords_en": "Fistula-in-ano, Fistulotomy, Infants, Perianal abscess, Perirectal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/40983150/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 22 Sep 2025"}, {"id": "40936062", "title_en": "Effectiveness of Laser-Based Fistula Therapies with and without Adjunctive Measures in Anal Fistulas Management: A Systematic Review and Single-Arm Meta-Analysis", "title_zh": "æ¿€å…‰ç˜˜ç®¡æ²»ç–—åœ¨è‚›ç˜˜æ²»ç–—ä¸­è”åˆæˆ–ä¸è”åˆè¾…åŠ©æªæ–½çš„æœ‰æ•ˆæ€§ï¼šç³»ç»Ÿè¯„ä»·å’Œå•è‡‚èŸèƒåˆ†æ", "authors": "Stefano Baraldo", "abstract_en": "**Purpose:** Fistula Laser Closure (FiLaCÂ®) is a sphincter-preserving technique for anal fistulas, but its efficacy and safety remain under discussion. Therefore, we aim to evaluate the efficacy and safety of FiLaCÂ® in the management of patients with cryptoglandular fistulas.\n\n**Methods:** A systematic review was performed in MEDLINE, Embase, and Cochrane databases in January 2025, following PRISMA guidelines. We included randomized controlled trials (RCTs) and observational studies assessing FiLaCÂ® for cryptoglandular fistulas, with or without surgical adjunctive measures. The main outcome was the primary healing rate. Secondary outcomes included fistula recurrence, incontinence, reoperation rates, and postoperative complications. Subgroup analyses explored variables related to the primary healing rate. Data are presented as percentages (95% confidence interval).Â Statistical analyses were performed using R (version 4.4.1 (2024-06-14 (ucrt)).\n\n**Results:** We included 24 studies with 1,503 patients. The pooled primary healing rate was 57.46% (49.40-65.33). Recurrence occurred in 18.48% of patients (10.14-28.47), while new-onset incontinence was rare (0.57%; 0.00-2.15). The reoperation rate was 36.49% (28.95-44.36), and anal abscesses or infections affected 6.54% (1.93-13.09) of patients. Subgroup analysis showed no statistically significant differences in the primary healing rate based on fistula type, adjunctive measures, or sex. Sensitivity analysis confirmed the robustness of our findings.\n\n**Conclusions:** FiLaCÂ® seems to be a safe option with an intermediate healing rate in patients with cryptoglandular fistulas, although it is associated with a considerable recurrence rate. While its sphincter preservation advantage is evident, further RCTs standardizing the technique and adjunctive approaches are needed to optimize outcomes and refine its application in fistula management.", "abstract_zh": "**Purposeï¼š** ç˜˜ç®¡æ¿€å…‰é—­åˆæœ¯ (FiLaCÂ®) æ˜¯ä¸€ç§æ²»ç–—è‚›ç˜˜çš„æ‹¬çº¦è‚Œä¿ç•™æŠ€æœ¯ï¼Œä½†å…¶æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ä»åœ¨è®¨è®ºä¸­ã€‚å› æ­¤ï¼Œæˆ‘ä»¬çš„ç›®çš„æ˜¯è¯„ä¼° FiLaCÂ® åœ¨éšçªè…ºç˜˜æ‚£è€…æ²»ç–—ä¸­çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** 2025 å¹´ 1 æœˆï¼ŒæŒ‰ç…§ PRISMA æŒ‡å—åœ¨ MEDLINEã€Embase å’Œ Cochrane æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚æˆ‘ä»¬çº³å…¥äº†éšæœºå¯¹ç…§è¯•éªŒ (RCT) å’Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œè¯„ä¼° FiLaCÂ® åœ¨æœ‰æˆ–æ²¡æœ‰æ‰‹æœ¯è¾…åŠ©æªæ–½çš„æƒ…å†µä¸‹æ²»ç–—éšçªè…ºç˜˜ã€‚ä¸»è¦ç»“æœæ˜¯åˆæ¬¡æ²»æ„ˆç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ç˜˜ç®¡å¤å‘ã€å¤±ç¦ã€å†æ¬¡æ‰‹æœ¯ç‡å’Œæœ¯åå¹¶å‘ç—‡ã€‚äºšç»„åˆ†ææ¢è®¨äº†ä¸åˆæ¬¡æ²»æ„ˆç‡ç›¸å…³çš„å˜é‡ã€‚æ•°æ®ä»¥ç™¾åˆ†æ¯”å½¢å¼å‘ˆç°ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼‰ã€‚Â ä½¿ç”¨ Rï¼ˆç‰ˆæœ¬ 4.4.1 (2024-06-14 (ucrt)ï¼‰è¿›è¡Œç»Ÿè®¡åˆ†æã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬çº³å…¥äº† 24 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 1,503 åæ‚£è€…ã€‚åˆå¹¶ä¸€æœŸæ„ˆåˆç‡ä¸º 57.46% (49.40-65.33)ã€‚ 18.48% çš„æ‚£è€…ï¼ˆ10.14-28.47ï¼‰å¤å‘ï¼Œè€Œæ–°å‘å°¿å¤±ç¦å¾ˆå°‘è§ï¼ˆ0.57%ï¼›0.00-2.15ï¼‰ã€‚å†æ¬¡æ‰‹æœ¯ç‡ä¸º36.49%ï¼ˆ28.95-44.36ï¼‰ï¼Œè‚›é—¨è„“è‚¿æˆ–æ„ŸæŸ“å 6.54%ï¼ˆ1.93-13.09ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºï¼ŒåŸºäºç˜˜ç®¡ç±»å‹ã€è¾…åŠ©æªæ–½æˆ–æ€§åˆ«çš„åˆæ¬¡æ„ˆåˆç‡æ²¡æœ‰ç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ã€‚æ•æ„Ÿæ€§åˆ†æè¯å®äº†æˆ‘ä»¬ç ”ç©¶ç»“æœçš„ç¨³å¥æ€§ã€‚\n\n**ç»“è®ºï¼š** FiLaCÂ® ä¼¼ä¹æ˜¯éšçªè…ºç˜˜æ‚£è€…çš„ä¸€ç§å®‰å…¨é€‰æ‹©ï¼Œå…·æœ‰ä¸­ç­‰çš„æ²»æ„ˆç‡ï¼Œå°½ç®¡å®ƒä¸ç›¸å½“å¤§çš„å¤å‘ç‡ç›¸å…³ã€‚è™½ç„¶å…¶ä¿ç•™æ‹¬çº¦è‚Œçš„ä¼˜åŠ¿æ˜¾è€Œæ˜“è§ï¼Œä½†ä»éœ€è¦è¿›ä¸€æ­¥çš„éšæœºå¯¹ç…§è¯•éªŒæ¥æ ‡å‡†åŒ–è¯¥æŠ€æœ¯å’Œè¾…åŠ©æ–¹æ³•ï¼Œä»¥ä¼˜åŒ–ç»“æœå¹¶å®Œå–„å…¶åœ¨ç˜˜ç®¡æ²»ç–—ä¸­çš„åº”ç”¨ã€‚", "keywords_zh": "éšè…ºç˜˜ç®¡ï¼ŒFiLaCï¼Œæ„ˆåˆç‡ï¼ŒèŸèƒåˆ†æï¼Œç›´è‚ ç˜˜", "keywords_en": "Cryptoglandular fistulas, FiLaC, Healing rate, Meta-analysis, Rectal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/40936062/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 11 Sep 2025"}, {"id": "40933558", "title_en": "Adipose-derived stem cell therapies for complex anal fistula: a systematic review and meta-analysis of randomized controlled trials", "title_zh": "è„‚è‚ªå¹²ç»†èƒæ²»ç–—å¤æ‚è‚›ç˜˜ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Wenjiang Wu", "abstract_en": "**Purpose:** This study aimed to systematically investigate the efficacy of adipose-derived stem cells (ASCs) in complex anal fistula treatment.\n\n**Methods:** This study systematically searched randomized controlled studies on the efficacy of ASCs in treating complex anal fistula published before June 2024 in PubMed, EMBASE, Web of Science, and Cochrane Library. Further, relevant journals were manually searched for relevant references, and two researchers independently performed literature search and screening, data extraction, and bias assessment. Stata version 12.0 was utilized to statistically analyze the healing rate of the anal fistula and the incidence of adverse events.\n\n**Results:** This study involved 1,056 patients from five randomized controlled trials, including 561 patients in the treatment group (ASCs/ASCs + fibrin glue) and 495 patients in the control group (fibrin glue/placebo). Meta-analysis revealed better short- and long-term efficacy of adipose mesenchymal stem cell treatment for complex perianal fistulas than in conventional treatment. However, no statistical difference was observed between mid-term and ultra-long-term treatments. Subgroup meta-analysis demonstrated a difference in efficacy between various cell doses. Further, all treatments with different sources of ASCs were superior to conventional quality.\n\n**Conclusion:** This study confirms that Adipose-derived Stem Cells can effectively improve short-term and long-term (1-year) clinical outcomes in patients with complex perianal fistulas, supporting their potential as a novel therapeutic strategy.\n\n**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/view/CRD42024602327.", "abstract_zh": "**Purposeï¼š** æœ¬ç ”ç©¶æ—¨åœ¨ç³»ç»Ÿç ”ç©¶è„‚è‚ªå¹²ç»†èƒï¼ˆASCï¼‰åœ¨å¤æ‚è‚›ç˜˜æ²»ç–—ä¸­çš„åŠŸæ•ˆã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç ”ç©¶ç³»ç»Ÿæ£€ç´¢äº† 2024 å¹´ 6 æœˆä¹‹å‰å‘è¡¨åœ¨ PubMedã€EMBASEã€Web of Science å’Œ Cochrane Library ä¸Šçš„å…³äº ASC æ²»ç–—å¤æ‚è‚›ç˜˜ç–—æ•ˆçš„éšæœºå¯¹ç…§ç ”ç©¶ã€‚æ­¤å¤–ï¼Œäººå·¥æ£€ç´¢ç›¸å…³æœŸåˆŠç›¸å…³å‚è€ƒæ–‡çŒ®ï¼Œç”±ä¸¤åç ”ç©¶äººå‘˜ç‹¬ç«‹è¿›è¡Œæ–‡çŒ®æ£€ç´¢å’Œç­›é€‰ã€æ•°æ®æå–å’Œåå€šè¯„ä¼°ã€‚é‡‡ç”¨Stata 12.0ç‰ˆæœ¬å¯¹è‚›ç˜˜æ„ˆåˆç‡åŠä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡è¿›è¡Œç»Ÿè®¡åˆ†æã€‚\n\n**ç»“æœï¼š** è¿™é¡¹ç ”ç©¶æ¶‰åŠæ¥è‡ªäº”é¡¹éšæœºå¯¹ç…§è¯•éªŒçš„ 1,056 åæ‚£è€…ï¼Œå…¶ä¸­æ²»ç–—ç»„ï¼ˆASCs/ASCs + çº¤ç»´è›‹ç™½èƒ¶ï¼‰561 åæ‚£è€…ï¼Œå¯¹ç…§ç»„ï¼ˆçº¤ç»´è›‹ç™½èƒ¶/å®‰æ…°å‰‚ï¼‰495 åæ‚£è€…ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œè„‚è‚ªé—´å……è´¨å¹²ç»†èƒæ²»ç–—å¤æ‚è‚›å‘¨ç˜˜çš„çŸ­æœŸå’Œé•¿æœŸç–—æ•ˆä¼˜äºä¼ ç»Ÿæ²»ç–—ã€‚ç„¶è€Œï¼Œä¸­æœŸå’Œè¶…é•¿æœŸæ²»ç–—ä¹‹é—´æ²¡æœ‰è§‚å¯Ÿåˆ°ç»Ÿè®¡å­¦å·®å¼‚ã€‚äºšç»„èŸèƒåˆ†æè¯æ˜ä¸åŒç»†èƒå‰‚é‡ä¹‹é—´çš„åŠŸæ•ˆå­˜åœ¨å·®å¼‚ã€‚æ­¤å¤–ï¼Œä½¿ç”¨ä¸åŒæ¥æºçš„ ASC è¿›è¡Œçš„æ‰€æœ‰æ²»ç–—å‡ä¼˜äºå¸¸è§„è´¨é‡ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¯å®ï¼Œè„‚è‚ªå¹²ç»†èƒå¯ä»¥æœ‰æ•ˆæ”¹å–„å¤æ‚è‚›å‘¨ç˜˜æ‚£è€…çš„çŸ­æœŸå’Œé•¿æœŸï¼ˆ1 å¹´ï¼‰ä¸´åºŠç»“æœï¼Œæ”¯æŒå…¶ä½œä¸ºä¸€ç§æ–°å‹æ²»ç–—ç­–ç•¥çš„æ½œåŠ›ã€‚\n\n**Systematic review registrationï¼š** https://www.crd.york.ac.uk/PROSPERO/view/CRD42024602327ã€‚", "keywords_zh": "è„‚è‚ªå¹²ç»†èƒï¼Œè„‚è‚ªé—´å……è´¨å¹²ç»†èƒï¼Œè‚›å‘¨ç˜˜ï¼Œéšæœºå¯¹ç…§è¯•éªŒï¼Œç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "keywords_en": "adipose stem cells, adipose-derived mesenchymal stem cell, perianal fistula, randomized controlled trial, systematic review and meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/40933558/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 11 Sep 2025"}, {"id": "40929949", "title_en": "A systematic review and meta-analysis of the outcomes of anal fistula clips in the treatment of anal fistulas", "title_zh": "è‚›ç˜˜å¤¹æ²»ç–—è‚›ç˜˜ç–—æ•ˆçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Giovanna DaSilva", "abstract_en": "**Introduction:** One recent novel method for the treatment of anal fistulas is the over-the-scope clip. This meta-analysis aimed to examine the success of anal fistula clips.\n\n**Methods:** This Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review searched PubMed, Scopus, and Cochrane Library from January 2000 through March 2025 for observational and randomized controlled trials that used over-the-scope clips in treating cryptoglandular and inflammatory bowel disease-related anal fistulas. Main outcomes were pooled healing and complication rates, and length of stay.\n\n**Results:** 12 studies (2 randomized controlled trials) incorporating a total of 438 patients were included; 293 patients underwent anal fistula clip placement. The median age of the patients was 45.5 years. The pooled healing rate was 67.7% (95% confidence interval: 54.7%-80.7%) with a median follow-up of 11.3 months. Pooled healing was 78.7% (95% confidence interval: 62.3%-95.1%) in cryptoglandular fistulas and 59.5% (95% confidence interval: 41.8%-77.2%) in studies that included both cryptoglandular and inflammatory bowel disease fistulas. The medical hospital stay across 3 studies was 4.9 days. Pooled complication rate was 30.9% (95% confidence interval: 14.6%-47.2%). The most common complications were spontaneous migration or unscheduled removal of a clip (17.3%, 95% confidence interval: 8.3%-26.4%) and clinically significant pain (3.8%, 95% confidence interval: 0.9%-6.7%). Seven studies assessed continence after over-the-scope clip placement, and no cases of fecal incontinence were reported.\n\n**Conclusions:** The over-the-scope clip is a promising and novel minimally invasive treatment for anal fistulas. The pooled healing rate was 67.7% overall and >75% for cryptoglandular fistulas. Despite its encouraging success, the over-the-scope clip's complication rate of 30.9% highlights the need for further refinement of this technique and patient selection.", "abstract_zh": "**ä»‹ç»ï¼š** æœ€è¿‘æ²»ç–—è‚›ç˜˜çš„ä¸€ç§æ–°æ–¹æ³•æ˜¯è¶…é•œå¤¹ã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨æ£€æŸ¥è‚›ç˜˜å¤¹çš„æˆåŠŸç‡ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç³»ç»Ÿè¯„ä»·å’Œç¬¦åˆèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®æ£€ç´¢äº† 2000 å¹´ 1 æœˆè‡³ 2025 å¹´ 3 æœˆæœŸé—´çš„ PubMedã€Scopus å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œä»¥æŸ¥æ‰¾ä½¿ç”¨è¶…èŒƒå›´å¤¹å­æ²»ç–—éšè…ºå’Œç‚ç—‡æ€§è‚ ç—…ç›¸å…³è‚›ç˜˜çš„è§‚å¯Ÿæ€§å’Œéšæœºå¯¹ç…§è¯•éªŒã€‚ä¸»è¦ç»“æœæ˜¯æ±‡æ€»æ²»æ„ˆç‡ã€å¹¶å‘ç—‡å‘ç”Ÿç‡ä»¥åŠä½é™¢æ—¶é—´ã€‚\n\n**ç»“æœï¼š** çº³å…¥ 12 é¡¹ç ”ç©¶ï¼ˆ2 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼‰ï¼Œå…±çº³å…¥ 438 åæ‚£è€…ï¼› 293 åæ‚£è€…æ¥å—äº†è‚›ç˜˜å¤¹ç½®å…¥æœ¯ã€‚æ‚£è€…çš„ä¸­ä½å¹´é¾„ä¸º 45.5 å²ã€‚æ±‡æ€»æ²»æ„ˆç‡ä¸º 67.7%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼š54.7%-80.7%ï¼‰ï¼Œä¸­ä½éšè®¿æ—¶é—´ä¸º 11.3 ä¸ªæœˆã€‚éšè…ºç˜˜çš„åˆå¹¶æ„ˆåˆç‡ä¸º 78.7%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼š62.3%-95.1%ï¼‰ï¼Œè€ŒåŒ…æ‹¬éšè…ºç˜˜å’Œç‚ç—‡æ€§è‚ ç—…ç˜˜çš„ç ”ç©¶ä¸­çš„åˆå¹¶æ„ˆåˆç‡ä¸º 59.5%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼š41.8%-77.2%ï¼‰ã€‚ 3 é¡¹ç ”ç©¶çš„ä½é™¢æ—¶é—´ä¸º 4.9 å¤©ã€‚åˆå¹¶å¹¶å‘ç—‡ç‡ä¸º 30.9%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼š14.6%-47.2%ï¼‰ã€‚æœ€å¸¸è§çš„å¹¶å‘ç—‡æ˜¯å¤¹å­è‡ªå‘ç§»ä½æˆ–æ„å¤–ç§»é™¤ï¼ˆ17.3%ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š8.3%-26.4%ï¼‰å’Œä¸´åºŠæ˜¾ç€ç–¼ç—›ï¼ˆ3.8%ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š0.9%-6.7%ï¼‰ã€‚ä¸ƒé¡¹ç ”ç©¶è¯„ä¼°äº†è¶…èŒƒå›´å¤¹å­æ”¾ç½®åçš„å¤±ç¦æƒ…å†µï¼Œæ²¡æœ‰æŠ¥å‘Šå¤§ä¾¿å¤±ç¦çš„ç—…ä¾‹ã€‚\n\n**ç»“è®ºï¼š** è¶…é•œå¤¹æ˜¯ä¸€ç§æœ‰å‰æ™¯çš„æ–°å‹å¾®åˆ›æ²»ç–—è‚›ç˜˜çš„æ–¹æ³•ã€‚æ€»ä½“æ„ˆåˆç‡ä¸º 67.7%ï¼Œéšçªç˜˜çš„åˆå¹¶æ„ˆåˆç‡ä¸º >75%ã€‚å°½ç®¡å–å¾—äº†ä»¤äººé¼“èˆçš„æˆåŠŸï¼Œä½†è¶…èŒƒå›´å¤¹å­çš„å¹¶å‘ç—‡ç‡ä¸º 30.9%ï¼Œè¿™å‡¸æ˜¾äº†è¿›ä¸€æ­¥å®Œå–„è¯¥æŠ€æœ¯å’Œæ‚£è€…é€‰æ‹©çš„å¿…è¦æ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40929949/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 10 Sep 2025"}, {"id": "40844884", "title_en": "A commentary on \"Transanal Opening of Intersphincteric Space (TROPIS) treatment for high complex anal fistula: a systematic review and meta-analysis\"", "title_zh": "â€œç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ï¼ˆTROPISï¼‰æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€çš„è¯„è®º", "authors": "Chunxue Li", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40844884/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 22 Aug 2025"}, {"id": "40833840", "title_en": "Bacteriology of Anorectal Abscess and Anal Fistula: A Systematic Review of the Literature", "title_zh": "è‚›é—¨ç›´è‚ è„“è‚¿å’Œè‚›ç˜˜çš„ç»†èŒå­¦ï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "David ParÃ©s", "abstract_en": "<b><i>Aim:</i></b> A cryptoglandular anorectal abscess is a collection of purulent material around the anus, often leading to the development of an anal fistula after drainage. Although <i>Escherichia coli</i> and <i>Bacteroides fragilis</i> have been considered key bacteria in these conditions, recent evidence suggests the need to revisit this assumption. This work aimed to analyze the presence and role of bacteria in the development of anal fistulas following anorectal abscesses. <b><i>Patients and Methods:</i></b> A search was conducted using MEDLINE via PubMed, EMBASE, Cochrane Library, and Google Scholar. Articles reporting the microbiology of cryptoglandular anorectal abscesses and the resulting anal fistulas in human beings were included. The main outcome was to evaluate the presence of bacteria in cultures of anorectal abscesses or in patients who developed anal fistulas. Additional goals included identifying patient characteristics and assessing clinical outcomes on the basis of the isolated bacteria. <b><i>Results:</i></b> In total, 22 articles on anorectal abscesses and seven on anal fistulas met the inclusion criteria. Men were the most prevalent in both cases. <i>Escherichia coli</i> and the <i>Bacteroides</i> genus were the most isolated microorganisms in abscesses and fistulas, though inconsistently in the latter. <i>Bilophila wadsworthia</i> was newly isolated in abscesses, and <i>Rothia</i> sp. was notable in fistulas using new molecular techniques. <b><i>Conclusions:</i></b> <i>Escherichia coli</i> and <i>Bacteroides</i> sp. are involved in anorectal abscesses and anal fistula formation. Recently, using new technology non-well-known bacteria had been isolated involved in this clinical problem.", "abstract_zh": "<b><i>ç›®çš„ï¼š</i></b>éšçªè…ºè‚›é—¨ç›´è‚ è„“è‚¿æ˜¯è‚›é—¨å‘¨å›´åŒ–è„“æ€§ç‰©è´¨çš„èšé›†ï¼Œé€šå¸¸åœ¨å¼•æµåå¯¼è‡´è‚›ç˜˜çš„å‘å±•ã€‚å°½ç®¡å¤§è‚ æ†èŒå’Œè„†å¼±æ‹Ÿæ†èŒè¢«è®¤ä¸ºæ˜¯è¿™äº›æƒ…å†µä¸‹çš„å…³é”®ç»†èŒï¼Œä½†æœ€è¿‘çš„è¯æ®è¡¨æ˜æœ‰å¿…è¦é‡æ–°å®¡è§†è¿™ä¸€å‡è®¾ã€‚è¿™é¡¹å·¥ä½œæ—¨åœ¨åˆ†æç»†èŒåœ¨è‚›é—¨ç›´è‚ è„“è‚¿åè‚›ç˜˜å‘å±•ä¸­çš„å­˜åœ¨å’Œä½œç”¨ã€‚ <b><i>æ‚£è€…å’Œæ–¹æ³•ï¼š</i></b>ä½¿ç”¨ MEDLINE é€šè¿‡ PubMedã€EMBASEã€Cochrane å›¾ä¹¦é¦†å’Œ Google Scholar è¿›è¡Œæœç´¢ã€‚æŠ¥å‘Šäººç±»éšè…ºè‚›é—¨ç›´è‚ è„“è‚¿å’Œç”±æ­¤äº§ç”Ÿçš„è‚›ç˜˜çš„å¾®ç”Ÿç‰©å­¦çš„æ–‡ç« ä¹Ÿè¢«çº³å…¥å…¶ä¸­ã€‚ä¸»è¦ç»“æœæ˜¯è¯„ä¼°è‚›é—¨ç›´è‚ è„“è‚¿åŸ¹å…»ç‰©æˆ–å‘ç”Ÿè‚›ç˜˜çš„æ‚£è€…ä¸­ç»†èŒçš„å­˜åœ¨ã€‚å…¶ä»–ç›®æ ‡åŒ…æ‹¬è¯†åˆ«æ‚£è€…ç‰¹å¾å¹¶æ ¹æ®åˆ†ç¦»çš„ç»†èŒè¯„ä¼°ä¸´åºŠç»“æœã€‚ <b><i>ç»“æœï¼š</i></b>æ€»å…±æœ‰ 22 ç¯‡å…³äºè‚›é—¨ç›´è‚ è„“è‚¿çš„æ–‡ç« å’Œ 7 ç¯‡å…³äºè‚›ç˜˜çš„æ–‡ç« ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚åœ¨è¿™ä¸¤ç§æƒ…å†µä¸‹ï¼Œç”·æ€§æœ€ä¸ºå¸¸è§ã€‚å¤§è‚ æ†èŒå’Œæ‹Ÿæ†èŒå±æ˜¯è„“è‚¿å’Œç˜˜ç®¡ä¸­åˆ†ç¦»åº¦æœ€é«˜çš„å¾®ç”Ÿç‰©ï¼Œå°½ç®¡åè€…çš„æƒ…å†µä¸ä¸€è‡´ã€‚ <i>Bilophila wadsworthia</i>æ˜¯æ–°åœ¨è„“è‚¿ä¸­åˆ†ç¦»å‡ºæ¥çš„ï¼Œè€Œ<i>Rothia</i> spã€‚åœ¨ä½¿ç”¨æ–°åˆ†å­æŠ€æœ¯çš„ç˜˜ç®¡æ²»ç–—ä¸­å€¼å¾—æ³¨æ„ã€‚ <b><i>ç»“è®ºï¼š</i></b> <i>å¤§è‚ æ†èŒ</i>å’Œ<i>æ‹Ÿæ†èŒ</i> spã€‚å‚ä¸è‚›é—¨ç›´è‚ è„“è‚¿å’Œè‚›ç˜˜çš„å½¢æˆã€‚æœ€è¿‘ï¼Œåˆ©ç”¨æ–°æŠ€æœ¯åˆ†ç¦»å‡ºäº†ä¸è¿™ä¸€ä¸´åºŠé—®é¢˜æœ‰å…³çš„éçŸ¥åç»†èŒã€‚", "keywords_zh": "è‚›ç˜˜ã€è‚›é—¨ç›´è‚ è„“è‚¿ã€ç»†èŒå­¦ã€åŸ¹å…»", "keywords_en": "anal fistula, anorectal abscess, bacteriology, cultures", "link": "https://pubmed.ncbi.nlm.nih.gov/40833840/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 20 Aug 2025"}, {"id": "40824311", "title_en": "Abdominoperineal pull-through with delayed coloanal anastomosis for pelvic anastomotic failure-a systematic review", "title_zh": "è…¹ä¼šé˜´ç‰µå¼•å»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ²»ç–—ç›†è…”å»åˆå¤±è´¥çš„ç³»ç»Ÿè¯„ä»·", "authors": "I Seow-En", "abstract_en": "**Aim:** Despite theÂ potential benefits of abdominoperineal pull-through with delayed coloanal anastomosis (DCAA), it is still infrequently performed as a salvage procedure for pelvic anastomotic failure. We aimed to perform a systematic review on the subject to guide practice.\n\n**Method:** PubMed, Embase and Cochrane were used to identify studies evaluating DCAA for salvage after pelvic surgery from inception to August 2024. Risk of bias assessment was performed using the Newcastle-Ottawa scale. The primary outcome was overall stoma-free survival. Secondary outcomes included hospital length of stay, high-grade postoperative complication rates, 30-day postoperative mortality rates, incidence of redo surgical intervention after DCAA, and postoperative anorectal function.\n\n**Results:** Five retrospective cohort studies evaluating a total of 97 patientsÂ who underwent salvage abdominoperineal pull-through and DCAA were included in this review. All patients had previous pelvic surgery, predominantly proctectomy (nâ€‰=â€‰84, 86.6%). The most common indication forÂ redo surgery was chronic fistula (nâ€‰=â€‰62, 63.9%) followed by anastomotic leak or chronic pelvic sepsis (nâ€‰=â€‰34, 35.1%). The pooled overall stoma-free survival rate across all five studies was 81.4% over a mean 24-month postoperative follow-up duration. The overall incidence of high-grade complicationsÂ after DCAA was 39.1% (nâ€‰=â€‰38). Pooled mean length of stay was 17 days. There were no cases of early postoperative death. Pooled rate of repeat surgery across four studies was 11.6% (nâ€‰=â€‰8). Pooled mean functional scores across three studies indicated minor low anterior resection syndrome at 26 months.\n\n**Conclusion:** Abdominoperineal pull-through with delayed coloanal anastomosis is a viable option for salvage surgery following pelvic anastomotic complications, with low rates of permanent stoma and acceptable long-term anorectal function.", "abstract_zh": "**Aimï¼š** å°½ç®¡è…¹ä¼šé˜´æ‹‰ç©¿å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ (DCAA) å…·æœ‰æ½œåœ¨ç›Šå¤„ï¼Œä½†å®ƒä»ç„¶å¾ˆå°‘ä½œä¸ºéª¨ç›†å»åˆå¤±è´¥çš„æŒ½æ•‘æ‰‹æœ¯è¿›è¡Œã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯å¯¹è¯¥ä¸»é¢˜è¿›è¡Œç³»ç»Ÿå›é¡¾ä»¥æŒ‡å¯¼å®è·µã€‚\n\n**Methodï¼š** PubMedã€Embase å’Œ Cochrane è¢«ç”¨æ¥è¯†åˆ«ä»å¼€å§‹åˆ° 2024 å¹´ 8 æœˆè¯„ä¼° DCAA åœ¨ç›†è…”æ‰‹æœ¯åæŒ½æ•‘æ•ˆæœçš„ç ”ç©¶ã€‚ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨è¿›è¡Œåå€šé£é™©è¯„ä¼°ã€‚ä¸»è¦ç»“æœæ˜¯æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ä½é™¢æ—¶é—´ã€æœ¯åé«˜çº§å¹¶å‘ç—‡å‘ç”Ÿç‡ã€æœ¯å 30 å¤©æ­»äº¡ç‡ã€DCAA åé‡åšæ‰‹æœ¯å¹²é¢„çš„å‘ç”Ÿç‡ä»¥åŠæœ¯åè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** æœ¬ç»¼è¿°çº³å…¥äº†äº”é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œè¯„ä¼°äº†æ€»å…± 97 åæ¥å—æŒ½æ•‘æ€§è…¹ä¼šé˜´ç‰µå¼•æœ¯å’Œ DCAA çš„æ‚£è€…ã€‚æ‰€æœ‰æ‚£è€…å‡æ›¾æ¥å—è¿‡ç›†è…”æ‰‹æœ¯ï¼Œä¸»è¦æ˜¯ç›´è‚ åˆ‡é™¤æœ¯ï¼ˆnâ€‰=â€‰84ï¼Œ86.6%ï¼‰ã€‚é‡åšæ‰‹æœ¯æœ€å¸¸è§çš„é€‚åº”ç—‡æ˜¯æ…¢æ€§ç˜˜ï¼ˆnâ€‰=â€‰62ï¼Œ63.9%ï¼‰ï¼Œå…¶æ¬¡æ˜¯å»åˆå£ç˜˜æˆ–æ…¢æ€§ç›†è…”è„“æ¯’ç—‡ï¼ˆnâ€‰=â€‰34ï¼Œ35.1%ï¼‰ã€‚åœ¨å¹³å‡ 24 ä¸ªæœˆçš„æœ¯åéšè®¿æœŸé—´ï¼Œæ‰€æœ‰äº”é¡¹ç ”ç©¶çš„æ±‡æ€»æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ä¸º 81.4%ã€‚ DCAA åé«˜çº§å¹¶å‘ç—‡çš„æ€»ä½“å‘ç”Ÿç‡ä¸º 39.1% (nâ€‰=â€‰38)ã€‚åˆå¹¶å¹³å‡ä½é™¢æ—¶é—´ä¸º 17 å¤©ã€‚æ— æœ¯åæ—©æœŸæ­»äº¡ç—…ä¾‹ã€‚å››é¡¹ç ”ç©¶çš„é‡å¤æ‰‹æœ¯æ±‡æ€»ç‡ä¸º 11.6% (nâ€‰=â€‰8)ã€‚ä¸‰é¡¹ç ”ç©¶çš„æ±‡æ€»å¹³å‡åŠŸèƒ½è¯„åˆ†è¡¨æ˜ 26 ä¸ªæœˆæ—¶æœ‰è½»å¾®çš„ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ã€‚\n\n**ç»“è®ºï¼š** è…¹ä¼šé˜´ç‰µå¼•è”åˆå»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ˜¯ç›†è…”å»åˆå¹¶å‘ç—‡åæŒ½æ•‘æ‰‹æœ¯çš„å¯è¡Œé€‰æ‹©ï¼Œå…·æœ‰è¾ƒä½çš„æ°¸ä¹…æ€§é€ å£ç‡å’Œå¯æ¥å—çš„é•¿æœŸè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚", "keywords_zh": "è…¹ä¼šé˜´ç‰µå¼•ã€ç»“ç›´è‚ æ‰‹æœ¯ã€å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ã€é‡åšæ‰‹æœ¯", "keywords_en": "Abdominoperineal pull-through, Colorectal surgery, Delayed coloanal anastomosis, Redo surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40824311/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 18 Aug 2025"}, {"id": "40780867", "title_en": "PAVFCOS: The development of a core outcome set for pouch anal and vaginal fistula", "title_zh": "PAVFCOSï¼šé’ˆå¯¹å‚¨è¢‹è‚›ç˜˜å’Œé˜´é“ç˜˜åˆ¶å®šæ ¸å¿ƒç»“æœé›†", "authors": "Phil Tozer", "abstract_en": "**Aims:** The primary aim was to develop a patient-centred core outcome set (COS) for interventional studies in patients with pouch anal and vaginal fistula (PAVF).\n\n**Method:** PAVFCOS was developed using the methodology outlined by the Core Outcome Measures in Effectiveness Trials (COMET). Systematic review and qualitative patient interviews produced a long list of candidate outcomes. An online Delphi exercise was conducted with stakeholders to prioritise and shortlist outcomes. A consensus meeting of patients and clinicians ratified the final core outcome set.\n\n**Results:** A systematic review of the literature and 14 qualitative patient interviews produced a long list of 99 outcomes. These were reduced to 46 outcomes and subjected to two rounds of a Delphi exercise with 70 participants, including patients (45%), colorectal surgeons (31%), radiologists (6%), gastroenterologists (11%) and pouch specialist nurses (7%). Thirty-six outcomes were discussed in a consensus meeting of seven clinicians and seven patients. Seven core outcomes were selected for inclusion: global assessment of continence, pain related to fistula and surrounding area, impact on quality of life of fistula discharge, fistula healing (clinical and radiological), new fistula or abscess, need for rescue intervention (minor or major) and global quality-of-life assessment.\n\n**Conclusion:** PAVFCOS is the first to establish outcomes that are important to patients with pouch anal and vaginal fistula. PAVFCOS should be used in interventional studies to introduce much-needed standardisation of outcome reporting in this challenging condition.", "abstract_zh": "**Aimsï¼š** ä¸»è¦ç›®çš„æ˜¯å¼€å‘ä¸€ä¸ªä»¥æ‚£è€…ä¸ºä¸­å¿ƒçš„æ ¸å¿ƒç»“æœé›†ï¼ˆCOSï¼‰ï¼Œç”¨äºå‚¨è¢‹è‚›ç˜˜å’Œé˜´é“ç˜˜ï¼ˆPAVFï¼‰æ‚£è€…çš„ä»‹å…¥ç ”ç©¶ã€‚\n\n**Methodï¼š** PAVFCOS æ˜¯ä½¿ç”¨æœ‰æ•ˆæ€§è¯•éªŒæ ¸å¿ƒç»“æœè¡¡é‡æ ‡å‡† (COMET) æ¦‚è¿°çš„æ–¹æ³•å¼€å‘çš„ã€‚ç³»ç»Ÿå®¡æŸ¥å’Œå®šæ€§æ‚£è€…è®¿è°ˆäº§ç”Ÿäº†ä¸€é•¿ä¸²å€™é€‰ç»“æœã€‚ä¸åˆ©ç›Šç›¸å…³è€…ä¸€èµ·è¿›è¡Œäº†åœ¨çº¿å¾·å°”è²ç»ƒä¹ ï¼Œä»¥ç¡®å®šç»“æœçš„ä¼˜å…ˆé¡ºåºå’Œæœ€ç»ˆåå•ã€‚æ‚£è€…å’Œä¸´åºŠåŒ»ç”Ÿçš„å…±è¯†ä¼šè®®æ‰¹å‡†äº†æœ€ç»ˆçš„æ ¸å¿ƒç»“æœé›†ã€‚\n\n**ç»“æœï¼š** å¯¹æ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾å’Œ 14 æ¬¡å®šæ€§æ‚£è€…è®¿è°ˆäº§ç”Ÿäº† 99 é¡¹ç»“æœçš„é•¿åˆ—è¡¨ã€‚è¿™äº›ç»“æœè¢«å‡å°‘åˆ° 46 ç§ï¼Œå¹¶æ¥å—äº†ä¸¤è½®å¾·å°”è²æ¼”ä¹ ï¼Œå…±æœ‰ 70 åå‚ä¸è€…ï¼ŒåŒ…æ‹¬æ‚£è€… (45%)ã€ç»“ç›´è‚ å¤–ç§‘åŒ»ç”Ÿ (31%)ã€æ”¾å°„ç§‘åŒ»ç”Ÿ (6%)ã€èƒƒè‚ ç§‘åŒ»ç”Ÿ (11%) å’Œé€ å£è¢‹ä¸“ç§‘æŠ¤å£« (7%)ã€‚ä¸ƒåä¸´åºŠåŒ»ç”Ÿå’Œä¸ƒåæ‚£è€…å‚åŠ çš„å…±è¯†ä¼šè®®è®¨è®ºäº† 36 é¡¹ç»“æœã€‚é€‰æ‹©çº³å…¥ä¸ƒä¸ªæ ¸å¿ƒç»“å±€ï¼šå¤±ç¦çš„æ€»ä½“è¯„ä¼°ã€ä¸ç˜˜ç®¡åŠå‘¨å›´åŒºåŸŸç›¸å…³çš„ç–¼ç—›ã€ç˜˜ç®¡æ’å‡ºå¯¹ç”Ÿæ´»è´¨é‡çš„å½±å“ã€ç˜˜ç®¡æ„ˆåˆï¼ˆä¸´åºŠå’Œæ”¾å°„å­¦ï¼‰ã€æ–°çš„ç˜˜ç®¡æˆ–è„“è‚¿ã€æ•‘æ´å¹²é¢„çš„éœ€è¦ï¼ˆè½»å¾®æˆ–ä¸¥é‡ï¼‰ä»¥åŠæ€»ä½“ç”Ÿæ´»è´¨é‡è¯„ä¼°ã€‚\n\n**ç»“è®ºï¼š** PAVFCOS é¦–æ¬¡ç¡®ç«‹äº†å¯¹å‚¨è¢‹è‚›ç˜˜å’Œé˜´é“ç˜˜æ‚£è€…é‡è¦çš„ç»“æœã€‚ PAVFCOS åº”è¯¥ç”¨äºä»‹å…¥ç ”ç©¶ï¼Œä»¥åœ¨è¿™ç§å…·æœ‰æŒ‘æˆ˜æ€§çš„æƒ…å†µä¸‹å¼•å…¥æ€¥éœ€çš„ç»“æœæŠ¥å‘Šæ ‡å‡†åŒ–ã€‚", "keywords_zh": "æ ¸å¿ƒç»“æœé›†ã€å›è‚ è‚›è¢‹ã€ç‚ç—‡æ€§è‚ ç—…ã€æ‚£è€…æŠ¥å‘Šçš„ç»“æœ", "keywords_en": "core outcome set, ileoanal pouch, inflammatory bowel disease, patientâ€reported outcomes", "link": "https://pubmed.ncbi.nlm.nih.gov/40780867/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 08 Aug 2025"}, {"id": "40693967", "title_en": "Transanal opening of intersphincteric space (TROPIS) treatment for high complex anal fistula: a systematic review and meta-analysis", "title_zh": "ç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ï¼ˆTROPISï¼‰æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jiawen Wang", "abstract_en": "**Background:** The transanal opening of intersphincteric space (TROPIS) is a new surgical modality for treating anal fistulas. This procedure involves a transanal incision between the sphincters to promote drainage, excision of the infected areas, and maintenance of sphincter patency. In this meta-analysis, we evaluated the efficacy and safety of TROPIS in treating high complex anal fistula.\n\n**Methods:** We searched the PubMed (NLM), LISTA (EBSCO), and Web of Science Core Collection (Clarivate) databases for all related clinical research literature on highly complex anal fistulas treated with TROPIS from the time of database creation to 31 December 2024, with inclusion restricted to studies published in English. All included articles follow the PICO principle. Data on surgical one-time cure rate, recurrence rate after the first surgery, final cure rate, and occurrence of adverse events were extracted for further analysis.\n\n**Results:** Six studies involving 499 patients were included. The heterogeneity test revealed no heterogeneity, and results for one-time cure rate showed I 2 Â =Â 0.00%Â <Â 50%, and Q test P =Â 0.81Â >Â 0.1 (effect size [ES]Â =Â 0.80, 95% confidence interval [CI] (0.77, 0.84), Z =Â 45.96, P =Â 0.00), where the one-time cure rate was 80%; recurrence rate after first surgery I 2 Â =Â 0.00%Â <Â 50%, and Q test P =Â 0.81Â >Â 0.1 (ESÂ =Â 0.20, 95% CI (0.16, 0.23), Z =Â 17.49, P =Â 0.00), and the recurrence rate is 20%; final cure rate I 2 Â =Â 0.00%Â <Â 50%, and Q test P =Â 0.82Â >Â 0.1 (ESÂ =Â 0.89, 95% CI (0.86, 0.92), Z =Â 51.21, P =Â 0.00), and the final cure rate was 89%. No adverse events were reported in any of the patients. Sensitivity analyses showed excellent stability of the surgical cure results in all studies. No publication bias was detected in any of the included studies.\n\n**Conclusions:** The TROPIS procedure for highly complex anal fistulas exhibits a high one-time cure rate, low recurrence rate, and high overall cure rate and is not associated with any adverse events.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»è‚›é—¨æ‹¬çº¦è‚Œé—´éš™å¼€æ”¾æœ¯ï¼ˆTROPISï¼‰æ˜¯æ²»ç–—è‚›ç˜˜çš„ä¸€ç§æ–°æ‰‹æœ¯æ–¹å¼ã€‚è¯¥æ‰‹æœ¯æ¶‰åŠåœ¨æ‹¬çº¦è‚Œä¹‹é—´è¿›è¡Œç»è‚›é—¨åˆ‡å£ä»¥ä¿ƒè¿›å¼•æµã€åˆ‡é™¤æ„ŸæŸ“åŒºåŸŸå¹¶ä¿æŒæ‹¬çº¦è‚Œé€šç•…ã€‚åœ¨è¿™é¡¹èŸèƒåˆ†æä¸­ï¼Œæˆ‘ä»¬è¯„ä¼°äº† TROPIS æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº† PubMed (NLM)ã€LISTA (EBSCO) å’Œ Web of Science Core Collection (Clarivate) æ•°æ®åº“ï¼ŒæŸ¥æ‰¾ä»æ•°æ®åº“åˆ›å»ºä¹‹æ—¶åˆ° 2024 å¹´ 12 æœˆ 31 æ—¥æœŸé—´æ‰€æœ‰å…³äº TROPIS æ²»ç–—é«˜åº¦å¤æ‚è‚›ç˜˜çš„ç›¸å…³ä¸´åºŠç ”ç©¶æ–‡çŒ®ï¼Œä»…é™äºä»¥è‹±æ–‡å‘è¡¨çš„ç ”ç©¶ã€‚æ‰€æœ‰åŒ…å«çš„æ–‡ç« éƒ½éµå¾ª PICO åŸåˆ™ã€‚æå–æ‰‹æœ¯ä¸€æ¬¡æ€§æ²»æ„ˆç‡ã€é¦–æ¬¡æ‰‹æœ¯åå¤å‘ç‡ã€æœ€ç»ˆæ²»æ„ˆç‡ä»¥åŠä¸è‰¯äº‹ä»¶å‘ç”Ÿæƒ…å†µçš„æ•°æ®è¿›è¡Œè¿›ä¸€æ­¥åˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥äº†æ¶‰åŠ 499 åæ‚£è€…çš„å…­é¡¹ç ”ç©¶ã€‚å¼‚è´¨æ€§æ£€éªŒæœªå‘ç°å¼‚è´¨æ€§ï¼Œä¸€æ¬¡æ€§æ²»æ„ˆç‡ç»“æœæ˜¾ç¤º I 2 = 0.00% < 50%ï¼ŒQ æ£€éªŒ P = 0.81 > 0.1ï¼ˆæ•ˆåº”é‡ [ES] = 0.80ï¼Œ95% ç½®ä¿¡åŒºé—´ [CI] (0.77, 0.84)ï¼ŒZ = 45.96ï¼ŒP = 0.00ï¼‰ï¼Œå…¶ä¸­ä¸€æ¬¡æ€§æ²»æ„ˆç‡ä¸º80%ï¼›é¦–æ¬¡æ‰‹æœ¯åå¤å‘ç‡ I 2 = 0.00% < 50%ï¼ŒQ æ£€éªŒ P = 0.81 > 0.1 (ES = 0.20, 95% CI (0.16, 0.23), Z = 17.49, P = 0.00)ï¼Œå¤å‘ç‡ä¸º 20%ï¼›æœ€ç»ˆæ²»æ„ˆç‡ I 2 = 0.00% < 50%ï¼ŒQ æ£€éªŒ P = 0.82 > 0.1ï¼ˆES = 0.89ï¼Œ95% CIï¼ˆ0.86ï¼Œ0.92ï¼‰ï¼ŒZ = 51.21ï¼ŒP = 0.00ï¼‰ï¼Œæœ€ç»ˆæ²»æ„ˆç‡ä¸º 89%ã€‚æ‰€æœ‰æ‚£è€…å‡æœªæŠ¥å‘Šä¸è‰¯äº‹ä»¶ã€‚æ•æ„Ÿæ€§åˆ†ææ˜¾ç¤ºæ‰€æœ‰ç ”ç©¶ä¸­æ‰‹æœ¯æ²»æ„ˆç»“æœå‡å…·æœ‰å‡ºè‰²çš„ç¨³å®šæ€§ã€‚åœ¨æ‰€æœ‰çº³å…¥çš„ç ”ç©¶ä¸­å‡æœªå‘ç°å‘è¡¨åå€šã€‚\n\n**ç»“è®ºï¼š** TROPISæ‰‹æœ¯æ²»ç–—é«˜åº¦å¤æ‚çš„è‚›ç˜˜å…·æœ‰ä¸€æ¬¡æ€§æ²»æ„ˆç‡é«˜ã€å¤å‘ç‡ä½ã€æ€»ä½“æ²»æ„ˆç‡é«˜çš„ç‰¹ç‚¹ï¼Œä¸”ä¸äº§ç”Ÿä»»ä½•ä¸è‰¯äº‹ä»¶ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œé«˜ä½å¤æ‚æ€§è‚›ç˜˜ï¼ŒèŸèƒåˆ†æï¼Œç³»ç»Ÿè¯„ä»·ï¼Œç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ï¼ˆTROPISï¼‰", "keywords_en": "anal fistula, high complex anal fistula, meta-analysis, systematic review, transanal opening of intersphincteric space (TROPIS)", "link": "https://pubmed.ncbi.nlm.nih.gov/40693967/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 22 Jul 2025"}, {"id": "40672439", "title_en": "Diagnosis and treatment for anal fistula: a systematic review of clinical practice guidelines and consensus statements", "title_zh": "è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—ï¼šä¸´åºŠå®è·µæŒ‡å—å’Œå…±è¯†å£°æ˜çš„ç³»ç»Ÿå›é¡¾", "authors": "Rong Shi", "abstract_en": "**Background:** Anal fistula constitutes a pathological channel originating either from the anal canal or rectum to the skin surrounding the anus, primarily characterized by recurrent pain, purulent discharge, and pruritus. This study aims to compare and standardize the recommendations for the diagnosis and treatment of anal fistula, drawing on contemporary clinical practice guidelines.\n\n**Methods:** A comprehensive search was conducted across multiple databases including PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biological Medicine Database, from their inception through April 1, 2024. The objective was to collate all published guidelines on anal fistula. The quality of the eligible guidelines was appraised by two reviewers using the Appraisal of Guidelines for Research and Evaluation II instrument.\n\n**Results:** The search yielded fifteen guidance documents -comprising nine guidelines and six consensus statements -each offering specific recommendations. Twelve of these documents address screening and diagnosis of anal fistula, while all fifteen discuss various treatment and management strategies. Document analysis highlighted MRI as the predominant diagnostic recommendation. Treatment and management strategies were categorized into four categories: preoperative management, surgical method selection, pharmacological interventions, and postoperative management. Regarding surgical interventions, all guidelines address incision and drainage of fistulas. Most guidelines offer a low recommendation for cutting setons, mainly attributed to the presence of incontinence. For high-positioned anal fistula, a push-pull flap procedure is recommended, whereas the LIFT procedure is advocated for newly identified, high, and sphincter-penetrating fistulas. Among the 15 guidelines and consensus statements evaluated in this study, more than half demonstrated methodological limitations, with particularly deficient performance in the applicability domain. As a critical determinant of implementation effectiveness, these deficiencies may undermine guidelines' capacity to optimize health outcomes.\n\n**Conclusion:** There is a pressing need for an updated search of potential evidence on the diagnosis and treatment of anal fistula. Effective diagnoses and therapeutic approaches, whether conventional or complementary and alternative medicine, should be thoroughly evaluated and incorporated based on robust evidence.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›ç˜˜æ˜¯ä»è‚›ç®¡æˆ–ç›´è‚ åˆ°è‚›é—¨å‘¨å›´çš®è‚¤çš„ç—…ç†é€šé“ï¼Œä¸»è¦è¡¨ç°ä¸ºåå¤ç–¼ç—›ã€è„“æ€§åˆ†æ³Œç‰©å’Œç˜™ç—’ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å€Ÿé‰´å½“ä»£ä¸´åºŠå®è·µæŒ‡å—ï¼Œå¯¹è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—å»ºè®®è¿›è¡Œæ¯”è¾ƒå’Œæ ‡å‡†åŒ–ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹PubMedã€EMBASEã€ä¸­å›½å›½å®¶çŸ¥è¯†åŸºç¡€è®¾æ–½ã€ä¸‡æ–¹æ•°æ®åº“ã€ä¸­å›½ç§‘æŠ€æœŸåˆŠæ•°æ®åº“å’Œä¸­å›½ç”Ÿç‰©åŒ»å­¦æ•°æ®åº“ç­‰å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œä»å»ºåº“åˆ°2024å¹´4æœˆ1æ—¥ã€‚ç›®çš„æ˜¯æ•´ç†æ‰€æœ‰å·²å‘å¸ƒçš„è‚›ç˜˜æŒ‡å—ã€‚åˆæ ¼æŒ‡å—çš„è´¨é‡ç”±ä¸¤åè¯„å®¡å‘˜ä½¿ç”¨â€œç ”ç©¶å’Œè¯„ä¼°æŒ‡å— II è¯„ä¼°â€å·¥å…·è¿›è¡Œè¯„ä¼°ã€‚\n\n**ç»“æœï¼š** æœç´¢äº§ç”Ÿäº†åäº”ä»½æŒ‡å¯¼æ–‡ä»¶ï¼Œå…¶ä¸­åŒ…æ‹¬ä¹ä»½æŒ‡å—å’Œå…­ä»½å…±è¯†å£°æ˜ï¼Œæ¯ä»½æ–‡ä»¶éƒ½æä¾›äº†å…·ä½“å»ºè®®ã€‚å…¶ä¸­åäºŒä»½æ–‡ä»¶æ¶‰åŠè‚›ç˜˜çš„ç­›æŸ¥å’Œè¯Šæ–­ï¼Œæ‰€æœ‰åäº”ä»½æ–‡ä»¶éƒ½è®¨è®ºäº†å„ç§æ²»ç–—å’Œç®¡ç†ç­–ç•¥ã€‚æ–‡æ¡£åˆ†æå¼ºè°ƒ MRI æ˜¯ä¸»è¦çš„è¯Šæ–­å»ºè®®ã€‚æ²»ç–—å’Œç®¡ç†ç­–ç•¥åˆ†ä¸ºå››ç±»ï¼šæœ¯å‰ç®¡ç†ã€æ‰‹æœ¯æ–¹æ³•é€‰æ‹©ã€è¯ç‰©å¹²é¢„å’Œæœ¯åç®¡ç†ã€‚å…³äºæ‰‹æœ¯å¹²é¢„ï¼Œæ‰€æœ‰æŒ‡å—å‡æ¶‰åŠç˜˜ç®¡åˆ‡å¼€å’Œå¼•æµã€‚å¤§å¤šæ•°æŒ‡å—å¯¹åˆ‡æŒ‚çº¿çš„å»ºè®®è¾ƒä½ï¼Œè¿™ä¸»è¦æ˜¯ç”±äºå­˜åœ¨å¤±ç¦ã€‚å¯¹äºé«˜ä½è‚›ç˜˜ï¼Œå»ºè®®é‡‡ç”¨æ¨æ‹‰çš®ç“£æ‰‹æœ¯ï¼Œè€Œå¯¹äºæ–°å‘ç°çš„é«˜ä½è‚›ç˜˜å’Œæ‹¬çº¦è‚Œç©¿é€æ€§è‚›ç˜˜åˆ™æå€¡é‡‡ç”¨ LIFT æ‰‹æœ¯ã€‚åœ¨æœ¬ç ”ç©¶è¯„ä¼°çš„ 15 æ¡æŒ‡å—å’Œå…±è¯†å£°æ˜ä¸­ï¼Œè¶…è¿‡ä¸€åŠè¡¨ç°å‡ºæ–¹æ³•å­¦å±€é™æ€§ï¼Œå°¤å…¶æ˜¯åœ¨é€‚ç”¨æ€§é¢†åŸŸè¡¨ç°ä¸è¶³ã€‚ä½œä¸ºå®æ–½æœ‰æ•ˆæ€§çš„å…³é”®å†³å®šå› ç´ ï¼Œè¿™äº›ç¼ºé™·å¯èƒ½ä¼šå‰Šå¼±æŒ‡å—ä¼˜åŒ–å¥åº·ç»“æœçš„èƒ½åŠ›ã€‚\n\n**ç»“è®ºï¼š** è¿«åˆ‡éœ€è¦æ›´æ–°æœ‰å…³è‚›ç˜˜è¯Šæ–­å’Œæ²»ç–—çš„æ½œåœ¨è¯æ®ã€‚æœ‰æ•ˆçš„è¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ï¼Œæ— è®ºæ˜¯ä¼ ç»ŸåŒ»å­¦è¿˜æ˜¯è¡¥å……å’Œæ›¿ä»£åŒ»å­¦ï¼Œéƒ½åº”åŸºäºå¼ºæœ‰åŠ›çš„è¯æ®è¿›è¡Œå½»åº•è¯„ä¼°å’Œæ•´åˆã€‚", "keywords_zh": "è‚›ç˜˜, è¯Šæ–­, æŒ‡å—, ç³»ç»Ÿè¯„ä»·, æ²»ç–—", "keywords_en": "anal fistula, diagnosis, guidelines, systematic review, therapeutic", "link": "https://pubmed.ncbi.nlm.nih.gov/40672439/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 17 Jul 2025"}, {"id": "40607121", "title_en": "Systematic review and meta-analysis of Transanal Opening of Intersphincteric Space (TROPIS) versus conventional treatments for anal fistula", "title_zh": "ç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾ (TROPIS) ä¸è‚›ç˜˜å¸¸è§„æ²»ç–—çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Jing Wang", "abstract_en": "Transanal Opening of Intersphincteric Space (TROPIS) has emerged as a promising surgical approach for anal fistula management over recent years. This meta-analysis comprehensively evaluates the comparative efficacy and safety of TROPIS versus conventional treatments through systematic analysis of 24 clinical studies involving 2813 patients. Through systematic searches across 7 major biomedical databases (including PubMed, EMBASE, and Chinese repositories) from inception to March 2024, we identified comparative studies assessing TROPIS against six established interventions: incision-thread-drawing, seton placement, LIFT, EAFR, fistulotomy, and incision-suture techniques. Pooled analysis demonstrated TROPIS achieved superior clinical outcomes, with a 3.15-fold higher total efficacy rate (95Â % CI 1.22-8.13, <i>p</i>Â =Â 0.02) and 64Â % lower complication risk compared to conventional methods (OR 0.28, 95Â % CI 0.18-0.42, <i>p</i>Â <Â 0.00001). Sensitivity analyses confirmed result stability across study designs, while publication bias assessment via funnel plots and Egger's test revealed no significant distortion. Importantly, TROPIS maintained its advantage across various complication subtypes including incontinence (OR 0.31), infection (OR 0.27), and recurrence (OR 0.19). These findings establish TROPIS as a clinically superior alternative that significantly improves therapeutic outcomes while reducing procedure-related risks, suggesting its potential to become the new reference standard in anal fistula management. The consistent results across diverse patient populations and comparator procedures underscore the robustness of this evidence synthesis.", "abstract_zh": "è¿‘å¹´æ¥ï¼Œç»è‚›é—¨æ‹¬çº¦è‚Œé—´å¼€æ”¾æœ¯ï¼ˆTROPISï¼‰å·²æˆä¸ºæ²»ç–—è‚›ç˜˜çš„ä¸€ç§æœ‰å‰é€”çš„æ‰‹æœ¯æ–¹æ³•ã€‚è¿™é¡¹èŸèƒåˆ†æé€šè¿‡å¯¹æ¶‰åŠ 2813 åæ‚£è€…çš„ 24 é¡¹ä¸´åºŠç ”ç©¶è¿›è¡Œç³»ç»Ÿåˆ†æï¼Œå…¨é¢è¯„ä¼°äº† TROPIS ä¸ä¼ ç»Ÿæ²»ç–—çš„ç–—æ•ˆå’Œå®‰å…¨æ€§æ¯”è¾ƒã€‚é€šè¿‡ä»æˆç«‹åˆ° 2024 å¹´ 3 æœˆå¯¹ 7 ä¸ªä¸»è¦ç”Ÿç‰©åŒ»å­¦æ•°æ®åº“ï¼ˆåŒ…æ‹¬ PubMedã€EMBASE å’Œä¸­å›½å­˜å‚¨åº“ï¼‰çš„ç³»ç»Ÿæœç´¢ï¼Œæˆ‘ä»¬å‘ç°äº†è¯„ä¼° TROPIS ä¸å…­ç§æ—¢å®šå¹²é¢„æªæ–½çš„æ¯”è¾ƒç ”ç©¶ï¼šåˆ‡å£æŒ‚çº¿ã€æŒ‚çº¿æ”¾ç½®ã€LIFTã€EAFRã€ç˜˜ç®¡åˆ‡å¼€æœ¯å’Œåˆ‡å£ç¼åˆæŠ€æœ¯ã€‚æ±‡æ€»åˆ†æè¡¨æ˜ï¼ŒTROPIS å–å¾—äº†ä¼˜å¼‚çš„ä¸´åºŠç»“æœï¼Œä¸ä¼ ç»Ÿæ–¹æ³•ç›¸æ¯”ï¼Œæ€»æœ‰æ•ˆç‡æé«˜äº† 3.15 å€ï¼ˆ95% CI 1.22-8.13ï¼Œ<i>p</i>=0.02ï¼‰ï¼Œå¹¶å‘ç—‡é£é™©é™ä½äº† 64%ï¼ˆOR 0.28ï¼Œ95% CI 0.18-0.42ï¼Œ<i>p</i><0.00001ï¼‰ã€‚æ•æ„Ÿæ€§åˆ†æè¯å®äº†æ•´ä¸ªç ”ç©¶è®¾è®¡çš„ç»“æœç¨³å®šæ€§ï¼Œè€Œé€šè¿‡æ¼æ–—å›¾å’Œè‰¾æ ¼æ£€éªŒè¿›è¡Œçš„å‘è¡¨åå€šè¯„ä¼°æ˜¾ç¤ºæ²¡æœ‰æ˜æ˜¾çš„å¤±çœŸã€‚é‡è¦çš„æ˜¯ï¼ŒTROPIS åœ¨å„ç§å¹¶å‘ç—‡äºšå‹ä¸­ä¿æŒäº†å…¶ä¼˜åŠ¿ï¼ŒåŒ…æ‹¬å¤±ç¦ (OR 0.31)ã€æ„ŸæŸ“ (OR 0.27) å’Œå¤å‘ (OR 0.19)ã€‚è¿™äº›ç ”ç©¶ç»“æœè¡¨æ˜ TROPIS æ˜¯ä¸€ç§ä¸´åºŠä¸Šä¼˜è¶Šçš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¯æ˜¾ç€æ”¹å–„æ²»ç–—ç»“æœï¼ŒåŒæ—¶é™ä½æ‰‹æœ¯ç›¸å…³é£é™©ï¼Œè¡¨æ˜å…¶æœ‰å¯èƒ½æˆä¸ºè‚›ç˜˜æ²»ç–—çš„æ–°å‚è€ƒæ ‡å‡†ã€‚ä¸åŒæ‚£è€…ç¾¤ä½“å’Œæ¯”è¾ƒç¨‹åºçš„ä¸€è‡´ç»“æœå¼ºè°ƒäº†è¿™ä¸€è¯æ®ç»¼åˆçš„ç¨³å¥æ€§ã€‚", "keywords_zh": "è‚›ç˜˜ï¼ŒèŸèƒåˆ†æï¼ŒTROPISï¼Œç»è‚›é—¨æ‹¬çº¦è‚Œé—´é—´éš™å¼€æ”¾", "keywords_en": "Anal fistula, Meta-analysis, TROPIS, Transanal Opening of Intersphincteric Space", "link": "https://pubmed.ncbi.nlm.nih.gov/40607121/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 03 Jul 2025"}, {"id": "40590873", "title_en": "Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery in the Treatment of Rectal Neuroendocrine Tumors: Systematic Review and Meta-Analysis of the Observational Studies", "title_zh": "å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯å’Œç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯æ²»ç–—ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼šè§‚å¯Ÿæ€§ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Andrzej BiaÅ‚ek", "abstract_en": "**Introduction:** Rectal neuroendocrine tumors (rNETs) are subepithelial lesions with potential of malignancy. Despite the guidelines recommending that rNETs measuring 10-20 mm should be removed either endoscopic submucosal dissection (ESD) or transanal endoscopic microsurgery (TEM), the management with these entities is still a clinical dilemma. We performed a meta-analysis to compare ESD and TEM regarding method effectiveness and safety in the treatment of rNETs.\n\n**Methods:** PubMed/MEDLINE/Embase/EBSCO/CINAHL was searched up for observational studies analyzing the efficacy and safety of both methods in the treatment of rNETs.\n\n**Results:** A total of 59 observational studies with a total of n = 2,804 participants were included. In a subgroup analysis, we demonstrated that the R0 resection rate was significantly ( P = 0.002) lower for ESD (rate: 0.854) than for TEM (0.924). The recurrence rate differed significantly ( P = 0.008); the lowest (event rate [ER] = 0.015) was found for ESD and the highest for TEM (ER = 0.035). The overall bleeding rate was 0.046 and perforation rate was 0.023 and no significant differences ( P = 0.274 for bleeding, P = 0.808 for perforation) were found by intervention type. The rate of other complications (wound dehiscence, soilage, incontinence, rectovaginal fistula, pelvic pain, retroperitoneal emphysema, coagulation syndrome) was significantly ( P = 0.000) higher for TEM (ER = 0.107) than ESD (ER = 0.013). We also included 4 comparative studies with 490 patients. Using random-effects analysis, we found that the risk ratio for R0 resection was approximately 10% lower for ESD. Our analysis showed significantly greater size ( P = 0.01) and follow-up ( P = 0.03) in the group treated with TEM.\n\n**Discussion:** The efficacy of TEM is higher than ESD with a higher risk of complications in this method. Lesions with a greater size are treated with TEM, and recurrence rate is greater for this procedure. Long follow-up is needed after the treatment of rNETs to detect the recurrence early.", "abstract_zh": "**ä»‹ç»ï¼š** ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼ˆrNETï¼‰æ˜¯å…·æœ‰æ¶æ€§æ½œåŠ›çš„ä¸Šçš®ä¸‹ç—…å˜ã€‚å°½ç®¡æŒ‡å—å»ºè®®åº”é€šè¿‡å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯ (ESD) æˆ–ç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯ (TEM) åˆ‡é™¤ 10-20 æ¯«ç±³çš„ rNETï¼Œä½†è¿™äº›å®ä½“çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªä¸´åºŠå›°å¢ƒã€‚æˆ‘ä»¬è¿›è¡Œäº†ä¸€é¡¹èŸèƒåˆ†æï¼Œä»¥æ¯”è¾ƒ ESD å’Œ TEM æ²»ç–— rNET çš„æ–¹æ³•æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† PubMed/MEDLINE/Embase/EBSCO/CINAHL çš„è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œåˆ†æè¿™ä¸¤ç§æ–¹æ³•æ²»ç–— rNET çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 59 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œå…±æœ‰ 2,804 åå‚ä¸è€…ã€‚åœ¨äºšç»„åˆ†æä¸­ï¼Œæˆ‘ä»¬è¯æ˜ ESD çš„ R0 åˆ‡é™¤ç‡ï¼ˆæ¯”ç‡ï¼š0.854ï¼‰æ˜¾ç€ä½äº TEMï¼ˆ0.924ï¼‰ï¼ˆP = 0.002ï¼‰ã€‚å¤å‘ç‡å·®å¼‚æ˜¾ç€ï¼ˆP=0.008ï¼‰ï¼› ESD æœ€ä½ï¼ˆäº‹ä»¶ç‡ [ER] = 0.015ï¼‰ï¼ŒTEM æœ€é«˜ï¼ˆER = 0.035ï¼‰ã€‚æ€»å‡ºè¡€ç‡ä¸º0.046ï¼Œç©¿å­”ç‡ä¸º0.023ï¼Œä¸åŒå¹²é¢„ç±»å‹å·®å¼‚æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆå‡ºè¡€P=0.274ï¼Œç©¿å­”P=0.808ï¼‰ã€‚ TEM (ER = 0.107) çš„å…¶ä»–å¹¶å‘ç—‡ï¼ˆä¼¤å£è£‚å¼€ã€æ±¡æ¸ã€å¤±ç¦ã€ç›´è‚ é˜´é“ç˜˜ã€éª¨ç›†ç–¼ç—›ã€è…¹è†œåæ°”è‚¿ã€å‡è¡€ç»¼åˆå¾ï¼‰å‘ç”Ÿç‡æ˜¾ç€é«˜äº ESD (ER = 0.013) (P = 0.000)ã€‚æˆ‘ä»¬è¿˜çº³å…¥äº† 4 é¡¹æ¯”è¾ƒç ”ç©¶ï¼Œæ¶‰åŠ 490 åæ‚£è€…ã€‚é€šè¿‡éšæœºæ•ˆåº”åˆ†æï¼Œæˆ‘ä»¬å‘ç° R0 åˆ‡é™¤çš„é£é™©æ¯” ESD å¤§çº¦ä½ 10%ã€‚æˆ‘ä»¬çš„åˆ†ææ˜¾ç¤ºï¼ŒTEM æ²»ç–—ç»„çš„ä½“å‹æ˜¾ç€å¢å¤§ (P = 0.01)ï¼Œéšè®¿æ—¶é—´ä¹Ÿæ˜æ˜¾å¢å¤§ (P = 0.03)ã€‚\n\n**è®¨è®ºï¼š** TEM çš„ç–—æ•ˆé«˜äº ESDï¼Œä½†è¯¥æ–¹æ³•å‡ºç°å¹¶å‘ç—‡çš„é£é™©è¾ƒé«˜ã€‚ç—…å˜å°ºå¯¸è¶Šå¤§ï¼Œåˆ™é‡‡ç”¨ TEM æ²»ç–—ï¼Œå¤å‘ç‡è¶Šé«˜ã€‚ rNET æ²»ç–—åéœ€è¦é•¿æœŸéšè®¿ï¼Œä»¥ä¾¿åŠæ—©å‘ç°å¤å‘æƒ…å†µã€‚", "keywords_zh": "ESDã€TEMã€rNETã€ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ã€æ²»ç–—", "keywords_en": "ESD, TEM, rNETs, rectal neuroendocrine tumors, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40590873/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 01 Jul 2025"}, {"id": "40585484", "title_en": "Treatment of perianal abscess and anal fistula in infants: a systematic review", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Li Xu", "abstract_en": "**Introduction:** The optimal treatment approach for perianal abscess (PA) and fistula-in-ano (FIA) in infants remains a subject of debate.\n\n**Material And Methods:** A thorough literature search was conducted across multiple databases, including Embase, PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar.\n\n**Results:** A total of eighteen retrospective studies, encompassing 1,770 patients, were analyzed. Of the 702 cases (38.7%) that underwent conservative treatment, 528 cases (75.2%) achieved a cure, while 174 cases (24.8%) were unsuccessful, with 93 experiencing PA recurrence and 81 developing FIA. In contrast, among the 1,068 cases (61.3%) that received surgical interventions, 784 cases (73.4%) were cured, whereas 284 cases (26.6%) were not, with 151 experiencing PA recurrence and 133 developing FIA.\n\n**Conclusion:** The available studies indicate minimal differences in the cure and recurrence rates of PA and FIA between the conservative and surgical treatment groups.\n\n**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/, PROSPERO (CRD42023472249).", "abstract_zh": "**ä»‹ç»ï¼š** å©´å„¿è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰å’Œè‚›ç˜˜ï¼ˆFIAï¼‰çš„æœ€ä½³æ²»ç–—æ–¹æ³•ä»ç„¶æ˜¯ä¸€ä¸ªäº‰è®ºçš„è¯é¢˜ã€‚\n\n**Material and methodsï¼š** å¯¹å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å½»åº•çš„æ–‡çŒ®æ£€ç´¢ï¼ŒåŒ…æ‹¬ Embaseã€PubMedã€Web of Scienceã€Cochrane Libraryã€ClinicalTrials.gov å’Œ Google Scholarã€‚\n\n**ç»“æœï¼š** æ€»å…±åˆ†æäº† 18 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œæ¶µç›– 1,770 åæ‚£è€…ã€‚æ¥å—ä¿å®ˆæ²»ç–—çš„702ä¾‹ï¼ˆ38.7%ï¼‰ä¸­ï¼Œæ²»æ„ˆ528ä¾‹ï¼ˆ75.2%ï¼‰ï¼Œæœªæ²»æ„ˆ174ä¾‹ï¼ˆ24.8%ï¼‰ï¼Œå…¶ä¸­93ä¾‹å‡ºç°PAå¤å‘ï¼Œ81ä¾‹å‡ºç°FIAã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œåœ¨æ¥å—æ‰‹æœ¯å¹²é¢„çš„1,068ä¾‹ï¼ˆ61.3%ï¼‰ä¸­ï¼Œ784ä¾‹ï¼ˆ73.4%ï¼‰æ²»æ„ˆï¼Œ284ä¾‹ï¼ˆ26.6%ï¼‰æœªæ²»æ„ˆï¼Œå…¶ä¸­151ä¾‹å‡ºç°PAå¤å‘ï¼Œ133ä¾‹å‡ºç°FIAã€‚\n\n**ç»“è®ºï¼š** ç°æœ‰ç ”ç©¶è¡¨æ˜ï¼Œä¿å®ˆæ²»ç–—ç»„å’Œæ‰‹æœ¯æ²»ç–—ç»„ä¹‹é—´ PA å’Œ FIA çš„æ²»æ„ˆç‡å’Œå¤å‘ç‡å·®å¼‚å¾ˆå°ã€‚\n\n**Systematic review registrationï¼š** https://www.crd.york.ac.uk/PROSPERO/ï¼ŒPROSPERO (CRD42023472249)ã€‚", "keywords_zh": "ä¿å®ˆæ²»ç–—, è‚›ç˜˜, å©´å„¿, è‚›å‘¨è„“è‚¿, æ‰‹æœ¯æ²»ç–—", "keywords_en": "conservative treatment, fistula-in-ano, infants, perianal abscess, surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40585484/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 30 Jun 2025"}, {"id": "40518593", "title_en": "Outcomes of Fecal Diversion in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "è‚›å‘¨å…‹ç½—æ©ç—…ç²ªä¾¿æ”¹é“çš„ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Nik Sheng Ding", "abstract_en": "**Objectives:** Perianal fistulizing Crohn's disease (pfCD) is a severe type of inflammatory bowel disease resulting in significant patient morbidity. Despite advancements in treatments, pfCD remains challenging to manage with low healing rates. Fecal diversion (FD) has previously demonstrated clinical improvement for patients with refractory disease. Our meta-analysis aimed to explore the clinical response to FD, rates of successful restoration of bowel continuity after FD, rates of re-diversion, and factors affecting the success of FD in pfCD.\n\n**Methods:** A systematic review and meta-analysis was carried out of adult patients who had undergone FD for pfCD, with detailed patient outcome data. Studies were identified through a literature search of six bibliographic databases and one trial register, all run on February 28, 2025, including MEDLINE ALL, EMBASE, Emcare, APA PsycInfo, CINAHL, Cochrane Library, and Clinicaltrials.gov.\n\n**Results:** Seventeen studies encompassing 714 adult pfCD patients were included. FD resulted in a 65% clinical improvement rate, yet considerable heterogeneity existed in study methodologies and outcome definitions. While 29% of patients achieved bowel restoration within a median follow-up of 58.2â€‰months, challenges in sustaining the effects were evident, with 10% requiring repeat diversion and a 37% overall proctectomy/proctocolectomy rate. Factors associated with diversion success included the absence of rectal involvement and quiescent luminal disease, with biologic use showing no impact on outcomes.\n\n**Conclusions:** FD offers symptom control in pfCD, although restoration rates remain low. These findings emphasize the need for individualized patient counseling. Future research should strive for uniform measures and refined approaches to enhance pfCD management.", "abstract_zh": "**Objectivesï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (pfCD) æ˜¯ä¸€ç§ä¸¥é‡çš„ç‚ç—‡æ€§è‚ ç—…ï¼Œå¯å¯¼è‡´æ‚£è€…ä¸¥é‡å‘ç—…ã€‚å°½ç®¡æ²»ç–—æ–¹æ³•å–å¾—äº†è¿›æ­¥ï¼Œä½† pfCD çš„æ²»ç–—ä»ç„¶å…·æœ‰æŒ‘æˆ˜æ€§ï¼Œä¸”æ²»æ„ˆç‡è¾ƒä½ã€‚ç²ªä¾¿æ”¹é“ï¼ˆFDï¼‰å…ˆå‰å·²è¯æ˜å¯¹éš¾æ²»æ€§ç–¾ç—…æ‚£è€…æœ‰ä¸´åºŠæ”¹å–„ã€‚æˆ‘ä»¬çš„èŸèƒåˆ†ææ—¨åœ¨æ¢è®¨ pfCD ä¸­ FD çš„ä¸´åºŠååº”ã€FD åè‚ é“è¿ç»­æ€§æˆåŠŸæ¢å¤ç‡ã€å†æ”¹é“ç‡ä»¥åŠå½±å“ FD æˆåŠŸçš„å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹å›  pfCD æ¥å— FD çš„æˆå¹´æ‚£è€…è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œå¹¶æä¾›äº†è¯¦ç»†çš„æ‚£è€…ç»“æœæ•°æ®ã€‚ç ”ç©¶æ˜¯é€šè¿‡å¯¹ 2025 å¹´ 2 æœˆ 28 æ—¥è¿è¡Œçš„ 6 ä¸ªä¹¦ç›®æ•°æ®åº“å’Œ 1 ä¸ªè¯•éªŒæ³¨å†Œåº“è¿›è¡Œæ–‡çŒ®æ£€ç´¢è€Œç¡®å®šçš„ï¼Œå…¶ä¸­åŒ…æ‹¬ MEDLINE ALLã€EMBASEã€Emcareã€APA PsycInfoã€CINAHLã€Cochrane Library å’Œ ClinicalTrials.govã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 17 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 714 åæˆå¹´ pfCD æ‚£è€…ã€‚ FD çš„ä¸´åºŠæ”¹å–„ç‡ä¸º 65%ï¼Œä½†ç ”ç©¶æ–¹æ³•å’Œç»“æœå®šä¹‰å­˜åœ¨ç›¸å½“å¤§çš„å¼‚è´¨æ€§ã€‚è™½ç„¶ 29% çš„æ‚£è€…åœ¨ä¸­ä½éšè®¿æ—¶é—´ 58.2 ä¸ªæœˆå†…å®ç°äº†è‚ é“æ¢å¤ï¼Œä½†ç»´æŒæ•ˆæœçš„æŒ‘æˆ˜æ˜¯æ˜¾è€Œæ˜“è§çš„ï¼Œå…¶ä¸­ 10% éœ€è¦é‡å¤æ”¹é“ï¼Œæ€»ä½“ç›´è‚ åˆ‡é™¤æœ¯/ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯ç‡ä¸º 37%ã€‚ä¸æ”¹é“æˆåŠŸç›¸å…³çš„å› ç´ åŒ…æ‹¬æ²¡æœ‰ç›´è‚ å—ç´¯å’Œé™æ­¢æ€§ç®¡è…”ç–¾ç—…ï¼Œç”Ÿç‰©åˆ¶å‰‚çš„ä½¿ç”¨å¯¹ç»“æœæ²¡æœ‰å½±å“ã€‚\n\n**ç»“è®ºï¼š** FD å¯ä»¥æ§åˆ¶ pfCD çš„ç—‡çŠ¶ï¼Œä½†æ¢å¤ç‡ä»ç„¶å¾ˆä½ã€‚è¿™äº›å‘ç°å¼ºè°ƒäº†ä¸ªæ€§åŒ–æ‚£è€…å’¨è¯¢çš„å¿…è¦æ€§ã€‚æœªæ¥çš„ç ”ç©¶åº”åŠªåŠ›å¯»æ±‚ç»Ÿä¸€çš„æªæ–½å’Œç²¾ç»†çš„æ–¹æ³•æ¥åŠ å¼º pfCD ç®¡ç†ã€‚", "keywords_zh": "ç²ªä¾¿æ”¹é“ã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "fecal diversion, inflammatory bowel diseases, perianal fistulizing Crohn's disease", "link": "https://pubmed.ncbi.nlm.nih.gov/40518593/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 16 Jun 2025"}, {"id": "40474832", "title_en": "Comment on \"Efficacy and safety of 13 surgical techniques for the treatment of complex anal fistula, non-Crohn CAF: a systematic review and network meta-analysis\"", "title_zh": "è¯„è®ºã€Š13ç§æ‰‹æœ¯æŠ€æœ¯æ²»ç–—å¤æ‚æ€§è‚›ç˜˜ã€éå…‹ç½—æ©CAFçš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æã€‹", "authors": "Libo Zhou", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40474832/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 06 Jun 2025"}, {"id": "40442569", "title_en": "Systematic review and network meta-analysis of cryptoglandular complex anal fistula treatment: evaluation of surgical strategies", "title_zh": "éšè…ºå¤æ‚æ€§è‚›ç˜˜æ²»ç–—çš„ç³»ç»Ÿå›é¡¾å’Œç½‘ç»œèŸèƒåˆ†æï¼šæ‰‹æœ¯ç­–ç•¥è¯„ä¼°", "authors": "Natalia Uribe Quintana", "abstract_en": "**Background:** Several surgical approaches are available for managing complex cryptoglandular perianal fistulas. However, a gold standard surgical technique has not yet been established. This network meta-analysis aims to assess and compare postoperative failure and anal incontinence pooled rates for different available surgical techniques for complex cryptoglandular anal fistulas.\n\n**Methods:** Systematic searches were carried out on Pubmed, Ovid, the Cochrane Library database and ClinicalTrials.gov up to June 2023. All randomized comparative trials of nine surgical techniques for cryptoglandular complex perianal fistulas in adult patients were included. A systematic review and network meta-analysis was conducted using the PRISMA-NMA methodology. The endorectal advancement flap was used as the control technique, and the odds ratios (ORs) were calculated through pairwise and network meta-analysis with random effects.\n\n**Results:** 16 randomized trials were included in this study. Network meta-analysis was conducted for each outcome. Techniques, such as cutting seton, fistulotomy with sphincter reconstruction, LIFT, and VAAFT, obtained similar results in terms of technique failure to the transanal advancement flap with no statistically significant differences. PLUG (ORâ€‰=â€‰3.6 [95%CI 1.1-11.5]), fibrin glue (ORâ€‰=â€‰7.5 [95%CI 2.2-25], and platelet-rich plasma (PRP) (ORâ€‰=â€‰11.5[95%CI 1.3-99]) demonstrated a statistically significant increase in the pooled failure rate. For anal incontinence, only the cutting seton technique exhibited a higher risk of postoperative incontinence (ORâ€‰=â€‰8.6 [95%CI 1-72.5]).\n\n**Conclusion:** Our research highlights effective therapeutic approaches for complex anal fistulas, stressing the need to customize treatment based on location, anatomy, patient characteristics, and preferences. However, it advises against using plugs, fibrin glue, PRP therapy due to lower healing rates, and the seton technique because of its potential impact on anal continence. PROSPERO number CRD42022304345.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ‰å‡ ç§æ‰‹æœ¯æ–¹æ³•å¯ç”¨äºæ²»ç–—å¤æ‚çš„éšçªè…ºå‘¨ç˜˜ã€‚ç„¶è€Œï¼Œé‡‘æ ‡å‡†æ‰‹æœ¯æŠ€æœ¯å°šæœªå»ºç«‹ã€‚è¯¥ç½‘ç»œèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°å’Œæ¯”è¾ƒå¤æ‚éšè…ºè‚›ç˜˜çš„ä¸åŒå¯ç”¨æ‰‹æœ¯æŠ€æœ¯çš„æœ¯åå¤±è´¥å’Œè‚›é—¨å¤±ç¦æ±‡æ€»ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2023 å¹´ 6 æœˆï¼Œæˆ‘ä»¬åœ¨ Pubmedã€Ovidã€Cochrane å›¾ä¹¦é¦†æ•°æ®åº“å’Œ ClinicalTrials.gov ä¸Šè¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚çº³å…¥äº†é’ˆå¯¹æˆäººæ‚£è€…éšè…ºå¤æ‚æ€§è‚›ç˜˜çš„ä¹ç§æ‰‹æœ¯æŠ€æœ¯çš„æ‰€æœ‰éšæœºæ¯”è¾ƒè¯•éªŒã€‚ä½¿ç”¨ PRISMA-NMA æ–¹æ³•è¿›è¡Œç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æã€‚ä½¿ç”¨ç›´è‚ å†…æ¨è¿›çš®ç“£ä½œä¸ºå¯¹ç…§æŠ€æœ¯ï¼Œé€šè¿‡å…·æœ‰éšæœºæ•ˆåº”çš„æˆå¯¹å’Œç½‘ç»œèŸèƒåˆ†æè®¡ç®—ä¼˜åŠ¿æ¯”ï¼ˆORï¼‰ã€‚\n\n**ç»“æœï¼š** æœ¬ç ”ç©¶çº³å…¥äº† 16 é¡¹éšæœºè¯•éªŒã€‚å¯¹æ¯ä¸ªç»“æœè¿›è¡Œç½‘ç»œèŸèƒåˆ†æã€‚è¯¸å¦‚åˆ‡å‰²æŒ‚çº¿ã€ç˜˜ç®¡åˆ‡å¼€æœ¯ä¼´æ‹¬çº¦è‚Œé‡å»ºã€LIFT å’Œ VAAFT ç­‰æŠ€æœ¯åœ¨ç»è‚›é—¨æ¨è¿›çš®ç“£çš„æŠ€æœ¯å¤±è´¥æ–¹é¢è·å¾—äº†ç›¸ä¼¼çš„ç»“æœï¼Œä½†æ²¡æœ‰ç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ã€‚ PLUG (ORâ€‰=â€‰3.6 [95%CI 1.1-11.5])ã€çº¤ç»´è›‹ç™½èƒ¶ (ORâ€‰=â€‰7.5 [95%CI 2.2-25]) å’Œå¯Œè¡€å°æ¿è¡€æµ† (PRP) (ORâ€‰=â€‰11.5[95%CI 1.3-99]) è¡¨ç°å‡ºåˆå¹¶å¤±è´¥ç‡å…·æœ‰ç»Ÿè®¡æ˜¾ç€æ€§å¢åŠ ã€‚æœ¯åå°¿å¤±ç¦ï¼Œä»…åˆ‡å‰²æŒ‚çº¿æŠ€æœ¯è¡¨ç°å‡ºè¾ƒé«˜çš„æœ¯åå°¿å¤±ç¦é£é™©ï¼ˆORâ€‰=â€‰8.6 [95%CI 1-72.5]ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç ”ç©¶å¼ºè°ƒäº†å¤æ‚è‚›ç˜˜çš„æœ‰æ•ˆæ²»ç–—æ–¹æ³•ï¼Œå¼ºè°ƒéœ€è¦æ ¹æ®ä½ç½®ã€è§£å‰–ç»“æ„ã€æ‚£è€…ç‰¹å¾å’Œåå¥½å®šåˆ¶æ²»ç–—ã€‚ç„¶è€Œï¼Œå®ƒå»ºè®®ä¸è¦ä½¿ç”¨å¡å­ã€çº¤ç»´è›‹ç™½èƒ¶ã€PRP æ²»ç–—ï¼ˆå› ä¸ºæ²»æ„ˆç‡è¾ƒä½ï¼‰å’ŒæŒ‚çº¿æŠ€æœ¯ï¼ˆå› ä¸ºå®ƒå¯¹è‚›é—¨å¤±ç¦æœ‰æ½œåœ¨å½±å“ï¼‰ã€‚æ™®æ´›æ–¯å½¼ç½—ç¼–å· CRD42022304345ã€‚", "keywords_zh": "è‚›é—¨å¤±ç¦ï¼Œå¤æ‚æ€§è‚›ç˜˜ï¼Œç½‘ç»œèŸèƒåˆ†æï¼ŒæŒç»­æ€§ï¼Œå¤å‘ï¼Œæ‰‹æœ¯æ²»ç–—", "keywords_en": "Anal incontinence, Complex anal fistula, Network meta-analysis, Persistence, Recurrence, Surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40442569/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 29 May 2025"}, {"id": "40392371", "title_en": "Failure rates and complications of four sphincter-sparing techniques for the treatment of fistula-in-ano: a systematic review and network meta-analysis", "title_zh": "å››ç§ä¿ç•™æ‹¬çº¦è‚ŒæŠ€æœ¯æ²»ç–—è‚›ç˜˜çš„å¤±è´¥ç‡å’Œå¹¶å‘ç—‡ï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æ", "authors": "G Pellino", "abstract_en": "**Background:** Several techniques are available to reduce the risk of sphincter injury when treating anal fistula, such as ligation of the intersphincteric fistula tract (LIFT), video-assisted anal fistula treatment (VAAFT), fistula laser closure (FiLaC) and endoanal flap (EAF). The aim of this meta-analysis is to provide data on the safety, complications and failure of these techniques.\n\n**Methods:** Studies published after 2017, with patients undergoing at least one among LIFT, VAAFT, FiLaC and EAF for perianal fistula and providing data regarding failure, were retrieved from PubMed and EMBASE. Primary outcome was failure; other outcomes included continence disturbance and complications.\n\n**Results:** Forty-nine articles with 3520 patients were included. The failure rates were 28.6% (range 3.8-75) for LIFT, 22.3% (6.2-65.2) for VAAFT, 43.9% (11.1-80) for FiLaC and 25.9% (4.7-100) for EAF, with a mean follow-up of 35.4 (6-80.4), 32.4 (6-48), 31.6(6.3-60) and 42.4 (12-155) months. The available network meta-analysis on failure showed RD of -0.08 (95% CI -â€‰0.58 to 0.42) comparing LIFT vs VAAFT and 0.30 (95% CI 0.03 to 0.58) comparing LIFT vs EAF. No patients undergoing VAAFT or FiLaC reported worsening continence, while for LIFT and EAF, the continence disturbance rate was 1.5% and 7.3%, respectively. No major complications were observed. The most common minor complications were pain (1.4%), bleeding (1.1%) and wound infection (1.2%). Overall, minor complication rates were 4.3% for LIFT, 7.2% for VAAFT, 10.2% for FiLaC and 6.2% for EAF. Crohn's disease was associated with a higher failure rate (39.5% vs 31.4%).\n\n**Conclusions:** FiLaC, VAAFT, LIFT and EAF may represent a valid option in the treatment of anal fistula. VAAFT showed the lowest rate of failure but with no differences from network metanalysis. Wider homogeneous studies with long-term follow-up are necessary to obtain more robust data.\n\n**Prospero Number:** CRD42022375600.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ‰å‡ ç§æŠ€æœ¯å¯ä»¥é™ä½æ²»ç–—è‚›ç˜˜æ—¶æ‹¬çº¦è‚ŒæŸä¼¤çš„é£é™©ï¼Œä¾‹å¦‚æ‹¬çº¦è‚Œé—´ç˜˜é“ç»“æ‰ï¼ˆLIFTï¼‰ã€è§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—ï¼ˆVAAFTï¼‰ã€ç˜˜ç®¡æ¿€å…‰é—­åˆï¼ˆFiLaCï¼‰å’Œè‚›å†…çš®ç“£ï¼ˆEAFï¼‰ã€‚è¿™é¡¹èŸèƒåˆ†æçš„ç›®çš„æ˜¯æä¾›æœ‰å…³è¿™äº›æŠ€æœ¯çš„å®‰å…¨æ€§ã€å¹¶å‘ç—‡å’Œå¤±è´¥çš„æ•°æ®ã€‚\n\n**æ–¹æ³•ï¼š** ä» PubMed å’Œ EMBASE æ£€ç´¢ 2017 å¹´ä¹‹åå‘è¡¨çš„ç ”ç©¶ï¼Œå…¶ä¸­æ‚£è€…æ¥å—äº† LIFTã€VAAFTã€FiLaC å’Œ EAF ä¸­è‡³å°‘ä¸€ç§æ²»ç–—è‚›å‘¨ç˜˜å¹¶æä¾›äº†æœ‰å…³å¤±è´¥çš„æ•°æ®ã€‚ä¸»è¦ç»“æœæ˜¯å¤±è´¥ï¼›å…¶ä»–ç»“æœåŒ…æ‹¬å¤±ç¦éšœç¢å’Œå¹¶å‘ç—‡ã€‚\n\n**ç»“æœï¼š** çº³å…¥ 49 ç¯‡æ–‡ç« ï¼Œæ¶‰åŠ 3520 åæ‚£è€…ã€‚ LIFT çš„å¤±è´¥ç‡ä¸º 28.6%ï¼ˆèŒƒå›´ 3.8-75ï¼‰ï¼ŒVAAFT ä¸º 22.3%ï¼ˆ6.2-65.2ï¼‰ï¼ŒFiLaC ä¸º 43.9%ï¼ˆ11.1-80ï¼‰ï¼ŒEAF ä¸º 25.9%ï¼ˆ4.7-100ï¼‰ï¼Œå¹³å‡éšè®¿æ¬¡æ•°ä¸º 35.4ï¼ˆ6-80.4ï¼‰ï¼Œ32.4 (6-48)ã€31.6(6.3-60) å’Œ 42.4 (12-155) ä¸ªæœˆã€‚å¯ç”¨çš„å¤±è´¥ç½‘ç»œèŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ¯”è¾ƒ LIFT ä¸ VAAFT çš„ RD ä¸º -0.08ï¼ˆ95% CI -â€‰0.58 è‡³ 0.42ï¼‰ï¼Œæ¯”è¾ƒ LIFT ä¸ EAF çš„ RD ä¸º 0.30ï¼ˆ95% CI 0.03 è‡³ 0.58ï¼‰ã€‚æ¥å— VAAFT æˆ– FiLaC çš„æ‚£è€…å‡æœªæŠ¥å‘Šå¤±ç¦æƒ…å†µæ¶åŒ–ï¼Œè€Œæ¥å— LIFT å’Œ EAF çš„æ‚£è€…å¤±ç¦ç‡åˆ†åˆ«ä¸º 1.5% å’Œ 7.3%ã€‚æ²¡æœ‰è§‚å¯Ÿåˆ°é‡å¤§å¹¶å‘ç—‡ã€‚æœ€å¸¸è§çš„è½»å¾®å¹¶å‘ç—‡æ˜¯ç–¼ç—›ï¼ˆ1.4%ï¼‰ã€å‡ºè¡€ï¼ˆ1.1%ï¼‰å’Œä¼¤å£æ„ŸæŸ“ï¼ˆ1.2%ï¼‰ã€‚æ€»ä½“è€Œè¨€ï¼ŒLIFT çš„è½»å¾®å¹¶å‘ç—‡å‘ç”Ÿç‡ä¸º 4.3%ï¼ŒVAAFT ä¸º 7.2%ï¼ŒFiLaC ä¸º 10.2%ï¼ŒEAF ä¸º 6.2%ã€‚å…‹ç½—æ©ç—…ä¸è¾ƒé«˜çš„å¤±è´¥ç‡ç›¸å…³ï¼ˆ39.5% vs 31.4%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** FiLaCã€VAAFTã€LIFT å’Œ EAF å¯èƒ½æ˜¯æ²»ç–—è‚›ç˜˜çš„æœ‰æ•ˆé€‰æ‹©ã€‚ VAAFT æ˜¾ç¤ºå¤±è´¥ç‡æœ€ä½ï¼Œä½†ä¸ç½‘ç»œèŸèƒåˆ†ææ²¡æœ‰å·®å¼‚ã€‚ä¸ºäº†è·å¾—æ›´å¯é çš„æ•°æ®ï¼Œéœ€è¦è¿›è¡Œæ›´å¹¿æ³›çš„åŒè´¨ç ”ç©¶å’Œé•¿æœŸéšè®¿ã€‚\n\n**Prospero numberï¼š** CRD42022375600ã€‚", "keywords_zh": "è‚›ç˜˜ã€å¹¶å‘ç—‡ã€è‚›å†…çš®ç“£ã€FILACã€LIFTã€å¤å‘ã€VAAFT", "keywords_en": "Anal fistula, Complications, Endoanal flap, FILAC, LIFT, Recurrence, VAAFT", "link": "https://pubmed.ncbi.nlm.nih.gov/40392371/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 20 May 2025"}, {"id": "40353830", "title_en": "Early Resuturing versus expectant Management for Perineal Wound Dehiscence: A systematic review", "title_zh": "ä¼šé˜´ä¼¤å£è£‚å¼€çš„æ—©æœŸç¼åˆä¸æœŸå¾…æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Debjyoti Karmakar", "abstract_en": "**Background And Objective:** Perineal wound dehiscence is a common complication of vaginal birth that impacts maternal well-being and quality of life. This systematic review compares early resuturing with expectant management in the treatment of perineal wound dehiscence.\n\n**Methods:** We searched Ovid MEDLINE, CINAHL, and PubMed databases, and hand-searched recent reviews and relevant studies. Human prospective and retrospective studies, randomized controlled trials (RCTs), and case series evaluating early resuturing within the postnatal period were included. Two reviewers independently assessed the studies for outcomes and risk of bias. The primary outcome was healing time; secondary outcomes included dyspareunia, long-term symptoms, functional outcomes, infection rates, and anal sphincter injury.\n\n**Results:** Thirteen studies (1987-2022) were included: three RCTs, four prospective cohort studies or case series, and six retrospective studies-heterogeneity in study designs and outcomes limited data synthesis. Early resuturing was associated with reduced healing time, particularly for wounds not involving the anal sphincter, but increased the risk of complications such as fistula formation. Many studies emphasized meticulous preoperative wound care.\n\n**Conclusions:** Limited evidence suggests that early resuturing may reduce healing time without increasing wound infection risk. However, the increased risk of complications necessitates cautious application and highlights the importance of preoperative wound care. Further robust research is needed, although challenging to conduct. Alternative analytical methods, such as data mining and decision tree algorithms, should be explored. Based on current evidence, clinicians should carefully individualize recommendations on the benefits and risks of early resuturing.", "abstract_zh": "**Background and objectiveï¼š** ä¼šé˜´ä¼¤å£è£‚å¼€æ˜¯é˜´é“åˆ†å¨©çš„å¸¸è§å¹¶å‘ç—‡ï¼Œå½±å“äº§å¦‡çš„å¥åº·å’Œç”Ÿæ´»è´¨é‡ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ¯”è¾ƒäº†ä¼šé˜´ä¼¤å£è£‚å¼€æ²»ç–—ä¸­çš„æ—©æœŸç¼åˆä¸æœŸå¾…æ²»ç–—ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº† Ovid MEDLINEã€CINAHL å’Œ PubMed æ•°æ®åº“ï¼Œå¹¶æ‰‹åŠ¨æ£€ç´¢äº†æœ€è¿‘çš„è¯„è®ºå’Œç›¸å…³ç ”ç©¶ã€‚åŒ…æ‹¬äººç±»å‰ç»æ€§å’Œå›é¡¾æ€§ç ”ç©¶ã€éšæœºå¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰ä»¥åŠè¯„ä¼°äº§åæ—©æœŸå†ç¼åˆçš„ç—…ä¾‹ç³»åˆ—ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¯„ä¼°äº†ç ”ç©¶çš„ç»“æœå’Œåå€šé£é™©ã€‚ä¸»è¦ç»“æœæ˜¯æ„ˆåˆæ—¶é—´ï¼›æ¬¡è¦ç»“å±€åŒ…æ‹¬æ€§äº¤å›°éš¾ã€é•¿æœŸç—‡çŠ¶ã€åŠŸèƒ½ç»“å±€ã€æ„ŸæŸ“ç‡å’Œè‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº†åä¸‰é¡¹ç ”ç©¶ï¼ˆ1987-2022ï¼‰ï¼šä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒã€å››é¡¹å‰ç»æ€§é˜Ÿåˆ—ç ”ç©¶æˆ–ç—…ä¾‹ç³»åˆ—ä»¥åŠå…­é¡¹å›é¡¾æ€§ç ”ç©¶â€”â€”ç ”ç©¶è®¾è®¡å’Œç»“æœçš„å¼‚è´¨æ€§é™åˆ¶äº†æ•°æ®åˆæˆã€‚æ—©æœŸé‡æ–°ç¼åˆä¼šç¼©çŸ­æ„ˆåˆæ—¶é—´ï¼Œç‰¹åˆ«æ˜¯å¯¹äºä¸æ¶‰åŠè‚›é—¨æ‹¬çº¦è‚Œçš„ä¼¤å£ï¼Œä½†ä¼šå¢åŠ ç˜˜ç®¡å½¢æˆç­‰å¹¶å‘ç—‡çš„é£é™©ã€‚è®¸å¤šç ”ç©¶å¼ºè°ƒæœ¯å‰ç»†è‡´çš„ä¼¤å£æŠ¤ç†ã€‚\n\n**ç»“è®ºï¼š** æœ‰é™çš„è¯æ®è¡¨æ˜ï¼Œæ—©æœŸé‡æ–°ç¼åˆå¯èƒ½ä¼šç¼©çŸ­æ„ˆåˆæ—¶é—´ï¼Œè€Œä¸ä¼šå¢åŠ ä¼¤å£æ„ŸæŸ“çš„é£é™©ã€‚ç„¶è€Œï¼Œå¹¶å‘ç—‡é£é™©çš„å¢åŠ éœ€è¦è°¨æ…ä½¿ç”¨ï¼Œå¹¶å‡¸æ˜¾äº†æœ¯å‰ä¼¤å£æŠ¤ç†çš„é‡è¦æ€§ã€‚å°½ç®¡è¿›è¡Œèµ·æ¥å…·æœ‰æŒ‘æˆ˜æ€§ï¼Œä½†ä»éœ€è¦è¿›ä¸€æ­¥å¼ºæœ‰åŠ›çš„ç ”ç©¶ã€‚åº”æ¢ç´¢æ›¿ä»£åˆ†ææ–¹æ³•ï¼Œä¾‹å¦‚æ•°æ®æŒ–æ˜å’Œå†³ç­–æ ‘ç®—æ³•ã€‚æ ¹æ®ç›®å‰çš„è¯æ®ï¼Œä¸´åºŠåŒ»ç”Ÿåº”ä»”ç»†é’ˆå¯¹æ—©æœŸå†ç¼åˆçš„ç›Šå¤„å’Œé£é™©æå‡ºä¸ªæ€§åŒ–å»ºè®®ã€‚", "keywords_zh": "æ—©æœŸç¼åˆã€ä¼šé˜´è£‚å¼€ã€ä¼šé˜´ä¼¤å£ç ´è£‚ã€äº§å", "keywords_en": "early resuturing, perineal dehiscence, perineal wound breakdown, postpartum", "link": "https://pubmed.ncbi.nlm.nih.gov/40353830/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 12 May 2025"}, {"id": "40325545", "title_en": "The Current Applications in Surgery of Three-Dimensional Modelling Technology for Complex Fistula-In-Ano: A Systematic Review", "title_zh": "å¤æ‚è‚›ç˜˜ä¸‰ç»´å»ºæ¨¡æŠ€æœ¯åœ¨å¤–ç§‘æ‰‹æœ¯ä¸­çš„åº”ç”¨ç°çŠ¶ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Roland Shannon", "abstract_en": "**Background:** Complex fistula-in-ano (FIA) poses significant clinical challenges due to its intricate anatomy and high recurrence rates. Traditional imaging techniques like MRI are limited by their two-dimensional (2D) nature, prompting the use of three-dimensional (3D) modeling for enhanced visualization.\n\n**Methods:** This systematic review, adhering to PRISMA guidelines, analysed 17 studies using 3D models for surgical planning, education, and patient engagement in managing complex FIA. A risk of bias assessment was conducted using the Cochrane Risk of Bias Tool for randomized studies and ROBINS-I for non-randomized studies, revealing that all included studies had at least a moderate risk of bias.\n\n**Results:** Three-dimensional models improved anatomical visualization compared to 2D MRI, potentially enhancing surgical planning accuracy and reducing recurrence rates. They also offered educational benefits for surgeons and patients. However, the evidence is limited by methodological weaknesses such as small sample sizes and subjective outcome measures.\n\n**Conclusion:** Three-dimensional modelling technology shows promise in improving surgical precision and patient outcomes for complex FIA, but further high-quality research is needed to validate its clinical utility due to methodological weaknesses in current studies.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¤æ‚æ€§è‚›ç˜˜ï¼ˆFIAï¼‰ç”±äºå…¶å¤æ‚çš„è§£å‰–ç»“æ„å’Œé«˜å¤å‘ç‡è€Œå¸¦æ¥äº†é‡å¤§çš„ä¸´åºŠæŒ‘æˆ˜ã€‚ MRI ç­‰ä¼ ç»ŸæˆåƒæŠ€æœ¯å—åˆ°äºŒç»´ (2D) æ€§è´¨çš„é™åˆ¶ï¼Œä¿ƒä½¿ä½¿ç”¨ä¸‰ç»´ (3D) å»ºæ¨¡æ¥å¢å¼ºå¯è§†åŒ–ã€‚\n\n**æ–¹æ³•ï¼š** è¿™é¡¹ç³»ç»Ÿç»¼è¿°éµå¾ª PRISMA æŒ‡å—ï¼Œåˆ†æäº† 17 é¡¹ä½¿ç”¨ 3D æ¨¡å‹è¿›è¡Œæ‰‹æœ¯è§„åˆ’ã€æ•™è‚²å’Œæ‚£è€…å‚ä¸ç®¡ç†å¤æ‚ FIA çš„ç ”ç©¶ã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·è¿›è¡Œéšæœºç ”ç©¶ï¼Œä½¿ç”¨ ROBINS-I è¿›è¡Œééšæœºç ”ç©¶è¿›è¡Œåå€šé£é™©è¯„ä¼°ï¼Œç»“æœæ˜¾ç¤ºæ‰€æœ‰çº³å…¥çš„ç ”ç©¶è‡³å°‘å…·æœ‰ä¸­ç­‰åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** ä¸ 2D MRI ç›¸æ¯”ï¼Œä¸‰ç»´æ¨¡å‹æ”¹å–„äº†è§£å‰–å¯è§†åŒ–ï¼Œæœ‰å¯èƒ½æé«˜æ‰‹æœ¯è®¡åˆ’çš„å‡†ç¡®æ€§å¹¶é™ä½å¤å‘ç‡ã€‚ä»–ä»¬è¿˜ä¸ºå¤–ç§‘åŒ»ç”Ÿå’Œæ‚£è€…æä¾›æ•™è‚²ç¦åˆ©ã€‚ç„¶è€Œï¼Œè¯æ®å—åˆ°æ–¹æ³•è®ºç¼ºé™·çš„é™åˆ¶ï¼Œä¾‹å¦‚æ ·æœ¬é‡å°å’Œä¸»è§‚ç»“æœæµ‹é‡ã€‚\n\n**ç»“è®ºï¼š** ä¸‰ç»´å»ºæ¨¡æŠ€æœ¯æœ‰æœ›æé«˜å¤æ‚ FIA çš„æ‰‹æœ¯ç²¾åº¦å’Œæ‚£è€…é¢„åï¼Œä½†ç”±äºå½“å‰ç ”ç©¶æ–¹æ³•å­¦ä¸Šçš„ç¼ºé™·ï¼Œéœ€è¦è¿›ä¸€æ­¥é«˜è´¨é‡çš„ç ”ç©¶æ¥éªŒè¯å…¶ä¸´åºŠå®ç”¨æ€§ã€‚", "keywords_zh": "è‚›ç˜˜ã€æ‚£è€…æ•™è‚²ã€æ‰‹æœ¯æ•™è‚²ã€æ‰‹æœ¯è®¡åˆ’ã€ä¸‰ç»´å»ºæ¨¡", "keywords_en": "fistulaâ€inâ€ano, patient education, surgical education, surgical planning, threeâ€dimensional modelling", "link": "https://pubmed.ncbi.nlm.nih.gov/40325545/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 06 May 2025"}, {"id": "40315877", "title_en": "Isolated perianal Crohn's disease: a systematic review and expert consensus proposing novel diagnostic criteria and management advice", "title_zh": "å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…ï¼šæå‡ºæ–°è¯Šæ–­æ ‡å‡†å’Œç®¡ç†å»ºè®®çš„ç³»ç»Ÿè¯„ä»·å’Œä¸“å®¶å…±è¯†", "authors": "TOpClass Collaborators", "abstract_en": "Perianal fistulae can present a diagnostic challenge when distinguishing perianal Crohn's disease from idiopathic perianal fistulae. This distinction is key, as perianal Crohn's disease requires inflammatory bowel disease (IBD) therapy, whereas idiopathic perianal fistulae are primarily managed surgically. When luminal inflammation is absent, but Crohn's disease is suspected, the term isolated perianal Crohn's disease is sometimes applied. However, no formal guidance exists for diagnosing or managing isolated perianal Crohn's disease. Furthermore, whereas fistula granuloma might provide specific evidence of Crohn's disease, they are rarely detected in perianal fistulae, so are unlikely to sensitively delineate aetiology. This project aimed to develop an opinion-based framework for isolated perianal Crohn's disease. A systematic review evaluated clinical features suggestive of isolated perianal Crohn's disease and evidence for IBD therapies in patients with perianal fistulae without luminal IBD. The findings of this systematic review informed a multidisciplinary consensus process with IBD specialists, resulting in the formulation of diagnostic criteria and management recommendations for isolated perianal Crohn's disease. We then tested this diagnostic approach in a prospective cohort of 50 patients treated as having idiopathic perianal fistulae at a proctology referral centre, identifying six (12%) individuals as meeting the diagnostic criteria. Our findings underscore the scarcity of evidence guiding isolated perianal Crohn's disease diagnosis and the need for a composite risk-based assessment. The proposed framework provides a tool for clinical practice and research but requires validation and refinement. Clear communication with patients is essential, given the diagnostic and therapeutic uncertainties. Future studies should refine these criteria, explore biological markers for isolated perianal Crohn's disease, and establish evidence-based methods to differentiate isolated perianal Crohn's disease within the perianal fistulae spectrum.", "abstract_zh": "åœ¨åŒºåˆ†è‚›å‘¨å…‹ç½—æ©ç—…å’Œç‰¹å‘æ€§è‚›å‘¨ç˜˜æ—¶ï¼Œè‚›å‘¨ç˜˜å¯èƒ½å¸¦æ¥è¯Šæ–­æŒ‘æˆ˜ã€‚è¿™ç§åŒºåˆ«å¾ˆå…³é”®ï¼Œå› ä¸ºè‚›å‘¨å…‹ç½—æ©ç—…éœ€è¦ç‚ç—‡æ€§è‚ ç—… (IBD) æ²»ç–—ï¼Œè€Œç‰¹å‘æ€§è‚›å‘¨ç˜˜ä¸»è¦é€šè¿‡æ‰‹æœ¯æ²»ç–—ã€‚å½“ä¸å­˜åœ¨ç®¡è…”ç‚ç—‡ä½†æ€€ç–‘å…‹ç½—æ©ç—…æ—¶ï¼Œæœ‰æ—¶ä½¿ç”¨æœ¯è¯­â€œå­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…â€ã€‚ç„¶è€Œï¼Œç›®å‰å°šæ— è¯Šæ–­æˆ–æ²»ç–—å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…çš„æ­£å¼æŒ‡å—ã€‚æ­¤å¤–ï¼Œè™½ç„¶ç˜˜ç®¡è‚‰èŠ½è‚¿å¯èƒ½æä¾›å…‹ç½—æ©ç—…çš„å…·ä½“è¯æ®ï¼Œä½†åœ¨è‚›å‘¨ç˜˜ç®¡ä¸­å¾ˆå°‘æ£€æµ‹åˆ°å®ƒä»¬ï¼Œå› æ­¤ä¸å¤ªå¯èƒ½æ•æ„Ÿåœ°æè¿°ç—…å› ã€‚è¯¥é¡¹ç›®æ—¨åœ¨ä¸ºå­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…å¼€å‘ä¸€ä¸ªåŸºäºæ„è§çš„æ¡†æ¶ã€‚ä¸€é¡¹ç³»ç»Ÿè¯„ä»·è¯„ä¼°äº†æç¤ºå­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…çš„ä¸´åºŠç‰¹å¾ä»¥åŠæ— ç®¡è…” IBD çš„è‚›å‘¨ç˜˜æ‚£è€…çš„ IBD æ²»ç–—è¯æ®ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·çš„ç»“æœä¸º IBD ä¸“å®¶çš„å¤šå­¦ç§‘å…±è¯†è¿‡ç¨‹æä¾›äº†ä¿¡æ¯ï¼Œä»è€Œåˆ¶å®šäº†å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…çš„è¯Šæ–­æ ‡å‡†å’Œç®¡ç†å»ºè®®ã€‚ç„¶åï¼Œæˆ‘ä»¬åœ¨ç›´è‚ ç§‘è½¬è¯Šä¸­å¿ƒæ²»ç–—çš„ 50 åç‰¹å‘æ€§è‚›å‘¨ç˜˜æ‚£è€…çš„å‰ç»æ€§é˜Ÿåˆ—ä¸­æµ‹è¯•äº†è¿™ç§è¯Šæ–­æ–¹æ³•ï¼Œç¡®å®š 6 å (12%) æ‚£è€…ç¬¦åˆè¯Šæ–­æ ‡å‡†ã€‚æˆ‘ä»¬çš„ç ”ç©¶ç»“æœå¼ºè°ƒäº†æŒ‡å¯¼å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…è¯Šæ–­çš„è¯æ®çš„ç¼ºä¹ä»¥åŠåŸºäºé£é™©çš„ç»¼åˆè¯„ä¼°çš„å¿…è¦æ€§ã€‚æ‹Ÿè®®çš„æ¡†æ¶ä¸ºä¸´åºŠå®è·µå’Œç ”ç©¶æä¾›äº†å·¥å…·ï¼Œä½†éœ€è¦éªŒè¯å’Œå®Œå–„ã€‚é‰´äºè¯Šæ–­å’Œæ²»ç–—çš„ä¸ç¡®å®šæ€§ï¼Œä¸æ‚£è€…çš„æ¸…æ™°æ²Ÿé€šè‡³å…³é‡è¦ã€‚æœªæ¥çš„ç ”ç©¶åº”å®Œå–„è¿™äº›æ ‡å‡†ï¼Œæ¢ç´¢å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…çš„ç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œå¹¶å»ºç«‹åŸºäºè¯æ®çš„æ–¹æ³•æ¥åŒºåˆ†è‚›å‘¨ç˜˜è°±ä¸­çš„å­¤ç«‹æ€§è‚›å‘¨å…‹ç½—æ©ç—…ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40315877/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 02 May 2025"}, {"id": "40269939", "title_en": "Fish bone migration: complications, diagnostic challenges, and treatment strategies", "title_zh": "é±¼éª¨è¿ç§»ï¼šå¹¶å‘ç—‡ã€è¯Šæ–­æŒ‘æˆ˜å’Œæ²»ç–—ç­–ç•¥", "authors": "Jichuan Chen", "abstract_en": "**Background:** Fish bone impaction in the pharynx is a common otolaryngological emergency. However, if the fish bone perforates the pharyngeal wall or the gastrointestinal wall and migrates to the neck tissues or organs, entering the lungs, mediastinum, heart, liver, biliary tract, spleen, pancreas, or other structures, or damages major blood vessels in the thoracic or abdominal cavities, it can lead to severe complications. This condition is rare and dangerous, potentially resulting in a series of serious complications, including neck abscess, thyroid abscess, thrombosis or air embolism of the cervical vessels, esophageal perforation, rupture of major mediastinal vessels, mediastinitis, aorto-esophageal fistula, lung abscess, spinal injury, sepsis, splenic abscess, hepatic abscess, anal fistula, and it may even be misdiagnosed as a tumor.\n\n**Objective:** This narrative review synthesizes evidence on fish bone translocation complications to (1) identify high-risk clinical presentations, (2) guide site-specific imaging selection, and (3) inform multidisciplinary management strategies.\n\n**Methods:** Use the keyword \"fishbone\" to systematically search articles from PubMedã€CNKI and Embase databases from 1972 to 2024. Review all original articles and include them in this review where appropriate. This narrative review synthesizes evidence from case reports and observational studies to explore complications and management of fish bone translocation in uncommon sites. Given the predominance of heterogeneous case reports, a formal systematic review with meta-analysis was not feasible; however, we employed systematic search strategies to minimize selection bias.\n\n**Conclusion:** To avoid severe complications, it is crucial to provide comprehensive information on the management of fish bone impaction. When fish bone removal cannot be achieved using laryngoscopy, prompt and decisive surgical intervention is required to extract the foreign body.", "abstract_zh": "**èƒŒæ™¯ï¼š** å’½éƒ¨é±¼éª¨åµŒå¡æ˜¯å¸¸è§çš„è€³é¼»å–‰æ€¥ç—‡ã€‚ä½†å¦‚æœé±¼åˆºç©¿é€å’½å£æˆ–èƒƒè‚ å£ï¼Œè¿ç§»åˆ°é¢ˆéƒ¨ç»„ç»‡æˆ–å™¨å®˜ï¼Œè¿›å…¥è‚ºã€çºµéš”ã€å¿ƒè„ã€è‚è„ã€èƒ†é“ã€è„¾è„ã€èƒ°è…ºç­‰ç»“æ„ï¼Œæˆ–æŸä¼¤èƒ¸è…”æˆ–è…¹è…”çš„ä¸»è¦è¡€ç®¡ï¼Œå°±ä¼šå¯¼è‡´ä¸¥é‡çš„å¹¶å‘ç—‡ã€‚è¿™ç§æƒ…å†µç½•è§ä¸”å±é™©ï¼Œå¯èƒ½å¯¼è‡´ä¸€ç³»åˆ—ä¸¥é‡å¹¶å‘ç—‡ï¼ŒåŒ…æ‹¬é¢ˆéƒ¨è„“è‚¿ã€ç”²çŠ¶è…ºè„“è‚¿ã€é¢ˆéƒ¨è¡€ç®¡è¡€æ “æˆ–ç©ºæ°”æ “å¡ã€é£Ÿç®¡ç©¿å­”ã€çºµéš”å¤§è¡€ç®¡ç ´è£‚ã€çºµéš”ç‚ã€ä¸»é£Ÿç®¡ç˜˜ã€è‚ºè„“è‚¿ã€è„ŠæŸ±æŸä¼¤ã€è´¥è¡€ç—‡ã€è„¾è„“è‚¿ã€è‚è„“è‚¿ã€è‚›ç˜˜ï¼Œç”šè‡³å¯èƒ½è¢«è¯¯è¯Šä¸ºè‚¿ç˜¤ã€‚\n\n**ç›®çš„ï¼š** è¿™ç¯‡å™è¿°æ€§ç»¼è¿°ç»¼åˆäº†é±¼éª¨æ˜“ä½å¹¶å‘ç—‡çš„è¯æ®ï¼Œä»¥ï¼ˆ1ï¼‰è¯†åˆ«é«˜é£é™©çš„ä¸´åºŠè¡¨ç°ï¼Œï¼ˆ2ï¼‰æŒ‡å¯¼ç‰¹å®šéƒ¨ä½çš„å½±åƒå­¦é€‰æ‹©ï¼Œä»¥åŠï¼ˆ3ï¼‰ä¸ºå¤šå­¦ç§‘ç®¡ç†ç­–ç•¥æä¾›ä¿¡æ¯ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨å…³é”®è¯â€œfishboneâ€ä»PubMedã€CNKIå’ŒEmbaseæ•°æ®åº“ä¸­ç³»ç»Ÿæ£€ç´¢1972å¹´è‡³2024å¹´çš„æ–‡ç« ã€‚å®¡é˜…æ‰€æœ‰åŸå§‹æ–‡ç« ï¼Œå¹¶åœ¨é€‚å½“çš„æƒ…å†µä¸‹å°†å…¶çº³å…¥æœ¬ç»¼è¿°ã€‚è¿™ç¯‡å™è¿°æ€§ç»¼è¿°ç»¼åˆäº†ç—…ä¾‹æŠ¥å‘Šå’Œè§‚å¯Ÿæ€§ç ”ç©¶çš„è¯æ®ï¼Œä»¥æ¢è®¨ç½•è§éƒ¨ä½é±¼éª¨æ˜“ä½çš„å¹¶å‘ç—‡å’Œå¤„ç†ã€‚é‰´äºå¼‚è´¨ç—…ä¾‹æŠ¥å‘Šå ä¸»å¯¼åœ°ä½ï¼Œé‡‡ç”¨èŸèƒåˆ†æè¿›è¡Œæ­£å¼çš„ç³»ç»Ÿè¯„ä»·æ˜¯ä¸å¯è¡Œçš„ï¼›ç„¶è€Œï¼Œæˆ‘ä»¬é‡‡ç”¨ç³»ç»Ÿæœç´¢ç­–ç•¥æ¥å°½é‡å‡å°‘é€‰æ‹©åå·®ã€‚\n\n**ç»“è®ºï¼š** ä¸ºäº†é¿å…ä¸¥é‡çš„å¹¶å‘ç—‡ï¼Œæä¾›æœ‰å…³é±¼éª¨åµŒå¡å¤„ç†çš„å…¨é¢ä¿¡æ¯è‡³å…³é‡è¦ã€‚å½“å–‰é•œæ— æ³•å–å‡ºé±¼éª¨æ—¶ï¼Œéœ€è¦åŠæ—¶ã€æœæ–­çš„æ‰‹æœ¯å¹²é¢„ä»¥å–å‡ºå¼‚ç‰©ã€‚", "keywords_zh": "å¹¶å‘ç—‡ã€é±¼åˆºã€èƒƒè‚ é“å¼‚ç‰©ã€å’½éƒ¨å¼‚ç‰©", "keywords_en": "Complications, Fishbone, Gastrointestinal foreign body, Pharyngeal foreign body", "link": "https://pubmed.ncbi.nlm.nih.gov/40269939/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 24 Apr 2025"}, {"id": "40210078", "title_en": "Defining Radiological Healing in Perianal Fistulizing Crohn's Disease: A TOpClass Global Expert Delphi Consensus", "title_zh": "å®šä¹‰è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…çš„æ”¾å°„æ²»ç–—ï¼šé¡¶çº§å…¨çƒä¸“å®¶å¾·å°”è²å…±è¯†", "authors": "TOpClass collaborative authors", "abstract_en": "**Background & Aims:** Perianal fistulising Crohn's disease (pfCD) affects one-fifth of patients with Crohn's disease (CD), significantly affecting their quality of life. Magnetic resonance imaging is the gold standard for evaluating fistula healing in pfCD, but variability in radiological definitions hampers meaningful clinical interpretation and consistent trial design. This study aimed to establish an international consensus on the definition of radiological healing in pfCD.\n\n**Methods:** The study was conducted in 2 phases. Phase 1 involved a systematic review to identify magnetic resonance imaging-based variables and indices used to define healing in pfCD, assessing methodological quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework. Phase 2 utilized a 2-round online Delphi consensus process with 84 international experts, followed by a stakeholder meeting to achieve consensus (agreement threshold >80%). Results were reported as per Accurate Consensus Reporting Document (ACCORD) guidelines.\n\n**Results:** A radiologically healed fistula can be defined by the absence of T2-weighted hyperintensity, a completely fibrotic fistula tract and, when contrast is used, the absence of contrast enhancement on post-contrast T1-weighted images (95% consensus). Radiological improvement of a fistula can be defined (80% consensus) by the presence of a least one essential criterion: an increasingly fibrotic fistula tract, an unequivocal reduction in one or more of the following: T2-weighted hyperintensity, fistula diameter, fistula length, abscess size, or contrast enhancement of the fistula tract.\n\n**Conclusions:** This international Delphi consensus standardizes radiological endpoints in pfCD, improving consistency in clinical and research settings. Future studies will validate this definition and assess how radiological changes predict long-term clinical outcomes and quality of life improvements.", "abstract_zh": "**Background & aimsï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (pfCD) å½±å“äº”åˆ†ä¹‹ä¸€çš„å…‹ç½—æ©ç—… (CD) æ‚£è€…ï¼Œæ˜¾ç€å½±å“ä»–ä»¬çš„ç”Ÿæ´»è´¨é‡ã€‚ç£å…±æŒ¯æˆåƒæ˜¯è¯„ä¼° pfCD ç˜˜ç®¡æ„ˆåˆçš„é»„é‡‘æ ‡å‡†ï¼Œä½†æ”¾å°„å­¦å®šä¹‰çš„å¯å˜æ€§å¦¨ç¢äº†æœ‰æ„ä¹‰çš„ä¸´åºŠè§£é‡Šå’Œä¸€è‡´çš„è¯•éªŒè®¾è®¡ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å°± pfCD æ”¾å°„æ²»ç–—çš„å®šä¹‰å»ºç«‹å›½é™…å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥ç ”ç©¶åˆ†ä¸¤ä¸ªé˜¶æ®µè¿›è¡Œã€‚ç¬¬ä¸€é˜¶æ®µæ¶‰åŠç³»ç»Ÿå®¡æŸ¥ï¼Œä»¥ç¡®å®šç”¨äºå®šä¹‰ pfCD æ„ˆåˆçš„åŸºäºç£å…±æŒ¯æˆåƒçš„å˜é‡å’ŒæŒ‡æ•°ï¼Œä½¿ç”¨åŸºäºå…±è¯†çš„å¥åº·æµ‹é‡ä»ªå™¨é€‰æ‹©æ ‡å‡† (COSMIN) æ¡†æ¶è¯„ä¼°æ–¹æ³•å­¦è´¨é‡ã€‚ç¬¬äºŒé˜¶æ®µé‡‡ç”¨äº†ç”±84ä½å›½é™…ä¸“å®¶å‚ä¸çš„ä¸¤è½®åœ¨çº¿å¾·å°”è²å…±è¯†æµç¨‹ï¼Œéšåå¬å¼€åˆ©ç›Šç›¸å…³è€…ä¼šè®®ä»¥è¾¾æˆå…±è¯†ï¼ˆåŒæ„é˜ˆå€¼>80%ï¼‰ã€‚ç»“æœæŒ‰ç…§å‡†ç¡®å…±è¯†æŠ¥å‘Šæ–‡ä»¶ (ACCORD) æŒ‡å—è¿›è¡ŒæŠ¥å‘Šã€‚\n\n**ç»“æœï¼š** æ”¾å°„å­¦æ„ˆåˆçš„ç˜˜ç®¡å¯ä»¥å®šä¹‰ä¸ºä¸å­˜åœ¨ T2 åŠ æƒé«˜ä¿¡å·ã€å®Œå…¨çº¤ç»´åŒ–çš„ç˜˜ç®¡ï¼Œä»¥åŠä½¿ç”¨é€ å½±å‰‚æ—¶ï¼Œé€ å½±å T1 åŠ æƒå›¾åƒä¸Šä¸å­˜åœ¨é€ å½±å‰‚å¢å¼ºï¼ˆ95% å…±è¯†ï¼‰ã€‚ç˜˜ç®¡çš„æ”¾å°„å­¦æ”¹å–„å¯ä»¥é€šè¿‡è‡³å°‘ä¸€ä¸ªåŸºæœ¬æ ‡å‡†çš„å­˜åœ¨æ¥å®šä¹‰ï¼ˆ80%å…±è¯†ï¼‰ï¼šç˜˜ç®¡çº¤ç»´åŒ–ç¨‹åº¦ä¸æ–­å¢åŠ ï¼Œä»¥ä¸‹ä¸€é¡¹æˆ–å¤šé¡¹æŒ‡æ ‡æ˜ç¡®å‡å°‘ï¼šT2åŠ æƒé«˜ä¿¡å·ã€ç˜˜ç®¡ç›´å¾„ã€ç˜˜ç®¡é•¿åº¦ã€è„“è‚¿å¤§å°æˆ–ç˜˜ç®¡é€ å½±å¢å¼ºã€‚\n\n**ç»“è®ºï¼š** è¿™ä¸€å›½é™…å¾·å°”è²å…±è¯†æ ‡å‡†åŒ–äº† pfCD çš„æ”¾å°„å­¦ç»ˆç‚¹ï¼Œæé«˜äº†ä¸´åºŠå’Œç ”ç©¶ç¯å¢ƒçš„ä¸€è‡´æ€§ã€‚æœªæ¥çš„ç ”ç©¶å°†éªŒè¯è¿™ä¸€å®šä¹‰ï¼Œå¹¶è¯„ä¼°æ”¾å°„å­¦å˜åŒ–å¦‚ä½•é¢„æµ‹é•¿æœŸä¸´åºŠç»“æœå’Œç”Ÿæ´»è´¨é‡çš„æ”¹å–„ã€‚", "keywords_zh": "ç»ˆç‚¹ã€ç˜˜ç®¡ã€æ„ˆåˆã€MRIã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "Endpoints, Fistula, Healing, MRI, Perianal Fistulising Crohnâ€™s Disease", "link": "https://pubmed.ncbi.nlm.nih.gov/40210078/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 10 Apr 2025"}, {"id": "40205247", "title_en": "Systematic review and meta-analysis of the efficacy and safety of stem cell treatment of anal fistulas", "title_zh": "å¹²ç»†èƒæ²»ç–—è‚›ç˜˜ç–—æ•ˆå’Œå®‰å…¨æ€§çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S D Wexner", "abstract_en": "**Background:** Since anal fistulas can be challenging to treat; numerous innovative treatments have been proposed, including stem cell therapy. This systematic review aimed to assess pooled rates of fistula healing and adverse events associated with stem cell treatment.\n\n**Methods:** In this PRISMA-compliant systematic review we searched PubMed and Scopus for observational and randomized studies reporting outcomes of stem cell treatment for anal fistulas. The main outcome measures were successful healing and adverse effects of stem cell therapy.\n\n**Results:** In total, 43 studies incorporating 1160 patients (53.6% male) were included. Underlying fistula etiologies were Crohn's disease (30 studies) and cryptoglandular disease (12 studies). The main origin of stem cells was from adipose tissue (34 studies) or bone marrow (6 studies). The median follow-up duration was 12Â months. The combined overall pooled healing rate was 58.1% (95% confidence interval (CI) 51.5-64.7%). The pooled healing rate for Crohn's fistulas was 60.4% (95% CI 54.7-66.2%) with adipose-derived stem cells and 63.6% (95% CI 49.4-77.7%) with bone-marrow-derived cells. The pooled healing rate for cryptoglandular fistulas was 53.8% (95% CI 35.5-72.2%) with adipose-derived stem cells. The pooled complication rate was 37.3% (95% CI 27.1-47.5%). Stem cells were associated with higher odds of anal fistula healing (odds ratio (OR): 1.81, pâ€‰=â€‰0.003) and similar odds of complications (OR: 1, pâ€‰=â€‰0.986) compared with controls.\n\n**Conclusions:** Stem cell treatment of anal fistulas was associated with promising results. The healing rate in Crohn's anal fistulas was higher than in cryptoglandular fistulas. Bone-marrow-derived stem cells were associated with marginally better outcomes thanÂ were adipose-derived cells. This finding suggests that the autoimmune inflammatory etiology of Crohn's disease may respond better to autologous myoblasts than does the infectious etiology of cryptoglandular fistulas.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç”±äºè‚›ç˜˜å¾ˆéš¾æ²»ç–—ï¼›å·²ç»æå‡ºäº†è®¸å¤šåˆ›æ–°ç–—æ³•ï¼ŒåŒ…æ‹¬å¹²ç»†èƒç–—æ³•ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼°ä¸å¹²ç»†èƒæ²»ç–—ç›¸å…³çš„ç˜˜ç®¡æ„ˆåˆå’Œä¸è‰¯äº‹ä»¶çš„æ±‡æ€»ç‡ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨è¿™ç¯‡ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿè¯„ä»·ä¸­ï¼Œæˆ‘ä»¬æ£€ç´¢äº† PubMed å’Œ Scopus ä¸­æŠ¥å‘Šå¹²ç»†èƒæ²»ç–—è‚›ç˜˜ç»“æœçš„è§‚å¯Ÿæ€§å’Œéšæœºç ”ç©¶ã€‚ä¸»è¦ç»“æœæŒ‡æ ‡æ˜¯å¹²ç»†èƒæ²»ç–—çš„æˆåŠŸæ²»æ„ˆå’Œä¸è‰¯ååº”ã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥äº† 43 é¡¹ç ”ç©¶ï¼Œçº³å…¥äº† 1160 åæ‚£è€…ï¼ˆ53.6% ä¸ºç”·æ€§ï¼‰ã€‚ç˜˜ç®¡çš„æ½œåœ¨ç—…å› æ˜¯å…‹ç½—æ©ç—…ï¼ˆ30 é¡¹ç ”ç©¶ï¼‰å’Œéšè…ºç–¾ç—…ï¼ˆ12 é¡¹ç ”ç©¶ï¼‰ã€‚å¹²ç»†èƒçš„ä¸»è¦æ¥æºæ˜¯è„‚è‚ªç»„ç»‡ï¼ˆ34 é¡¹ç ”ç©¶ï¼‰æˆ–éª¨é«“ï¼ˆ6 é¡¹ç ”ç©¶ï¼‰ã€‚ä¸­ä½éšè®¿æ—¶é—´ä¸º 12 ä¸ªæœˆã€‚åˆå¹¶åçš„æ€»ä½“æ²»æ„ˆç‡ä¸º 58.1%ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI) 51.5-64.7%ï¼‰ã€‚è„‚è‚ªæºæ€§å¹²ç»†èƒå…‹ç½—æ©ç˜˜ç®¡çš„ç»¼åˆæ²»æ„ˆç‡ä¸º 60.4% (95% CI 54.7-66.2%)ï¼Œéª¨é«“æºæ€§ç»†èƒä¸º 63.6% (95% CI 49.4-77.7%)ã€‚ä½¿ç”¨è„‚è‚ªå¹²ç»†èƒæ²»ç–—éšçªè…ºç˜˜çš„ç»¼åˆæ²»æ„ˆç‡ä¸º 53.8% (95% CI 35.5-72.2%)ã€‚åˆå¹¶å¹¶å‘ç—‡ç‡ä¸º 37.3%ï¼ˆ95% CI 27.1-47.5%ï¼‰ã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œå¹²ç»†èƒä¸è‚›ç˜˜æ„ˆåˆçš„å‡ ç‡è¾ƒé«˜ï¼ˆæ¯”å€¼æ¯”ï¼ˆORï¼‰ï¼š1.81ï¼Œpâ€‰=â€‰0.003ï¼‰å’Œç›¸ä¼¼çš„å¹¶å‘ç—‡å‡ ç‡ï¼ˆORï¼š1ï¼Œpâ€‰=â€‰0.986ï¼‰ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** è‚›ç˜˜çš„å¹²ç»†èƒæ²»ç–—å…·æœ‰è‰¯å¥½çš„æ•ˆæœã€‚å…‹ç½—æ©ç—…è‚›ç˜˜çš„æ²»æ„ˆç‡é«˜äºéšçªè‚›ç˜˜ã€‚éª¨é«“æ¥æºçš„å¹²ç»†èƒæ¯”è„‚è‚ªæ¥æºçš„ç»†èƒå…·æœ‰ç¨å¾®æ›´å¥½çš„ç»“æœã€‚è¿™ä¸€å‘ç°è¡¨æ˜ï¼Œå…‹ç½—æ©ç—…çš„è‡ªèº«å…ç–«ç‚ç—‡ç—…å› å¯èƒ½æ¯”éšè…ºç˜˜çš„æ„ŸæŸ“ç—…å› å¯¹è‡ªä½“æˆè‚Œç»†èƒçš„ååº”æ›´å¥½ã€‚", "keywords_zh": "ä¸è‰¯ååº”, è‚›ç˜˜, æ„ˆåˆ, å¹²ç»†èƒ, ç³»ç»Ÿè¯„ä»·", "keywords_en": "Adverse effects, Anal fistulas, Healing, Stem cells, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40205247/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 09 Apr 2025"}, {"id": "40192869", "title_en": "Sphincter repair procedures may be favored in the treatment of obstetrical recto-vaginal fistula: a systematic review of the literature and meta-analysis", "title_zh": "æ‹¬çº¦è‚Œä¿®å¤æ‰‹æœ¯å¯èƒ½æœ‰åˆ©äºäº§ç§‘ç›´è‚ é˜´é“ç˜˜çš„æ²»ç–—ï¼šæ–‡çŒ®å’ŒèŸèƒåˆ†æçš„ç³»ç»Ÿå›é¡¾", "authors": "J F Hamel", "abstract_en": "**Background:** The management of obstetric rectovaginal fistula (RVF) is challenging for the surgeon. The best surgical procedure to repair RVFs, specifically after obstetric anal sphincter injury, has not been extensively studied. The objective was to compare the success of the different procedures performed to repair obstetric RVF.\n\n**Methods:** The literature search was carried out on PubMed<sup>Â®</sup> and Web of Science<sup>Â®</sup> from database inception until 31 December 2022. Selection criteria were: (1) patients with a diagnosis of obstetric-related RVF; (2) patients treated surgically with no restriction concerning the considered surgery; (3) clinical trials or epidemiological studies. Meta-analysis was conducted considering the network meta-analysis framework to allow studying the relative value of each treatment mentioned in the selected articles.\n\n**Results:** The quantitative synthesis included 32 studies (18 retrospective and 14 prospective) accounting for 595 patients. The quality of these studies was low because of the lack of prospective randomization. Nineteen procedure types were described and assessed. Most patients (nâ€‰=â€‰180) underwent endorectal advancement flap (ERAF) followed by excision and layered closure (ELC) (nâ€‰=â€‰213) and Musset procedure (nâ€‰=â€‰65). A diverting stoma was performed in 66/132 patients. Only 13 studies reported the functional results of the procedure. In the meta-analysis, the Musset procedure (ORâ€‰=â€‰4.29; 95% CI: 1.18-16.14), transvaginal ELC (ORâ€‰=â€‰11.84; 95% CI: 2.18-91.80) and transperineal ELC (ORâ€‰=â€‰3.56; 95% CI: 1.26-10) significantly improved the anatomical results compared to ERAF.\n\n**Conclusions:** A further randomized controlled trial in the literature assessing ERAF and sphincteroplasty to compare the anatomical results, functional results and morbidity of this treatment is needed.\n\n**Registration:** PROSPERO CRD42023447875.", "abstract_zh": "**èƒŒæ™¯ï¼š** äº§ç§‘ç›´è‚ é˜´é“ç˜˜ï¼ˆRVFï¼‰çš„æ²»ç–—å¯¹äºå¤–ç§‘åŒ»ç”Ÿæ¥è¯´æ˜¯ä¸€é¡¹æŒ‘æˆ˜ã€‚ä¿®å¤ RVF çš„æœ€ä½³æ‰‹æœ¯æ–¹æ³•ï¼Œç‰¹åˆ«æ˜¯åœ¨äº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤åï¼Œå°šæœªå¾—åˆ°å¹¿æ³›ç ”ç©¶ã€‚ç›®çš„æ˜¯æ¯”è¾ƒä¿®å¤äº§ç§‘ RVF çš„ä¸åŒæ‰‹æœ¯çš„æˆåŠŸç‡ã€‚\n\n**æ–¹æ³•ï¼š** æ–‡çŒ®æ£€ç´¢åœ¨ PubMed<sup>Â®</sup> å’Œ Web of Science<sup>Â®</sup> ä¸Šè¿›è¡Œï¼Œä»æ•°æ®åº“å»ºç«‹åˆ° 2022 å¹´ 12 æœˆ 31 æ—¥ã€‚é€‰æ‹©æ ‡å‡†ä¸ºï¼š (1) è¯Šæ–­ä¸ºäº§ç§‘ç›¸å…³ RVF çš„æ‚£è€…ï¼› (2) æ¥å—æ‰‹æœ¯æ²»ç–—ä¸”å¯¹æ‰€è€ƒè™‘æ‰‹æœ¯æ²¡æœ‰é™åˆ¶çš„æ‚£è€…ï¼› (3)ä¸´åºŠè¯•éªŒæˆ–æµè¡Œç—…å­¦ç ”ç©¶ã€‚è€ƒè™‘ç½‘ç»œèŸèƒåˆ†ææ¡†æ¶è¿›è¡ŒèŸèƒåˆ†æï¼Œä»¥ç ”ç©¶æ‰€é€‰æ–‡ç« ä¸­æåˆ°çš„æ¯ç§æ²»ç–—æ–¹æ³•çš„ç›¸å¯¹ä»·å€¼ã€‚\n\n**ç»“æœï¼š** å®šé‡ç»¼åˆåŒ…æ‹¬ 32 é¡¹ç ”ç©¶ï¼ˆ18 é¡¹å›é¡¾æ€§ç ”ç©¶å’Œ 14 é¡¹å‰ç»æ€§ç ”ç©¶ï¼‰ï¼Œæ¶‰åŠ 595 åæ‚£è€…ã€‚ç”±äºç¼ºä¹å‰ç»æ€§éšæœºåŒ–ï¼Œè¿™äº›ç ”ç©¶çš„è´¨é‡è¾ƒä½ã€‚æè¿°å¹¶è¯„ä¼°äº†åä¹ç§æ‰‹æœ¯ç±»å‹ã€‚å¤§å¤šæ•°æ‚£è€… (nâ€‰=â€‰180) æ¥å—ç›´è‚ å†…æ¨è¿›çš®ç“£ (ERAF)ï¼Œç„¶åè¿›è¡Œåˆ‡é™¤å’Œåˆ†å±‚é—­åˆ (ELC) (nâ€‰=â€‰213) å’Œ Musset æ‰‹æœ¯ (nâ€‰=â€‰65)ã€‚ 66/132 åæ‚£è€…è¿›è¡Œäº†æ”¹é“é€ å£ã€‚åªæœ‰ 13 é¡¹ç ”ç©¶æŠ¥å‘Šäº†è¯¥æ‰‹æœ¯çš„åŠŸèƒ½ç»“æœã€‚åœ¨èŸèƒåˆ†æä¸­ï¼ŒMussetæ‰‹æœ¯ï¼ˆORâ€‰=â€‰4.29ï¼›95% CIï¼š1.18-16.14ï¼‰ã€ç»é˜´é“ELCï¼ˆORâ€‰=â€‰11.84ï¼›95% CIï¼š2.18-91.80ï¼‰å’Œç»ä¼šé˜´ELCï¼ˆORâ€‰=â€‰3.56ï¼›95% CIï¼š 1.26-10) ä¸ ERAF ç›¸æ¯”ï¼Œæ˜¾ç€æ”¹å–„äº†è§£å‰–ç»“æœã€‚\n\n**ç»“è®ºï¼š** éœ€è¦åœ¨æ–‡çŒ®ä¸­è¿›è¡Œè¿›ä¸€æ­¥çš„éšæœºå¯¹ç…§è¯•éªŒæ¥è¯„ä¼° ERAF å’Œæ‹¬çº¦è‚Œæˆå½¢æœ¯ï¼Œä»¥æ¯”è¾ƒè¿™ç§æ²»ç–—çš„è§£å‰–ç»“æœã€åŠŸèƒ½ç»“æœå’Œå‘ç—…ç‡ã€‚\n\n**Registrationï¼š** æ™®æ´›æ–¯å½¼ç½— CRD42023447875ã€‚", "keywords_zh": "è‚›é—¨é˜´é“ç˜˜ã€äº§ç§‘ã€ç›´è‚ é˜´é“ç˜˜ã€ä¿®å¤", "keywords_en": "Anovaginal fistula, Obstetric, Rectovaginal fistula, Repair", "link": "https://pubmed.ncbi.nlm.nih.gov/40192869/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 07 Apr 2025"}, {"id": "40185644", "title_en": "Oncological and functional outcomes after sacrectomy for colorectal cancer: A systematic review", "title_zh": "ç»“ç›´è‚ ç™Œéª¶éª¨åˆ‡é™¤æœ¯åçš„è‚¿ç˜¤å­¦å’ŒåŠŸèƒ½ç»“æœï¼šç³»ç»Ÿè¯„ä»·", "authors": "GabriÃ«lle H van Ramshorst", "abstract_en": "**Aim:** Worldwide, of all cancers, colorectal cancer has the fourth highest rate of mortality. Curative treatment for locally advanced or recurrent rectal cancer can require extended resections with sacrectomy, but this sugery can have major consequences for patients. The aim of this study was to investigate the oncological and functional outcomes after sacrectomy in patients with colorectal cancer.\n\n**Method:** The protocol was registered in (PROSPERO), the international prospective register of systematic reviews. PubMed, Embase, The Cochrane Library, Scopus and Google Scholar were searched using a predetermined search strategy. Article selection, quality of evidence [Grading of Recommendation, Assessment, Development and Evaluation (GRADE)] and risk of bias [The Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I)] were assessed by two independent reviewers. Studies reporting on sacrectomy for colorectal cancer were included. Oncological and functional outcomes after sacrectomy for colorectal cancer were the primary outcomes.\n\n**Results:** Forty-six articles with 1687 patients (1115 men; 506 women) were included. Median follow-up was 31.4â€‰months. Mean 30-day mortality was 1.1%. After R0 resection, overall survival was achieved in 86.2%, 68.0% and 42.1% patients, and disease-free survival was achieved in 75.0%, 51.0% and 43.0% patients, respectively, after 1, 3 and 5â€‰years. Survival rates were lower after R1 or R2 resection. Most patients reported elimination of or significantly reduced pain after surgery, and 82.2% were able to walk independently, without the use of assistive devices. More patients were dependent on walking-assist devices after high sacrectomy than after low sacrectomy. The most commonly reported bowel dysfunctions were bowel obstruction (22.3%) and fistula (4.6%). Bladder dysfunction was mainly reported as incontinence (8.3%) and neurogenic bladder (23.3%). No study included quality of life as an outcome.\n\n**Conclusions:** The mortality was limited, and the morbidity rates were in concordance with published literature. The results suggest that R0 resection has higher survival rates than R1/R2 resections. Both short- and long-term functional outcomes could have major impact on a patient's quality of life. Heterogeneity was high, and neither comparative analyses nor meta-analysis could be performed.", "abstract_zh": "**Aimï¼š** åœ¨ä¸–ç•ŒèŒƒå›´å†…ï¼Œåœ¨æ‰€æœ‰ç™Œç—‡ä¸­ï¼Œç»“ç›´è‚ ç™Œçš„æ­»äº¡ç‡æ’åç¬¬å››ã€‚å±€éƒ¨æ™šæœŸæˆ–å¤å‘æ€§ç›´è‚ ç™Œçš„æ²»æ„ˆæ€§æ²»ç–—å¯èƒ½éœ€è¦é€šè¿‡éª¶éª¨åˆ‡é™¤æœ¯è¿›è¡Œæ‰©å¤§åˆ‡é™¤ï¼Œä½†è¿™ç§æ‰‹æœ¯å¯èƒ½ä¼šç»™æ‚£è€…å¸¦æ¥é‡å¤§åæœã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è°ƒæŸ¥ç»“ç›´è‚ ç™Œæ‚£è€…éª¶éª¨åˆ‡é™¤æœ¯åçš„è‚¿ç˜¤å­¦å’ŒåŠŸèƒ½ç»“æœã€‚\n\n**Methodï¼š** è¯¥æ–¹æ¡ˆå·²åœ¨å›½é™…å‰ç»æ€§ç³»ç»Ÿè¯„ä»·ç™»è®°å†Œï¼ˆPROSPEROï¼‰ä¸­æ³¨å†Œã€‚ä½¿ç”¨é¢„å®šçš„æœç´¢ç­–ç•¥å¯¹ PubMedã€Embaseã€Cochrane å›¾ä¹¦é¦†ã€Scopus å’Œ Google Scholar è¿›è¡Œæœç´¢ã€‚æ–‡ç« é€‰æ‹©ã€è¯æ®è´¨é‡[æ¨èã€è¯„ä¼°ã€å¼€å‘å’Œè¯„ä»·åˆ†çº§(GRADE)]å’Œåå€šé£é™©[ééšæœºå¹²é¢„ç ”ç©¶ä¸­çš„åå€šé£é™©(ROBINS-I)]ç”±ä¸¤åç‹¬ç«‹å®¡ç¨¿äººè¿›è¡Œè¯„ä¼°ã€‚åŒ…æ‹¬å…³äºç»“ç›´è‚ ç™Œéª¶éª¨åˆ‡é™¤æœ¯çš„ç ”ç©¶æŠ¥å‘Šã€‚ç»“ç›´è‚ ç™Œéª¶éª¨åˆ‡é™¤æœ¯åçš„è‚¿ç˜¤å­¦å’ŒåŠŸèƒ½ç»“æœæ˜¯ä¸»è¦ç»“æœã€‚\n\n**ç»“æœï¼š** çº³å…¥ 46 ç¯‡æ–‡ç« ï¼Œæ¶‰åŠ 1687 åæ‚£è€…ï¼ˆ1115 åç”·æ€§ï¼›506 åå¥³æ€§ï¼‰ã€‚ä¸­ä½éšè®¿æ—¶é—´ä¸º 31.4 ä¸ªæœˆã€‚å¹³å‡ 30 å¤©æ­»äº¡ç‡ä¸º 1.1%ã€‚ R0åˆ‡é™¤åï¼Œ1å¹´ã€3å¹´å’Œ5å¹´åï¼Œæ€»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º86.2%ã€68.0%å’Œ42.1%ï¼Œæ— ç—…ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º75.0%ã€51.0%å’Œ43.0%ã€‚ R1 æˆ– R2 åˆ‡é™¤åå­˜æ´»ç‡è¾ƒä½ã€‚å¤§å¤šæ•°æ‚£è€…æŠ¥å‘Šæœ¯åç–¼ç—›æ¶ˆé™¤æˆ–æ˜¾ç€å‡è½»ï¼Œ82.2% çš„æ‚£è€…èƒ½å¤Ÿç‹¬ç«‹è¡Œèµ°ï¼Œæ— éœ€ä½¿ç”¨è¾…åŠ©è®¾å¤‡ã€‚é«˜ä½éª¶éª¨åˆ‡é™¤æœ¯åæ¯”ä½ä½éª¶éª¨åˆ‡é™¤æœ¯åæ›´å¤šçš„æ‚£è€…ä¾èµ–æ­¥è¡Œè¾…åŠ©è£…ç½®ã€‚æœ€å¸¸è§çš„è‚ åŠŸèƒ½éšœç¢æ˜¯è‚ æ¢—é˜»ï¼ˆ22.3%ï¼‰å’Œç˜˜ç®¡ï¼ˆ4.6%ï¼‰ã€‚è†€èƒ±åŠŸèƒ½éšœç¢ä¸»è¦ä¸ºå¤±ç¦ï¼ˆ8.3%ï¼‰å’Œç¥ç»æºæ€§è†€èƒ±ï¼ˆ23.3%ï¼‰ã€‚æ²¡æœ‰ç ”ç©¶å°†ç”Ÿæ´»è´¨é‡ä½œä¸ºç»“æœã€‚\n\n**ç»“è®ºï¼š** æ­»äº¡ç‡æœ‰é™ï¼Œå‘ç—…ç‡ä¸å·²å‘è¡¨çš„æ–‡çŒ®ä¸€è‡´ã€‚ç»“æœè¡¨æ˜ï¼ŒR0 åˆ‡é™¤æ¯” R1/R2 åˆ‡é™¤å…·æœ‰æ›´é«˜çš„ç”Ÿå­˜ç‡ã€‚çŸ­æœŸå’Œé•¿æœŸåŠŸèƒ½ç»“æœéƒ½å¯èƒ½å¯¹æ‚£è€…çš„ç”Ÿæ´»è´¨é‡äº§ç”Ÿé‡å¤§å½±å“ã€‚å¼‚è´¨æ€§è¾ƒé«˜ï¼Œæ— æ³•è¿›è¡Œæ¯”è¾ƒåˆ†æå’ŒèŸèƒåˆ†æã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œ, åŠŸèƒ½ç»“æœ, è‚¿ç˜¤å­¦ç»“æœ, éª¶éª¨åˆ‡é™¤æœ¯", "keywords_en": "colorectal cancer, functional outcomes, oncological outcomes, sacrectomy", "link": "https://pubmed.ncbi.nlm.nih.gov/40185644/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 04 Apr 2025"}, {"id": "40156066", "title_en": "Efficacy of mesenchymal stem cell-based therapies in the treatment of perianal fistulizing Crohn's disease: a systematic review and meta-analysis", "title_zh": "åŸºäºé—´å……è´¨å¹²ç»†èƒçš„ç–—æ³•æ²»ç–—è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…çš„ç–—æ•ˆï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "JÃ©rÃ©my Magalon", "abstract_en": "**Background:** Perianal lesions of Crohn's disease (CD) are complex and disabling conditions. Mesenchymal stem cell (MSC)-based therapies have emerged as an innovative approach in managing refractory perianal fistulizing CD. We conducted a systematic review and meta-analysis to describe and compare combined remission and clinical outcomes of MSC-based therapies, and then whether one approach stands out from the rest.\n\n**Methods:** We searched in MEDLINE, EMBASE and CENTRAL (up to December 31, 2023) all prospective studies assessing a local injection of MSC-based therapy in perianal fistulas of CD. The primary outcome was achievement of combined remission. MSC-based therapy strategies were compared.\n\n**Results:** Twenty-five studies were included in the meta-analysis, enrolling 596 patients with perianal fistulizing CD. The combined remission rate at 3, 6 and 12Â months were 36.2% (95% confidence interval (CI), 24.5-49.7), 57.9% (95% CI 51.3-64.2) and 52% (95% CI 38.8-64.8), respectively. MSC-based therapies demonstrated a significant effect in achieving combined remission compared to placebo at 3Â months (relative risk (RR)â€‰=â€‰1.6; 95% CI 1.0-2.8) and at 6Â months (RRâ€‰=â€‰1.5; 95% CI 1.1-1.9). At 6Â months, the combined remission rate was 57.2% (95% CI 47.2-66.6) for adipose-derived stem cells (ASCs) and 55.7% (95% CI 26.4-81.5) for bone marrow-derived stem cells (BMSCs). In the network meta-analysis, allogeneic ASCs and BMSCs did not demonstrate superiority over each other (RRâ€‰=â€‰0.74; 95% CI 0.31-1.77).\n\n**Conclusion:** MSC-based therapies are effective for achieving combined remission of refractory and/or complex perianal fistulizing CD. The optimal efficacy effect is reached after 6Â months of treatment. No superiority has yet been demonstrated between ASCs and BMSCs therapies.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—… (CD) çš„è‚›å‘¨ç—…å˜æ˜¯å¤æ‚ä¸”è‡´æ®‹çš„ç—…ç—‡ã€‚åŸºäºé—´å……è´¨å¹²ç»†èƒ (MSC) çš„ç–—æ³•å·²æˆä¸ºæ²»ç–—éš¾æ²»æ€§è‚›å‘¨ç˜˜ç®¡ CD çš„åˆ›æ–°æ–¹æ³•ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œä»¥æè¿°å’Œæ¯”è¾ƒåŸºäº MSC çš„ç–—æ³•çš„ç»¼åˆç¼“è§£å’Œä¸´åºŠç»“æœï¼Œä»¥åŠä¸€ç§æ–¹æ³•æ˜¯å¦è„±é¢–è€Œå‡ºã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬åœ¨ MEDLINEã€EMBASE å’Œ CENTRALï¼ˆæˆªè‡³ 2023 å¹´ 12 æœˆ 31 æ—¥ï¼‰ä¸­æ£€ç´¢äº†æ‰€æœ‰è¯„ä¼°å±€éƒ¨æ³¨å°„ MSC æ²»ç–— CD è‚›å‘¨ç˜˜çš„å‰ç»æ€§ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯å®ç°ç»¼åˆç¼“è§£ã€‚æ¯”è¾ƒäº†åŸºäº MSC çš„æ²»ç–—ç­–ç•¥ã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†æçº³å…¥äº† 25 é¡¹ç ”ç©¶ï¼Œçº³å…¥äº† 596 åè‚›å‘¨ç˜˜ç®¡æ€§ CD æ‚£è€…ã€‚ 3ã€6 å’Œ 12 ä¸ªæœˆæ—¶çš„ç»¼åˆç¼“è§£ç‡åˆ†åˆ«ä¸º 36.2%ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI)ï¼Œ24.5-49.7ï¼‰ã€57.9%ï¼ˆ95% CI 51.3-64.2ï¼‰å’Œ 52%ï¼ˆ95% CI 38.8-64.8ï¼‰ã€‚ä¸å®‰æ…°å‰‚ç›¸æ¯”ï¼ŒåŸºäº MSC çš„ç–—æ³•åœ¨ 3 ä¸ªæœˆï¼ˆç›¸å¯¹é£é™© (RR)â€‰=â€‰1.6ï¼›95% CI 1.0-2.8ï¼‰å’Œ 6 ä¸ªæœˆï¼ˆRRâ€‰=â€‰1.5ï¼›95% CI 1.1-1.9ï¼‰æ—¶æ˜¾ç¤ºå‡ºåœ¨å®ç°è”åˆç¼“è§£æ–¹é¢å…·æœ‰æ˜¾ç€æ•ˆæœã€‚ 6 ä¸ªæœˆæ—¶ï¼Œè„‚è‚ªæºæ€§å¹²ç»†èƒ (ASC) çš„ç»¼åˆç¼“è§£ç‡ä¸º 57.2% (95% CI 47.2-66.6)ï¼Œéª¨é«“æºæ€§å¹²ç»†èƒ (BMSC) çš„ç»¼åˆç¼“è§£ç‡ä¸º 55.7% (95% CI 26.4-81.5)ã€‚åœ¨ç½‘ç»œèŸèƒåˆ†æä¸­ï¼ŒåŒç§å¼‚ä½“ ASC å’Œ BMSC å¹¶æœªè¡¨ç°å‡ºå½¼æ­¤ä¹‹é—´çš„ä¼˜è¶Šæ€§ï¼ˆRRâ€‰=â€‰0.74ï¼›95% CI 0.31-1.77ï¼‰ã€‚\n\n**ç»“è®ºï¼š** åŸºäº MSC çš„ç–—æ³•å¯æœ‰æ•ˆå®ç°éš¾æ²»æ€§å’Œ/æˆ–å¤æ‚æ€§è‚›å‘¨ç˜˜ç®¡ CD çš„è”åˆç¼“è§£ã€‚æ²»ç–—6ä¸ªæœˆåè¾¾åˆ°æœ€ä½³ç–—æ•ˆã€‚ ASC å’Œ BMSC ç–—æ³•ä¹‹é—´å°šæœªè¯æ˜å…¶ä¼˜è¶Šæ€§ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€ç˜˜ç®¡ã€é—´å……è´¨å¹²ç»†èƒã€èŸèƒåˆ†æã€åŸºè´¨è¡€ç®¡åˆ†æ•°", "keywords_en": "Crohnâ€™s disease, Fistula, Mesenchymal stem cells, Meta-analysis, Stromal vascular fraction", "link": "https://pubmed.ncbi.nlm.nih.gov/40156066/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 29 Mar 2025"}, {"id": "40155532", "title_en": "Early diagnosis of Crohn's disease in patients presenting with a perianal fistula: systematic review and development of a perianal red flags index", "title_zh": "è‚›å‘¨ç˜˜æ‚£è€…å…‹ç½—æ©ç—…çš„æ—©æœŸè¯Šæ–­ï¼šç³»ç»Ÿå›é¡¾å’Œè‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°çš„åˆ¶å®š", "authors": "J D W van der Bilt", "abstract_en": "**Background:** Delay in diagnosing Crohn's disease (CD) in patients presenting with perianal abscess (PAA) and/or fistula (PAF) is common. The aim of this study was to identify red flags suggestive of CD.\n\n**Methods:** A systematic literature review was conducted to identify symptoms associated with CD in patients presenting with PAA/PAF. A questionnaire including those symptoms, supplemented with items from the International Organization for the Study of Inflammatory Bowel Diseases (IO-IBD) red flags index for luminal CD, was administered to all adult patients presenting with a PAF and eventually diagnosed with CD and matched patients (1:3) from the same study period with a cryptoglandular PAF (2012-2023) at a single non-academic teaching hospital. All patients were asked to recall symptoms/signs experienced during their first PAF.\n\n**Results:** The systematic review identified 8 articles reporting on 15 clinical characteristics in patients presenting with PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6), supplemented with 13 items from the IO-IBD red flags index (28 items in total). A total of 25 patients with CD and 75 patients with PAF without CD answered the questionnaire. Univariate analysis identified seven items associated with CD (age, family history,â€‰>â€‰2 perianal interventions, weight loss, abdominal pain, diarrhoea and fatigue), and four items remained significant in multivariate analysis: age (OR 3.4 [1.0-11.5]),â€‰>â€‰2 previous perianal interventions (OR 3.4 [1.0-10.1]), weight loss (OR 14.4 [3.7-55.6]) and abdominal pain (OR 9.8 [1.9-49.8]). Receiver-operating characteristic curve (ROC) analysis showed that a combination of these red flags was associated with good discrimination of CD versus non-CD (AUC 0.83 [0.72-0.94]).\n\n**Conclusions:** The perianal red flags index has a good predictive value for early identification of patients with PAF at risk for underlying CD.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¯¹äºæ‚£æœ‰è‚›å‘¨è„“è‚¿ (PAA) å’Œ/æˆ–ç˜˜ç®¡ (PAF) çš„æ‚£è€…ï¼Œå…‹ç½—æ©ç—… (CD) çš„è¯Šæ–­å»¶è¿Ÿå¾ˆå¸¸è§ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è¯†åˆ«æç¤º CD çš„å±é™©ä¿¡å·ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿæ€§æ–‡çŒ®ç»¼è¿°ï¼Œä»¥ç¡®å®š PAA/PAF æ‚£è€…ä¸­ä¸ CD ç›¸å…³çš„ç—‡çŠ¶ã€‚å¯¹æ‰€æœ‰å‡ºç° PAF å¹¶æœ€ç»ˆè¯Šæ–­ä¸º CD çš„æˆå¹´æ‚£è€…è¿›è¡Œäº†ä¸€ä»½åŒ…å«è¿™äº›ç—‡çŠ¶çš„è°ƒæŸ¥é—®å·ï¼Œå¹¶è¡¥å……äº†å›½é™…ç‚ç—‡æ€§è‚ ç—…ç ”ç©¶ç»„ç»‡ (IO-IBD) ç®¡è…” CD å±é™©ä¿¡å·æŒ‡æ•°çš„é¡¹ç›®ï¼Œå¹¶ä¸æ¥è‡ªåŒä¸€ç ”ç©¶æ—¶æœŸ (2012-2023) åœ¨ä¸€å®¶éå­¦æœ¯æ€§æ•™å­¦åŒ»é™¢çš„éšè…º PAF çš„åŒ¹é…æ‚£è€… (1:3) è¿›è¡Œäº†æ¯”è¾ƒã€‚æ‰€æœ‰æ‚£è€…éƒ½è¢«è¦æ±‚å›å¿†ç¬¬ä¸€æ¬¡ PAF æœŸé—´ç»å†çš„ç—‡çŠ¶/ä½“å¾ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·ç¡®å®šäº† 8 ç¯‡æ–‡ç« ï¼ŒæŠ¥å‘Šäº† PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6) æ‚£è€…çš„ 15 é¡¹ä¸´åºŠç‰¹å¾ï¼Œå¹¶è¡¥å……äº† IO-IBD å±é™©ä¿¡å·æŒ‡æ•°ä¸­çš„ 13 é¡¹ï¼ˆæ€»å…± 28 é¡¹ï¼‰ã€‚å…±æœ‰ 25 åæ‚£æœ‰ CD çš„æ‚£è€…å’Œ 75 åæ²¡æœ‰ CD çš„ PAF æ‚£è€…å›ç­”äº†é—®å·ã€‚å•å˜é‡åˆ†æç¡®å®šäº†ä¸ CD ç›¸å…³çš„ 7 ä¸ªé¡¹ç›®ï¼ˆå¹´é¾„ã€å®¶æ—å²ã€â€‰>â€‰2 æ¬¡è‚›å‘¨å¹²é¢„ã€ä½“é‡å‡è½»ã€è…¹ç—›ã€è…¹æ³»å’Œç–²åŠ³ï¼‰ï¼Œ4 ä¸ªé¡¹ç›®åœ¨å¤šå˜é‡åˆ†æä¸­ä»ç„¶æ˜¾ç€ï¼šå¹´é¾„ (OR 3.4 [1.0-11.5])ã€â€‰>â€‰2 æ¬¡æ—¢å¾€è‚›å‘¨å¹²é¢„ (OR 3.4 [1.0-10.1])ã€ä½“é‡å‡è½» (OR 14.4) [3.7-55.6]ï¼‰å’Œè…¹ç—›ï¼ˆOR 9.8 [1.9-49.8]ï¼‰ã€‚å—è¯•è€…å·¥ä½œç‰¹å¾æ›²çº¿ (ROC) åˆ†æè¡¨æ˜ï¼Œè¿™äº›å±é™©ä¿¡å·çš„ç»„åˆä¸ CD ä¸é CD çš„è‰¯å¥½åŒºåˆ†ç›¸å…³ï¼ˆAUC 0.83 [0.72-0.94]ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°å¯¹äºæ—©æœŸè¯†åˆ«æœ‰æ½œåœ¨ CD é£é™©çš„ PAF æ‚£è€…å…·æœ‰è‰¯å¥½çš„é¢„æµ‹ä»·å€¼ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€å»¶è¿Ÿã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜", "keywords_en": "Crohnâ€™s disease, Delay, Inflammatory bowel disease, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/40155532/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 29 Mar 2025"}, {"id": "40125894", "title_en": "Fistulotomy versus fistulectomy for simple fistula-in-ano: a systematic review and meta-analysis of randomized controlled trials", "title_zh": "å•çº¯æ€§è‚›ç˜˜çš„ç˜˜ç®¡åˆ‡å¼€æœ¯ä¸ç˜˜ç®¡åˆ‡é™¤æœ¯ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Rebecca J Lendzion", "abstract_en": "**Background:** Perianal fistulas are a common anorectal pathology. The sphincter-cutting techniques of fistulectomy and fistulotomy are associated with high cure rates for low or simple fistula-in-ano, with negligible risk of incontinence. However, the superiority of either technique has not previously been conclusively demonstrated. The aim of this systematic review is to compare the outcomes of the two surgical techniques for the management of simple fistula-in-ano.\n\n**Methods:** A search of MEDLINE, EMBASE and Cochrane Databases for randomized controlled trials (RCT) comparing fistulotomy to fistulectomy for simple fistula-in-ano was conducted. The primary outcome was healing time; secondary outcomes included operative time, length of hospital stay, post-operative pain score, post-operative complications and fistula recurrence.\n\n**Results:** Thirteen RCTs meet inclusion criteria, comprising a total of 685 fistulectomy and 688 fistulotomy patients. There was no significant difference between the techniques for healing time (Pâ€‰=â€‰0.15), operative time (Pâ€‰=â€‰0.13), length of stay (Pâ€‰=â€‰0.05), wound infection (Pâ€‰=â€‰0.97), flatus or faecal incontinence (Pâ€‰=â€‰0.35 and Pâ€‰=â€‰0.70, respectively) or recurrence (Pâ€‰=â€‰0.19). Post-operative pain at 24â€‰h, assessed using a visual analogue scale, was significantly lower in the fistulectomy group (MD-0.49, 95% CI: -0.90, -0.08; Pâ€‰=â€‰0.02), and we found significantly fewer post-operative bleeding complications in the fistulotomy group (OR: 3.81, 95% CI: 1.23, 11.80; Pâ€‰=â€‰0.02).\n\n**Conclusion:** This systematic review did not find conclusive evidence of the superiority of either fistulectomy or fistulotomy in terms of healing time. The two statistically significant findings were lower post-operative pain scores with fistulectomy and reduced post-operative bleeding with fistulotomy.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜æ˜¯ä¸€ç§å¸¸è§çš„è‚›è‚ ç–¾ç—…ã€‚ç˜˜ç®¡åˆ‡é™¤æœ¯å’Œç˜˜ç®¡åˆ‡å¼€æœ¯çš„æ‹¬çº¦è‚Œåˆ‡å‰²æŠ€æœ¯ä¸ä½åº¦æˆ–å•çº¯æ€§è‚›é—¨ç˜˜çš„æ²»æ„ˆç‡è¾ƒé«˜ï¼Œå¹¶ä¸”å¤±ç¦çš„é£é™©å¯ä»¥å¿½ç•¥ä¸è®¡ã€‚ç„¶è€Œï¼Œè¿™ä¸¤ç§æŠ€æœ¯çš„ä¼˜è¶Šæ€§ä¹‹å‰éƒ½æ²¡æœ‰å¾—åˆ°æœ€ç»ˆè¯æ˜ã€‚æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯æ¯”è¾ƒä¸¤ç§æ‰‹æœ¯æŠ€æœ¯æ²»ç–—å•çº¯æ€§è‚›ç˜˜çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ MEDLINEã€EMBASE å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†éšæœºå¯¹ç…§è¯•éªŒ (RCT) çš„æ£€ç´¢ï¼Œæ¯”è¾ƒäº†å•çº¯æ€§è‚›ç˜˜çš„ç˜˜ç®¡åˆ‡å¼€æœ¯å’Œç˜˜ç®¡åˆ‡é™¤æœ¯ã€‚ä¸»è¦ç»“æœæ˜¯æ„ˆåˆæ—¶é—´ï¼›æ¬¡è¦ç»“å±€åŒ…æ‹¬æ‰‹æœ¯æ—¶é—´ã€ä½é™¢æ—¶é—´ã€æœ¯åç–¼ç—›è¯„åˆ†ã€æœ¯åå¹¶å‘ç—‡å’Œç˜˜ç®¡å¤å‘ã€‚\n\n**ç»“æœï¼š** 13 é¡¹éšæœºå¯¹ç…§è¯•éªŒç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œæ€»å…±åŒ…æ‹¬ 685 ä¾‹ç˜˜ç®¡åˆ‡é™¤æœ¯æ‚£è€…å’Œ 688 ä¾‹ç˜˜ç®¡åˆ‡å¼€æœ¯æ‚£è€…ã€‚æ„ˆåˆæ—¶é—´ï¼ˆPâ€‰=â€‰0.15ï¼‰ã€æ‰‹æœ¯æ—¶é—´ï¼ˆPâ€‰=â€‰0.13ï¼‰ã€ä½é™¢æ—¶é—´ï¼ˆPâ€‰=â€‰0.05ï¼‰ã€ä¼¤å£æ„ŸæŸ“ï¼ˆPâ€‰=â€‰0.97ï¼‰ã€æ’æ°”æˆ–å¤§ä¾¿å¤±ç¦ï¼ˆPâ€‰=â€‰0.35å’ŒPâ€‰=â€‰0.70ï¼‰ä¹‹é—´æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚åˆ†åˆ«ï¼‰æˆ–å¤å‘ï¼ˆPâ€‰=â€‰0.19ï¼‰ã€‚ä½¿ç”¨è§†è§‰æ¨¡æ‹Ÿé‡è¡¨è¯„ä¼°ï¼Œç˜˜ç®¡åˆ‡é™¤ç»„çš„æœ¯å 24 å°æ—¶ç–¼ç—›æ˜æ˜¾è¾ƒä½ï¼ˆMD-0.49ï¼Œ95% CIï¼š-0.90ï¼Œ-0.08ï¼›Pâ€‰=â€‰0.02ï¼‰ï¼Œå¹¶ä¸”æˆ‘ä»¬å‘ç°ç˜˜ç®¡åˆ‡å¼€ç»„çš„æœ¯åå‡ºè¡€å¹¶å‘ç—‡æ˜æ˜¾è¾ƒå°‘ï¼ˆORï¼š3.81ï¼Œ95% CIï¼š1.23ï¼Œ11.80ï¼› Pâ€‰=â€‰0.02ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç³»ç»Ÿè¯„ä»·æ²¡æœ‰æ‰¾åˆ°ç¡®å‡¿çš„è¯æ®è¯æ˜ç˜˜ç®¡åˆ‡é™¤æœ¯æˆ–ç˜˜ç®¡åˆ‡å¼€æœ¯åœ¨æ„ˆåˆæ—¶é—´æ–¹é¢å…·æœ‰ä¼˜è¶Šæ€§ã€‚ä¸¤é¡¹å…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰çš„å‘ç°æ˜¯ç˜˜ç®¡åˆ‡é™¤æœ¯æœ¯åç–¼ç—›è¯„åˆ†è¾ƒä½ï¼Œä»¥åŠç˜˜ç®¡åˆ‡å¼€æœ¯å‡å°‘æœ¯åå‡ºè¡€ã€‚", "keywords_zh": "è‚›ç˜˜, ç˜˜ç®¡åˆ‡é™¤æœ¯, ç˜˜ç®¡åˆ‡å¼€æœ¯, éšæœºå¯¹ç…§è¯•éªŒ", "keywords_en": "anal fistula, fistulectomy, fistulotomy, randomized controlled trials", "link": "https://pubmed.ncbi.nlm.nih.gov/40125894/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 24 Mar 2025"}, {"id": "40024986", "title_en": "A systematic review of outcome measurement instruments used in pouch anal and vaginal fistulae: a COSMIN-based analysis", "title_zh": "å¯¹å‚¨è¢‹è‚›ç˜˜å’Œé˜´é“ç˜˜ä½¿ç”¨çš„ç»“æœæµ‹é‡ä»ªå™¨è¿›è¡Œç³»ç»Ÿè¯„ä»·ï¼šåŸºäº COSMIN çš„åˆ†æ", "authors": "Phil Tozer", "abstract_en": "**Purpose:** Pouch-related fistulae are devastating complications of ileoanal pouch surgery, which is performed to improve the quality of life (QoL) for patients who have had a proctocolectomy. Their management is limited by inconsistent evidence, including using poorly and heterogeneously defined outcomes. This study aims to identify all Outcome Measurement Instruments (OMIs) used in pouch fistula research, including Patient-Reported Outcome Measures (PROMs) and Clinician-Reported Outcome Measures (ClinROMs) and evaluate their quality using COSMIN guidelines to help select the best tool for a standardised core outcome measurement set in a future consensus study.\n\n**Methods:** A systematic review was conducted to identify all OMIs used in ileo-anal pouch fistulae studies, from MEDLINE, Embase, and the Cochrane Library. We evaluated existing OMIs based on COSMIN guidelines and used the GRADE approach to assess evidence quality. Results were synthesized narratively.\n\n**Results:** Among 91 studies, 13 OMIs were reviewed. Pouch-specific instruments performed poorly in key domains of reliability, validity, and responsiveness. Only 17.6% of studies assessed QoL using PROMs. The best-performing instruments were the SF-36 and IBDQ. The Ileoanal Pouch Syndrome Severity Score was the only pouch-specific instrument that involved patients in its development and although useful for pouch dysfunction, it lacks specific QoL assessment and was not validated in pouch-fistulae patients.\n\n**Conclusion:** Existing OMIs for pouch-related fistulae lack adequate measurement properties, with no PROMs specifically validated for QoL in this population and very few instruments involving patients in their development. There is an unmet need for a validated PROM specifically for QoL in pouch-related fistulae.", "abstract_zh": "**Purposeï¼š** å‚¨è¢‹ç›¸å…³ç˜˜ç®¡æ˜¯å›è‚ è‚›ç®¡å‚¨è¢‹æ‰‹æœ¯çš„ä¸¥é‡å¹¶å‘ç—‡ï¼Œè¯¥æ‰‹æœ¯çš„ç›®çš„æ˜¯æé«˜ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯æ‚£è€…çš„ç”Ÿæ´»è´¨é‡ (QoL)ã€‚ä»–ä»¬çš„ç®¡ç†å—åˆ°ä¸ä¸€è‡´çš„è¯æ®çš„é™åˆ¶ï¼ŒåŒ…æ‹¬ä½¿ç”¨ä¸æ˜ç¡®ä¸”å¼‚è´¨å®šä¹‰çš„ç»“æœã€‚æœ¬ç ”ç©¶æ—¨åœ¨ç¡®å®šå‚¨è¢‹ç˜˜ç ”ç©¶ä¸­ä½¿ç”¨çš„æ‰€æœ‰ç»“æœæµ‹é‡ä»ªå™¨ (OMIs)ï¼ŒåŒ…æ‹¬æ‚£è€…æŠ¥å‘Šçš„ç»“æœæµ‹é‡ (PROM) å’Œä¸´åºŠåŒ»ç”ŸæŠ¥å‘Šçš„ç»“æœæµ‹é‡ (ClinROM)ï¼Œå¹¶ä½¿ç”¨ COSMIN æŒ‡å—è¯„ä¼°å…¶è´¨é‡ï¼Œä»¥å¸®åŠ©åœ¨æœªæ¥çš„å…±è¯†ç ”ç©¶ä¸­é€‰æ‹©æ ‡å‡†åŒ–æ ¸å¿ƒç»“æœæµ‹é‡é›†çš„æœ€ä½³å·¥å…·ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ MEDLINEã€Embase å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥ç¡®å®šå›è‚ è‚›è¢‹ç˜˜ç ”ç©¶ä¸­ä½¿ç”¨çš„æ‰€æœ‰ OMIã€‚æˆ‘ä»¬æ ¹æ® COSMIN æŒ‡å—è¯„ä¼°äº†ç°æœ‰çš„ OMIï¼Œå¹¶ä½¿ç”¨ GRADE æ–¹æ³•æ¥è¯„ä¼°è¯æ®è´¨é‡ã€‚ç»“æœä»¥å™è¿°æ–¹å¼ç»¼åˆã€‚\n\n**ç»“æœï¼š** åœ¨ 91 é¡¹ç ”ç©¶ä¸­ï¼Œå®¡æŸ¥äº† 13 é¡¹ OMIã€‚é€ å£è¢‹ä¸“ç”¨ä»ªå™¨åœ¨å¯é æ€§ã€æœ‰æ•ˆæ€§å’Œå“åº”æ€§ç­‰å…³é”®é¢†åŸŸè¡¨ç°ä¸ä½³ã€‚åªæœ‰ 17.6% çš„ç ”ç©¶ä½¿ç”¨ PROM è¯„ä¼°ç”Ÿæ´»è´¨é‡ã€‚æ€§èƒ½æœ€å¥½çš„ä»ªå™¨æ˜¯ SF-36 å’Œ IBDQã€‚å›è‚ å‚¨è¢‹ç»¼åˆå¾ä¸¥é‡ç¨‹åº¦è¯„åˆ†æ˜¯å”¯ä¸€è®©æ‚£è€…å‚ä¸å…¶å‘å±•çš„å‚¨è¢‹ç‰¹å¼‚æ€§å·¥å…·ï¼Œè™½ç„¶å¯¹äºå‚¨è¢‹åŠŸèƒ½éšœç¢æœ‰ç”¨ï¼Œä½†ç¼ºä¹å…·ä½“çš„ç”Ÿæ´»è´¨é‡è¯„ä¼°ï¼Œå¹¶ä¸”æœªåœ¨å‚¨è¢‹ç˜˜æ‚£è€…ä¸­è¿›è¡ŒéªŒè¯ã€‚\n\n**ç»“è®ºï¼š** ç°æœ‰çš„ç”¨äºä¸é€ å£è¢‹ç›¸å…³çš„ç˜˜ç®¡çš„ OMI ç¼ºä¹è¶³å¤Ÿçš„æµ‹é‡ç‰¹æ€§ï¼Œæ²¡æœ‰ä¸“é—¨é’ˆå¯¹è¯¥äººç¾¤çš„ QoL è¿›è¡ŒéªŒè¯çš„ PROMï¼Œå¹¶ä¸”æ¶‰åŠæ‚£è€…å¼€å‘çš„ä»ªå™¨ä¹Ÿå¾ˆå°‘ã€‚å¯¹äºä¸“ä¸ºé€ å£è¢‹ç›¸å…³ç˜˜ç®¡çš„ç”Ÿæ´»è´¨é‡è€Œè®¾è®¡çš„ç»è¿‡éªŒè¯çš„ PROM çš„éœ€æ±‚å°šæœªå¾—åˆ°æ»¡è¶³ã€‚", "keywords_zh": "COSMINï¼Œæ‚£è€…æŠ¥å‘Šçš„ç»“æœæµ‹é‡ï¼Œå‚¨è¢‹ç˜˜ï¼Œå‚¨è¢‹è‚›ç˜˜ï¼Œå‚¨è¢‹é˜´é“ç˜˜", "keywords_en": "COSMIN, Patient reported outcome measures, Pouch Fistula, Pouch anal fistula, Pouch vaginal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/40024986/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sun, 02 Mar 2025"}, {"id": "39946821", "title_en": "A systematic review and meta-analysis of the diagnostic test accuracy of diffusion weighted imaging and apparent diffusion coefficient in differentiating active from inactive perianal fistula", "title_zh": "å¯¹å¼¥æ•£åŠ æƒæˆåƒå’Œè¡¨è§‚å¼¥æ•£ç³»æ•°åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "G S Octavius", "abstract_en": "**Introduction:** This systematic review and meta-analysis evaluated the diagnostic accuracy of MRI-based apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) for differentiating active from inactive perianal fistulas.\n\n**Methods:** The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024596604). The review included five databases (MEDLINE, Cochrane Library, PubMed, Science Direct, and Google Scholar). Meta-analyses were performed on studies reporting ADC values and other sequences using STATA software with the \"Midas\" command.\n\n**Results:** Of 21 studies included in the review, 12 were meta-analyzed, encompassing 1007 patients (77.5Â % male) with 1092 fistulas and 321 abscesses. Six studies reported ADC values for active vs. inactive fistulas, with a pooled sensitivity of 83Â % (95%CI 68-92), specificity of 75Â % (95%CI 60-85), and AUC of 0.85 (95%CI 0.81-0.87). Pooled ADC cut-offs ranged from 1.105 to 1.109Â Ã—Â 10â»Â³ mm<sup>2</sup>/s. The T2WIÂ +Â DWI sequence demonstrated the highest diagnostic accuracy, with a pooled sensitivity of 99Â % (95%CI 90-100), specificity of 97Â % (95%CI 79-100), and an AUC of 1.\n\n**Conclusion:** ADC alone is inadequate for reliably distinguishing active from inactive fistulas. T2WI combined with DWI offers superior diagnostic performance, surpassing contrast-enhanced T1WI, and is promising for non-invasive evaluation of perianal fistulas. However, several limitations, such as moderate to high risk of bias and heterogeneity, may bias this conclusion.\n\n**Implications For Practice:** T2WIÂ +Â DWI could become the standard for assessing perianal fistulas, avoiding contrast agents, and benefiting patients contraindicated for Gadolinium-based contrast media. Variability and potential bias across studies warrant further research.", "abstract_zh": "**ä»‹ç»ï¼š** è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æè¯„ä¼°äº†åŸºäº MRI çš„è¡¨è§‚æ‰©æ•£ç³»æ•° (ADC) å’Œæ‰©æ•£åŠ æƒæˆåƒ (DWI) åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥æ–¹æ¡ˆå·²åœ¨å›½é™…ç³»ç»Ÿè¯„ä»·å‰ç»æ€§ç™»è®°å†Œ (PROSPERO) ä¸­æ³¨å†Œ (CRD42024596604)ã€‚è¯¥ç»¼è¿°åŒ…æ‹¬äº”ä¸ªæ•°æ®åº“ï¼ˆMEDLINEã€Cochrane Libraryã€PubMedã€Science Direct å’Œ Google Scholarï¼‰ã€‚ä½¿ç”¨å¸¦æœ‰â€œMidasâ€å‘½ä»¤çš„ STATA è½¯ä»¶å¯¹æŠ¥å‘Š ADC å€¼å’Œå…¶ä»–åºåˆ—çš„ç ”ç©¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** åœ¨è¯¥è¯„ä»·çº³å…¥çš„ 21 é¡¹ç ”ç©¶ä¸­ï¼Œæœ‰ 12 é¡¹è¿›è¡Œäº†èŸèƒåˆ†æï¼Œæ¶‰åŠ 1007 åæ‚£è€…ï¼ˆ77.5% ç”·æ€§ï¼‰ï¼Œæœ‰ 1092 ä¸ªç˜˜ç®¡å’Œ 321 ä¸ªè„“è‚¿ã€‚å…­é¡¹ç ”ç©¶æŠ¥å‘Šäº†æ´»åŠ¨æ€§ç˜˜ç®¡ä¸éæ´»åŠ¨æ€§ç˜˜ç®¡çš„ ADC å€¼ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 83% (95%CI 68-92)ï¼Œç‰¹å¼‚æ€§ä¸º 75% (95%CI 60-85)ï¼ŒAUC ä¸º 0.85 (95%CI 0.81-0.87)ã€‚æ±‡é›†çš„ ADC æˆªæ­¢èŒƒå›´ä¸º 1.105 è‡³ 1.109Â Ã—Â 10â»3 mm<sup>2</sup>/sã€‚ T2WI + DWI åºåˆ—æ˜¾ç¤ºå‡ºæœ€é«˜çš„è¯Šæ–­å‡†ç¡®æ€§ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 99% (95%CI 90-100)ï¼Œç‰¹å¼‚æ€§ä¸º 97% (95%CI 79-100)ï¼ŒAUC ä¸º 1ã€‚\n\n**ç»“è®ºï¼š** å•ç‹¬ä½¿ç”¨ ADC ä¸è¶³ä»¥å¯é åœ°åŒºåˆ†æ´»åŠ¨æ€§ç˜˜ç®¡å’Œéæ´»åŠ¨æ€§ç˜˜ç®¡ã€‚ T2WI ä¸ DWI ç›¸ç»“åˆæä¾›äº†ä¼˜äºå¯¹æ¯”å¢å¼º T1WI çš„è¯Šæ–­æ€§èƒ½ï¼Œå¹¶ä¸”æœ‰æœ›ç”¨äºè‚›å‘¨ç˜˜çš„æ— åˆ›è¯„ä¼°ã€‚ç„¶è€Œï¼Œä¸€äº›é™åˆ¶ï¼Œä¾‹å¦‚ä¸­åº¦è‡³é«˜é£é™©çš„åå€šå’Œå¼‚è´¨æ€§ï¼Œå¯èƒ½ä¼šå¯¼è‡´è¿™ä¸€ç»“è®ºäº§ç”Ÿåå·®ã€‚\n\n**Implications for practiceï¼š** T2WI + DWI å¯ä»¥æˆä¸ºè¯„ä¼°è‚›å‘¨ç˜˜ç®¡ã€é¿å…ä½¿ç”¨é€ å½±å‰‚ä»¥åŠä½¿é’†é€ å½±å‰‚ç¦å¿Œæ‚£è€…å—ç›Šçš„æ ‡å‡†ã€‚ç ”ç©¶ä¹‹é—´çš„å˜å¼‚æ€§å’Œæ½œåœ¨åå·®å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "è¡¨è§‚æ‰©æ•£ç³»æ•°ã€è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§ã€æ‰©æ•£åŠ æƒæˆåƒã€ç£å…±æŒ¯æˆåƒã€è‚›å‘¨ç˜˜", "keywords_en": "Apparent diffusion coefficient, Diagnostic test accuracy, Diffusion weighted imaging, Magnetic resonance imaging, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/39946821/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 13 Feb 2025"}, {"id": "39876853", "title_en": "Rectovaginal Fistula Repair Following Vaginoplasty in Transgender Females: A Systematic Review of Surgical Techniques", "title_zh": "å˜æ€§å¥³æ€§é˜´é“æˆå½¢æœ¯åç›´è‚ é˜´é“ç˜˜ä¿®å¤ï¼šæ‰‹æœ¯æŠ€æœ¯çš„ç³»ç»Ÿå›é¡¾", "authors": "Gabriel A Del Corral", "abstract_en": "<b>Background:</b> Rectovaginal fistula (RVF) remains a complex complication following gender-affirming vaginoplasty. This review aims to evaluate RVF repair techniques and outcomes following vaginoplasty. <b>Methods:</b> A systematic review was performed per PRISMA guidelines. Ovid MEDLINE, Ovid EMBASE, Cochrane, and Web of Science were queried for records pertaining to RVF repair following vaginoplasty. Study characteristics, operative details, and demographics were collected. Outcomes included RVF repair method, recurrence rate, and complications. <b>Results:</b> Among 282 screened citations, 17 articles representing 41 patients were included. Rectovaginal fistula repair methods identified included 4 conservative management approaches (nâ€‰=â€‰12 patients), primary closure with or without fistulectomy and ostomy (nâ€‰=â€‰22), 10 reconstructive surgical techniques (nâ€‰=â€‰18). The most common reconstructive techniques were V-Y full-thickness advancement with rectal flap (nâ€‰=â€‰5) and infragluteal fasciocutaneous flap (nâ€‰=â€‰4). Median time to recurrence was 6 months (interquartile range 7.5). Reported RVF repair complications included RVF recurrence (nâ€‰=â€‰5, 14.7%) and wound complication or dehiscence (nâ€‰=â€‰2, 5.88%). Three cases of RVF recurred after primary closure with or without fistulectomy and ostomy, while 2 cases of recurrence followed reconstruction. <b>Conclusion:</b> There remains a high level of variability in the approach to RVF repair following vaginoplasty. Reconstructive surgical techniques may be a more optimal solution without necessitating ostomies, but this decision must be considered in the context of RVF location, individual patient expectations, and clinical presentation.", "abstract_zh": "<b>èƒŒæ™¯ï¼š</b>ç›´è‚ é˜´é“ç˜˜ï¼ˆRVFï¼‰ä»ç„¶æ˜¯æ€§åˆ«è‚¯å®šé˜´é“æˆå½¢æœ¯åçš„å¤æ‚å¹¶å‘ç—‡ã€‚æœ¬ç»¼è¿°æ—¨åœ¨è¯„ä¼°é˜´é“æˆå½¢æœ¯åçš„ RVF ä¿®å¤æŠ€æœ¯å’Œç»“æœã€‚ <b>æ–¹æ³•ï¼š</b>æ ¹æ® PRISMA æŒ‡å—è¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚å‘ Ovid MEDLINEã€Ovid EMBASEã€Cochrane å’Œ Web of Science æŸ¥è¯¢äº†æœ‰å…³é˜´é“æˆå½¢æœ¯å RVF ä¿®å¤çš„è®°å½•ã€‚æ”¶é›†ç ”ç©¶ç‰¹å¾ã€æ‰‹æœ¯ç»†èŠ‚å’Œäººå£ç»Ÿè®¡æ•°æ®ã€‚ç»“æœåŒ…æ‹¬ RVF ä¿®å¤æ–¹æ³•ã€å¤å‘ç‡å’Œå¹¶å‘ç—‡ã€‚ <b>ç»“æœï¼š</b> åœ¨ 282 ç¯‡ç­›é€‰çš„å¼•æ–‡ä¸­ï¼Œçº³å…¥äº†ä»£è¡¨ 41 åæ‚£è€…çš„ 17 ç¯‡æ–‡ç« ã€‚ç¡®å®šçš„ç›´è‚ é˜´é“ç˜˜ä¿®å¤æ–¹æ³•åŒ…æ‹¬ 4 ç§ä¿å®ˆæ²»ç–—æ–¹æ³•ï¼ˆnâ€‰=â€‰12 åæ‚£è€…ï¼‰ã€ä¸€æœŸé—­åˆï¼ˆå¸¦æˆ–ä¸å¸¦ç˜˜ç®¡åˆ‡é™¤æœ¯å’Œé€ å£æœ¯ï¼‰ï¼ˆnâ€‰=â€‰22ï¼‰ã€10 ç§é‡å»ºæ‰‹æœ¯æŠ€æœ¯ï¼ˆnâ€‰=â€‰18ï¼‰ã€‚æœ€å¸¸è§çš„é‡å»ºæŠ€æœ¯æ˜¯ç›´è‚ çš®ç“£ V-Y å…¨å±‚æ¨è¿› (nâ€‰=â€‰5) å’Œè‡€ä¸‹ç­‹è†œçš®ç“£ (nâ€‰=â€‰4)ã€‚å¤å‘çš„ä¸­ä½æ—¶é—´ä¸º 6 ä¸ªæœˆï¼ˆå››åˆ†ä½æ•°é—´è· 7.5ï¼‰ã€‚æŠ¥å‘Šçš„ RVF ä¿®å¤å¹¶å‘ç—‡åŒ…æ‹¬ RVF å¤å‘ï¼ˆnâ€‰=â€‰5ï¼Œ14.7%ï¼‰å’Œä¼¤å£å¹¶å‘ç—‡æˆ–è£‚å¼€ï¼ˆnâ€‰=â€‰2ï¼Œ5.88%ï¼‰ã€‚ 3 ä¾‹ RVF åœ¨åˆæ¬¡é—­åˆï¼ˆæ— è®ºæ˜¯å¦è¡Œç˜˜ç®¡åˆ‡é™¤å’Œé€ å£ï¼‰åå¤å‘ï¼Œ2 ä¾‹åœ¨é‡å»ºåå¤å‘ã€‚ <b>ç»“è®ºï¼š</b>é˜´é“æˆå½¢æœ¯å RVF ä¿®å¤æ–¹æ³•ä»ç„¶å­˜åœ¨å¾ˆå¤§å·®å¼‚ã€‚é‡å»ºæ‰‹æœ¯æŠ€æœ¯å¯èƒ½æ˜¯ä¸€ç§æ›´ä¼˜åŒ–çš„è§£å†³æ–¹æ¡ˆï¼Œæ— éœ€é€ å£ï¼Œä½†å¿…é¡»æ ¹æ® RVF ä½ç½®ã€æ‚£è€…ä¸ªä½“æœŸæœ›å’Œä¸´åºŠè¡¨ç°æ¥è€ƒè™‘è¿™ä¸€å†³å®šã€‚", "keywords_zh": "æ–°é˜´é“, ç›´è‚ é˜´é“ç˜˜, æ‰‹æœ¯æŠ€æœ¯, å˜æ€§äºº, é˜´é“æˆå½¢æœ¯", "keywords_en": "neovagina, rectovaginal fistula, surgical technique, transgender, vaginoplasty", "link": "https://pubmed.ncbi.nlm.nih.gov/39876853/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 29 Jan 2025"}, {"id": "39833536", "title_en": "Fistulae Secondary to Vaginal Pessary Use for Pelvic Organ Prolapse: A Systematic Review", "title_zh": "ä½¿ç”¨é˜´é“å­å®«æ‰˜æ²»ç–—ç›†è…”å™¨å®˜è„±å‚ç»§å‘ç˜˜ç®¡ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Thomas Giles Gray", "abstract_en": "**Introduction And Hypothesis:** Urogenital and rectovaginal fistulae are rare complications of pessary use for pelvic organ prolapse (POP). This systematic review investigates the prevalence of these complications in patients using pessary for POP, potential risk factors and approaches to their investigation and management.\n\n**Methods:** All studies in English reporting urogenital or rectovaginal fistulae secondary to pessaries for POP were eligible for inclusion. AMED, CINAHL, MedLine, Scopus and Web of Science databases were searched from inception to March 2024. Risk of bias was assessed using validated tools: Murad et al.'s tool for case series/reports and ROBINS-I for non-randomised studies. Quantitative synthesis of descriptive statistics and narrative summary were performed.\n\n**Results:** Two retrospective studies and 60 case series/reports were included, describing 76 fistulae (34 urogenital, 42 rectovaginal). The retrospective studies estimated the prevalence of fistulae to be 3%. Of reported fistulae, 45% occurred with Gellhorn, 16% with ring, 11% with shelf and 9% with cube pessaries. Fifty percent were associated with neglected pessary care. Conservative management resulted in size reduction or resolution in 69% of fistulae: this approach should be considered. Vaginal (88%) and abdominal (100%) vesicovaginal fistula repairs were successful. Diverting ostomies were popular for rectovaginal fistulae but often resulted in permanent stoma without reducing mortality, recurrence or repair failure. Colpocleisis represents an effective procedure for managing co-existing POP.\n\n**Conclusions:** The prevalence of fistulae from pessary use is likelyâ€‰<â€‰1% but may rise to 3% with risk factors present, including Gellhorn pessaries and neglected care. Both conservative and surgical management are viable treatment options.", "abstract_zh": "**Introduction and hypothesisï¼š** æ³Œå°¿ç”Ÿæ®–é“å’Œç›´è‚ é˜´é“ç˜˜æ˜¯ä½¿ç”¨å­å®«æ‰˜æ²»ç–—ç›†è…”å™¨å®˜è„±å‚ (POP) çš„ç½•è§å¹¶å‘ç—‡ã€‚æœ¬ç³»ç»Ÿç»¼è¿°è°ƒæŸ¥äº†ä½¿ç”¨å­å®«æ‰˜æ²»ç–— POP çš„æ‚£è€…ä¸­è¿™äº›å¹¶å‘ç—‡çš„å‘ç”Ÿç‡ã€æ½œåœ¨å±é™©å› ç´ åŠå…¶è°ƒæŸ¥å’Œç®¡ç†æ–¹æ³•ã€‚\n\n**æ–¹æ³•ï¼š** æ‰€æœ‰æŠ¥å‘Šç»§å‘äº POP å­å®«æ‰˜çš„æ³Œå°¿ç”Ÿæ®–é“æˆ–ç›´è‚ é˜´é“ç˜˜çš„è‹±æ–‡ç ”ç©¶å‡ç¬¦åˆçº³å…¥æ¡ä»¶ã€‚ AMEDã€CINAHLã€MedLineã€Scopus å’Œ Web of Science æ•°æ®åº“çš„æ£€ç´¢æ—¶é—´ä»å¼€å§‹åˆ° 2024 å¹´ 3 æœˆã€‚ä½¿ç”¨ç»è¿‡éªŒè¯çš„å·¥å…·è¯„ä¼°åå€šé£é™©ï¼šMurad ç­‰äººç”¨äºç—…ä¾‹ç³»åˆ—/æŠ¥å‘Šçš„å·¥å…·å’Œç”¨äºééšæœºç ”ç©¶çš„ ROBINS-I å·¥å…·ã€‚è¿›è¡Œäº†æè¿°æ€§ç»Ÿè®¡å’Œå™è¿°æ€§æ€»ç»“çš„å®šé‡ç»¼åˆã€‚\n\n**ç»“æœï¼š** çº³å…¥ä¸¤é¡¹å›é¡¾æ€§ç ”ç©¶å’Œ 60 ä¸ªç—…ä¾‹ç³»åˆ—/æŠ¥å‘Šï¼Œæè¿° 76 ä¸ªç˜˜ç®¡ï¼ˆ34 ä¸ªæ³Œå°¿ç”Ÿæ®–ç˜˜ç®¡ï¼Œ42 ä¸ªç›´è‚ é˜´é“ç˜˜ï¼‰ã€‚å›é¡¾æ€§ç ”ç©¶ä¼°è®¡ç˜˜ç®¡çš„æ‚£ç—…ç‡ä¸º 3%ã€‚åœ¨æŠ¥å‘Šçš„ç˜˜ç®¡ä¸­ï¼Œ45% å‘ç”Ÿåœ¨ Gellhorn ä¸Šï¼Œ16% å‘ç”Ÿåœ¨ç¯ä¸Šï¼Œ11% å‘ç”Ÿåœ¨æ¶å­ä¸Šï¼Œ9% å‘ç”Ÿåœ¨ç«‹æ–¹ä½“å­å®«æ‰˜ä¸Šã€‚ç™¾åˆ†ä¹‹äº”åä¸å¿½è§†å­å®«æ‰˜æŠ¤ç†æœ‰å…³ã€‚ä¿å®ˆæ²»ç–—ä½¿ 69% çš„ç˜˜ç®¡å°ºå¯¸å‡å°æˆ–æ¶ˆé€€ï¼šåº”è€ƒè™‘è¿™ç§æ–¹æ³•ã€‚é˜´é“ï¼ˆ88%ï¼‰å’Œè…¹éƒ¨ï¼ˆ100%ï¼‰è†€èƒ±é˜´é“ç˜˜ä¿®å¤æˆåŠŸã€‚æ”¹é“é€ å£æœ¯åœ¨ç›´è‚ é˜´é“ç˜˜æ²»ç–—ä¸­å¾ˆæµè¡Œï¼Œä½†é€šå¸¸ä¼šå¯¼è‡´æ°¸ä¹…æ€§é€ å£ï¼Œè€Œä¸ä¼šé™ä½æ­»äº¡ç‡ã€å¤å‘æˆ–ä¿®å¤å¤±è´¥ã€‚é˜´é“å°é—­æœ¯æ˜¯æ²»ç–—å…±å­˜ POP çš„æœ‰æ•ˆæ–¹æ³•ã€‚\n\n**ç»“è®ºï¼š** ä½¿ç”¨å­å®«æ‰˜å¼•èµ·çš„ç˜˜ç®¡æ‚£ç—…ç‡å¯èƒ½<<1%ï¼Œä½†å¦‚æœå­˜åœ¨å±é™©å› ç´ ï¼ŒåŒ…æ‹¬ç›–å°”éœæ©å­å®«æ‰˜å’Œå¿½è§†æŠ¤ç†ï¼Œåˆ™å¯èƒ½ä¸Šå‡è‡³ 3%ã€‚ä¿å®ˆæ²»ç–—å’Œæ‰‹æœ¯æ²»ç–—éƒ½æ˜¯å¯è¡Œçš„æ²»ç–—é€‰æ‹©ã€‚", "keywords_zh": "ç›†è…”å™¨å®˜è„±å‚ã€å­å®«æ‰˜ã€ç›´è‚ é˜´é“ç˜˜ã€ç³»ç»Ÿå›é¡¾ã€è†€èƒ±é˜´é“ç˜˜", "keywords_en": "Pelvic organ prolapse, Pessaries, Rectovaginal fistula, Systematic review, Vesicovaginal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/39833536/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 20 Jan 2025"}, {"id": "39623055", "title_en": "Salvage irreversible electroporation for locally recurrent prostate cancer after definitive radiotherapy: a systematic review", "title_zh": "æ ¹æ²»æ€§æ”¾å°„æ²»ç–—åå±€éƒ¨å¤å‘æ€§å‰åˆ—è…ºç™Œçš„æŒ½æ•‘æ€§ä¸å¯é€†ç”µç©¿å­”ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Gencay Hatiboglu", "abstract_en": "**Background:** To systematically evaluate the available evidence regarding the effect of salvage irreversible electroporation (IRE) in patients with local recurrent prostate cancer (PCa) after definitive radiotherapy (RT).\n\n**Methods:** A systematic search was conducted in the electronic databases PubMed-MEDLINE and the Web of Science. The following search terms were used: \"irreversible electroporation AND recurrent prostate cancer\", ''salvage irreversible electroporation AND prostate cancer AND radiation\", \"nanoknife AND recurrent prostate cancer\", and ''salvage irreversible electroporation AND prostate cancer\" by combining PICO (population, intervention, comparison, and outcome) terms.\n\n**Results:** We identified 5 eligible studies. Following IRE, local oncological control was ranging from 67 to 78%. In-field and out-field lesion recurrences after IRE were ranging from 3 to 10% and from 8 to 14%, respectively. Only one study reported an overall metastasis-free survival rate of 91% and a 5-year progression-free survival rate of 60%. The post-IRE continence status ranged 73-100%. Two studies reported a decline in the proportion of patients maintaining erections sufficient for sexual intercourse and two studies reported 50% preservation of erection. The majority of complications were of a low-to-mild nature, classified as Clavien-Dindo grade I-II, with the exception of the development of a rectal fistula in a single case.\n\n**Conclusions:** IRE represents an alternative salvage treatment option for patients with localised recurrent PCa following RT. The procedure offers a favourable safety profile and effective preservation of urinary function. The oncological results are promising, but further investigation is required.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç³»ç»Ÿè¯„ä¼°å…³äºæŒ½æ•‘æ€§ä¸å¯é€†ç”µç©¿å­” (IRE) å¯¹æ ¹æ²»æ€§æ”¾å°„æ²»ç–— (RT) åå±€éƒ¨å¤å‘æ€§å‰åˆ—è…ºç™Œ (PCa) æ‚£è€…æ•ˆæœçš„ç°æœ‰è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ç”µå­æ•°æ®åº“ PubMed-MEDLINE å’Œ Web of Science ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚ä½¿ç”¨ä»¥ä¸‹æœç´¢æœ¯è¯­ï¼šâ€œä¸å¯é€†ç”µç©¿å­”å’Œå¤å‘æ€§å‰åˆ—è…ºç™Œâ€ã€â€œæŒ½æ•‘ä¸å¯é€†ç”µç©¿å­”å’Œå‰åˆ—è…ºç™Œå’Œè¾å°„â€ã€â€œçº³ç±³åˆ€å’Œå¤å‘æ€§å‰åˆ—è…ºç™Œâ€å’Œâ€œæŒ½æ•‘ä¸å¯é€†ç”µç©¿å­”å’Œå‰åˆ—è…ºç™Œâ€ï¼Œé€šè¿‡ç»„åˆ PICOï¼ˆç¾¤ä½“ã€å¹²é¢„ã€æ¯”è¾ƒå’Œç»“æœï¼‰æœ¯è¯­ã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬ç¡®å®šäº† 5 é¡¹ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶ã€‚ IRE åï¼Œå±€éƒ¨è‚¿ç˜¤æ§åˆ¶èŒƒå›´ä¸º 67% è‡³ 78%ã€‚ IRE åè§†é‡å†…å’Œè§†é‡å¤–ç—…å˜å¤å‘ç‡åˆ†åˆ«ä¸º 3% è‡³ 10% å’Œ 8% è‡³ 14%ã€‚åªæœ‰ä¸€é¡¹ç ”ç©¶æŠ¥å‘Šæ€»ä½“æ— è½¬ç§»ç”Ÿå­˜ç‡ä¸º 91%ï¼Œ5 å¹´æ— è¿›å±•ç”Ÿå­˜ç‡ä¸º 60%ã€‚ IRE åçš„å¤±ç¦çŠ¶æ€èŒƒå›´ä¸º 73-100%ã€‚ä¸¤é¡¹ç ”ç©¶æŠ¥å‘Šç§°ï¼Œç»´æŒè¶³ä»¥è¿›è¡Œæ€§äº¤çš„å‹ƒèµ·çš„æ‚£è€…æ¯”ä¾‹æœ‰æ‰€ä¸‹é™ï¼Œå¦å¤–ä¸¤é¡¹ç ”ç©¶æŠ¥å‘Šç§°ï¼Œ50% çš„æ‚£è€…ä¿ç•™äº†å‹ƒèµ·ã€‚å¤§å¤šæ•°å¹¶å‘ç—‡çš„æ€§è´¨ä¸ºä½è‡³è½»åº¦ï¼Œåˆ†ç±»ä¸º Clavien-Dindo I-II çº§ï¼Œä½†å•ä¸ªç—…ä¾‹å‡ºç°ç›´è‚ ç˜˜é™¤å¤–ã€‚\n\n**ç»“è®ºï¼š** IRE ä»£è¡¨äº†æ”¾ç–—åå±€éƒ¨å¤å‘ PCa æ‚£è€…çš„å¦ä¸€ç§æŒ½æ•‘æ²»ç–—é€‰æ‹©ã€‚è¯¥æ‰‹æœ¯å…·æœ‰è‰¯å¥½çš„å®‰å…¨æ€§å¹¶èƒ½æœ‰æ•ˆä¿ç•™æ³Œå°¿åŠŸèƒ½ã€‚è‚¿ç˜¤å­¦ç»“æœä»¤äººé¼“èˆï¼Œä½†è¿˜éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39623055/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 02 Dec 2024"}, {"id": "39422801", "title_en": "Perianal Mucinous Adenocarcinoma: A Case Report and a Systematic Review of the Literature", "title_zh": "è‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œï¼šä¸€ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Apostolos P Stamatiadis", "abstract_en": "**Background:** Mucinous adenocarcinoma of anus is an uncommon neoplasm of the gastrointestinal tract. In most of the cases, early diagnosis of this disease is difficult since its symptoms frequently mimic benign inflammatory conditions.\n\n**Methods:** A systematic PubMed and Scopus search was conducted, a propos of a case report.\n\n**Results:** One hundred fifty patients from 93 case reports were included. The mean age of the patients was 60.5Â years (range: 18-81). The majority of them were males (124 out of 150, 82.7%), while the main known risk factor was the history of chronic fistula (109 out of 150, 72.7%). Recurrent perianal sepsis and perianal pain were the principal symptoms at the time of presentation. No symptoms have been reported only in three patients (3 out of 150, 2%). Regarding the prior surgical history of the patients, multiple abscess drainage and perianal fistula's related interventions were present in 62 (41.3%) and 19 (12.7%) patients, respectively. Neoadjuvant chemoradiotherapy was administered in 53 out of 150 patients (35.3%), while the majority of them have been treated with combined treatment of chemotherapy and radiotherapy. APR and its variations were the most applied surgical treatment (68%). Adjuvant chemoradiotherapy was administered almost up to one-third of the included patients (34%). Recurrence of the disease was reported in 41 out of 150 patients (27.3%). Death was reported in 44 out of 150 patients (29.3%).\n\n**Conclusion:** Review of the available published literature suggests that perianal mucinous adenocarcinoma is an extremely rare neoplasia. Î¤here is no consensus as far as the diagnosis and the treatment strategies, due to the rarity of this neoplasm. High degree of clinical suspicion as well as histopathological confirmation is the principal requisites for the diagnosis of mucinous adenocarcinoma, especially in the ground of chronic ulcero-proliferative perianal lesions.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›é—¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§ç½•è§çš„èƒƒè‚ é“è‚¿ç˜¤ã€‚åœ¨å¤§å¤šæ•°æƒ…å†µä¸‹ï¼Œè¿™ç§ç–¾ç—…çš„æ—©æœŸè¯Šæ–­å¾ˆå›°éš¾ï¼Œå› ä¸ºå®ƒçš„ç—‡çŠ¶ç»å¸¸æ¨¡ä»¿è‰¯æ€§ç‚ç—‡ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç—…ä¾‹æŠ¥å‘Šçš„å»ºè®®ï¼Œè¿›è¡Œäº†ç³»ç»Ÿçš„ PubMed å’Œ Scopus æ£€ç´¢ã€‚\n\n**ç»“æœï¼š** çº³å…¥ 93 ä»½ç—…ä¾‹æŠ¥å‘Šä¸­çš„ 150 åæ‚£è€…ã€‚æ‚£è€…çš„å¹³å‡å¹´é¾„ä¸º 60.5 å²ï¼ˆèŒƒå›´ï¼š18-81 å²ï¼‰ã€‚å…¶ä¸­å¤§å¤šæ•°ä¸ºç”·æ€§ï¼ˆ150 äººä¸­çš„ 124 äººï¼Œ82.7%ï¼‰ï¼Œè€Œå·²çŸ¥çš„ä¸»è¦å±é™©å› ç´ æ˜¯æ…¢æ€§ç˜˜ç®¡ç—…å²ï¼ˆ150 äººä¸­çš„ 109 äººï¼Œ72.7%ï¼‰ã€‚å¤å‘æ€§è‚›å‘¨è´¥è¡€ç—‡å’Œè‚›å‘¨ç–¼ç—›æ˜¯å°±è¯Šæ—¶çš„ä¸»è¦ç—‡çŠ¶ã€‚ä»… 3 åæ‚£è€…æ²¡æœ‰æŠ¥å‘Šä»»ä½•ç—‡çŠ¶ï¼ˆ150 åæ‚£è€…ä¸­æœ‰ 3 åï¼Œ2%ï¼‰ã€‚å…³äºæ‚£è€…æ—¢å¾€æ‰‹æœ¯å²ï¼Œåˆ†åˆ«æœ‰62ä¾‹ï¼ˆ41.3%ï¼‰å’Œ19ä¾‹ï¼ˆ12.7%ï¼‰æ‚£è€…æ¥å—è¿‡å¤šå¤„è„“è‚¿å¼•æµå’Œè‚›å‘¨ç˜˜ç›¸å…³å¹²é¢„ã€‚ 150ä¾‹æ‚£è€…ä¸­ï¼Œæœ‰53ä¾‹ï¼ˆ35.3%ï¼‰æ¥å—äº†æ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼Œå…¶ä¸­å¤§å¤šæ•°æ‚£è€…æ¥å—äº†åŒ–ç–—å’Œæ”¾ç–—çš„è”åˆæ²»ç–—ã€‚ APR åŠå…¶å˜ä½“æ˜¯æœ€å¸¸ç”¨çš„æ‰‹æœ¯æ²»ç–—æ–¹æ³• (68%)ã€‚å‡ ä¹ä¸‰åˆ†ä¹‹ä¸€çš„çº³å…¥æ‚£è€…ï¼ˆ34%ï¼‰æ¥å—äº†è¾…åŠ©æ”¾åŒ–ç–—ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 41 åï¼ˆ27.3%ï¼‰æŠ¥å‘Šç–¾ç—…å¤å‘ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 44 åæ­»äº¡ï¼ˆ29.3%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** å¯¹ç°æœ‰å·²å‘è¡¨æ–‡çŒ®çš„å›é¡¾è¡¨æ˜ï¼Œè‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§æå…¶ç½•è§çš„è‚¿ç˜¤ã€‚ç”±äºè¿™ç§è‚¿ç˜¤çš„ç½•è§æ€§ï¼Œåœ¨è¯Šæ–­å’Œæ²»ç–—ç­–ç•¥æ–¹é¢å°šæœªè¾¾æˆå…±è¯†ã€‚é«˜åº¦çš„ä¸´åºŠæ€€ç–‘å’Œç»„ç»‡ç—…ç†å­¦è¯å®æ˜¯è¯Šæ–­ç²˜æ¶²è…ºç™Œçš„ä¸»è¦å¿…è¦æ¡ä»¶ï¼Œç‰¹åˆ«æ˜¯åœ¨æ…¢æ€§æºƒç–¡å¢æ®–æ€§è‚›å‘¨ç—…å˜çš„æƒ…å†µä¸‹ã€‚", "keywords_zh": "è‚›é—¨ã€è‚›é—¨ã€è‚›é—¨å†…è¶…å£°æ£€æŸ¥ã€ç²˜æ¶²æ€§è…ºç™Œã€è‚›å‘¨", "keywords_en": "Anal, Anus, Endoanal ultrasonography, Mucinous adenocarcinoma, Perianal", "link": "https://pubmed.ncbi.nlm.nih.gov/39422801/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 18 Oct 2024"}, {"id": "39360706", "title_en": "Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis", "title_zh": "Darvadstrocel æ²»ç–—å…‹ç½—æ©ç—…å¤æ‚è‚›å‘¨ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Cristina Alba", "abstract_en": "**Background:** Local injection of darvadstrocel, a suspension of expanded adipose-derived allogenic mesenchymal stem cells, has been used for treatment-refractory perianal fistulas in Crohn's disease (CD).\n\n**Objective:** This study aimed to investigate efficacy and safety of darvadstrocel for complex perianal fistulas in CD.\n\n**Methods:** A systematic search was conducted through April 2024 in relevant databases for observational studies evaluating darvadstrocel. A random-effects meta-analysis model was used to calculate the pooled effect sizes (proportions or incidence rates [IRs]) with 95% confidence intervals (CIs) of effectiveness and safety outcomes. The risk of bias was evaluated using the Joanna Briggs Institute Critical Appraisal Tool. The I<sup>2</sup> value assessed heterogeneity. Sensitivity and subgroup analyses were also conducted.\n\n**Results:** Twelve studies were included with 595 patients. The pooled rate of patients achieving clinical remission, defined as fistula healing, was 68.1% at month 6 (95% CI 63.4-72.7) and 77.2% (95% CI 70.1-83.8) at month 12. Combined remission, defined as clinical remission and absence of collections >2Â cm confirmed by magnetic resonance imaging, was reported in 60.6% and in 69.7% of patients at months 6 and 12, respectively. The rate of patients with treatment failure, defined as no clinical remission at the last follow-up (mean 18.7Â months; SD 9.9), was 34.5%. Failure rate was independent of follow-up time (pÂ =Â 0.85). For effectiveness outcomes, between-study heterogeneity was negligible. Subgroup analysis indicated that none of the covariates modified the treatment effect. Pooled IRs per 100 patient-years of adverse events (AE), serious AEs, perianal abscesses, and reoperations were 19.6, 3.2, 16.9 and 7.1, respectively.\n\n**Conclusion:** Evidence from observational studies supports the efficacy and safety of darvadstrocel for complex perianal fistulas in CD. Studies have reported high fistula healing rates that can be sustained long-term in most patients, with negligible between-study heterogeneity, as well as a favorable safety profile.", "abstract_zh": "**èƒŒæ™¯ï¼š** å±€éƒ¨æ³¨å°„darvadstrocelï¼ˆä¸€ç§æ‰©å¢çš„è„‚è‚ªæ¥æºåŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒæ‚¬æµ®æ¶²ï¼‰å·²ç”¨äºæ²»ç–—å…‹ç½—æ©ç—…ï¼ˆCDï¼‰éš¾æ²»æ€§è‚›å‘¨ç˜˜ã€‚\n\n**ç›®çš„ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨æ¢è®¨ darvadstrocel æ²»ç–— CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2024 å¹´ 4 æœˆï¼Œæˆ‘ä»¬åœ¨ç›¸å…³æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ€§æ£€ç´¢ï¼Œä»¥è¯„ä¼° darvadstrocel çš„è§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†ææ¨¡å‹æ¥è®¡ç®—æ±‡æ€»æ•ˆåº”å¤§å°ï¼ˆæ¯”ä¾‹æˆ–å‘ç”Ÿç‡ [IR]ï¼‰ï¼Œæœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ç»“æœçš„ç½®ä¿¡åŒºé—´ (CI) ä¸º 95%ã€‚ä½¿ç”¨ä¹”å®‰å¨œÂ·å¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€æ‰¹åˆ¤æ€§è¯„ä¼°å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚ I<sup>2</sup> å€¼è¯„ä¼°å¼‚è´¨æ€§ã€‚è¿˜è¿›è¡Œäº†æ•æ„Ÿæ€§å’Œäºšç»„åˆ†æã€‚\n\n**ç»“æœï¼š** 12 é¡¹ç ”ç©¶çº³å…¥äº† 595 åæ‚£è€…ã€‚ç¬¬ 6 ä¸ªæœˆæ—¶è¾¾åˆ°ä¸´åºŠç¼“è§£ï¼ˆå®šä¹‰ä¸ºç˜˜ç®¡æ„ˆåˆï¼‰çš„æ‚£è€…çš„æ±‡æ€»ç‡ä¸º 68.1%ï¼ˆ95% CI 63.4-72.7ï¼‰ï¼Œç¬¬ 12 ä¸ªæœˆæ—¶ä¸º 77.2%ï¼ˆ95% CI 70.1-83.8ï¼‰ã€‚ç»¼åˆç¼“è§£ï¼ˆå®šä¹‰ä¸ºä¸´åºŠç¼“è§£ä¸”ç»ç£å…±æŒ¯æˆåƒè¯å®æ²¡æœ‰ >2 cm çš„ç§¯æ¶²ï¼‰çš„æ‚£è€…æ¯”ä¾‹ä¸º 60.6% å’Œ 69.7%åˆ†åˆ«åœ¨ç¬¬ 6 ä¸ªæœˆå’Œç¬¬ 12 ä¸ªæœˆã€‚æ²»ç–—å¤±è´¥ï¼ˆå®šä¹‰ä¸ºæœ€åä¸€æ¬¡éšè®¿æ—¶æ— ä¸´åºŠç¼“è§£ï¼‰çš„æ‚£è€…æ¯”ä¾‹ï¼ˆå¹³å‡ 18.7 ä¸ªæœˆï¼›SD 9.9ï¼‰ä¸º 34.5%ã€‚å¤±è´¥ç‡ä¸éšè®¿æ—¶é—´æ— å…³ (p = 0.85)ã€‚å¯¹äºæœ‰æ•ˆæ€§ç»“æœï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ã€‚äºšç»„åˆ†æè¡¨æ˜æ²¡æœ‰ä»»ä½•åå˜é‡æ”¹å˜æ²»ç–—æ•ˆæœã€‚æ¯ 100 æ‚£è€…å¹´ä¸è‰¯äº‹ä»¶ (AE)ã€ä¸¥é‡ AEã€è‚›å‘¨è„“è‚¿å’Œå†æ¬¡æ‰‹æœ¯çš„æ±‡æ€» IR åˆ†åˆ«ä¸º 19.6ã€3.2ã€16.9 å’Œ 7.1ã€‚\n\n**ç»“è®ºï¼š** è§‚å¯Ÿæ€§ç ”ç©¶çš„è¯æ®æ”¯æŒ darvadstrocel å¯¹äº CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚ç ”ç©¶è¡¨æ˜ï¼Œå¤§å¤šæ•°æ‚£è€…çš„ç˜˜ç®¡æ„ˆåˆç‡è¾ƒé«˜ï¼Œå¯ä»¥é•¿æœŸç»´æŒï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ï¼Œå¹¶ä¸”å®‰å…¨æ€§è‰¯å¥½ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è„‚è‚ªæ¥æºçš„åŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒã€alofiselã€darvadstrocelã€ç‚ç—‡æ€§è‚ ç—…ã€èŸèƒåˆ†æã€è‚›å‘¨ç˜˜", "keywords_en": "Crohn's disease, adiposeâ€derived allogenic mesenchymal stem cells, alofisel, darvadstrocel, inflammatory bowel disease, metaâ€analysis, perianal fistulas", "link": "https://pubmed.ncbi.nlm.nih.gov/39360706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 03 Oct 2024"}, {"id": "39332832", "title_en": "Role of prolonged packing in postoperative anorectal abscess management: a systematic review and meta-analysis", "title_zh": "é•¿æ—¶é—´å¡«å¡åœ¨æœ¯åè‚›é—¨ç›´è‚ è„“è‚¿å¤„ç†ä¸­çš„ä½œç”¨ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Valentin Mocanu", "abstract_en": "**Background:** Prolonged packing of anorectal abscess cavities with internal dressings after incision and drainage is frequently used, but the efficacy of this practice remains controversial. Some studies highlight its use in hemostasis and preventing fistula and abscess recurrence, whereas others describe its economic burden and increase in pain. In this systematic review, we examine current evidence on the impact of packing after incision and drainage for anorectal abscesses.\n\n**Methods:** The medical librarian conducted a comprehensive literature search on January 5, 2023. We conducted the meta-analysis using RevMan 5.4.1 software with a Mantel-Haenszel random-effects model.\n\n**Results:** We identified 3 randomized controlled trials, comprising 490 patients. Of those, 241 patients (49%) received postoperative packing; most patients were male (<i>n</i> = 158, 65.6%), with a median age of 40.5 years and a follow-up of 6 months. Meta-analysis showed that prolonged wound packing was associated with delayed wound healing and increased pain, but no difference in abscess recurrence or fistula formation.\n\n**Conclusion:** In this systematic review of current evidence highlighting the impact of packing after incision and drainage for anorectal abscesses, we found that the practice is not associated with significant differences in abscess recurrence and fistula formation, but is associated with increased postoperative pain and delayed wound healing.", "abstract_zh": "**èƒŒæ™¯ï¼š** åˆ‡å¼€å¼•æµåï¼Œç»å¸¸ä½¿ç”¨å†…éƒ¨æ•·æ–™é•¿æ—¶é—´å¡«å¡è‚›é—¨ç›´è‚ è„“è…”ï¼Œä½†è¿™ç§åšæ³•çš„ç–—æ•ˆä»å­˜åœ¨äº‰è®®ã€‚ä¸€äº›ç ”ç©¶å¼ºè°ƒå…¶åœ¨æ­¢è¡€å’Œé¢„é˜²ç˜˜ç®¡å’Œè„“è‚¿å¤å‘æ–¹é¢çš„ç”¨é€”ï¼Œè€Œå…¶ä»–ç ”ç©¶åˆ™æè¿°äº†å…¶ç»æµè´Ÿæ‹…å’Œç–¼ç—›å¢åŠ ã€‚åœ¨è¿™ç¯‡ç³»ç»Ÿè¯„ä»·ä¸­ï¼Œæˆ‘ä»¬ç ”ç©¶äº†æœ‰å…³è‚›é—¨ç›´è‚ è„“è‚¿åˆ‡å¼€å¼•æµåå¡«å¡å½±å“çš„ç°æœ‰è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** åŒ»å­¦å›¾ä¹¦é¦†å‘˜äº 2023 å¹´ 1 æœˆ 5 æ—¥è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚æˆ‘ä»¬ä½¿ç”¨ RevMan 5.4.1 è½¯ä»¶å’Œ Mantel-Haenszel éšæœºæ•ˆåº”æ¨¡å‹è¿›è¡Œäº†èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬ç¡®å®šäº† 3 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œæ¶‰åŠ 490 åæ‚£è€…ã€‚å…¶ä¸­ï¼Œ241 åæ‚£è€…ï¼ˆ49%ï¼‰æ¥å—äº†æœ¯åå¡«å¡ï¼›å¤§å¤šæ•°æ‚£è€…ä¸ºç”·æ€§ï¼ˆ<i>n</i> = 158ï¼Œ65.6%ï¼‰ï¼Œä¸­ä½å¹´é¾„ä¸º 40.5 å²ï¼Œéšè®¿æ—¶é—´ä¸º 6 ä¸ªæœˆã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œé•¿æ—¶é—´åŒ…æ‰ä¼¤å£ä¸ä¼¤å£æ„ˆåˆå»¶è¿Ÿå’Œç–¼ç—›å¢åŠ æœ‰å…³ï¼Œä½†è„“è‚¿å¤å‘æˆ–ç˜˜ç®¡å½¢æˆæ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** åœ¨å¯¹å½“å‰è¯æ®çš„ç³»ç»Ÿå›é¡¾ä¸­ï¼Œå¼ºè°ƒäº†è‚›é—¨ç›´è‚ è„“è‚¿åˆ‡å¼€å¼•æµåå¡«å¡çš„å½±å“ï¼Œæˆ‘ä»¬å‘ç°è¿™ç§åšæ³•ä¸è„“è‚¿å¤å‘å’Œç˜˜ç®¡å½¢æˆçš„æ˜¾ç€å·®å¼‚æ— å…³ï¼Œä½†ä¸æœ¯åç–¼ç—›å¢åŠ å’Œä¼¤å£æ„ˆåˆå»¶è¿Ÿæœ‰å…³ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39332832/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 27 Sep 2024"}, {"id": "39298676", "title_en": "Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review", "title_zh": "ä½¿ç”¨æŒ‚çº¿å¯¹å¤æ‚å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ç»“æœçš„å½±å“ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Phillip Fleshner", "abstract_en": "**Background:** Optimal treatment strategies for seton use in patients with Crohn's perianal fistulas (CPF) remain elusive. This systematic literature review aimed to summarize clinical, patient-reported, and healthcare resource utilization (HCRU) outcomes associated with seton use for symptomatic relief and treatment of complex CPF.\n\n**Methods:** Electronic databases (MEDLINE, Embase, EBM Reviews, EconLit) were searched. Titles, abstracts, and relevant full texts were screened by 2 reviewers for inclusion using prespecified PICOS-T criteria. Articles published in English between January 1, 1980 and September 6, 2021 were included; animal/in vitro studies and case reports with <5 patients were excluded. Outcomes of interest included rates of complete response/remission and fistula recurrence in patients receiving seton with/without infliximab or biologics. Data were summarized using descriptive statistics.\n\n**Results:** Overall, 56 studies were included (full texts: nâ€…=â€…43; congress abstracts: nâ€…=â€…13). CPF and clinical outcome definitions were heterogeneous. Rates (range) of complete response/remission varied widely (seton: 13%-75%; setonâ€…+â€…infliximab: 23%-100%; setonâ€…+â€…biologics: 23%-59%) as did rates for fistula recurrence (seton: 4%-68%; setonâ€…+â€…infliximab: 0%-50%; setonâ€…+â€…biologics: 0%-17%). Rates of fistula-related reintervention, new fistula or abscess formation, and abscess recurrence were also varied; more consistency was observed regarding the use of patient-reported outcomes. Few studies reported outcomes from pediatric/adolescent patients or HCRU.\n\n**Conclusions:** Optimal use of seton in patients with CPF remains unclear. International standardization of definitions for CPF and related clinical outcomes are required to permit data comparability and identify the most effective treatment strategies involving seton use in CPF.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ï¼ˆCPFï¼‰æ‚£è€…æŒ‚çº¿çš„æœ€ä½³æ²»ç–—ç­–ç•¥ä»ç„¶éš¾ä»¥æ‰æ‘¸ã€‚æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ—¨åœ¨æ€»ç»“ä¸ä½¿ç”¨æŒ‚çº¿ç¼“è§£ç—‡çŠ¶å’Œæ²»ç–—å¤æ‚ CPF ç›¸å…³çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ (HCRU) ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº†ç”µå­æ•°æ®åº“ï¼ˆMEDLINEã€Embaseã€EBM Reviewsã€EconLitï¼‰ã€‚æ ‡é¢˜ã€æ‘˜è¦å’Œç›¸å…³å…¨æ–‡ç”± 2 åå®¡ç¨¿äººç­›é€‰ï¼Œä»¥ä½¿ç”¨é¢„å…ˆæŒ‡å®šçš„ PICOS-T æ ‡å‡†è¿›è¡Œçº³å…¥ã€‚æ”¶å½•äº†1980å¹´1æœˆ1æ—¥è‡³2021å¹´9æœˆ6æ—¥æœŸé—´ä»¥è‹±æ–‡å‘è¡¨çš„æ–‡ç« ï¼›åŠ¨ç‰©/ä½“å¤–ç ”ç©¶å’Œç—…ä¾‹æŠ¥å‘Š<5åæ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æ„Ÿå…´è¶£çš„ç»“æœåŒ…æ‹¬æ¥å—æŒ‚çº¿å¹¶ä½¿ç”¨/ä¸ä½¿ç”¨è‹±å¤«åˆ©æ˜”å•æŠ—æˆ–ç”Ÿç‰©åˆ¶å‰‚çš„æ‚£è€…çš„å®Œå…¨ç¼“è§£/ç¼“è§£ç‡å’Œç˜˜ç®¡å¤å‘ç‡ã€‚ä½¿ç”¨æè¿°æ€§ç»Ÿè®¡æ€»ç»“æ•°æ®ã€‚\n\n**ç»“æœï¼š** æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 56 é¡¹ç ”ç©¶ï¼ˆå…¨æ–‡ï¼šnâ€…=â€…43ï¼›ä¼šè®®æ‘˜è¦ï¼šnâ€…=â€…13ï¼‰ã€‚ CPF å’Œä¸´åºŠç»“æœçš„å®šä¹‰æ˜¯ä¸åŒçš„ã€‚å®Œå…¨ç¼“è§£/ç¼“è§£ç‡ï¼ˆèŒƒå›´ï¼‰å·®å¼‚å¾ˆå¤§ï¼ˆæŒ‚çº¿ï¼š13%-75%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š23%-100%ï¼›æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š23%-59%ï¼‰ï¼Œç˜˜ç®¡å¤å‘ç‡ä¹Ÿæœ‰å¾ˆå¤§å·®å¼‚ï¼ˆæŒ‚çº¿ï¼š4%-68%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼‰ã€‚æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š0%-17%ï¼‰ã€‚ä¸ç˜˜ç®¡ç›¸å…³çš„å†å¹²é¢„ã€æ–°ç˜˜ç®¡æˆ–è„“è‚¿å½¢æˆä»¥åŠè„“è‚¿å¤å‘ç‡ä¹Ÿå„ä¸ç›¸åŒï¼›åœ¨ä½¿ç”¨æ‚£è€…æŠ¥å‘Šçš„ç»“æœæ–¹é¢è§‚å¯Ÿåˆ°æ›´åŠ ä¸€è‡´ã€‚å¾ˆå°‘æœ‰ç ”ç©¶æŠ¥å‘Šå„¿ç§‘/é’å°‘å¹´æ‚£è€…æˆ– HCRU çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** CPF æ‚£è€…æŒ‚çº¿çš„æœ€ä½³ä½¿ç”¨æ–¹å¼ä»ä¸æ¸…æ¥šã€‚éœ€è¦å¯¹ CPF å®šä¹‰å’Œç›¸å…³ä¸´åºŠç»“æœè¿›è¡Œå›½é™…æ ‡å‡†åŒ–ï¼Œä»¥å®ç°æ•°æ®å¯æ¯”æ€§å¹¶ç¡®å®šæ¶‰åŠ CPF æŒ‚çº¿ä½¿ç”¨çš„æœ€æœ‰æ•ˆæ²»ç–—ç­–ç•¥ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è‚›å‘¨ç˜˜ã€æŒ‚çº¿", "keywords_en": "Crohnâ€™s disease, perianal fistula, seton", "link": "https://pubmed.ncbi.nlm.nih.gov/39298676/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 19 Sep 2024"}, {"id": "39186335", "title_en": "Efficacy and Safety of Endorectal Advancement Flap for the Treatment of Anal Fistula: A Systematic Review and Meta-Analysis", "title_zh": "ç›´è‚ å†…æ¨è¿›çš®ç“£æ²»ç–—è‚›ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Wencong Xu", "abstract_en": "**Aim:** Complex anal fistula poses a significant challenge for anorectal surgeons due to its high risks of recurrence and incontinence. A sphincter-preserving procedure named endorectal advancement flap (ERAF) is gradually being applied to clinical practice. Therefore, this meta-analysis aims to evaluate the efficacy and safety of ERAF in managing anal fistula.\n\n**Methods:** We searched PubMed, Embase, Cochrane, and Web of Science databases for relevant manuscripts published from 29 August 2003 to 29 August 2023. Among these studies, outcomes included healing rate, recurrence rate, incontinence rate, and complications. Furthermore, the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) and the Cochrane risk-of-bias tool. The heterogeneity was determined using the chi-squared test and I2 statistic. A random effects model was applied if significant heterogeneity (p < 0.05 and I2 > 50%) was observed. Sensitivity analysis was conducted by excluding studies with a high risk of bias.\n\n**Results:** Thirty-eight studies were included in the present analysis, involving 1559 participants. The pooled healing rate and recurrence rate of ERAF were 65.5% (95% confidence intervals (CI): 57.6%-73.4%) and 19.6% (95% CI: 14.8%-24.4%), respectively. The pooled incontinence rate was 10.6% (95% CI: 6.0%-15.1%). According to the subgroup analysis, the healing rate, recurrence rate, and incontinence rate of ERAF for fistula associated with inflammatory bowel disease (IBD) were 53.9% (95% CI: 38.1%-69.7%), 32.6% (95% CI: 21.3%-43.8%), and 2.8% (95% CI: 0%-10.6%), respectively. For patients without IBD, the healing rate, recurrence rate, and incontinence rate of ERAF were 70.6% (95% CI: 63.9%-77.4%), 15.7% (95% CI: 9.9%-21.5%), and 16.5% (95% CI: 8.1%-24.9%), respectively. We observed that bleeding, local infection or abscess, flap dehiscence, and haematomas were the common complications, with incidences of 2.2% (95% CI: 0%-4.5%), 9.5% (95% CI: 4.7%-14.4%), 10.4% (95% CI: 0.0%-21.6%), and 12.4% (95% CI: 0%-27.6%), respectively.\n\n**Conclusions:** ERAF may be an optional treatment for anal fistula from the perspective of effectiveness and safety.\n\n**Systematic Review Registration:** PROSPERO: CRD42023451451.", "abstract_zh": "**Aimï¼š** å¤æ‚è‚›ç˜˜ç”±äºå…¶å¤å‘å’Œå¤±ç¦çš„é«˜é£é™©ï¼Œç»™è‚›è‚ å¤–ç§‘åŒ»ç”Ÿå¸¦æ¥äº†é‡å¤§æŒ‘æˆ˜ã€‚ç›´è‚ å†…æ¨è¿›çš®ç“£ï¼ˆERAFï¼‰çš„ä¿ç•™æ‹¬çº¦è‚Œæ‰‹æœ¯æ­£é€æ¸åº”ç”¨äºä¸´åºŠã€‚å› æ­¤ï¼Œæœ¬èŸèƒåˆ†ææ—¨åœ¨è¯„ä¼° ERAF æ²»ç–—è‚›ç˜˜çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº† PubMedã€Embaseã€Cochrane å’Œ Web of Science æ•°æ®åº“ï¼ŒæŸ¥æ‰¾ 2003 å¹´ 8 æœˆ 29 æ—¥è‡³ 2023 å¹´ 8 æœˆ 29 æ—¥å‘è¡¨çš„ç›¸å…³æ‰‹ç¨¿ã€‚åœ¨è¿™äº›ç ”ç©¶ä¸­ï¼Œç»“æœåŒ…æ‹¬æ²»æ„ˆç‡ã€å¤å‘ç‡ã€å¤±ç¦ç‡å’Œå¹¶å‘ç—‡ã€‚æ­¤å¤–ï¼Œä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ï¼ˆNOSï¼‰å’Œ Cochrane åå€šé£é™©å·¥å…·è¯„ä¼°äº†çº³å…¥ç ”ç©¶çš„è´¨é‡ã€‚ä½¿ç”¨å¡æ–¹æ£€éªŒå’Œ I2 ç»Ÿè®¡é‡ç¡®å®šå¼‚è´¨æ€§ã€‚å¦‚æœè§‚å¯Ÿåˆ°æ˜¾ç€çš„å¼‚è´¨æ€§ï¼ˆp < 0.05 ä¸” I2 > 50%ï¼‰ï¼Œåˆ™åº”ç”¨éšæœºæ•ˆåº”æ¨¡å‹ã€‚é€šè¿‡æ’é™¤å…·æœ‰é«˜åå€šé£é™©çš„ç ”ç©¶æ¥è¿›è¡Œæ•æ„Ÿæ€§åˆ†æã€‚\n\n**ç»“æœï¼š** æœ¬åˆ†æçº³å…¥ 38 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 1559 åå‚ä¸è€…ã€‚ ERAF çš„åˆå¹¶æ²»æ„ˆç‡å’Œå¤å‘ç‡åˆ†åˆ«ä¸º 65.5%ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI)ï¼š57.6%-73.4%ï¼‰å’Œ 19.6%ï¼ˆ95% CIï¼š14.8%-24.4%ï¼‰ã€‚åˆå¹¶å¤±ç¦ç‡ä¸º 10.6%ï¼ˆ95% CIï¼š6.0%-15.1%ï¼‰ã€‚æ ¹æ®äºšç»„åˆ†æï¼ŒERAFæ²»ç–—ç‚ç—‡æ€§è‚ ç—…ï¼ˆIBDï¼‰ç›¸å…³ç˜˜ç®¡çš„æ²»æ„ˆç‡ã€å¤å‘ç‡å’Œå¤±ç¦ç‡åˆ†åˆ«ä¸º53.9%ï¼ˆ95% CIï¼š38.1%-69.7%ï¼‰ã€32.6%ï¼ˆ95% CIï¼š21.3%-43.8%ï¼‰å’Œ2.8%ï¼ˆ95% CIï¼š0%-10.6%ï¼‰ã€‚å¯¹äºæ— IBDçš„æ‚£è€…ï¼ŒERAFçš„æ²»æ„ˆç‡ã€å¤å‘ç‡å’Œå¤±ç¦ç‡åˆ†åˆ«ä¸º70.6%ï¼ˆ95% CIï¼š63.9%-77.4%ï¼‰ã€15.7%ï¼ˆ95% CIï¼š9.9%-21.5%ï¼‰å’Œ16.5%ï¼ˆ95% CIï¼š8.1%-24.9%ï¼‰ã€‚æˆ‘ä»¬è§‚å¯Ÿåˆ°å‡ºè¡€ã€å±€éƒ¨æ„ŸæŸ“æˆ–è„“è‚¿ã€çš®ç“£è£‚å¼€å’Œè¡€è‚¿æ˜¯å¸¸è§çš„å¹¶å‘ç—‡ï¼Œå‘ç”Ÿç‡åˆ†åˆ«ä¸º2.2%ï¼ˆ95% CIï¼š0%-4.5%ï¼‰ã€9.5%ï¼ˆ95% CIï¼š4.7%-14.4%ï¼‰ã€10.4%ï¼ˆ95% CIï¼š0.0%-21.6%ï¼‰å’Œ12.4%ï¼ˆ95% CIï¼š 0%-27.6%ï¼‰ï¼Œåˆ†åˆ«ã€‚\n\n**ç»“è®ºï¼š** ä»æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§çš„è§’åº¦æ¥çœ‹ï¼ŒERAFå¯èƒ½æ˜¯è‚›ç˜˜çš„ä¸€ç§å¯é€‰æ²»ç–—æ–¹æ³•ã€‚\n\n**Systematic review registrationï¼š** æ™®æ´›æ–¯å½¼ç½—ï¼šCRD42023451451ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39186335/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 26 Aug 2024"}, {"id": "39175475", "title_en": "Efficacy and safety evaluation of mixed nutrition for postoperative esophageal cancer patients in China: a meta-analysis", "title_zh": "ä¸­å›½é£Ÿç®¡ç™Œæœ¯åæ‚£è€…æ··åˆè¥å…»çš„ç–—æ•ˆå’Œå®‰å…¨æ€§è¯„ä»·ï¼šèŸèƒåˆ†æ", "authors": "Xiaochuan Liu", "abstract_en": "**Objective:** The purpose of this study was to evaluate the clinical effect of mixed nutrition and parenteral nutrition support on postoperative patients with esophageal cancer.\n\n**Method:** By searching PubMed, Web of Science, Cochrane, CNKI, Wanfang and other databases, all the literatures until March 2024 about the comparison of randomized controlled Trial (RCT) of mixed nutrition and parenteral nutrition support in postoperative patients with esophageal cancer were screened. The inclusion criteria were that the patients were from randomized controlled trials or clinical trials in China, and the patients were all diagnosed with esophageal cancer by pathological biopsy. The exclusion criteria were the literature other than the above, including repeated published literature, non-Chinese and English literature, incomplete or missing analysis data, etc. After two researchers independently screened the literature, extracted the data and evaluated the risk of bias according to the criteria, Meta-analysis was carried out with RevMan 5.4 software.\n\n**Results:** A total of 11 studies were included, including 1216 patients. Meta-analysis showed that, compared with parenteral nutrition, mixed nutrition can improve the levels of transferrin, serum albumin, prealbumin and lymphocyte counts in patients with esophageal cancer after surgery, shorten the time of anal recovery of exhaust, defecation and hospital stay after surgery, and reduce the incidence of pulmonary infection, abdominal distension, incision infection and anastomotic fistula, with statistical significance between the two groups (<i>P</i> < 0.05). The heterogeneity of individual results in this study is relatively high, the analysis comes from clinical heterogeneity, and the publication bias is analyzed through Funnel plot. Taking the incidence of lung infection as an example, the results are evenly distributed on both sides of the Funnel plot, and the publication bias has little impact on the results of the study.\n\n**Conclusion:** Compared with parenteral nutrition, mixed nutrition can improve the prognosis of postoperative patients with esophageal cancer and reduce the incidence of related adverse events.", "abstract_zh": "**ç›®çš„ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä»·æ··åˆè¥å…»ä¸è‚ å¤–è¥å…»æ”¯æŒå¯¹é£Ÿç®¡ç™Œæœ¯åæ‚£è€…çš„ä¸´åºŠæ•ˆæœã€‚\n\n**Methodï¼š** é€šè¿‡æ£€ç´¢PubMedã€Web of Scienceã€Cochraneã€CNKIã€ä¸‡æ–¹ç­‰æ•°æ®åº“ï¼Œç­›é€‰æˆªè‡³2024å¹´3æœˆå…³äºé£Ÿç®¡ç™Œæœ¯åæ‚£è€…æ··åˆè¥å…»ä¸è‚ å¤–è¥å…»æ”¯æŒéšæœºå¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰æ¯”è¾ƒçš„æ–‡çŒ®ã€‚çº³å…¥æ ‡å‡†ä¸ºæ‚£è€…æ¥è‡ªä¸­å›½çš„éšæœºå¯¹ç…§è¯•éªŒæˆ–ä¸´åºŠè¯•éªŒï¼Œä¸”æ‚£è€…å‡ç»ç—…ç†æ´»æ£€ç¡®è¯Šä¸ºé£Ÿç®¡ç™Œã€‚æ’é™¤æ ‡å‡†ä¸ºä¸Šè¿°ä»¥å¤–çš„æ–‡çŒ®ï¼ŒåŒ…æ‹¬é‡å¤å‘è¡¨çš„æ–‡çŒ®ã€éä¸­è‹±æ–‡æ–‡çŒ®ã€åˆ†ææ•°æ®ä¸å®Œæ•´æˆ–ç¼ºå¤±ç­‰ã€‚ä¸¤åç ”ç©¶è€…æ ¹æ®æ ‡å‡†ç‹¬ç«‹ç­›é€‰æ–‡çŒ®ã€æå–æ•°æ®å¹¶è¯„ä¼°åå€šé£é™©åï¼Œé‡‡ç”¨RevMan 5.4è½¯ä»¶è¿›è¡ŒMetaåˆ†æã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥ 11 é¡¹ç ”ç©¶ï¼ŒåŒ…æ‹¬ 1216 åæ‚£è€…ã€‚ Metaåˆ†ææ˜¾ç¤ºï¼Œä¸è‚ å¤–è¥å…»ç›¸æ¯”ï¼Œæ··åˆè¥å…»å¯æé«˜é£Ÿç®¡ç™Œæœ¯åæ‚£è€…è½¬é“è›‹ç™½ã€è¡€æ¸…ç™½è›‹ç™½ã€å‰ç™½è›‹ç™½å’Œæ·‹å·´ç»†èƒè®¡æ•°æ°´å¹³ï¼Œç¼©çŸ­æœ¯åè‚›é—¨æ¢å¤æ’æ°”ã€æ’ä¾¿å’Œä½é™¢æ—¶é—´ï¼Œå‡å°‘è‚ºéƒ¨æ„ŸæŸ“ã€è…¹èƒ€ã€åˆ‡å£æ„ŸæŸ“å’Œå»åˆå£ç˜˜çš„å‘ç”Ÿç‡ï¼Œä¸¤ç»„æ¯”è¾ƒå·®å¼‚æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆ<i>P</i> < 0.05ï¼‰ã€‚æœ¬ç ”ç©¶ä¸ªä½“ç»“æœå¼‚è´¨æ€§è¾ƒé«˜ï¼Œåˆ†ææ¥è‡ªä¸´åºŠå¼‚è´¨æ€§ï¼Œé€šè¿‡æ¼æ–—å›¾åˆ†æå‘è¡¨åå€šã€‚ä»¥è‚ºéƒ¨æ„ŸæŸ“çš„å‘ç”Ÿç‡ä¸ºä¾‹ï¼Œç»“æœå‡åŒ€åˆ†å¸ƒåœ¨æ¼æ–—å›¾ä¸¤ä¾§ï¼Œå‘è¡¨åå€šå¯¹ç ”ç©¶ç»“æœå½±å“ä¸å¤§ã€‚\n\n**ç»“è®ºï¼š** ä¸è‚ å¤–è¥å…»ç›¸æ¯”ï¼Œæ··åˆè¥å…»å¯ä»¥æ”¹å–„é£Ÿç®¡ç™Œæœ¯åæ‚£è€…çš„é¢„åï¼Œå‡å°‘ç›¸å…³ä¸è‰¯äº‹ä»¶çš„å‘ç”Ÿã€‚", "keywords_zh": "ç–—æ•ˆä¸å®‰å…¨æ€§ã€èŸèƒåˆ†æã€æ··åˆè¥å…»ã€è‚ å¤–è¥å…»ã€é£Ÿç®¡ç™Œæœ¯å", "keywords_en": "efficacy and safety, meta-analysis, mixed nutrition, parenteral nutrition, postoperative esophageal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39175475/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 23 Aug 2024"}, {"id": "39127896", "title_en": "Efficacy and safety of autologous platelet-rich plasma in anal fistula: a systematic review and meta-analysis", "title_zh": "è‡ªä½“å¯Œè¡€å°æ¿è¡€æµ†æ²»ç–—è‚›ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Chang Ge", "abstract_en": "**Introduction:** This study aimed to determine the efficacy and safety of autologous PRP in anal fistula.\n\n**Methods:** The search was done in electronic databases such as; PubMed, Scopus, Google Scholar, Embase, and Cochrane Library. The outcomes investigated in this study were the rate of improvement, the rate of recurrence, and the rate of fecal incontinence.\n\n**Results:** Cure, incontinence, and recurrence rates were 68% (95% CI, .60-.76), 27% (95% CI, .12-.46), and 18% (95% CI, .12-.26), respectively. The pooled improvement ratio in patients treated with PRP compared to control group was 1.35 times, which was statistically significant (pooled OR=1.35, 95% CI, 1.14-1.60, <i>P</i><001). The pooled recurrence ratio in patients treated with PRP compared to control group was 1.17, which was not statistically significant (pooled OR=1.17, 95% CI, 0.44-3.11).\n\n**Discussion:** Platelet-rich plasma is an effective method of healing people with anal fistula.", "abstract_zh": "**ä»‹ç»ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨ç¡®å®šè‡ªä½“ PRP æ²»ç–—è‚›ç˜˜çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æœç´¢æ˜¯åœ¨ç”µå­æ•°æ®åº“ä¸­å®Œæˆçš„ï¼Œä¾‹å¦‚ï¼š PubMedã€Scopusã€Google Scholarã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ã€‚æœ¬ç ”ç©¶è°ƒæŸ¥çš„ç»“æœæ˜¯æ”¹å–„ç‡ã€å¤å‘ç‡å’Œå¤§ä¾¿å¤±ç¦ç‡ã€‚\n\n**ç»“æœï¼š** æ²»æ„ˆç‡ã€å¤±ç¦ç‡å’Œå¤å‘ç‡åˆ†åˆ«ä¸º 68% (95% CI, .60-.76)ã€27% (95% CI, .12-.46) å’Œ 18% (95% CI, .12-.26)ã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼ŒPRPæ²»ç–—ç»„æ‚£è€…çš„æ±‡æ€»æ”¹å–„ç‡ä¸º1.35å€ï¼Œå…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆæ±‡æ€»OR=1.35ï¼Œ95% CIï¼Œ1.14-1.60ï¼Œ<i>P</i><001ï¼‰ã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œæ¥å— PRP æ²»ç–—çš„æ‚£è€…çš„æ±‡æ€»å¤å‘ç‡ä¸º 1.17ï¼Œæ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆæ±‡æ€» OR=1.17ï¼Œ95% CIï¼Œ0.44-3.11ï¼‰ã€‚\n\n**è®¨è®ºï¼š** å¯Œå«è¡€å°æ¿çš„è¡€æµ†æ˜¯æ²»ç–—è‚›ç˜˜æ‚£è€…çš„æœ‰æ•ˆæ–¹æ³•ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39127896/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sun, 11 Aug 2024"}, {"id": "39118327", "title_en": "The prevalence of pouch fistulas in ulcerative colitis following restorative proctocolectomy: a systematic review and meta-analysis", "title_zh": "æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯åæºƒç–¡æ€§ç»“è‚ ç‚å‚¨è¢‹ç˜˜çš„æ‚£ç—…ç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jonathan P Segal", "abstract_en": "**Background/Aims:** One complication of restorative proctocolectomy with ileo-anal pouch anastomosis is fistula formation in the pouch. Fistulas can be associated with significant morbidity and pouch failure. We conducted a systematic review with meta- analysis to try and understand the prevalence of pouch fistulas in patients with ulcerative colitis following restorative proctocolectomy.\n\n**Methods:** The Embase, Embase Classic, and PubMed databases were searched between January 1979 and April 2022. Studies were included if there were cross-sectional, case-controlled, population-based or cohort studies reporting on prevalence of pouch fistulas in ulcerative colitis. Studies had to report the number of patients with pouch fistulas using either clinical, endoscopic, or radiological diagnosis in an adult population.\n\n**Results:** Thirty-three studies screened met the inclusion criteria. The pooled prevalence of developing at least 1 fistula was 0.05 (95% confidence interval [CI], 0.04-0.07). The pooled prevalence of pouch failure in patients with pouch fistula was found to be 0.24 (95% CI, 0.19-0.30). The pooled prevalence of developing a pouch fistula at 3 years, 5 years and more than 5 years was 0.04 (95% CI, 0.02-0.07), 0.05 (95% CI, 0.02-0.07), and 0.05 (95% CI, 0.02-0.10), respectively.\n\n**Conclusions:** This is the first systematic review and meta-analysis to report the prevalence of pouch fistula. It also provides a pooled prevalence of pouch failure in these patients. These results can help to shape future guidelines, power future studies, and help counsel patients.", "abstract_zh": "**Background/aimsï¼š** æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯è”åˆå›è‚ è‚›ç®¡å‚¨è¢‹å»åˆæœ¯çš„å¹¶å‘ç—‡ä¹‹ä¸€æ˜¯å‚¨è¢‹å†…å½¢æˆç˜˜ç®¡ã€‚ç˜˜ç®¡å¯èƒ½ä¸æ˜¾ç€çš„å‘ç—…ç‡å’Œé€ å£è¢‹å¤±è´¥æœ‰å…³ã€‚æˆ‘ä»¬è¿›è¡Œäº†ä¸€é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œè¯•å›¾äº†è§£æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯åæºƒç–¡æ€§ç»“è‚ ç‚æ‚£è€…å‚¨è¢‹ç˜˜çš„æ‚£ç—…ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† 1979 å¹´ 1 æœˆè‡³ 2022 å¹´ 4 æœˆæœŸé—´çš„ Embaseã€Embase Classic å’Œ PubMed æ•°æ®åº“ã€‚å¦‚æœå­˜åœ¨æŠ¥å‘Šæºƒç–¡æ€§ç»“è‚ ç‚ä¸­å‚¨è¢‹ç˜˜æ‚£ç—…ç‡çš„æ¨ªæ–­é¢ã€ç—…ä¾‹å¯¹ç…§ã€åŸºäºäººç¾¤æˆ–é˜Ÿåˆ—ç ”ç©¶ï¼Œåˆ™çº³å…¥ç ”ç©¶ã€‚ç ”ç©¶å¿…é¡»æŠ¥å‘Šæˆå¹´äººç¾¤ä¸­ä½¿ç”¨ä¸´åºŠã€å†…çª¥é•œæˆ–æ”¾å°„å­¦è¯Šæ–­çš„å‚¨è¢‹ç˜˜æ‚£è€…çš„æ•°é‡ã€‚\n\n**ç»“æœï¼š** ç­›é€‰çš„ 33 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚è‡³å°‘å‘ç”Ÿ 1 ä¸ªç˜˜ç®¡çš„æ±‡æ€»æ‚£ç—…ç‡ä¸º 0.05ï¼ˆ95% ç½®ä¿¡åŒºé—´ [CI]ï¼Œ0.04-0.07ï¼‰ã€‚å‚¨è¢‹ç˜˜æ‚£è€…å‚¨è¢‹å¤±è´¥çš„æ±‡æ€»æ‚£ç—…ç‡ä¸º 0.24ï¼ˆ95% CIï¼Œ0.19-0.30ï¼‰ã€‚ 3å¹´ã€5å¹´å’Œ5å¹´ä»¥ä¸Šå‘ç”Ÿå‚¨è¢‹ç˜˜çš„æ±‡æ€»æ‚£ç—…ç‡åˆ†åˆ«ä¸º0.04ï¼ˆ95% CIï¼Œ0.02-0.07ï¼‰ã€0.05ï¼ˆ95% CIï¼Œ0.02-0.07ï¼‰å’Œ0.05ï¼ˆ95% CIï¼Œ0.02-0.10ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™æ˜¯ç¬¬ä¸€ä¸ªæŠ¥å‘Šå‚¨è¢‹ç˜˜æ‚£ç—…ç‡çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚å®ƒè¿˜æä¾›äº†è¿™äº›æ‚£è€…å‚¨è¢‹å¤±è´¥çš„æ±‡æ€»æ‚£ç—…ç‡ã€‚è¿™äº›ç»“æœå¯ä»¥å¸®åŠ©åˆ¶å®šæœªæ¥çš„æŒ‡å¯¼æ–¹é’ˆï¼Œä¸ºæœªæ¥çš„ç ”ç©¶æä¾›åŠ¨åŠ›ï¼Œå¹¶å¸®åŠ©ä¸ºæ‚£è€…æä¾›å’¨è¯¢ã€‚", "keywords_zh": "ç˜˜ç®¡ã€å‚¨è¢‹ã€æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯ã€æºƒç–¡æ€§ç»“è‚ ç‚", "keywords_en": "Fistula, Pouch, Restorative proctocolectomy, Ulcerative colitis", "link": "https://pubmed.ncbi.nlm.nih.gov/39118327/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 09 Aug 2024"}, {"id": "38910957", "title_en": "Current Status and Role of Artificial Intelligence in Anorectal Diseases and Pelvic Floor Disorders", "title_zh": "äººå·¥æ™ºèƒ½åœ¨è‚›è‚ ç–¾ç—…å’Œç›†åº•ç–¾ç—…ä¸­çš„ç°çŠ¶å’Œä½œç”¨", "authors": "Jasneet Bhullar", "abstract_en": "**Background:** Anorectal diseases and pelvic floor disorders are prevalent among the general population. Patients may present with overlapping symptoms, delaying diagnosis, and lowering quality of life. Treating physicians encounter numerous challenges attributed to the complex nature of pelvic anatomy, limitations of diagnostic techniques, and lack of available resources. This article is an overview of the current state of artificial intelligence (AI) in tackling the difficulties of managing benign anorectal disorders and pelvic floor disorders.\n\n**Methods:** A systematic literature review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched the PubMed database to identify all potentially relevant studies published from January 2000 to August 2023. Search queries were built using the following terms: AI, machine learning, deep learning, benign anorectal disease, pelvic floor disorder, fecal incontinence, obstructive defecation, anal fistula, rectal prolapse, and anorectal manometry. Malignant anorectal articles and abstracts were excluded. Data from selected articles were analyzed.\n\n**Results:** 139 articles were found, 15 of which met our inclusion and exclusion criteria. The most common AI module was convolutional neural network. researchers were able to develop AI modules to optimize imaging studies for pelvis, fistula, and abscess anatomy, facilitated anorectal manometry interpretation, and improved high-definition anoscope use. None of the modules were validated in an external cohort.\n\n**Conclusion:** There is potential for AI to enhance the management of pelvic floor and benign anorectal diseases. Ongoing research necessitates the use of multidisciplinary approaches and collaboration between physicians and AI programmers to tackle pressing challenges.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›é—¨ç›´è‚ ç–¾ç—…å’Œç›†åº•ç–¾ç—…åœ¨æ™®é€šäººç¾¤ä¸­æ™®éå­˜åœ¨ã€‚æ‚£è€…å¯èƒ½ä¼šå‡ºç°é‡å çš„ç—‡çŠ¶ï¼Œä»è€Œå»¶è¯¯è¯Šæ–­å¹¶é™ä½ç”Ÿæ´»è´¨é‡ã€‚ç”±äºç›†è…”è§£å‰–ç»“æ„çš„å¤æ‚æ€§ã€è¯Šæ–­æŠ€æœ¯çš„å±€é™æ€§ä»¥åŠå¯ç”¨èµ„æºçš„ç¼ºä¹ï¼Œæ²»ç–—åŒ»ç”Ÿé¢ä¸´ç€è®¸å¤šæŒ‘æˆ˜ã€‚æœ¬æ–‡æ¦‚è¿°äº†äººå·¥æ™ºèƒ½ (AI) åœ¨è§£å†³è‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…å’Œç›†åº•ç–¾ç—…ç®¡ç†éš¾é¢˜æ–¹é¢çš„ç°çŠ¶ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææŒ‡å—çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®è¿›è¡Œäº†ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°ã€‚æˆ‘ä»¬æœç´¢äº† PubMed æ•°æ®åº“ï¼Œä»¥ç¡®å®šä» 2000 å¹´ 1 æœˆåˆ° 2023 å¹´ 8 æœˆå‘è¡¨çš„æ‰€æœ‰æ½œåœ¨ç›¸å…³ç ”ç©¶ã€‚æœç´¢æŸ¥è¯¢æ˜¯ä½¿ç”¨ä»¥ä¸‹æœ¯è¯­æ„å»ºçš„ï¼šäººå·¥æ™ºèƒ½ã€æœºå™¨å­¦ä¹ ã€æ·±åº¦å­¦ä¹ ã€è‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…ã€ç›†åº•ç–¾ç—…ã€å¤§ä¾¿å¤±ç¦ã€é˜»å¡æ€§æ’ä¾¿ã€è‚›ç˜˜ã€ç›´è‚ è„±å‚å’Œè‚›é—¨ç›´è‚ æµ‹å‹ã€‚æ¶æ€§è‚›é—¨ç›´è‚ æ–‡ç« å’Œæ‘˜è¦è¢«æ’é™¤åœ¨å¤–ã€‚å¯¹é€‰å®šæ–‡ç« çš„æ•°æ®è¿›è¡Œäº†åˆ†æã€‚\n\n**ç»“æœï¼š** å…±æ‰¾åˆ° 139 ç¯‡æ–‡ç« ï¼Œå…¶ä¸­ 15 ç¯‡ç¬¦åˆæˆ‘ä»¬çš„çº³å…¥å’Œæ’é™¤æ ‡å‡†ã€‚æœ€å¸¸è§çš„äººå·¥æ™ºèƒ½æ¨¡å—æ˜¯å·ç§¯ç¥ç»ç½‘ç»œã€‚ç ”ç©¶äººå‘˜èƒ½å¤Ÿå¼€å‘äººå·¥æ™ºèƒ½æ¨¡å—æ¥ä¼˜åŒ–éª¨ç›†ã€ç˜˜ç®¡å’Œè„“è‚¿è§£å‰–çš„æˆåƒç ”ç©¶ï¼Œä¿ƒè¿›è‚›é—¨ç›´è‚ æµ‹å‹è§£é‡Šï¼Œå¹¶æ”¹è¿›é«˜æ¸…è‚›é—¨é•œçš„ä½¿ç”¨ã€‚æ‰€æœ‰æ¨¡å—å‡æœªåœ¨å¤–éƒ¨é˜Ÿåˆ—ä¸­å¾—åˆ°éªŒè¯ã€‚\n\n**ç»“è®ºï¼š** äººå·¥æ™ºèƒ½æœ‰æ½œåŠ›åŠ å¼ºç›†åº•å’Œè‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…çš„ç®¡ç†ã€‚æ­£åœ¨è¿›è¡Œçš„ç ”ç©¶éœ€è¦ä½¿ç”¨å¤šå­¦ç§‘æ–¹æ³•ä»¥åŠåŒ»ç”Ÿå’Œäººå·¥æ™ºèƒ½ç¨‹åºå‘˜ä¹‹é—´çš„åˆä½œæ¥åº”å¯¹ç´§è¿«çš„æŒ‘æˆ˜ã€‚", "keywords_zh": "è‚›è‚ ç–¾ç—…ã€äººå·¥æ™ºèƒ½ã€æ·±åº¦å­¦ä¹ ã€ç›†åº•ç–¾ç—…", "keywords_en": "Anorectal disease, Artificial intelligence, Deep learning, Pelvic floor disorder", "link": "https://pubmed.ncbi.nlm.nih.gov/38910957/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 24 Jun 2024"}, {"id": "38871152", "title_en": "Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus", "title_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ç›¸å…³çš„è‚›é—¨ç›´è‚ ç™Œå’Œç˜˜ç®¡ç™Œï¼šç³»ç»Ÿè¯„ä»·å’Œä¸“å®¶å…±è¯†", "authors": "Jean-Frederic Colombel", "abstract_en": "**Background & Aims:** Perianal fistulizing Crohn's disease (PFCD)-associated anorectal and fistula cancers are rare but often devastating diagnoses. However, given the low incidence and consequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of these cancers. To inform clinical practice, we developed consensus guidelines on PFCD-associated anorectal and fistula cancers by multidisciplinary experts from the international TOpClass consortium.\n\n**Methods:** We conducted a systematic review by standard methodology, using the Newcastle-Ottawa Scale quality assessment tool. We subsequently developed consensus statements using a Delphi consensus approach.\n\n**Results:** Of 561 articles identified, 110 were eligible, and 76 articles were included. The overall quality of evidence was low. The TOpClass consortium reached consensus on 6 structured statements addressing screening, risk assessment, and management of PFCD-associated anorectal and fistula cancers. Patients with long-standing (>10 years) PFCD should be considered at small but increased risk of developing perianal cancer, including squamous cell carcinoma of the anus and anorectal carcinoma. Risk factors for squamous cell carcinoma of the anus, notably human papilloma virus, should be considered. New, refractory, or progressive perianal symptoms should prompt evaluation for fistula cancer. There was no consensus on timing or frequency of screening in patients with asymptomatic perianal fistula. Multiple modalities may be required for diagnosis, including an examination under anesthesia with biopsy. Multidisciplinary team efforts were deemed central to the management of fistula cancers.\n\n**Conclusions:** Inflammatory bowel disease clinicians should be aware of the risk of PFCD-associated anorectal and fistula cancers in all patients with PFCD. The TOpClass consortium consensus statements outlined herein offer guidance in managing this challenging scenario.", "abstract_zh": "**Background & aimsï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (PFCD) ç›¸å…³çš„è‚›é—¨ç›´è‚ ç™Œå’Œç˜˜ç®¡ç™Œå¾ˆå°‘è§ï¼Œä½†è¯Šæ–­ç»“æœå¾€å¾€æ˜¯æ¯ç­æ€§çš„ã€‚ç„¶è€Œï¼Œç”±äºå‘ç—…ç‡ä½ä»¥åŠå› æ­¤ç¼ºä¹è¯¥é¢†åŸŸçš„æ•°æ®å’Œä¸´åºŠè¯•éªŒï¼Œå› æ­¤å¯¹è¿™äº›ç™Œç—‡çš„ç­›æŸ¥å’Œç®¡ç†å‡ ä¹æ²¡æœ‰æŒ‡å¯¼ã€‚ä¸ºäº†æŒ‡å¯¼ä¸´åºŠå®è·µï¼Œæˆ‘ä»¬ç”±å›½é™… TOpClass è”ç›Ÿçš„å¤šå­¦ç§‘ä¸“å®¶åˆ¶å®šäº†æœ‰å…³ PFCD ç›¸å…³è‚›é—¨ç›´è‚ ç™Œå’Œç˜˜ç®¡ç™Œçš„å…±è¯†æŒ‡å—ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨è´¨é‡è¯„ä¼°å·¥å…·ï¼Œé€šè¿‡æ ‡å‡†æ–¹æ³•è¿›è¡Œäº†ç³»ç»Ÿå®¡æŸ¥ã€‚æˆ‘ä»¬éšåä½¿ç”¨å¾·å°”è²å…±è¯†æ–¹æ³•åˆ¶å®šäº†å…±è¯†å£°æ˜ã€‚\n\n**ç»“æœï¼š** åœ¨ç¡®å®šçš„ 561 ç¯‡æ–‡ç« ä¸­ï¼Œ110 ç¯‡ç¬¦åˆæ¡ä»¶ï¼Œ76 ç¯‡æ–‡ç« è¢«çº³å…¥ã€‚è¯æ®çš„æ€»ä½“è´¨é‡è¾ƒä½ã€‚ TOpClass è”ç›Ÿå°± 6 é¡¹ç»“æ„åŒ–å£°æ˜è¾¾æˆå…±è¯†ï¼Œæ¶‰åŠ PFCD ç›¸å…³è‚›é—¨ç›´è‚ ç™Œå’Œç˜˜ç®¡ç™Œçš„ç­›æŸ¥ã€é£é™©è¯„ä¼°å’Œç®¡ç†ã€‚æ‚£æœ‰é•¿æœŸï¼ˆ> 10 å¹´ï¼‰PFCD çš„æ‚£è€…åº”è€ƒè™‘æ‚£è‚›å‘¨ç™Œçš„é£é™©è™½å°ä½†å¢åŠ ï¼ŒåŒ…æ‹¬è‚›é—¨é³çŠ¶ç»†èƒç™Œå’Œè‚›é—¨ç›´è‚ ç™Œã€‚åº”è€ƒè™‘è‚›é—¨é³çŠ¶ç»†èƒç™Œçš„å±é™©å› ç´ ï¼Œç‰¹åˆ«æ˜¯äººä¹³å¤´ç˜¤ç—…æ¯’ã€‚æ–°å‡ºç°çš„ã€éš¾æ²»æ€§çš„æˆ–è¿›è¡Œæ€§çš„è‚›å‘¨ç—‡çŠ¶åº”ä¿ƒä½¿è¯„ä¼°ç˜˜ç®¡ç™Œã€‚å¯¹äºæ— ç—‡çŠ¶è‚›å‘¨ç˜˜æ‚£è€…çš„ç­›æŸ¥æ—¶é—´æˆ–é¢‘ç‡å°šæœªè¾¾æˆå…±è¯†ã€‚è¯Šæ–­å¯èƒ½éœ€è¦å¤šç§æ–¹å¼ï¼ŒåŒ…æ‹¬éº»é†‰ä¸‹è¿›è¡Œæ´»æ£€ã€‚å¤šå­¦ç§‘å›¢é˜Ÿçš„åŠªåŠ›è¢«è®¤ä¸ºæ˜¯ç˜˜ç®¡ç™Œæ²»ç–—çš„æ ¸å¿ƒã€‚\n\n**ç»“è®ºï¼š** ç‚ç—‡æ€§è‚ ç—…ä¸´åºŠåŒ»ç”Ÿåº”äº†è§£æ‰€æœ‰ PFCD æ‚£è€…æ‚£ PFCD ç›¸å…³è‚›é—¨ç›´è‚ ç™Œå’Œç˜˜ç®¡ç™Œçš„é£é™©ã€‚æœ¬æ–‡æ¦‚è¿°çš„ TOpClass è”ç›Ÿå…±è¯†å£°æ˜ä¸ºç®¡ç†è¿™ä¸€å…·æœ‰æŒ‘æˆ˜æ€§çš„åœºæ™¯æä¾›äº†æŒ‡å¯¼ã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç™Œã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "Anorectal Cancer, Inflammatory Bowel Disease, Perianal Fistulizing Crohnâ€™s Disease", "link": "https://pubmed.ncbi.nlm.nih.gov/38871152/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 13 Jun 2024"}, {"id": "38491943", "title_en": "Does Combined Medical and Surgical Treatment Improve Perianal Fistula Outcomes in Patients With Crohn's Disease? A Systematic Review and Meta-Analysis", "title_zh": "è¯ç‰©å’Œæ‰‹æœ¯è”åˆæ²»ç–—èƒ½å¦æ”¹å–„å…‹ç½—æ©ç—…æ‚£è€…è‚›å‘¨ç˜˜çš„æ²»ç–—æ•ˆæœï¼Ÿç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** The optimal treatment of perianal fistulizing Crohn's disease [PFCD] is unknown. We performed a systematic review with meta-analysis to compare combined surgical intervention and anti-tumour necrosis factor [anti-TNF] therapy [combined therapy] vs either therapy alone.\n\n**Methods:** MEDLINE, EMBASE, and Cochrane databases were searched systematically up to end December 2023. Surgical intervention was defined as an exam under anaesthesiaâ€…Â±â€…setons. We calculated weighted risk ratios [RRs] with 95% confidence intervals [CIs] for our co-primary outcomes: fistula response and healing, defined clinically as a reduction in fistula drainage or number of draining fistulas and fistula closure respectively.\n\n**Results:** Thirteen studies were analysed: 515 patients treated with combined therapy, 330 patients with surgical intervention, and 406 patients with anti-TNF therapy with follow-up between 10 weeks and 3 years. Fistula response [RR 1.10; 95% CI 0.93-1.30, pâ€…=â€…0.28] and healing [RR 1.06; 95% CI 0.86-1.31, pâ€…=â€…0.58] was not significantly different when comparing combined therapy with anti-TNF therapy alone. In contrast, combined therapy was associated with significantly higher rates of fistula response [RR 1.25; 95% CI 1.10-1.41, pâ€…<â€…0.001] and healing [RR 1.17; 95% CI 1.00-1.36, pâ€…=â€…0.05] compared with surgical intervention alone. Our results remained stable when limiting to studies that assessed outcomes within 1 year and studies where <10% of patients underwent fistula closure procedures.\n\n**Conclusion:** Combined surgery and anti-TNF therapy was not associated with improved PFCD outcomes compared with anti-TNF therapy alone. Due to an inability to control for confounding and small study sizes, future, controlled trials are warranted to confirm these findings.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… [PFCD] çš„æœ€ä½³æ²»ç–—æ–¹æ³•å°šä¸æ¸…æ¥šã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥æ¯”è¾ƒè”åˆæ‰‹æœ¯å¹²é¢„å’ŒæŠ—è‚¿ç˜¤åæ­»å› å­ [æŠ— TNF] ç–—æ³• [è”åˆç–—æ³•] ä¸å•ç‹¬ç–—æ³•çš„æ¯”è¾ƒã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2023 å¹´ 12 æœˆï¼Œç³»ç»Ÿæ£€ç´¢äº† MEDLINEã€EMBASE å’Œ Cochrane æ•°æ®åº“ã€‚æ‰‹æœ¯å¹²é¢„è¢«å®šä¹‰ä¸ºéº»é†‰ä¸‹çš„æ£€æŸ¥ã€‚æˆ‘ä»¬è®¡ç®—äº†å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ [CI] çš„åŠ æƒé£é™©æ¯” [RR]ï¼Œç”¨äºæˆ‘ä»¬çš„å…±åŒä¸»è¦ç»“æœï¼šç˜˜ç®¡ååº”å’Œæ„ˆåˆï¼Œä¸´åºŠä¸Šåˆ†åˆ«å®šä¹‰ä¸ºç˜˜ç®¡å¼•æµæˆ–å¼•æµç˜˜ç®¡æ•°é‡å‡å°‘ä»¥åŠç˜˜ç®¡é—­åˆã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 13 é¡¹ç ”ç©¶ï¼š515 åæ‚£è€…æ¥å—è”åˆæ²»ç–—ï¼Œ330 åæ‚£è€…æ¥å—æ‰‹æœ¯å¹²é¢„ï¼Œ406 åæ‚£è€…æ¥å—æŠ— TNF æ²»ç–—ï¼Œéšè®¿æ—¶é—´ä¸º 10 å‘¨è‡³ 3 å¹´ã€‚ç˜˜ååº”[RR 1.10ï¼› 95% CI 0.93-1.30ï¼Œpâ€…=â€…0.28] å’Œæ²»æ„ˆ [RR 1.06ï¼›è”åˆæ²»ç–—ä¸å•ç‹¬æŠ— TNF æ²»ç–—æ¯”è¾ƒæ—¶ï¼Œ95% CI 0.86-1.31ï¼Œpâ€…=â€…0.58] æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç›¸åï¼Œè”åˆæ²»ç–—ä¸æ˜¾ç€è¾ƒé«˜çš„ç˜˜ç®¡ååº”ç‡ç›¸å…³[RR 1.25ï¼›RR 1.25ï¼›RR 1.25]ã€‚ 95% CI 1.10-1.41ï¼Œpâ€…<â€…0.001] å’Œæ„ˆåˆ [RR 1.17ï¼›RR 1.17ï¼›ä¸å•ç‹¬æ‰‹æœ¯å¹²é¢„ç›¸æ¯”ï¼Œ95% CI 1.00-1.36ï¼Œpâ€…=â€…0.05]ã€‚å½“ä»…é™äºè¯„ä¼° 1 å¹´å†…ç»“æœçš„ç ”ç©¶ä»¥åŠ <10% çš„æ‚£è€…æ¥å—ç˜˜ç®¡é—­åˆæ‰‹æœ¯çš„ç ”ç©¶æ—¶ï¼Œæˆ‘ä»¬çš„ç»“æœä¿æŒç¨³å®šã€‚\n\n**ç»“è®ºï¼š** ä¸å•ç‹¬çš„æŠ— TNF æ²»ç–—ç›¸æ¯”ï¼Œè”åˆæ‰‹æœ¯å’ŒæŠ— TNF æ²»ç–—ä¸æ”¹å–„ PFCD ç»“å±€æ— å…³ã€‚ç”±äºæ— æ³•æ§åˆ¶æ··æ‚å› ç´ å’Œå°ç ”ç©¶è§„æ¨¡ï¼Œæœªæ¥æœ‰å¿…è¦è¿›è¡Œå¯¹ç…§è¯•éªŒæ¥è¯å®è¿™äº›å‘ç°ã€‚", "keywords_zh": "è‚›å‘¨ç˜˜ï¼ŒæŠ—TNFï¼Œè¯ç‰©å’Œæ‰‹æœ¯ç›¸ç»“åˆ", "keywords_en": "Perianal fistula, anti-TNF, combined medical and surgical", "link": "https://pubmed.ncbi.nlm.nih.gov/38491943/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 16 Mar 2024"}, {"id": "38475976", "title_en": "Martius flaps for low rectovaginal fistulae: a systematic review and proportional meta-analysis", "title_zh": "Martius çš®ç“£æ²»ç–—ä½ä½ç›´è‚ é˜´é“ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’Œæ¯”ä¾‹èŸèƒåˆ†æ", "authors": "Shaheel Mohammad Sahebally", "abstract_en": "**Background:** Rectovaginal fistulae (RVF) are notoriously challenging to treat. Martius flap (MF) is a technique employed to manage RVF, among various others, with none being universally successful. We aimed to assess the outcomes of RVF managed with MF interposition.\n\n**Methods:** A PRISMA-compliant meta-analysis searching for all studies specifically reporting on the outcomes of MF for RVF was performed. The primary objective was the mean success rate, whilst secondary objectives included complications and recurrence. The MedCalc software (version 20.118) was used to conduct proportional meta-analyses of data. Weighted mean values with 95% CI are presented and stratified according to aetiology where possible.\n\n**Results:** Twelve non-randomized (11 retrospective, 1 prospective) studies, assessing 137 MF were included. The mean age of the study population was 42.4 (Â±15.7), years. There were 44 primary and 93 recurrent RVF. The weighted mean success rate for MF when performed for primary RVF was 91.4% (95% CI: 79.45-98.46; I<sup>2</sup>â€‰=â€‰32.1%; Pâ€‰=â€‰0.183) and that for recurrent RVF was 77.5% (95% CI: 62.24-89.67; I<sup>2</sup>â€‰=â€‰58.1%; Pâ€‰=â€‰0.008). The weighted mean complication rate was 29% (95% CI: 8.98-54.68; I<sup>2</sup>â€‰=â€‰85.4%; Pâ€‰<â€‰0.0001) and the overall recurrence rate was 12.0% (95% CI: 5.03-21.93; I<sup>2</sup>â€‰=â€‰52.3%; Pâ€‰=â€‰0.021). When purely radiotherapy-induced RVF were evaluated, the mean overall success rate was 94.6% (95% CI: 83.33-99.75; I<sup>2</sup>â€‰=â€‰0%; Pâ€‰=â€‰0.350).\n\n**Conclusions:** MF interposition appears to be more effective for primary than recurrent RVF. However, the poor quality of the data limits definitive conclusions being drawn and demands further assessment with randomized studies.", "abstract_zh": "**èƒŒæ™¯ï¼š** ä¼—æ‰€å‘¨çŸ¥ï¼Œç›´è‚ é˜´é“ç˜˜ï¼ˆRVFï¼‰çš„æ²»ç–—å…·æœ‰æŒ‘æˆ˜æ€§ã€‚ Martius çš®ç“£ (MF) æ˜¯ä¸€ç§ç”¨äºæ²»ç–— RVF çš„æŠ€æœ¯ï¼Œä½†æ²¡æœ‰ä¸€ç§æŠ€æœ¯èƒ½å¤Ÿæ™®éæˆåŠŸã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯è¯„ä¼° MF å¹²é¢„æ²»ç–— RVF çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** è¿›è¡Œäº†ç¬¦åˆ PRISMA æ ‡å‡†çš„èŸèƒåˆ†æï¼Œæœç´¢äº†ä¸“é—¨æŠ¥å‘Š MF æ²»ç–— RVF ç»“æœçš„æ‰€æœ‰ç ”ç©¶ã€‚ä¸»è¦ç›®æ ‡æ˜¯å¹³å‡æˆåŠŸç‡ï¼Œæ¬¡è¦ç›®æ ‡åŒ…æ‹¬å¹¶å‘ç—‡å’Œå¤å‘ã€‚ MedCalc è½¯ä»¶ï¼ˆç‰ˆæœ¬ 20.118ï¼‰ç”¨äºå¯¹æ•°æ®è¿›è¡Œæ¯”ä¾‹èŸèƒåˆ†æã€‚å‘ˆç° 95% CI çš„åŠ æƒå¹³å‡å€¼ï¼Œå¹¶å°½å¯èƒ½æ ¹æ®ç—…å› è¿›è¡Œåˆ†å±‚ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 12 é¡¹ééšæœºç ”ç©¶ï¼ˆ11 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œ1 é¡¹å‰ç»æ€§ç ”ç©¶ï¼‰ï¼Œè¯„ä¼°äº† 137 ä¾‹ MFã€‚ç ”ç©¶äººç¾¤çš„å¹³å‡å¹´é¾„ä¸º 42.4 (Â±15.7) å²ã€‚å…¶ä¸­ 44 ä¾‹ä¸ºåŸå‘æ€§ RVFï¼Œ93 ä¾‹ä¸ºå¤å‘æ€§ RVFã€‚åŸå‘æ€§ RVF çš„ MF åŠ æƒå¹³å‡æˆåŠŸç‡ä¸º 91.4%ï¼ˆ95% CIï¼š79.45-98.46ï¼›I<sup>2</sup>â€‰=â€‰32.1%ï¼›Pâ€‰=â€‰0.183ï¼‰ï¼Œå¤å‘æ€§ RVF çš„åŠ æƒå¹³å‡æˆåŠŸç‡ä¸º 77.5%ï¼ˆ95% CIï¼š62.24-89.67ï¼›I<sup>2</sup>â€‰=â€‰32.1%ï¼›Pâ€‰=â€‰0.183ï¼‰ã€‚ I<sup>2</sup>â€‰=â€‰58.1%ï¼›Pâ€‰=â€‰0.008)ã€‚åŠ æƒå¹³å‡å¹¶å‘ç—‡ç‡ä¸º29%ï¼ˆ95% CIï¼š8.98-54.68ï¼›I<sup>2</sup>â€‰=â€‰85.4%ï¼›Pâ€‰<â€‰0.0001ï¼‰ï¼Œæ€»å¤å‘ç‡ä¸º12.0%ï¼ˆ95% CIï¼š5.03-21.93ï¼›I<sup>2</sup>â€‰=â€‰85.4%ï¼›Pâ€‰<â€‰0.0001ï¼‰ã€‚ I<sup>2</sup>â€‰=â€‰52.3%ï¼›Pâ€‰=â€‰0.021ï¼‰ã€‚å½“è¯„ä¼°å•çº¯æ”¾ç–—å¼•èµ·çš„RVFæ—¶ï¼Œå¹³å‡æ€»ä½“æˆåŠŸç‡ä¸º94.6%ï¼ˆ95% CIï¼š83.33-99.75ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›Pâ€‰=â€‰0.350ï¼‰ã€‚\n\n**ç»“è®ºï¼š** MF å¹²é¢„å¯¹äºåŸå‘æ€§ RVF ä¼¼ä¹æ¯”å¤å‘æ€§ RVF æ›´æœ‰æ•ˆã€‚ç„¶è€Œï¼Œæ•°æ®è´¨é‡å·®é™åˆ¶äº†å¾—å‡ºæ˜ç¡®çš„ç»“è®ºï¼Œéœ€è¦é€šè¿‡éšæœºç ”ç©¶è¿›è¡Œè¿›ä¸€æ­¥è¯„ä¼°ã€‚", "keywords_zh": "å¹¶å‘ç—‡ã€ç˜˜ç®¡ã€åŸå‘æ€§ã€ç›´è‚ é˜´é“ã€å¤å‘ã€æˆåŠŸ", "keywords_en": "complication, fistula, primary, rectovaginal, recurrence, success", "link": "https://pubmed.ncbi.nlm.nih.gov/38475976/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 13 Mar 2024"}, {"id": "38315695", "title_en": "Obstetric fistula repair failure and its associated factors among women who underwent repair in sub-Saharan Africa. A systematic review and meta-analysis", "title_zh": "æ’’å“ˆæ‹‰ä»¥å—éæ´²æ¥å—ä¿®å¤çš„å¦‡å¥³äº§ç§‘ç˜˜ä¿®å¤å¤±è´¥åŠå…¶ç›¸å…³å› ç´ ã€‚ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Mesfin Abebe", "abstract_en": "**Background:** Obstetric fistula repair failure can result in increased depression, social isolation, financial burden for the woman, and fistula care programs. However, there is limited, comprehensive evidence on obstetric fistula repair failure in Sub-Saharan African countries. This systematic review and meta-analysis aimed to determine the pooled prevalence of obstetric fistula repair failure and associated factors among women who underwent surgical repair in Sub-Saharan African countries.\n\n**Methods:** To identify potential articles, a systematic search was done utilizing online databases (PubMed, Hinari, and Google Scholar). The Preferred Reporting Items for Systematic Review and Meta-Analysis Statement (PRISMA) guideline was used to report the review's findings. I2 test statistics were employed to examine study heterogeneity. A random-effects model was used to assess the pooled prevalence of obstetric fistula repair failure, and the association was determined using the log odds ratio. Publication bias was investigated using the funnel plot and Egger's statistical test at the 5% level of significance. Meta-regression and subgroup analysis were done to identify potential sources of heterogeneity. The data were analyzed using STATA version 17 statistical software.\n\n**Results:** A total of 24 articles with 9866 study participants from 13 Sub-Saharan African countries were included in this meta-analysis. The pooled prevalence of obstetric fistula repair failure in sub-Saharan Africa was 24.92% [95% CI: 20.34-29.50%]. The sub-group analysis by country revealed that the highest prevalence was in Angola (58%, 95% CI: 53.20-62.80%) and the lowest in Rwanda (13.9, 95% CI: 9.79-18.01%). Total urethral damage [ORâ€‰ = â€‰3.50, 95% CI: 2.09, 4.91], large fistula [OR = 3.09, 95% CI: (2.00, 4.10)], duration of labor [OR = 0.45, 95% CI: 0.27, 0.76], and previous fistula repair [OR = 2.70, 95% CI: 1.94, 3.45] were factors associated with obstetric fistula repair failure.\n\n**Conclusion:** Women who received surgical treatment for obstetric fistulas in Sub-Saharan African countries experienced more repair failures than the WHO standards. Obstetric fistula repair failure was affected by urethral damage, fistula size, duration of labor, types of fistula, and history of previous repairs. Therefore, we suggest policy measures specific to each country to provide special attention to the prevention of all risk factors, including poor nutrition, multiparty, obstructed labor, and maternal age, which can result in conditions like large fistulas, urethral damage, and repeat repair, in order to reduce obstetric fistula repair failure.", "abstract_zh": "**èƒŒæ™¯ï¼š** äº§ç§‘ç˜˜ç®¡ä¿®å¤å¤±è´¥å¯èƒ½ä¼šå¯¼è‡´æŠ‘éƒã€ç¤¾ä¼šå­¤ç«‹ã€å¥³æ€§ç»æµè´Ÿæ‹…ä»¥åŠç˜˜ç®¡æŠ¤ç†è®¡åˆ’çš„å¢åŠ ã€‚ç„¶è€Œï¼Œå…³äºæ’’å“ˆæ‹‰ä»¥å—éæ´²å›½å®¶äº§ç§‘ç˜˜ä¿®å¤å¤±è´¥çš„å…¨é¢è¯æ®æœ‰é™ã€‚è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨ç¡®å®šæ’’å“ˆæ‹‰ä»¥å—éæ´²å›½å®¶æ¥å—æ‰‹æœ¯ä¿®å¤çš„å¦‡å¥³ä¸­äº§ç§‘ç˜˜ç®¡ä¿®å¤å¤±è´¥çš„æ±‡æ€»æ‚£ç—…ç‡å’Œç›¸å…³å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** ä¸ºäº†è¯†åˆ«æ½œåœ¨çš„æ–‡ç« ï¼Œåˆ©ç”¨åœ¨çº¿æ•°æ®åº“ï¼ˆPubMedã€Hinari å’Œ Google Scholarï¼‰è¿›è¡Œäº†ç³»ç»Ÿæœç´¢ã€‚ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æå£°æ˜çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ç”¨äºæŠ¥å‘Šè¯„ä»·ç»“æœã€‚ I2 æ£€éªŒç»Ÿè®¡æ•°æ®ç”¨äºæ£€æŸ¥ç ”ç©¶å¼‚è´¨æ€§ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è¯„ä¼°äº§ç§‘ç˜˜ä¿®å¤å¤±è´¥çš„æ±‡æ€»æ‚£ç—…ç‡ï¼Œå¹¶ä½¿ç”¨å¯¹æ•°æ¯”å€¼æ¯”ç¡®å®šç›¸å…³æ€§ã€‚ä½¿ç”¨æ¼æ–—å›¾å’Œ Egger ç»Ÿè®¡æ£€éªŒåœ¨ 5% æ˜¾ç€æ€§æ°´å¹³ä¸Šè°ƒæŸ¥å‘è¡¨åå€šã€‚è¿›è¡ŒèŸèƒå›å½’å’Œäºšç»„åˆ†æä»¥ç¡®å®šå¼‚è´¨æ€§çš„æ½œåœ¨æ¥æºã€‚ä½¿ç”¨STATA 17ç‰ˆç»Ÿè®¡è½¯ä»¶å¯¹æ•°æ®è¿›è¡Œåˆ†æã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡èŸèƒåˆ†æå…±çº³å…¥ 24 ç¯‡æ–‡ç« ï¼Œæ¶‰åŠæ¥è‡ª 13 ä¸ªæ’’å“ˆæ‹‰ä»¥å—éæ´²å›½å®¶çš„ 9866 åç ”ç©¶å‚ä¸è€…ã€‚æ’’å“ˆæ‹‰ä»¥å—éæ´²åœ°åŒºäº§ç§‘ç˜˜ç®¡ä¿®å¤å¤±è´¥çš„æ±‡æ€»æ‚£ç—…ç‡ä¸º 24.92% [95% CI: 20.34-29.50%]ã€‚æŒ‰å›½å®¶è¿›è¡Œçš„äºšç»„åˆ†ææ˜¾ç¤ºï¼Œæ‚£ç—…ç‡æœ€é«˜çš„æ˜¯å®‰å“¥æ‹‰ï¼ˆ58%ï¼Œ95% CIï¼š53.20-62.80%ï¼‰ï¼Œæœ€ä½çš„æ˜¯å¢æ—ºè¾¾ï¼ˆ13.9ï¼Œ95% CIï¼š9.79-18.01%ï¼‰ã€‚å°¿é“æ€»æŸä¼¤ [ORâ€‰ = â€‰3.50, 95% CI: 2.09, 4.91]ã€å¤§ç˜˜ç®¡ [OR = 3.09, 95% CI: (2.00, 4.10)]ã€äº§ç¨‹æŒç»­æ—¶é—´ [OR = 0.45, 95% CI: 0.27, 0.76] å’Œæ—¢å¾€ç˜˜ç®¡ä¿®å¤æœ¯ [OR = 2.70, 95% CI: 1.94, 3.45] æ˜¯ä¸äº§ç§‘ç˜˜ä¿®å¤å¤±è´¥ç›¸å…³çš„å› ç´ ã€‚\n\n**ç»“è®ºï¼š** åœ¨æ’’å“ˆæ‹‰ä»¥å—éæ´²å›½å®¶æ¥å—äº§ç§‘ç˜˜æ‰‹æœ¯æ²»ç–—çš„å¦‡å¥³ç»å†çš„ä¿®å¤å¤±è´¥ç‡é«˜äºä¸–ç•Œå«ç”Ÿç»„ç»‡çš„æ ‡å‡†ã€‚äº§ç§‘ç˜˜ç®¡ä¿®å¤å¤±è´¥å—å°¿é“æŸä¼¤ã€ç˜˜ç®¡å¤§å°ã€äº§ç¨‹æŒç»­æ—¶é—´ã€ç˜˜ç®¡ç±»å‹å’Œæ—¢å¾€ä¿®å¤å²çš„å½±å“ã€‚å› æ­¤ï¼Œæˆ‘ä»¬å»ºè®®é’ˆå¯¹æ¯ä¸ªå›½å®¶é‡‡å–å…·ä½“çš„æ”¿ç­–æªæ–½ï¼Œç‰¹åˆ«å…³æ³¨é¢„é˜²æ‰€æœ‰é£é™©å› ç´ ï¼ŒåŒ…æ‹¬è¥å…»ä¸è‰¯ã€å¤šæ–¹ã€éš¾äº§å’Œäº§å¦‡å¹´é¾„ï¼Œè¿™äº›å› ç´ å¯èƒ½å¯¼è‡´ç˜˜ç®¡å¤§ã€å°¿é“æŸä¼¤å’Œé‡å¤ä¿®å¤ç­‰æƒ…å†µï¼Œä»¥å‡å°‘äº§ç§‘ç˜˜ç®¡ä¿®å¤å¤±è´¥ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/38315695/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 05 Feb 2024"}, {"id": "38296841", "title_en": "The use of core descriptors from the ENiGMA code study in recent literature: a systematic review", "title_zh": "æœ€è¿‘æ–‡çŒ®ä¸­ ENiGMA ä»£ç ç ”ç©¶çš„æ ¸å¿ƒæè¿°ç¬¦çš„ä½¿ç”¨ï¼šç³»ç»Ÿå›é¡¾", "authors": "Sharon L Stein", "abstract_en": "**Aim:** The heterogeneity in data quality presented in studies regarding Crohn's anal fistula (CAF) limit extrapolation into clinical practice. The ENiGMA collaborators established a core descriptor set to standardize reporting of CAF. The aim of this work was to quantify the use of these descriptors in recent literature.\n\n**Method:** We completed a systematic review of PubMed and the Cochrane Library, extracting publications from the past 10â€‰years specific to the clinical interventions and outcomes of CAF, and reported in line with PRISMA guidance. Each article was assessed for inclusion of ENiGMA descriptors. The median number of descriptors per publication was evaluated along with the overall frequency of each individual descriptor. Use of ENiGMA descriptors was compared between medical and procedural publications.\n\n**Results:** Ninety publications were included. The median number of descriptors was 15 of 37; 16 descriptors were used in over half of the publications while 17 were used in fewer than a third. Descriptors were more frequently used in procedural (nâ€‰=â€‰16) than medical publications (nâ€‰=â€‰14) (pâ€‰=â€‰0.031). In procedural publications, eight descriptors were more frequently used including Faecal incontinence, Number of previous fistula interventions, Presence and severity of anorectal stenosis and Current proctitis. Medical publications were more likely to include Previous response to biological therapy and Duration and type of current course of biological therapy.\n\n**Conclusion:** With many descriptors being used infrequently and variations between medical and procedural literature, the colorectal community should assess the need for all 37 descriptors.", "abstract_zh": "**Aimï¼š** æœ‰å…³å…‹ç½—æ©ç—…è‚›ç˜˜ (CAF) çš„ç ”ç©¶ä¸­æ•°æ®è´¨é‡çš„å¼‚è´¨æ€§é™åˆ¶äº†å¤–æ¨åˆ°ä¸´åºŠå®è·µã€‚ ENiGMA åˆä½œè€…å»ºç«‹äº†ä¸€ä¸ªæ ¸å¿ƒæè¿°ç¬¦é›†æ¥æ ‡å‡†åŒ– CAF æŠ¥å‘Šã€‚è¿™é¡¹å·¥ä½œçš„ç›®çš„æ˜¯é‡åŒ–è¿™äº›æè¿°ç¬¦åœ¨æœ€è¿‘æ–‡çŒ®ä¸­çš„ä½¿ç”¨ã€‚\n\n**Methodï¼š** æˆ‘ä»¬å®Œæˆäº†å¯¹ PubMed å’Œ Cochrane å›¾ä¹¦é¦†çš„ç³»ç»Ÿå›é¡¾ï¼Œæå–äº†è¿‡å» 10 å¹´é’ˆå¯¹ CAF ä¸´åºŠå¹²é¢„å’Œç»“æœçš„å‡ºç‰ˆç‰©ï¼Œå¹¶æ ¹æ® PRISMA æŒ‡å—è¿›è¡ŒæŠ¥å‘Šã€‚æ¯ç¯‡æ–‡ç« éƒ½ç»è¿‡è¯„ä¼°ä»¥åŒ…å« ENiGMA æè¿°ç¬¦ã€‚æ¯ä¸ªå‡ºç‰ˆç‰©çš„æè¿°ç¬¦ä¸­ä½æ•°ä»¥åŠæ¯ä¸ªå•ç‹¬æè¿°ç¬¦çš„æ€»ä½“é¢‘ç‡è¿›è¡Œäº†è¯„ä¼°ã€‚å¯¹åŒ»å­¦å‡ºç‰ˆç‰©å’Œç¨‹åºå‡ºç‰ˆç‰©ä¸­ ENiGMA æè¿°ç¬¦çš„ä½¿ç”¨è¿›è¡Œäº†æ¯”è¾ƒã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ä¹åç§å‡ºç‰ˆç‰©ã€‚æè¿°ç¬¦æ•°é‡ä¸­ä½æ•°ä¸º 37 ä¸ªä¸­çš„ 15 ä¸ªï¼›è¶…è¿‡ä¸€åŠçš„å‡ºç‰ˆç‰©ä½¿ç”¨äº† 16 ä¸ªæè¿°ç¬¦ï¼Œè€Œä¸åˆ°ä¸‰åˆ†ä¹‹ä¸€çš„å‡ºç‰ˆç‰©ä½¿ç”¨äº† 17 ä¸ªæè¿°ç¬¦ã€‚æè¿°ç¬¦åœ¨ç¨‹åºæ€§å‡ºç‰ˆç‰© (nâ€‰=â€‰16) ä¸­çš„ä½¿ç”¨é¢‘ç‡é«˜äºåŒ»å­¦å‡ºç‰ˆç‰© (nâ€‰=â€‰14) (pâ€‰=â€‰0.031)ã€‚åœ¨ç¨‹åºæ€§å‡ºç‰ˆç‰©ä¸­ï¼Œå…«ä¸ªæè¿°è¯è¢«æ›´é¢‘ç¹åœ°ä½¿ç”¨ï¼ŒåŒ…æ‹¬å¤§ä¾¿å¤±ç¦ã€æ—¢å¾€ç˜˜ç®¡å¹²é¢„æ¬¡æ•°ã€è‚›é—¨ç›´è‚ ç‹­çª„çš„å­˜åœ¨å’Œä¸¥é‡ç¨‹åº¦ä»¥åŠå½“å‰ç›´è‚ ç‚ã€‚åŒ»å­¦å‡ºç‰ˆç‰©æ›´æœ‰å¯èƒ½åŒ…æ‹¬ä»¥å‰å¯¹ç”Ÿç‰©æ²»ç–—çš„ååº”ä»¥åŠå½“å‰ç”Ÿç‰©æ²»ç–—è¿‡ç¨‹çš„æŒç»­æ—¶é—´å’Œç±»å‹ã€‚\n\n**ç»“è®ºï¼š** ç”±äºè®¸å¤šæè¿°ç¬¦å¾ˆå°‘ä½¿ç”¨ï¼Œå¹¶ä¸”åŒ»å­¦å’Œç¨‹åºæ–‡çŒ®ä¹‹é—´å­˜åœ¨å·®å¼‚ï¼Œç»“ç›´è‚ ç¤¾åŒºåº”è¯„ä¼°æ‰€æœ‰ 37 ä¸ªæè¿°ç¬¦çš„éœ€æ±‚ã€‚", "keywords_zh": "æ ¸å¿ƒæè¿°ç¬¦é›†ã€å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ã€å¤šå­¦ç§‘æŠ¤ç†ã€ç”Ÿæ´»è´¨é‡", "keywords_en": "core descriptor set, crohnâ€™s perianal fistulae, multidisciplinary care, quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/38296841/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 31 Jan 2024"}, {"id": "38197847", "title_en": "Efficacy and safety of video-assisted anal fistula treatment in anorectal fistula: a meta-analysis", "title_zh": "è§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—è‚›è‚ ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šèŸèƒåˆ†æ", "authors": "Xuebing Wang", "abstract_en": "**Introduction:** By searching relevant literature, the recurrence rate, complication rate after video-assisted anal fistula treatment (VAAFT), and efficacy and safety of the treatment were analyzed.\n\n**Evidence Acquisition:** Articles that reported the outcomes of VAAFT up to December 2020 were searched in PubMed (Medline) and Cochrane Library, in accordance with the preferred reporting items for systematic review and meta-analysis (PRISMA) screening guidelines. Two researchers independently completed the whole process from screening and inclusion to quality evaluation and bias risk assessment, and the data was included in the RevMan 5.3 software for analysis. The main outcomes were demographic data of patients, detection rate, classification of internal opening of anorectal fistula, postoperative recurrence rate, and incidence of complications.\n\n**Evidence Synthesis:** A total of 10 articles were included (779 patients). The average age of the patients was 44 years old, average operation time was 60 min, and the average follow-up time was 22 months. The ratio of male to female was 2.4:1, the ratio of high anorectal fistula to low anorectal fistula was 6.6:1, the detection rate of internal openings was 98%, the weighted recurrence rate was 24%, and the weighted complication rate was 1%.\n\n**Conclusions:** VAAFT is effective and safe in the treatment of anorectal fistulas.", "abstract_zh": "**ä»‹ç»ï¼š** é€šè¿‡æ£€ç´¢ç›¸å…³æ–‡çŒ®ï¼Œåˆ†æè§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—ï¼ˆVAAFTï¼‰åçš„å¤å‘ç‡ã€å¹¶å‘ç—‡å‘ç”Ÿç‡ä»¥åŠæ²»ç–—çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**Evidence acquisitionï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ (PRISMA) ç­›é€‰æŒ‡å—çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼Œåœ¨ PubMed (Medline) å’Œ Cochrane å›¾ä¹¦é¦†ä¸­æ£€ç´¢äº†æŠ¥å‘Šæˆªè‡³ 2020 å¹´ 12 æœˆ VAAFT ç»“æœçš„æ–‡ç« ã€‚ä¸¤åç ”ç©¶äººå‘˜ç‹¬ç«‹å®Œæˆäº†ä»ç­›é€‰ã€çº³å…¥åˆ°è´¨é‡è¯„ä»·å’Œåå€šé£é™©è¯„ä¼°çš„å…¨è¿‡ç¨‹ï¼Œæ•°æ®çº³å…¥RevMan 5.3è½¯ä»¶è¿›è¡Œåˆ†æã€‚ä¸»è¦ç»“å±€æŒ‡æ ‡ä¸ºæ‚£è€…äººå£å­¦èµ„æ–™ã€æ£€å‡ºç‡ã€è‚›ç›´è‚ ç˜˜å†…å£åˆ†ç±»ã€æœ¯åå¤å‘ç‡åŠå¹¶å‘ç—‡å‘ç”Ÿç‡ã€‚\n\n**Evidence synthesisï¼š** æ€»å…±çº³å…¥ 10 ç¯‡æ–‡ç« ï¼ˆ779 åæ‚£è€…ï¼‰ã€‚æ‚£è€…å¹³å‡å¹´é¾„44å²ï¼Œå¹³å‡æ‰‹æœ¯æ—¶é—´60åˆ†é’Ÿï¼Œå¹³å‡éšè®¿æ—¶é—´22ä¸ªæœˆã€‚ç”·å¥³æ¯”ä¾‹ä¸º2.4:1ï¼Œé«˜ä½è‚›ç˜˜ä¸ä½ä½è‚›ç˜˜æ¯”ä¾‹ä¸º6.6:1ï¼Œå†…å£æ£€å‡ºç‡ä¸º98%ï¼ŒåŠ æƒå¤å‘ç‡ä¸º24%ï¼ŒåŠ æƒå¹¶å‘ç—‡ç‡ä¸º1%ã€‚\n\n**ç»“è®ºï¼š** VAAFTæ²»ç–—è‚›é—¨ç›´è‚ ç˜˜æœ‰æ•ˆä¸”å®‰å…¨ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/38197847/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 10 Jan 2024"}, {"id": "38126903", "title_en": "Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic Review", "title_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…è¯„åˆ†æŒ‡æ•°ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Vipul Jairath", "abstract_en": "**Background And Aims:** In this systematic review we summarise existing scoring indices for assessing disease activity and quality of life in perianal fistulising Crohn's disease [PFCD], and highlight gaps in the literature.\n\n**Methods:** MEDLINE, EMBASE, and CENTRAL were searched from August 24, 2022, to identify studies evaluating clinical, radiological, or patient-reported outcome measures [PROMS] in PFCD. The primary objective was to identify all available scoring indices and describe the operating properties of these indices.\n\n**Results:** A total of 53 studies reported on the use of one clinical index [Perianal Disease Activity Index: PDAI], three PROMs, and 10 radiological indices; 25 studies evaluated the operating properties of these indices. The PDAI demonstrated content validity, construct validity, and responsiveness but criterion validity or reliability were not assessed. The Van Assche Index [VAI], modified VAI, and the Magnetic Resonance Index for Assessing Fistulas in Patients with CD [MAGNIFI-CD] were the most studied radiological indices. These indices demonstrated responsiveness and reliability. The VAI and MAGNIFI-CD demonstrated construct validity; criterion and content validity and feasibility have not been assessed. Among the three PROMs, the Crohn's Anal Fistula Quality of Life index demonstrated content and construct validity, inter-observer reliability, and responsiveness; criterion validity, intra-observer reliability, and feasibility have not been assessed for this index.\n\n**Conclusions:** There are no fully valid, reliable, and responsive clinical disease or radiological indices for PFCD. Although the radiological indices demonstrated responsiveness and reliability, well-defined cut-offs for response and remission are lacking. Future research should focus on establishing standardised definitions and thresholds for outcomes.", "abstract_zh": "**Background and aimsï¼š** åœ¨è¿™ç¯‡ç³»ç»Ÿç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬æ€»ç»“äº†è¯„ä¼°è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… [PFCD] ç–¾ç—…æ´»åŠ¨æ€§å’Œç”Ÿæ´»è´¨é‡çš„ç°æœ‰è¯„åˆ†æŒ‡æ•°ï¼Œå¹¶å¼ºè°ƒäº†æ–‡çŒ®ä¸­çš„ç©ºç™½ã€‚\n\n**æ–¹æ³•ï¼š** è‡ª 2022 å¹´ 8 æœˆ 24 æ—¥èµ·å¯¹ MEDLINEã€EMBASE å’Œ CENTRAL è¿›è¡Œæ£€ç´¢ï¼Œä»¥ç¡®å®šè¯„ä¼° PFCD ä¸´åºŠã€æ”¾å°„å­¦æˆ–æ‚£è€…æŠ¥å‘Šç»“æœæµ‹é‡ [PROMS] çš„ç ”ç©¶ã€‚ä¸»è¦ç›®æ ‡æ˜¯ç¡®å®šæ‰€æœ‰å¯ç”¨çš„è¯„åˆ†æŒ‡æ•°å¹¶æè¿°è¿™äº›æŒ‡æ•°çš„æ“ä½œå±æ€§ã€‚\n\n**ç»“æœï¼š** å…±æœ‰ 53 é¡¹ç ”ç©¶æŠ¥å‘Šäº†ä¸€é¡¹ä¸´åºŠæŒ‡æ ‡[è‚›å‘¨ç–¾ç—…æ´»åŠ¨æŒ‡æ•°ï¼šPDAI]ã€ä¸‰é¡¹ PROM å’Œ 10 é¡¹æ”¾å°„å­¦æŒ‡æ ‡çš„ä½¿ç”¨ï¼› 25 é¡¹ç ”ç©¶è¯„ä¼°äº†è¿™äº›æŒ‡æ•°çš„æ“ä½œç‰¹æ€§ã€‚ PDAI è¯æ˜äº†å†…å®¹æœ‰æ•ˆæ€§ã€ç»“æ„æœ‰æ•ˆæ€§å’Œå“åº”æ€§ï¼Œä½†æœªè¯„ä¼°æ ‡å‡†æœ‰æ•ˆæ€§æˆ–å¯é æ€§ã€‚ Van Assche æŒ‡æ•° [VAI]ã€æ”¹è‰¯ VAI å’Œè¯„ä¼° CD æ‚£è€…ç˜˜ç®¡çš„ç£å…±æŒ¯æŒ‡æ•° [MAGNIFI-CD] æ˜¯ç ”ç©¶æœ€å¤šçš„æ”¾å°„å­¦æŒ‡æ•°ã€‚è¿™äº›æŒ‡æ•°æ˜¾ç¤ºäº†å“åº”æ€§å’Œå¯é æ€§ã€‚ VAI å’Œ MAGNIFI-CD è¯æ˜äº†ç»“æ„æœ‰æ•ˆæ€§ï¼›æ ‡å‡†å’Œå†…å®¹çš„æœ‰æ•ˆæ€§å’Œå¯è¡Œæ€§å°šæœªè¯„ä¼°ã€‚åœ¨ä¸‰ä¸ª PROM ä¸­ï¼Œå…‹ç½—æ©ç—…è‚›ç˜˜ç”Ÿæ´»è´¨é‡æŒ‡æ•°å±•ç¤ºäº†å†…å®¹å’Œç»“æ„çš„æœ‰æ•ˆæ€§ã€è§‚å¯Ÿè€…é—´çš„å¯é æ€§å’Œå“åº”æ€§ï¼›å°šæœªè¯„ä¼°è¯¥æŒ‡æ•°çš„æ ‡å‡†æœ‰æ•ˆæ€§ã€è§‚å¯Ÿè€…å†…éƒ¨å¯é æ€§å’Œå¯è¡Œæ€§ã€‚\n\n**ç»“è®ºï¼š** PFCD å°šæ— å®Œå…¨æœ‰æ•ˆã€å¯é ä¸”æœ‰ååº”çš„ä¸´åºŠç–¾ç—…æˆ–æ”¾å°„å­¦æŒ‡æ ‡ã€‚å°½ç®¡æ”¾å°„å­¦æŒ‡æ ‡æ˜¾ç¤ºå‡ºååº”æ€§å’Œå¯é æ€§ï¼Œä½†ç¼ºä¹æ˜ç¡®çš„ååº”å’Œç¼“è§£ç•Œé™ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¾§é‡äºå»ºç«‹ç»“æœçš„æ ‡å‡†åŒ–å®šä¹‰å’Œé˜ˆå€¼ã€‚", "keywords_zh": "ç»“æœã€ç–¾ç—…æ´»åŠ¨æŒ‡æ•°ã€æ“ä½œç‰¹æ€§ã€ç”Ÿæ´»è´¨é‡", "keywords_en": "Outcomes, disease activity indices, operating properties, quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/38126903/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 21 Dec 2023"}, {"id": "38091125", "title_en": "Cutting seton for the treatment of cryptoglandular fistula-in-ano: a systematic review and meta-analysis", "title_zh": "åˆ‡å‰²æŒ‚çº¿æ²»ç–—è‚›é—¨éšçªç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "C Eskicioglu", "abstract_en": "**Background:** The use of cutting seton (CS) for the management of cryptoglandular fistula-in-ano has remained controversial because of reports of fecal incontinence, postoperative pain, and extended healing time. The aim of this review was to provide the first synthesis of studies investigating the use of CS for the treatment of cryptoglandular fistula-in-ano.\n\n**Methods:** MEDLINE, Embase, and CENTRAL were searched up to October 2022. Randomized controlled trials and observational studies comparing CS with alternative interventions were included, along with single-arm studies evaluating CS alone. The primary outcome was fistula-in-ano recurrence, and secondary outcomes included incontinence, healing time, proportion with complete healing, and postoperative pain. Inverse variance random-effects meta-analyses were used to pool effect estimates.\n\n**Results:** After screening 661 citations, 29 studies were included. Overall, 1513 patients undergoing CS (18.8% female, mean age: 43.1Â years) were included. Patients with CS had a 6% (95% CI: 3-12%) risk of recurrence and a 16% (95% CI: 5-38%) risk of incontinence at 6 months. CS patients had an average healing time of 14.6Â weeks (95% CI: 10-19Â weeks) with 73% (95% CI: 48-89%) of patients achieving complete healing at 6 months postoperatively. There was no difference in recurrence between CS and fistulotomy, advancement flap, two-stage seton fistulotomy, or draining seton.\n\n**Conclusions:** Overall, this analysis shows that CS has comparable recurrence and incontinence ratesÂ to other modalities. However, this may be at the expense of more postoperative pain and extended healing time. Further comparative studies between CS and other modalities are warranted.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç”±äºå¤§ä¾¿å¤±ç¦ã€æœ¯åç–¼ç—›å’Œæ„ˆåˆæ—¶é—´å»¶é•¿çš„æŠ¥é“ï¼Œä½¿ç”¨åˆ‡å‰²æŒ‚çº¿ï¼ˆCSï¼‰æ²»ç–—è‚›é—¨éšçªç˜˜ä»å­˜åœ¨äº‰è®®ã€‚æœ¬ç»¼è¿°çš„ç›®çš„æ˜¯é¦–æ¬¡ç»¼åˆç ”ç©¶ä½¿ç”¨ CS æ²»ç–—éšçªè…ºç˜˜çš„ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** MEDLINEã€Embase å’Œ CENTRAL çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2022 å¹´ 10 æœˆã€‚å…¶ä¸­åŒ…æ‹¬æ¯”è¾ƒ CS ä¸æ›¿ä»£å¹²é¢„æªæ–½çš„éšæœºå¯¹ç…§è¯•éªŒå’Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œä»¥åŠå•ç‹¬è¯„ä¼° CS çš„å•ç»„ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯è‚›ç˜˜å¤å‘ï¼Œæ¬¡è¦ç»“å±€åŒ…æ‹¬å¤±ç¦ã€æ„ˆåˆæ—¶é—´ã€å®Œå…¨æ„ˆåˆæ¯”ä¾‹å’Œæœ¯åç–¼ç—›ã€‚ä½¿ç”¨é€†æ–¹å·®éšæœºæ•ˆåº”èŸèƒåˆ†ææ¥æ±‡æ€»æ•ˆåº”ä¼°è®¡ã€‚\n\n**ç»“æœï¼š** ç­›é€‰äº† 661 æ¡å¼•ç”¨åï¼Œçº³å…¥äº† 29 é¡¹ç ”ç©¶ã€‚æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 1513 åæ¥å— CS çš„æ‚£è€…ï¼ˆ18.8% ä¸ºå¥³æ€§ï¼Œå¹³å‡å¹´é¾„ï¼š43.1 å²ï¼‰ã€‚ CS æ‚£è€…åœ¨ 6 ä¸ªæœˆæ—¶å¤å‘é£é™©ä¸º 6%ï¼ˆ95% CIï¼š3-12%ï¼‰ï¼Œå¤±ç¦é£é™©ä¸º 16%ï¼ˆ95% CIï¼š5-38%ï¼‰ã€‚ CS æ‚£è€…çš„å¹³å‡æ„ˆåˆæ—¶é—´ä¸º 14.6 å‘¨ï¼ˆ95% CIï¼š10-19 å‘¨ï¼‰ï¼Œå…¶ä¸­ 73%ï¼ˆ95% CIï¼š48-89%ï¼‰çš„æ‚£è€…åœ¨æœ¯å 6 ä¸ªæœˆæ—¶å®ç°å®Œå…¨æ„ˆåˆã€‚ CSä¸ç˜˜ç®¡åˆ‡å¼€æœ¯ã€æ¨è¿›çš®ç“£ã€ä¸¤é˜¶æ®µæŒ‚çº¿ç˜˜ç®¡åˆ‡å¼€æœ¯æˆ–å¼•æµæŒ‚çº¿ä¹‹é—´çš„å¤å‘ç‡æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ€»ä½“è€Œè¨€ï¼Œè¯¥åˆ†æè¡¨æ˜ï¼ŒCS çš„å¤å‘ç‡å’Œå¤±ç¦ç‡ä¸å…¶ä»–æ²»ç–—æ–¹å¼ç›¸å½“ã€‚ç„¶è€Œï¼Œè¿™å¯èƒ½ä¼šä»¥æ›´å¤šçš„æœ¯åç–¼ç—›å’Œæ›´é•¿çš„æ„ˆåˆæ—¶é—´ä¸ºä»£ä»·ã€‚éœ€è¦å¯¹ CS å’Œå…¶ä»–æ–¹å¼è¿›è¡Œè¿›ä¸€æ­¥çš„æ¯”è¾ƒç ”ç©¶ã€‚", "keywords_zh": "è‚›è‚ ç˜˜ã€ç»“ç›´è‚ æ‰‹æœ¯ã€éšè…ºç˜˜ã€åˆ‡å‰²æŒ‚çº¿ã€è‚›ç˜˜", "keywords_en": "Anorectal fistula, Colorectal surgery, Cryptoglandular fistula, Cutting seton, Fistula-in-ano", "link": "https://pubmed.ncbi.nlm.nih.gov/38091125/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 13 Dec 2023"}, {"id": "38018554", "title_en": "FISTULIZING PERIANAL CROHN'S DISEASE: IS THE PATIENT'S SEX A BURDEN? A SYSTEMATIC REVIEW", "title_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ï¼šæ‚£è€…çš„æ€§åˆ«æ˜¯ä¸€ç§è´Ÿæ‹…å—ï¼Ÿç³»ç»Ÿå›é¡¾", "authors": "Odery Ramos JÃºnior", "abstract_en": "**Background:** Fistulizing perianal Crohn's disease poses a treatment challenge, and researchers postulate that this phenotype in young male patients could have a worst outcome.\n\n**Objective:** Thus, the aim of this study was to assess whether sex influences the response to treatment for these patients.\n\n**Methods:** This systematic review (PROSPERO CRD42022319629) was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. We selected articles published in English, Spanish, Portuguese, and Italian between 2010 and 2020 in the PubMed and Science Direct databases. According to the PICO acronym, prospective studies in patients older than 18 years with the objective of treating fistulizing perianal Crohn's disease were selected. Studies in pediatric populations, retrospective, without treatment objectives, and that included only rectovaginal fistulas or a single sex were excluded. Study quality was assessed using the Cochrane risk of bias tool and Newcastle-Ottawa scale.\n\n**Results:** Of the 1887 articles found, 33 were included. Most studies used anti-TNF drugs as treatment (n=11). Ten studies had subgroup analyses; of them, the two studies reporting sex differences used infliximab and adalimumab as treatment and showed that women had a longer fistula closure time than men.\n\n**Conclusion:** This systematic review showed that few data corroborate the difference between sexes in the treatment of fistulizing perianal Crohn's disease, possibly having a greater relationship with the phenotype. However, considering the lack of results, further studies with this objective and with standardization of fistulas and response assessment methods are needed.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ç»™æ²»ç–—å¸¦æ¥äº†æŒ‘æˆ˜ï¼Œç ”ç©¶äººå‘˜æ¨æµ‹ï¼Œå¹´è½»ç”·æ€§æ‚£è€…çš„è¿™ç§è¡¨å‹å¯èƒ½ä¼šäº§ç”Ÿæœ€ç³Ÿç³•çš„ç»“æœã€‚\n\n**ç›®çš„ï¼š** å› æ­¤ï¼Œæœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è¯„ä¼°æ€§åˆ«æ˜¯å¦å½±å“è¿™äº›æ‚£è€…å¯¹æ²»ç–—çš„ååº”ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç³»ç»Ÿè¯„ä»·ï¼ˆPROSPERO CRD42022319629ï¼‰æ˜¯æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æåè®®çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®è¿›è¡Œçš„ã€‚æˆ‘ä»¬é€‰æ‹©äº† 2010 å¹´è‡³ 2020 å¹´é—´åœ¨ PubMed å’Œ Science Direct æ•°æ®åº“ä¸­ä»¥è‹±è¯­ã€è¥¿ç­ç‰™è¯­ã€è‘¡è„ç‰™è¯­å’Œæ„å¤§åˆ©è¯­å‘è¡¨çš„æ–‡ç« ã€‚æ ¹æ® PICO ç¼©å†™ï¼Œé€‰æ‹©äº†é’ˆå¯¹ 18 å²ä»¥ä¸Šæ‚£è€…çš„å‰ç»æ€§ç ”ç©¶ï¼Œç›®çš„æ˜¯æ²»ç–—è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ã€‚å¯¹å„¿ç§‘äººç¾¤è¿›è¡Œçš„å›é¡¾æ€§ç ”ç©¶ã€æ— æ²»ç–—ç›®æ ‡ä¸”ä»…åŒ…æ‹¬ç›´è‚ é˜´é“ç˜˜æˆ–å•ä¸€æ€§åˆ«çš„ç ”ç©¶è¢«æ’é™¤åœ¨å¤–ã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·å’Œçº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨è¯„ä¼°ç ”ç©¶è´¨é‡ã€‚\n\n**ç»“æœï¼š** åœ¨æ‰¾åˆ°çš„ 1887 ç¯‡æ–‡ç« ä¸­ï¼Œæ”¶å½•äº† 33 ç¯‡ã€‚å¤§å¤šæ•°ç ”ç©¶ä½¿ç”¨æŠ— TNF è¯ç‰©ä½œä¸ºæ²»ç–—ï¼ˆn=11ï¼‰ã€‚åé¡¹ç ”ç©¶è¿›è¡Œäº†äºšç»„åˆ†æï¼›å…¶ä¸­ï¼ŒæŠ¥å‘Šæ€§åˆ«å·®å¼‚çš„ä¸¤é¡¹ç ”ç©¶ä½¿ç”¨è‹±å¤«åˆ©æ˜”å•æŠ—å’Œé˜¿è¾¾æœ¨å•æŠ—ä½œä¸ºæ²»ç–—ï¼Œå¹¶è¡¨æ˜å¥³æ€§çš„ç˜˜ç®¡é—­åˆæ—¶é—´æ¯”ç”·æ€§æ›´é•¿ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç³»ç»Ÿè¯„ä»·è¡¨æ˜ï¼Œå¾ˆå°‘æœ‰æ•°æ®è¯å®è‚›å‘¨å…‹ç½—æ©ç—…æ²»ç–—ä¸­çš„æ€§åˆ«å·®å¼‚ï¼Œå¯èƒ½ä¸è¡¨å‹æœ‰æ›´å¤§çš„å…³ç³»ã€‚ç„¶è€Œï¼Œè€ƒè™‘åˆ°ç¼ºä¹ç»“æœï¼Œéœ€è¦ä¸ºæ­¤ç›®æ ‡ä»¥åŠç˜˜ç®¡æ ‡å‡†åŒ–å’Œååº”è¯„ä¼°æ–¹æ³•è¿›è¡Œè¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/38018554/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 29 Nov 2023"}, {"id": "37933849", "title_en": "Pharmacological Therapies for the Management of Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "æ²»ç–—ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…çš„è¯ç‰©ç–—æ³•ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Vipul Jairath", "abstract_en": "**Background:** Fistulas are a debilitating complication of Crohn's disease [CD]. We conducted a systematic review to assess the efficacy of medical therapies for fistulizing CD.\n\n**Methods:** MEDLINE, Embase, and CENTRAL were searched on May 26, 2022, for randomized controlled trials [RCTs] of pharmacological therapy in adults with fistulizing CD. The primary outcome was induction and maintenance of fistula response. Pooled risk ratios [RRs] and 95% confidence intervals [CIs] were calculated. GRADE was used to assess the certainty of evidence.\n\n**Results:** Thirty-eight RCTs were included. Nineteen trials [50%] exclusively involved perianal fistula. The remaining studies included some participants with non-perianal fistula. Pooled RRs for anti-tumour necrosis factor [TNF] agents were not statistically significant for induction [RR 1.36, 95% CI 0.97-1.91] or maintenance of fistula response [RR 1.48, 95% CI 0.97-2.27]. However, in a sensitivity analysis of studies with fistula response as the primary outcome, anti-TNFs were superior to placebo for induction [RR 1.94, 95% CI 1.10-3.41] and maintenance [RR 1.88, 95% CI 1.23-2.88] of fistula response. Oral small molecules [RR 2.56, 95% CI 1.18-5.53] and mesenchymal stem cell [MSC] therapy [RR 1.26, 95% CI 1.01-1.57] were effective for induction of fistula response. Ustekinumab was associated with maintenance of fistula response [RR 1.80, 95% CI 1.04-3.11]. Vedolizumab was not superior to placebo. The certainty of evidence ranged from very low to moderate.\n\n**Conclusion:** Very low- to moderate-certainty evidence suggests that anti-TNF therapy, oral small molecules, ustekinumab, and MSCs are effective for perianal fistulizing CD. Dedicated fistula studies evaluating biologics and small molecules are needed.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç˜˜ç®¡æ˜¯å…‹ç½—æ©ç—… [CD] çš„ä¸€ç§ä½¿äººè¡°å¼±çš„å¹¶å‘ç—‡ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¯„ä¼°å†…ç§‘æ²»ç–—å¯¹ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…çš„ç–—æ•ˆã€‚\n\n**æ–¹æ³•ï¼š** MEDLINEã€Embase å’Œ CENTRAL äº 2022 å¹´ 5 æœˆ 26 æ—¥æ£€ç´¢äº†æˆäººç˜˜ç®¡æ€§ CD è¯ç‰©æ²»ç–—çš„éšæœºå¯¹ç…§è¯•éªŒ [RCT]ã€‚ä¸»è¦ç»“æœæ˜¯ç˜˜ç®¡ååº”çš„è¯±å¯¼å’Œç»´æŒã€‚è®¡ç®—æ±‡æ€»é£é™©æ¯” [RRs] å’Œ 95% ç½®ä¿¡åŒºé—´ [CIs]ã€‚ GRADE ç”¨äºè¯„ä¼°è¯æ®çš„ç¡®å®šæ€§ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 38 é¡¹éšæœºå¯¹ç…§è¯•éªŒã€‚åä¹é¡¹è¯•éªŒ [50%] ä¸“é—¨æ¶‰åŠè‚›å‘¨ç˜˜ã€‚å…¶ä½™çš„ç ”ç©¶åŒ…æ‹¬ä¸€äº›æ‚£æœ‰éè‚›å‘¨ç˜˜çš„å‚ä¸è€…ã€‚æŠ—è‚¿ç˜¤åæ­»å› å­ [TNF] è¯ç‰©çš„æ±‡æ€» RR å¯¹äºè¯±å¯¼ [RR 1.36ï¼Œ95% CI 0.97-1.91] æˆ–ç»´æŒç˜˜ç®¡ååº” [RR 1.48ï¼Œ95% CI 0.97-2.27] æ²¡æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚ç„¶è€Œï¼Œåœ¨ä»¥ç˜˜ç®¡ååº”ä½œä¸ºä¸»è¦ç»“å±€çš„ç ”ç©¶çš„æ•æ„Ÿæ€§åˆ†æä¸­ï¼ŒæŠ—-TNF åœ¨è¯±å¯¼ [RR 1.94ï¼Œ95% CI 1.10-3.41] å’Œç»´æŒ [RR 1.88ï¼Œ95% CI 1.23-2.88] ç˜˜ç®¡ååº”æ–¹é¢ä¼˜äºå®‰æ…°å‰‚ã€‚å£æœå°åˆ†å­[RR 2.56ï¼Œ95% CI 1.18-5.53]å’Œé—´å……è´¨å¹²ç»†èƒ[MSC]æ²»ç–—[RR 1.26ï¼Œ95% CI 1.01-1.57]å¯æœ‰æ•ˆè¯±å¯¼ç˜˜ç®¡ååº”ã€‚ä¹Œå¸å¥´å•æŠ—ä¸ç»´æŒç˜˜ç®¡ååº”ç›¸å…³[RR 1.80ï¼Œ95% CI 1.04-3.11]ã€‚ç»´å¤šç å•æŠ—å¹¶ä¸ä¼˜äºå®‰æ…°å‰‚ã€‚è¯æ®çš„è´¨é‡ä»æä½åˆ°ä¸­ç­‰ã€‚\n\n**ç»“è®ºï¼š** æä½åˆ°ä¸­ç­‰è´¨é‡çš„è¯æ®è¡¨æ˜ï¼ŒæŠ— TNF ç–—æ³•ã€å£æœå°åˆ†å­ã€ä¼˜ç‰¹å…‹å•æŠ—å’Œ MSC å¯¹è‚›å‘¨ç˜˜ç®¡æ€§ CD æœ‰æ•ˆã€‚éœ€è¦ä¸“é—¨è¯„ä¼°ç”Ÿç‰©åˆ¶å‰‚å’Œå°åˆ†å­çš„ç˜˜ç®¡ç ”ç©¶ã€‚", "keywords_zh": "ç”Ÿç‰©ã€ç˜˜ç®¡ã€å¹²ç»†èƒ", "keywords_en": "Biologic, fistula, stem cells", "link": "https://pubmed.ncbi.nlm.nih.gov/37933849/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 07 Nov 2023"}, {"id": "37882975", "title_en": "Comparison of clinical outcomes of anal fistula plug and endoanal advancement flap repair treating the complex anal fistula: a systematic review and meta-analysis", "title_zh": "è‚›ç˜˜å¡ä¸è‚›å†…æ¨è¿›çš®ç“£ä¿®å¤æœ¯æ²»ç–—å¤æ‚æ€§è‚›ç˜˜çš„ä¸´åºŠæ•ˆæœæ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jihua Gao", "abstract_en": "Anal fistula (AF) is a common disease with high prevalence and surgical operations are effective treatments in clinical work. There exist many well-known surgical techniques treating complex anal fistula (CAF), however, none is ideal. To compare the superiority of Anal fistula plug (AFP) and Endoanal advancement flap repair (EAFR) for complex anal fistula. We searched worldwide databases including Pubmed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, VIP, and SinoMed from their inception to March 2023. Studies comparing the outcomes of AFP and EAFR were included according to the PICO principles. The indicators of the healing rate, recurrence rate, wound infection rate, and complication rate, et al. were extracted and compared between different surgical methods. 5 RCTS and 7 non-RCTs were included in the meta-analysis with a total of 847 patients (341 patients conducted with AFP and 506 patients with EAFR). By combining the total effect of the 12 articles, we found that there was a statistical difference reporting the healing rate of AFP 48.3% and EAFR 64.4% treating the CAF (OR 0.68, 95% CI 0.30,1.55, Pâ€‰=â€‰0.03), and EAFR has a better healing rate. However, there was no significant difference in terms of the recurrence rate (OR 1.68, 95% CI 0.80,3.54, Pâ€‰=â€‰0.17), the wound infection rate (OR 1.82, 95% CI 0.95,3.52, Pâ€‰=â€‰0.07), and the complication rate (OR 1.06, 95% CI 0.70,1.61, Pâ€‰=â€‰0.77) either in the 12 articles or in the subgroup. The meta-analysis indicated that the EAFR was superior to AFP in terms of the healing rate treating the CAF, however, there were no significant differences between the two groups when it came to the recurrence rate, the wound infection rate, and the complication rate. EAFR might be one initial treatment for the complex cryptoglandular anal fistulas compared with AFP.", "abstract_zh": "è‚›ç˜˜ï¼ˆAFï¼‰æ˜¯ä¸€ç§å‘ç—…ç‡è¾ƒé«˜çš„å¸¸è§ç—…ï¼Œå¤–ç§‘æ‰‹æœ¯æ˜¯ä¸´åºŠä¸Šæœ‰æ•ˆçš„æ²»ç–—æ–¹æ³•ã€‚å­˜åœ¨è®¸å¤šæ²»ç–—å¤æ‚æ€§è‚›ç˜˜ï¼ˆCAFï¼‰çš„ä¼—æ‰€å‘¨çŸ¥çš„æ‰‹æœ¯æŠ€æœ¯ï¼Œä½†æ²¡æœ‰ä¸€ç§æ˜¯ç†æƒ³çš„ã€‚æ¯”è¾ƒè‚›ç˜˜å¡ï¼ˆAFPï¼‰å’Œè‚›å†…æ¨è¿›çš®ç“£ä¿®å¤æœ¯ï¼ˆEAFRï¼‰æ²»ç–—å¤æ‚è‚›ç˜˜çš„ä¼˜è¶Šæ€§ã€‚æˆ‘ä»¬æ£€ç´¢äº†åŒ…æ‹¬ Pubmedã€Embaseã€Cochrane Libraryã€Web of Scienceã€CNKIã€ä¸‡æ–¹ã€VIP å’Œ SinMed åœ¨å†…çš„å…¨çƒæ•°æ®åº“ï¼Œä»å»ºåº“åˆ° 2023 å¹´ 3 æœˆã€‚æ ¹æ® PICO åŸåˆ™çº³å…¥äº†æ¯”è¾ƒ AFP å’Œ EAFR ç»“æœçš„ç ”ç©¶ã€‚æ„ˆåˆç‡ã€å¤å‘ç‡ã€ä¼¤å£æ„ŸæŸ“ç‡ã€å¹¶å‘ç—‡ç‡ç­‰æŒ‡æ ‡ã€‚æå–å¹¶æ¯”è¾ƒä¸åŒæ‰‹æœ¯æ–¹æ³•ä¹‹é—´çš„å·®å¼‚ã€‚èŸèƒåˆ†æä¸­çº³å…¥äº† 5 é¡¹éšæœºå¯¹ç…§è¯•éªŒå’Œ 7 é¡¹ééšæœºå¯¹ç…§è¯•éªŒï¼Œå…±çº³å…¥ 847 åæ‚£è€…ï¼ˆå…¶ä¸­ 341 åæ‚£è€…æ¥å— AFP æ²»ç–—ï¼Œ506 åæ‚£è€…æ¥å— EAFRï¼‰ã€‚ç»¼åˆ12ç¯‡æ–‡ç« çš„æ€»æ•ˆæœï¼Œæˆ‘ä»¬å‘ç°AFP 48.3%å’ŒEAFR 64.4%æ²»ç–—CAFçš„æ²»æ„ˆç‡å­˜åœ¨ç»Ÿè®¡å­¦å·®å¼‚ï¼ˆOR 0.68ï¼Œ95% CI 0.30ï¼Œ1.55ï¼ŒPâ€‰=â€‰0.03ï¼‰ï¼Œä¸”EAFRçš„æ²»æ„ˆç‡æ›´å¥½ã€‚ç„¶è€Œï¼Œå¤å‘ç‡ï¼ˆOR 1.68ï¼Œ95% CI 0.80,3.54ï¼ŒPâ€‰=â€‰0.17ï¼‰ã€ä¼¤å£æ„ŸæŸ“ç‡ï¼ˆOR 1.82ï¼Œ95% CI 0.95,3.52ï¼ŒPâ€‰=â€‰0.07ï¼‰å’Œå¹¶å‘ç—‡å‘ç”Ÿç‡ï¼ˆOR 1.06ï¼Œ95% CIï¼‰ä¹‹é—´æ— æ˜¾ç€å·®å¼‚ã€‚ 0.70,1.61, Pâ€‰=â€‰0.77) åœ¨ 12 ç¯‡æ–‡ç« æˆ–å­ç»„ä¸­ã€‚ Metaåˆ†ææ˜¾ç¤ºï¼ŒEAFRæ²»ç–—CAFçš„æ„ˆåˆç‡ä¼˜äºAFPï¼Œä½†åœ¨å¤å‘ç‡ã€ä¼¤å£æ„ŸæŸ“ç‡å’Œå¹¶å‘ç—‡å‘ç”Ÿç‡æ–¹é¢ï¼Œä¸¤ç»„ä¹‹é—´æ— æ˜¾ç€å·®å¼‚ã€‚ä¸ AFP ç›¸æ¯”ï¼ŒEAFR å¯èƒ½æ˜¯å¤æ‚éšè…ºè‚›ç˜˜çš„åˆå§‹æ²»ç–—æ–¹æ³•ä¹‹ä¸€ã€‚", "keywords_zh": "è‚›ç˜˜å¡ã€å¤æ‚è‚›ç˜˜ã€è‚›é—¨å†…æ¨è¿›çš®ç“£ä¿®å¤ã€Meta åˆ†æ", "keywords_en": "Anal fistula plug, Complex anal fistula, Endoanal advancement flap repair, Meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/37882975/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 26 Oct 2023"}, {"id": "37737881", "title_en": "Efficacy and safety of 13 surgical techniques for the treatment of complex anal fistula, non-Crohn CAF: a systematic review and network meta-analysis", "title_zh": "13ç§æ‰‹æœ¯æŠ€æœ¯æ²»ç–—å¤æ‚æ€§è‚›ç˜˜ã€éå…‹ç½—æ©CAFçš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æ", "authors": "Maosheng Tian", "abstract_en": "**Background:** Considering the difficulty of treating complex anal fistula (CAF), various surgical techniques exist in clinical work. However, none are ideal. Evidence on the efficacy and safety of different surgical treatments is scarce. The authors aimed to compare the outcomes of the 13 surgical techniques and tried to find the best surgical method for treating CAF.\n\n**Materials And Methods:** The authors searched worldwide databases, including Pubmed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, VIP, and SinoMed, from inception to March 2023. All randomized controlled trials comparing the outcomes of 13 surgical techniques were included according to the PICO principles. The indicators of the cure rate, the recurrence rate, the complication rate, the operating time, the postoperative pain on day 1 (VAS), and the postoperative incontinence in month 1 (Wexner) were extracted and analyzed using STATA software 15.1, Review Manager 5.4, and GeMTC14.3.\n\n**Results:** Twenty-eight randomized controlled trials with a total of 2274 patients were included in the network meta-analysis. There was no statistically significant difference in the comparison among any surgical interventions in terms of the cure rate ( P >0.05 Table 2) and recurrence rate ( P >0.05 Table 3). However, in terms of complication rate, fistulectomy was lower than FPS (Median: 0.14; 95% CI: 0.02-0.70) or fistulotomy (Median: 0.09; 95% CI: 0.01-0.55), and fistulotomy was lower than EAFR (Median: 0.24; 95% CI: 0.05-0.84), LIFT (Median: 0.17; 95% CI: 0.02-0.66) or LIFT-EAFR (Median: 0.11; 95% CI: 0.01-0.69) ( P >0.05 Table 4). The surface estimated the advantages and disadvantages under the cumulative ranking (SUCRA). The ranking results indicated that fistulectomy might have the lowest complication rate (SUCRA=7.9%). Because the network results of the operating time, the postoperative pain, and the postoperative incontinence contained no closed loops, the results of their probability ranking could only be referenced, demonstrating that fistulectomy might have the shortest operating time (SUCRA=23.4%), video-assisted modified ligation of the intersphincteric fistula tract (VAMLIFT) might have the lowest postoperative pain on day 1 (VAS) (SUCRA=0.4%) and LIFT might have the lowest postoperative incontinence in month 1(Wexner) (SUCRA=16.2%).\n\n**Conclusion:** Fistulectomy might have the lowest complication rate, which might be the relatively superior surgical technique for treating CAF.", "abstract_zh": "**èƒŒæ™¯ï¼š** è€ƒè™‘åˆ°å¤æ‚æ€§è‚›ç˜˜ï¼ˆCAFï¼‰æ²»ç–—çš„éš¾åº¦ï¼Œä¸´åºŠå·¥ä½œä¸­å­˜åœ¨å¤šç§æ‰‹æœ¯æŠ€æœ¯ã€‚ç„¶è€Œï¼Œæ²¡æœ‰ä¸€ä¸ªæ˜¯ç†æƒ³çš„ã€‚å…³äºä¸åŒæ‰‹æœ¯æ²»ç–—çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§çš„è¯æ®å¾ˆå°‘ã€‚ä½œè€…æ—¨åœ¨æ¯”è¾ƒ 13 ç§æ‰‹æœ¯æŠ€æœ¯çš„ç»“æœï¼Œå¹¶è¯•å›¾æ‰¾åˆ°æ²»ç–— CAF çš„æœ€ä½³æ‰‹æœ¯æ–¹æ³•ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** ä½œè€…æ£€ç´¢äº†å…¨çƒæ•°æ®åº“ï¼ŒåŒ…æ‹¬Pubmedã€Embaseã€Cochrane Libraryã€Web of Scienceã€CNKIã€ä¸‡æ–¹ã€ç»´æ™®å’ŒSinoMedï¼Œä»å»ºåº“åˆ°2023å¹´3æœˆã€‚æ ¹æ®PICOåŸåˆ™çº³å…¥äº†æ‰€æœ‰æ¯”è¾ƒ13ç§æ‰‹æœ¯æŠ€æœ¯ç»“æœçš„éšæœºå¯¹ç…§è¯•éªŒã€‚é‡‡ç”¨STATAè½¯ä»¶15.1ã€Review Manager 5.4ã€GeMTC14.3æå–æ²»æ„ˆç‡ã€å¤å‘ç‡ã€å¹¶å‘ç—‡ç‡ã€æ‰‹æœ¯æ—¶é—´ã€æœ¯åç¬¬1å¤©ç–¼ç—›ï¼ˆVASï¼‰ã€æœ¯åç¬¬1ä¸ªæœˆå¤±ç¦ï¼ˆWexnerï¼‰ç­‰æŒ‡æ ‡å¹¶è¿›è¡Œåˆ†æã€‚\n\n**ç»“æœï¼š** ç½‘ç»œèŸèƒåˆ†æçº³å…¥äº† 28 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œå…±è®¡ 2274 åæ‚£è€…ã€‚å„æ‰‹æœ¯å¹²é¢„æªæ–½çš„æ²»æ„ˆç‡ï¼ˆP>0.05ï¼Œè¡¨2ï¼‰å’Œå¤å‘ç‡ï¼ˆP>0.05ï¼Œè¡¨3ï¼‰æ¯”è¾ƒï¼Œå·®å¼‚æ— ç»Ÿè®¡å­¦æ„ä¹‰ã€‚ç„¶è€Œï¼Œå°±å¹¶å‘ç—‡å‘ç”Ÿç‡è€Œè¨€ï¼Œç˜˜ç®¡åˆ‡é™¤æœ¯ä½äºFPSï¼ˆä¸­ä½æ•°ï¼š0.14ï¼›95% CIï¼š0.02-0.70ï¼‰æˆ–ç˜˜ç®¡åˆ‡å¼€æœ¯ï¼ˆä¸­ä½æ•°ï¼š0.09ï¼›95% CIï¼š0.01-0.55ï¼‰ï¼Œç˜˜ç®¡åˆ‡å¼€æœ¯ä½äºEAFRï¼ˆä¸­ä½æ•°ï¼š0.24ï¼›95% CIï¼š0.05-0.84ï¼‰ï¼Œ LIFTï¼ˆä¸­ä½æ•°ï¼š0.17ï¼›95% CIï¼š0.02-0.66ï¼‰æˆ– LIFT-EAFRï¼ˆä¸­ä½æ•°ï¼š0.11ï¼›95% CIï¼š0.01-0.69ï¼‰ï¼ˆP > 0.05 è¡¨ 4ï¼‰ã€‚è¡¨é¢ä¼°è®¡äº†ç´¯ç§¯æ’åï¼ˆSUCRAï¼‰ä¸‹çš„ä¼˜ç¼ºç‚¹ã€‚æ’åç»“æœè¡¨æ˜ï¼Œç˜˜ç®¡åˆ‡é™¤æœ¯çš„å¹¶å‘ç—‡å‘ç”Ÿç‡å¯èƒ½æœ€ä½ï¼ˆSUCRA=7.9%ï¼‰ã€‚ç”±äºæ‰‹æœ¯æ—¶é—´ã€æœ¯åç–¼ç—›å’Œæœ¯åå¤±ç¦çš„ç½‘ç»œç»“æœä¸åŒ…å«é—­ç¯ï¼Œå› æ­¤å®ƒä»¬çš„æ¦‚ç‡æ’åºç»“æœåªèƒ½ä½œä¸ºå‚è€ƒï¼Œè¯æ˜ç˜˜ç®¡åˆ‡é™¤æœ¯å¯èƒ½å…·æœ‰æœ€çŸ­çš„æ‰‹æœ¯æ—¶é—´ï¼ˆSUCRA=23.4%ï¼‰ï¼Œè§†é¢‘è¾…åŠ©æ‹¬çº¦è‚Œé—´ç˜˜é“ç»“æ‰æœ¯ï¼ˆVAMLIFTï¼‰å¯èƒ½å…·æœ‰æœ€ä½çš„æœ¯åç¬¬1å¤©ç–¼ç—›ï¼ˆVASï¼‰ï¼ˆSUCRA=0.4%ï¼‰ï¼ŒLIFTå¯èƒ½å…·æœ‰æœ€ä½çš„æœ¯åç¬¬1å¤©ç–¼ç—›ï¼ˆVASï¼‰ï¼ˆSUCRA=0.4%ï¼‰ï¼Œè€ŒLIFTå¯èƒ½å…·æœ‰æœ€ä½çš„æ‰‹æœ¯æ—¶é—´ã€‚ç¬¬ 1 ä¸ªæœˆæœ¯åå¤±ç¦ (Wexner) (SUCRA=16.2%)ã€‚\n\n**ç»“è®ºï¼š** ç˜˜ç®¡åˆ‡é™¤æœ¯çš„å¹¶å‘ç—‡å‘ç”Ÿç‡å¯èƒ½æœ€ä½ï¼Œå¯èƒ½æ˜¯æ²»ç–— CAF ç›¸å¯¹è¾ƒå¥½çš„æ‰‹æœ¯æŠ€æœ¯ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/37737881/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 22 Sep 2023"}, {"id": "37707561", "title_en": "Comparing the efficacy and safety of different thread-drawing surgery method for treating high complex anal fistula: a systematic review and network meta-analysis", "title_zh": "ä¸åŒæ‹”çº¿æ‰‹æœ¯æ–¹æ³•æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æ", "authors": "Guofeng Li", "abstract_en": "**Purpose:** To evaluate the effect of different surgical methods in the treatment of high complex anal fistula by systematic review and network meta-analysis.\n\n**Methods:** Randomized controlled trials that met the inclusion criteria in PubMed, Cochrane Library, Embase, Web of Science, CBM, CNKI, WANFANG DATA, VIP were searched from the date of database construction to May 23, 2023.\n\n**Results:** Among the 48 randomized controlled trials (RCTs), 4205 patients were included in the network meta-analysis. Incision thread-drawing counter-drainage procedure (ITCP) in improving the effective rate, the cure rate; reduce the recurrence rate, reduce the anal canal damage has a huge advantage. Directional line-hanging method (DLM) is optimal for safety and postoperative pain relief. Directional line-hanging method (ITSS) protect the optimal anal function after surgery. Sphincter preserving thread-hanging method (SPTM) has a significant advantage in accelerating wound healing time. Main tube incision combined with thread-hanging branch tube drainage (MIBD) is second only to incision thread-drawing counter-drainage procedure (ITCP) in improving effective rate, cure rate, reducing recurrence rate and reduce complication rate.\n\n**Conclusion:** In general, different thread-drawing surgery methods have good clinical effect for the treatment of high complex anal fistula. In general, these methods provide evidence-based medical evidence for early treatment in terms of improving clinical efficacy, relieving anal pain and reducing wound healing time. However, there are differences in the number of included literature studies, and further verification by large-sample, high-quality, multicenter RCTS is still needed in the next stage.", "abstract_zh": "**Purposeï¼š** é€šè¿‡ç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æè¯„ä»·ä¸åŒæ‰‹æœ¯æ–¹æ³•æ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜çš„æ•ˆæœã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢å»ºåº“ä¹‹æ—¥è‡³2023å¹´5æœˆ23æ—¥æœŸé—´åœ¨PubMedã€Cochraneå›¾ä¹¦é¦†ã€Embaseã€Web of Scienceã€CBMã€CNKIã€ä¸‡æ–¹æ•°æ®ã€VIPä¸­ç¬¦åˆçº³å…¥æ ‡å‡†çš„éšæœºå¯¹ç…§è¯•éªŒã€‚\n\n**ç»“æœï¼š** åœ¨ 48 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT) ä¸­ï¼Œç½‘ç»œèŸèƒåˆ†æçº³å…¥äº† 4205 åæ‚£è€…ã€‚åˆ‡å¼€æ‹‰çº¿åå¼•æµæ‰‹æœ¯ï¼ˆITCPï¼‰åœ¨æé«˜æœ‰æ•ˆç‡ã€æ²»æ„ˆç‡æ–¹é¢ï¼›å¯¹é™ä½å¤å‘ç‡ã€å‡å°‘è‚›ç®¡æŸä¼¤æœ‰ç€å·¨å¤§çš„ä¼˜åŠ¿ã€‚å®šå‘æŒ‚çº¿æ³• (DLM) æ˜¯å®‰å…¨æ€§å’Œæœ¯åç–¼ç—›ç¼“è§£çš„æœ€ä½³é€‰æ‹©ã€‚å®šå‘æŒ‚çº¿æ³•ï¼ˆITSSï¼‰å¯ä¿æŠ¤æœ¯åæœ€ä½³è‚›é—¨åŠŸèƒ½ã€‚ä¿è‚›æŒ‚çº¿æ³•ï¼ˆSPTMï¼‰åœ¨åŠ å¿«ä¼¤å£æ„ˆåˆæ—¶é—´æ–¹é¢å…·æœ‰æ˜¾ç€ä¼˜åŠ¿ã€‚ä¸»ç®¡åˆ‡å¼€è”åˆæŒ‚çº¿æ”¯ç®¡å¼•æµæœ¯ï¼ˆMIBDï¼‰åœ¨æé«˜æœ‰æ•ˆç‡ã€æ²»æ„ˆç‡ã€é™ä½å¤å‘ç‡ã€é™ä½å¹¶å‘ç—‡ç‡æ–¹é¢ä»…æ¬¡äºåˆ‡å¼€æŒ‚çº¿åå¼•æµæ‰‹æœ¯ï¼ˆITCPï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ€»çš„æ¥è¯´ï¼Œä¸åŒçš„æ‹”çº¿æ‰‹æœ¯æ–¹æ³•å¯¹äºæ²»ç–—é«˜ä½å¤æ‚æ€§è‚›ç˜˜éƒ½æœ‰è‰¯å¥½çš„ä¸´åºŠæ•ˆæœã€‚æ€»çš„æ¥è¯´ï¼Œè¿™äº›æ–¹æ³•åœ¨æé«˜ä¸´åºŠç–—æ•ˆã€ç¼“è§£è‚›é—¨ç–¼ç—›ã€ç¼©çŸ­ä¼¤å£æ„ˆåˆæ—¶é—´ç­‰æ–¹é¢ä¸ºæ—©æœŸæ²»ç–—æä¾›äº†å¾ªè¯åŒ»å­¦è¯æ®ã€‚ä½†çº³å…¥æ–‡çŒ®ç ”ç©¶æ•°é‡å­˜åœ¨å·®å¼‚ï¼Œä¸‹ä¸€é˜¶æ®µä»éœ€å¤§æ ·æœ¬ã€é«˜è´¨é‡ã€å¤šä¸­å¿ƒRCTSè¿›ä¸€æ­¥éªŒè¯ã€‚", "keywords_zh": "é«˜ä½å¤æ‚æ€§è‚›ç˜˜ ç½‘ç»œèŸèƒåˆ†æ ç³»ç»Ÿè¯„ä»· æŒ‚çº¿æ‰‹æœ¯æ–¹æ³•", "keywords_en": "High complex anal fistula, Network meta-analysis, Systematic review, Thread-drawing surgery method", "link": "https://pubmed.ncbi.nlm.nih.gov/37707561/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 14 Sep 2023"}, {"id": "37704476", "title_en": "Risk factors for anastomotic stenosis after radical resection of rectal cancer: A systematic review and meta-analysis", "title_zh": "ç›´è‚ ç™Œæ ¹æ²»æœ¯åå»åˆå£ç‹­çª„çš„å±é™©å› ç´ ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Kun Qian", "abstract_en": "Radical resection of rectal cancer is a safe and effective treatment, but there remain several complications related to anastomosis. We aimed to assess the risk factors and incidence of rectal anastomotic stenosis (AS) after rectal cancer resection. We conducted a systematic review and meta-analysis after searching PubMed, Embase, Web of Science, and Medline databases from inception until May 2023. Data are reported as the combined odds ratio (OR) for categorical variables and the weighted mean difference (WMD) for continuous variables. Six hundred and fifty-nine studies were retrieved, nine (3031 patients) of which were included in the meta-analysis. Young age (WMDÂ =Â -3.09, PÂ =Â 0.0002), male sex (ORÂ =Â 1.53, PÂ =Â 0.0002), smoking (ORÂ =Â 1.54, PÂ =Â 0.009), radiotherapy (ORÂ =Â 2.34, PÂ =Â 0.0002), protective stoma (ORÂ =Â 2.88, PÂ =Â 0.007), intersphincteric resection surgery (ORÂ =Â 6.28, PÂ =Â 0.05), anastomotic fistula (ORÂ =Â 3.72, PÂ =Â 0.003), and anastomotic distance (WMDÂ =Â -3.11, PÂ =Â 0.0006) were identified as factors that increased the risk of AS, while staple (ORÂ =Â 0.39, PÂ <Â 0.001) was a protective factor. The incidence of AS after rectal cancer resection was approximately 17% (95% CI: 13%-21%). We identified eight risk factors and one protective factor associated with AS after rectal cancer resection. These factors may be combined in future studies to develop a more comprehensive and accurate prediction model related to AS after rectal cancer resection.", "abstract_zh": "ç›´è‚ ç™Œæ ¹æ²»æ€§åˆ‡é™¤æœ¯æ˜¯ä¸€ç§å®‰å…¨æœ‰æ•ˆçš„æ²»ç–—æ–¹æ³•ï¼Œä½†ä»ç„¶å­˜åœ¨ä¸€äº›ä¸å»åˆç›¸å…³çš„å¹¶å‘ç—‡ã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯è¯„ä¼°ç›´è‚ ç™Œåˆ‡é™¤æœ¯åç›´è‚ å»åˆå£ç‹­çª„ï¼ˆASï¼‰çš„å±é™©å› ç´ å’Œå‘ç”Ÿç‡ã€‚æˆ‘ä»¬åœ¨æœç´¢ PubMedã€Embaseã€Web of Science å’Œ Medline æ•°æ®åº“ï¼ˆä»æˆç«‹åˆ° 2023 å¹´ 5 æœˆï¼‰åè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚æ•°æ®æŠ¥å‘Šä¸ºåˆ†ç±»å˜é‡çš„ç»„åˆæ¯”å€¼æ¯” (OR) å’Œè¿ç»­å˜é‡çš„åŠ æƒå¹³å‡å·® (WMD)ã€‚æ£€ç´¢åˆ° 659 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­ 9 é¡¹ï¼ˆ3031 åæ‚£è€…ï¼‰çº³å…¥èŸèƒåˆ†æã€‚å¹´è½»ï¼ˆWMD=-3.09ï¼ŒP=0.0002ï¼‰ï¼Œç”·æ€§ï¼ˆOR=1.53ï¼ŒP=0.0002ï¼‰ï¼Œå¸çƒŸï¼ˆOR=1.54ï¼ŒP=0.009ï¼‰ï¼Œæ”¾ç–—ï¼ˆOR=2.34ï¼ŒP=0.0002ï¼‰ï¼Œä¿æŠ¤æ€§é€ å£ï¼ˆOR=2.88ï¼Œ P = 0.007ï¼‰ã€æ‹¬çº¦è‚Œé—´åˆ‡é™¤æ‰‹æœ¯ï¼ˆOR = 6.28ï¼ŒP = 0.05ï¼‰ã€å»åˆå£ç˜˜ï¼ˆOR = 3.72ï¼ŒP = 0.003ï¼‰å’Œå»åˆè·ç¦»ï¼ˆWMD = -3.11ï¼ŒP = 0.0006ï¼‰è¢«ç¡®å®šä¸ºå¢åŠ  AS é£é™©çš„å› ç´ ï¼Œè€Œå»åˆé’‰ï¼ˆOR = 0.39ï¼ŒP < 0.001ï¼‰æ˜¯ä¸€ä¸ªä¿æŠ¤å› ç´ ã€‚ç›´è‚ ç™Œåˆ‡é™¤æœ¯å AS çš„å‘ç”Ÿç‡çº¦ä¸º 17%ï¼ˆ95% CIï¼š13%-21%ï¼‰ã€‚æˆ‘ä»¬ç¡®å®šäº†ç›´è‚ ç™Œåˆ‡é™¤æœ¯åä¸ AS ç›¸å…³çš„ 8 ä¸ªå±é™©å› ç´ å’Œ 1 ä¸ªä¿æŠ¤å› ç´ ã€‚åœ¨æœªæ¥çš„ç ”ç©¶ä¸­å¯èƒ½ä¼šç»“åˆè¿™äº›å› ç´ ï¼Œå¼€å‘å‡ºä¸ç›´è‚ ç™Œåˆ‡é™¤æœ¯åASç›¸å…³çš„æ›´å…¨é¢ã€æ›´å‡†ç¡®çš„é¢„æµ‹æ¨¡å‹ã€‚", "keywords_zh": "å»åˆå£ç‹­çª„ï¼ŒMetaåˆ†æï¼Œç›´è‚ ç™Œæ ¹æ²»æœ¯", "keywords_en": "Anastomotic stenosis, Meta-analysis, Radical resection of rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/37704476/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 13 Sep 2023"}, {"id": "37608385", "title_en": "Comparative efficacy of oral drugs for chronic radiation proctitis - a systematic review", "title_zh": "å£æœè¯ç‰©æ²»ç–—æ…¢æ€§æ”¾å°„æ€§ç›´è‚ ç‚çš„ç–—æ•ˆæ¯”è¾ƒâ€”â€”ç³»ç»Ÿè¯„ä»·", "authors": "Jinjun Liang", "abstract_en": "**Background:** Chronic radiation proctitis (CRP) is a long-term complication of pelvic radiotherapy that manifests as rectal bleeding, diarrhoea, fistula formation and obstruction. Treatments such as endoscopic argon plasma coagulation, hyperbaric oxygen therapy and rectal topical formalin have imposed a significant medical burden on CRP patients. In contrast, oral therapies offer a more accessible and acceptable option for managing CRP. Here, we conducted a systematic review of the efficacy of oral treatments for CRP to assess their potential as an effective and convenient treatment option for this condition.\n\n**Methods:** We searched the Cochrane Central Register of Controlled Trials, PubMed, Web of Science, China National Knowledge Infrastructure and Chinese VIP in February 2021. We included post-radiotherapy participants with CRP that compared oral medicine alone or in combination with other treatments versus control treatments. The primary outcomes were bleeding, diarrhoea and symptom score. Heterogeneity between studies was checked using Cochrane Q test statistics and I<sup>2</sup> test statistics. The Cochrane risk-of-bias tool was used to assess the quality of the included studies.\n\n**Results:** We included 10 randomised controlled trials (RCTs) and 1 retrospective study with 898 participants. Three placebo-controlled trials evaluated the effects of oral sucralfate on CRP, with meta-analysis showing no significant different with placebo arm. Four trials on TCM demonstrated significant improvement of symptoms, especially for the 3 trials on oral TCM drinks. Retinyl palmitate and high-fibre diet were found to reduce rectal bleeding. The combination of oral pentoxifylline and tocopherol did not significantly change the process of CRP.\n\n**Conclusions:** Our study implies that oral TCM drinks, retinyl palmitate and a high-fiber diet showed significant improvement in CRP symptoms, but not with the combination of oral pentoxifylline and tocopherol. Further multicentre, larger-scale RCTs are needed to confirm the efficacy and safety of these treatments and optimize treatment strategies, ultimately improving the quality of life for patients with CRP.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ…¢æ€§æ”¾å°„æ€§ç›´è‚ ç‚ï¼ˆCRPï¼‰æ˜¯ç›†è…”æ”¾ç–—çš„é•¿æœŸå¹¶å‘ç—‡ï¼Œè¡¨ç°ä¸ºç›´è‚ å‡ºè¡€ã€è…¹æ³»ã€ç˜˜ç®¡å½¢æˆå’Œæ¢—é˜»ã€‚å†…é•œä¸‹æ°©æ°”ç­‰ç¦»å­å‡å›ºã€é«˜å‹æ°§æ²»ç–—å’Œç›´è‚ å±€éƒ¨ç¦å°”é©¬æ—ç­‰æ²»ç–—ç»™CRPæ‚£è€…å¸¦æ¥äº†æ²‰é‡çš„åŒ»ç–—è´Ÿæ‹…ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œå£æœç–—æ³•ä¸ºæ§åˆ¶ CRP æä¾›äº†æ›´å®¹æ˜“è·å¾—å’Œæ¥å—çš„é€‰æ‹©ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬å¯¹å£æœæ²»ç–— CRP çš„ç–—æ•ˆè¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¯„ä¼°å…¶ä½œä¸ºè¿™ç§ç–¾ç—…æœ‰æ•ˆä¸”æ–¹ä¾¿çš„æ²»ç–—é€‰æ‹©çš„æ½œåŠ›ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬äº 2021 å¹´ 2 æœˆæ£€ç´¢äº† Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“ã€PubMedã€Web of Scienceã€ä¸­å›½å›½å®¶çŸ¥è¯†åŸºç¡€è®¾æ–½å’Œä¸­å›½ VIPã€‚æˆ‘ä»¬çº³å…¥äº†æ¥å— CRP çš„æ”¾å°„æ²»ç–—åå‚ä¸è€…ï¼Œå°†å•ç‹¬å£æœè¯ç‰©æˆ–è”åˆå…¶ä»–æ²»ç–—ä¸å¯¹ç…§æ²»ç–—è¿›è¡Œæ¯”è¾ƒã€‚ä¸»è¦ç»“å±€æ˜¯å‡ºè¡€ã€è…¹æ³»å’Œç—‡çŠ¶è¯„åˆ†ã€‚ä½¿ç”¨ Cochrane Q æ£€éªŒç»Ÿè®¡æ•°æ®å’Œ I<sup>2</sup> æ£€éªŒç»Ÿè®¡æ•°æ®æ£€æŸ¥ç ”ç©¶ä¹‹é—´çš„å¼‚è´¨æ€§ã€‚ Cochrane åå€šé£é™©å·¥å…·ç”¨äºè¯„ä¼°çº³å…¥ç ”ç©¶çš„è´¨é‡ã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬çº³å…¥äº† 10 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT) å’Œ 1 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œå…±æœ‰ 898 åå‚ä¸è€…å‚ä¸ã€‚ä¸‰é¡¹å®‰æ…°å‰‚å¯¹ç…§è¯•éªŒè¯„ä¼°äº†å£æœç¡«ç³–é“å¯¹ CRP çš„å½±å“ï¼ŒèŸèƒåˆ†ææ˜¾ç¤ºä¸å®‰æ…°å‰‚ç»„æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ 4é¡¹ä¸­è¯è¯•éªŒæ˜¾ç¤ºç—‡çŠ¶æœ‰æ˜¾ç€æ”¹å–„ï¼Œå°¤å…¶æ˜¯3é¡¹å£æœä¸­è¯é¥®æ–™è¯•éªŒã€‚ç ”ç©¶å‘ç°æ£•æ¦ˆé…¸è§†é»„é…¯å’Œé«˜çº¤ç»´é¥®é£Ÿå¯ä»¥å‡å°‘ç›´è‚ å‡ºè¡€ã€‚å£æœå·±é…®å¯å¯ç¢±å’Œç”Ÿè‚²é…šçš„ç»„åˆå¹¶æ²¡æœ‰æ˜¾ç€æ”¹å˜CRPçš„è¿‡ç¨‹ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç ”ç©¶è¡¨æ˜ï¼Œå£æœä¸­è¯é¥®æ–™ã€æ£•æ¦ˆé…¸è§†é»„é…¯å’Œé«˜çº¤ç»´é¥®é£Ÿå¯ä»¥æ˜¾ç€æ”¹å–„ CRP ç—‡çŠ¶ï¼Œä½†å£æœå·±é…®å¯å¯ç¢±å’Œç”Ÿè‚²é…šçš„ç»„åˆå´æ²¡æœ‰æ˜¾ç€æ”¹å–„ã€‚éœ€è¦è¿›ä¸€æ­¥çš„å¤šä¸­å¿ƒã€æ›´å¤§è§„æ¨¡çš„éšæœºå¯¹ç…§è¯•éªŒæ¥ç¡®è®¤è¿™äº›æ²»ç–—çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ï¼Œå¹¶ä¼˜åŒ–æ²»ç–—ç­–ç•¥ï¼Œæœ€ç»ˆæ”¹å–„ CRP æ‚£è€…çš„ç”Ÿæ´»è´¨é‡ã€‚", "keywords_zh": "æ…¢æ€§æ”¾å°„æ€§ç›´è‚ ç‚ã€è…¹æ³»ã€å£æœæ²»ç–—ã€æ”¾å°„æ¯’æ€§ã€ç›´è‚ å‡ºè¡€", "keywords_en": "Chronic radiation proctitis, Diarrhoea, Oral treatments, Radiation toxicity, Rectal bleeding", "link": "https://pubmed.ncbi.nlm.nih.gov/37608385/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 23 Aug 2023"}, {"id": "37359408", "title_en": "Predictors of outcome in cryptoglandular anal fistula according to magnetic resonance imaging: A systematic review", "title_zh": "æ ¹æ®ç£å…±æŒ¯æˆåƒé¢„æµ‹éšè…ºè‚›ç˜˜çš„ç»“æœï¼šç³»ç»Ÿè¯„ä»·", "authors": "Amirhosein Naseri", "abstract_en": "**Background And Aims:** Anal fistula (AF) with cryptoglandular origin tends to recur, and multiple risk factors are implicated. Recently, some magnetic resonance imaging (MRI) findings with predictive value for disease outcomes have been proposed. These intrinsic anatomic features include those of the AF and its surrounding structures. This study aims to clarify the prognostic role of MRI in AF.\n\n**Methods:** We performed a systematic search of PubMed, Embase, and EBSCO databases. Two independent reviewers conducted the search and screened the articles. We selected studies that used MRI to assess AF and reported its relationship to disease outcome. We extracted data regarding the study design, type of intervention, outcome, MRI-measured items, and their significance.\n\n**Results:** Out of 1230 retrieved articles, 18 were eligible for final inclusion, and a total of 4026 patients were enrolled in the selected studies. For preoperative MRI, the significant items affecting the outcome were the length of the fistula, horseshoe type, presence of multiple tracts, supralevator extension, and apparent diffusion coefficient (ADC) value. Other studies investigated the healing process using postoperative MRI.\n\n**Conclusion:** This review found that MRI can be useful in the management of AF, both preoperatively and postoperatively. Factors, such as fistula length, horseshoe type, presence of multiple tracts, supralevator extension, and ADC value were found to be significantly associated with treatment outcomes. The presence of the fistula tract and the development of new abscesses on postoperative MRI was found to hinder the healing process. Further studies are needed to confirm these findings.", "abstract_zh": "**Background and aimsï¼š** éšè…ºèµ·æºçš„è‚›ç˜˜ï¼ˆAFï¼‰å®¹æ˜“å¤å‘ï¼Œå¹¶ä¸”æ¶‰åŠå¤šç§å±é™©å› ç´ ã€‚æœ€è¿‘ï¼Œæœ‰äººæå‡ºäº†ä¸€äº›å¯¹ç–¾ç—…ç»“æœå…·æœ‰é¢„æµ‹ä»·å€¼çš„ç£å…±æŒ¯æˆåƒï¼ˆMRIï¼‰ç»“æœã€‚è¿™äº›å†…åœ¨çš„è§£å‰–å­¦ç‰¹å¾åŒ…æ‹¬ AF åŠå…¶å‘¨å›´ç»“æ„çš„è§£å‰–å­¦ç‰¹å¾ã€‚æœ¬ç ”ç©¶æ—¨åœ¨é˜æ˜ MRI åœ¨ AF ä¸­çš„é¢„åä½œç”¨ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ PubMedã€Embase å’Œ EBSCO æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚ä¸¤åç‹¬ç«‹å®¡ç¨¿äººè¿›è¡Œäº†æ£€ç´¢å¹¶ç­›é€‰äº†æ–‡ç« ã€‚æˆ‘ä»¬é€‰æ‹©äº†ä½¿ç”¨ MRI è¯„ä¼° AF çš„ç ”ç©¶ï¼Œå¹¶æŠ¥å‘Šäº†å…¶ä¸ç–¾ç—…ç»“æœçš„å…³ç³»ã€‚æˆ‘ä»¬æå–äº†æœ‰å…³ç ”ç©¶è®¾è®¡ã€å¹²é¢„ç±»å‹ã€ç»“æœã€MRI æµ‹é‡é¡¹ç›®åŠå…¶æ„ä¹‰çš„æ•°æ®ã€‚\n\n**ç»“æœï¼š** åœ¨ 1230 ç¯‡æ£€ç´¢åˆ°çš„æ–‡ç« ä¸­ï¼Œæœ‰ 18 ç¯‡ç¬¦åˆæœ€ç»ˆçº³å…¥æ¡ä»¶ï¼Œå…±æœ‰ 4026 åæ‚£è€…çº³å…¥æ‰€é€‰ç ”ç©¶ã€‚å¯¹äºæœ¯å‰MRIï¼Œå½±å“ç»“æœçš„é‡è¦é¡¹ç›®æ˜¯ç˜˜ç®¡é•¿åº¦ã€é©¬è¹„å½¢ã€æ˜¯å¦å­˜åœ¨å¤šæŸã€æè‚Œä¸Šå»¶ä¼¸å’Œè¡¨è§‚æ‰©æ•£ç³»æ•°ï¼ˆADCï¼‰å€¼ã€‚å…¶ä»–ç ”ç©¶ä½¿ç”¨æœ¯å MRI æ¥ç ”ç©¶æ„ˆåˆè¿‡ç¨‹ã€‚\n\n**ç»“è®ºï¼š** æœ¬ç»¼è¿°å‘ç° MRI å¯ç”¨äºæœ¯å‰å’Œæœ¯åæˆ¿é¢¤çš„æ²»ç–—ã€‚ç ”ç©¶å‘ç°ï¼Œç˜˜ç®¡é•¿åº¦ã€é©¬è¹„å½¢ç±»å‹ã€å¤šæŸç˜˜ç®¡çš„å­˜åœ¨ã€æè‚Œä¸Šå»¶ä¼¸å’Œ ADC å€¼ç­‰å› ç´ ä¸æ²»ç–—ç»“æœæ˜¾ç€ç›¸å…³ã€‚æœ¯å MRI å‘ç°ç˜˜é“çš„å­˜åœ¨å’Œæ–°è„“è‚¿çš„å½¢æˆé˜»ç¢äº†æ„ˆåˆè¿‡ç¨‹ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥è¯å®è¿™äº›å‘ç°ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œç£å…±æŒ¯æˆåƒï¼Œå¤å‘ï¼Œæ²»ç–—ç»“æœ", "keywords_en": "Anal fistula, magnetic resonance imaging, recurrence, treatment outcomes", "link": "https://pubmed.ncbi.nlm.nih.gov/37359408/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 26 Jun 2023"}, {"id": "37277090", "title_en": "Neonatal head circumference as a risk factor for obstetric anal sphincter injuries: a systematic review and meta-analysis", "title_zh": "æ–°ç”Ÿå„¿å¤´å›´ä½œä¸ºäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤çš„å±é™©å› ç´ ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Ahmad Azmi Nasution", "abstract_en": "**Objective:** Between 53% and 79% of women will sustain some degree of perineal laceration during vaginal delivery. Third- and fourth-degree perineal lacerations are known as obstetric anal sphincter injuries. Timely diagnosis and prompt treatment of obstetric anal sphincter injuries can help to prevent the development of severe consequences like fecal incontinence, urinary incontinence, and rectovaginal fistula. Neonatal head circumference is routinely measured postpartum but is often not mentioned as a risk factor for obstetric anal sphincter injuries in clinical guidelines. Thus far, no review article on the risk factors for obstetric anal sphincter injuries has discussed the role of neonatal head circumference. This study aimed to review and analyze the relationship between head circumference and the occurrence of obstetric anal sphincter injuries among previous studies to conclude whether head circumference should be recognized as an important risk factor.\n\n**Data Sources:** Through study screening on Google Scholar, PubMed, Scopus, and Science Direct for articles published between 2013 to 2023, followed by assessment of eligibility, this study ended up reviewing 25 studies, 17 of which were included in the meta-analysis.\n\n**Study Eligibility Criteria:** Only studies that reported both the neonatal head circumference and the occurrence of obstetric anal sphincter injuries were included in this review.\n\n**Methods:** The included studies were appraised using the Dartmouth Library risk of bias assessment checklist. Qualitative synthesis was based on the study population, findings, adjusted confounding factors, and suggested causative links in each study. Quantitative synthesis was conducted using calculation and pooling of odds ratios and inverse variance using Review Manager 5.4.1.\n\n**Results:** A statistically significant association between head circumference and obstetric anal sphincter injuries was reported in 21 of 25 studies; 4 studies reported that head circumference was a true independent risk factor. A meta-analysis of the studies that reported neonatal head circumference as a dichotomous categorical variable with a cutoff point of 35Â±1 cm yielded statistically significant pooled results (odds ratio, 1.92; 95% confidence interval, 1.80-2.04).\n\n**Conclusion:** The risk for obstetric anal sphincter injuries increased as the neonatal head circumference increased-this should be considered in decision-making during labor and postpartum management to attain the best outcome.", "abstract_zh": "**ç›®çš„ï¼š** 53% è‡³ 79% çš„å¥³æ€§åœ¨é˜´é“åˆ†å¨©æœŸé—´ä¼šå‡ºç°ä¸€å®šç¨‹åº¦çš„ä¼šé˜´æ’•è£‚ä¼¤ã€‚ä¸‰åº¦å’Œå››åº¦ä¼šé˜´æ’•è£‚ä¼¤è¢«ç§°ä¸ºäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤ã€‚äº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤çš„åŠæ—¶è¯Šæ–­å’ŒåŠæ—¶æ²»ç–—æœ‰åŠ©äºé˜²æ­¢å¤§ä¾¿å¤±ç¦ã€å°¿å¤±ç¦å’Œç›´è‚ é˜´é“ç˜˜ç­‰ä¸¥é‡åæœçš„å‘ç”Ÿã€‚äº§åå¸¸è§„æµ‹é‡æ–°ç”Ÿå„¿å¤´å›´ï¼Œä½†ä¸´åºŠæŒ‡å—ä¸­é€šå¸¸æ²¡æœ‰å°†å…¶ä½œä¸ºäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤çš„å±é™©å› ç´ æåŠã€‚è¿„ä»Šä¸ºæ­¢ï¼Œè¿˜æ²¡æœ‰å…³äºäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤å±é™©å› ç´ çš„ç»¼è¿°æ–‡ç« è®¨è®ºäº†æ–°ç”Ÿå„¿å¤´å›´çš„ä½œç”¨ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å›é¡¾å’Œåˆ†æä»¥å¾€ç ”ç©¶ä¸­å¤´å›´ä¸äº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤å‘ç”Ÿçš„å…³ç³»ï¼Œä»¥å¾—å‡ºå¤´å›´æ˜¯å¦åº”è¢«è§†ä¸ºé‡è¦å±é™©å› ç´ çš„ç»“è®ºã€‚\n\n**Data sourcesï¼š** é€šè¿‡åœ¨ Google Scholarã€PubMedã€Scopus å’Œ Science Direct ä¸Šç­›é€‰ 2013 å¹´è‡³ 2023 å¹´æœŸé—´å‘è¡¨çš„æ–‡ç« ï¼Œç„¶åè¯„ä¼°èµ„æ ¼ï¼Œæœ¬ç ”ç©¶æœ€ç»ˆå®¡æŸ¥äº† 25 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­ 17 é¡¹çº³å…¥èŸèƒåˆ†æã€‚\n\n**Study eligibility criteriaï¼š** æœ¬ç»¼è¿°ä»…çº³å…¥æŠ¥å‘Šæ–°ç”Ÿå„¿å¤´å›´å’Œäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤å‘ç”Ÿç‡çš„ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨è¾¾ç‰¹èŒ…æ–¯å›¾ä¹¦é¦†åå€šé£é™©è¯„ä¼°æ¸…å•å¯¹çº³å…¥çš„ç ”ç©¶è¿›è¡Œè¯„ä¼°ã€‚å®šæ€§ç»¼åˆåŸºäºç ”ç©¶äººç¾¤ã€ç ”ç©¶ç»“æœã€è°ƒæ•´åçš„æ··æ‚å› ç´ ä»¥åŠæ¯é¡¹ç ”ç©¶ä¸­å»ºè®®çš„å› æœå…³ç³»ã€‚ä½¿ç”¨ Review Manager 5.4.1 è®¡ç®—å¹¶åˆå¹¶ä¼˜åŠ¿æ¯”å’Œé€†æ–¹å·®ï¼Œè¿›è¡Œå®šé‡ç»¼åˆã€‚\n\n**ç»“æœï¼š** 25 é¡¹ç ”ç©¶ä¸­æœ‰ 21 é¡¹æŠ¥å‘Šç§°å¤´å›´ä¸äº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤ä¹‹é—´å­˜åœ¨ç»Ÿè®¡å­¦æ˜¾ç€å…³è”ï¼› 4 é¡¹ç ”ç©¶æŠ¥å‘Šç§°å¤´å›´æ˜¯ä¸€ä¸ªçœŸæ­£çš„ç‹¬ç«‹å±é™©å› ç´ ã€‚å¯¹å°†æ–°ç”Ÿå„¿å¤´å›´ä½œä¸ºäºŒåˆ†åˆ†ç±»å˜é‡ï¼ˆæˆªæ­¢ç‚¹ä¸º 35Â±1 å˜ç±³ï¼‰çš„ç ”ç©¶è¿›è¡ŒèŸèƒåˆ†æï¼Œå¾—å‡ºäº†ç»Ÿè®¡æ˜¾ç€çš„æ±‡æ€»ç»“æœï¼ˆæ¯”å€¼æ¯”ï¼Œ1.92ï¼›95% ç½®ä¿¡åŒºé—´ï¼Œ1.80-2.04ï¼‰ã€‚\n\n**ç»“è®ºï¼š** éšç€æ–°ç”Ÿå„¿å¤´å›´çš„å¢åŠ ï¼Œäº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤çš„é£é™©ä¹Ÿä¼šå¢åŠ â€”â€”åœ¨åˆ†å¨©å’Œäº§åç®¡ç†è¿‡ç¨‹ä¸­çš„å†³ç­–ä¸­åº”è€ƒè™‘è¿™ä¸€ç‚¹ï¼Œä»¥è·å¾—æœ€ä½³ç»“æœã€‚", "keywords_zh": "åˆ†å¨©ã€æ–°ç”Ÿå„¿å¤´å›´ã€äº§ç§‘è‚›é—¨æ‹¬çº¦è‚ŒæŸä¼¤", "keywords_en": "delivery, neonatal head circumference, obstetric anal sphincter injuries", "link": "https://pubmed.ncbi.nlm.nih.gov/37277090/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 05 Jun 2023"}, {"id": "37213241", "title_en": "Incidence of Rectal Injury After Radical Prostatectomy: A Systematic Review and Meta-analysis", "title_zh": "æ ¹æ²»æ€§å‰åˆ—è…ºåˆ‡é™¤æœ¯åç›´è‚ æŸä¼¤çš„å‘ç”Ÿç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Vincenzo Ficarra", "abstract_en": "**Context:** Rectal injury (RI) is a dreaded complication after radical prostatectomy (RP), increasing the risk of early postoperative complications, such as bleeding and severe infection/sepsis, and late sequelae, such as a rectourethral fistula (RUF). Considering its traditionally low incidence, uncertainty remains as to predisposing risk factors and management.\n\n**Objective:** To examine the incidence of RI after RP in contemporary series and to propose a pragmatic algorithm for its management.\n\n**Evidence Acquisition:** A systematic literature search was performed using the Medline and Scopus databases. Studies reporting data on RI incidence were selected. Subgroup analyses were conducted to assess the differential incidence by age, surgical approach, salvage RP after radiation therapy, and previous benign prostatic hyperplasia (BPH)-related surgery.\n\n**Evidence Synthesis:** Eighty-eight, mostly retrospective noncomparative, studies were selected. The meta-analysis obtained a pooled RI incidence of 0.58% (95% confidence interval [CI] 0.46-0.73) in contemporary series with significant across-study heterogeneity (I<sup>2</sup>Â =Â 100%, <i>p</i>Â <Â 0.00001). The highest RI incidence was found in patients undergoing open RP (1.25%; 95% CI 0.66-2.38) and laparoscopic RP (1.25%; 95% CI 0.75-2.08) followed by perineal RP (0.19%; 95% CI 0-276.95) and robotic RP (0.08%; 95% CI 0.02-0.31). Age â‰¥60 yr (0.56%; 95% CI 0.37-06) and salvage RP after radiation therapy (6.01%; 95% CI 3.99-9.05), but not previous BPH-related surgery (4.08%, 95% CI 0.92-18.20), were also associated with an increased RI incidence. Intraoperative versus postoperative RI detection was associated with a significantly decreased risk of severe postoperative complications (such as sepsis and bleeding) and subsequent formation of a RUF.\n\n**Conclusions:** RI is a rare, but potentially devastating, complication following RP. RI incidence was higher in patients â‰¥60 yr of age, and in those who underwent open/laparoscopic approach or salvage RP after radiation therapy. Intraoperative RI detection and repair apparently constitute the single most critical step to significantly decrease the risk of major postoperative complications and subsequent RUF formation. Conversely, intraoperatively undetected RI can lead more often to severe infective complications and RUF, the management of which remains poorly standardised and requires complex procedures.\n\n**Patient Summary:** Accidental rectum tear is a rare, but potentially devastating, complication in men undergoing prostate removal for cancer. It occurs more often in patients aged 60 yr or older as well as in those who underwent prostate removal via an open/laparoscopic approach and/or prostate removal after radiation therapy for recurrent disease. Prompt identification and repair of this condition during the initial operation are the key to reduce further complications such as the formation of an abnormal opening between the rectum and the urinary tract.", "abstract_zh": "**Contextï¼š** ç›´è‚ æŸä¼¤ï¼ˆRIï¼‰æ˜¯æ ¹æ²»æ€§å‰åˆ—è…ºåˆ‡é™¤æœ¯ï¼ˆRPï¼‰åçš„ä¸€ç§å¯æ€•å¹¶å‘ç—‡ï¼Œå¢åŠ äº†æœ¯åæ—©æœŸå¹¶å‘ç—‡ï¼ˆä¾‹å¦‚å‡ºè¡€å’Œä¸¥é‡æ„ŸæŸ“/è´¥è¡€ç—‡ï¼‰ä»¥åŠæ™šæœŸåé—ç—‡ï¼ˆä¾‹å¦‚ç›´è‚ å°¿é“ç˜˜ï¼ˆRUFï¼‰ï¼‰çš„é£é™©ã€‚è€ƒè™‘åˆ°å…¶ä¼ ç»Ÿä¸Šå‘ç—…ç‡è¾ƒä½ï¼Œè¯±å‘é£é™©å› ç´ å’Œç®¡ç†ä»å­˜åœ¨ä¸ç¡®å®šæ€§ã€‚\n\n**ç›®çš„ï¼š** æ£€æŸ¥å½“ä»£ç³»åˆ—ä¸­ RP ä¹‹å RI çš„å‘ç”Ÿç‡ï¼Œå¹¶æå‡ºä¸€ç§å®ç”¨çš„ç®¡ç†ç®—æ³•ã€‚\n\n**Evidence acquisitionï¼š** ä½¿ç”¨ Medline å’Œ Scopus æ•°æ®åº“è¿›è¡Œç³»ç»Ÿæ–‡çŒ®æ£€ç´¢ã€‚é€‰æ‹©æŠ¥å‘Š RI å‘ç”Ÿç‡æ•°æ®çš„ç ”ç©¶ã€‚è¿›è¡Œäºšç»„åˆ†æä»¥è¯„ä¼°ä¸åŒå¹´é¾„ã€æ‰‹æœ¯æ–¹å¼ã€æ”¾å°„æ²»ç–—åçš„æŒ½æ•‘æ€§ RP ä»¥åŠæ—¢å¾€è‰¯æ€§å‰åˆ—è…ºå¢ç”Ÿ (BPH) ç›¸å…³æ‰‹æœ¯çš„å‘ç—…ç‡å·®å¼‚ã€‚\n\n**Evidence synthesisï¼š** é€‰æ‹©äº† 88 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­å¤§éƒ¨åˆ†æ˜¯å›é¡¾æ€§éæ¯”è¾ƒæ€§ç ”ç©¶ã€‚èŸèƒåˆ†æå¾—å‡ºå½“ä»£ç³»åˆ—ä¸­ RI çš„æ±‡æ€»å‘ç”Ÿç‡ä¸º 0.58%ï¼ˆ95% ç½®ä¿¡åŒºé—´ [CI] 0.46-0.73ï¼‰ï¼Œå…·æœ‰æ˜¾ç€çš„è·¨ç ”ç©¶å¼‚è´¨æ€§ï¼ˆI<sup>2</sup> = 100%ï¼Œ<i>p</i> < 0.00001ï¼‰ã€‚ RI å‘ç”Ÿç‡æœ€é«˜çš„æ˜¯æ¥å—å¼€æ”¾å¼ RPï¼ˆ1.25%ï¼›95% CI 0.66-2.38ï¼‰å’Œè…¹è…”é•œ RPï¼ˆ1.25%ï¼›95% CI 0.75-2.08ï¼‰çš„æ‚£è€…ï¼Œå…¶æ¬¡æ˜¯ä¼šé˜´ RPï¼ˆ0.19%ï¼›95% CI 0-276.95ï¼‰å’Œæœºå™¨äºº RPï¼ˆ0.08%ï¼›95% CIï¼‰ 0.02-0.31ï¼‰ã€‚å¹´é¾„â‰¥60å²ï¼ˆ0.56%ï¼›95% CI 0.37-06ï¼‰å’Œæ”¾å°„æ²»ç–—åçš„æŒ½æ•‘æ€§RPï¼ˆ6.01%ï¼›95% CI 3.99-9.05ï¼‰ï¼Œä½†ä¸æ—¢å¾€BPHç›¸å…³æ‰‹æœ¯æ— å…³ï¼ˆ4.08%ï¼Œ95% CI 0.92-18.20ï¼‰ä¹Ÿä¸RIå‘ç”Ÿç‡å¢åŠ ç›¸å…³ã€‚æœ¯ä¸­ä¸æœ¯å RI æ£€æµ‹ä¸ä¸¥é‡æœ¯åå¹¶å‘ç—‡ï¼ˆå¦‚è„“æ¯’ç—‡å’Œå‡ºè¡€ï¼‰ä»¥åŠéšå RUF å½¢æˆçš„é£é™©æ˜¾ç€é™ä½ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** RI æ˜¯ RP åä¸€ç§ç½•è§ä½†å…·æœ‰æ½œåœ¨ç ´åæ€§çš„å¹¶å‘ç—‡ã€‚å¹´é¾„â‰¥60 å²çš„æ‚£è€…ä»¥åŠæ”¾å°„æ²»ç–—åæ¥å—å¼€è…¹/è…¹è…”é•œæ‰‹æœ¯æˆ–æŒ½æ•‘æ€§ RP çš„æ‚£è€…ä¸­ RI å‘ç”Ÿç‡è¾ƒé«˜ã€‚æœ¯ä¸­ RI æ£€æµ‹å’Œä¿®å¤æ˜¾ç„¶æ˜¯æ˜¾ç€é™ä½ä¸»è¦æœ¯åå¹¶å‘ç—‡å’Œéšå RUF å½¢æˆé£é™©çš„æœ€å…³é”®æ­¥éª¤ã€‚ç›¸åï¼Œæœ¯ä¸­æœªæ£€æµ‹åˆ°çš„ RI æ›´å®¹æ˜“å¯¼è‡´ä¸¥é‡çš„æ„ŸæŸ“å¹¶å‘ç—‡å’Œ RUFï¼Œå…¶ç®¡ç†æ ‡å‡†åŒ–ç¨‹åº¦è¾ƒä½ï¼Œä¸”éœ€è¦å¤æ‚çš„ç¨‹åºã€‚\n\n**Patient summaryï¼š** å¯¹äºå› ç™Œç—‡è€Œæ¥å—å‰åˆ—è…ºåˆ‡é™¤æœ¯çš„ç”·æ€§æ¥è¯´ï¼Œæ„å¤–ç›´è‚ æ’•è£‚æ˜¯ä¸€ç§ç½•è§ä½†å¯èƒ½å…·æœ‰æ¯ç­æ€§çš„å¹¶å‘ç—‡ã€‚å®ƒæ›´å¸¸å‘ç”Ÿåœ¨ 60 å²æˆ–ä»¥ä¸Šçš„æ‚£è€…ä»¥åŠé€šè¿‡å¼€æ”¾/è…¹è…”é•œæ–¹æ³•æ¥å—å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œ/æˆ–å› å¤å‘æ€§ç–¾ç—…è¿›è¡Œæ”¾å°„æ²»ç–—åå‰åˆ—è…ºåˆ‡é™¤æœ¯çš„æ‚£è€…ä¸­ã€‚åœ¨åˆæ¬¡æ‰‹æœ¯æœŸé—´åŠæ—¶è¯†åˆ«å’Œä¿®å¤è¿™ç§æƒ…å†µæ˜¯å‡å°‘è¿›ä¸€æ­¥å¹¶å‘ç—‡çš„å…³é”®ï¼Œä¾‹å¦‚ç›´è‚ å’Œå°¿è·¯ä¹‹é—´å½¢æˆå¼‚å¸¸å¼€å£ã€‚", "keywords_zh": "å¹¶å‘ç—‡ã€å‰åˆ—è…ºç™Œã€æ ¹æ²»æ€§å‰åˆ—è…ºåˆ‡é™¤æœ¯ã€ç›´è‚ æŸä¼¤ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "Complications, Prostate cancer, Radical prostatectomy, Rectal injury, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/37213241/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 22 May 2023"}, {"id": "37198039", "title_en": "Endorectal advancement flap compared to ligation of inter-sphincteric fistula tract in the treatment of complex anal fistulas: A meta-analysis of randomized clinical trials", "title_zh": "ç›´è‚ å†…æ¨è¿›çš®ç“£ä¸æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰æ²»ç–—å¤æ‚æ€§è‚›ç˜˜çš„æ¯”è¾ƒï¼šéšæœºä¸´åºŠè¯•éªŒçš„èŸèƒåˆ†æ", "authors": "Steven D Wexner", "abstract_en": "**Background:** Rectal advancement flap and ligation of intersphincteric fistula tract are common procedures for treating complex anal fistula. The present meta-analysis aimed to compare the surgical outcomes of advancement flap and ligation of intersphincteric fistula tract.\n\n**Methods:** A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review of randomized clinical trials comparing the ligation of intersphincteric fistula tract and advancement flap was conducted. PubMed, Scopus, and Web of Science were searched through January 2023. The risk of bias was assessed using the Risk of Bias 2 tool and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation approach. The primary outcomes were healing and recurrence of anal fistulas, and secondary outcomes were operative time, complications, fecal incontinence, and early pain.\n\n**Results:** Three randomized clinical trials (193 patients, 74.6% male) were included. The median follow-up was 19.2 months. Two trials had a low risk of bias, and 1 had some risk of bias. The odds of healing (odds ratio: 1.363, 95% confidence interval: 0.373-4.972, PÂ = .639), recurrence (odds ratio: 0.525, 95% confidence interval: 0.263-1.047, PÂ = .067), and complications (odds ratio: 0.356, 95% confidence interval: 0.085-1.487, PÂ = .157) were similar between the 2 procedures. Ligation of intersphincteric fistula tract was associated with a significantly shorter operation time (weighted mean difference: -4.876, 95% confidence interval: -7.988 to -1.764, PÂ = .002) and less postoperative pain (weighted mean difference: -1.030, 95% confidence interval: -1.418 to -0.641, 0.198, P < .001, I<sup>2</sup>Â = 3.85%) than advancement flap. Ligation of intersphincteric fistula tract was associated with marginally lower odds of fecal incontinence than advancement flap (odds ratio: 0.27, 95% confidence interval: 0.069-1.06, PÂ = .06).\n\n**Conclusion:** Ligation of intersphincteric fistula tract and advancement flap had similar odds of healing, recurrence, and complications. The odds of fecal incontinence and extent of pain after ligation of intersphincteric fistula tract were lower than after advancement flap.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ æ¨è¿›çš®ç“£å’Œæ‹¬çº¦è‚Œé—´ç˜˜é“ç»“æ‰æ˜¯æ²»ç–—å¤æ‚æ€§è‚›ç˜˜çš„å¸¸ç”¨æ‰‹æœ¯ã€‚æœ¬èŸèƒåˆ†ææ—¨åœ¨æ¯”è¾ƒæ¨è¿›çš®ç“£å’Œæ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰çš„æ‰‹æœ¯ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** å¯¹æ¯”è¾ƒæ‹¬çº¦è‚Œé—´ç˜˜é“ç»“æ‰å’Œæ¨è¿›çš®ç“£çš„éšæœºä¸´åºŠè¯•éªŒè¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·å’Œç¬¦åˆèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ã€‚ PubMedã€Scopus å’Œ Web of Science çš„æ£€ç´¢æ—¶é—´æˆªè‡³ 2023 å¹´ 1 æœˆã€‚ä½¿ç”¨åå€šé£é™© 2 å·¥å…·è¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨å»ºè®®è¯„ä¼°ã€åˆ¶å®šå’Œè¯„ä¼°åˆ†çº§æ–¹æ³•è¯„ä¼°è¯æ®çš„ç¡®å®šæ€§ã€‚ä¸»è¦ç»“å±€æ˜¯è‚›ç˜˜çš„æ„ˆåˆå’Œå¤å‘ï¼Œæ¬¡è¦ç»“å±€æ˜¯æ‰‹æœ¯æ—¶é—´ã€å¹¶å‘ç—‡ã€å¤§ä¾¿å¤±ç¦å’Œæ—©æœŸç–¼ç—›ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº†ä¸‰é¡¹éšæœºä¸´åºŠè¯•éªŒï¼ˆ193 åæ‚£è€…ï¼Œ74.6% ç”·æ€§ï¼‰ã€‚ä¸­ä½éšè®¿æ—¶é—´ä¸º 19.2 ä¸ªæœˆã€‚ä¸¤é¡¹è¯•éªŒçš„åå€šé£é™©è¾ƒä½ï¼Œä¸€é¡¹è¯•éªŒå­˜åœ¨ä¸€å®šçš„åå€šé£é™©ã€‚æ²»æ„ˆå‡ ç‡ï¼ˆæ¯”å€¼æ¯”ï¼š1.363ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š0.373-4.972ï¼ŒP = .639ï¼‰ã€å¤å‘ï¼ˆæ¯”å€¼æ¯”ï¼š0.525ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š0.263-1.047ï¼ŒP = .067ï¼‰å’Œå¹¶å‘ç—‡ï¼ˆæ¯”å€¼æ¯”ï¼š0.356ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š 0.085-1.487ï¼ŒP = .157) ä¸¤ä¸ªç¨‹åºä¹‹é—´ç›¸ä¼¼ã€‚æ‹¬çº¦è‚Œé—´ç˜˜é“ç»“æ‰ä¸æ‰‹æœ¯æ—¶é—´æ˜¾ç€ç¼©çŸ­ï¼ˆåŠ æƒå¹³å‡å·®ï¼š-4.876ï¼Œ95%ç½®ä¿¡åŒºé—´ï¼š-7.988è‡³-1.764ï¼ŒP = .002ï¼‰å’Œè¾ƒå°‘çš„æœ¯åç–¼ç—›ï¼ˆåŠ æƒå¹³å‡å·®ï¼š-1.030ï¼Œ95%ç½®ä¿¡åŒºé—´ï¼š-1.418è‡³-0.641ã€0.198ï¼ŒP < .001ï¼Œ I<sup>2</sup>Â = 3.85%ï¼‰æ¯”è¿›æ­¥è¥Ÿç¿¼ã€‚æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰ä¸æ¨è¿›çš®ç“£ç›¸æ¯”ï¼Œå¤§ä¾¿å¤±ç¦çš„å‡ ç‡ç•¥ä½ï¼ˆä¼˜åŠ¿æ¯”ï¼š0.27ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š0.069-1.06ï¼ŒP = .06ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰å’Œæ¨è¿›çš®ç“£çš„æ„ˆåˆã€å¤å‘å’Œå¹¶å‘ç—‡çš„å‡ ç‡ç›¸ä¼¼ã€‚æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰æœ¯åå¤§ä¾¿å¤±ç¦çš„å‡ ç‡å’Œç–¼ç—›ç¨‹åº¦å‡ä½äºæ¨è¿›çš®ç“£æœ¯åã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/37198039/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 17 May 2023"}, {"id": "37101285", "title_en": "Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials", "title_zh": "é—´å……è´¨å¹²ç»†èƒç§»æ¤æ²»ç–—è‚›å‘¨ç˜˜ï¼šä¸´åºŠè¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "J L Jiang", "abstract_en": "**Background:** Perianal fistulas, characterised as granulomatous inflammation of fistulas around the anal canal, are associated with significant morbidity resulting in a negative impact on quality of life and a tremendous burden to the healthcare system. Treatment of anal fistulas usually consists of anal surgery; however, results of closure rates are not satisfactory especially with complex perianal fistulas, after which many patients may suffer from anal incontinence. Recently, the administration of mesenchymal stem cells (MSCs) has shown promising efficacy. Herein, we aim to explore whether MSCs are effective for complex perianal fistulas and if they have either short-term, medium-term, long-term or over-long-term efficacy. Additionally, we want to elucidate whether factors such as drug dosage, MSC source, cell type, and disease aetiology influence treatment efficacy. We searched four online databases and analysed data based on information within the clinical trials registry. The outcomes of eligible trials were analysed with Review Manager 5.4.1. Relative risk and related 95% confidence interval were calculated to compare the effect between the MSCs and control groups. In addition, the Cochrane risk of bias tool was applied to evaluate the bias risk of eligible studies. Meta-analyses showed that therapy with MSCs was superior to conventional treatment for complex perianal fistulas in short-, long- and over-long-term follow-up phases. However, there was no statistical difference in treatment efficacy in the medium term between the two methods. Subgroup meta-analyses showed factors including cell type, cell source and cell dosage were superior compared to the control, but there was no significant difference between different experimental groups of those factors. Besides, local MSCs therapy has shown more promising results for fistulas as a result of Crohn's Disease (CD). Although we tend to maintain that MSCs therapy is effective for cryptoglandular fistulas equally, more studies are needed to confirm this conclusion in the future.\n\n**Short Conclusion:** MSCs Transplantation could be a new therapeutic method for complex perianal fistulas of both cryptoglandular and CD origin showing high efficacy in the short-term to over-long-term phases, as well as high efficacy in sustained healing. The difference in cell types, cell sources and cell dosages did not influence MSCs' efficacy.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜ç®¡çš„ç‰¹å¾æ˜¯è‚›ç®¡å‘¨å›´ç˜˜ç®¡çš„è‚‰èŠ½è‚¿æ€§ç‚ç—‡ï¼Œå…¶å‘ç—…ç‡å¾ˆé«˜ï¼Œä¼šå¯¹ç”Ÿæ´»è´¨é‡äº§ç”Ÿè´Ÿé¢å½±å“ï¼Œå¹¶ç»™åŒ»ç–—ä¿å¥ç³»ç»Ÿå¸¦æ¥å·¨å¤§è´Ÿæ‹…ã€‚è‚›ç˜˜çš„æ²»ç–—é€šå¸¸åŒ…æ‹¬è‚›é—¨æ‰‹æœ¯ï¼›ç„¶è€Œï¼Œé—­åˆç‡çš„ç»“æœå¹¶ä¸ä»¤äººæ»¡æ„ï¼Œå°¤å…¶æ˜¯å¯¹äºå¤æ‚çš„è‚›å‘¨ç˜˜ï¼Œæœ¯åè®¸å¤šæ‚£è€…å¯èƒ½ä¼šå‡ºç°è‚›é—¨å¤±ç¦ã€‚æœ€è¿‘ï¼Œé—´å……è´¨å¹²ç»†èƒï¼ˆMSCï¼‰çš„æ–½ç”¨æ˜¾ç¤ºå‡ºæœ‰å¸Œæœ›çš„åŠŸæ•ˆã€‚åœ¨æ­¤ï¼Œæˆ‘ä»¬çš„ç›®çš„æ˜¯æ¢è®¨é—´å……è´¨å¹²ç»†èƒæ²»ç–—å¤æ‚æ€§è‚›å‘¨ç˜˜æ˜¯å¦æœ‰æ•ˆï¼Œä»¥åŠæ˜¯å¦å…·æœ‰çŸ­æœŸã€ä¸­æœŸã€é•¿æœŸæˆ–è¶…é•¿æœŸç–—æ•ˆã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬å¸Œæœ›é˜æ˜è¯ç‰©å‰‚é‡ã€MSC æ¥æºã€ç»†èƒç±»å‹å’Œç–¾ç—…ç—…å› ç­‰å› ç´ æ˜¯å¦å½±å“æ²»ç–—æ•ˆæœã€‚æˆ‘ä»¬æœç´¢äº†å››ä¸ªåœ¨çº¿æ•°æ®åº“ï¼Œå¹¶æ ¹æ®ä¸´åºŠè¯•éªŒç™»è®°å¤„çš„ä¿¡æ¯åˆ†æäº†æ•°æ®ã€‚ä½¿ç”¨ Review Manager 5.4.1 åˆ†æåˆæ ¼è¯•éªŒçš„ç»“æœã€‚è®¡ç®—ç›¸å¯¹é£é™©å’Œç›¸å…³çš„ 95% ç½®ä¿¡åŒºé—´ï¼Œä»¥æ¯”è¾ƒ MSC å’Œå¯¹ç…§ç»„ä¹‹é—´çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œåº”ç”¨Cochraneåå€šé£é™©å·¥å…·æ¥è¯„ä¼°åˆæ ¼ç ”ç©¶çš„åå€šé£é™©ã€‚èŸèƒåˆ†æè¡¨æ˜ï¼Œåœ¨çŸ­æœŸã€é•¿æœŸå’Œè¶…é•¿æœŸéšè®¿é˜¶æ®µï¼Œé—´å……è´¨å¹²ç»†èƒæ²»ç–—å¤æ‚è‚›å‘¨ç˜˜çš„æ•ˆæœä¼˜äºä¼ ç»Ÿæ²»ç–—ã€‚ç„¶è€Œï¼Œä¸¤ç§æ–¹æ³•çš„ä¸­æœŸæ²»ç–—æ•ˆæœæ²¡æœ‰ç»Ÿè®¡å­¦å·®å¼‚ã€‚äºšç»„èŸèƒåˆ†ææ˜¾ç¤ºï¼Œç»†èƒç±»å‹ã€ç»†èƒæ¥æºå’Œç»†èƒå‰‚é‡ç­‰å› ç´ å‡ä¼˜äºå¯¹ç…§ç»„ï¼Œä½†ä¸åŒå®éªŒç»„ä¹‹é—´è¿™äº›å› ç´ æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚æ­¤å¤–ï¼Œå±€éƒ¨é—´å……è´¨å¹²ç»†èƒæ²»ç–—å¯¹äºå…‹ç½—æ©ç—…ï¼ˆCDï¼‰å¼•èµ·çš„ç˜˜ç®¡æ˜¾ç¤ºå‡ºæ›´æœ‰å¸Œæœ›çš„æ•ˆæœã€‚å°½ç®¡æˆ‘ä»¬å€¾å‘äºè®¤ä¸ºé—´å……è´¨å¹²ç»†èƒæ²»ç–—å¯¹éšè…ºç˜˜åŒæ ·æœ‰æ•ˆï¼Œä½†æœªæ¥è¿˜éœ€è¦æ›´å¤šçš„ç ”ç©¶æ¥è¯å®è¿™ä¸€ç»“è®ºã€‚\n\n**Short conclusionï¼š** é—´å……è´¨å¹²ç»†èƒç§»æ¤å¯èƒ½æ˜¯æ²»ç–—éšè…ºå’Œ CD èµ·æºçš„å¤æ‚è‚›å‘¨ç˜˜çš„æ–°æ–¹æ³•ï¼Œåœ¨çŸ­æœŸè‡³è¶…é•¿æœŸé˜¶æ®µæ˜¾ç¤ºå‡ºé«˜æ•ˆèƒ½ï¼Œå¹¶ä¸”åœ¨æŒç»­æ„ˆåˆæ–¹é¢ä¹Ÿå…·æœ‰é«˜æ•ˆèƒ½ã€‚ç»†èƒç±»å‹ã€ç»†èƒæ¥æºå’Œç»†èƒå‰‚é‡çš„å·®å¼‚å¹¶ä¸å½±å“MSCçš„åŠŸæ•ˆã€‚", "keywords_zh": "ä¸´åºŠè¯•éªŒ, ç–—æ•ˆä¸å®‰å…¨æ€§, æ²»æ„ˆç‡, é—´å……è´¨å¹²ç»†èƒç§»æ¤, è‚›å‘¨ç˜˜, éšæœºå¯¹ç…§è¯•éªŒ, ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "keywords_en": "Clinical trials, Efficacy and safety, Healing rate, Mesenchymal stem cells transplantation, Perianal fistulas, Randomised controlled trial, Systematic review and meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/37101285/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 26 Apr 2023"}, {"id": "37023788", "title_en": "A Systematic Review and Meta-Analysis of Comparing Drainage Alone versus Drainage with Primary Fistula Treatment for the Perianal Abscess in Children", "title_zh": "å•ç‹¬å¼•æµä¸å¼•æµè”åˆç˜˜ç®¡æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Chen Wang", "abstract_en": "This systematic review and meta-analysis of nonrandomized studies (NRSs) aimed to evaluate the clinical efficacy and safety of two types of surgical interventions (respectively drainage alone and drainage with primary fistula treatment) for perianal abscesses (PAs) in children. Studies from 1992 to July 2022 were searched in 10 electronic databases. All relevant NRSs with available data which compared surgical drainage with or without primary fistula treatment were included. Patients with underlying diseases which led to abscess formation were excluded. The Newcastle-Ottawa Scale was used to assess the risk of bias and quality of the included studies. The outcomes were the healing rate, fistula formation rate, fecal incontinence, and wound healing duration. A total of 16 articles with 1,262 patients were considered suitable for the final meta-analysis. Primary fistula treatment was associated with a significantly higher healing rate when compared with incision and drainage alone (odds ratio [OR]: 5.76, 95% confidence interval [CI]: 4.04-8.22). This aggressive procedure for PA resulted in an 86% reduction in the fistula formation rate (OR: 0.14, 95% CI: 0.06-0.32). Limited data showed patients who underwent primary fistula treatment have a minor effect on postoperative fecal incontinence. Primary fistula treatment demonstrates a better clinical efficacy in promoting the healing rate and decreasing the formation of fistulas in PAs in children. The available evidence for a minor impact on anal function after this intervention is less strong.", "abstract_zh": "è¿™é¡¹ééšæœºç ”ç©¶ï¼ˆNRSï¼‰çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°ä¸¤ç§ç±»å‹çš„æ‰‹æœ¯å¹²é¢„ï¼ˆåˆ†åˆ«å•ç‹¬å¼•æµå’Œå¼•æµè”åˆåˆæ¬¡ç˜˜ç®¡æ²»ç–—ï¼‰æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰çš„ä¸´åºŠç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚åœ¨ 10 ä¸ªç”µå­æ•°æ®åº“ä¸­æ£€ç´¢äº† 1992 å¹´è‡³ 2022 å¹´ 7 æœˆçš„ç ”ç©¶ã€‚åŒ…æ‹¬æ‰€æœ‰å…·æœ‰å¯ç”¨æ•°æ®çš„ç›¸å…³ NRSï¼Œè¿™äº› NRS æ¯”è¾ƒäº†æ‰‹æœ¯å¼•æµä¸æˆ–ä¸è¿›è¡Œåˆæ¬¡ç˜˜ç®¡æ²»ç–—çš„æƒ…å†µã€‚æ’é™¤æ‚£æœ‰å¯¼è‡´è„“è‚¿å½¢æˆçš„åŸºç¡€ç–¾ç—…çš„æ‚£è€…ã€‚çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ç”¨äºè¯„ä¼°çº³å…¥ç ”ç©¶çš„åå€šé£é™©å’Œè´¨é‡ã€‚ç»“æœæ˜¯æ„ˆåˆç‡ã€ç˜˜ç®¡å½¢æˆç‡ã€å¤§ä¾¿å¤±ç¦å’Œä¼¤å£æ„ˆåˆæŒç»­æ—¶é—´ã€‚å…±æœ‰ 16 ç¯‡æ–‡ç« ã€1,262 åæ‚£è€…è¢«è®¤ä¸ºé€‚åˆæœ€ç»ˆçš„èŸèƒåˆ†æã€‚ä¸å•ç‹¬åˆ‡å¼€å¼•æµç›¸æ¯”ï¼ŒåŸå‘æ€§ç˜˜ç®¡æ²»ç–—å…·æœ‰æ˜¾ç€æ›´é«˜çš„æ²»æ„ˆç‡ï¼ˆæ¯”å€¼æ¯” [OR]ï¼š5.76ï¼Œ95% ç½®ä¿¡åŒºé—´ [CI]ï¼š4.04-8.22ï¼‰ã€‚è¿™ç§ç§¯æçš„ PA æ‰‹æœ¯ä½¿ç˜˜ç®¡å½¢æˆç‡é™ä½äº† 86%ï¼ˆORï¼š0.14ï¼Œ95% CIï¼š0.06-0.32ï¼‰ã€‚æœ‰é™çš„æ•°æ®æ˜¾ç¤ºï¼Œæ¥å—åŸå‘æ€§ç˜˜ç®¡æ²»ç–—çš„æ‚£è€…å¯¹æœ¯åå¤§ä¾¿å¤±ç¦çš„å½±å“è¾ƒå°ã€‚åŸå‘æ€§ç˜˜ç®¡æ²»ç–—åœ¨ä¿ƒè¿›å„¿ç«¥PAsçš„æ„ˆåˆç‡å’Œå‡å°‘ç˜˜ç®¡å½¢æˆæ–¹é¢æ˜¾ç¤ºå‡ºæ›´å¥½çš„ä¸´åºŠç–—æ•ˆã€‚ç°æœ‰è¯æ®è¡¨æ˜è¿™ç§å¹²é¢„åå¯¹è‚›é—¨åŠŸèƒ½æœ‰è½»å¾®å½±å“ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/37023788/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 06 Apr 2023"}, {"id": "36905499", "title_en": "A Systematic Review of Epidemiology and Outcomes Associated with Local Surgical and Intersphincteric Ligation Procedures for Complex Cryptoglandular Fistulas", "title_zh": "ä¸å¤æ‚éšè…ºç˜˜çš„å±€éƒ¨æ‰‹æœ¯å’Œæ‹¬çº¦è‚Œé—´ç»“æ‰æ‰‹æœ¯ç›¸å…³çš„æµè¡Œç—…å­¦å’Œç»“æœçš„ç³»ç»Ÿè¯„ä»·", "authors": "Suzanne F Cook", "abstract_en": "**Introduction:** This systematic literature review (SLR) assessed incidence/prevalence of cryptoglandular fistulas (CCF) and outcomes associated with local surgical and intersphincteric ligation procedures for CCFs.\n\n**Methods:** Two trained reviewers searched PubMed and Embase for observational studies evaluating the incidence/prevalence of cryptoglandular fistula and clinical outcomes of treatments for CCF after local surgical and intersphincteric ligation procedures for CCF.\n\n**Results:** In total 148 studies met a priori eligibility criteria for all cryptoglandular fistulas and all intervention types. Of those, two assessed incidence/prevalence of cryptoglandular fistulas. Eighteen reported clinical outcomes of surgeries of interest in CCF and were published in the past 5Â years. Prevalence was reported as 1.35/10,000 non-Crohn's patients, and 52.6% of non-IBD patients were found to progress from anorectal abscess to fistula over 12Â months. Primary healing rates ranged from 57.1% to 100%; recurrence occurred in a range of 4.9-60.7% and failure in 2.8-18.0% of patients. Limited published evidence suggests postoperative fecal incontinence and long-term postoperative pain were rare. Several of the studies were limited by single-center design with small sample sizes and short follow-up durations.\n\n**Discussion:** This SLR summarizes outcomes from specific surgical procedures for the treatment of CCF. Healing rates vary according to procedure and clinical factors. Differences in study design, outcome definition, and length of follow-up prevent direct comparison. Overall, published studies offer a wide range of findings with respect to recurrence. Postsurgical incontinence and long-term postoperative pain were rare in the included studies, but more research is needed to confirm rates of these conditions following CCF treatments.\n\n**Conclusion:** Published studies on the epidemiology of CCF are rare and limited. Outcomes of local surgical and intersphincteric ligation procedures show differing success and failure rates, and more research is needed to compare outcomes across various procedures. (PROSPERO; registration number CRD42020177732).", "abstract_zh": "**ä»‹ç»ï¼š** æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿° (SLR) è¯„ä¼°äº†éšè…ºç˜˜ (CCF) çš„å‘ç—…ç‡/æ‚£ç—…ç‡ä»¥åŠä¸ CCF å±€éƒ¨æ‰‹æœ¯å’Œæ‹¬çº¦è‚Œé—´ç»“æ‰æ‰‹æœ¯ç›¸å…³çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ä¸¤åè®­ç»ƒæœ‰ç´ çš„å®¡ç¨¿äººåœ¨ PubMed å’Œ Embase ä¸­æ£€ç´¢äº†è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œè¯„ä¼°éšè…ºç˜˜çš„å‘ç”Ÿç‡/æ‚£ç—…ç‡ä»¥åŠ CCF å±€éƒ¨æ‰‹æœ¯å’Œæ‹¬çº¦è‚Œé—´ç»“æ‰æ‰‹æœ¯å CCF æ²»ç–—çš„ä¸´åºŠç»“æœã€‚\n\n**ç»“æœï¼š** æ€»å…± 148 é¡¹ç ”ç©¶ç¬¦åˆæ‰€æœ‰éšè…ºç˜˜å’Œæ‰€æœ‰å¹²é¢„ç±»å‹çš„å…ˆéªŒèµ„æ ¼æ ‡å‡†ã€‚å…¶ä¸­ï¼Œæœ‰ä¸¤é¡¹è¯„ä¼°äº†éšè…ºç˜˜ç®¡çš„å‘ç—…ç‡/æ‚£ç—…ç‡ã€‚è¿‡å» 5 å¹´å‘è¡¨äº† 18 ä»½æŠ¥å‘Šï¼Œå…¶ä¸­æ¶‰åŠ CCF æ‰‹æœ¯çš„ä¸´åºŠç»“æœã€‚æ®æŠ¥é“ï¼Œéå…‹ç½—æ©ç—…æ‚£è€…çš„æ‚£ç—…ç‡ä¸º 1.35/10,000ï¼Œå¹¶ä¸”å‘ç° 52.6% çš„é IBD æ‚£è€…åœ¨ 12 ä¸ªæœˆå†…ä»è‚›é—¨ç›´è‚ è„“è‚¿è¿›å±•ä¸ºç˜˜ç®¡ã€‚ä¸€æœŸæ„ˆåˆç‡ä»57.1%åˆ°100%ï¼›å¤å‘ç‡ä¸º 4.9-60.7%ï¼Œå¤±è´¥ç‡ä¸º 2.8-18.0%ã€‚æœ‰é™çš„å·²å‘è¡¨è¯æ®è¡¨æ˜æœ¯åå¤§ä¾¿å¤±ç¦å’Œé•¿æœŸæœ¯åç–¼ç—›å¾ˆå°‘è§ã€‚ä¸€äº›ç ”ç©¶å—åˆ°å•ä¸­å¿ƒè®¾è®¡çš„é™åˆ¶ï¼Œæ ·æœ¬é‡å°ï¼Œéšè®¿æ—¶é—´çŸ­ã€‚\n\n**è®¨è®ºï¼š** æœ¬ SLR æ€»ç»“äº†æ²»ç–— CCF çš„ç‰¹å®šå¤–ç§‘æ‰‹æœ¯çš„ç»“æœã€‚æ²»æ„ˆç‡æ ¹æ®æ‰‹æœ¯å’Œä¸´åºŠå› ç´ è€Œæœ‰æ‰€ä¸åŒã€‚ç ”ç©¶è®¾è®¡ã€ç»“æœå®šä¹‰å’Œéšè®¿æ—¶é—´é•¿åº¦çš„å·®å¼‚é˜»ç¢äº†ç›´æ¥æ¯”è¾ƒã€‚æ€»ä½“è€Œè¨€ï¼Œå·²å‘è¡¨çš„ç ”ç©¶æä¾›äº†æœ‰å…³å¤å‘çš„å¹¿æ³›å‘ç°ã€‚åœ¨çº³å…¥çš„ç ”ç©¶ä¸­ï¼Œæœ¯åå¤±ç¦å’Œé•¿æœŸæœ¯åç–¼ç—›å¾ˆå°‘è§ï¼Œä½†éœ€è¦æ›´å¤šçš„ç ”ç©¶æ¥ç¡®è®¤ CCF æ²»ç–—åè¿™äº›æƒ…å†µçš„å‘ç”Ÿç‡ã€‚\n\n**ç»“è®ºï¼š** å·²å‘è¡¨çš„ CCF æµè¡Œç—…å­¦ç ”ç©¶å¾ˆå°‘ä¸”æœ‰é™ã€‚å±€éƒ¨æ‰‹æœ¯å’Œæ‹¬çº¦è‚Œé—´ç»“æ‰æ‰‹æœ¯çš„ç»“æœæ˜¾ç¤ºå‡ºä¸åŒçš„æˆåŠŸç‡å’Œå¤±è´¥ç‡ï¼Œéœ€è¦æ›´å¤šçš„ç ”ç©¶æ¥æ¯”è¾ƒä¸åŒæ‰‹æœ¯çš„ç»“æœã€‚ ï¼ˆPROSPEROï¼›æ³¨å†Œå· CRD42020177732ï¼‰ã€‚", "keywords_zh": "è‚›ç˜˜ã€å¤æ‚éšè…ºç˜˜ã€æ„ˆåˆã€å¤±ç¦ã€ç–¼ç—›ã€å¤å‘", "keywords_en": "Anal fistula, Complex cryptoglandular fistula, Healing, Incontinence, Pain, Recurrence", "link": "https://pubmed.ncbi.nlm.nih.gov/36905499/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 11 Mar 2023"}, {"id": "36905475", "title_en": "Platelet-rich plasma in the treatment of anal fistula: a systematic review and meta-analysis", "title_zh": "å¯Œå«è¡€å°æ¿è¡€æµ†æ²»ç–—è‚›ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Xiaofei Li", "abstract_en": "**Objective:** To analyse the safety and effectiveness of platelet-rich plasma (PRP) in anal fistula patients.\n\n**Methods:** Online databases including PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to December 5, 2022, for eligible studies about evaluating the efficacy of platelet-rich plasma (PRP) in treating anal fistula. Literature search, screening, data extraction, and quality assessment were carried out by two independent investigators. The overall cure rate, the complete cure rate, the recurrence rate, and the adverse event rate with their 95% confidence intervals (95% CI) were the primary calculation indexes. Subgroup analyses were conducted primarily according to whether PRP was combined with other treatments. Softwares of MedCalc 18.2 and Review Manager 5.3 were used for meta-analysis.\n\n**Results:** A total of 14 studies with 514 patients were included in the meta-analysis. The overall cure rate of 14 studies was 72.11% (95% CI 0.64-0.79). The cure rate of PRP alone was 62.39% (95% CI 0.55-0.69). The combined cure rate of PRP with other treatments was 83.12% (95% CI 0.77-0.88). The cure rate of interventions involving PRP were superior to the cure rate of surgery methods without using PRP significantly in the 4 randomized controlled studies (RRâ€‰=â€‰1.30, 95% CI 1.10-1.54, pâ€‰=â€‰0.002). The complete cure rate of the 8 studies was 66.37% (95% CI 0.52-0.79). The recurrence rate of the 12 studies was 14.84% (95% CI 0.08-0.24). The adverse event rate of the 12 studies was 6.31% (95% CI 0.02-0.12).\n\n**Conclusion:** PRP showed favorable safety and effectiveness in the treatment of anal fistula, especially combined with other treatment procedures.", "abstract_zh": "**ç›®çš„ï¼š** åˆ†æå¯Œè¡€å°æ¿è¡€æµ†ï¼ˆPRPï¼‰å¯¹è‚›ç˜˜æ‚£è€…çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** ä»æˆç«‹åˆ° 2022 å¹´ 12 æœˆ 5 æ—¥ï¼Œæˆ‘ä»¬å¯¹åŒ…æ‹¬ PubMedã€Embaseã€Cochrane Library å’Œ Web of Science åœ¨å†…çš„åœ¨çº¿æ•°æ®åº“è¿›è¡Œäº†æ£€ç´¢ï¼ŒæŸ¥æ‰¾æœ‰å…³è¯„ä¼°å¯Œè¡€å°æ¿è¡€æµ† (PRP) æ²»ç–—è‚›ç˜˜ç–—æ•ˆçš„åˆæ ¼ç ”ç©¶ã€‚æ–‡çŒ®æ£€ç´¢ã€ç­›é€‰ã€æ•°æ®æå–å’Œè´¨é‡è¯„ä¼°ç”±ä¸¤åç‹¬ç«‹ç ”ç©¶è€…è¿›è¡Œã€‚ä¸»è¦è®¡ç®—æŒ‡æ ‡ä¸ºæ€»æ²»æ„ˆç‡ã€å®Œå…¨æ²»æ„ˆç‡ã€å¤å‘ç‡ã€ä¸è‰¯äº‹ä»¶ç‡åŠå…¶95%ç½®ä¿¡åŒºé—´ï¼ˆ95% CIï¼‰ã€‚ä¸»è¦æ ¹æ®PRPæ˜¯å¦ä¸å…¶ä»–æ²»ç–—è”åˆè¿›è¡Œäºšç»„åˆ†æã€‚ä½¿ç”¨MedCalc 18.2å’ŒReview Manager 5.3è½¯ä»¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†æå…±çº³å…¥ 14 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 514 åæ‚£è€…ã€‚ 14é¡¹ç ”ç©¶çš„æ€»ä½“æ²»æ„ˆç‡ä¸º72.11%ï¼ˆ95% CI 0.64-0.79ï¼‰ã€‚å•ç‹¬ PRP çš„æ²»æ„ˆç‡ä¸º 62.39% (95% CI 0.55-0.69)ã€‚ PRPä¸å…¶ä»–æ²»ç–—çš„ç»¼åˆæ²»æ„ˆç‡ä¸º83.12%ï¼ˆ95% CI 0.77-0.88ï¼‰ã€‚åœ¨4é¡¹éšæœºå¯¹ç…§ç ”ç©¶ä¸­ï¼Œæ¶‰åŠPRPçš„å¹²é¢„æªæ–½çš„æ²»æ„ˆç‡æ˜¾ç€ä¼˜äºä¸ä½¿ç”¨PRPçš„æ‰‹æœ¯æ–¹æ³•çš„æ²»æ„ˆç‡ï¼ˆRRâ€‰=â€‰1.30ï¼Œ95% CI 1.10-1.54ï¼Œpâ€‰=â€‰0.002ï¼‰ã€‚ 8é¡¹ç ”ç©¶çš„å®Œå…¨æ²»æ„ˆç‡ä¸º66.37%ï¼ˆ95% CI 0.52-0.79ï¼‰ã€‚ 12é¡¹ç ”ç©¶çš„å¤å‘ç‡ä¸º14.84%ï¼ˆ95% CI 0.08-0.24ï¼‰ã€‚ 12é¡¹ç ”ç©¶çš„ä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡ä¸º6.31%ï¼ˆ95% CI 0.02-0.12ï¼‰ã€‚\n\n**ç»“è®ºï¼š** PRP åœ¨æ²»ç–—è‚›ç˜˜æ–¹é¢æ˜¾ç¤ºå‡ºè‰¯å¥½çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ï¼Œç‰¹åˆ«æ˜¯ä¸å…¶ä»–æ²»ç–—æ–¹æ³•è”åˆä½¿ç”¨ã€‚", "keywords_zh": "ä¸è‰¯äº‹ä»¶ã€è‚›ç˜˜ã€æ²»æ„ˆç‡ã€èŸèƒåˆ†æã€PRPã€å¤å‘ç‡", "keywords_en": "Adverse events, Anal fistula, Cure rate, Meta-analysis, PRP, Recurrence rate", "link": "https://pubmed.ncbi.nlm.nih.gov/36905475/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 11 Mar 2023"}, {"id": "36894443", "title_en": "The Optimal Primary Treatment for Pediatric Perianal Abscess and Anal Fistula: A Systemic Review and Meta-Analysis", "title_zh": "å°å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æœ€ä½³åˆæ­¥æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Hou-Chuan Chen", "abstract_en": "**Background:** Perianal abscesses and anal fistulas are common. The principle of intention-to-treat has not been considered in previous systemic reviews. Thus, the comparison between primary and post-recurrence management was confused, and the recommendation of primary treatment is obscure. The current study aims to identify the optimal initial treatment for pediatric patients.\n\n**Methods:** Using PRISMA guidelines, studies were identified from MEDLINE, EMBASE, PubMed, Cochrane Library, and Google Scholar without any language or study design restriction. The inclusion criteria include original articles or articles with original data, studies of management for a perianal abscess with or without anal fistula, and patient age of <18 years. Patients with local malignancy, Crohn's disease, or other underlying predisposing conditions were excluded. Studies without analyzing recurrence, case series of <5, and irrelevant articles were excluded in the screening stage. Of the 124 screened articles, 14 articles had no full texts or detailed information. Articles written in a language other than English or Mandarin were translated by Google Translation first and confirmed with native speakers. After the eligibility process, studies that compared identified primary managements were then included in the qualitative synthesis.\n\n**Results:** Thirty-one studies involving 2507 pediatric patients met the inclusion criteria. The study design consisted of two prospective case series of 47 patients and retrospective cohort studies. No randomized control trials were identified. Meta-analyses for recurrence after initial management were performed with a random-effects model. Conservative treatment and drainage revealed no difference (Odds ratio [OR], 1.222; 95% Confidential interval [CI]: 0.615-2.427, pÂ =Â 0.567). Conservative management had a higher risk of recurrence than surgery without statistical significance (OR 0.278, 95% CI: 0.109-0.707, pÂ =Â 0.007). Compared with incision/drainage, surgery can prevent recurrence remarkably (OR 4.360, 95% CI: 1.761-10.792, pÂ =Â 0.001). Subgroup analysis of different approaches within conservative treatment and operation was not performed for lacking information.\n\n**Conclusion:** Strong recommendations cannot be made due to the lack of prospective or randomized controlled studies. However, the current study based on real primary management supports initial surgical intervention for pediatric patients with perianal abscesses and anal fistula to prevent recurrence.\n\n**Level Of Evidence:** Type of study: Systemic review; Evidence level: Level II.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜å¾ˆå¸¸è§ã€‚ä»¥å¾€çš„ç³»ç»Ÿè¯„ä»·å¹¶æœªè€ƒè™‘æ„å‘æ²»ç–—åŸåˆ™ã€‚å› æ­¤ï¼Œåˆçº§æ²»ç–—å’Œå¤å‘åæ²»ç–—ä¹‹é—´çš„æ¯”è¾ƒæ˜¯æ··ä¹±çš„ï¼Œåˆçº§æ²»ç–—çš„å»ºè®®ä¹Ÿå«ç³Šä¸æ¸…ã€‚ç›®å‰çš„ç ”ç©¶æ—¨åœ¨ç¡®å®šå„¿ç§‘æ‚£è€…çš„æœ€ä½³åˆå§‹æ²»ç–—ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨ PRISMA æŒ‡å—ï¼Œä» MEDLINEã€EMBASEã€PubMedã€Cochrane å›¾ä¹¦é¦†å’Œ Google Scholar ä¸­è¯†åˆ«ç ”ç©¶ï¼Œæ²¡æœ‰ä»»ä½•è¯­è¨€æˆ–ç ”ç©¶è®¾è®¡é™åˆ¶ã€‚çº³å…¥æ ‡å‡†åŒ…æ‹¬åŸåˆ›æ–‡ç« æˆ–å¸¦æœ‰åŸå§‹æ•°æ®çš„æ–‡ç« ã€ä¼´æˆ–ä¸ä¼´è‚›ç˜˜çš„è‚›å‘¨è„“è‚¿çš„æ²»ç–—ç ”ç©¶ä»¥åŠæ‚£è€…å¹´é¾„<18å²ã€‚æ‚£æœ‰å±€éƒ¨æ¶æ€§è‚¿ç˜¤ã€å…‹ç½—æ©ç—…æˆ–å…¶ä»–æ½œåœ¨è¯±å‘å› ç´ çš„æ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æœªåˆ†æå¤å‘çš„ç ”ç©¶ã€ç—…ä¾‹ç³»åˆ—<5å’Œä¸ç›¸å…³çš„æ–‡ç« åœ¨ç­›é€‰é˜¶æ®µè¢«æ’é™¤ã€‚åœ¨ç­›é€‰çš„ 124 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 14 ç¯‡æ–‡ç« æ²¡æœ‰å…¨æ–‡æˆ–è¯¦ç»†ä¿¡æ¯ã€‚ç”¨è‹±è¯­æˆ–æ™®é€šè¯ä»¥å¤–çš„è¯­è¨€æ’°å†™çš„æ–‡ç« é¦–å…ˆé€šè¿‡è°·æ­Œç¿»è¯‘è¿›è¡Œç¿»è¯‘ï¼Œå¹¶ä¸æ¯è¯­äººå£«ç¡®è®¤ã€‚èµ„æ ¼å®¡æŸ¥ç»“æŸåï¼Œå¯¹å·²ç¡®å®šçš„ä¸»è¦ç®¡ç†æªæ–½è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶éšåè¢«çº³å…¥å®šæ€§ç»¼åˆã€‚\n\n**ç»“æœï¼š** æ¶‰åŠ 2507 åå„¿ç§‘æ‚£è€…çš„ 31 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ç ”ç©¶è®¾è®¡åŒ…æ‹¬ä¸¤ä¸ªåŒ…å« 47 åæ‚£è€…çš„å‰ç»æ€§ç—…ä¾‹ç³»åˆ—å’Œå›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹å¯¹åˆå§‹æ²»ç–—åçš„å¤å‘è¿›è¡ŒèŸèƒåˆ†æã€‚ä¿å®ˆæ²»ç–—å’Œå¼•æµæ˜¾ç¤ºæ²¡æœ‰å·®å¼‚ï¼ˆä¼˜åŠ¿æ¯” [OR]ï¼Œ1.222ï¼›95% ç½®ä¿¡åŒºé—´ [CI]ï¼š0.615-2.427ï¼Œp = 0.567ï¼‰ã€‚ä¿å®ˆæ²»ç–—çš„å¤å‘é£é™©é«˜äºæ‰‹æœ¯ï¼Œä½†æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆOR 0.278ï¼Œ95% CIï¼š0.109-0.707ï¼Œp = 0.007ï¼‰ã€‚ä¸åˆ‡å¼€/å¼•æµç›¸æ¯”ï¼Œæ‰‹æœ¯å¯ä»¥æ˜¾ç€é¢„é˜²å¤å‘ï¼ˆOR 4.360ï¼Œ95% CIï¼š1.761-10.792ï¼Œp = 0.001ï¼‰ã€‚ç”±äºç¼ºä¹ä¿¡æ¯ï¼Œæœªå¯¹ä¿å®ˆæ²»ç–—å’Œæ‰‹æœ¯ä¸­çš„ä¸åŒæ–¹æ³•è¿›è¡Œäºšç»„åˆ†æã€‚\n\n**ç»“è®ºï¼š** ç”±äºç¼ºä¹å‰ç»æ€§æˆ–éšæœºå¯¹ç…§ç ”ç©¶ï¼Œæ— æ³•æå‡ºå¼ºçƒˆå»ºè®®ã€‚ç„¶è€Œï¼Œç›®å‰åŸºäºçœŸå®åˆçº§ç®¡ç†çš„ç ”ç©¶æ”¯æŒå¯¹è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„å„¿ç§‘æ‚£è€…è¿›è¡Œåˆæ­¥æ‰‹æœ¯å¹²é¢„ä»¥é¢„é˜²å¤å‘ã€‚\n\n**Level of evidenceï¼š** ç ”ç©¶ç±»å‹ï¼šç³»ç»Ÿè¯„ä»·ï¼›è¯æ®çº§åˆ«ï¼šIIçº§ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œå„¿ç§‘ï¼Œè‚›å‘¨è„“è‚¿ï¼Œåˆçº§æ²»ç–—", "keywords_en": "Anal fistula, Pediatric, Perianal abscess, Primary management", "link": "https://pubmed.ncbi.nlm.nih.gov/36894443/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 09 Mar 2023"}, {"id": "36847868", "title_en": "Conservative surgery versus colorectal resection for endometriosis with rectal involvement: a systematic review and meta-analysis of surgical and long-term outcomes", "title_zh": "ä¿å®ˆæ‰‹æœ¯ä¸ç»“ç›´è‚ åˆ‡é™¤æœ¯æ²»ç–—ç›´è‚ å—ç´¯å­å®«å†…è†œå¼‚ä½ç—‡ï¼šæ‰‹æœ¯å’Œé•¿æœŸç»“æœçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Cillian Clancy", "abstract_en": "**Purpose:** The optimal surgical approach for removal of colorectal endometrial deposits is unclear. Shaving and discoid excision of colorectal deposits allow organ preservation but risk recurrence with associated functional issues and re-operation. Formal resection risks potential higher complications but may be associated with lower recurrence rates. This meta-analysis compares peri-operative and long-term outcomes between conservative surgery (shaving and disc excision) versus formal colorectal resection.\n\n**Methods:** The study was registered with PROSPERO. A systematic search was performed on PubMed and EMBASE databases. All comparative studies examining surgical outcomes in patients that underwent conservative surgery versus colorectal resection for rectal endometrial deposits were included. The two main groups (conservative versus resection) were compared in three main blocks of variables including group comparability, operative outcomes and long-term outcomes.\n\n**Results:** Seventeen studies including 2861 patients were analysed with patients subdivided by procedure: colorectal resection (nâ€‰=â€‰1389), shaving (nâ€‰=â€‰703) and discoid excision (nâ€‰=â€‰742). When formal colorectal resection was compared to conservative surgery there was lower risk of recurrence (pâ€‰=â€‰0.002), comparable functional outcomes (minor LARS, pâ€‰=â€‰0.30, major LARS, pâ€‰=â€‰0.54), similar rates of postoperative leaks (pâ€‰=â€‰0.22), pelvic abscesses (pâ€‰=â€‰0.18) and rectovaginal fistula (pâ€‰=â€‰0.92). On subgroup analysis, shaving had the highest recurrence rate (pâ€‰=â€‰0.0007), however a lower rate of stoma formation (pâ€‰<â€‰0.00001) and rectal stenosis (pâ€‰=â€‰0.01). Discoid excision and formal resection were comparable.\n\n**Conclusion:** Colorectal resection has a significantly lower recurrence rate compared to shaving. There is no difference in complications or functional outcomes between discoid excision and formal resection and both have similar recurrence rates.", "abstract_zh": "**Purposeï¼š** å»é™¤ç»“ç›´è‚ å­å®«å†…è†œæ²‰ç§¯ç‰©çš„æœ€ä½³æ‰‹æœ¯æ–¹æ³•å°šä¸æ¸…æ¥šã€‚ç»“ç›´è‚ æ²‰ç§¯ç‰©çš„å‰ƒé™¤å’Œç›˜çŠ¶åˆ‡é™¤å¯ä»¥ä¿ç•™å™¨å®˜ï¼Œä½†å­˜åœ¨ç›¸å…³åŠŸèƒ½é—®é¢˜å’Œå†æ¬¡æ‰‹æœ¯å¤å‘çš„é£é™©ã€‚æ­£å¼åˆ‡é™¤å¯èƒ½ä¼šå¸¦æ¥æ›´é«˜å¹¶å‘ç—‡çš„é£é™©ï¼Œä½†å¯èƒ½ä¼šé™ä½å¤å‘ç‡ã€‚è¿™é¡¹èŸèƒåˆ†ææ¯”è¾ƒäº†ä¿å®ˆæ‰‹æœ¯ï¼ˆå‰ƒæ¯›å’Œæ¤é—´ç›˜åˆ‡é™¤ï¼‰ä¸æ­£å¼ç»“ç›´è‚ åˆ‡é™¤æœ¯çš„å›´æ‰‹æœ¯æœŸå’Œé•¿æœŸç»“æœã€‚\n\n**æ–¹æ³•ï¼š** è¯¥ç ”ç©¶å·²åœ¨ PROSPERO æ³¨å†Œã€‚å¯¹ PubMed å’Œ EMBASE æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚æ‰€æœ‰æ¯”è¾ƒç ”ç©¶å‡çº³å…¥äº†é’ˆå¯¹ç›´è‚ å­å®«å†…è†œæ²‰ç§¯ç‰©æ¥å—ä¿å®ˆæ‰‹æœ¯ä¸ç»“ç›´è‚ åˆ‡é™¤æœ¯çš„æ‚£è€…çš„æ‰‹æœ¯ç»“æœã€‚ä¸¤ä¸ªä¸»è¦ç»„ï¼ˆä¿å®ˆç»„ä¸åˆ‡é™¤ç»„ï¼‰åœ¨ä¸‰ä¸ªä¸»è¦å˜é‡æ–¹é¢è¿›è¡Œæ¯”è¾ƒï¼ŒåŒ…æ‹¬ç»„å¯æ¯”æ€§ã€æ‰‹æœ¯ç»“æœå’Œé•¿æœŸç»“æœã€‚\n\n**ç»“æœï¼š** å¯¹åŒ…æ‹¬ 2861 åæ‚£è€…çš„ 17 é¡¹ç ”ç©¶è¿›è¡Œäº†åˆ†æï¼Œæ‚£è€…æŒ‰æ‰‹æœ¯ç»†åˆ†ä¸ºï¼šç»“ç›´è‚ åˆ‡é™¤æœ¯ (nâ€‰=â€‰1389)ã€å‰ƒé¡»æœ¯ (nâ€‰=â€‰703) å’Œç›˜çŠ¶åˆ‡é™¤æœ¯ (nâ€‰=â€‰742)ã€‚å½“æ­£å¼ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸ä¿å®ˆæ‰‹æœ¯ç›¸æ¯”æ—¶ï¼Œå¤å‘é£é™©è¾ƒä½ï¼ˆpâ€‰=â€‰0.002ï¼‰ï¼ŒåŠŸèƒ½ç»“æœç›¸å½“ï¼ˆè½»å¾® LARSï¼Œpâ€‰=â€‰0.30ï¼Œä¸¥é‡ LARSï¼Œpâ€‰=â€‰0.54ï¼‰ï¼Œæœ¯åæ¼å°¿ç‡ç›¸ä¼¼ï¼ˆpâ€‰=â€‰0.22ï¼‰ï¼Œç›†è…”è„“è‚¿ï¼ˆpâ€‰=â€‰0.18ï¼‰å’Œç›´è‚ é˜´é“ç˜˜ (pâ€‰=â€‰0.92)ã€‚åœ¨äºšç»„åˆ†æä¸­ï¼Œå‰ƒæ¯›çš„å¤å‘ç‡æœ€é«˜ï¼ˆpâ€‰=â€‰0.0007ï¼‰ï¼Œä½†é€ å£å½¢æˆç‡ï¼ˆpâ€‰<â€‰0.00001ï¼‰å’Œç›´è‚ ç‹­çª„ç‡è¾ƒä½ï¼ˆpâ€‰=â€‰0.01ï¼‰ã€‚ç›˜çŠ¶åˆ‡é™¤å’Œæ­£å¼åˆ‡é™¤å…·æœ‰å¯æ¯”æ€§ã€‚\n\n**ç»“è®ºï¼š** ä¸å‰ƒé™¤ç›¸æ¯”ï¼Œç»“ç›´è‚ åˆ‡é™¤æœ¯çš„å¤å‘ç‡æ˜¾ç€é™ä½ã€‚ç›˜çŠ¶åˆ‡é™¤å’Œæ­£å¼åˆ‡é™¤ä¹‹é—´çš„å¹¶å‘ç—‡æˆ–åŠŸèƒ½ç»“æœæ²¡æœ‰å·®å¼‚ï¼Œå¹¶ä¸”ä¸¤è€…çš„å¤å‘ç‡ç›¸ä¼¼ã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€å­å®«å†…è†œå¼‚ä½ç—‡ã€èŸèƒåˆ†æã€æ‰‹æœ¯ã€æ‰‹æœ¯ç»“æœ", "keywords_en": "Colorectal surgery, Endometriosis, Meta-analysis, Surgery, Surgery outcomes", "link": "https://pubmed.ncbi.nlm.nih.gov/36847868/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 27 Feb 2023"}, {"id": "36740680", "title_en": "Surgical management of complex perianal fistula revisited in a systematic review: a critical view of available scientific evidence", "title_zh": "ç³»ç»Ÿè¯„ä»·é‡æ–°å®¡è§†å¤æ‚è‚›å‘¨ç˜˜çš„æ‰‹æœ¯æ²»ç–—ï¼šå¯¹ç°æœ‰ç§‘å­¦è¯æ®çš„æ‰¹åˆ¤æ€§è§‚ç‚¹", "authors": "F de la Portilla", "abstract_en": "**Background:** Treating complex perianal fistulas in Crohn's disease patients remains a challenge. Classical surgical treatments for Crohn's disease fistulas have been extrapolated from cryptoglandular fistulas treatment, which have different etiology, and this might interfere with its effectiveness, in addition, they increase fecal incontinence risk. Recently, new surgical techniques with support from biological approaches, like stem cells, have been developed to preserve the function of the sphincter. We have performed a systematic literature review to compare the results of these different techniques in the treatment of Crohn's or Cryptoglandular fistula.\n\n**Methods:** PubMed, EMBASE, Database of Abstracts of Reviews of Effectiveness, Cochrane Central Register of Controlled Trials were searched systematically for relevant articles. We included randomized controlled trials and observational studies that referred to humans, were written in English, included adults 18+ years old, and were published during the 10-year period from 2/01/2010 to 2/29/2020. Evidence level was assigned as designated by the Scottish Intercollegiate Guidelines Network.\n\n**Results:** Of the 577 citations screened, a total of 79 were ultimately included in our review. In Crohn's disease patients, classical techniques such as primarily seton, Ligation of Intersphincteric Fistula Tracks, or lay open, healing rates were approximately 50-60%, while in cryptoglandular fistula were around, 70-80% for setons or flaps. In Crohn's disease patients, new surgical techniques using derivatives of adipose tissue reported healing rates exceeding 70%, stem cells-treated patients achieved higher combined remission versus controls (56.3% vs 38.6%, pâ€‰=â€‰0.010), mesenchymal cells reported a healing rate of 80% at week 12. In patients with cryptoglandular fistulas, a healing rate of 70% using derivatives of adipose tissue or platelets was achieved, and a healing rate of 80% was achieved using laser technology. Fecal incontinence was improved after the use of autologous platelet growth factors and Nitinol Clips.\n\n**Conclusion:** New surgical techniques showed better healing rates in Crohn's disease patients than classical techniques, which have better results in cryptoglandular fistula than in Crohn's disease. Healing rates for complex cryptoglandular fistulas were similar between the classic and new techniques, being the new techniques less invasive; the incontinence rate improved with the current techniques.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ²»ç–—å…‹ç½—æ©ç—…æ‚£è€…çš„å¤æ‚è‚›å‘¨ç˜˜ä»ç„¶æ˜¯ä¸€ä¸ªæŒ‘æˆ˜ã€‚å…‹ç½—æ©ç—…ç˜˜ç®¡çš„ç»å…¸æ‰‹æœ¯æ²»ç–—æ˜¯ä»éšè…ºç˜˜ç®¡æ²»ç–—ä¸­æ¨æ–­å‡ºæ¥çš„ï¼Œå…¶ç—…å› ä¸åŒï¼Œè¿™å¯èƒ½ä¼šå¹²æ‰°å…¶æœ‰æ•ˆæ€§ï¼Œæ­¤å¤–ï¼Œè¿˜ä¼šå¢åŠ å¤§ä¾¿å¤±ç¦çš„é£é™©ã€‚æœ€è¿‘ï¼Œåœ¨ç”Ÿç‰©æ–¹æ³•ï¼ˆå¦‚å¹²ç»†èƒï¼‰æ”¯æŒä¸‹çš„æ–°æ‰‹æœ¯æŠ€æœ¯å·²è¢«å¼€å‘å‡ºæ¥ï¼Œä»¥ä¿ç•™æ‹¬çº¦è‚Œçš„åŠŸèƒ½ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿçš„æ–‡çŒ®ç»¼è¿°ï¼Œä»¥æ¯”è¾ƒè¿™äº›ä¸åŒæŠ€æœ¯æ²»ç–—å…‹ç½—æ©ç—…æˆ–éšçªç˜˜çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ç³»ç»Ÿåœ°æ£€ç´¢äº† PubMedã€EMBASEã€æœ‰æ•ˆæ€§è¯„ä»·æ‘˜è¦æ•°æ®åº“ã€Cochrane å¯¹ç…§è¯•éªŒä¸­å¿ƒæ³¨å†Œåº“ä¸­çš„ç›¸å…³æ–‡ç« ã€‚æˆ‘ä»¬çº³å…¥äº†æ¶‰åŠäººç±»çš„éšæœºå¯¹ç…§è¯•éªŒå’Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œä»¥è‹±æ–‡æ’°å†™ï¼ŒåŒ…æ‹¬ 18 å²ä»¥ä¸Šçš„æˆå¹´äººï¼Œå¹¶åœ¨ 2010 å¹´ 2 æœˆ 1 æ—¥è‡³ 2020 å¹´ 2 æœˆ 29 æ—¥çš„ 10 å¹´é—´å‘è¡¨ã€‚è¯æ®çº§åˆ«ç”±è‹æ ¼å…°æ ¡é™…æŒ‡å—ç½‘ç»œæŒ‡å®šã€‚\n\n**ç»“æœï¼š** åœ¨ç­›é€‰çš„ 577 æ¡å¼•ç”¨ä¸­ï¼Œæœ€ç»ˆå…±æœ‰ 79 æ¡è¢«çº³å…¥æˆ‘ä»¬çš„å®¡æŸ¥ä¸­ã€‚åœ¨å…‹ç½—æ©ç—…æ‚£è€…ä¸­ï¼Œç»å…¸æŠ€æœ¯ï¼Œå¦‚ä¸»è¦æŒ‚çº¿ã€æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰æˆ–åˆ‡å¼€ï¼Œæ„ˆåˆç‡çº¦ä¸º 50-60%ï¼Œè€Œéšçªç˜˜çš„æ„ˆåˆç‡çº¦ä¸º 70-80%ï¼Œé‡‡ç”¨æŒ‚çº¿æˆ–çš®ç“£æ²»ç–—ã€‚åœ¨å…‹ç½—æ©ç—…æ‚£è€…ä¸­ï¼Œä½¿ç”¨è„‚è‚ªç»„ç»‡è¡ç”Ÿç‰©çš„æ–°æ‰‹æœ¯æŠ€æœ¯æŠ¥å‘Šæ²»æ„ˆç‡è¶…è¿‡ 70%ï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œå¹²ç»†èƒæ²»ç–—çš„æ‚£è€…å®ç°äº†æ›´é«˜çš„ç»¼åˆç¼“è§£ç‡ï¼ˆ56.3% vs 38.6%ï¼Œpâ€‰=â€‰0.010ï¼‰ï¼Œé—´å……è´¨ç»†èƒæŠ¥å‘Šç¬¬ 12 å‘¨æ—¶çš„æ²»æ„ˆç‡ä¸º 80%ã€‚åœ¨éšè…ºç˜˜æ‚£è€…ä¸­ï¼Œä½¿ç”¨è„‚è‚ªç»„ç»‡æˆ–è¡€å°æ¿è¡ç”Ÿç‰©çš„æ²»æ„ˆç‡ä¸º 70%å¹¶åˆ©ç”¨æ¿€å…‰æŠ€æœ¯å®ç°äº†80%çš„æ²»æ„ˆç‡ã€‚ä½¿ç”¨è‡ªä½“è¡€å°æ¿ç”Ÿé•¿å› å­å’Œé•é’›è¯ºå¤¹åï¼Œå¤§ä¾¿å¤±ç¦å¾—åˆ°æ”¹å–„ã€‚\n\n**ç»“è®ºï¼š** æ–°çš„æ‰‹æœ¯æŠ€æœ¯åœ¨å…‹ç½—æ©ç—…æ‚£è€…ä¸­æ˜¾ç¤ºå‡ºæ¯”ä¼ ç»ŸæŠ€æœ¯æ›´å¥½çš„æ²»æ„ˆç‡ï¼Œè€Œä¼ ç»ŸæŠ€æœ¯åœ¨éšçªè…ºç˜˜æ–¹é¢çš„æ•ˆæœä¼˜äºå…‹ç½—æ©ç—…ã€‚å¤æ‚çš„éšè…ºç˜˜çš„æ„ˆåˆç‡åœ¨ç»å…¸æŠ€æœ¯å’Œæ–°æŠ€æœ¯ä¹‹é—´ç›¸ä¼¼ï¼Œå› ä¸ºæ–°æŠ€æœ¯ä¾µå…¥æ€§è¾ƒå°ï¼›ä½¿ç”¨å½“å‰æŠ€æœ¯ï¼Œå¤±ç¦ç‡æœ‰æ‰€æ”¹å–„ã€‚", "keywords_zh": "å¤æ‚è‚›å‘¨ç˜˜ã€å…‹ç½—æ©ç—…ã€éšè…ºç˜˜ã€æ‰‹æœ¯", "keywords_en": "Complex perianal fistula, Crohnâ€™s disease, Cryptoglandular fistula, Surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/36740680/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sun, 05 Feb 2023"}, {"id": "36735766", "title_en": "Gracilis Muscle Interposition for the Treatment of Rectovaginal Fistula: A Systematic Review and Pooled Analysis", "title_zh": "è‚¡è–„è‚Œä»‹å…¥æ²»ç–—ç›´è‚ é˜´é“ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’Œæ±‡æ€»åˆ†æ", "authors": "Tracy L Hull", "abstract_en": "**Background:** A rectovaginal fistula is a debilitating condition that often severely impacts quality of life. Despite many treatment options available, the best surgical treatment is far from being established, and many patients will undergo several procedures before fistula closure is achieved. Gracilis muscle interposition, which is the transposition of the gracilis muscle into the rectovaginal septum, is an option for complex and persistent fistulas, but literature on the subject is scarce, mainly consisting of small case series.\n\n**Objective:** This study aimed to assess the success rate of gracilis muscle interposition for the surgical treatment of rectovaginal fistula.\n\n**Data Sources:** MEDLINE, Embase, Cochrane Library, and Web of Science.\n\n**Study Selection:** Studies comprising at least 5 patients who underwent gracilis muscle interposition for rectovaginal fistula were included. No date or language restrictions was applied.\n\n**Intervention:** Gracilis muscle interposition.\n\n**Main Outcome Measures:** The primary outcome is the fistula closure rate (%). Other domains analyzed are stoma closure rate, postoperative complications, quality of life, fecal continence, and sexual function.\n\n**Results:** Twenty studies were included for a total of 384 patients. The pooled fistula closure rate for gracilis muscle interposition was 64% (95% CI, 53%-74%; range, 33%-100%). Risk factors for failure were smoking, underlying Crohn's disease, and more than 2 previous repairs, whereas stoma formation was associated with improved outcomes. Postoperative complications ranged from 0% to 37%, mostly related to surgical site occurrences at the harvest site and perineal area. No deaths occurred. Gracilis muscle interposition improved quality of life and fecal continence, but impairment of sexual function was common.\n\n**Limitations:** Most of the included studies were small case series.\n\n**Conclusions:** Gracilis muscle interposition is a safe and moderately effective treatment that could be taken into consideration as second- or third-line therapy for recurrent rectovaginal fistula.\n\n**Registration No:** CRD42022319621.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ é˜´é“ç˜˜æ˜¯ä¸€ç§ä½¿äººè¡°å¼±çš„ç–¾ç—…ï¼Œå¸¸å¸¸ä¸¥é‡å½±å“ç”Ÿæ´»è´¨é‡ã€‚å°½ç®¡æœ‰è®¸å¤šæ²»ç–—é€‰æ‹©ï¼Œä½†æœ€ä½³çš„æ‰‹æœ¯æ²»ç–—è¿˜è¿œæœªç¡®å®šï¼Œè®¸å¤šæ‚£è€…åœ¨å®ç°ç˜˜ç®¡é—­åˆä¹‹å‰å°†æ¥å—å¤šæ¬¡æ‰‹æœ¯ã€‚è‚¡è–„è‚Œä»‹å…¥æœ¯ï¼Œå³å°†è‚¡è–„è‚Œè½¬ä½è‡³ç›´è‚ é˜´é“éš”è†œï¼Œæ˜¯å¤æ‚ä¸”æŒç»­æ€§ç˜˜ç®¡çš„ä¸€ç§é€‰æ‹©ï¼Œä½†æœ‰å…³è¯¥ä¸»é¢˜çš„æ–‡çŒ®å¾ˆå°‘ï¼Œä¸»è¦ç”±å°ç—…ä¾‹ç³»åˆ—ç»„æˆã€‚\n\n**ç›®çš„ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°è‚¡è–„è‚Œä»‹å…¥æ‰‹æœ¯æ²»ç–—ç›´è‚ é˜´é“ç˜˜çš„æˆåŠŸç‡ã€‚\n\n**Data sourcesï¼š** MEDLINEã€Embaseã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Scienceã€‚\n\n**Study selectionï¼š** ç ”ç©¶çº³å…¥äº†è‡³å°‘ 5 åæ¥å—è‚¡è–„è‚Œä»‹å…¥æ²»ç–—ç›´è‚ é˜´é“ç˜˜çš„æ‚£è€…ã€‚æ²¡æœ‰æ—¥æœŸæˆ–è¯­è¨€é™åˆ¶ã€‚\n\n**Interventionï¼š** è‚¡è–„è‚Œä»‹å…¥ã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“æœæ˜¯ç˜˜ç®¡é—­åˆç‡ï¼ˆ%ï¼‰ã€‚å…¶ä»–åˆ†æé¢†åŸŸåŒ…æ‹¬é€ å£é—­åˆç‡ã€æœ¯åå¹¶å‘ç—‡ã€ç”Ÿæ´»è´¨é‡ã€å¤§ä¾¿å¤±ç¦å’Œæ€§åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 20 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 384 åæ‚£è€…ã€‚è‚¡è–„è‚Œä»‹å…¥çš„åˆå¹¶ç˜˜ç®¡é—­åˆç‡ä¸º 64%ï¼ˆ95% CIï¼Œ53%-74%ï¼›èŒƒå›´ï¼Œ33%-100%ï¼‰ã€‚å¤±è´¥çš„å±é™©å› ç´ åŒ…æ‹¬å¸çƒŸã€æ½œåœ¨çš„å…‹ç½—æ©ç—…ä»¥åŠä¸¤æ¬¡ä»¥ä¸Šçš„ä¿®å¤æ‰‹æœ¯ï¼Œè€Œé€ å£å½¢æˆä¸é¢„åæ”¹å–„ç›¸å…³ã€‚æœ¯åå¹¶å‘ç—‡çš„å‘ç”Ÿç‡ä» 0% åˆ° 37% ä¸ç­‰ï¼Œä¸»è¦ä¸é‡‡é›†éƒ¨ä½å’Œä¼šé˜´åŒºåŸŸçš„æ‰‹æœ¯éƒ¨ä½å‘ç”Ÿæœ‰å…³ã€‚æ²¡æœ‰å‘ç”Ÿæ­»äº¡äº‹ä»¶ã€‚è‚¡è–„è‚Œä»‹å…¥æ”¹å–„äº†ç”Ÿæ´»è´¨é‡å’Œå¤§ä¾¿å¤±ç¦ï¼Œä½†æ€§åŠŸèƒ½å—æŸå¾ˆå¸¸è§ã€‚\n\n**Limitationsï¼š** å¤§å¤šæ•°çº³å…¥çš„ç ”ç©¶éƒ½æ˜¯å°ç—…ä¾‹ç³»åˆ—ã€‚\n\n**ç»“è®ºï¼š** è‚¡è–„è‚Œä»‹å…¥æ²»ç–—æ˜¯ä¸€ç§å®‰å…¨ä¸”ä¸­ç­‰æœ‰æ•ˆçš„æ²»ç–—æ–¹æ³•ï¼Œå¯è€ƒè™‘ä½œä¸ºå¤å‘æ€§ç›´è‚ é˜´é“ç˜˜çš„äºŒçº¿æˆ–ä¸‰çº¿æ²»ç–—ã€‚\n\n**Registration noï¼š** CRD42022319621ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/36735766/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 03 Feb 2023"}, {"id": "36658773", "title_en": "Autologous fat graft injections for the treatment of perianal fistulas in Crohn's disease: a systematic review and single-arm meta-analysis", "title_zh": "è‡ªä½“è„‚è‚ªç§»æ¤æ³¨å°„æ²»ç–—å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’Œå•è‡‚èŸèƒåˆ†æ", "authors": "SVHM IBD Collaborative Group", "abstract_en": "**Background:** Crohn's perianal fistulas are often refractory to standard management. Fat graft injections are hypothesised to improve fistula healing rates. We evaluated the treatment efficacy of fat graft injections for Crohn's perianal fistulas in a systematic review (PRISMA).\n\n**Methods:** We completed database searches of MEDLINE (Ovid), Embase, and PubMed. All studies published in English in full text or abstract, from January 2001 to August 2021, evaluating fat graft injections for Crohn's perianal fistulas were selected. Included randomized controlled trials, single-arm intervention trials, cohort studies, and case series; excluded single case reports. Primary outcome was pooled clinical healing, defined as non-draining treated fistulas, or closure, defined as closure of treated fistulas. Secondary outcomes were clinical healing, clinical closure, radiologic response, and adverse events.\n\n**Results:** Of 1258 publications identified, 891 articles were assessed for eligibility, and 107 relevant for manuscript review. Forty-nine patients received fat graft injections for Crohn's perianal fistulas across four single-arm intervention trials. Clinical healing or closure was achieved in 74% in a pooled single-arm meta-analysis (95% confidence interval: 57%, 85%), with moderate heterogeneity between studies. Clinical healing was achieved in 20% and 60% at 3 and 12â€‰months, respectively. Clinical closure was achieved in 83% at 6Â months. Variable parameters were used to define radiologic response, with success rates from 20% to 67%. Minimal adverse events were reported.\n\n**Conclusion:** Fat graft injections show promise as a novel treatment for Crohn's perianal fistulas in this systematic review and meta-analysis. Assessment in controlled matched studies is warranted.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜é€šå¸¸éš¾ä»¥é€šè¿‡æ ‡å‡†æ²»ç–—æ²»ç–—ã€‚å‡è®¾è„‚è‚ªç§»æ¤æ³¨å°„å¯ä»¥æé«˜ç˜˜ç®¡æ„ˆåˆç‡ã€‚æˆ‘ä»¬åœ¨ç³»ç»Ÿè¯„ä»·ï¼ˆPRISMAï¼‰ä¸­è¯„ä¼°äº†è„‚è‚ªç§»æ¤æ³¨å°„æ²»ç–—å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„æ²»ç–—æ•ˆæœã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å®Œæˆäº† MEDLINE (Ovid)ã€Embase å’Œ PubMed çš„æ•°æ®åº“æ£€ç´¢ã€‚é€‰æ‹©2001å¹´1æœˆè‡³2021å¹´8æœˆä»¥è‹±æ–‡å…¨æ–‡æˆ–æ‘˜è¦å‘è¡¨çš„æ‰€æœ‰è¯„ä¼°è„‚è‚ªç§»æ¤æ³¨å°„æ²»ç–—å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„ç ”ç©¶ã€‚åŒ…æ‹¬éšæœºå¯¹ç…§è¯•éªŒã€å•è‡‚å¹²é¢„è¯•éªŒã€é˜Ÿåˆ—ç ”ç©¶å’Œç—…ä¾‹ç³»åˆ—ï¼›æ’é™¤å•ä¾‹æŠ¥å‘Šã€‚ä¸»è¦ç»“æœæ˜¯æ±‡æ€»ä¸´åºŠæ„ˆåˆï¼ˆå®šä¹‰ä¸ºæœªå¼•æµæ²»ç–—çš„ç˜˜ç®¡ï¼‰æˆ–é—­åˆï¼ˆå®šä¹‰ä¸ºç»æ²»ç–—çš„ç˜˜ç®¡é—­åˆï¼‰ã€‚æ¬¡è¦ç»“å±€æ˜¯ä¸´åºŠæ²»æ„ˆã€ä¸´åºŠç»“æŸã€æ”¾å°„å­¦ååº”å’Œä¸è‰¯äº‹ä»¶ã€‚\n\n**ç»“æœï¼š** åœ¨ç¡®å®šçš„ 1258 ç¯‡å‡ºç‰ˆç‰©ä¸­ï¼Œæœ‰ 891 ç¯‡æ–‡ç« è¿›è¡Œäº†èµ„æ ¼è¯„ä¼°ï¼Œ107 ç¯‡æ–‡ç« è¿›è¡Œäº†æ‰‹ç¨¿å®¡æŸ¥ã€‚åœ¨å››é¡¹å•è‡‚å¹²é¢„è¯•éªŒä¸­ï¼Œ49 åæ‚£è€…æ¥å—äº†è„‚è‚ªç§»æ¤æ³¨å°„æ²»ç–—å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ã€‚åœ¨ä¸€é¡¹æ±‡æ€»çš„å•è‡‚èŸèƒåˆ†æä¸­ï¼Œ74% çš„æ‚£è€…å®ç°äº†ä¸´åºŠæ²»æ„ˆæˆ–é—­åˆï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼š57%ã€85%ï¼‰ï¼Œç ”ç©¶ä¹‹é—´å­˜åœ¨ä¸­ç­‰å¼‚è´¨æ€§ã€‚ 3 ä¸ªæœˆå’Œ 12 ä¸ªæœˆæ—¶ï¼Œä¸´åºŠæ²»æ„ˆç‡åˆ†åˆ«ä¸º 20% å’Œ 60%ã€‚ 83% çš„æ‚£è€…åœ¨ 6 ä¸ªæœˆå†…å®ç°äº†ä¸´åºŠå°é—­ã€‚ä½¿ç”¨å¯å˜å‚æ•°æ¥å®šä¹‰æ”¾å°„å­¦ååº”ï¼ŒæˆåŠŸç‡ä» 20% åˆ° 67%ã€‚æŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶æå°‘ã€‚\n\n**ç»“è®ºï¼š** åœ¨æœ¬æ¬¡ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æä¸­ï¼Œè„‚è‚ªç§»æ¤æ³¨å°„æ˜¾ç¤ºå‡ºä½œä¸ºå…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„æ–°å‹æ²»ç–—æ–¹æ³•çš„å‰æ™¯ã€‚å¯¹ç…§åŒ¹é…ç ”ç©¶ä¸­çš„è¯„ä¼°æ˜¯æœ‰å¿…è¦çš„ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ï¼Œè„‚è‚ªç§»æ¤ï¼ŒèŸèƒåˆ†æï¼Œè‚›å‘¨ç˜˜ï¼Œç³»ç»Ÿè¯„ä»·", "keywords_en": "Crohn's disease, fat graft, metaanalysis, perianal fistula, systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/36658773/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 20 Jan 2023"}, {"id": "36474515", "title_en": "Postoperative complications of colectomy and J-pouch with ileostomy versus without ileostomy in children with inflammatory bowel diseases: a systematic review and meta-analysis", "title_zh": "ç‚ç—‡æ€§è‚ ç—…å„¿ç«¥ç»“è‚ åˆ‡é™¤æœ¯å’Œ J å‹è¢‹å›è‚ é€ å£ä¸ä¸å›è‚ é€ å£çš„æœ¯åå¹¶å‘ç—‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Ahmed Nasr", "abstract_en": "**Background:** The efficacy of performing a restorative proctocolectomy and J-pouch ileoanal anastomosis without diverting ileostomy in children with inflammatory bowel disease has been a longstanding debate. A systematic review and meta-analysis is presented comparing the occurrence of postoperative complications in children who underwent either the pouch-anal anastomosis (IPAA) with ileostomy (diverted) versus the undiverted procedure.\n\n**Methods:** Records were sourced from CINAHL, CENTRAL, EMBASE and MEDLINE databases. Studies followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and compared postoperative complications in pediatric patients diagnosed with inflammatory diseases aged less than 18 years who underwent J-pouch with ileostomy versus without ileostomy. The primary outcome was the occurrence of postoperative leaks, and the secondary outcomes were presence of postoperative small bowel obstruction (SBO), pouchitis, stricture and fistula complications. A random-effects meta-analysis was used.\n\n**Results:** Twenty-three observational studies in the systematic review were included with 658 patients (83% diverted, 17% undiverted). Pooled estimates showed no difference in occurrence of leaks in children who underwent J-pouch/IPAA with ileostomy versus without (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.17 to 1.64, I<sup>2</sup>=16%). There was no difference in the occurrence of SBO, pouchitis or strictures in children who underwent J-pouch/IPAA with ileostomy versus without (SBO: OR 2.27, 95%â€‰CI 0.52 to 9.92, I<sup>2</sup>=0%, pouchitis: OR 1.76, 95%â€‰CI 0.95 to 3.24, I<sup>2</sup>=0%, strictures: OR 2.72, 95%â€‰CI 0.44 to 16.69, I<sup>2</sup>=66%).\n\n**Conclusion:** The meta-analysis did not find differences in the occurrence of complications in pediatric patients who underwent the IPAA with ileostomy procedure versus without ileostomy.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¯¹äºæ‚£æœ‰ç‚ç—‡æ€§è‚ ç—…çš„å„¿ç«¥ï¼Œåœ¨ä¸æ”¹é“å›è‚ é€ å£çš„æƒ…å†µä¸‹è¿›è¡Œæ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯å’Œ J å‹è¢‹å›è‚ è‚›é—¨å»åˆæœ¯çš„ç–—æ•ˆä¸€ç›´å­˜åœ¨äº‰è®®ã€‚ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¯”è¾ƒäº†æ¥å—å›è‚ é€ å£æœ¯ï¼ˆè½¬è¡Œï¼‰çš„å‚¨è¢‹è‚›é—¨å»åˆæœ¯ï¼ˆIPAAï¼‰ä¸æœªè½¬è¡Œæ‰‹æœ¯çš„å„¿ç«¥æœ¯åå¹¶å‘ç—‡çš„å‘ç”Ÿç‡ã€‚\n\n**æ–¹æ³•ï¼š** è®°å½•æ¥æºäº CINAHLã€CENTRALã€EMBASE å’Œ MEDLINE æ•°æ®åº“ã€‚ç ”ç©¶éµå¾ªç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææŒ‡å—çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼Œå¹¶æ¯”è¾ƒäº† 18 å²ä»¥ä¸‹è¢«è¯Šæ–­æ‚£æœ‰ç‚ç—‡æ€§ç–¾ç—…çš„å„¿ç§‘æ‚£è€…æ¥å—å›è‚ é€ å£æœ¯ä¸æœªæ¥å—å›è‚ é€ å£æœ¯çš„ J å‹è¢‹çš„æœ¯åå¹¶å‘ç—‡ã€‚ä¸»è¦ç»“å±€æ˜¯æœ¯åæ¼çš„å‘ç”Ÿï¼Œæ¬¡è¦ç»“å±€æ˜¯æœ¯åå°è‚ æ¢—é˜»ï¼ˆSBOï¼‰ã€å‚¨è¢‹ç‚ã€ç‹­çª„å’Œç˜˜ç®¡å¹¶å‘ç—‡çš„å­˜åœ¨ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·ä¸­çº³å…¥äº† 23 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œæ¶‰åŠ 658 åæ‚£è€…ï¼ˆ83% è½¬ç§»ï¼Œ17% æœªè½¬ç§»ï¼‰ã€‚æ±‡æ€»ä¼°è®¡æ˜¾ç¤ºï¼Œæ¥å— J-pouch/IPAA å¹¶è¿›è¡Œå›è‚ é€ å£æœ¯çš„å„¿ç«¥ä¸æœªè¿›è¡Œå›è‚ é€ å£æœ¯çš„å„¿ç«¥åœ¨æ¼æ°”å‘ç”Ÿç‡ä¸Šæ²¡æœ‰å·®å¼‚ï¼ˆæ¯”å€¼æ¯” (OR) 0.54ï¼Œ95% ç½®ä¿¡åŒºé—´ (CI) 0.17 è‡³ 1.64ï¼ŒI<sup>2</sup>=16%ï¼‰ã€‚æ¥å— J-å‚¨è¢‹/IPAA å›è‚ é€ å£æœ¯çš„å„¿ç«¥ä¸æœªæ¥å—å›è‚ é€ å£æœ¯çš„å„¿ç«¥ç›¸æ¯”ï¼ŒSBOã€å‚¨è¢‹ç‚æˆ–ç‹­çª„çš„å‘ç”Ÿç‡æ²¡æœ‰å·®å¼‚ï¼ˆSBOï¼šOR 2.27ï¼Œ95%â€‰CI 0.52 è‡³ 9.92ï¼ŒI<sup>2</sup>=0%ï¼Œå‚¨è¢‹ç‚ï¼šOR 1.76ï¼Œ95%â€‰CI 0.95 è‡³ 3.24ï¼Œ I<sup>2</sup>=0%ï¼Œç‹­çª„ï¼šOR 2.72ï¼Œ95%â€‰CI 0.44 è‡³ 16.69ï¼ŒI<sup>2</sup>=66%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** èŸèƒåˆ†ææœªå‘ç°æ¥å— IPAA å¹¶è¿›è¡Œå›è‚ é€ å£æœ¯çš„å„¿ç§‘æ‚£è€…ä¸æœªè¿›è¡Œå›è‚ é€ å£æœ¯çš„å„¿ç§‘æ‚£è€…çš„å¹¶å‘ç—‡å‘ç”Ÿç‡å­˜åœ¨å·®å¼‚ã€‚", "keywords_zh": "é’å°‘å¹´å¥åº·ã€æ•™è‚²ã€å¾ªè¯åŒ»å­¦ã€åŒ»å­¦ã€ç»Ÿè®¡", "keywords_en": "adolescent health, education, evidence-based medicine, medical, statistics", "link": "https://pubmed.ncbi.nlm.nih.gov/36474515/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 07 Dec 2022"}, {"id": "36413086", "title_en": "Gracilis muscle interposition for complex perineal fistulas: A systematic review and meta-analysis of the literature", "title_zh": "è‚¡è–„è‚Œä»‹å…¥æ²»ç–—å¤æ‚ä¼šé˜´ç˜˜ï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Steven D Wexner", "abstract_en": "**Aim:** Complex perineal fistulas (CPFs) are among the most challenging problems in colorectal practice. Various procedures have been used to treat CPFs, with none being a panacea. Our study aimed to assess the overall success and complication rates after gracilis muscle interposition in patients with CPF.\n\n**Method:** PubMed, Scopus and Google Scholar databases were systematically searched until January 2022 according to PRISMA 2020 guidelines. Studies including children <18â€‰years or <10 patients were excluded, as well as reviews, duplicate or animal studies, studies with poor documentation (no report of success rate) and non-English text. An open-source, cross-platform software for advanced meta-analysis openMeta [Analyst]â„¢ version 12.11.14 and Cochrane Review Manager 5.4Â® were used to conduct the meta-analysis of data.\n\n**Results:** Twenty-five studies published between 2002 and 2021 were identified. The studies included 658 patients (409 women). Most patients had rectovaginal (50.7%) or rectourethral fistulas (33.7%). The most common causes of CPF were pelvic surgery (29.4%) and inflammatory bowel disease (25.2%). A history of radiotherapy was reported in approximately 18% of the patients. 498 (75.7%) patients with CPF achieved complete healing after gracilis muscle interposition. The weighted mean rate of success of the gracilis interposition procedure was 79.4% (95% CI 73.8%-85%, I<sup>2</sup> Â =â€‰75.3%), the weighted mean short-term complication rate was 25.7% (95% CI 18.1-33.2, I<sup>2</sup> Â =â€‰84.1%) and the weighted mean rate for 30-day reoperation was 3.6% (95% CI 1.6-5.6, I<sup>2</sup> Â =â€‰42%). The weighted mean rate of fistula recurrence was 16.7% (95% CI 11%-22.3%, I<sup>2</sup> Â =Â 61%).\n\n**Conclusion:** The gracilis muscle interposition technique is a viable treatment option for CPF. Surgeons should be familiar with indications and techniques to offer it as an option for patients. Given the relatively infrequent use of the operation, referral rather than performance of graciloplasty is an acceptable option.", "abstract_zh": "**Aimï¼š** å¤æ‚çš„ä¼šé˜´ç˜˜ï¼ˆCPFï¼‰æ˜¯ç»“ç›´è‚ å®è·µä¸­æœ€å…·æŒ‘æˆ˜æ€§çš„é—®é¢˜ä¹‹ä¸€ã€‚äººä»¬å·²ç»ä½¿ç”¨äº†å¤šç§æ–¹æ³•æ¥æ²»ç–— CPFï¼Œä½†æ²¡æœ‰ä¸€ç§æ–¹æ³•æ˜¯ä¸‡èƒ½çš„ã€‚æˆ‘ä»¬çš„ç ”ç©¶æ—¨åœ¨è¯„ä¼° CPF æ‚£è€…è‚¡è–„è‚Œä»‹å…¥æ²»ç–—åçš„æ€»ä½“æˆåŠŸç‡å’Œå¹¶å‘ç—‡å‘ç”Ÿç‡ã€‚\n\n**Methodï¼š** æ ¹æ® PRISMA 2020 æŒ‡å—ï¼Œå¯¹ PubMedã€Scopus å’Œ Google Scholar æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œç›´è‡³ 2022 å¹´ 1 æœˆã€‚æ’é™¤äº†åŒ…æ‹¬ <18 å²å„¿ç«¥æˆ– <10 åæ‚£è€…çš„ç ”ç©¶ï¼Œä»¥åŠç»¼è¿°ã€é‡å¤ç ”ç©¶æˆ–åŠ¨ç‰©ç ”ç©¶ã€è®°å½•è¾ƒå·®çš„ç ”ç©¶ï¼ˆæ²¡æœ‰æˆåŠŸç‡æŠ¥å‘Šï¼‰å’Œéè‹±æ–‡æ–‡æœ¬ã€‚ç”¨äºé«˜çº§èŸèƒåˆ†æçš„å¼€æºè·¨å¹³å°è½¯ä»¶ openMeta [Analyst]â„¢ 12.11.14 ç‰ˆå’Œ Cochrane Review Manager 5.4Â® ç”¨äºè¿›è¡Œæ•°æ®èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº† 2002 å¹´è‡³ 2021 å¹´é—´å‘è¡¨çš„ 25 é¡¹ç ”ç©¶ã€‚è¯¥ç ”ç©¶åŒ…æ‹¬ 658 åæ‚£è€…ï¼ˆ409 åå¥³æ€§ï¼‰ã€‚å¤§å¤šæ•°æ‚£è€…æœ‰ç›´è‚ é˜´é“ç˜˜ï¼ˆ50.7%ï¼‰æˆ–ç›´è‚ å°¿é“ç˜˜ï¼ˆ33.7%ï¼‰ã€‚ CPF æœ€å¸¸è§çš„åŸå› æ˜¯ç›†è…”æ‰‹æœ¯ï¼ˆ29.4%ï¼‰å’Œç‚ç—‡æ€§è‚ ç—…ï¼ˆ25.2%ï¼‰ã€‚å¤§çº¦ 18% çš„æ‚£è€…æŠ¥å‘Šæœ‰æ”¾å°„æ²»ç–—å²ã€‚ 498 åï¼ˆ75.7%ï¼‰CPF æ‚£è€…åœ¨è‚¡è–„è‚Œä»‹å…¥æ²»ç–—åå®ç°å®Œå…¨æ„ˆåˆã€‚è‚¡è–„è‚Œä»‹å…¥æ‰‹æœ¯çš„åŠ æƒå¹³å‡æˆåŠŸç‡ä¸º 79.4%ï¼ˆ95% CI 73.8%-85%ï¼ŒI<sup>2</sup> =â€‰75.3%ï¼‰ï¼ŒåŠ æƒå¹³å‡çŸ­æœŸå¹¶å‘ç—‡ç‡ä¸º 25.7%ï¼ˆ95% CI 18.1-33.2ï¼ŒI<sup>2</sup> =â€‰84.1%ï¼‰ï¼Œ30 å¤©å†æ‰‹æœ¯çš„åŠ æƒå¹³å‡ç‡ä¸º 3.6%ï¼ˆ95% CI 1.6-5.6ï¼ŒI<sup>2</sup> =â€‰42%ï¼‰ã€‚ç˜˜ç®¡å¤å‘çš„åŠ æƒå¹³å‡ç‡ä¸º 16.7%ï¼ˆ95% CI 11%-22.3%ï¼ŒI<sup>2</sup> = 61%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è‚¡è–„è‚Œä»‹å…¥æŠ€æœ¯æ˜¯ CPF çš„å¯è¡Œæ²»ç–—é€‰æ‹©ã€‚å¤–ç§‘åŒ»ç”Ÿåº”è¯¥ç†Ÿæ‚‰é€‚åº”ç—‡å’ŒæŠ€æœ¯ï¼Œä¸ºæ‚£è€…æä¾›å®ƒä½œä¸ºä¸€ç§é€‰æ‹©ã€‚é‰´äºè¯¥æ‰‹æœ¯çš„ä½¿ç”¨ç›¸å¯¹è¾ƒå°‘ï¼Œè½¬è¯Šè€Œä¸æ˜¯è¿›è¡Œè‚¡è–„æˆå½¢æœ¯æ˜¯å¯ä»¥æ¥å—çš„é€‰æ‹©ã€‚", "keywords_zh": "è‚›é—¨ã€å¤æ‚ä¼šé˜´ã€ç˜˜ç®¡ã€è‚¡è–„è‚Œã€è‚¡è–„è‚Œä»‹å…¥ã€è‚¡è–„æˆå½¢æœ¯ã€ç›´è‚ å°¿é“ã€ç›´è‚ é˜´é“", "keywords_en": "anal, complex perineal, fistula, gracilis, gracilis muscle interposition, graciloplasty, rectourethral, rectovaginal", "link": "https://pubmed.ncbi.nlm.nih.gov/36413086/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 22 Nov 2022"}, {"id": "36294834", "title_en": "Negative Pressure Wound Therapy for the Treatment of Fournier's Gangrene: A Rare Case with Rectal Fistula and Systematic Review of the Literature", "title_zh": "è´Ÿå‹åˆ›é¢ç–—æ³•æ²»ç–—ç¦å°¼å°”åç–½ï¼šä¸€ä¾‹ç½•è§çš„ç›´è‚ ç˜˜ç—…ä¾‹åŠæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Stefania Cimbanassi", "abstract_en": "Fournier's gangrene (FG) is a Necrotizing Soft Tissue Infection (NSTI) of the perineal region characterized by high morbidity and mortality even if appropriately treated. The main treatment strategies are surgical debridement, broad-spectrum antibiotics, hyperbaric oxygen therapy, NPWT (Negative Pressure Wound Therapy), and plastic surgery reconstruction. We present the case of a 50-year-old woman with an NSTI of the abdomen, pelvis, and perineal region associated with a rectal fistula referred to our department. After surgical debridement and a diverting blow-out colostomy, an NPWT system composed of two sponges connected by a bridge through a rectal fistula was performed. Our target was to obtain healing in a lateral-to-medial direction instead of depth-to-surface to prevent the enlargement of the rectal fistula, promoting granulation tissue growth towards the rectum. This eso-endo-NPWT technique allowed for the primary suture of the perineal wounds bilaterally, simultaneously treating the rectal fistula and the perineum lesions. A systematic review of the literature underlines the spreading of NPWT and its effects.", "abstract_zh": "ç¦å°¼å°”åç–½ (FG) æ˜¯ä¸€ç§ä¼šé˜´åŒºåŸŸåæ­»æ€§è½¯ç»„ç»‡æ„ŸæŸ“ (NSTI)ï¼Œå³ä½¿æ²»ç–—å¾—å½“ï¼Œå…¶å‘ç—…ç‡å’Œæ­»äº¡ç‡ä¹Ÿå¾ˆé«˜ã€‚ä¸»è¦æ²»ç–—ç­–ç•¥æ˜¯æ‰‹æœ¯æ¸…åˆ›ã€å¹¿è°±æŠ—ç”Ÿç´ ã€é«˜å‹æ°§æ²»ç–—ã€NPWTï¼ˆè´Ÿå‹ä¼¤å£æ²»ç–—ï¼‰å’Œæ•´å½¢å¤–ç§‘é‡å»ºã€‚æˆ‘ä»¬ä»‹ç»äº†ä¸€å 50 å²å¥³æ€§çš„ç—…ä¾‹ï¼Œå¥¹æ‚£æœ‰è…¹éƒ¨ã€éª¨ç›†å’Œä¼šé˜´åŒºåŸŸçš„ NSTIï¼Œå¹¶ä¼´æœ‰ç›´è‚ ç˜˜ï¼Œè½¬è‡³æˆ‘ä»¬ç§‘å®¤ã€‚ç»è¿‡æ‰‹æœ¯æ¸…åˆ›å’Œè½¬å‘å¹å‡ºç»“è‚ é€ å£æœ¯åï¼Œè¿›è¡Œäº† NPWT ç³»ç»Ÿï¼Œè¯¥ç³»ç»Ÿç”±ä¸¤ä¸ªæµ·ç»µç»„æˆï¼Œé€šè¿‡ç›´è‚ ç˜˜é€šè¿‡æ¡¥è¿æ¥ã€‚æˆ‘ä»¬çš„ç›®æ ‡æ˜¯åœ¨æ¨ªå‘åˆ°å†…ä¾§æ–¹å‘è€Œä¸æ˜¯ä»æ·±åº¦åˆ°è¡¨é¢è·å¾—æ„ˆåˆï¼Œä»¥é˜²æ­¢ç›´è‚ ç˜˜æ‰©å¤§ï¼Œä¿ƒè¿›è‚‰èŠ½ç»„ç»‡å‘ç›´è‚ ç”Ÿé•¿ã€‚è¿™ç§eso-endo-NPWTæŠ€æœ¯å¯ä»¥å¯¹åŒä¾§ä¼šé˜´ä¼¤å£è¿›è¡Œä¸€æœŸç¼åˆï¼ŒåŒæ—¶æ²»ç–—ç›´è‚ ç˜˜å’Œä¼šé˜´ç—…å˜ã€‚å¯¹æ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾å¼ºè°ƒäº† NPWT çš„ä¼ æ’­åŠå…¶å½±å“ã€‚", "keywords_zh": "ç¦å°¼å°”åç–½ï¼Œè´Ÿå‹ä¼¤å£æ²»ç–—ï¼ˆNPWTï¼‰ï¼Œç—…ä¾‹æŠ¥å‘Šï¼Œé«˜å‹æ°§æ²»ç–—ï¼Œç›´è‚ ç˜˜ï¼Œæ‰‹æœ¯æŠ€æœ¯", "keywords_en": "Fournierâ€™s gangrene, Negative Pressure Wound Therapy (NPWT), case report, hyperbaric oxygen therapy, rectal fistula, surgical technique", "link": "https://pubmed.ncbi.nlm.nih.gov/36294834/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 27 Oct 2022"}, {"id": "36271904", "title_en": "Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "è‚›å‘¨å…‹ç½—æ©ç—…éšæœºå¯¹ç…§è¯•éªŒä¸­çš„å®‰æ…°å‰‚ååº”ç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Vipul Jairath", "abstract_en": "**Background And Aims:** Perianal fistulizing disease is a common complication of Crohn's disease [CD], for which new therapies are urgently needed. To assist the design of clinical trials for novel therapeutics, we conducted a systematic review and meta-analysis of randomised controlled trials [RCTs] to quantify placebo rates and identify factors influencing them in perianal CD [pCD].\n\n**Methods:** We searched MEDLINE, Embase and CENTRAL from inception to June 2021. Eligible studies were placebo-controlled trials of pharmacological interventions for pCD. Placebo fistula response and remission rates for induction and maintenance trials were extracted and pooled using a random-effects model. Mixed-effects meta-regression was used to evaluate the impact of patient and study-level characteristics on point estimates.\n\n**Results:** In 17 RCTs [13 induction, five maintenance] the pooled placebo fistula response and remission rate for induction trials was 25% (95% confidence interval [CI] 17-36%) and 17% [95% CI 11-25%], respectively. For maintenance trials, the pooled placebo fistula response and remission rate was 23% [95% CI 17-32%] and 19% [95% CI 14-25%], respectively. Trials enrolling patients with less disease activity and a higher proportion with ileal predominant disease were associated with significantly higher placebo response rates. Trials originating in Europe [compared to North America], therapies requiring perianal injection and a longer timepoint to measure remission were associated with higher placebo remission rates.\n\n**Conclusions:** Placebo response and remission rates in pCD trials are influenced by patient and disease-related factors, as well as the type of intervention being studied. These contemporary rates will inform trial design for novel therapeutics.", "abstract_zh": "**Background and aimsï¼š** è‚›å‘¨ç˜˜ç®¡ç—…æ˜¯å…‹ç½—æ©ç—…[CD]çš„å¸¸è§å¹¶å‘ç—‡ï¼Œè¿«åˆ‡éœ€è¦æ–°çš„æ²»ç–—æ–¹æ³•ã€‚ä¸ºäº†ååŠ©è®¾è®¡æ–°ç–—æ³•çš„ä¸´åºŠè¯•éªŒï¼Œæˆ‘ä»¬å¯¹éšæœºå¯¹ç…§è¯•éªŒ [RCT] è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œä»¥é‡åŒ–è‚›å‘¨ CD [pCD] ä¸­çš„å®‰æ…°å‰‚ç‡å¹¶ç¡®å®šå½±å“å®‰æ…°å‰‚ç‡çš„å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº†ä»å¼€å§‹åˆ° 2021 å¹´ 6 æœˆçš„ MEDLINEã€Embase å’Œ CENTRALã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶æ˜¯ pCD è¯ç‰©å¹²é¢„çš„å®‰æ…°å‰‚å¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹æå–å¹¶æ±‡æ€»è¯±å¯¼å’Œç»´æŒè¯•éªŒçš„å®‰æ…°å‰‚ç˜˜ç®¡ååº”å’Œç¼“è§£ç‡ã€‚æ··åˆæ•ˆåº”å…ƒå›å½’ç”¨äºè¯„ä¼°æ‚£è€…å’Œç ”ç©¶æ°´å¹³ç‰¹å¾å¯¹ç‚¹ä¼°è®¡çš„å½±å“ã€‚\n\n**ç»“æœï¼š** åœ¨ 17 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ˆ13 é¡¹è¯±å¯¼ï¼Œ5 é¡¹ç»´æŒï¼‰ä¸­ï¼Œè¯±å¯¼è¯•éªŒçš„æ±‡æ€»å®‰æ…°å‰‚ç˜˜ååº”å’Œç¼“è§£ç‡åˆ†åˆ«ä¸º 25%ï¼ˆ95% ç½®ä¿¡åŒºé—´ [CI] 17-36%ï¼‰å’Œ 17% [95% CI 11-25%]ã€‚å¯¹äºç»´æŒè¯•éªŒï¼Œåˆå¹¶å®‰æ…°å‰‚ç˜˜ç®¡ååº”å’Œç¼“è§£ç‡åˆ†åˆ«ä¸º 23% [95% CI 17-32%] å’Œ 19% [95% CI 14-25%]ã€‚æ‹›å‹Ÿç–¾ç—…æ´»åŠ¨æ€§è¾ƒä½ä¸”å›è‚ ä¸»è¦ç–¾ç—…æ¯”ä¾‹è¾ƒé«˜çš„æ‚£è€…çš„è¯•éªŒä¸æ˜¾ç€è¾ƒé«˜çš„å®‰æ…°å‰‚ååº”ç‡ç›¸å…³ã€‚æºè‡ªæ¬§æ´²çš„è¯•éªŒ[ä¸åŒ—ç¾ç›¸æ¯”]ï¼Œéœ€è¦è‚›å‘¨æ³¨å°„å’Œè¾ƒé•¿æ—¶é—´ç‚¹æ¥æµ‹é‡ç¼“è§£çš„æ²»ç–—ä¸è¾ƒé«˜çš„å®‰æ…°å‰‚ç¼“è§£ç‡ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** pCD è¯•éªŒä¸­çš„å®‰æ…°å‰‚ååº”å’Œç¼“è§£ç‡å—åˆ°æ‚£è€…å’Œç–¾ç—…ç›¸å…³å› ç´ ä»¥åŠæ­£åœ¨ç ”ç©¶çš„å¹²é¢„ç±»å‹çš„å½±å“ã€‚è¿™äº›å½“ä»£çš„æ¯”ç‡å°†ä¸ºæ–°ç–—æ³•çš„è¯•éªŒè®¾è®¡æä¾›ä¿¡æ¯ã€‚", "keywords_zh": "è‚›å‘¨å…‹ç½—æ©ç—…ï¼Œä¸´åºŠè¯•éªŒï¼Œå®‰æ…°å‰‚", "keywords_en": "Peri-anal Crohnâ€™s disease, clinical trials, placebo", "link": "https://pubmed.ncbi.nlm.nih.gov/36271904/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 22 Oct 2022"}, {"id": "36267197", "title_en": "Rare complications of pessary use: A systematic review of case reports", "title_zh": "ä½¿ç”¨å­å®«æ‰˜çš„ç½•è§å¹¶å‘ç—‡ï¼šç—…ä¾‹æŠ¥å‘Šçš„ç³»ç»Ÿå›é¡¾", "authors": "Bilal Chughtai", "abstract_en": "**Introduction:** Pessaries are desirable for its overall safety profiles. Serious complications have been reported; however, there is little summative evidence. This systematic review aimed to consolidate all reported serious outcomes from pessaries usage to better identify and counsel patients who might be at higher risk of developing these adverse events.\n\n**Methods:** We performed a systematic literature review using search terms such as 'prolapse', 'stress urinary incontinence' and 'pessary or pessaries or pessarium' on PubMed, Embase and CINAHL. A total of 36 articles were identified. Patient-level data were extracted from case reports to further describe complications on an individual level.\n\n**Results:** Overall median age of the patients was 82â€‰years (range 62-98). The most frequent complications were vesicovaginal fistula (25%, <i>n</i>Â =â€‰9/36), rectovaginal fistula (19%, <i>n</i>Â =â€‰7/36), vaginal impaction (11%, <i>n</i>Â =â€‰4/36) and vaginal evisceration of small bowel through vaginal vault (8%, <i>n</i>Â =â€‰3/36). In the vesicovaginal fistula cohort, none of the patients had a history of radiation, and two had histories of total abdominal hysterectomy (22%). In the rectovaginal fistula cohort, one patient had a history of pelvic radiation for rectal squamous cell carcinoma, and another had a history of chronic steroid use for rheumatoid arthritis. No other risk factors were reported in the other groups. Ring and Gellhorn were the most represented pessary types among the studies, 16 (44%) and 12 (33%), respectively. No complications were reported with surgical and non-surgical treatment of the complications.\n\n**Conclusion:** Pessaries are a reasonable and durable treatment for POP with exceedingly rare reports of severe adverse complications. The ideal candidate for pessary should have a good self-care index. Studies to determine causative factors of the more serious adverse events are needed; however, this may be difficult given the long follow-up that is required.", "abstract_zh": "**ä»‹ç»ï¼š** å­å®«æ‰˜å› å…¶æ•´ä½“å®‰å…¨æ€§è€Œå¤‡å—é’çã€‚æ®æŠ¥é“å­˜åœ¨ä¸¥é‡å¹¶å‘ç—‡ï¼›ç„¶è€Œï¼Œå‡ ä¹æ²¡æœ‰æ€»ç»“æ€§è¯æ®ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·æ—¨åœ¨æ•´åˆæ‰€æœ‰æŠ¥å‘Šçš„å­å®«æ‰˜ä½¿ç”¨é€ æˆçš„ä¸¥é‡åæœï¼Œä»¥æ›´å¥½åœ°è¯†åˆ«å’Œå»ºè®®å¯èƒ½é¢ä¸´æ›´é«˜é£é™©å‘ç”Ÿè¿™äº›ä¸è‰¯äº‹ä»¶çš„æ‚£è€…ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ä½¿ç”¨â€œè„±å‚â€ã€â€œå‹åŠ›æ€§å°¿å¤±ç¦â€å’Œâ€œå­å®«æ‰˜æˆ–å­å®«æ‰˜æˆ–å­å®«æ‰˜â€ç­‰æœç´¢æœ¯è¯­åœ¨ PubMedã€Embase å’Œ CINAHL ä¸Šè¿›è¡Œäº†ç³»ç»Ÿçš„æ–‡çŒ®ç»¼è¿°ã€‚å…±é‰´å®šå‡º36ç¯‡æ–‡ç« ã€‚ä»ç—…ä¾‹æŠ¥å‘Šä¸­æå–æ‚£è€…å±‚é¢çš„æ•°æ®ï¼Œä»¥è¿›ä¸€æ­¥æè¿°ä¸ªä½“å±‚é¢çš„å¹¶å‘ç—‡ã€‚\n\n**ç»“æœï¼š** æ‚£è€…çš„æ€»ä½“ä¸­ä½å¹´é¾„ä¸º 82 å²ï¼ˆèŒƒå›´ 62-98 å²ï¼‰ã€‚æœ€å¸¸è§çš„å¹¶å‘ç—‡æ˜¯è†€èƒ±é˜´é“ç˜˜ï¼ˆ25%ï¼Œ<i>n</i>Â =â€‰9/36ï¼‰ã€ç›´è‚ é˜´é“ç˜˜ï¼ˆ19%ï¼Œ<i>n</i>Â =â€‰7/36ï¼‰ã€é˜´é“åµŒå¡ï¼ˆ11%ï¼Œ<i>n</i>Â =â€‰4/36ï¼‰å’Œé€šè¿‡é˜´é“ç©¹çª¿é˜´é“å–å‡ºå°è‚ å†…è„ï¼ˆ8%ï¼Œ <i>n</i>Â =â€‰3/36)ã€‚åœ¨è†€èƒ±é˜´é“ç˜˜é˜Ÿåˆ—ä¸­ï¼Œæ²¡æœ‰æ‚£è€…æœ‰æ”¾å°„å²ï¼Œä¸¤åæ‚£è€…æœ‰å…¨è…¹éƒ¨å­å®«åˆ‡é™¤å²ï¼ˆ22%ï¼‰ã€‚åœ¨ç›´è‚ é˜´é“ç˜˜é˜Ÿåˆ—ä¸­ï¼Œä¸€åæ‚£è€…æœ‰å› ç›´è‚ é³çŠ¶ç»†èƒç™Œæ¥å—ç›†è…”æ”¾å°„æ²»ç–—çš„ç—…å²ï¼Œå¦ä¸€åæ‚£è€…æœ‰å› ç±»é£æ¹¿æ€§å…³èŠ‚ç‚è€Œé•¿æœŸä½¿ç”¨ç±»å›ºé†‡çš„ç—…å²ã€‚å…¶ä»–ç»„ä¸­æ²¡æœ‰æŠ¥å‘Šå…¶ä»–å±é™©å› ç´ ã€‚ Ring å’Œ Gellhorn æ˜¯ç ”ç©¶ä¸­æœ€å…·ä»£è¡¨æ€§çš„å­å®«æ‰˜ç±»å‹ï¼Œåˆ†åˆ«ä¸º 16 ä¸ª (44%) å’Œ 12 ä¸ª (33%)ã€‚æ‰‹æœ¯å’Œéæ‰‹æœ¯æ²»ç–—å¹¶å‘ç—‡å‡æœªæŠ¥å‘Šå¹¶å‘ç—‡ã€‚\n\n**ç»“è®ºï¼š** å­å®«æ‰˜æ˜¯ POP çš„åˆç†ä¸”æŒä¹…çš„æ²»ç–—æ–¹æ³•ï¼Œä¸¥é‡ä¸è‰¯å¹¶å‘ç—‡çš„æŠ¥å‘Šæä¸ºç½•è§ã€‚ç†æƒ³çš„å­å®«æ‰˜å€™é€‰äººåº”è¯¥å…·æœ‰è‰¯å¥½çš„è‡ªæˆ‘æŠ¤ç†æŒ‡æ•°ã€‚éœ€è¦è¿›è¡Œç ”ç©¶ä»¥ç¡®å®šæ›´ä¸¥é‡ä¸è‰¯äº‹ä»¶çš„è‡´ç—…å› ç´ ï¼›ç„¶è€Œï¼Œé‰´äºéœ€è¦é•¿æœŸçš„åç»­è¡ŒåŠ¨ï¼Œè¿™å¯èƒ½å¾ˆå›°éš¾ã€‚", "keywords_zh": "ä¸è‰¯ååº”ã€ç˜˜ç®¡ã€å¤±ç¦ã€å­å®«æ‰˜ã€è„±å‚ã€ç½•è§å¹¶å‘ç—‡", "keywords_en": "adverse effects, fistula, incontinence, pessary, prolapse, rare complications", "link": "https://pubmed.ncbi.nlm.nih.gov/36267197/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 21 Oct 2022"}, {"id": "36176822", "title_en": "A Comparison of Different Surgical Treatments for Complex Anal Fistula: A Systematic Review", "title_zh": "å¤æ‚è‚›ç˜˜ä¸åŒæ‰‹æœ¯æ²»ç–—çš„æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·", "authors": "Pousette Hamid", "abstract_en": "Fistula-in-ano is a common proctological condition that primarily affects younger people and leads to chronic morbidity. An anal fistula is divided into simple and complex fistulas. A complex fistula is a challenging problem due to higher recurrence rates and incontinence associated with surgery. Many new methods have been developed for the closure of complexÂ fistula-in-ano, but there is no single best method. The aim of this study is to identify a superior surgical technique for treating complex/high cryptoglandular perianal fistulas (HCPFs). A literature search was done using PubMed and Google Scholar for the period of 2012-2021. Articles that contain surgical treatment for complex anal fistula in the English language published in the last 10 years were included. The types of studies included were randomized controlled trials (RCTs), meta-analyses, systematic reviews, cohort studies, and traditional reviews. Articles excluded were those done more than 10 years ago, in other languages, and containing simple fistula management only. Nine studies were included in the review; a systematic review and meta-analysis concluded that no single method is effective. The ligation of the intersphincteric fistula tract (LIFT) procedure seems to be a promising and effective technique as it has a low rate of fecal incontinence as compared to other methods. Biological techniques give variable success rates so does fistula plug (FP). Mucosal advancement flap (MAF) and rerouting seton give good results according to one study. Fistula plug gives variable results and is not a preferred method. Ligation of the intersphincteric fistula tract (LIFT) seems to be a promising new technique for complex anal fistulas, but the data available is not enough to determine the best method. More randomized trials are required to compare traditional techniques and emerging new biological methods to see the best technique available.", "abstract_zh": "è‚›ç˜˜æ˜¯ä¸€ç§å¸¸è§çš„ç›´è‚ ç–¾ç—…ï¼Œä¸»è¦å½±å“å¹´è½»äººå¹¶å¯¼è‡´æ…¢æ€§å‘ç—…ã€‚è‚›ç˜˜åˆ†ä¸ºå•çº¯æ€§è‚›ç˜˜å’Œå¤æ‚æ€§è‚›ç˜˜ã€‚ç”±äºè¾ƒé«˜çš„å¤å‘ç‡å’Œä¸æ‰‹æœ¯ç›¸å…³çš„å¤±ç¦ï¼Œå¤æ‚çš„ç˜˜ç®¡æ˜¯ä¸€ä¸ªå…·æœ‰æŒ‘æˆ˜æ€§çš„é—®é¢˜ã€‚äººä»¬å·²ç»å¼€å‘å‡ºè®¸å¤šæ–°æ–¹æ³•æ¥é—­åˆå¤æ‚çš„è‚›ç˜˜ï¼Œä½†æ²¡æœ‰å•ä¸€çš„æœ€ä½³æ–¹æ³•ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯ç¡®å®šä¸€ç§æ²»ç–—å¤æ‚/é«˜ä½éšçªè‚›ç˜˜ï¼ˆHCPFï¼‰çš„ä¼˜è¶Šæ‰‹æœ¯æŠ€æœ¯ã€‚ä½¿ç”¨ PubMed å’Œ Google Scholar è¿›è¡Œäº† 2012-2021 å¹´æœŸé—´çš„æ–‡çŒ®æ£€ç´¢ã€‚åŒ…å«è¿‡å» 10 å¹´å‘è¡¨çš„è‹±æ–‡ç‰ˆå¤æ‚è‚›ç˜˜æ‰‹æœ¯æ²»ç–—çš„æ–‡ç« ã€‚çº³å…¥çš„ç ”ç©¶ç±»å‹åŒ…æ‹¬éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€èŸèƒåˆ†æã€ç³»ç»Ÿè¯„ä»·ã€é˜Ÿåˆ—ç ”ç©¶å’Œä¼ ç»Ÿè¯„ä»·ã€‚æ’é™¤çš„æ–‡ç« æ˜¯ 10 å¤šå¹´å‰ä»¥å…¶ä»–è¯­è¨€å‘è¡¨çš„æ–‡ç« ï¼Œå¹¶ä¸”ä»…åŒ…å«ç®€å•çš„ç˜˜ç®¡æ²»ç–—ã€‚å®¡æŸ¥ä¸­çº³å…¥äº†ä¹é¡¹ç ”ç©¶ï¼›ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æå¾—å‡ºçš„ç»“è®ºæ˜¯ï¼Œæ²¡æœ‰ä»»ä½•å•ä¸€æ–¹æ³•æ˜¯æœ‰æ•ˆçš„ã€‚æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰æœ¯ï¼ˆLIFTï¼‰ä¼¼ä¹æ˜¯ä¸€ç§æœ‰å‰é€”ä¸”æœ‰æ•ˆçš„æŠ€æœ¯ï¼Œå› ä¸ºä¸å…¶ä»–æ–¹æ³•ç›¸æ¯”ï¼Œå®ƒçš„å¤§ä¾¿å¤±ç¦ç‡è¾ƒä½ã€‚ç”Ÿç‰©æŠ€æœ¯çš„æˆåŠŸç‡å„ä¸ç›¸åŒï¼Œç˜˜ç®¡å¡ (FP) ä¹Ÿæ˜¯å¦‚æ­¤ã€‚ä¸€é¡¹ç ”ç©¶è¡¨æ˜ï¼Œç²˜è†œæ¨è¿›ç“£ (MAF) å’Œæ”¹é“æŒ‚çº¿å¯å–å¾—è‰¯å¥½æ•ˆæœã€‚ç˜˜ç®¡å¡ä¼šäº§ç”Ÿä¸åŒçš„ç»“æœï¼Œä¸æ˜¯é¦–é€‰æ–¹æ³•ã€‚æ‹¬çº¦è‚Œé—´ç˜˜ç®¡ç»“æ‰æœ¯ï¼ˆLIFTï¼‰ä¼¼ä¹æ˜¯æ²»ç–—å¤æ‚è‚›ç˜˜çš„ä¸€ç§æœ‰å‰æ™¯çš„æ–°æŠ€æœ¯ï¼Œä½†ç°æœ‰æ•°æ®ä¸è¶³ä»¥ç¡®å®šæœ€ä½³æ–¹æ³•ã€‚éœ€è¦æ›´å¤šçš„éšæœºè¯•éªŒæ¥æ¯”è¾ƒä¼ ç»ŸæŠ€æœ¯å’Œæ–°å…´çš„æ–°ç”Ÿç‰©æ–¹æ³•ï¼Œä»¥ç¡®å®šå¯ç”¨çš„æœ€ä½³æŠ€æœ¯ã€‚", "keywords_zh": "å¼•æµæŒ‚çº¿ã€ç›´è‚ å†…æ¨è¿›çš®ç“£ã€å¤§ä¾¿å¤±ç¦ã€é«˜ä½éšè…ºè‚›å‘¨ç˜˜ã€ç›´è‚ ç˜˜", "keywords_en": "draining seton, endorectal advancement flap, fecal incontinence, high cryptoglandular perianal fistula, rectal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/36176822/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 30 Sep 2022"}, {"id": "36130090", "title_en": "Perianal Crohn's Disease and the Development of Colorectal and Anal Cancer: A Systematic Review and Meta-analysis", "title_zh": "è‚›å‘¨å…‹ç½—æ©ç—…ä¸ç»“ç›´è‚ ç™Œå’Œè‚›é—¨ç™Œçš„å‘å±•ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Johan Burisch", "abstract_en": "**Background And Aims:** The aim of this systematic review was to assess the literature on the incidence and risk factors for colorectal cancer and anal cancer in patients with perianal Crohn's disease.\n\n**Method:** A systematic review of the literature was performed using PubMed, Embase and Google Scholar. A meta-analysis was then conducted using a random-effects model.\n\n**Results:** Five studies were included in the systematic review. Of the total patients, 26.5% had perianal Crohn's disease. The median follow-up was 6 years. In total, 127 cases of colorectal cancer were found [0.43% of the included Crohn's disease patients]. Perianal involvement was present in 50% of colorectal cancer patients [0.89% of the population]. Three of the studies specified the cancer to be rectal or anal, which were present in 68 and 24 cases [0.3% and 0.1% of patients], respectively. In a subgroup analysis of rectal and anal cancer, perianal involvement was most frequent in anal cancer, accounting for 46% of the cases. In the rectal cancer group, 37% had perianal involvement. The higher incidence of colorectal cancer in patients with perianal Crohn's disease was confirmed in a meta-analysis.\n\n**Conclusion:** Half of the patients with colorectal cancer and anal cancer were found to have perianal Crohn's disease. In patients with perianal involvement, there was a higher percentage of anal cancer compared with rectal cancer. These results support the theory that patients with perianal Crohn's disease are at increased risk for developing colorectal and anal cancer. Studies collecting more detailed data regarding patients and their cancers are needed to further specify the disease course.", "abstract_zh": "**Background and aimsï¼š** æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯è¯„ä¼°æœ‰å…³è‚›å‘¨å…‹ç½—æ©ç—…æ‚£è€…ç»“ç›´è‚ ç™Œå’Œè‚›é—¨ç™Œçš„å‘ç—…ç‡å’Œå±é™©å› ç´ çš„æ–‡çŒ®ã€‚\n\n**Methodï¼š** ä½¿ç”¨ PubMedã€Embase å’Œ Google Scholar å¯¹æ–‡çŒ®è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚ç„¶åä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·ä¸­çº³å…¥äº†äº”é¡¹ç ”ç©¶ã€‚åœ¨æ‰€æœ‰æ‚£è€…ä¸­ï¼Œ26.5%æ‚£æœ‰è‚›å‘¨å…‹ç½—æ©ç—…ã€‚ä¸­ä½éšè®¿æ—¶é—´ä¸º 6 å¹´ã€‚æ€»å…±å‘ç°äº† 127 ä¾‹ç»“ç›´è‚ ç™Œç—…ä¾‹[å å…‹ç½—æ©ç—…æ‚£è€…çš„ 0.43%]ã€‚ 50% çš„ç»“ç›´è‚ ç™Œæ‚£è€…ï¼ˆå äººå£çš„ 0.89%ï¼‰å­˜åœ¨è‚›å‘¨å—ç´¯ã€‚å…¶ä¸­ä¸‰é¡¹ç ”ç©¶æŒ‡å®šç™Œç—‡ä¸ºç›´è‚ ç™Œæˆ–è‚›é—¨ç™Œï¼Œåˆ†åˆ«æœ‰ 68 ä¾‹å’Œ 24 ä¾‹ç—…ä¾‹[å æ‚£è€…çš„ 0.3% å’Œ 0.1%]ã€‚åœ¨ç›´è‚ ç™Œå’Œè‚›é—¨ç™Œçš„äºšç»„åˆ†æä¸­ï¼Œè‚›é—¨ç™Œä¸­è‚›å‘¨å—ç´¯æœ€å¸¸è§ï¼Œå ç—…ä¾‹çš„ 46%ã€‚åœ¨ç›´è‚ ç™Œç»„ä¸­ï¼Œ37% æœ‰è‚›å‘¨å—ç´¯ã€‚ä¸€é¡¹èŸèƒåˆ†æè¯å®ï¼Œè‚›å‘¨å…‹ç½—æ©ç—…æ‚£è€…ç»“ç›´è‚ ç™Œçš„å‘ç—…ç‡è¾ƒé«˜ã€‚\n\n**ç»“è®ºï¼š** ä¸€åŠçš„ç»“ç›´è‚ ç™Œå’Œè‚›é—¨ç™Œæ‚£è€…è¢«å‘ç°æ‚£æœ‰è‚›å‘¨å…‹ç½—æ©ç—…ã€‚åœ¨è‚›å‘¨å—ç´¯çš„æ‚£è€…ä¸­ï¼Œä¸ç›´è‚ ç™Œç›¸æ¯”ï¼Œè‚›é—¨ç™Œçš„æ¯”ä¾‹æ›´é«˜ã€‚è¿™äº›ç»“æœæ”¯æŒè¿™æ ·çš„ç†è®ºï¼šè‚›å‘¨å…‹ç½—æ©ç—…æ‚£è€…æ‚£ç»“ç›´è‚ ç™Œå’Œè‚›é—¨ç™Œçš„é£é™©å¢åŠ ã€‚éœ€è¦æ”¶é›†æœ‰å…³æ‚£è€…åŠå…¶ç™Œç—‡çš„æ›´è¯¦ç»†æ•°æ®çš„ç ”ç©¶æ¥è¿›ä¸€æ­¥æ˜ç¡®ç–¾ç—…è¿›ç¨‹ã€‚", "keywords_zh": "è‚›å‘¨å…‹ç½—æ©ç—…ã€ç»“ç›´è‚ ç™Œã€èŸèƒåˆ†æ", "keywords_en": "Perianal Crohnâ€™s disease, colorectal cancer, meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/36130090/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 21 Sep 2022"}, {"id": "36005069", "title_en": "Do Patient-Reported Quality-of-Life (QoL) Scales Provide an Adequate Assessment of Patients with Cryptoglandular Anal Fistulae? A Systematic Review of Measurement Instruments and Their Content Validity", "title_zh": "æ‚£è€…æŠ¥å‘Šçš„ç”Ÿæ´»è´¨é‡ (QoL) é‡è¡¨æ˜¯å¦å¯ä»¥å¯¹éšè…ºè‚›ç˜˜æ‚£è€…è¿›è¡Œå……åˆ†çš„è¯„ä¼°ï¼Ÿæµ‹é‡ä»ªå™¨åŠå…¶å†…å®¹æœ‰æ•ˆæ€§çš„ç³»ç»Ÿå®¡æŸ¥", "authors": "Phil Tozer", "abstract_en": "**Background:** Cryptoglandular anal fistulae can significantly affect patient quality of life (QoL), making it essential to ensure that any study of fistula treatment assesses the impact on QoL. The aim of this systematic review was to evaluate the content validity of Patient-Reported Outcome Measures (PROMs) that assess QoL in patients with a fistula.\n\n**Methods:** MEDLINE, EMBASE, PsycINFO, and Scopus were searched and studies assessing the content validity of patient-reported QoL measurement instruments, or PROM development studies in patients with cryptoglandular anal fistulae, were included. Data were extracted from eligible studies to determine the instruments' relevance, comprehensiveness, and comprehensibility, and their quality was assessed according to COnsensus-based Standards for the Selection of health Measurement Instruments (COSMIN).\n\n**Results:** Two PROM development studies were identified, both of which described the development of a disease-specific QoL measurement instrument for patients with cryptoglandular anal fistulae. The overall content validity of these instruments was inconsistent and supported by very low-quality evidence. There were no studies assessing the content validity of established QoL measurement instruments in patients with fistulae.\n\n**Conclusions:** This systematic review could not establish the content validity of the available QoL PROMs for patients with anal fistulae, due either to the absence of designated content validity studies or a lack of comprehensiveness of the available PROMs. This highlights an important gap in the literature that needs to be addressed to ensure high-quality outcome assessment in patients with fistulae.", "abstract_zh": "**èƒŒæ™¯ï¼š** éšè…ºè‚›ç˜˜å¯æ˜¾ç€å½±å“æ‚£è€…çš„ç”Ÿæ´»è´¨é‡ (QoL)ï¼Œå› æ­¤å¿…é¡»ç¡®ä¿ä»»ä½•ç˜˜ç®¡æ²»ç–—ç ”ç©¶éƒ½èƒ½è¯„ä¼°å…¶å¯¹ç”Ÿæ´»è´¨é‡çš„å½±å“ã€‚æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯è¯„ä¼°è¯„ä¼°ç˜˜ç®¡æ‚£è€…ç”Ÿæ´»è´¨é‡çš„æ‚£è€…æŠ¥å‘Šç»“æœæµ‹é‡ (PROM) çš„å†…å®¹æœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† MEDLINEã€EMBASEã€PsycINFO å’Œ Scopusï¼Œçº³å…¥äº†è¯„ä¼°æ‚£è€…æŠ¥å‘Šçš„ QoL æµ‹é‡ä»ªå™¨å†…å®¹æœ‰æ•ˆæ€§çš„ç ”ç©¶ï¼Œæˆ–éšçªè…ºè‚›ç˜˜æ‚£è€…çš„ PROM å‘å±•ç ”ç©¶ã€‚ä»ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶ä¸­æå–æ•°æ®ï¼Œä»¥ç¡®å®šå·¥å…·çš„ç›¸å…³æ€§ã€å…¨é¢æ€§å’Œå¯ç†è§£æ€§ï¼Œå¹¶æ ¹æ®åŸºäºå…±è¯†çš„å¥åº·æµ‹é‡å·¥å…·é€‰æ‹©æ ‡å‡† (COSMIN) è¯„ä¼°å…¶è´¨é‡ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº†ä¸¤é¡¹ PROM å¼€å‘ç ”ç©¶ï¼Œä¸¤é¡¹ç ”ç©¶å‡æè¿°äº†é’ˆå¯¹éšè…ºè‚›ç˜˜æ‚£è€…çš„ç–¾ç—…ç‰¹å¼‚æ€§ QoL æµ‹é‡ä»ªå™¨çš„å¼€å‘ã€‚è¿™äº›å·¥å…·çš„æ•´ä½“å†…å®¹æœ‰æ•ˆæ€§ä¸ä¸€è‡´ï¼Œå¹¶ä¸”å¾—åˆ°çš„è¯æ®è´¨é‡éå¸¸ä½ã€‚å°šæ— ç ”ç©¶è¯„ä¼°å·²å»ºç«‹çš„ç˜˜ç®¡æ‚£è€…ç”Ÿæ´»è´¨é‡æµ‹é‡å·¥å…·çš„å†…å®¹æœ‰æ•ˆæ€§ã€‚\n\n**ç»“è®ºï¼š** ç”±äºç¼ºä¹æŒ‡å®šçš„å†…å®¹æœ‰æ•ˆæ€§ç ”ç©¶æˆ–ç°æœ‰ PROM ç¼ºä¹å…¨é¢æ€§ï¼Œæœ¬ç³»ç»Ÿè¯„ä»·æ— æ³•ç¡®å®šè‚›ç˜˜æ‚£è€…å¯ç”¨ QoL PROM çš„å†…å®¹æœ‰æ•ˆæ€§ã€‚è¿™å‡¸æ˜¾äº†æ–‡çŒ®ä¸­çš„ä¸€ä¸ªé‡è¦ç©ºç™½ï¼Œéœ€è¦åŠ ä»¥è§£å†³ï¼Œä»¥ç¡®ä¿å¯¹ç˜˜ç®¡æ‚£è€…è¿›è¡Œé«˜è´¨é‡çš„ç»“æœè¯„ä¼°ã€‚", "keywords_zh": "COSMINã€PROMã€QoLã€è‚›ç˜˜ã€ç»“æœæµ‹é‡ã€æ‚£è€…æŠ¥å‘Šçš„ç»“æœæµ‹é‡ã€ç”Ÿæ´»è´¨é‡", "keywords_en": "COSMIN, PROMs, QoL, anal fistula, outcome measures, patient-reported outcome measures, quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/36005069/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 25 Aug 2022"}, {"id": "35962294", "title_en": "Efficacy and safety of FiLaC for perianal fistulizing Crohn's disease: a systematic review and meta-analysis", "title_zh": "FiLaC æ²»ç–—è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Z Cui", "abstract_en": "**Background:** Most patients with perianal fistulizing Crohn's disease (pfCD) present with complex types of perianal fistulas and need repetitive repair operations, resulting in a high risk of sphincter injury. Fistula-tract Laser Closure (FiLaCâ„¢) is a novel sphincter-saving technique that obliterates the fistula tract with a photothermal effect. The aim of the present systematic review and meta-analysis was to evaluate the efficacy and safety of FiLaC in pfCD.\n\n**Methods:** This study was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Electronic databases, including PubMed, Embase, Cochrane Library and Wanfang Data were searched for published articles from January 2000 to June 2021. The clinicaltrials.gov website was searched for completed or ongoing trials on pfCD and FiLaCâ„¢. The references of each article were also searched for eligible data. The main outcome was the primary healing rate of the FiLaCâ„¢ procedure. Additionally, fecal incontinence was analyzed as the secondary outcome to evaluate the safety of FiLaCâ„¢.\n\n**Results:** Six studies met the eligibility criteria and were included in the final analysis. All studies were published within the past 6Â years and came from European countries. There were 50 pfCD patients recruited, and 31 patients' fistulas were healed after FiLaCâ„¢. The pooled primary healing rate was 68% (95% CI 53.0-84.0%, I<sup>2</sup>â€‰=â€‰27%, pâ€‰=â€‰0.23). There was no major fecal incontinence after surgery.\n\n**Conclusions:** These data suggest that FiLaCâ„¢ may be an effective and safe procedure for pfCD patients. However, the evidence is poor and there is a need for more high-quality prospective controlled studies with long-term follow-up before this minimally invasive technique is recommended for surgical treatment of pfCD.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¤§å¤šæ•°è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ï¼ˆpfCDï¼‰æ‚£è€…çš„è‚›å‘¨ç˜˜ç®¡ç±»å‹å¤æ‚ï¼Œéœ€è¦é‡å¤ä¿®å¤æ‰‹æœ¯ï¼Œå¯¼è‡´æ‹¬çº¦è‚ŒæŸä¼¤çš„é£é™©å¾ˆé«˜ã€‚ç˜˜ç®¡æ¿€å…‰é—­åˆæœ¯ (FiLaCâ„¢) æ˜¯ä¸€ç§æ–°é¢–çš„ä¿ç•™æ‹¬çº¦è‚Œçš„æŠ€æœ¯ï¼Œé€šè¿‡å…‰çƒ­æ•ˆåº”æ¶ˆé™¤ç˜˜ç®¡ã€‚æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„ç›®çš„æ˜¯è¯„ä¼° FiLaC åœ¨ pfCD ä¸­çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** è¿™é¡¹ç ”ç©¶æ˜¯æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—è¿›è¡Œçš„ã€‚æ£€ç´¢äº†åŒ…æ‹¬ PubMedã€Embaseã€Cochrane Library å’Œä¸‡æ–¹æ•°æ®åœ¨å†…çš„ç”µå­æ•°æ®åº“ï¼ŒæŸ¥æ‰¾ 2000 å¹´ 1 æœˆè‡³ 2021 å¹´ 6 æœˆæœŸé—´å‘è¡¨çš„æ–‡ç« ã€‚æ£€ç´¢ ClinicalTrials.gov ç½‘ç«™ï¼ŒæŸ¥æ‰¾å·²å®Œæˆæˆ–æ­£åœ¨è¿›è¡Œçš„ pfCD å’Œ FiLaCâ„¢ è¯•éªŒã€‚è¿˜æœç´¢äº†æ¯ç¯‡æ–‡ç« çš„å‚è€ƒæ–‡çŒ®ä»¥è·å–ç¬¦åˆæ¡ä»¶çš„æ•°æ®ã€‚ä¸»è¦ç»“æœæ˜¯ FiLaCâ„¢ æ‰‹æœ¯çš„åˆæ¬¡æ„ˆåˆç‡ã€‚æ­¤å¤–ï¼Œå°†å¤§ä¾¿å¤±ç¦ä½œä¸ºæ¬¡è¦ç»“æœè¿›è¡Œåˆ†æï¼Œä»¥è¯„ä¼° FiLaCâ„¢ çš„å®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** å…­é¡¹ç ”ç©¶ç¬¦åˆèµ„æ ¼æ ‡å‡†å¹¶çº³å…¥æœ€ç»ˆåˆ†æã€‚æ‰€æœ‰ç ”ç©¶éƒ½æ˜¯åœ¨è¿‡å» 6 å¹´å†…å‘è¡¨çš„ï¼Œå¹¶ä¸”æ¥è‡ªæ¬§æ´²å›½å®¶ã€‚æ‹›å‹Ÿäº† 50 å pfCD æ‚£è€…ï¼Œå…¶ä¸­ 31 åæ‚£è€…çš„ç˜˜ç®¡åœ¨ FiLaCâ„¢ æ²»ç–—åæ„ˆåˆã€‚æ±‡æ€»çš„ä¸€æœŸæ„ˆåˆç‡ä¸º 68%ï¼ˆ95% CI 53.0-84.0%ï¼ŒI<sup>2</sup>â€‰=â€‰27%ï¼Œpâ€‰=â€‰0.23ï¼‰ã€‚æœ¯åæœªå‡ºç°ä¸¥é‡å¤§ä¾¿å¤±ç¦ã€‚\n\n**ç»“è®ºï¼š** è¿™äº›æ•°æ®è¡¨æ˜ FiLaCâ„¢ å¯¹äº pfCD æ‚£è€…å¯èƒ½æ˜¯ä¸€ç§æœ‰æ•ˆä¸”å®‰å…¨çš„æ‰‹æœ¯ã€‚ç„¶è€Œï¼Œè¯æ®ä¸è¶³ï¼Œåœ¨æ¨èè¿™ç§å¾®åˆ›æŠ€æœ¯ç”¨äº pfCD çš„æ‰‹æœ¯æ²»ç–—ä¹‹å‰ï¼Œéœ€è¦è¿›è¡Œæ›´å¤šé«˜è´¨é‡çš„å‰ç»æ€§å¯¹ç…§ç ”ç©¶å’Œé•¿æœŸéšè®¿ã€‚", "keywords_zh": "å¤§ä¾¿å¤±ç¦ã€FiLaCâ„¢ã€æ²»æ„ˆç‡ã€èŸèƒåˆ†æã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "Fecal incontinence, FiLaCâ„¢, Healing rate, Meta-analysis, Perianal fistulizing Crohnâ€™s disease", "link": "https://pubmed.ncbi.nlm.nih.gov/35962294/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 12 Aug 2022"}, {"id": "35688686", "title_en": "Ileoanal pouch-related fistulae: A systematic review with meta-analysis on incidence, treatment options and outcomes", "title_zh": "å›è‚ è‚›ç®¡ç›¸å…³ç˜˜ç®¡ï¼šå¯¹å‘ç—…ç‡ã€æ²»ç–—æ–¹æ¡ˆå’Œç»“æœè¿›è¡ŒèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·", "authors": "Guido Sciaudone", "abstract_en": "**Background:** Ileoanal pouch related fistulae (PRF) are a complication of restorative proctocolectomy often requiring repeated surgical interventions and with a high risk of long-term recurrence and pouch failure.\n\n**Aims:** To assess the incidence of PRF and to report on the outcomes of available surgical treatments.\n\n**Methods:** A PRISMA-compliant systematic literature search for articles reporting on PRF in patients with inflammatory bowel diseases (IBD) or familial adenomatous polyposis (FAP) from 1985 to 2020.\n\n**Results:** 34 studies comprising 770 patients with PRF after ileal-pouch anal anastomosis (IPAA) were included. Incidence of PRF was 1.5-12%. In IBD patients Crohn's Disease (CD) was responsible for one every four pouch-vaginal fistulae (PVF) (OR 24.7; p=0.001). The overall fistula recurrence was 49.4%; procedure-specific recurrence was: repeat IPAA (OR 42.1; GRADE +); transvaginal repair (OR 52.3; GRADE ++) and transanal ileal pouch advancement flap (OR 56.9; GRADE ++). The overall failure rate was 19%: pouch excision (OR 0.20; GRADE ++); persistence of diverting stoma (OR 0.13; GRADE +) and persistent fistula (OR 0.18; GRADE +).\n\n**Conclusion:** PVFs are more frequent compared to other types of PRF and are often associated to CD; surgical treatment has a risk of 50% recurrence. Repeat IPAA is the best surgical approach with a 42.1% recurrence rate.", "abstract_zh": "**èƒŒæ™¯ï¼š** å›è‚ å‚¨è¢‹ç›¸å…³ç˜˜ç®¡ï¼ˆPRFï¼‰æ˜¯æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯çš„å¹¶å‘ç—‡ï¼Œé€šå¸¸éœ€è¦é‡å¤æ‰‹æœ¯å¹²é¢„ï¼Œå¹¶ä¸”é•¿æœŸå¤å‘å’Œå‚¨è¢‹å¤±è´¥çš„é£é™©å¾ˆé«˜ã€‚\n\n**Aimsï¼š** è¯„ä¼° PRF çš„å‘ç”Ÿç‡å¹¶æŠ¥å‘Šå¯ç”¨æ‰‹æœ¯æ²»ç–—çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿæ–‡çŒ®æ£€ç´¢ï¼Œæ£€ç´¢æŠ¥å‘Š 1985 å¹´è‡³ 2020 å¹´ç‚ç—‡æ€§è‚ ç—… (IBD) æˆ–å®¶æ—æ€§è…ºç˜¤æ€§æ¯è‚‰ç—… (FAP) æ‚£è€… PRF çš„æ–‡ç« ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 34 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­åŒ…æ‹¬ 770 åå›è‚ è¢‹è‚›ç®¡å»åˆæœ¯ (IPAA) åå‡ºç° PRF çš„æ‚£è€…ã€‚ PRF çš„å‘ç”Ÿç‡ä¸º 1.5-12%ã€‚åœ¨ IBD æ‚£è€…ä¸­ï¼Œæ¯ 4 ä¸ªå‚¨è¢‹é˜´é“ç˜˜ (PVF) ä¸­å°±æœ‰ 1 ä¸ªæ˜¯ç”±å…‹ç½—æ©ç—… (CD) å¼•èµ·çš„ï¼ˆOR 24.7ï¼›p=0.001ï¼‰ã€‚æ€»çš„ç˜˜ç®¡å¤å‘ç‡ä¸º49.4%ï¼›æ‰‹æœ¯ç‰¹å¼‚æ€§å¤å‘ä¸ºï¼šé‡å¤ IPAAï¼ˆOR 42.1ï¼›GRADE +ï¼‰ï¼›ç»é˜´é“ä¿®å¤æœ¯ï¼ˆOR 52.3ï¼›GRADE ++ï¼‰å’Œç»è‚›é—¨å›è‚ è¢‹æ¨è¿›çš®ç“£ï¼ˆOR 56.9ï¼›GRADE ++ï¼‰ã€‚æ€»ä½“å¤±è´¥ç‡ä¸º 19%ï¼šå‚¨è¢‹åˆ‡é™¤æœ¯ï¼ˆOR 0.20ï¼›GRADE ++ï¼‰ï¼›æŒç»­å­˜åœ¨åˆ†æµé€ å£ï¼ˆOR 0.13ï¼›GRADE +ï¼‰å’ŒæŒç»­æ€§ç˜˜ç®¡ï¼ˆOR 0.18ï¼›GRADE +ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ä¸å…¶ä»–ç±»å‹çš„ PRF ç›¸æ¯”ï¼ŒPVF æ›´ä¸ºå¸¸è§ï¼Œå¹¶ä¸”é€šå¸¸ä¸ CD ç›¸å…³ï¼›æ‰‹æœ¯æ²»ç–—æœ‰50%çš„å¤å‘é£é™©ã€‚é‡å¤ IPAA æ˜¯æœ€å¥½çš„æ‰‹æœ¯æ–¹æ³•ï¼Œå¤å‘ç‡ä¸º 42.1%ã€‚", "keywords_zh": "æ¢å¤æ€§ç›´è‚ ç»“è‚ åˆ‡é™¤æœ¯ã€å›è‚ å‚¨è¢‹ç˜˜çš„æ²»ç–—ã€å‚¨è¢‹é˜´é“ç˜˜çš„æ²»ç–—", "keywords_en": "Restorative proctocolectomy, Treatment of ileal pouch fistula, Treatment of pouch-vaginal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/35688686/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 10 Jun 2022"}, {"id": "35661342", "title_en": "Different segmental resection techniques and postoperative complications in patients with colorectal endometriosis: A systematic review", "title_zh": "ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ‚£è€…ä¸åŒèŠ‚æ®µåˆ‡é™¤æŠ€æœ¯ä¸æœ¯åå¹¶å‘ç—‡çš„ç³»ç»Ÿè¯„ä»·", "authors": "Gernot Hudelist", "abstract_en": "**Introduction:** The aim of this study was to analyze the available literature by conducting a systematic review to assess the possible effects of nerve-sparing segmental resection and conventional bowel resection on postoperative complications for the treatment of colorectal endometriosis.\n\n**Material And Methods:** Pubmed, Clinical Trials.gov, Cochrane Library, and Web of Science were comprehensively searched from 1997 to 2021 in order to perform a systematic review. Studies including patients undergoing segmental resection for colorectal endometriosis including adequate follow-up, data on postoperative complications and postoperative sequelae were enrolled in this review. Selected articles were evaluated and divided in two groups: Nerve-sparing resection (NSR), and conventional segmental resection not otherwise specified (SRNOS). Within the NSRs, studies mentioning preservation of the rectal artery supply (artery and nerve-sparing SR - ANSR) and not reporting preservation of the artery supply (NSR not otherwise specified - NSRNOS) were further analyzed.\n\n**Prospero Id:** CRD42021250974.\n\n**Results:** A total of 7549 patients from 63 studies were included in the data analysis. Forty-three of these publications did not mention the preservation or the removal of the hypogastric nerve plexus, or main rectal artery supply and were summarized as SRNOS. The remaining 22 studies were listed under the NSR group. The mean size of the resected deep endometriosis lesions and patients' body mass index were comparable between SRNOS and NSR. A mean of 3.6% (0-16.6) and 2.3% (0-10.5%) of rectovaginal fistula development was reported in patients who underwent SRNOS and NSR, respectively. Anastomotic leakage rates varied from 0% to 8.6% (mean 1.7â€‰Â±â€‰2%) in SRNOS compared with 0% to 8% (mean 1.7â€‰Â±â€‰2%) in patients undergoing NSR. Urinary retention (4.5% and 4.9%) and long-term bladder catheterization (4.9% and 5.6%) were frequently reported in SRNOS and NSR. There was insufficient information about pain or the recurrence rates for women undergoing SRNOS and NSR.\n\n**Conclusions:** Current data describe the outcomes of different segmental resection techniques. However, the data are inhomogeneous and not sufficient to reach a conclusion regarding a possible advantage of one technique over the other.", "abstract_zh": "**ä»‹ç»ï¼š** æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯é€šè¿‡ç³»ç»Ÿè¯„ä»·æ¥åˆ†æç°æœ‰æ–‡çŒ®ï¼Œä»¥è¯„ä¼°ä¿ç•™ç¥ç»çš„èŠ‚æ®µåˆ‡é™¤æœ¯å’Œå¸¸è§„è‚ åˆ‡é™¤æœ¯å¯¹ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ²»ç–—æœ¯åå¹¶å‘ç—‡çš„å¯èƒ½å½±å“ã€‚\n\n**Material and methodsï¼š** ä» 1997 å¹´åˆ° 2021 å¹´ï¼Œå¯¹ Pubmedã€Clinical Trials.govã€Cochrane Library å’Œ Web of Science è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œä»¥è¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚æœ¬æ¬¡ç»¼è¿°çº³å…¥äº†åŒ…æ‹¬å› ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ¥å—èŠ‚æ®µåˆ‡é™¤æœ¯çš„æ‚£è€…åœ¨å†…çš„ç ”ç©¶ï¼ŒåŒ…æ‹¬å……åˆ†çš„éšè®¿ã€æœ¯åå¹¶å‘ç—‡å’Œæœ¯ååé—ç—‡çš„æ•°æ®ã€‚å¯¹é€‰å®šçš„æ–‡ç« è¿›è¡Œè¯„ä¼°å¹¶åˆ†ä¸ºä¸¤ç»„ï¼šä¿ç•™ç¥ç»åˆ‡é™¤æœ¯ï¼ˆNSRï¼‰å’Œæœªå¦è¡ŒæŒ‡å®šçš„å¸¸è§„èŠ‚æ®µåˆ‡é™¤æœ¯ï¼ˆSRNOSï¼‰ã€‚åœ¨ NSR ä¸­ï¼Œè¿›ä¸€æ­¥åˆ†æäº†æåŠä¿ç•™ç›´è‚ åŠ¨è„‰ä¾›åº”ï¼ˆåŠ¨è„‰å’Œç¥ç»ä¿ç•™ SR - ANSRï¼‰å’ŒæœªæŠ¥å‘ŠåŠ¨è„‰ä¾›åº”ä¿ç•™ï¼ˆNSR æœªå¦è¡ŒæŒ‡å®š - NSRNOSï¼‰çš„ç ”ç©¶ã€‚\n\n**Prospero idï¼š** CRD42021250974ã€‚\n\n**ç»“æœï¼š** æ•°æ®åˆ†æå…±çº³å…¥ 63 é¡¹ç ”ç©¶çš„ 7549 åæ‚£è€…ã€‚å…¶ä¸­ 43 ç¯‡å‡ºç‰ˆç‰©æ²¡æœ‰æåŠä¿ç•™æˆ–å»é™¤è…¹ä¸‹ç¥ç»ä¸›æˆ–ä¸»è¦ç›´è‚ åŠ¨è„‰ä¾›åº”ï¼Œå¹¶è¢«æ€»ç»“ä¸º SRNOSã€‚å…¶ä½™ 22 é¡¹ç ”ç©¶åˆ—åœ¨ NSR ç»„ä¸‹ã€‚ SRNOS å’Œ NSR åˆ‡é™¤çš„æ·±éƒ¨å­å®«å†…è†œå¼‚ä½ç—…ç¶çš„å¹³å‡å¤§å°å’Œæ‚£è€…çš„ä½“é‡æŒ‡æ•°ç›¸å½“ã€‚æ®æŠ¥é“ï¼Œæ¥å— SRNOS å’Œ NSR çš„æ‚£è€…å¹³å‡å‘ç”Ÿç›´è‚ é˜´é“ç˜˜çš„æ¯”ä¾‹åˆ†åˆ«ä¸º 3.6% (0-16.6) å’Œ 2.3% (0-10.5%)ã€‚ SRNOS æ‚£è€…çš„å»åˆå£æ¼ç‡ä» 0% åˆ° 8.6%ï¼ˆå¹³å‡ 1.7Â±Â±2%ï¼‰ä¸ç­‰ï¼Œè€Œæ¥å— NSR çš„æ‚£è€…å»åˆå£æ¼ç‡ä¸º 0% åˆ° 8%ï¼ˆå¹³å‡ 1.7Â±Â±2%ï¼‰ã€‚ SRNOS å’Œ NSR ä¸­ç»å¸¸æŠ¥å‘Šå°¿æ½´ç•™ï¼ˆ4.5% å’Œ 4.9%ï¼‰å’Œé•¿æœŸè†€èƒ±å¯¼å°¿ï¼ˆ4.9% å’Œ 5.6%ï¼‰ã€‚å…³äºæ¥å— SRNOS å’Œ NSR çš„å¥³æ€§çš„ç–¼ç—›æˆ–å¤å‘ç‡çš„ä¿¡æ¯ä¸è¶³ã€‚\n\n**ç»“è®ºï¼š** ç›®å‰çš„æ•°æ®æè¿°äº†ä¸åŒèŠ‚æ®µåˆ‡é™¤æŠ€æœ¯çš„ç»“æœã€‚ç„¶è€Œï¼Œæ•°æ®ä¸å‡åŒ€ï¼Œä¸è¶³ä»¥å¾—å‡ºå…³äºä¸€ç§æŠ€æœ¯ç›¸å¯¹äºå¦ä¸€ç§æŠ€æœ¯çš„å¯èƒ½ä¼˜åŠ¿çš„ç»“è®ºã€‚", "keywords_zh": "å­å®«å†…è†œå¼‚ä½ç—‡ã€å†…çª¥é•œæ‰‹æœ¯ã€è…¹è…”é•œæ£€æŸ¥ã€å‘ç—…ç‡ã€æ‰‹æœ¯æŠ€æœ¯", "keywords_en": "endometriosis, endoscopic surgery, laparoscopy, morbidity, surgical techniques", "link": "https://pubmed.ncbi.nlm.nih.gov/35661342/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Mon, 06 Jun 2022"}, {"id": "35611255", "title_en": "Prevalence of anal fistulas: a systematic review and meta-analysis", "title_zh": "è‚›ç˜˜çš„æ‚£ç—…ç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Mahmoud Yousefifard", "abstract_en": "Anal fistula refers to a clinical condition with local pain and inflammation associated with purulent discharge that affects the quality of life. Due to the lack of studies, the presence of bias, and high heterogeneity in the studies, the present systematic review is the first to be performed on the population-based database in this field. The present systematic review and meta-analysis was performed according to MOOSE guidelines. After systematic searching in electronic databases, only four articles met the inclusion criteria. After preparing a checklist and extracting data from the relevant articles, a meta-analysis was performed. All studies on the prevalence of anal fistula are related to Europe, and so far, no study has been conducted on other continents. The overall prevalence of anal fistula in European countries was 18.37 (95% CI: 18.20-18.55%) per 100,000 individuals, and the highest prevalence was reported for Italy (23.20 (95% CI: 22.82 to 23.59) per 100,000 people). From the present population-based (224,097,362) study results, it can be concluded that there is a prominent knowledge gap in this context. Because all the studies included in the current study relate only to Europe, the need for further research in this field in other countries is inevitably sensible.", "abstract_zh": "è‚›ç˜˜æ˜¯æŒ‡ä¸€ç§ä¼´æœ‰å±€éƒ¨ç–¼ç—›å’Œç‚ç—‡ã€ä¼´æœ‰è„“æ€§åˆ†æ³Œç‰©ã€å½±å“ç”Ÿæ´»è´¨é‡çš„ä¸´åºŠç—…ç—‡ã€‚ç”±äºç ”ç©¶ç¼ºä¹ã€å­˜åœ¨åå€šã€å¼‚è´¨æ€§é«˜ï¼Œæœ¬ç³»ç»Ÿè¯„ä»·æ˜¯è¯¥é¢†åŸŸé¦–æ¬¡é’ˆå¯¹äººç¾¤æ•°æ®åº“è¿›è¡Œçš„ç³»ç»Ÿè¯„ä»·ã€‚æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ˜¯æ ¹æ® MOOSE æŒ‡å—è¿›è¡Œçš„ã€‚ç»è¿‡ç³»ç»Ÿæ£€ç´¢ç”µå­æ•°æ®åº“ï¼Œåªæœ‰å››ç¯‡æ–‡ç« ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚åœ¨å‡†å¤‡æ¸…å•å¹¶ä»ç›¸å…³æ–‡ç« ä¸­æå–æ•°æ®åï¼Œè¿›è¡Œäº†èŸèƒåˆ†æã€‚æ‰€æœ‰å…³äºè‚›ç˜˜æ‚£ç—…ç‡çš„ç ”ç©¶éƒ½ä¸æ¬§æ´²æœ‰å…³ï¼Œåˆ°ç›®å‰ä¸ºæ­¢ï¼Œè¿˜æ²¡æœ‰åœ¨å…¶ä»–å¤§é™†è¿›è¡Œè¿‡ç ”ç©¶ã€‚æ¬§æ´²å›½å®¶è‚›ç˜˜çš„æ€»ä½“æ‚£ç—…ç‡ä¸ºæ¯ 10 ä¸‡äºº 18.37 ä¾‹ï¼ˆ95% CIï¼š18.20-18.55%ï¼‰ï¼Œå…¶ä¸­æ„å¤§åˆ©æ‚£ç—…ç‡æœ€é«˜ï¼ˆæ¯ 10 ä¸‡äºº 23.20 ä¾‹ï¼ˆ95% CIï¼š22.82 è‡³ 23.59ï¼‰ï¼‰ã€‚ä»ç›®å‰åŸºäºäººç¾¤ï¼ˆ224,097,362ï¼‰çš„ç ”ç©¶ç»“æœå¯ä»¥å¾—å‡ºç»“è®ºï¼Œåœ¨è¿™æ–¹é¢å­˜åœ¨ç€æ˜¾ç€çš„çŸ¥è¯†å·®è·ã€‚ç”±äºå½“å‰ç ”ç©¶ä¸­åŒ…å«çš„æ‰€æœ‰ç ”ç©¶ä»…ä¸æ¬§æ´²æœ‰å…³ï¼Œå› æ­¤åœ¨å…¶ä»–å›½å®¶è¿›è¡Œè¯¥é¢†åŸŸçš„è¿›ä¸€æ­¥ç ”ç©¶çš„å¿…è¦æ€§ä¸å¯é¿å…åœ°æ˜¯åˆç†çš„ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œæ‚£ç—…ç‡ï¼Œç³»ç»Ÿè¯„ä»·ã€‚", "keywords_en": "Anal Fistulas, Prevalence, Systematic Review.", "link": "https://pubmed.ncbi.nlm.nih.gov/35611255/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 25 May 2022"}, {"id": "35442833", "title_en": "Role of fluorescence imaging for intraoperative intestinal assessment in gynecological surgery: a systematic review", "title_zh": "è§å…‰æˆåƒåœ¨å¦‡ç§‘æ‰‹æœ¯ä¸­è‚ é“è¯„ä¼°ä¸­çš„ä½œç”¨ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mikel Gorostidi", "abstract_en": "**Background:** Our aim was to review the current knowledge of the role of fluorescence imaging for intraoperative intestinal assessment in gynecological surgery.\n\n**Material And Methods:** A computer-based systematic review was performed from 2000 to 2020. All articles describing the use of indocyanine green (ICG) applied to bowel assessments in gynecology or endometriosis surgery were considered for review.\n\n**Results:** ICG is an effective tool for assessing bowel vascularization, potentially preventing anastomotic leakage and recto-vaginal fistula and can therefore be useful for endometriosis surgery or bowel assessment in gynecological oncology procedures. Real-time characterization of the hypovascular pattern of endometriotic nodules has been associated with a larger nodule size and lower microvessel density, helping surgeons choose the best transecting line and the most appropriate technique. ICG angiography allows for a laparoscopic and intrarectal bowel assessment, which can act as a double check of bowel perfusion, enabling the assessment of mucosa vascularization. ICG fluorescence can guide intraoperative decision-making after intestinal anastomosis, discoid resection, and rectal shaving, preventing anastomotic leakage and postoperative recto-vaginal fistula in low anterior resections.\n\n**Conclusions:** ICG angiography provides a better intestinal assessment. Larger, prospective, randomized controlled studies are needed to validate the technique and confirm these encouraging results.", "abstract_zh": "**èƒŒæ™¯ï¼š** æˆ‘ä»¬çš„ç›®çš„æ˜¯å›é¡¾ç›®å‰è§å…‰æˆåƒåœ¨å¦‡ç§‘æ‰‹æœ¯ä¸­è‚ é“è¯„ä¼°ä¸­çš„ä½œç”¨çš„çŸ¥è¯†ã€‚\n\n**Material and methodsï¼š** 2000å¹´è‡³2020å¹´è¿›è¡Œäº†ä¸€é¡¹åŸºäºè®¡ç®—æœºçš„ç³»ç»Ÿè¯„ä»·ã€‚æ‰€æœ‰æè¿°å²å“šèç»¿ï¼ˆICGï¼‰åº”ç”¨äºå¦‡ç§‘æˆ–å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯è‚ é“è¯„ä¼°çš„æ–‡ç« å‡è¢«è€ƒè™‘è¿›è¡Œå®¡æŸ¥ã€‚\n\n**ç»“æœï¼š** ICG æ˜¯è¯„ä¼°è‚ é“è¡€ç®¡åŒ–çš„æœ‰æ•ˆå·¥å…·ï¼Œæœ‰å¯èƒ½é¢„é˜²å»åˆå£ç˜˜å’Œç›´è‚ é˜´é“ç˜˜ï¼Œå› æ­¤å¯ç”¨äºå­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯æˆ–å¦‡ç§‘è‚¿ç˜¤æ‰‹æœ¯ä¸­çš„è‚ é“è¯„ä¼°ã€‚å­å®«å†…è†œå¼‚ä½ç»“èŠ‚ç¼ºè¡€ç®¡æ¨¡å¼çš„å®æ—¶è¡¨å¾ä¸è¾ƒå¤§çš„ç»“èŠ‚å°ºå¯¸å’Œè¾ƒä½çš„å¾®è¡€ç®¡å¯†åº¦ç›¸å…³ï¼Œæœ‰åŠ©äºå¤–ç§‘åŒ»ç”Ÿé€‰æ‹©æœ€ä½³æ¨ªæ–­çº¿å’Œæœ€åˆé€‚çš„æŠ€æœ¯ã€‚ ICG è¡€ç®¡é€ å½±å¯ä»¥è¿›è¡Œè…¹è…”é•œå’Œç›´è‚ å†…è‚ é“è¯„ä¼°ï¼Œå¯ä»¥ä½œä¸ºè‚ é“çŒæ³¨çš„åŒé‡æ£€æŸ¥ï¼Œä»è€Œèƒ½å¤Ÿè¯„ä¼°ç²˜è†œè¡€ç®¡åŒ–ã€‚ ICGè§å…‰å¯ä»¥æŒ‡å¯¼è‚ å»åˆã€ç›˜çŠ¶åˆ‡é™¤å’Œç›´è‚ å‰ƒé™¤åçš„æœ¯ä¸­å†³ç­–ï¼Œé˜²æ­¢ä½ä½å‰åˆ‡é™¤æœ¯ä¸­çš„å»åˆå£ç˜˜å’Œæœ¯åç›´è‚ é˜´é“ç˜˜ã€‚\n\n**ç»“è®ºï¼š** ICG è¡€ç®¡é€ å½±å¯æä¾›æ›´å¥½çš„è‚ é“è¯„ä¼°ã€‚éœ€è¦æ›´å¤§è§„æ¨¡çš„å‰ç»æ€§éšæœºå¯¹ç…§ç ”ç©¶æ¥éªŒè¯è¯¥æŠ€æœ¯å¹¶ç¡®è®¤è¿™äº›ä»¤äººé¼“èˆçš„ç»“æœã€‚", "keywords_zh": "å¾®åˆ›æ‰‹æœ¯ã€è‚ é“å¹¶å‘ç—‡ã€å¦‡ç§‘æ‰‹æœ¯ã€å²å“šèç»¿", "keywords_en": "Minimally invasive surgery, bowel complication, gynecological surgery, indocyanine green", "link": "https://pubmed.ncbi.nlm.nih.gov/35442833/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Wed, 20 Apr 2022"}, {"id": "35357610", "title_en": "A systematic review and meta-analysis of the outcome of ileal pouch-anal anastomosis in patients with ulcerative colitis versus patients with familial adenomatous polyposis", "title_zh": "æºƒç–¡æ€§ç»“è‚ ç‚æ‚£è€…ä¸å®¶æ—æ€§è…ºç˜¤æ€§æ¯è‚‰ç—…æ‚£è€…å›è‚ å‚¨è¢‹è‚›é—¨å»åˆæœ¯ç»“æœçš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "S D Wexner", "abstract_en": "**Background:** Ileal pouch-anal anastomosis (IPAA) is commonly used to restore gastrointestinal continuity after surgical treatment of mucosal ulcerative colitis (MUC) and familial adenomatous polyposis (FAP). The aim of the present systematic review was to compare the outcomes of patients with MUC and patients with FAP who underwent IPAA.\n\n**Methods:** A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant systematic review was performed. PubMed, Scopus, and Web of Science were searched through December 2021. Cohort and randomized studies were eligible for inclusion if they directly compared patients with MUC and FAP who underwent IPAA. The main outcome measures were pouch failure, complications, and need for pouch excision or revision. ROBINS-I tool was used to assess the risk of bias across the studies. A random-effect meta-analysis was conducted.\n\n**Results:** Twenty-three studies (9200 patients) were included in this meta-analysis. Seven thousand nine hundred fifty (86.4%) had MUC and 1250 (13.6%) hadÂ FAP. The median age of patients was 33.1Â years. The male to female ratio was 1.4:1. MUC had higher odds of pouchitis (OR 3.9, 95% CI 2.8-5.4, pâ€‰<â€‰0.001), stricture (OR 1.82, 95% CI 1.25-2.65, pâ€‰=â€‰0.002), fistula (OR 1.74, 95% CI 1.18-2.54, pâ€‰=â€‰0.004), and total complications (OR 1.89, 95% CI 1.3-2.77, pâ€‰<â€‰0.001) as compared to FAP. Both groups had similar odds of pelvic sepsis, leakage, pouch failure, excision, revision, and fecal incontinence.\n\n**Conclusions:** Although patients with MUC undergoing IPAA may be at a higher risk of developing complications, particularly pouchitis, stricture, and fistula; the ultimate and functional outcome of the pouch is similar to patients with FAP. Pouch failure, excision and revision were similar in the two groups.", "abstract_zh": "**èƒŒæ™¯ï¼š** å›è‚ å‚¨è¢‹è‚›é—¨å»åˆæœ¯ï¼ˆIPAAï¼‰é€šå¸¸ç”¨äºåœ¨ç²˜è†œæºƒç–¡æ€§ç»“è‚ ç‚ï¼ˆMUCï¼‰å’Œå®¶æ—æ€§è…ºç˜¤æ€§æ¯è‚‰ç—…ï¼ˆFAPï¼‰çš„æ‰‹æœ¯æ²»ç–—åæ¢å¤èƒƒè‚ é“è¿ç»­æ€§ã€‚æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯æ¯”è¾ƒæ¥å— IPAA çš„ MUC æ‚£è€…å’Œ FAP æ‚£è€…çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** è¿›è¡Œäº†ç¬¦åˆç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ (PRISMA) çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®çš„ç³»ç»Ÿè¯„ä»·ã€‚ PubMedã€Scopus å’Œ Web of Science çš„æ£€ç´¢æˆªæ­¢æ—¶é—´ä¸º 2021 å¹´ 12 æœˆã€‚é˜Ÿåˆ—ç ”ç©¶å’Œéšæœºç ”ç©¶å¦‚æœç›´æ¥æ¯”è¾ƒæ¥å— IPAA çš„ MUC å’Œ FAP æ‚£è€…ï¼Œåˆ™ç¬¦åˆçº³å…¥æ¡ä»¶ã€‚ä¸»è¦ç»“æœæŒ‡æ ‡æ˜¯é€ å£è¢‹å¤±è´¥ã€å¹¶å‘ç—‡ä»¥åŠé€ å£è¢‹åˆ‡é™¤æˆ–ç¿»ä¿®çš„éœ€è¦ã€‚ ROBINS-I å·¥å…·ç”¨äºè¯„ä¼°ç ”ç©¶ä¸­çš„åå€šé£é™©ã€‚è¿›è¡Œäº†éšæœºæ•ˆåº”èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** æœ¬èŸèƒåˆ†æçº³å…¥äº† 23 é¡¹ç ”ç©¶ï¼ˆ9200 åæ‚£è€…ï¼‰ã€‚ 7950 äºº (86.4%) æ‚£æœ‰ MUCï¼Œ1250 äºº (13.6%) æ‚£æœ‰ FAPã€‚æ‚£è€…çš„ä¸­ä½å¹´é¾„ä¸º 33.1 å²ã€‚ç”·å¥³æ¯”ä¾‹ä¸º1.4ï¼š1ã€‚ MUC å‘ç”Ÿå‚¨è¢‹ç‚ (OR 3.9, 95% CI 2.8-5.4, p<0.001)ã€ç‹­çª„ (OR 1.82, 95% CI 1.25-2.65, pâ€‰=â€‰0.002)ã€ç˜˜ç®¡ (OR 1.74, 95% CI 1.18-2.54,ä¸ FAP ç›¸æ¯”ï¼Œpâ€‰=â€‰0.004ï¼‰å’Œæ€»å¹¶å‘ç—‡ï¼ˆOR 1.89ï¼Œ95% CI 1.3-2.77ï¼Œp<â€‰0.001ï¼‰ã€‚ä¸¤ç»„å‘ç”Ÿç›†è…”è´¥è¡€ç—‡ã€æ¸—æ¼ã€é€ å£è¢‹å¤±è´¥ã€åˆ‡é™¤ã€ç¿»ä¿®å’Œå¤§ä¾¿å¤±ç¦çš„å‡ ç‡ç›¸ä¼¼ã€‚\n\n**ç»“è®ºï¼š** å°½ç®¡æ¥å— IPAA çš„ MUC æ‚£è€…å‡ºç°å¹¶å‘ç—‡çš„é£é™©å¯èƒ½æ›´é«˜ï¼Œç‰¹åˆ«æ˜¯å‚¨è¢‹ç‚ã€ç‹­çª„å’Œç˜˜ç®¡ï¼›é€ å£è¢‹çš„æœ€ç»ˆåŠŸèƒ½ç»“æœä¸ FAP æ‚£è€…ç›¸ä¼¼ã€‚ä¸¤ç»„çš„å‚¨è¢‹å¤±è´¥ã€åˆ‡é™¤å’Œç¿»ä¿®ç›¸ä¼¼ã€‚", "keywords_zh": "å®¶æ—æ€§è…ºç˜¤æ€§æ¯è‚‰ç—…, å›è‚ è´®è¢‹-è‚›é—¨å»åˆæœ¯, èŸèƒåˆ†æ, ç»“æœ, ç³»ç»Ÿè¯„ä»·, æºƒç–¡æ€§ç»“è‚ ç‚", "keywords_en": "Familial adenomatous polyposis, Ileal pouch-anal anastomosis, Meta-analysis, Outcome, Systematic review, Ulcerative colitis", "link": "https://pubmed.ncbi.nlm.nih.gov/35357610/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 31 Mar 2022"}, {"id": "35347492", "title_en": "Video-assisted anal fistula treatment for complex anorectal fistulas in adults: a systematic review and meta-analysis", "title_zh": "æˆäººå¤æ‚æ€§è‚›è‚ ç˜˜çš„è§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Y Q Wang", "abstract_en": "**Background:** Video-assisted anal fistula treatment (VAAFT) has gained increasing acceptance as a sphincter-sparing procedure for treating complex anorectal fistulas (CAF), but no unequivocal conclusions can yet be drawn regarding its ultimate effectiveness. We reviewed the literature and performed a meta-analysis to evaluate the efficacy and safety of VAAFT in CAF patients.\n\n**Methods:** The study protocol was registered with the PROSPERO database (CRD42021279085). A systematic literature search was performed in the PubMed, Embase, and Cochrane Library databases up to June 2021 with no restriction on language based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We used the keywords video-assisted surgery, video-assisted anal fistula treatment, and complex anorectal fistula to identify relevant studies.\n\n**Results:** Fourteen trials (7 prospective and 7 retrospective)Â with a total of 1201 patients (mean age 43.5Â years) were included. The median follow-up duration was 16.5(8-48) months. Pooled analysis showed that the rates of success, recurrence and postoperative complication across the studies were 83% (95% CI 81-85%, I<sup>2</sup>â€‰=â€‰37.9%), 16% (95% CI 14-18%, I<sup>2</sup>â€‰=â€‰4.8%), 11% (95% CI 7-15%, I<sup>2</sup>â€‰=â€‰72.1%), respectively. The postoperative Jorge-Wexner score used to assess the level of anal incontinence was 1.09 (95% CI, 0.9-1.27, I<sup>2</sup>â€‰=â€‰74.6%). The internal opening detection rate was 97.6% (95% CI 96.1-99.6%, I<sup>2</sup>â€‰=â€‰48.2%). Recurrence rates varied according to the closure method of internal opening from 21.4% after using staplers, 18.7% after suturing, to 23.5% after advancement flap. The hospital stay was 3.15Â days (95% CI 2.96-3.35, I<sup>2</sup>â€‰=â€‰49.7%). Subgroup analysis indicated thatÂ the risk of heterogeneity in the urine retention group was higher Â compared with that of the overall group andÂ that retrospective studies may be the source of heterogeneity for postoperative anal incontinence.Â r . Sensitivity analysis confirmed the stability of the pooled results. Begg's and Egger's tests showed no evidence of publication bias.\n\n**Conclusions:** According to the available evidence, VAAFT may be a valuable alternative to fistulotomy or seton in treating CAF and has the additional long-term benefits of reducing anal incontinence and surgical morbidity, permitting earlier healing and accelerated rehabilitation.", "abstract_zh": "**èƒŒæ™¯ï¼š** è§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—ï¼ˆVAAFTï¼‰ä½œä¸ºä¸€ç§æ²»ç–—å¤æ‚æ€§è‚›è‚ ç˜˜ï¼ˆCAFï¼‰çš„ä¿ç•™æ‹¬çº¦è‚Œçš„æ‰‹æœ¯å·²è·å¾—è¶Šæ¥è¶Šå¤šçš„è®¤å¯ï¼Œä½†å…³äºå…¶æœ€ç»ˆæ•ˆæœå°šæ— æ˜ç¡®çš„ç»“è®ºã€‚æˆ‘ä»¬å›é¡¾äº†æ–‡çŒ®å¹¶è¿›è¡Œäº†èŸèƒåˆ†æï¼Œä»¥è¯„ä¼° VAAFT åœ¨ CAF æ‚£è€…ä¸­çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** ç ”ç©¶æ–¹æ¡ˆå·²åœ¨ PROSPERO æ•°æ®åº“ä¸­æ³¨å†Œ (CRD42021279085)ã€‚æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææŒ‡å—çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼Œåœ¨ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“ä¸­è¿›è¡Œäº†æˆªè‡³ 2021 å¹´ 6 æœˆçš„ç³»ç»Ÿæ–‡çŒ®æ£€ç´¢ï¼Œå¯¹è¯­è¨€æ²¡æœ‰é™åˆ¶ã€‚æˆ‘ä»¬ä½¿ç”¨å…³é”®è¯è§†é¢‘è¾…åŠ©æ‰‹æœ¯ã€è§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—å’Œå¤æ‚æ€§è‚›è‚ ç˜˜æ¥è¯†åˆ«ç›¸å…³ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 14 é¡¹è¯•éªŒï¼ˆ7 é¡¹å‰ç»æ€§è¯•éªŒå’Œ 7 é¡¹å›é¡¾æ€§è¯•éªŒï¼‰ï¼Œå…±æœ‰ 1201 åæ‚£è€…ï¼ˆå¹³å‡å¹´é¾„ 43.5 å²ï¼‰ã€‚ä¸­ä½éšè®¿æ—¶é—´ä¸º16.5ï¼ˆ8-48ï¼‰ä¸ªæœˆã€‚æ±‡æ€»åˆ†ææ˜¾ç¤ºï¼Œæ‰€æœ‰ç ”ç©¶çš„æˆåŠŸç‡ã€å¤å‘ç‡å’Œæœ¯åå¹¶å‘ç—‡åˆ†åˆ«ä¸º 83% (95% CI 81-85%ï¼ŒI<sup>2</sup>â€‰=â€‰37.9%)ã€16% (95% CI 14-18%ï¼ŒI<sup>2</sup>â€‰=â€‰4.8%)ã€11% (95% CI 7-15%ï¼Œ I<sup>2</sup>â€‰=â€‰72.1%ï¼‰ã€‚æœ¯åç”¨äºè¯„ä¼°è‚›é—¨å¤±ç¦ç¨‹åº¦çš„ Jorge-Wexner è¯„åˆ†ä¸º 1.09ï¼ˆ95% CIï¼Œ0.9-1.27ï¼ŒI<sup>2</sup>â€‰=â€‰74.6%ï¼‰ã€‚å†…éƒ¨å¼€å£æ£€å‡ºç‡ä¸º97.6%ï¼ˆ95% CI 96.1-99.6%ï¼ŒI<sup>2</sup>â€‰=â€‰48.2%ï¼‰ã€‚æ ¹æ®å†…éƒ¨å¼€å£çš„é—­åˆæ–¹æ³•ï¼Œå¤å‘ç‡æœ‰æ‰€ä¸åŒï¼Œä»ä½¿ç”¨å»åˆå™¨åçš„ 21.4%ã€ç¼åˆåçš„ 18.7% åˆ°æ¨è¿›çš®ç“£åçš„ 23.5%ã€‚ä½é™¢æ—¶é—´ä¸º 3.15 å¤©ï¼ˆ95% CI 2.96-3.35ï¼ŒI<sup>2</sup>â€‰=â€‰49.7%ï¼‰ã€‚äºšç»„åˆ†æè¡¨æ˜ï¼Œå°¿æ½´ç•™ç»„çš„å¼‚è´¨æ€§é£é™©é«˜äºæ•´ä½“ç»„ï¼Œå›é¡¾æ€§ç ”ç©¶å¯èƒ½æ˜¯æœ¯åè‚›é—¨å¤±ç¦å¼‚è´¨æ€§çš„æ ¹æºã€‚Â æ²³ã€‚æ•æ„Ÿæ€§åˆ†æè¯å®äº†æ±‡æ€»ç»“æœçš„ç¨³å®šæ€§ã€‚è´æ ¼å’Œè‰¾æ ¼çš„æµ‹è¯•æ²¡æœ‰æ˜¾ç¤ºå‘è¡¨åè§çš„è¯æ®ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®ç°æœ‰è¯æ®ï¼ŒVAAFT å¯èƒ½æ˜¯æ²»ç–— CAF æ—¶ç˜˜ç®¡åˆ‡å¼€æœ¯æˆ–æŒ‚çº¿çš„æœ‰ä»·å€¼çš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¹¶ä¸”å…·æœ‰å‡å°‘è‚›é—¨å¤±ç¦å’Œæ‰‹æœ¯å‘ç—…ç‡ã€å…è®¸æ—©æœŸæ„ˆåˆå’ŒåŠ é€Ÿåº·å¤çš„é¢å¤–é•¿æœŸç›Šå¤„ã€‚", "keywords_zh": "å¤æ‚æ€§è‚›è‚ ç˜˜ï¼ŒMetaåˆ†æï¼ŒVAAFTï¼Œè§†é¢‘è¾…åŠ©è‚›ç˜˜æ²»ç–—", "keywords_en": "Complex anorectal fistula, Meta-analysis, VAAFT, Video-assisted anal fistula treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/35347492/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 29 Mar 2022"}, {"id": "35211503", "title_en": "Efficacy and Safety of Sphincter-Preserving Surgery in the Treatment of Complex Anal Fistula: A Network Meta-Analysis", "title_zh": "ä¿ç•™æ‹¬çº¦è‚Œæ‰‹æœ¯æ²»ç–—å¤æ‚è‚›ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç½‘ç»œèŸèƒåˆ†æ", "authors": "Shanshan Xu", "abstract_en": "**Background:** There are many surgical methods of sphincter preservation in treating complex anal fistula, but the therapeutic effects of each operation are different. Therefore, this study aimed to compare the impact of other treatment methods through a network meta-analysis to evaluate the best sphincter preservation method for treating complex anal fistula.\n\n**Methods:** We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, VIP Journal Database, and the Wanfang Database to collate randomized controlled trials on sphincter-preserving surgery for complex anal fistula.\n\n**Results:** A total of 29 articles were included in this meta-analysis. The cure rates showed no statistically significant differences between any two interventions (<i>P</i> > 0.05). The recurrence rate results showed that the rate of patients after Fistulectomy was higher than others (<i>P</i> < 0.05). The incidence rate of complications showed that the incidence rate after fistulectomy treatment was higher than that of others (<i>P</i> < 0.05). The surface under the cumulative ranking (SUCRA) was used to arrange their advantages and disadvantages, and a larger SUCRA value indicates that the intervention may be more effective. The results showed that TROPIS may have the highest cure rate (SUCRA = 78.6%), stem cell transplantation (SCT) may have the lowest recurrence rate (SUCRA = 85.5%), and imLIFT may have the least complications (SUCRA = 88.2%).\n\n**Conclusion:** According to the existing literature data, for patients with complex anal fistula, TROPIS may be the surgical method with the highest cure rate, SCT may be the treatment method with the lowest recurrence rate, and imLIFT may be the surgical method with the lowest incidence of postoperative complications.\n\n**Systematic Review Registration:** PROSPERO, identifier: CRD42020221907.", "abstract_zh": "**èƒŒæ™¯ï¼š** ä¿ç•™æ‹¬çº¦è‚Œæ²»ç–—å¤æ‚æ€§è‚›ç˜˜çš„æ‰‹æœ¯æ–¹æ³•æœ‰å¤šç§ï¼Œä½†æ¯ç§æ‰‹æœ¯çš„æ²»ç–—æ•ˆæœå„ä¸ç›¸åŒã€‚å› æ­¤ï¼Œæœ¬ç ”ç©¶æ—¨åœ¨é€šè¿‡ç½‘ç»œèŸèƒåˆ†ææ¯”è¾ƒå…¶ä»–æ²»ç–—æ–¹æ³•çš„å½±å“ï¼Œä»¥è¯„ä¼°æ²»ç–—å¤æ‚æ€§è‚›ç˜˜çš„æœ€ä½³ä¿ç•™æ‹¬çº¦è‚Œæ–¹æ³•ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº†PubMedã€Embaseã€Cochraneå›¾ä¹¦é¦†ã€ä¸­å›½çŸ¥è¯†åŸºç¡€è®¾æ–½ã€ä¸­å›½ç”Ÿç‰©åŒ»å­¦æ–‡çŒ®æ•°æ®åº“ã€ç»´æ™®æœŸåˆŠæ•°æ®åº“å’Œä¸‡æ–¹æ•°æ®åº“ï¼Œæ•´ç†å¤æ‚æ€§è‚›ç˜˜ä¿ç•™æ‹¬çº¦è‚Œæ‰‹æœ¯çš„éšæœºå¯¹ç…§è¯•éªŒã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡èŸèƒåˆ†æå…±çº³å…¥ 29 ç¯‡æ–‡ç« ã€‚ä»»æ„ä¸¤ç§å¹²é¢„æªæ–½çš„æ²»æ„ˆç‡å‡æ— ç»Ÿè®¡å­¦å·®å¼‚ï¼ˆ<i>P</i> > 0.05ï¼‰ã€‚å¤å‘ç‡ç»“æœæ˜¾ç¤ºï¼Œç˜˜ç®¡åˆ‡é™¤æœ¯åæ‚£è€…çš„å¤å‘ç‡é«˜äºå…¶ä»–æ‚£è€…ï¼ˆ<i>P</i><0.05ï¼‰ã€‚å¹¶å‘ç—‡å‘ç”Ÿç‡æ˜¾ç¤ºï¼Œç˜˜ç®¡åˆ‡é™¤æ²»ç–—åçš„å‘ç”Ÿç‡é«˜äºå…¶ä»–ç»„ï¼ˆ<i>P</i><0.05ï¼‰ã€‚é‡‡ç”¨ç´¯ç§¯æ’åºæ›²é¢ï¼ˆSUCRAï¼‰æ¥æ’åˆ—å…¶ä¼˜åŠ£åŠ¿ï¼ŒSUCRAå€¼è¶Šå¤§è¡¨æ˜å¹²é¢„å¯èƒ½è¶Šæœ‰æ•ˆã€‚ç»“æœæ˜¾ç¤ºï¼ŒTROPIS çš„æ²»æ„ˆç‡å¯èƒ½æœ€é«˜ï¼ˆSUCRA = 78.6%ï¼‰ï¼Œå¹²ç»†èƒç§»æ¤ï¼ˆSCTï¼‰çš„å¤å‘ç‡å¯èƒ½æœ€ä½ï¼ˆSUCRA = 85.5%ï¼‰ï¼Œè€Œ imLIFT çš„å¹¶å‘ç—‡å¯èƒ½æœ€å°‘ï¼ˆSUCRA = 88.2%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®ç°æœ‰æ–‡çŒ®æ•°æ®ï¼Œå¯¹äºå¤æ‚æ€§è‚›ç˜˜æ‚£è€…ï¼ŒTROPISå¯èƒ½æ˜¯æ²»æ„ˆç‡æœ€é«˜çš„æ‰‹æœ¯æ–¹æ³•ï¼ŒSCTå¯èƒ½æ˜¯å¤å‘ç‡æœ€ä½çš„æ²»ç–—æ–¹æ³•ï¼ŒimLIFTå¯èƒ½æ˜¯æœ¯åå¹¶å‘ç—‡å‘ç”Ÿç‡æœ€ä½çš„æ‰‹æœ¯æ–¹æ³•ã€‚\n\n**Systematic review registrationï¼š** PROSPEROï¼Œæ ‡è¯†ç¬¦ï¼šCRD42020221907ã€‚", "keywords_zh": "å¤æ‚æ€§è‚›ç˜˜, æ²»æ„ˆç‡, å…ƒ, æ‹¬çº¦è‚Œ, æ²»ç–—", "keywords_en": "complex anal fistula, cure rate, meta, sphincter, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/35211503/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 25 Feb 2022"}, {"id": "35090384", "title_en": "A systematic review of the patient burden of Crohn's disease-related rectovaginal and anovaginal fistulas", "title_zh": "å…‹ç½—æ©ç—…ç›¸å…³ç›´è‚ é˜´é“å’Œè‚›é—¨é˜´é“ç˜˜æ‚£è€…è´Ÿæ‹…çš„ç³»ç»Ÿè¯„ä»·", "authors": "Suzanne F Cook", "abstract_en": "**Background:** Crohn's disease (CD)-related rectovaginal fistulas (RVFs) and anovaginal fistulas (AVFs) are rare, debilitating conditions that present a substantial disease and treatment burden for women. This systematic literature review (SLR) assessed the burden of Crohn's-related RVF and AVF, summarizing evidence from observational studies and highlighting knowledge gaps.\n\n**Methods:** This SLR identified articles in PubMed and Embase that provide data and insight into the patient experience and disease burden of Crohn's-related RVF and AVF. Two trained reviewers used pre-specified eligibility criteria to identify studies for inclusion and evaluate risk of bias using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool for observational studies.\n\n**Results:** Of the 582 records identified, 316 full-text articles were assessed, and 16 studies met a priori eligibility criteria and were included. Few epidemiology studies were identified, with one study estimating the prevalence of RVF to be 2.3% in females with Crohn's disease. Seven of 12 treatment pattern studies reported that patients had or required additional procedures before and/or after the intervention of interest, demonstrating a substantial treatment burden. Seven of 11 studies assessing clinical outcomes reported fistula healing rates between 50 and 75%, with varying estimates based on population and intervention.\n\n**Conclusions:** This SLR reports the high disease and treatment burden of Crohn's-related RVF and AVF and identifies multiple evidence gaps in this field. The literature lacks robust, generalizable data, and demonstrates a compelling need for substantial, novel research into these rare and debilitating sequelae of CD. Registration The PROSPERO registration number for the protocol for this systematic literature review is CRD42020177732.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—… (CD) ç›¸å…³çš„ç›´è‚ é˜´é“ç˜˜ (RVF) å’Œè‚›é—¨é˜´é“ç˜˜ (AVF) æ˜¯ç½•è§çš„ã€ä½¿äººè¡°å¼±çš„ç–¾ç—…ï¼Œç»™å¥³æ€§å¸¦æ¥æ²‰é‡çš„ç–¾ç—…å’Œæ²»ç–—è´Ÿæ‹…ã€‚è¿™ç¯‡ç³»ç»Ÿæ–‡çŒ®ç»¼è¿° (SLR) è¯„ä¼°äº†å…‹ç½—æ©ç—…ç›¸å…³çš„ RVF å’Œ AVF çš„è´Ÿæ‹…ï¼Œæ€»ç»“äº†è§‚å¯Ÿæ€§ç ”ç©¶çš„è¯æ®å¹¶å¼ºè°ƒäº†çŸ¥è¯†å·®è·ã€‚\n\n**æ–¹æ³•ï¼š** æ­¤ SLR è¯†åˆ«äº† PubMed å’Œ Embase ä¸­çš„æ–‡ç« ï¼Œè¿™äº›æ–‡ç« æä¾›äº†æœ‰å…³å…‹ç½—æ©ç—…ç›¸å…³ RVF å’Œ AVF æ‚£è€…ç»å†å’Œç–¾ç—…è´Ÿæ‹…çš„æ•°æ®å’Œè§è§£ã€‚ä¸¤åè®­ç»ƒæœ‰ç´ çš„è¯„å®¡å‘˜ä½¿ç”¨é¢„å…ˆæŒ‡å®šçš„èµ„æ ¼æ ‡å‡†æ¥ç¡®å®šçº³å…¥çš„ç ”ç©¶ï¼Œå¹¶ä½¿ç”¨è§‚å¯Ÿæ€§ç ”ç©¶çš„ééšæœºå¹²é¢„ç ”ç©¶ä¸­çš„åå€šé£é™© (ROBINS-I) å·¥å…·æ¥è¯„ä¼°åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨ç¡®å®šçš„ 582 æ¡è®°å½•ä¸­ï¼Œè¯„ä¼°äº† 316 ç¯‡å…¨æ–‡æ–‡ç« ï¼Œå…¶ä¸­ 16 é¡¹ç ”ç©¶ç¬¦åˆå…ˆéªŒèµ„æ ¼æ ‡å‡†å¹¶è¢«çº³å…¥ã€‚å¾ˆå°‘æœ‰æµè¡Œç—…å­¦ç ”ç©¶å‘ç°ï¼Œä¸€é¡¹ç ”ç©¶ä¼°è®¡æ‚£æœ‰å…‹ç½—æ©ç—…çš„å¥³æ€§ä¸­è£‚è°·çƒ­çš„æ‚£ç—…ç‡ä¸º 2.3%ã€‚ 12 é¡¹æ²»ç–—æ¨¡å¼ç ”ç©¶ä¸­æœ‰ 7 é¡¹æŠ¥å‘Šç§°ï¼Œæ‚£è€…åœ¨æ„Ÿå…´è¶£çš„å¹²é¢„ä¹‹å‰å’Œ/æˆ–ä¹‹åæ¥å—äº†æˆ–éœ€è¦é¢å¤–çš„æ‰‹æœ¯ï¼Œè¿™è¡¨æ˜æ²»ç–—è´Ÿæ‹…ç›¸å½“å¤§ã€‚è¯„ä¼°ä¸´åºŠç»“æœçš„ 11 é¡¹ç ”ç©¶ä¸­æœ‰ 7 é¡¹æŠ¥å‘Šç§°ï¼Œç˜˜ç®¡æ„ˆåˆç‡åœ¨ 50% è‡³ 75% ä¹‹é—´ï¼Œæ ¹æ®äººç¾¤å’Œå¹²é¢„æªæ–½çš„ä¸åŒï¼Œå¾—å‡ºä¸åŒçš„ä¼°è®¡å€¼ã€‚\n\n**ç»“è®ºï¼š** è¯¥ SLR æŠ¥å‘Šäº†å…‹ç½—æ©ç—…ç›¸å…³çš„ RVF å’Œ AVF çš„é«˜ç–¾ç—…å’Œæ²»ç–—è´Ÿæ‹…ï¼Œå¹¶ç¡®å®šäº†è¯¥é¢†åŸŸçš„å¤šä¸ªè¯æ®å·®è·ã€‚æ–‡çŒ®ç¼ºä¹å¯é ã€å¯æ¦‚æ‹¬çš„æ•°æ®ï¼Œå¹¶ä¸”è¡¨æ˜è¿«åˆ‡éœ€è¦å¯¹ CD çš„è¿™äº›ç½•è§ä¸”ä»¤äººè¡°å¼±çš„åé—ç—‡è¿›è¡Œå¤§é‡ã€æ–°é¢–çš„ç ”ç©¶ã€‚æ³¨å†Œ æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ–¹æ¡ˆçš„ PROSPERO æ³¨å†Œå·æ˜¯ CRD42020177732ã€‚", "keywords_zh": "è‚›é—¨é˜´é“ç˜˜ã€å…‹ç½—æ©ç—…ã€ç–¾ç—…è´Ÿæ‹…ã€æµè¡Œç—…å­¦ã€ç›´è‚ é˜´é“ç˜˜ã€æ²»ç–—æ¨¡å¼", "keywords_en": "Anovaginal fistula, Crohnâ€™s disease, Disease burden, Epidemiology, Rectovaginal fistula, Treatment patterns", "link": "https://pubmed.ncbi.nlm.nih.gov/35090384/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 29 Jan 2022"}, {"id": "35063254", "title_en": "Single-stage procedures for anorectal malformations: A systematic review and meta-analysis", "title_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢çš„å•é˜¶æ®µæ‰‹æœ¯ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Chris Westgarth-Taylor", "abstract_en": "**Background:** The purpose of this study is to describe all published studies of single-stage procedures for anorectal malformations and to perform a meta-analysis of studies that compared single-stage to staged procedures.\n\n**Methods:** Searches were conducted in Pubmed, Medline, Embase and CENTRAL. Meta-analysis was performed in RevMan and expressed as forest plots with odds ratios (OR) and 95% confidence intervals (CI).\n\n**Results:** Thirty-eight studies were included in the narrative synthesis. Nine studies were included in the meta-analysis, representing 537 patients. The majority (70%) of patients included in this meta-analysis had either perineal or vestibular fistulas. Surgical site infection (SSI) was defined as any reported infection involving the neoanus (both superficial infection and dehiscence) and occurred in 51 of the 291 patients who underwent single-stage procedures, and 26 of the 244 patients who underwent staged procedure. Meta-analysis showed a 2.2 times higher risk of surgical site infection (SSI) amongst patients who undergo single-stage procedures (OR 2.22, 95% CI 1.26, 3.92). Six of the 293 patients (2%) who underwent single-stage procedures required a rescue ostomy for wound dehiscence. In LMIC the risk of wound dehiscence was three-fold higher in single-stage (36/202) compared to staged procedures (12/126) (OR 3.07, 95% CI 1.42, 6.63). In HIC there was no evidence of an increased risk of wound dehiscence in patients who underwent a single-stage (15/91) compared to a staged procedure (14/118) (OR 1.51, 95% CI 0.65, 3.51). There is no evidence of a difference between single-stage versus staged procedures with regards to functional outcomes including voluntary bowel movements (79/90 versus 111/128), soiling (24/165 versus 20/203) or constipation (27/90 versus 36/128).\n\n**Conclusion:** This systematic review provides further evidence that single-stage procedures for selected patients with anorectal malformations are safe. Whilst there is evidence of an increased risk of SSI, this did not translate to a significant difference in long-term functional outcomes.\n\n**Levels Of Evidence:** Level II.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯æè¿°æ‰€æœ‰å·²å‘è¡¨çš„è‚›é—¨ç›´è‚ ç•¸å½¢å•é˜¶æ®µæ‰‹æœ¯çš„ç ”ç©¶ï¼Œå¹¶å¯¹å•é˜¶æ®µæ‰‹æœ¯ä¸åˆ†é˜¶æ®µæ‰‹æœ¯è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢åœ¨ Pubmedã€Medlineã€Embase å’Œ CENTRAL ä¸Šè¿›è¡Œã€‚åœ¨ RevMan ä¸­è¿›è¡ŒèŸèƒåˆ†æï¼Œå¹¶è¡¨ç¤ºä¸ºå…·æœ‰æ¯”å€¼æ¯” (OR) å’Œ 95% ç½®ä¿¡åŒºé—´ (CI) çš„æ£®æ—å›¾ã€‚\n\n**ç»“æœï¼š** å™è¿°ç»¼åˆä¸­çº³å…¥äº†ä¸‰åå…«é¡¹ç ”ç©¶ã€‚èŸèƒåˆ†æä¸­çº³å…¥äº† 9 é¡¹ç ”ç©¶ï¼Œä»£è¡¨ 537 åæ‚£è€…ã€‚æœ¬èŸèƒåˆ†æä¸­çº³å…¥çš„å¤§å¤šæ•°æ‚£è€…ï¼ˆ70%ï¼‰æ‚£æœ‰ä¼šé˜´ç˜˜æˆ–å‰åº­ç˜˜ã€‚æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) è¢«å®šä¹‰ä¸ºä»»ä½•æŠ¥å‘Šçš„æ¶‰åŠæ–°è‚›é—¨çš„æ„ŸæŸ“ï¼ˆåŒ…æ‹¬æµ…è¡¨æ„ŸæŸ“å’Œè£‚å¼€ï¼‰ï¼Œå‘ç”Ÿåœ¨æ¥å—å•é˜¶æ®µæ‰‹æœ¯çš„ 291 åæ‚£è€…ä¸­çš„ 51 åï¼Œä»¥åŠæ¥å—åˆ†æœŸæ‰‹æœ¯çš„ 244 åæ‚£è€…ä¸­çš„ 26 åã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ¥å—å•é˜¶æ®µæ‰‹æœ¯çš„æ‚£è€…æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) çš„é£é™©é«˜å‡º 2.2 å€ï¼ˆOR 2.22ï¼Œ95% CI 1.26ï¼Œ3.92ï¼‰ã€‚ 293 åæ¥å—å•é˜¶æ®µæ‰‹æœ¯çš„æ‚£è€…ä¸­ï¼Œæœ‰ 6 å (2%) å› ä¼¤å£è£‚å¼€è€Œéœ€è¦è¿›è¡ŒæŒ½æ•‘æ€§é€ å£æœ¯ã€‚åœ¨ä¸­ä½æ”¶å…¥å›½å®¶ä¸­ï¼Œå•æœŸæ‰‹æœ¯ (36/202) ä¼¤å£è£‚å¼€çš„é£é™©æ˜¯åˆ†æœŸæ‰‹æœ¯ (12/126) çš„ä¸‰å€ï¼ˆOR 3.07ï¼Œ95% CI 1.42ï¼Œ6.63ï¼‰ã€‚åœ¨ HIC ä¸­ï¼Œæ²¡æœ‰è¯æ®è¡¨æ˜æ¥å—å•æœŸæ‰‹æœ¯ (15/91) çš„æ‚£è€…ä¸åˆ†æœŸæ‰‹æœ¯ (14/118) ç›¸æ¯”ä¼¤å£è£‚å¼€çš„é£é™©å¢åŠ ï¼ˆOR 1.51ï¼Œ95% CI 0.65ï¼Œ3.51ï¼‰ã€‚æ²¡æœ‰è¯æ®è¡¨æ˜å•é˜¶æ®µæ‰‹æœ¯ä¸åˆ†é˜¶æ®µæ‰‹æœ¯åœ¨åŠŸèƒ½ç»“æœæ–¹é¢å­˜åœ¨å·®å¼‚ï¼ŒåŒ…æ‹¬éšæ„æ’ä¾¿ï¼ˆ79/90 ä¸ 111/128ï¼‰ã€æ’ä¾¿ï¼ˆ24/165 ä¸ 20/203ï¼‰æˆ–ä¾¿ç§˜ï¼ˆ27/90 ä¸ 36/128ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç³»ç»Ÿè¯„ä»·æä¾›äº†è¿›ä¸€æ­¥çš„è¯æ®ï¼Œè¯æ˜å¯¹é€‰å®šçš„è‚›é—¨ç›´è‚ ç•¸å½¢æ‚£è€…è¿›è¡Œå•é˜¶æ®µæ‰‹æœ¯æ˜¯å®‰å…¨çš„ã€‚è™½ç„¶æœ‰è¯æ®è¡¨æ˜ SSI é£é™©å¢åŠ ï¼Œä½†è¿™å¹¶æ²¡æœ‰è½¬åŒ–ä¸ºé•¿æœŸåŠŸèƒ½ç»“æœçš„æ˜¾ç€å·®å¼‚ã€‚\n\n**Levels of evidenceï¼š** äºŒçº§ã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢ã€ç»“è‚ é€ å£æœ¯ã€åŸå‘æ€§ PSARPã€å•é˜¶æ®µ", "keywords_en": "Anorectal malformations, Colostomy, Primary PSARP, Single-stage", "link": "https://pubmed.ncbi.nlm.nih.gov/35063254/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 22 Jan 2022"}, {"id": "35049123", "title_en": "Meta-analysis of platelet-rich plasma therapy for anal fistula", "title_zh": "å¯Œè¡€å°æ¿è¡€æµ†æ²»ç–—è‚›ç˜˜çš„Metaåˆ†æ", "authors": "Shuangqing Chang", "abstract_en": "**Objective:** To systematically evaluate the efficacy of platelet-rich plasma (PRP) in treating anal fistula.\n\n**Methods:** PubMed, EMBASE, and Cochrane Library databases were systematically searched for randomized controlled studies (RCTs) and case-control studies published before June 2021 on evaluating the efficacy of platelet-rich plasma (PRP) in treating anal fistula. References of the journals were manually searched for relevant studies. Literature search, screening, data extraction, and bias assessment were carried out by two researcher independently. Stata13.0 and RevMan 5.3 software were used for statistical analysis of the cure rate and recurrence rate of anal fistula.\n\n**Results:** A total of 6 case-control studies and 3 RCTs involving 289 patients were included. Meta-analysis showed that the pooled cure rate of all studies was 65% (95% CI 0.53-0.77), pÂ =Â 0.000, and the pooled recurrence rate of all studies was 12% (95% CI 0.08-0.17).\n\n**Conclusion:** Platelet-rich plasma is safe and effective in treating anal fistula and should be promoted and further studied in clinical practice.", "abstract_zh": "**ç›®çš„ï¼š** ç³»ç»Ÿè¯„ä»·å¯Œè¡€å°æ¿è¡€æµ†ï¼ˆPRPï¼‰æ²»ç–—è‚›ç˜˜çš„ç–—æ•ˆã€‚\n\n**æ–¹æ³•ï¼š** ç³»ç»Ÿåœ°æ£€ç´¢äº† PubMedã€EMBASE å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“ä¸­ 2021 å¹´ 6 æœˆä¹‹å‰å‘è¡¨çš„å…³äºè¯„ä¼°å¯Œè¡€å°æ¿è¡€æµ† (PRP) æ²»ç–—è‚›ç˜˜ç–—æ•ˆçš„éšæœºå¯¹ç…§ç ”ç©¶ (RCT) å’Œç—…ä¾‹å¯¹ç…§ç ”ç©¶ã€‚æ‰‹åŠ¨æ£€ç´¢æœŸåˆŠå‚è€ƒæ–‡çŒ®ä»¥æŸ¥æ‰¾ç›¸å…³ç ”ç©¶ã€‚æ–‡çŒ®æ£€ç´¢ã€ç­›é€‰ã€æ•°æ®æå–å’Œåå€šè¯„ä¼°ç”±ä¸¤åç ”ç©¶è€…ç‹¬ç«‹å®Œæˆã€‚é‡‡ç”¨Stata13.0å’ŒRevMan 5.3è½¯ä»¶å¯¹è‚›ç˜˜æ²»æ„ˆç‡å’Œå¤å‘ç‡è¿›è¡Œç»Ÿè®¡åˆ†æã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 6 é¡¹ç—…ä¾‹å¯¹ç…§ç ”ç©¶å’Œ 3 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œæ¶‰åŠ 289 åæ‚£è€…ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ‰€æœ‰ç ”ç©¶çš„æ±‡æ€»æ²»æ„ˆç‡ä¸º 65%ï¼ˆ95% CI 0.53-0.77ï¼‰ï¼Œp = 0.000ï¼Œæ‰€æœ‰ç ”ç©¶çš„æ±‡æ€»å¤å‘ç‡ä¸º 12%ï¼ˆ95% CI 0.08-0.17ï¼‰ã€‚\n\n**ç»“è®ºï¼š** å¯Œè¡€å°æ¿è¡€æµ†æ²»ç–—è‚›ç˜˜å®‰å…¨æœ‰æ•ˆï¼Œå€¼å¾—åœ¨ä¸´åºŠä¸Šæ¨å¹¿å’Œè¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "è‚›ç˜˜, ç–—æ•ˆ, èŸèƒåˆ†æ, å¯Œè¡€å°æ¿è¡€æµ†, éšæœºå¯¹ç…§è¯•éªŒ", "keywords_en": "anal fistula, efficacy, meta-analysis, platelet-rich plasma, randomized controlled trial", "link": "https://pubmed.ncbi.nlm.nih.gov/35049123/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 20 Jan 2022"}, {"id": "35029127", "title_en": "Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review", "title_zh": "ç£å…±æŒ¯æˆåƒå¼•å¯¼ç»å°¿é“è¶…å£°æ¶ˆèæ²»ç–—å‰åˆ—è…ºç™Œï¼šç³»ç»Ÿè¯„ä»·", "authors": "David Sella", "abstract_en": "<b><i>Purpose:</i></b> MRI-guided transurethral ultrasound ablation (TULSA) uses real-time MR thermometry feedback to target prostate disease. We systematically review the literature to synthesize efficacy, functional, and safety outcomes and assess the influence of planned ablation fraction on outcome. <b><i>Materials and Methods:</i></b> PubMed, Embase, and the Cochrane Library were searched from inception to June 2021 following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting at least one efficacy, functional, or safety outcome after a single TULSA treatment were included. The relationship of freedom from salvage treatment and potency preservation with planned ablation volume was modeled. <b><i>Results:</i></b> Two hundred twenty-four patients were treated in 10 studies with up to a 5-year follow-up, mainly for primary localized prostate cancer (PCa) plus smaller cohorts with recurrent PCa, and locally advanced PCa (LAPC). The prostate-specific antigen decline from baseline up to 2 years, including focal to whole-gland ablation plans, was 54% to 97%. The rate of salvage treatment after one TULSA treatment for primary PCa was 7% to 17%. Continence and potency preservation were from 92% to 100% and from 75% to 98%. Urinary symptoms were stable in men with good voiding function at baseline, and 85% of men with concurrent PCa and lower urinary tract symptoms met the criteria for improvement. Symptom relief in a small cohort of men with LAPC was observed. Grade III adverse events were incurred by 13/224 men (6%), with no rectal injury/fistula or Grade IV complication. The planned ablation fraction was linearly related to salvage-free survival. The relationship between potency preservation and planned ablation fraction followed a sigmoid curve. <b><i>Conclusions:</i></b> As an alternative to conventional treatments, TULSA is safe and effective for prostate tissue ablation in men with primary PCa. There is also evidence that TULSA delivers effective relief of urinary symptoms while treating PCa in a single, low-morbidity procedure. The likelihood of freedom from additional treatment or potency preservation is associated with the planned ablation fraction.", "abstract_zh": "<b><i>ç›®çš„ï¼š</i></b> MRI å¼•å¯¼çš„ç»å°¿é“è¶…å£°æ¶ˆè (TULSA) ä½¿ç”¨å®æ—¶ MR æµ‹æ¸©åé¦ˆæ¥æ²»ç–—å‰åˆ—è…ºç–¾ç—…ã€‚æˆ‘ä»¬ç³»ç»Ÿåœ°å›é¡¾æ–‡çŒ®ï¼Œç»¼åˆç–—æ•ˆã€åŠŸèƒ½å’Œå®‰å…¨æ€§ç»“æœï¼Œå¹¶è¯„ä¼°è®¡åˆ’æ¶ˆèåˆ†æ•°å¯¹ç»“æœçš„å½±å“ã€‚ <b><i>ææ–™å’Œæ–¹æ³•ï¼š</i></b>ä»ä¸€å¼€å§‹åˆ° 2021 å¹´ 6 æœˆï¼ŒæŒ‰ç…§ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—å¯¹ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†æ£€ç´¢ã€‚æŠ¥å‘Šäº†å•æ¬¡ TULSA æ²»ç–—åè‡³å°‘ä¸€é¡¹åŠŸæ•ˆã€åŠŸèƒ½æˆ–å®‰å…¨æ€§ç»“æœçš„ç ”ç©¶è¢«çº³å…¥å…¶ä¸­ã€‚å¯¹å…äºæŒ½æ•‘æ²»ç–—å’Œæ•ˆåŠ›ä¿ç•™ä¸è®¡åˆ’æ¶ˆèä½“ç§¯çš„å…³ç³»è¿›è¡Œäº†å»ºæ¨¡ã€‚ <b><i>ç»“æœï¼š</i></b> 10 é¡¹ç ”ç©¶å¯¹ 224 åæ‚£è€…è¿›è¡Œäº†é•¿è¾¾ 5 å¹´çš„éšè®¿ï¼Œä¸»è¦é’ˆå¯¹åŸå‘æ€§å±€é™æ€§å‰åˆ—è…ºç™Œ (PCa) ä»¥åŠè¾ƒå°è§„æ¨¡çš„å¤å‘æ€§ PCa å’Œå±€éƒ¨æ™šæœŸ PCa (LAPC) æ‚£è€…ã€‚å‰åˆ—è…ºç‰¹å¼‚æ€§æŠ—åŸä»åŸºçº¿åˆ° 2 å¹´çš„ä¸‹é™ï¼ˆåŒ…æ‹¬å±€ç¶æ€§åˆ°å…¨è…ºä½“æ¶ˆèè®¡åˆ’ï¼‰ä¸º 54% è‡³ 97%ã€‚ä¸€æ¬¡ TULSA æ²»ç–—åŸå‘æ€§ PCa åçš„æŒ½æ•‘æ²»ç–—ç‡ä¸º 7% è‡³ 17%ã€‚è‡ªåˆ¶åŠ›å’Œæ•ˆåŠ›ä¿ç•™åˆ†åˆ«ä¸º 92% è‡³ 100% å’Œ 75% è‡³ 98%ã€‚åŸºçº¿æ—¶æ’å°¿åŠŸèƒ½è‰¯å¥½çš„ç”·æ€§çš„æ³Œå°¿ç—‡çŠ¶ç¨³å®šï¼ŒåŒæ—¶æ‚£æœ‰å‰åˆ—è…ºç™Œå’Œä¸‹å°¿è·¯ç—‡çŠ¶çš„ç”·æ€§ä¸­æœ‰ 85% ç¬¦åˆæ”¹å–„æ ‡å‡†ã€‚åœ¨ä¸€å°ç¾¤æ‚£æœ‰ LAPC çš„ç”·æ€§ä¸­è§‚å¯Ÿåˆ°ç—‡çŠ¶ç¼“è§£ã€‚ 13/224 åç”·æ€§ (6%) å‘ç”Ÿäº† III çº§ä¸è‰¯äº‹ä»¶ï¼Œæ²¡æœ‰ç›´è‚ æŸä¼¤/ç˜˜ç®¡æˆ– IV çº§å¹¶å‘ç—‡ã€‚è®¡åˆ’æ¶ˆèåˆ†æ•°ä¸æ— æŒ½æ•‘ç”Ÿå­˜ç‡çº¿æ€§ç›¸å…³ã€‚æ•ˆåŠ›ä¿ç•™ä¸è®¡åˆ’æ¶ˆèåˆ†æ•°ä¹‹é—´çš„å…³ç³»éµå¾ª S å½¢æ›²çº¿ã€‚ <b><i>ç»“è®ºï¼š</i></b>ä½œä¸ºä¼ ç»Ÿæ²»ç–—çš„æ›¿ä»£æ–¹æ¡ˆï¼ŒTULSA å¯¹äºåŸå‘æ€§ PCa ç”·æ€§çš„å‰åˆ—è…ºç»„ç»‡æ¶ˆèæ˜¯å®‰å…¨æœ‰æ•ˆçš„ã€‚è¿˜æœ‰è¯æ®è¡¨æ˜ï¼ŒTULSA å¯æœ‰æ•ˆç¼“è§£æ³Œå°¿ç³»ç»Ÿç—‡çŠ¶ï¼ŒåŒæ—¶é€šè¿‡å•ä¸€ã€ä½å‘ç—…ç‡çš„æ‰‹æœ¯æ²»ç–— PCaã€‚å…äºé¢å¤–æ²»ç–—æˆ–æ•ˆåŠ›ä¿ç•™çš„å¯èƒ½æ€§ä¸è®¡åˆ’çš„æ¶ˆèåˆ†æ•°ç›¸å…³ã€‚", "keywords_zh": "MRIå¼•å¯¼æ²»ç–—ã€å¾®åˆ›æ²»ç–—ã€å‰åˆ—è…ºç™Œã€ç³»ç»Ÿè¯„ä»·ã€ç»å°¿é“MRIå¼•å¯¼è¶…å£°æ¶ˆè", "keywords_en": "MRI-guided therapy, minimally invasive therapy, prostate cancer, systematic review, transurethral MRI-guided ultrasound ablation", "link": "https://pubmed.ncbi.nlm.nih.gov/35029127/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Fri, 14 Jan 2022"}, {"id": "34920992", "title_en": "Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis", "title_zh": "ä¹Œå¸å¥´å•æŠ—å¯¹è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…æœ‰æ•ˆï¼šçœŸå®ä¸–ç•Œç»éªŒå’ŒèŸèƒåˆ†æç³»ç»Ÿè¯„ä»·", "authors": "Alyssa M Parian", "abstract_en": "**Background:** Perianal Crohn's disease (pCD) is a debilitating complication affecting up to 30% of Crohn's disease (CD) population, leading to increased morbidity, mortality and decreased quality of life. Despite the growing armamentarium of medications for luminal CD, their efficacy in pCD remains poorly studied.\n\n**Aim:** To determine the efficacy of ustekinumab, a biologic approved for luminal CD, in pCD through a retrospective cohort study and systematic review.\n\n**Methods:** A retrospective cohort study on patients with CD with active perianal fistulae treated with ustekinumab from September 2013 to August 2019 was performed to determine perianal fistula response and remission at 6 and 12 months after ustekinumab induction. A systematic review was performed to further establish rates of fistula response and remission with ustekinumab.\n\n**Results:** At 6 months, 48.1% (13/27) patients achieved fistula response with none achieving fistula remission on provider exam, and 59.3% (16/27) achieved patient-reported symptomatic improvement with 3.7% (1/27) achieving symptomatic remission. At 1â€‰year, on provider exam, 55.6% (5/9) had fistula response with none achieving fistula remission, and 100% (9/9) had symptomatic improvement with 22.2% (2/9) achieving symptomatic remission. There were no major safety signals during 1-year follow-up. The systematic review of 25 studies found 44% (92/209) of patients with active perianal fistulas had a clinical response within 6â€‰months of follow-up, and 53.9% (85/152) of patients with 12â€‰months of follow-up achieved clinical response.\n\n**Conclusion:** Ustekinumab presents a safe and effective therapy for treatment of pCD. Prospective, randomised trials are needed to further elucidate long-term efficacy of ustekinumab for pCD.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨å…‹ç½—æ©ç—… (pCD) æ˜¯ä¸€ç§ä½¿äººè¡°å¼±çš„å¹¶å‘ç—‡ï¼Œå½±å“å¤šè¾¾ 30% çš„å…‹ç½—æ©ç—… (CD) äººç¾¤ï¼Œå¯¼è‡´å‘ç—…ç‡ã€æ­»äº¡ç‡å¢åŠ å’Œç”Ÿæ´»è´¨é‡ä¸‹é™ã€‚å°½ç®¡æ²»ç–— Luminal CD çš„è¯ç‰©ç§ç±»ä¸æ–­å¢åŠ ï¼Œä½†å®ƒä»¬å¯¹ pCD çš„ç–—æ•ˆä»çŸ¥ä¹‹ç”šå°‘ã€‚\n\n**Aimï¼š** é€šè¿‡å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶å’Œç³»ç»Ÿè¯„ä»·æ¥ç¡®å®šä¼˜ç‰¹å…‹å•æŠ—ï¼ˆä¸€ç§è¢«æ‰¹å‡†ç”¨äºè…”å†… CD æ²»ç–—çš„ç”Ÿç‰©åˆ¶å‰‚ï¼‰åœ¨ pCD ä¸­çš„ç–—æ•ˆã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ 2013 å¹´ 9 æœˆè‡³ 2019 å¹´ 8 æœˆæœŸé—´æ¥å—ä¼˜ç‰¹å…‹å•æŠ—æ²»ç–—çš„æ‚£æœ‰æ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„ CD æ‚£è€…è¿›è¡Œäº†ä¸€é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œä»¥ç¡®å®šä¼˜ç‰¹å…‹å•æŠ—è¯±å¯¼å 6 ä¸ªæœˆå’Œ 12 ä¸ªæœˆæ—¶è‚›å‘¨ç˜˜çš„ååº”å’Œç¼“è§£æƒ…å†µã€‚è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¿›ä¸€æ­¥ç¡®å®šä¹Œå¸å¥´å•æŠ—çš„ç˜˜ç®¡ç¼“è§£ç‡å’Œç¼“è§£ç‡ã€‚\n\n**ç»“æœï¼š** 6 ä¸ªæœˆæ—¶ï¼Œ48.1% (13/27) çš„æ‚£è€…å®ç°äº†ç˜˜ç®¡ååº”ï¼Œä½†åœ¨æä¾›è€…æ£€æŸ¥æ—¶æ²¡æœ‰å®ç°ç˜˜ç®¡ç¼“è§£ï¼Œ59.3% (16/27) çš„æ‚£è€…å®ç°äº†æ‚£è€…æŠ¥å‘Šçš„ç—‡çŠ¶æ”¹å–„ï¼Œå…¶ä¸­ 3.7% (1/27) å®ç°äº†ç—‡çŠ¶ç¼“è§£ã€‚ 1 å¹´æ—¶ï¼Œåœ¨æä¾›è€…æ£€æŸ¥ä¸­ï¼Œ55.6% (5/9) çš„æ‚£è€…æœ‰ç˜˜ç®¡ååº”ï¼Œä½†æ²¡æœ‰äººå®ç°ç˜˜ç®¡ç¼“è§£ï¼Œ100% (9/9) çš„æ‚£è€…ç—‡çŠ¶æ”¹å–„ï¼Œå…¶ä¸­ 22.2% (2/9) çš„æ‚£è€…å®ç°ç—‡çŠ¶ç¼“è§£ã€‚ä¸€å¹´éšè®¿æœŸé—´æœªå‡ºç°é‡å¤§å®‰å…¨ä¿¡å·ã€‚å¯¹25é¡¹ç ”ç©¶çš„ç³»ç»Ÿè¯„ä»·å‘ç°ï¼Œ44%ï¼ˆ92/209ï¼‰çš„æ´»åŠ¨æ€§è‚›å‘¨ç˜˜æ‚£è€…åœ¨éšè®¿6ä¸ªæœˆå†…è·å¾—ä¸´åºŠç¼“è§£ï¼Œ53.9%ï¼ˆ85/152ï¼‰çš„æ‚£è€…åœ¨éšè®¿12ä¸ªæœˆå†…è·å¾—ä¸´åºŠç¼“è§£ã€‚\n\n**ç»“è®ºï¼š** Ustekinumab ä¸ºæ²»ç–— pCD æä¾›äº†ä¸€ç§å®‰å…¨æœ‰æ•ˆçš„ç–—æ³•ã€‚éœ€è¦å‰ç»æ€§éšæœºè¯•éªŒæ¥è¿›ä¸€æ­¥é˜æ˜ä¹Œç‰¹å…‹å•æŠ—æ²»ç–— pCD çš„é•¿æœŸç–—æ•ˆã€‚", "keywords_zh": "å…‹ç½—æ©ç»“è‚ ç‚ã€è‚›é—¨ã€èƒƒè‚ é“ç˜˜ã€ç‚ç—‡æ€§è‚ ç—…", "keywords_en": "Crohn's colitis, anal, gastrointestinal fistulae, inflammatory bowel disease", "link": "https://pubmed.ncbi.nlm.nih.gov/34920992/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Sat, 18 Dec 2021"}, {"id": "34872892", "title_en": "Diagnostic Accuracy of Three-Dimensional Endoanal Ultrasound for Anal Fistula: A Systematic Review and Meta-analysis", "title_zh": "ä¸‰ç»´è‚›é—¨å†…è¶…å£°è¯Šæ–­è‚›ç˜˜çš„å‡†ç¡®æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Shao-Dong Qiu", "abstract_en": "**Background:** Anal fistula is a relatively common anorectal disease. An accurate assessment of the main anal fistula type and the anatomy of the internal opening before surgery is necessary to obtain the best surgical results. Whether three-dimensional endoanal ultrasound (3D-EAUS) should be used as the first-line diagnostic tool for anal fistula is still controversial. The purpose of this study is to conduct a meta-analysis of the published literature on 3D-EAUS and anal fistula, and compare the results of 3D-EAUS and surgery to evaluate the diagnostic value of 3D-EAUS for anal fistula.\n\n**Methods:** An online search of databases in English included PubMed, Embase, and Cochrane Library. After the diagnostic accuracy of 3D-EAUS of all anal fistula types was integrated, a single-group rate meta-analysis was performed; we analyzed 3D-EAUS separately for the diagnosis of different anal fistula types, and conducted a meta-analysis of test accuracy. The analysis combined sensitivity, specificity, and the respective 95% CI, to draw a summary receiver operating characteristic curve (SROC), and estimate the area under curve (AUC).\n\n**Results:** Based on the inclusion criteria, we selected 8 studies covering 1057 cases of anal fistula and 548 cases of internal opening. The meta-analysis data show that 3D-EAUS has a total accuracy rate of 91% (95% CI, 88-94%). It has high sensitivity and specificity for different anal fistula classifications. The SROC curves for anal fistula internal openings were plotted, and the AUC was calculated to be 0.86 (95% CI, 0.83-0.89).\n\n**Conclusions:** 3D-EAUS can be used as the first-line diagnostic tool for anal fistula, because it has a high diagnostic accuracy for most anal fistulas. However, due to the insufficient diagnostic accuracy of 3D-EAUS for complex fistulas, 3D-EAUS combined with MRI examination can be used to more accurately detect the secondary extension of complex fistulas, so as to describe the complete anatomy of the fistula in more detail.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›ç˜˜æ˜¯ä¸€ç§æ¯”è¾ƒå¸¸è§çš„è‚›è‚ ç–¾ç—…ã€‚æœ¯å‰å‡†ç¡®è¯„ä¼°ä¸»è¦è‚›ç˜˜ç±»å‹å’Œå†…å£è§£å‰–ç»“æ„å¯¹äºè·å¾—æœ€ä½³æ‰‹æœ¯æ•ˆæœæ˜¯å¿…è¦çš„ã€‚ä¸‰ç»´è‚›å†…è¶…å£°ï¼ˆ3D-EAUSï¼‰æ˜¯å¦åº”ä½œä¸ºè‚›ç˜˜çš„ä¸€çº¿è¯Šæ–­å·¥å…·ä»å­˜åœ¨äº‰è®®ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯å¯¹å·²å‘è¡¨çš„3D-EAUSä¸è‚›ç˜˜çš„æ–‡çŒ®è¿›è¡ŒMetaåˆ†æï¼Œæ¯”è¾ƒ3D-EAUSä¸æ‰‹æœ¯ç»“æœï¼Œè¯„ä»·3D-EAUSå¯¹è‚›ç˜˜çš„è¯Šæ–­ä»·å€¼ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨çº¿æ£€ç´¢è‹±æ–‡æ•°æ®åº“åŒ…æ‹¬ PubMedã€Embase å’Œ Cochrane Libraryã€‚ç»¼åˆ3D-EAUSå¯¹æ‰€æœ‰è‚›ç˜˜ç±»å‹çš„è¯Šæ–­å‡†ç¡®æ€§åï¼Œè¿›è¡Œå•ç»„ç‡èŸèƒåˆ†æï¼›æˆ‘ä»¬åˆ†åˆ«åˆ†æäº† 3D-EAUS å¯¹ä¸åŒè‚›ç˜˜ç±»å‹çš„è¯Šæ–­ï¼Œå¹¶å¯¹æµ‹è¯•å‡†ç¡®æ€§è¿›è¡Œäº†èŸèƒåˆ†æã€‚è¯¥åˆ†æç»“åˆæ•æ„Ÿæ€§ã€ç‰¹å¼‚æ€§å’Œå„è‡ªçš„ 95% CIï¼Œç»˜åˆ¶æ±‡æ€»å—è¯•è€…å·¥ä½œç‰¹å¾æ›²çº¿ (SROC)ï¼Œå¹¶ä¼°è®¡æ›²çº¿ä¸‹é¢ç§¯ (AUC)ã€‚\n\n**ç»“æœï¼š** æ ¹æ®çº³å…¥æ ‡å‡†ï¼Œæˆ‘ä»¬é€‰æ‹©äº†8é¡¹ç ”ç©¶ï¼Œæ¶µç›–1057ä¾‹è‚›ç˜˜å’Œ548ä¾‹å†…å¼€æ”¾ç—…ä¾‹ã€‚èŸèƒåˆ†ææ•°æ®æ˜¾ç¤ºï¼Œ3D-EAUS çš„æ€»å‡†ç¡®ç‡ä¸º 91%ï¼ˆ95% CIï¼Œ88-94%ï¼‰ã€‚å®ƒå¯¹ä¸åŒè‚›ç˜˜åˆ†ç±»å…·æœ‰è¾ƒé«˜çš„æ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§ã€‚ç»˜åˆ¶è‚›ç˜˜å†…éƒ¨å¼€å£çš„ SROC æ›²çº¿ï¼Œè®¡ç®— AUC ä¸º 0.86ï¼ˆ95% CIï¼Œ0.83-0.89ï¼‰ã€‚\n\n**ç»“è®ºï¼š** 3D-EAUSå¯ä½œä¸ºè‚›ç˜˜çš„ä¸€çº¿è¯Šæ–­å·¥å…·ï¼Œå› ä¸ºå®ƒå¯¹å¤§å¤šæ•°è‚›ç˜˜å…·æœ‰è¾ƒé«˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚ä½†ç”±äº3D-EAUSå¯¹å¤æ‚ç˜˜ç®¡çš„è¯Šæ–­å‡†ç¡®æ€§ä¸è¶³ï¼Œ3D-EAUSç»“åˆMRIæ£€æŸ¥å¯ä»¥æ›´å‡†ç¡®åœ°æ£€æµ‹å¤æ‚ç˜˜ç®¡çš„äºŒæ¬¡å»¶ä¼¸ï¼Œä»è€Œæ›´è¯¦ç»†åœ°æè¿°ç˜˜ç®¡çš„å®Œæ•´è§£å‰–ç»“æ„ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/34872892/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Tue, 07 Dec 2021"}, {"id": "34856655", "title_en": "Gene and protein expression of epithelial to mesenchymal transition for intestinal and anal fistula: a systematic review", "title_zh": "è‚ ç˜˜å’Œè‚›ç˜˜ä¸Šçš®é—´è´¨è½¬åŒ–çš„åŸºå› å’Œè›‹ç™½è¡¨è¾¾ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Nazefah Abdul Hamid", "abstract_en": "**Purpose:** Intestinal fibrosis is a common complication of inflammatory bowel diseases. However, the possible involvement of epithelial-mesenchymal transition (EMT) has been scarcely investigated. This systematic review aims to search through research papers that are focusing on messenger RNA (mRNA) and protein expression profile in EMT in fistula or in intestinal fibrosis.\n\n**Methods:** Electronic exploration was performed until April 24, 2019 through PubMed, Ovid, Science Direct, and Scopus databases with the terms of \"fistula\" OR \"intestinal fibrosis\" AND \"epithelial-mesenchymal transition\". Two independent reviewers scrutinized the suitability of the title and abstract before examining the full text that met the inclusion criteria. For each study, the sample types that were used, methods for analysis, and genes expressed were identified. The list of genes was further analyzed using DAVID (Database for Annotation, Visualization, and Integrated Discovery) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway.\n\n**Results:** There were 896 citations found; however, only 3 studies fulfilled the requirements. Among the EMT-related genes, 5 were upregulated genes at mRNA level while 6 were at protein level. However, only 2 downregulated genes were found at each mRNA and protein level. Of the 4 inflammation-related genes found, 3 genes were upregulated at mRNA level and 1 at protein level. These genes were confirmed to be involved in the development of inflammatory induced fibrosis and fistula through EMT. Results from quantitative real-time polymerase chain reaction analysis were consistent with the process of EMT, confirmed by the western blot protein analysis.\n\n**Conclusion:** Many significant genes which are involved in the process of EMT in fistula and intestinal fibrosis have been identified. With high-end technology many more genes could be identified. These genes will be good molecular targets in the development of biomarkers for precision drug targeting in the future treatment of intestinal fibrosis and fistula.", "abstract_zh": "**Purposeï¼š** è‚ é“çº¤ç»´åŒ–æ˜¯ç‚ç—‡æ€§è‚ ç—…çš„å¸¸è§å¹¶å‘ç—‡ã€‚ç„¶è€Œï¼Œä¸Šçš®é—´è´¨è½¬åŒ–ï¼ˆEMTï¼‰å¯èƒ½å‚ä¸çš„ç ”ç©¶å´å¾ˆå°‘ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨æ£€ç´¢å…³æ³¨ç˜˜ç®¡æˆ–è‚ çº¤ç»´åŒ– EMT ä¸­ä¿¡ä½¿ RNA (mRNA) å’Œè›‹ç™½è´¨è¡¨è¾¾è°±çš„ç ”ç©¶è®ºæ–‡ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2019 å¹´ 4 æœˆ 24 æ—¥ï¼Œé€šè¿‡ PubMedã€Ovidã€Science Direct å’Œ Scopus æ•°æ®åº“ä½¿ç”¨â€œç˜˜ç®¡â€æˆ–â€œè‚ çº¤ç»´åŒ–â€å’Œâ€œä¸Šçš®é—´è´¨è½¬åŒ–â€æœ¯è¯­è¿›è¡Œç”µå­æ¢æŸ¥ã€‚ä¸¤åç‹¬ç«‹å®¡ç¨¿äººåœ¨å®¡æŸ¥ç¬¦åˆçº³å…¥æ ‡å‡†çš„å…¨æ–‡ä¹‹å‰ä»”ç»†å®¡æŸ¥äº†æ ‡é¢˜å’Œæ‘˜è¦çš„é€‚ç”¨æ€§ã€‚å¯¹äºæ¯é¡¹ç ”ç©¶ï¼Œéƒ½ç¡®å®šäº†æ‰€ä½¿ç”¨çš„æ ·æœ¬ç±»å‹ã€åˆ†ææ–¹æ³•å’Œè¡¨è¾¾çš„åŸºå› ã€‚ä½¿ç”¨ DAVIDï¼ˆæ³¨é‡Šã€å¯è§†åŒ–å’Œé›†æˆå‘ç°æ•°æ®åº“ï¼‰å’Œ KEGGï¼ˆäº¬éƒ½åŸºå› å’ŒåŸºå› ç»„ç™¾ç§‘å…¨ä¹¦ï¼‰é€”å¾„è¿›ä¸€æ­¥åˆ†æåŸºå› åˆ—è¡¨ã€‚\n\n**ç»“æœï¼š** å…±æ‰¾åˆ° 896 æ¬¡å¼•ç”¨ï¼›ç„¶è€Œï¼Œåªæœ‰ 3 é¡¹ç ”ç©¶æ»¡è¶³è¦æ±‚ã€‚åœ¨EMTç›¸å…³åŸºå› ä¸­ï¼Œ5ä¸ªåœ¨mRNAæ°´å¹³ä¸Šè°ƒï¼Œ6ä¸ªåœ¨è›‹ç™½è´¨æ°´å¹³ä¸Šè°ƒã€‚ç„¶è€Œï¼Œåœ¨æ¯ä¸ª mRNA å’Œè›‹ç™½è´¨æ°´å¹³ä¸Šä»…å‘ç° 2 ä¸ªä¸‹è°ƒåŸºå› ã€‚åœ¨å‘ç°çš„ 4 ä¸ªç‚ç—‡ç›¸å…³åŸºå› ä¸­ï¼Œ3 ä¸ªåŸºå› åœ¨ mRNA æ°´å¹³ä¸Šè°ƒï¼Œ1 ä¸ªåŸºå› åœ¨è›‹ç™½è´¨æ°´å¹³ä¸Šè°ƒã€‚è¿™äº›åŸºå› è¢«è¯å®é€šè¿‡EMTå‚ä¸ç‚ç—‡è¯±å¯¼çš„çº¤ç»´åŒ–å’Œç˜˜ç®¡çš„å‘ç”Ÿã€‚å®æ—¶å®šé‡èšåˆé…¶é“¾å¼ååº”åˆ†æç»“æœä¸ EMT è¿‡ç¨‹ä¸€è‡´ï¼Œç»è›‹ç™½è´¨å°è¿¹è›‹ç™½åˆ†æè¯å®ã€‚\n\n**ç»“è®ºï¼š** å·²é‰´å®šå‡ºè®¸å¤šå‚ä¸ç˜˜ç®¡å’Œè‚ çº¤ç»´åŒ– EMT è¿‡ç¨‹çš„é‡è¦åŸºå› ã€‚å€ŸåŠ©é«˜ç«¯æŠ€æœ¯ï¼Œå¯ä»¥è¯†åˆ«æ›´å¤šçš„åŸºå› ã€‚è¿™äº›åŸºå› å°†æˆä¸ºå¼€å‘ç”Ÿç‰©æ ‡å¿—ç‰©çš„è‰¯å¥½åˆ†å­é¶æ ‡ï¼Œç”¨äºæœªæ¥æ²»ç–—è‚ çº¤ç»´åŒ–å’Œç˜˜ç®¡çš„ç²¾å‡†è¯ç‰©é¶å‘ã€‚", "keywords_zh": "ä¸Šçš®é—´è´¨è½¬åŒ–ã€ç˜˜ç®¡ã€åŸºå› ã€è‚ çº¤ç»´åŒ–ã€è›‹ç™½è´¨", "keywords_en": "Epithelial-mesenchymal transition, Fistula, Gene, Intestinal fibrosis, Proteins", "link": "https://pubmed.ncbi.nlm.nih.gov/34856655/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1PQPGz2gzLgNzuaNos66c7B3c89tbZUZXKYTEvBxn0Ttaa8QdR&fc=20260103012404&ff=20260213212713&v=2.18.0.post22+67771e2", "date": "Thu, 02 Dec 2021"}], "ç—”ç–®": [{"id": "41665757", "title_en": "Perioperative impact of enhanced recovery after surgery (ERAS) for minimally invasive colorectal resection: a systematic review and meta-analysis", "title_zh": "åŠ é€Ÿåº·å¤å¤–ç§‘ï¼ˆERASï¼‰å¯¹å¾®åˆ›ç»“ç›´è‚ åˆ‡é™¤æœ¯å›´æ‰‹æœ¯æœŸçš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Bo-Wen Wu", "abstract_en": "**Purpose:** The added value of Enhanced Recovery After Surgery protocols in minimally invasive colorectal surgery remains debated. This study synthesized available evidence to examine how ERAS performs in minimally invasive colorectal resection, with attention to both effectiveness and safety.\n\n**Methods:** We conducted a systematic review of these documents, covering key databases such as the Cochrane Library, PubMed, EMBASE, and Web of Science. The latest information was updated up to December 2025. Data analyses were conducted using STATA 18. Continuous outcomes were expressed as weighted mean differences, while categorical outcomes were summarized with odds ratios, each accompanied by 95% confidence intervals. The rigor of the included studies was appraised using the Newcastle-Ottawa Scale (NOS).\n\n**Results:** Five eligible studies encompassing 2324 patients were synthesized. Compared with conventional care, ERAS implementation was associated with a meaningful reduction in length of hospital stay (WMDâ€‰=â€‰-â€‰2.38 days; 95% CI: -4.16, -â€‰0.61; Pâ€‰<â€‰0.01), alongside fewer overall postoperative complications (ORâ€‰=â€‰0.55; 95% CI: 0.44, 0.68; Pâ€‰<â€‰0.05) and a decreased occurrence of postoperative ileus (ORâ€‰=â€‰0.57; 95% CI: 0.38, 0.86; Pâ€‰<â€‰0.05). Readmission rates were comparable between groups (ORâ€‰=â€‰0.99, 95% CI: 0.55, 1.79; Pâ€‰=â€‰0.952), and no meaningful difference was observed in operative time (WMDâ€‰=â€‰3.53, 95% CI: -15.76, 22.81; Pâ€‰=â€‰0.115).\n\n**Conclusions:** ERAS protocols act synergistically with minimally invasive colorectal surgery to accelerate recovery and reduce complications without compromising safety. Future investigations with prospective designs are needed to confirm the robustness of these results.", "abstract_zh": "**Purposeï¼š** åŠ é€Ÿåº·å¤å¤–ç§‘æ–¹æ¡ˆåœ¨å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯ä¸­çš„é™„åŠ ä»·å€¼ä»å­˜åœ¨äº‰è®®ã€‚è¿™é¡¹ç ”ç©¶ç»¼åˆäº†ç°æœ‰è¯æ®æ¥æ£€éªŒ ERAS åœ¨å¾®åˆ›ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸­çš„è¡¨ç°ï¼ŒåŒæ—¶å…³æ³¨æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹è¿™äº›æ–‡çŒ®è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œæ¶µç›– Cochrane å›¾ä¹¦é¦†ã€PubMedã€EMBASE å’Œ Web of Science ç­‰å…³é”®æ•°æ®åº“ã€‚æœ€æ–°ä¿¡æ¯æ›´æ–°è‡³2025å¹´12æœˆã€‚ä½¿ç”¨STATA 18è¿›è¡Œæ•°æ®åˆ†æã€‚è¿ç»­ç»“æœè¡¨ç¤ºä¸ºåŠ æƒå¹³å‡å·®ï¼Œè€Œåˆ†ç±»ç»“æœåˆ™ç”¨æ¯”å€¼æ¯”æ€»ç»“ï¼Œæ¯ä¸ªç»“æœéƒ½å¸¦æœ‰95%ç½®ä¿¡åŒºé—´ã€‚ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ï¼ˆNOSï¼‰è¯„ä¼°çº³å…¥ç ”ç©¶çš„ä¸¥è°¨æ€§ã€‚\n\n**ç»“æœï¼š** ç»¼åˆäº†æ¶µç›– 2324 åæ‚£è€…çš„äº”é¡¹åˆæ ¼ç ”ç©¶ã€‚ä¸ä¼ ç»ŸæŠ¤ç†ç›¸æ¯”ï¼ŒERAS çš„å®æ–½å¯æ˜¾ç€ç¼©çŸ­ä½é™¢æ—¶é—´ï¼ˆWMDâ€‰=â€‰-â€‰2.38 å¤©ï¼›95% CIï¼š-4.16ï¼Œ-â€‰0.61ï¼›Pâ€‰<â€‰0.01ï¼‰ï¼ŒåŒæ—¶æ€»ä½“æœ¯åå¹¶å‘ç—‡è¾ƒå°‘ï¼ˆORâ€‰=â€‰0.55ï¼›95% CIï¼š0.44ï¼Œ0.68ï¼›Pâ€‰<â€‰0.01ï¼‰ã€‚ Pâ€‰<â€‰0.05ï¼‰å’Œæœ¯åè‚ æ¢—é˜»å‘ç”Ÿç‡é™ä½ï¼ˆORâ€‰=â€‰0.57ï¼›95% CIï¼š0.38ï¼Œ0.86ï¼›Pâ€‰<â€‰0.05ï¼‰ã€‚å„ç»„ä¹‹é—´çš„å†å…¥é™¢ç‡å…·æœ‰å¯æ¯”æ€§ï¼ˆORâ€‰=â€‰0.99ï¼Œ95% CIï¼š0.55ï¼Œ1.79ï¼›Pâ€‰=â€‰0.952ï¼‰ï¼Œæ‰‹æœ¯æ—¶é—´æ²¡æœ‰è§‚å¯Ÿåˆ°æœ‰æ„ä¹‰çš„å·®å¼‚ï¼ˆWMDâ€‰=â€‰3.53ï¼Œ95% CIï¼š-15.76ï¼Œ22.81ï¼›Pâ€‰=â€‰0.115ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ERAS æ–¹æ¡ˆä¸å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯ååŒä½œç”¨ï¼Œå¯åœ¨ä¸å½±å“å®‰å…¨æ€§çš„æƒ…å†µä¸‹åŠ é€Ÿåº·å¤å¹¶å‡å°‘å¹¶å‘ç—‡ã€‚æœªæ¥éœ€è¦å¯¹å‰ç»æ€§è®¾è®¡è¿›è¡Œè°ƒæŸ¥ï¼Œä»¥ç¡®è®¤è¿™äº›ç»“æœçš„ç¨³å¥æ€§ã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œã€ERASã€Metaåˆ†æã€å¾®åˆ›æ‰‹æœ¯ã€æœºå™¨äººæ‰‹æœ¯", "keywords_en": "Colorectal cancer, ERAS, Meta-analysis, Minimally invasive surgery, Robotic surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/41665757/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 10 Feb 2026"}, {"id": "41659148", "title_en": "Efficacy and safety of bipolar energy-based therapy for hemorrhoids: a systematic review", "title_zh": "åŒæèƒ½é‡ç–—æ³•æ²»ç–—ç—”ç–®çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Douglas G Adler", "abstract_en": "**Background:** Hemorrhoids arise from dilated vessels in the submucosal layer of the anorectal canal. Hemorrhoids are responsible for 4 million office and emergency visits annually in the US. Hemorrhoidal energy therapy (HET) is a novel nonsurgical, bipolar energy-based instrument for treating hemorrhoids. It has multiple benefits, such as requiring only a single session for resolution of symptoms, and minimizing heat-related collateral damage. However, there are limited data regarding the effectiveness and adverse events of HET. We performed the first systematic review to evaluate the efficacy and safety of HET in the treatment of internal hemorrhoids.\n\n**Methods:** A comprehensive search was performed from major databases to identify studies that investigated HET to treat hemorrhoids. The primary outcomes were technical success and clinical success. The secondary outcomes were total adverse events and individual adverse events, such as postprocedural bleeding and incontinence.\n\n**Results:** Eight studies with 512 patients were included in the meta-analysis. The average age was 55.6 years, and the majority of patients were female. Most patients presented with grade I and grade II hemorrhoids. The HET demonstrated technical and clinical success rates of 100% and 86.1%, respectively. All adverse events were determined to be mild, according to the ASGE lexicon, except for 1 case of perianal hematoma that required hospitalization.\n\n**Conclusion:** Our study demonstrates that HET is an effective and safe treatment for grade I and II internal hemorrhoids.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®ç”±è‚›é—¨ç›´è‚ ç®¡ç²˜è†œä¸‹å±‚æ‰©å¼ çš„è¡€ç®¡å¼•èµ·ã€‚åœ¨ç¾å›½ï¼Œæ¯å¹´æœ‰ 400 ä¸‡äººæ¬¡å› ç—”ç–®è€Œåˆ°åŠå…¬å®¤å°±è¯Šå’Œæ€¥è¯Šã€‚ç—”ç–®èƒ½é‡ç–—æ³•ï¼ˆHETï¼‰æ˜¯ä¸€ç§æ–°å‹éæ‰‹æœ¯ã€åŒæèƒ½é‡æ²»ç–—ç—”ç–®çš„ä»ªå™¨ã€‚å®ƒæœ‰å¤šç§å¥½å¤„ï¼Œä¾‹å¦‚åªéœ€ä¸€æ¬¡ç–—ç¨‹å³å¯è§£å†³ç—‡çŠ¶ï¼Œå¹¶æœ€å¤§é™åº¦åœ°å‡å°‘ä¸çƒ­ç›¸å…³çš„é™„å¸¦æŸå®³ã€‚ç„¶è€Œï¼Œå…³äº HET çš„æœ‰æ•ˆæ€§å’Œä¸è‰¯äº‹ä»¶çš„æ•°æ®æœ‰é™ã€‚æˆ‘ä»¬è¿›è¡Œäº†é¦–æ¬¡ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¯„ä¼° HET æ²»ç–—å†…ç—”çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ä¸»è¦æ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œä»¥ç¡®å®šç ”ç©¶ HET æ²»ç–—ç—”ç–®çš„ç ”ç©¶ã€‚ä¸»è¦æˆæœæ˜¯æŠ€æœ¯æˆåŠŸå’Œä¸´åºŠæˆåŠŸã€‚æ¬¡è¦ç»“å±€æ˜¯æ€»ä½“ä¸è‰¯äº‹ä»¶å’Œä¸ªä½“ä¸è‰¯äº‹ä»¶ï¼Œä¾‹å¦‚æœ¯åå‡ºè¡€å’Œå¤±ç¦ã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†æä¸­çº³å…¥äº† 8 é¡¹æ¶‰åŠ 512 åæ‚£è€…çš„ç ”ç©¶ã€‚å¹³å‡å¹´é¾„ä¸º55.6å²ï¼Œå¤§å¤šæ•°æ‚£è€…ä¸ºå¥³æ€§ã€‚å¤§å¤šæ•°æ‚£è€…æ‚£æœ‰ I çº§å’Œ II çº§ç—”ç–®ã€‚ HET çš„æŠ€æœ¯æˆåŠŸç‡å’Œä¸´åºŠæˆåŠŸç‡åˆ†åˆ«ä¸º 100% å’Œ 86.1%ã€‚æ ¹æ® ASGE è¯å…¸ï¼Œé™¤ 1 ä¾‹éœ€è¦ä½é™¢æ²»ç–—çš„è‚›å‘¨è¡€è‚¿å¤–ï¼Œæ‰€æœ‰ä¸è‰¯äº‹ä»¶å‡è¢«ç¡®å®šä¸ºè½»å¾®ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç ”ç©¶è¡¨æ˜ï¼ŒHET æ˜¯æ²»ç–— I çº§å’Œ II çº§å†…ç—”çš„æœ‰æ•ˆä¸”å®‰å…¨çš„æ–¹æ³•ã€‚", "keywords_zh": "åŒæèƒ½é‡ç–—æ³•ã€ç—”ç–®èƒ½é‡ç–—æ³•ã€å†…ç—”", "keywords_en": "Bipolar energy-based therapy, hemorrhoidal energy therapy, internal hemorrhoids", "link": "https://pubmed.ncbi.nlm.nih.gov/41659148/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 09 Feb 2026"}, {"id": "41640613", "title_en": "Is salvage treatment necessary after incomplete resection of rectal neuroendocrine tumors: A systematic review and meta-analysis", "title_zh": "ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ä¸å®Œå…¨åˆ‡é™¤åæ˜¯å¦éœ€è¦æŒ½æ•‘æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Seun Ja Park", "abstract_en": "**Background:** Incomplete resection of rectal neuroendocrine tumors (NETs), defined by positive or indeterminate margins or lymphovascular invasion, raises concerns regarding residual disease and recurrence. However, the benefits of salvage treatment in these cases remain unclear.\n\n**Aim:** To evaluate the oncologic impact of salvage treatment compared with observation after incomplete endoscopic resection of rectal NETs through a systematic review and meta-analysis.\n\n**Methods:** We conducted a systematic review and meta-analysis in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines. MEDLINE, EMBASE, and the Cochrane Library were searched from their inception until May 2025. Eligible studies included patients with incompletely resected rectal NETs managed with salvage treatment or observation, reporting outcomes of residual tumors or recurrence. Pooled estimates were calculated using random-effects models with Hartung-Knapp adjustments.\n\n**Results:** Thirty-four studies with 2279 cases of incomplete endoscopic resection met the inclusion criteria. The incomplete resection rates differed markedly according to the initial resection method (17 studies): 73.1% for cold snare polypectomy, 29.8% for conventional endoscopic mucosal resection (EMR), 28.4% for modified EMR, and 14.7% for endoscopic submucosal dissection. Among the 19 studies that evaluated salvage treatment, the pooled residual tumor rate was 25.0% [95% confidence interval (CI): 12.0%-40.0%]. The crude recurrence rates from 31 studies favored salvage treatment over observation (0.96% <i>vs</i> 2.96%, <i>P</i> = 0.003). However, a meta-analysis of nine comparative studies found no statistically significant difference in recurrence risk (odds ratio = 0.89; 95%CI: 0.40-2.02).\n\n**Conclusion:** Given the relatively high residual tumor rate and low incidence of recurrence, salvage treatment may be justified as both a diagnostic and therapeutic approach after incomplete resection of rectal NETs. Although its benefits in preventing recurrence remain unclear, clinical decisions should be individualized, as these findings are based on low-certainty evidence.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼ˆNETï¼‰çš„ä¸å®Œå…¨åˆ‡é™¤ï¼ˆå®šä¹‰ä¸ºé˜³æ€§æˆ–ä¸ç¡®å®šçš„åˆ‡ç¼˜æˆ–æ·‹å·´è¡€ç®¡ä¾µçŠ¯ï¼‰å¼•èµ·äº†å¯¹æ®‹ç•™ç–¾ç—…å’Œå¤å‘çš„æ‹…å¿§ã€‚ç„¶è€Œï¼Œåœ¨è¿™äº›ç—…ä¾‹ä¸­æŒ½æ•‘æ²»ç–—çš„ç›Šå¤„ä»ä¸æ¸…æ¥šã€‚\n\n**Aimï¼š** é€šè¿‡ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æï¼Œä¸ç›´è‚  NET ä¸å®Œå…¨å†…é•œåˆ‡é™¤æœ¯åè§‚å¯Ÿç›¸æ¯”ï¼Œè¯„ä¼°æŒ½æ•‘æ²»ç–—çš„è‚¿ç˜¤å­¦å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææŒ‡å—çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ MEDLINEã€EMBASE å’Œ Cochrane å›¾ä¹¦é¦†çš„æ£€ç´¢æ—¶é—´ä»æœ€åˆåˆ° 2025 å¹´ 5 æœˆã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬ç›´è‚  NET åˆ‡é™¤ä¸å®Œå…¨ã€æ¥å—æŒ½æ•‘æ²»ç–—æˆ–è§‚å¯Ÿçš„â€‹â€‹æ‚£è€…ï¼ŒæŠ¥å‘Šæ®‹ç•™è‚¿ç˜¤æˆ–å¤å‘çš„ç»“æœã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹å’Œ Hartung-Knapp è°ƒæ•´æ¥è®¡ç®—æ±‡æ€»ä¼°è®¡å€¼ã€‚\n\n**ç»“æœï¼š** 34 é¡¹ç ”ç©¶æ¶‰åŠ 2279 ä¾‹ä¸å®Œå…¨å†…é•œåˆ‡é™¤ç—…ä¾‹ï¼Œç¬¦åˆçº³å…¥æ ‡å‡†ã€‚æ ¹æ®åˆå§‹åˆ‡é™¤æ–¹æ³•ï¼ˆ17é¡¹ç ”ç©¶ï¼‰ï¼Œä¸å®Œå…¨åˆ‡é™¤ç‡å­˜åœ¨æ˜¾ç€å·®å¼‚ï¼šå†·åœˆå¥—å™¨æ¯è‚‰åˆ‡é™¤æœ¯ä¸º73.1%ï¼Œä¼ ç»Ÿå†…é•œç²˜è†œåˆ‡é™¤æœ¯ï¼ˆEMRï¼‰ä¸º29.8%ï¼Œæ”¹è‰¯EMRä¸º28.4%ï¼Œå†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯ä¸º14.7%ã€‚åœ¨è¯„ä¼°æŒ½æ•‘æ²»ç–—çš„ 19 é¡¹ç ”ç©¶ä¸­ï¼Œæ±‡æ€»æ®‹ç•™è‚¿ç˜¤ç‡ä¸º 25.0% [95% ç½®ä¿¡åŒºé—´ (CI)ï¼š12.0%-40.0%]ã€‚ 31 é¡¹ç ”ç©¶çš„ç²—å¤å‘ç‡å€¾å‘äºæŒ½æ•‘æ²»ç–—è€Œéè§‚å¯Ÿï¼ˆ0.96% <i>vs</i> 2.96%ï¼Œ<i>P</i> = 0.003ï¼‰ã€‚ç„¶è€Œï¼Œå¯¹ä¹é¡¹æ¯”è¾ƒç ”ç©¶çš„èŸèƒåˆ†æå‘ç°ï¼Œå¤å‘é£é™©æ²¡æœ‰ç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ï¼ˆæ¯”å€¼æ¯” = 0.89ï¼›95% CIï¼š0.40-2.02ï¼‰ã€‚\n\n**ç»“è®ºï¼š** é‰´äºç›¸å¯¹è¾ƒé«˜çš„æ®‹ç•™è‚¿ç˜¤ç‡å’Œè¾ƒä½çš„å¤å‘ç‡ï¼ŒæŒ½æ•‘æ²»ç–—å¯èƒ½æ˜¯ç›´è‚  NET ä¸å®Œå…¨åˆ‡é™¤åçš„ä¸€ç§è¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ã€‚å°½ç®¡å…¶é¢„é˜²å¤å‘çš„ç›Šå¤„å°šä¸æ¸…æ¥šï¼Œä½†ä¸´åºŠå†³ç­–åº”ä¸ªä½“åŒ–ï¼Œå› ä¸ºè¿™äº›å‘ç°åŸºäºä½è´¨é‡è¯æ®ã€‚", "keywords_zh": "ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼Œè§‚å¯Ÿï¼Œç›´è‚ ï¼Œæ®‹ç•™è‚¿ç˜¤ï¼ŒæŠ¢æ•‘æ²»ç–—", "keywords_en": "Neuroendocrine tumors, Observation, Rectum, Residual neoplasm, Salvage therapy", "link": "https://pubmed.ncbi.nlm.nih.gov/41640613/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 05 Feb 2026"}, {"id": "41629638", "title_en": "Fecal incontinence after prostate cancer irradiation: a systematic literature review", "title_zh": "å‰åˆ—è…ºç™Œç…§å°„åå¤§ä¾¿å¤±ç¦ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Jean-Michel Hannoun-Levi", "abstract_en": "**Goal:** Fecal incontinence (FI) is an underrecognized but clinically significant late gastrointestinal toxicity following radiotherapy (RT) for prostate cancer. This systematic review aimed to synthesize current knowledge on the definition and pathophysiology of post-radiation anal continence, as well as prevention strategies, technical considerations, and therapeutic approaches.\n\n**Method:** A systematic literature search was conducted according to PRISMA guidelines using the keywords: \"Fecal incontinence,\" \"Radiation therapy,\" and \"Prostatic neoplasms.\" Eligible studies included randomized phase III trials and prospective or retrospective series reporting on FI after definitive or adjuvant/salvage prostate RT. Fifty-four articles were included in the final analysis.\n\n**Results:** FI after prostate RT results from functional, morphological, and neurogenic alterations of the anorectal system. Reported incidence ranges from 1 to 12%, most often presenting as flatulence or liquid stool leakage, while severe forms requiring pads are uncommon. Variability is largely explained by heterogeneity in definitions and assessment tools, as no standardized scoring system is universally applied. Risk factors include advanced age, prior abdominal surgery, vascular comorbidities, chronic inflammatory bowel disease, hemorrhoids, and rectal urgency during RT. Dosimetric analyses indicate that low-to-intermediate doses to the anal canal and high doses to the rectum contribute differentially to FI. Based on current evidence, the mean dose to the anal canal should be kept below 37â€‰Gy, though further studies are needed to define precise constraints for both structures. Preventive strategies such as MRI-based contouring and endorectal balloon placement, perirectal hydrogel spacers placement show promise. Management is multidisciplinary, including dietary measures, medications, pelvic floor therapy, neuromodulation, and, in severe cases, diversion procedures.\n\n**Conclusion:** FI after prostate RT is likely underestimated due to the absence of a standardized assessment. Developing a validated, universally applicable scoring system is a priority to improve evaluation, enable cross-study comparisons, refine preventive measures, and guide therapeutic strategies.", "abstract_zh": "**Goalï¼š** å¤§ä¾¿å¤±ç¦ï¼ˆFIï¼‰æ˜¯å‰åˆ—è…ºç™Œæ”¾ç–—ï¼ˆRTï¼‰åä¸€ç§æœªè¢«å……åˆ†è®¤è¯†ä½†å…·æœ‰ä¸´åºŠæ„ä¹‰çš„æ™šæœŸèƒƒè‚ é“æ¯’æ€§ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨ç»¼åˆæœ‰å…³æ”¾å°„åè‚›é—¨å¤±ç¦çš„å®šä¹‰å’Œç—…ç†ç”Ÿç†å­¦ä»¥åŠé¢„é˜²ç­–ç•¥ã€æŠ€æœ¯è€ƒè™‘å’Œæ²»ç–—æ–¹æ³•çš„æœ€æ–°çŸ¥è¯†ã€‚\n\n**Methodï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œä½¿ç”¨å…³é”®è¯â€œå¤§ä¾¿å¤±ç¦â€ã€â€œæ”¾å°„æ²»ç–—â€å’Œâ€œå‰åˆ—è…ºè‚¿ç˜¤â€è¿›è¡Œç³»ç»Ÿæ–‡çŒ®æ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬éšæœº III æœŸè¯•éªŒä»¥åŠç¡®å®šæ€§æˆ–è¾…åŠ©/æŒ½æ•‘æ€§å‰åˆ—è…ºæ”¾ç–—å FI çš„å‰ç»æ€§æˆ–å›é¡¾æ€§ç³»åˆ—æŠ¥å‘Šã€‚æœ€ç»ˆåˆ†æçº³å…¥54ç¯‡æ–‡ç« ã€‚\n\n**ç»“æœï¼š** å‰åˆ—è…ºæ”¾ç–—åçš„ FI æ˜¯ç”±è‚›é—¨ç›´è‚ ç³»ç»Ÿçš„åŠŸèƒ½ã€å½¢æ€å’Œç¥ç»æºæ€§æ”¹å˜å¼•èµ·çš„ã€‚æŠ¥é“çš„å‘ç—…ç‡ä» 1% åˆ° 12% ä¸ç­‰ï¼Œæœ€å¸¸è¡¨ç°ä¸ºèƒ€æ°”æˆ–ç²ªä¾¿æ¸—æ¼ï¼Œè€Œéœ€è¦æŠ¤å«çš„ä¸¥é‡å½¢å¼å¹¶ä¸å¸¸è§ã€‚å˜å¼‚æ€§å¾ˆå¤§ç¨‹åº¦ä¸Šæ˜¯ç”±å®šä¹‰å’Œè¯„ä¼°å·¥å…·çš„å¼‚è´¨æ€§é€ æˆçš„ï¼Œå› ä¸ºæ²¡æœ‰æ™®éåº”ç”¨çš„æ ‡å‡†åŒ–è¯„åˆ†ç³»ç»Ÿã€‚å±é™©å› ç´ åŒ…æ‹¬é«˜é¾„ã€æ—¢å¾€è…¹éƒ¨æ‰‹æœ¯ã€è¡€ç®¡åˆå¹¶ç—‡ã€æ…¢æ€§ç‚ç—‡æ€§è‚ ç—…ã€ç—”ç–®å’Œæ”¾ç–—æœŸé—´çš„ç›´è‚ ç´§è¿«æ„Ÿã€‚å‰‚é‡åˆ†æè¡¨æ˜ï¼Œè‚›ç®¡ä½è‡³ä¸­å‰‚é‡å’Œç›´è‚ é«˜å‰‚é‡å¯¹ FI çš„å½±å“ä¸åŒã€‚æ ¹æ®ç›®å‰çš„è¯æ®ï¼Œè‚›ç®¡çš„å¹³å‡å‰‚é‡åº”ä¿æŒåœ¨ 37Gy ä»¥ä¸‹ï¼Œå°½ç®¡è¿˜éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶æ¥ç¡®å®šè¿™ä¸¤ç§ç»“æ„çš„ç²¾ç¡®é™åˆ¶ã€‚åŸºäº MRI çš„è½®å»“å¡‘é€ å’Œç›´è‚ å†…çƒå›Šæ”¾ç½®ã€ç›´è‚ å‘¨å›´æ°´å‡èƒ¶å«ç‰‡æ”¾ç½®ç­‰é¢„é˜²ç­–ç•¥æ˜¾ç¤ºå‡ºå¸Œæœ›ã€‚æ²»ç–—æ˜¯å¤šå­¦ç§‘çš„ï¼ŒåŒ…æ‹¬é¥®é£Ÿæªæ–½ã€è¯ç‰©ã€ç›†åº•æ²»ç–—ã€ç¥ç»è°ƒèŠ‚ï¼Œä»¥åŠä¸¥é‡æƒ…å†µä¸‹çš„åˆ†æµæ‰‹æœ¯ã€‚\n\n**ç»“è®ºï¼š** ç”±äºç¼ºä¹æ ‡å‡†åŒ–è¯„ä¼°ï¼Œå‰åˆ—è…ºæ”¾ç–—åçš„ FI å¯èƒ½è¢«ä½ä¼°ã€‚å¼€å‘ä¸€ä¸ªç»è¿‡éªŒè¯çš„ã€æ™®éé€‚ç”¨çš„è¯„åˆ†ç³»ç»Ÿæ˜¯æ”¹è¿›è¯„ä¼°ã€å®ç°äº¤å‰ç ”ç©¶æ¯”è¾ƒã€å®Œå–„é¢„é˜²æªæ–½å’ŒæŒ‡å¯¼æ²»ç–—ç­–ç•¥çš„é¦–è¦ä»»åŠ¡ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/41629638/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 02 Feb 2026"}, {"id": "41604561", "title_en": "Colitis cystica profunda: a systematic review", "title_zh": "æ·±éƒ¨å›Šæ€§ç»“è‚ ç‚ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Priyanka Kanth", "abstract_en": "Colitis cystica profunda (CCP) is an uncommon, benign colorectal lesion that can mimic malignancy. We conducted a systematic review of histologically confirmed CCP case reports and series to define epidemiology, presentation, diagnostic yield, management, and outcomes. Following PRISMA 2020, Embase, PubMed/MEDLINE, Web of Science, and CINAHL were searched (1965-2025); two reviewers independently screened studies and extracted demographic, clinical, imaging, histologic, treatment, and outcome data. Sixty-five studies (92 patients) met criteria. Mean age was 40â€…Â±â€…12 years (median 39), and 54% were male. Rectal bleeding (70%), mucus discharge (32%), diarrhea (24%), and abdominal/rectal pain (26%) were most common; 12% were asymptomatic. Lesions were predominantly distal (rectum 61%), and superficial biopsies reached the submucosa in only 32%, contributing to frequent sampling error; Endoscopic ultrasound (EUS) and cross-sectional imaging typically showed submucosal cystic lesions with intact muscularis propria. Conservative and medical therapy were each attempted in 16% of patients, endoscopic resection in 14%, and surgery in 67%, most commonly local transanal/perineal excision (40% of surgeries) or segmental/partial colectomy (32% of surgeries). Dysplasia was reported in 10% and coexisting invasive adenocarcinoma in 4% at diagnosis; no subsequent malignant transformation was reported over a median follow-up of 8.4 months. Post-operative morbidity occurred in 5% and recurrence in 4%. CCP is a rare but important mimic of colorectal cancer; diagnosis is optimized with deep tissue sampling and high-resolution imaging. When feasible, organ-preserving endoscopic or local excision can achieve durable symptom resolution with low morbidity while avoiding unnecessary radical surgery.", "abstract_zh": "æ·±éƒ¨å›Šæ€§ç»“è‚ ç‚ (CCP) æ˜¯ä¸€ç§ç½•è§çš„è‰¯æ€§ç»“ç›´è‚ ç—…å˜ï¼Œå¯èƒ½ç±»ä¼¼äºæ¶æ€§è‚¿ç˜¤ã€‚æˆ‘ä»¬å¯¹ç»„ç»‡å­¦è¯å®çš„ CCP ç—…ä¾‹æŠ¥å‘Šå’Œç³»åˆ—è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥ç¡®å®šæµè¡Œç—…å­¦ã€è¡¨ç°ã€è¯Šæ–­ç‡ã€ç®¡ç†å’Œç»“æœã€‚ PRISMA 2020 ä¹‹åï¼Œæ£€ç´¢äº† Embaseã€PubMed/MEDLINEã€Web of Science å’Œ CINAHLï¼ˆ1965-2025 å¹´ï¼‰ï¼›ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹ç­›é€‰ç ”ç©¶å¹¶æå–äººå£ç»Ÿè®¡ã€ä¸´åºŠã€å½±åƒã€ç»„ç»‡å­¦ã€æ²»ç–—å’Œç»“æœæ•°æ®ã€‚ 65 é¡¹ç ”ç©¶ï¼ˆ92 åæ‚£è€…ï¼‰ç¬¦åˆæ ‡å‡†ã€‚å¹³å‡å¹´é¾„ä¸º 40Â±12 å²ï¼ˆä¸­ä½æ•° 39 å²ï¼‰ï¼Œå…¶ä¸­ 54% ä¸ºç”·æ€§ã€‚æœ€å¸¸è§çš„æ˜¯ç›´è‚ å‡ºè¡€ï¼ˆ70%ï¼‰ã€ç²˜æ¶²æ’å‡ºï¼ˆ32%ï¼‰ã€è…¹æ³»ï¼ˆ24%ï¼‰å’Œè…¹éƒ¨/ç›´è‚ ç–¼ç—›ï¼ˆ26%ï¼‰ï¼› 12%æ— ç—‡çŠ¶ã€‚ç—…å˜ä¸»è¦ä½äºè¿œç«¯ï¼ˆç›´è‚  61%ï¼‰ï¼Œæµ…è¡¨æ´»æ£€ä»…åˆ°è¾¾ç²˜è†œä¸‹å±‚ï¼Œä»… 32%ï¼Œå¯¼è‡´é¢‘ç¹å‡ºç°é‡‡æ ·é”™è¯¯ï¼›è¶…å£°å†…é•œ (EUS) å’Œæ¨ªæˆªé¢æˆåƒé€šå¸¸æ˜¾ç¤ºç²˜è†œä¸‹å›Šæ€§ç—…å˜ï¼Œå›ºæœ‰è‚Œå±‚å®Œæ•´ã€‚ 16% çš„æ‚£è€…å°è¯•äº†ä¿å®ˆæ²»ç–—å’Œè¯ç‰©æ²»ç–—ï¼Œ14% çš„æ‚£è€…å°è¯•äº†å†…é•œåˆ‡é™¤æœ¯ï¼Œ67% çš„æ‚£è€…å°è¯•äº†æ‰‹æœ¯ï¼Œæœ€å¸¸è§çš„æ˜¯å±€éƒ¨ç»è‚›é—¨/ä¼šé˜´åˆ‡é™¤æœ¯ï¼ˆå æ‰‹æœ¯çš„ 40%ï¼‰æˆ–èŠ‚æ®µ/éƒ¨åˆ†ç»“è‚ åˆ‡é™¤æœ¯ï¼ˆå æ‰‹æœ¯çš„ 32%ï¼‰ã€‚æ®æŠ¥é“ï¼Œè¯Šæ–­æ—¶ 10% å­˜åœ¨ä¸å…¸å‹å¢ç”Ÿï¼Œ4% å­˜åœ¨å…±å­˜æµ¸æ¶¦æ€§è…ºç™Œï¼›ä¸­ä½éšè®¿æ—¶é—´ä¸º 8.4 ä¸ªæœˆï¼ŒæœªæŠ¥å‘Šéšåå‘ç”Ÿæ¶å˜ã€‚æœ¯åå‘ç—…ç‡ä¸º 5%ï¼Œå¤å‘ç‡ä¸º 4%ã€‚ CCP æ˜¯ä¸€ç§ç½•è§ä½†é‡è¦çš„ç»“ç›´è‚ ç™Œç±»ä¼¼ç‰©ï¼›é€šè¿‡æ·±å±‚ç»„ç»‡é‡‡æ ·å’Œé«˜åˆ†è¾¨ç‡æˆåƒä¼˜åŒ–è¯Šæ–­ã€‚åœ¨å¯è¡Œçš„æƒ…å†µä¸‹ï¼Œä¿ç•™å™¨å®˜çš„å†…çª¥é•œæˆ–å±€éƒ¨åˆ‡é™¤æœ¯å¯ä»¥ä»¥è¾ƒä½çš„å‘ç—…ç‡å®ç°æŒä¹…çš„ç—‡çŠ¶ç¼“è§£ï¼ŒåŒæ—¶é¿å…ä¸å¿…è¦çš„æ ¹æ²»æ€§æ‰‹æœ¯ã€‚", "keywords_zh": "æ·±éƒ¨å›Šæ€§ç»“è‚ ç‚ã€å†…çª¥é•œåˆ‡é™¤æœ¯ã€ç²˜æ¶²æ€§ç»“è‚ ç‚ã€ç›´è‚ å‡ºè¡€ã€ç²˜è†œä¸‹å›Šè‚¿", "keywords_en": "colitis cystica profunda, endoscopic resection, mucous colitis, rectal bleeding, submucosal cysts", "link": "https://pubmed.ncbi.nlm.nih.gov/41604561/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 28 Jan 2026"}, {"id": "41586878", "title_en": "Metronidazole is an effective method of analgesia following haemorrhoidectomy: a systematic review and meta-analysis", "title_zh": "ç”²ç¡å”‘æ˜¯ç—”åˆ‡é™¤æœ¯åé•‡ç—›çš„æœ‰æ•ˆæ–¹æ³•ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Christina A Fleming", "abstract_en": "**Background:** Haemorrhoids are one of the most frequently encountered benign anorectal conditions that negatively impact patients' quality of life. Excisional haemorrhoidectomy (closed or open) is a surgical procedure reserved for the treatment of third- and fourth-degree haemorrhoids, with considerable post-procedure pain reported. The aim of this study was to clarify the association between post operative metronidazole use (both oral and topical) and post-haemorrhoidectomy pain scores through systematic review and meta-analysis of randomised controlled trials (RCTs).\n\n**Methods:** This study was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Prospective registration was performed on PROSPERO (CRD42024580928). A systematic review was performed for RCTs reporting post-haemorrhoidectomy pain scores between patients who received metronidazole and patients who received placebo. Meta-analysis was performed using RevMan version 5.4.\n\n**Results:** Seventeen RCTs including 1297 participants were eligible for inclusion. Metronidazole administration was associated with significantly lower post-operative visual analogue scores (VAS) on day 1 (-1.18, pâ€‰<â€‰0.00001), day 2 (-1.15, pâ€‰=â€‰0.003), day 3 (-0.86, pâ€‰<â€‰0.00001), and day 7 post-operatively with a mean pain score difference of -1.72 (95% CI -2.27 to -1.18) (pâ€‰<â€‰0.00001). A significant difference in pain scores was seen on day 3 favouring topical metronidazole in comparison to the oral route (1.38, 95% CI [0.44, 2.32], pâ€‰=â€‰0.004).\n\n**Conclusion:** This review synthesises the best available evidence to support the use of metronidazole to reduce pain after excisional haemorrhoidectomy. While both oral and topical forms appear to be beneficial, topical administration appears to have a more effective analgesic effect from post-operative day 3.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®æ˜¯æœ€å¸¸è§çš„è‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…ä¹‹ä¸€ï¼Œä¼šå¯¹æ‚£è€…çš„ç”Ÿæ´»è´¨é‡äº§ç”Ÿè´Ÿé¢å½±å“ã€‚ç—”ç–®åˆ‡é™¤æœ¯ï¼ˆå°é—­å¼æˆ–å¼€æ”¾å¼ï¼‰æ˜¯ä¸€ç§ä¸“ä¸ºæ²»ç–—ä¸‰åº¦å’Œå››åº¦ç—”ç–®è€Œä¿ç•™çš„å¤–ç§‘æ‰‹æœ¯ï¼Œæ®æŠ¥é“æœ‰ç›¸å½“å¤§çš„æœ¯åç–¼ç—›ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯é€šè¿‡éšæœºå¯¹ç…§è¯•éªŒ (RCT) çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œé˜æ˜æœ¯åä½¿ç”¨ç”²ç¡å”‘ï¼ˆå£æœå’Œå±€éƒ¨ï¼‰ä¸ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›è¯„åˆ†ä¹‹é—´çš„å…³â€‹â€‹è”ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç ”ç©¶ä»¥ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æé¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ä¸ºæŒ‡å¯¼ã€‚åœ¨ PROSPERO (CRD42024580928) ä¸Šè¿›è¡Œäº†å‰ç»æ€§æ³¨å†Œã€‚å¯¹æŠ¥å‘Šæ¥å—ç”²ç¡å”‘çš„æ‚£è€…å’Œæ¥å—å®‰æ…°å‰‚çš„æ‚£è€…ä¹‹é—´ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›è¯„åˆ†çš„éšæœºå¯¹ç…§è¯•éªŒè¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚ä½¿ç”¨ RevMan 5.4 ç‰ˆè¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** åŒ…æ‹¬ 1297 åå‚ä¸è€…åœ¨å†…çš„ 17 é¡¹ RCT æœ‰èµ„æ ¼çº³å…¥ã€‚ç”²ç¡å”‘ç»™è¯ä¸æœ¯åç¬¬ 1 å¤©ï¼ˆ-1.18ï¼Œpâ€‰<â€‰0.00001ï¼‰ã€ç¬¬ 2 å¤©ï¼ˆ-1.15ï¼Œpâ€‰=â€‰0.003ï¼‰ã€ç¬¬ 3 å¤©ï¼ˆ-0.86ï¼Œpâ€‰<â€‰0.00001ï¼‰å’Œæœ¯åç¬¬ 7 å¤©æ˜¾ç€é™ä½çš„æœ¯åè§†è§‰æ¨¡æ‹Ÿè¯„åˆ†ï¼ˆVASï¼‰ç›¸å…³ï¼Œå¹³å‡ç–¼ç—›è¯„åˆ†å·®å¼‚ä¸º-1.72ï¼ˆ95% CI -2.27 è‡³ -1.18ï¼‰ï¼ˆpâ€‰<â€‰0.00001ï¼‰ã€‚ä¸å£æœé€”å¾„ç›¸æ¯”ï¼Œç¬¬ 3 å¤©å±€éƒ¨ä½¿ç”¨ç”²ç¡å”‘çš„ç–¼ç—›è¯„åˆ†å­˜åœ¨æ˜¾ç€å·®å¼‚ï¼ˆ1.38ï¼Œ95% CI [0.44ï¼Œ2.32]ï¼Œpâ€‰=â€‰0.004ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æœ¬ç»¼è¿°ç»¼åˆäº†ç°æœ‰çš„æœ€ä½³è¯æ®ï¼Œæ”¯æŒä½¿ç”¨ç”²ç¡å”‘æ¥å‡è½»ç—”ç–®åˆ‡é™¤æœ¯åçš„ç–¼ç—›ã€‚è™½ç„¶å£æœå’Œå¤–ç”¨å½¢å¼ä¼¼ä¹éƒ½æ˜¯æœ‰ç›Šçš„ï¼Œä½†ä»æœ¯åç¬¬ 3 å¤©å¼€å§‹ï¼Œå±€éƒ¨ç»™è¯ä¼¼ä¹å…·æœ‰æ›´æœ‰æ•ˆçš„é•‡ç—›æ•ˆæœã€‚", "keywords_zh": "ç—”ç–®ï¼Œç”²ç¡å”‘ï¼ŒRCT", "keywords_en": "Haemorrhoids, Metronidazole, RCT", "link": "https://pubmed.ncbi.nlm.nih.gov/41586878/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 26 Jan 2026"}, {"id": "41554450", "title_en": "Salvia plebeia R.Br.: A comprehensive review of its ethnopharmacology, phytochemistry, pharmacological activities, quality control, and current applications", "title_zh": "Salvia plebeia R.Br.ï¼šå¯¹å…¶æ°‘æ—è¯ç†å­¦ã€æ¤ç‰©åŒ–å­¦ã€è¯ç†æ´»æ€§ã€è´¨é‡æ§åˆ¶å’Œå½“å‰åº”ç”¨çš„å…¨é¢ç»¼è¿°", "authors": "Wei Jiang", "abstract_en": "**Ethnopharmacological Relevance:** Salvia plebeia R.Br. (Lamiaceae), the dried aerial parts, has been traditionally used across China and East/South Asia to treat sore throat, bronchitis, nephritis edema, abscesses, mastitis, hemorrhoids, and bleeding disorders, consistent with traditional indications of heat-clearing, detoxifying, cooling blood, and promoting diuresis.\n\n**Aim Of The Review:** This study provides a systematic overview of the ethnopharmacology, phytochemistry, pharmacological activities, quality control, and current applications of S. plebeia, while highlighting current research gaps and future perspectives.\n\n**Materials And Methods:** A comprehensive literature search was conducted using multiple scientific databases, including Web of Science, PubMed, Elsevier, ACS, CNKI, and Google Scholar, covering publications from database inception to October 2025. Relevant information on the ethnopharmacology, phytochemistry, pharmacological activities, quality control, and applications of S. plebeia was systematically collected, screened, and synthesized according to predefined inclusion/exclusion criteria.\n\n**Results:** To date, 325 constituents have been identified, dominated by flavonoids, phenolic acids, terpenoids, volatile oils, sterols, lignans, and others. Extracts and purified compounds show tradition-relevant anti-inflammatory, antiviral, immunoregulatory, and antioxidant activities, while other reported effects (hepatoprotective, hypolipidemic, cardiovascular-protective, sedative/anticonvulsant, anticancer, and anti-photoaging) are presented as exploratory findings. Quality evaluation evolved from UV and HPLC to UPLC-MS fingerprinting using flavonoids and sesquiterpenes as markers. In practical applications, S. plebeia has been used in medicinal preparations for the management of pharyngitis, bronchitis, nephritis, dermatitis, and anorectal inflammation. In food sector, it has been developed into functional products, including health teas, chewable or effervescent tablets, composite beverages, and co-fermented vinegars.\n\n**Conclusion:** Although S. plebeia shows broad pharmacological potential, current investigations remain constrained by incomplete chemical space coverage, limited pharmacokinetic and toxicological characterization, and insufficient well-designed clinical evidence. Future research should focus on comprehensive constituent profiling, mechanism-oriented validation aligned with traditional indications, standardized quality markers/fingerprints, and rigorous PK-toxicology-clinical translation, to promote safe, effective, and evidence-based utilization of S. plebeia in medicine and functional food development.", "abstract_zh": "**Ethnopharmacological relevanceï¼š** é¼ å°¾è‰ (Salvia plebeia R.Br.) ï¼ˆå”‡å½¢ç§‘ï¼‰å¹²ç‡¥çš„åœ°ä¸Šéƒ¨åˆ†ï¼Œåœ¨ä¸­å›½å’Œä¸œäºš/å—äºšä¼ ç»Ÿä¸Šç”¨äºæ²»ç–—å’½å–‰è‚¿ç—›ã€æ”¯æ°”ç®¡ç‚ã€è‚¾ç‚æ°´è‚¿ã€è„“è‚¿ã€ä¹³è…ºç‚ã€ç—”ç–®å’Œå‡ºè¡€æ€§ç–¾ç—…ï¼Œç¬¦åˆæ¸…çƒ­è§£æ¯’ã€å‡‰è¡€å’Œåˆ©å°¿çš„ä¼ ç»ŸåŠŸèƒ½ã€‚\n\n**Aim of the reviewï¼š** æœ¬ç ”ç©¶ç³»ç»Ÿæ¦‚è¿°äº†ç™½èŠ±è‰çš„æ°‘æ—è¯ç†å­¦ã€æ¤ç‰©åŒ–å­¦ã€è¯ç†æ´»æ€§ã€è´¨é‡æ§åˆ¶å’Œå½“å‰åº”ç”¨ï¼ŒåŒæ—¶å¼ºè°ƒäº†å½“å‰çš„ç ”ç©¶å·®è·å’Œæœªæ¥å‰æ™¯ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** åˆ©ç”¨Web of Scienceã€PubMedã€Elsevierã€ACSã€CNKIå’ŒGoogle Scholarç­‰å¤šä¸ªç§‘å­¦æ•°æ®åº“è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ï¼Œæ¶µç›–äº†ä»æ•°æ®åº“å»ºåº“åˆ°2025å¹´10æœˆçš„å‡ºç‰ˆç‰©ã€‚æ ¹æ®é¢„å…ˆç¡®å®šçš„çº³å…¥/æ’é™¤æ ‡å‡†ï¼Œç³»ç»Ÿæ”¶é›†ã€ç­›é€‰å’Œåˆæˆäº†ç™½èŠ±è‰çš„æ°‘æ—è¯ç†å­¦ã€æ¤ç‰©åŒ–å­¦ã€è¯ç†æ´»æ€§ã€è´¨é‡æ§åˆ¶å’Œåº”ç”¨çš„ç›¸å…³ä¿¡æ¯ã€‚\n\n**ç»“æœï¼š** è¿„ä»Šä¸ºæ­¢ï¼Œå·²é‰´å®šå‡º325ç§æˆåˆ†ï¼Œä¸»è¦ä¸ºé»„é…®ç±»ã€é…šé…¸ç±»ã€èœç±»ã€æŒ¥å‘æ²¹ç±»ã€ç”¾é†‡ç±»ã€æœ¨è„‚ç´ ç±»ç­‰ã€‚æå–ç‰©å’Œçº¯åŒ–çš„åŒ–åˆç‰©æ˜¾ç¤ºå‡ºä¼ ç»Ÿç›¸å…³çš„æŠ—ç‚ã€æŠ—ç—…æ¯’ã€å…ç–«è°ƒèŠ‚å’ŒæŠ—æ°§åŒ–æ´»æ€§ï¼Œè€Œå…¶ä»–æŠ¥é“çš„ä½œç”¨ï¼ˆä¿è‚ã€é™è¡€è„‚ã€å¿ƒè¡€ç®¡ä¿æŠ¤ã€é•‡é™/æŠ—æƒŠå¥ã€æŠ—ç™Œå’ŒæŠ—å…‰è€åŒ–ï¼‰åˆ™ä½œä¸ºæ¢ç´¢æ€§å‘ç°æå‡ºã€‚è´¨é‡è¯„ä¼°ä» UV å’Œ HPLC å‘å±•åˆ°ä½¿ç”¨ç±»é»„é…®å’Œå€åŠèœä½œä¸ºæ ‡è®°ç‰©çš„ UPLC-MS æŒ‡çº¹åˆ†æã€‚åœ¨å®é™…åº”ç”¨ä¸­ï¼ŒS. plebeiaå·²è¢«ç”¨äºæ²»ç–—å’½ç‚ã€æ”¯æ°”ç®¡ç‚ã€è‚¾ç‚ã€çš®ç‚å’Œè‚›é—¨ç›´è‚ ç‚ç—‡çš„è¯ç‰©åˆ¶å‰‚ã€‚åœ¨é£Ÿå“é¢†åŸŸï¼Œå·²å¼€å‘æˆåŠŸèƒ½æ€§äº§å“ï¼ŒåŒ…æ‹¬ä¿å¥èŒ¶ã€å’€åš¼ç‰‡æˆ–æ³¡è…¾ç‰‡ã€å¤åˆé¥®æ–™ã€å…±å‘é…µé†‹ç­‰ã€‚\n\n**ç»“è®ºï¼š** å°½ç®¡S. plebeiaæ˜¾ç¤ºå‡ºå¹¿æ³›çš„è¯ç†å­¦æ½œåŠ›ï¼Œä½†ç›®å‰çš„ç ”ç©¶ä»ç„¶å—åˆ°åŒ–å­¦ç©ºé—´è¦†ç›–ä¸å®Œæ•´ã€è¯ä»£åŠ¨åŠ›å­¦å’Œæ¯’ç†å­¦ç‰¹å¾æœ‰é™ä»¥åŠç²¾å¿ƒè®¾è®¡çš„ä¸´åºŠè¯æ®ä¸è¶³çš„é™åˆ¶ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¾§é‡äºå…¨é¢çš„æˆåˆ†åˆ†æã€ä¸ä¼ ç»Ÿé€‚åº”ç—‡ä¸€è‡´çš„æœºåˆ¶å¯¼å‘éªŒè¯ã€æ ‡å‡†åŒ–çš„è´¨é‡æ ‡è®°/æŒ‡çº¹ä»¥åŠä¸¥æ ¼çš„PK-æ¯’ç†å­¦-ä¸´åºŠè½¬åŒ–ï¼Œä»¥ä¿ƒè¿›å¹³çº¹è‰åœ¨åŒ»å­¦å’ŒåŠŸèƒ½æ€§é£Ÿå“å¼€å‘ä¸­å®‰å…¨ã€æœ‰æ•ˆå’Œå¾ªè¯çš„åˆ©ç”¨ã€‚", "keywords_zh": "å½“å‰åº”ç”¨ã€æ°‘æ—è¯ç†å­¦ã€è¯ç†æ´»æ€§ã€æ¤ç‰©åŒ–å­¦ã€è´¨é‡æ§åˆ¶ã€Salvia plebeia R.Brã€‚", "keywords_en": "Current applications, Ethnopharmacology, Pharmacological activity, Phytochemistry, Quality control, Salvia plebeia R.Br.", "link": "https://pubmed.ncbi.nlm.nih.gov/41554450/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 19 Jan 2026"}, {"id": "41535511", "title_en": "Long-term outcomes of stapled haemorrhoidopexy versus conventional haemorrhoidectomy: An updated systematic review, meta-analysis and trial-sequential analysis of randomized controlled trials", "title_zh": "å»åˆå™¨ç—”ç–®å›ºå®šæœ¯ä¸ä¼ ç»Ÿç—”ç–®åˆ‡é™¤æœ¯çš„é•¿æœŸç»“æœï¼šéšæœºå¯¹ç…§è¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·ã€èŸèƒåˆ†æå’Œè¯•éªŒåºè´¯åˆ†æ", "authors": "Roberto Cirocchi", "abstract_en": "**Purpose:** Stapled haemorrhoidopexy (SH) offers well-established short-term advantages over conventional haemorrhoidectomy (CH), but its long-term effectiveness remains controversial. This systematic review and meta-analysis aimed to compare long-term outcomes of SH versus CH in adult patients with grade II-IV haemorrhoids, incorporating Trial Sequential Analysis (TSA).\n\n**Methods:** MEDLINE, EMBASE and CENTRAL were searched from January 2001 to October 2025 for randomized controlled trials (RCTs) comparing SH and CH with a minimum follow-up of 12Â months. Two reviewers independently performed study selection, data extraction and risk-of-bias assessment (RoB-2). Primary outcomes included recurrence, reintervention, anal function, and quality of life (QoL). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. TSA was applied to overall recurrence.\n\n**Results:** Seventeen RCTs including 1,041 SH and 1,031 CH patients were analysed. SH was associated with a higher risk of overall recurrence compared with CH (RRâ€‰=â€‰1.56,95%CIâ€‰=â€‰1.00-2.44;I<sup>2</sup>â€‰=â€‰48%). TSA showed that the accrued information size (1,913 patients) did not reach the required information size (2,608 patients), indicating that current evidence remains underpowered. Prolapse-related recurrence was significantly more frequent after SH (RRâ€‰=â€‰3.28,95%CIâ€‰=â€‰1.49-7.25;I<sup>2</sup>â€‰=â€‰12%), whereas bleeding-related recurrence did not differ between groups (RRâ€‰=â€‰1.20,95%CIâ€‰=â€‰0.63-2.26;I<sup>2</sup>â€‰=â€‰23%). No significant differences were found for reintervention, persistent anal pain, functional impairment or QoL.\n\n**Conclusion:** SH is associated with a higher risk of long-term recurrence, particularly prolapse-related recurrence, compared with CH, while long-term pain, functional outcomes and QoL appear broadly comparable. These findings suggest that, although SH may remain an option for selected patients, CH provides more durable anatomical correction, and procedural choice should balance early recovery against long-term durability.", "abstract_zh": "**Purposeï¼š** ä¸ä¼ ç»Ÿç—”ç–®åˆ‡é™¤æœ¯ (CH) ç›¸æ¯”ï¼Œå»åˆå™¨ç—”ç–®å›ºå®šæœ¯ (SH) å…·æœ‰æ˜æ˜¾çš„çŸ­æœŸä¼˜åŠ¿ï¼Œä½†å…¶é•¿æœŸæœ‰æ•ˆæ€§ä»å­˜åœ¨äº‰è®®ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ—¨åœ¨æ¯”è¾ƒ SH ä¸ CH åœ¨ II-IV çº§ç—”ç–®æˆå¹´æ‚£è€…ä¸­çš„é•¿æœŸç»“å±€ï¼Œå¹¶ç»“åˆè¯•éªŒåºè´¯åˆ†æ (TSA)ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† 2001 å¹´ 1 æœˆè‡³ 2025 å¹´ 10 æœˆæœŸé—´ MEDLINEã€EMBASE å’Œ CENTRAL ä¸­æ¯”è¾ƒ SH å’Œ CH çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œéšè®¿æ—¶é—´è‡³å°‘ä¸º 12 ä¸ªæœˆã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¿›è¡Œç ”ç©¶é€‰æ‹©ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ï¼ˆRoB-2ï¼‰ã€‚ä¸»è¦ç»“å±€åŒ…æ‹¬å¤å‘ã€å†æ¬¡å¹²é¢„ã€è‚›é—¨åŠŸèƒ½å’Œç”Ÿæ´»è´¨é‡ (QoL)ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è®¡ç®—å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„åˆå¹¶é£é™©æ¯” (RR)ã€‚ TSA åº”ç”¨äºæ€»ä½“å¤å‘æƒ…å†µã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 17 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ŒåŒ…æ‹¬ 1,041 å SH å’Œ 1,031 å CH æ‚£è€…ã€‚ä¸CHç›¸æ¯”ï¼ŒSHä¸è¾ƒé«˜çš„æ€»ä½“å¤å‘é£é™©ç›¸å…³ï¼ˆRRâ€‰=â€‰1.56ï¼Œ95%CIâ€‰=â€‰1.00-2.44ï¼›I<sup>2</sup>â€‰=â€‰48%ï¼‰ã€‚ TSA æ˜¾ç¤ºï¼Œç´¯ç§¯çš„ä¿¡æ¯é‡ï¼ˆ1,913 åæ‚£è€…ï¼‰æœªè¾¾åˆ°æ‰€éœ€çš„ä¿¡æ¯é‡ï¼ˆ2,608 åæ‚£è€…ï¼‰ï¼Œè¡¨æ˜å½“å‰è¯æ®ä»ç„¶ä¸è¶³ã€‚ SH åè„±å‚ç›¸å…³å¤å‘æ˜¾ç€å¢åŠ  (RRâ€‰=â€‰3.28,95%CIâ€‰=â€‰1.49-7.25;I<sup>2</sup>â€‰=â€‰12%)ï¼Œè€Œå‡ºè¡€ç›¸å…³å¤å‘åœ¨ç»„é—´æ²¡æœ‰å·®å¼‚(RRâ€‰=â€‰1.20,95%CIâ€‰=â€‰0.63-2.26;I<sup>2</sup>â€‰=â€‰23%)ã€‚åœ¨é‡æ–°å¹²é¢„ã€æŒç»­æ€§è‚›é—¨ç–¼ç—›ã€åŠŸèƒ½éšœç¢æˆ–ç”Ÿæ´»è´¨é‡æ–¹é¢æ²¡æœ‰å‘ç°æ˜¾ç€å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** ä¸ CH ç›¸æ¯”ï¼ŒSH ä¸è¾ƒé«˜çš„é•¿æœŸå¤å‘é£é™©ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯ä¸è„±å‚ç›¸å…³çš„å¤å‘ï¼Œè€Œé•¿æœŸç–¼ç—›ã€åŠŸèƒ½ç»“æœå’Œç”Ÿæ´»è´¨é‡ä¼¼ä¹å¤§è‡´ç›¸å½“ã€‚è¿™äº›ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œå°½ç®¡ SH å¯èƒ½ä»ç„¶æ˜¯é€‰å®šæ‚£è€…çš„ä¸€ç§é€‰æ‹©ï¼Œä½† CH æä¾›äº†æ›´æŒä¹…çš„è§£å‰–çŸ«æ­£ï¼Œå¹¶ä¸”æ‰‹æœ¯é€‰æ‹©åº”å¹³è¡¡æ—©æœŸæ¢å¤ä¸é•¿æœŸè€ä¹…æ€§ã€‚", "keywords_zh": "åœ†å½¢å»åˆå™¨ã€å¼—æ ¼æ£®ã€ç—”åˆ‡é™¤æœ¯ã€ç—”ç–®ã€è°æ³¢æ‰‹æœ¯åˆ€ã€LigaSureã€Milligan-Morganã€PPHã€å»åˆå™¨ç—”ç–®å›ºå®šæœ¯", "keywords_en": "Circular stapler, Ferguson, Haemorrhoidectomy, Haemorrhoids, Harmonic scalpel, LigaSure, Milligan-Morgan, PPH, Stapled haemorrhoidopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/41535511/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 14 Jan 2026"}, {"id": "41503542", "title_en": "Arterial Embolization for the Internal Hemorrhoids Management: A Systematic Review", "title_zh": "åŠ¨è„‰æ “å¡æ²»ç–—å†…ç—”ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Hadi Rokni Yazdi", "abstract_en": "**Background And Aims:** Hemorrhoids are common vascular structures that can become symptomatic when prolapsed, representing the most prevalent benign anorectal condition worldwide. Despite affecting up to 11% of the population with symptoms including pain, bleeding, and discomfort, hemorrhoids remain underdiagnosed and often inappropriately managed. This systematic review aimed to evaluate the efficacy, clinical outcomes, and morbidity of endovascular artery embolization in hemorrhoids.\n\n**Method:** Up to August 2022, PubMed, Scopus, Web of Science, and Embase were searched comprehensively. All studies had eligible criteria included, except review articles, articles published in a language other than English, and case reports or series of cases. Two independent reviewers performed a literature review and data extraction. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 checklist was used for quality assessment.\n\n**Results:** The systematic review included 15 studies. The patient's age ranged from 40.5â€‰Â±â€‰9.51 to 72.2â€‰Â±â€‰10.9. Eleven studies mentioned the sample size as gender-specific, with 57.89% (<i>n</i>â€‰=â€‰187/323) male patients. The embolic site involved in embolization, according to the frequency, was 424 patients for the superior rectal artery in all studies, and coils and micro coils were utilized as Embolic material in most cases. No major complication or death was noted in 12 studies. The most frequent complications were postoperative pain and tenesmus, bleeding, ulceration and fibrotic scars, and low-grade fever. In 11.79% (<i>n</i>â€‰=â€‰27/229) of patients re-embolization and after-treatment surgery were due to surgical failure and symptom recurrence, such as bleeding.\n\n**Conclusion:** Rectal artery embolization using microcoils, embolic particles, or a combination is a new method for managing internal hemorrhoids with proper clinical efficacy without significant complications. QoL score has improved after emborrhoid, and most cases had a lower bleeding score.", "abstract_zh": "**Background and aimsï¼š** ç—”ç–®æ˜¯å¸¸è§çš„è¡€ç®¡ç»“æ„ï¼Œè„±å‚æ—¶ä¼šå‡ºç°ç—‡çŠ¶ï¼Œæ˜¯å…¨ä¸–ç•Œæœ€å¸¸è§çš„è‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…ã€‚å°½ç®¡æœ‰å¤šè¾¾ 11% çš„äººå£å‡ºç°ç–¼ç—›ã€å‡ºè¡€å’Œä¸é€‚ç­‰ç—‡çŠ¶ï¼Œä½†ç—”ç–®çš„è¯Šæ–­ç‡ä»ç„¶è¾ƒä½ï¼Œè€Œä¸”å¾€å¾€æ²»ç–—ä¸å½“ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼°è¡€ç®¡å†…åŠ¨è„‰æ “å¡æ²»ç–—ç—”ç–®çš„ç–—æ•ˆã€ä¸´åºŠç»“æœå’Œå‘ç—…ç‡ã€‚\n\n**Methodï¼š** æˆªè‡³2022å¹´8æœˆï¼ŒPubMedã€Scopusã€Web of Scienceã€Embaseå‡è¢«å…¨é¢æ£€ç´¢ã€‚æ‰€æœ‰ç ”ç©¶å‡åŒ…å«åˆæ ¼æ ‡å‡†ï¼Œä½†è¯„è®ºæ–‡ç« ã€ä»¥è‹±è¯­ä»¥å¤–çš„è¯­è¨€å‘è¡¨çš„æ–‡ç« ä»¥åŠç—…ä¾‹æŠ¥å‘Šæˆ–ç³»åˆ—ç—…ä¾‹é™¤å¤–ã€‚ä¸¤åç‹¬ç«‹è¯„å®¡å‘˜è¿›è¡Œäº†æ–‡çŒ®è¯„å®¡å’Œæ•°æ®æå–ã€‚ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) 2020 æ£€æŸ¥è¡¨ç”¨äºè´¨é‡è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·åŒ…æ‹¬ 15 é¡¹ç ”ç©¶ã€‚æ‚£è€…å¹´é¾„ä¸º40.5Â±9.51å²è‡³72.2Â±10.9å²ã€‚ 11 é¡¹ç ”ç©¶æåˆ°æ ·æœ¬é‡å…·æœ‰æ€§åˆ«ç‰¹å¼‚æ€§ï¼Œå…¶ä¸­ 57.89% (<i>n</i>â€‰=â€‰187/323) ä¸ºç”·æ€§æ‚£è€…ã€‚æ‰€æœ‰ç ”ç©¶ä¸­æ¶‰åŠæ “å¡çš„éƒ¨ä½ä¸ºç›´è‚ ä¸ŠåŠ¨è„‰424ä¾‹ï¼Œæ “å¡éƒ¨ä½å¤šé‡‡ç”¨å¼¹ç°§åœˆå’Œå¾®å¼¹ç°§åœˆä½œä¸ºæ “å¡ææ–™ã€‚ 12 é¡¹ç ”ç©¶ä¸­æœªå‘ç°é‡å¤§å¹¶å‘ç—‡æˆ–æ­»äº¡ã€‚æœ€å¸¸è§çš„å¹¶å‘ç—‡æ˜¯æœ¯åç–¼ç—›å’Œé‡Œæ€¥åé‡ã€å‡ºè¡€ã€æºƒç–¡å’Œçº¤ç»´åŒ–ç–¤ç—•ä»¥åŠä½çƒ§ã€‚ 11.79%ï¼ˆ<i>n</i>â€‰=â€‰27/229ï¼‰çš„æ‚£è€…å†æ¬¡æ “å¡å’Œæ²»ç–—åæ‰‹æœ¯æ˜¯ç”±äºæ‰‹æœ¯å¤±è´¥å’Œå‡ºè¡€ç­‰ç—‡çŠ¶å¤å‘ã€‚\n\n**ç»“è®ºï¼š** ä½¿ç”¨å¾®å¼¹ç°§åœˆã€æ “å¡é¢—ç²’æˆ–å…¶ç»„åˆè¿›è¡Œç›´è‚ åŠ¨è„‰æ “å¡æ˜¯ä¸€ç§æ²»ç–—å†…ç—”çš„æ–°æ–¹æ³•ï¼Œå…·æœ‰è‰¯å¥½çš„ä¸´åºŠç–—æ•ˆï¼Œä¸”æ— æ˜æ˜¾å¹¶å‘ç—‡ã€‚ç—”ç–®æœ¯åç”Ÿæ´»è´¨é‡è¯„åˆ†æœ‰æ‰€æ”¹å–„ï¼Œå¤§å¤šæ•°ç—…ä¾‹çš„å‡ºè¡€è¯„åˆ†è¾ƒä½ã€‚", "keywords_zh": "æ “å¡, ç—”ç–®, ç—”ç–®, ç—”åŠ¨è„‰, ç›´è‚ åŠ¨è„‰", "keywords_en": "embolization, emborrhoid, hemorrhoid, hemorrhoidal artery, rectal artery", "link": "https://pubmed.ncbi.nlm.nih.gov/41503542/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 08 Jan 2026"}, {"id": "41450176", "title_en": "Worldwide prevalence of haemorrhoids: a systematic review and meta-analysis", "title_zh": "å…¨çƒç—”ç–®æ‚£ç—…ç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Pouyan Ebrahimi", "abstract_en": "**Background:** Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis.\n\n**Methods:** We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600).\n\n**Results:** From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension.\n\n**Conclusion:** HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®ç–¾ç—…ï¼ˆHDï¼‰æ˜¯å…¨çƒæœ€å¸¸è§çš„è‚›é—¨ç›´è‚ ç–¾ç—…ä¹‹ä¸€ï¼Œæ˜¾ç€å½±å“ä¸ªäººçš„ç”Ÿæ´»è´¨é‡å’Œç”Ÿäº§åŠ›ã€‚å°½ç®¡å…¶é‡è¦æ€§ï¼Œä½†ç”±äºé’ˆå¯¹ç‰¹å®šäººç¾¤çš„ç ”ç©¶æœ‰é™ï¼Œå…¨çƒæ‚£ç—…ç‡ä»ä¸æ¸…æ¥šã€‚æœ¬ç ”ç©¶æ—¨åœ¨é€šè¿‡ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¥ç³»ç»Ÿè¯„ä¼° HD çš„å…¨çƒæ‚£ç—…ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬é€šè¿‡æ£€ç´¢æˆªè‡³ 2025 å¹´ 3 æœˆ 31 æ—¥çš„ PubMedã€Scopusã€Embaseã€Web of Science å’Œ Google Scholarï¼Œè¿›è¡Œäº†ç³»ç»Ÿç»¼è¿°å’ŒèŸèƒåˆ†æï¼Œæ²¡æœ‰è¯­è¨€é™åˆ¶ã€‚æŠ¥å‘ŠåŒ…æ‹¬ä¸€èˆ¬äººç¾¤ã€ä¸´åºŠäººç¾¤æˆ–é«˜å±äººç¾¤ä¸­ç—”ç–®æ‚£ç—…ç‡çš„ç ”ç©¶ã€‚æ’é™¤æ ‡å‡†åŒ…æ‹¬ç¼ºä¹æ€»æ ·æœ¬é‡ã€å…³æ³¨å…¶ä»–è‚›é—¨ç›´è‚ ç–¾ç—…æˆ–ä½¿ç”¨é‡å¤æˆ–ä¸è¶³æ•°æ®çš„ç ”ç©¶ã€‚å››ä½ç‹¬ç«‹è¯„å®¡å‘˜ä½¿ç”¨ä¹”å®‰å¨œå¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€å·¥å…·æå–å¹¶è¯„ä¼°ç ”ç©¶è´¨é‡ã€‚ä¸»è¦ç»“æœæ˜¯ HD çš„æ±‡æ€»ç‚¹æ‚£ç—…ç‡ï¼Œä½¿ç”¨å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„éšæœºæ•ˆåº”æ¨¡å‹è¿›è¡Œåˆ†æã€‚è¯¥ç ”ç©¶å·²åœ¨ PROSPERO ä¸­æ³¨å†Œï¼ˆCRD420251045600ï¼‰ã€‚\n\n**ç»“æœï¼š** ä» 6,312 æ¡è®°å½•ä¸­ï¼Œçº³å…¥äº† 150 é¡¹ç ”ç©¶ï¼ˆ210 ä¸ªæ•°æ®é›†ï¼‰ï¼Œæ¶‰åŠ 8,960,338 åä¸ªä½“ã€‚å…¨çƒæ±‡æ€»ç‚¹æ‚£ç—…ç‡ä¸º 25.92%ï¼ˆ95% CIï¼š22.62-29.22ï¼‰ã€‚ç»ˆç”Ÿæ‚£ç—…ç‡ä¸º 27.19%ï¼ˆ95% CIï¼š14.77-39.60ï¼‰ï¼Œä¸€å¹´æ‚£ç—…ç‡ä¸º 21.65%ï¼ˆ95% CIï¼š14.33-28.97ï¼‰ã€‚å¥³æ€§æ‚£ç—…ç‡ï¼ˆ27.33%ï¼Œ95% CIï¼š21.84-32.82ï¼‰é«˜äºç”·æ€§ï¼Œéæ´²åœ°åŒºæ‚£ç—…ç‡æœ€é«˜ï¼Œä¸º 28.07%ï¼ˆ95% CIï¼š15.34-40.79ï¼‰ã€‚ä¾µå…¥æ€§è¯Šæ–­æ–¹æ³•ï¼ˆ28.05%ï¼Œ95% CIï¼š23.86-32.26ï¼‰æ¯”éä¾µå…¥æ€§æ–¹æ³•äº§ç”Ÿæ›´é«˜çš„æ‚£ç—…ç‡ä¼°è®¡å€¼ã€‚æ­¤å¤–ï¼Œæœªç»è°ƒæ•´çš„åˆ†ææ˜¾ç¤ºä¸ HD ç›¸å…³çš„å› ç´ åŒ…æ‹¬å¹´é¾„è¾ƒå¤§ã€è‚¥èƒ–ã€æ€€å­•ã€ç³–å°¿ç—…ã€å®¶æ—å²ã€ä¾¿ç§˜å’Œé«˜è¡€å‹ã€‚\n\n**ç»“è®ºï¼š** HD åœ¨å…¨çƒèŒƒå›´å†…ä»ç„¶æ˜¯ä¸€ç§æµè¡Œç—…ï¼Œå„åœ°åŒºä¹‹é—´å·®å¼‚è¾ƒå°ã€‚æ— è®ºç¤¾ä¼šç»æµèƒŒæ™¯å¦‚ä½•ï¼Œè´Ÿæ‹…éƒ½æ˜¯ä¸€è‡´çš„ã€‚è¯Šæ–­æ–¹æ³•å’Œäººç¾¤ç‰¹å¾å½±å“æ‚£ç—…ç‡ä¼°è®¡ã€‚è¿™äº›å‘ç°å¼ºè°ƒäº†æœ‰é’ˆå¯¹æ€§çš„é¢„é˜²å’Œæ—©æœŸå¹²é¢„ç­–ç•¥çš„é‡è¦æ€§ï¼Œç‰¹åˆ«æ˜¯å¯¹äºé«˜å±äººç¾¤ã€‚", "keywords_zh": "ç—”ç–®ã€æµè¡Œç—…å­¦ã€ç—”ç–®ã€èŸèƒåˆ†æã€æ‚£ç—…ç‡", "keywords_en": "Haemorrhoids, epidemiology, haemorrhoid, meta-analysis, prevalence", "link": "https://pubmed.ncbi.nlm.nih.gov/41450176/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 26 Dec 2025"}, {"id": "41444098", "title_en": "Clinical factors affecting the therapeutic dose window in cervical cancer brachytherapy: A systematic review and meta-regression", "title_zh": "å½±å“å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—æ²»ç–—å‰‚é‡çª—çš„ä¸´åºŠå› ç´ ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒå›å½’", "authors": "Nick J van de Berg", "abstract_en": "**Background And Purpose:** Although dose planning aims in cervical cancer brachytherapy are well-defined, variability in clinical practices makes it difficult to draw generalizable conclusions on achievable dosimetry. This review and meta-regression aim to assess clinical practices in terms of their therapeutic dose window, that is, the balance between target and organs-at-risk (OAR) doses.\n\n**Materials And Methods:** A search of the literature was performed in Scopus, PubMed, and Web of Science databases. Peer-reviewed articles were included that described planning constraints and reported high-risk clinical target volume (CTV<sub>HR</sub>) D<sub>90%</sub> and OAR [Formula: see text] for intracavitary (IC) tandem and ring (T&R) / tandem and ovoid (T&O) / mold (M) applicators, possibly supplemented with interstitial (IS) needles (+N). To determine factors associated with target volume coverage (D<sub>90%</sub>) and OAR sparing ( [Formula: see text] ), multivariate meta-regressions were performed.\n\n**Results:** Out of 1590 articles, 34 met the full inclusion criteria. In most studies, the CTV<sub>HR</sub>D<sub>90%</sub> aimed at â‰¥84-86 Gy EQD2<sub>Î±/Î²â€¯=â€¯10Gy</sub>, and constraints for the OARs were 80-90 Gy, 65-75 Gy and 70-75 Gy EQD2<sub>Î±/Î²â€¯=â€¯3Gy</sub> for the bladder, rectum and sigmoid [Formula: see text] , respectively. Studies using IC/IS applicators were associated with a âˆ¼4 Gy increase in CTV<sub>HR</sub>D<sub>90%</sub> compared to IC only, with no effect on OAR dose. T&R studies achieved improvements of 3.2 Gy and 2.8-3.4 Gy at typical planning aims in comparison with T&O applicators in target and OAR doses. In 100% (15/15) of patient groups treated with T&Râ€¯+â€¯N both CTV<sub>HR</sub> and OAR objectives were met for the population average. For T&R, T&O, and T&Oâ€¯+â€¯N groups, this was the case in 89% (8/9), 43% (6/14), and 50% (4/8), respectively.\n\n**Conclusion:** Studies using interstitial needles with T&R applicators in MR-guided brachytherapy for cervical cancer seem to be associated with a favorable therapeutic target dose/OAR sparing ratio.", "abstract_zh": "**èƒŒæ™¯ä¸ç›®çš„ï¼š** å°½ç®¡å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—çš„å‰‚é‡è®¡åˆ’ç›®æ ‡æ˜¯æ˜ç¡®å®šä¹‰çš„ï¼Œä½†ä¸´åºŠå®è·µçš„å¯å˜æ€§ä½¿å¾—å¾ˆéš¾å°±å¯å®ç°çš„å‰‚é‡æµ‹å®šå¾—å‡ºæ™®éçš„ç»“è®ºã€‚æœ¬ç»¼è¿°å’ŒèŸèƒå›å½’æ—¨åœ¨è¯„ä¼°ä¸´åºŠå®è·µçš„æ²»ç–—å‰‚é‡çª—å£ï¼Œå³ç›®æ ‡å‰‚é‡å’Œå±åŠå™¨å®˜ï¼ˆOARï¼‰å‰‚é‡ä¹‹é—´çš„å¹³è¡¡ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** åœ¨ Scopusã€PubMed å’Œ Web of Science æ•°æ®åº“ä¸­è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚å…¶ä¸­åŒ…æ‹¬åŒè¡Œè¯„å®¡çš„æ–‡ç« ï¼Œæè¿°äº†è®¡åˆ’é™åˆ¶å¹¶æŠ¥å‘Šäº†è…”å†… (IC) ä¸²è”å’Œç¯å½¢ (T&R) / ä¸²è”å’Œåµå½¢ (T&O) / æ¨¡å…· (M) æ–½è¯å™¨çš„é«˜é£é™©ä¸´åºŠé¶åŒº (CTV<sub>HR</sub>) D<sub>90%</sub> å’Œ OAR [å…¬å¼ï¼šå‚è§æ–‡æœ¬]ï¼Œå¯èƒ½è¾…ä»¥é—´è´¨ (IS) é’ˆ (+N)ã€‚ä¸ºäº†ç¡®å®šä¸ç›®æ ‡ä½“ç§¯è¦†ç›– (D<sub>90%</sub>) å’Œ OAR ä¿ç•™ï¼ˆ[å…¬å¼ï¼šè§æ–‡æœ¬]ï¼‰ç›¸å…³çš„å› ç´ ï¼Œè¿›è¡Œäº†å¤šå˜é‡å…ƒå›å½’ã€‚\n\n**ç»“æœï¼š** åœ¨ 1590 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 34 ç¯‡ç¬¦åˆå®Œå…¨çº³å…¥æ ‡å‡†ã€‚åœ¨å¤§å¤šæ•°ç ”ç©¶ä¸­ï¼ŒCTV<sub>HR</sub>D<sub>90%</sub>çš„ç›®æ ‡æ˜¯â‰¥84-86 Gy EQD2<sub>Î±/Î²=10Gy</sub>ï¼ŒOARçš„é™åˆ¶ä¸ºè†€èƒ±ã€ç›´è‚ å’Œä¹™çŠ¶ç»“è‚ 80-90 Gyã€65-75 Gyå’Œ70-75 Gy EQD2<sub>Î±/Î²=3Gy</sub> [å¼ï¼šè§æ­£æ–‡] åˆ†åˆ«ã€‚ä¸ä»…ä½¿ç”¨ IC ç›¸æ¯”ï¼Œä½¿ç”¨ IC/IS æ–½è¯å™¨çš„ç ”ç©¶å‘ç° CTV<sub>HR</sub>D<sub>90%</sub> å¢åŠ çº¦ 4 Gyï¼Œä½†å¯¹ OAR å‰‚é‡æ²¡æœ‰å½±å“ã€‚ä¸ T&O æ–½æ”¾å™¨çš„ç›®æ ‡å‰‚é‡å’Œ OAR å‰‚é‡ç›¸æ¯”ï¼ŒT&R ç ”ç©¶åœ¨å…¸å‹è®¡åˆ’ç›®æ ‡ä¸‹å®ç°äº† 3.2 Gy å’Œ 2.8-3.4 Gy çš„æ”¹è¿›ã€‚åœ¨ 100% (15/15) æ¥å— T&R+N æ²»ç–—çš„æ‚£è€…ç»„ä¸­ï¼ŒCTV<sub>HR</sub> å’Œ OAR ç›®æ ‡å‡è¾¾åˆ°æ€»ä½“å¹³å‡æ°´å¹³ã€‚å¯¹äº T&Rã€T&O å’Œ T&O+N ç»„ï¼Œè¿™ç§æƒ…å†µçš„æ¯”ä¾‹åˆ†åˆ«ä¸º 89% (8/9)ã€43% (6/14) å’Œ 50% (4/8)ã€‚\n\n**ç»“è®ºï¼š** åœ¨ MR å¼•å¯¼çš„å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—ä¸­ä½¿ç”¨é—´è´¨é’ˆå’Œ T&R æ–½æºå™¨çš„ç ”ç©¶ä¼¼ä¹ä¸æœ‰åˆ©çš„æ²»ç–—ç›®æ ‡å‰‚é‡/OAR ä¿ç•™æ¯”ç›¸å…³ã€‚", "keywords_zh": "æ–½æºå™¨ä½¿ç”¨ã€å›¾åƒå¼•å¯¼é€‚åº”æ€§è¿‘è·ç¦»æ”¾å°„æ²»ç–—ã€å±€éƒ¨æ™šæœŸå®«é¢ˆç™Œã€æ²»ç–—å‰‚é‡çª—", "keywords_en": "Applicator use, Image-guided adaptive brachytherapy, Locally advanced cervical cancer, Therapeutic dose window", "link": "https://pubmed.ncbi.nlm.nih.gov/41444098/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 24 Dec 2025"}, {"id": "41413743", "title_en": "Altered molecular signature of the intestinal microbiota in irritable bowel syndrome patients versus healthy controls: An updated systematic review", "title_zh": "è‚ æ˜“æ¿€ç»¼åˆå¾æ‚£è€…ä¸å¥åº·å¯¹ç…§è€…è‚ é“å¾®ç”Ÿç‰©ç¾¤åˆ†å­ç‰¹å¾çš„æ”¹å˜ï¼šæ›´æ–°çš„ç³»ç»Ÿè¯„ä»·", "authors": "Hui Zheng", "abstract_en": "**Background And Aims:** Irritable bowel syndrome (IBS), a prevalent functional gastrointestinal disorder, poses significant challenges for both patients and medical practitioners. Recent investigations have indicated the gut microbiome as a potential therapeutic target for IBS. Nevertheless, the exact association between these microorganisms and IBS symptoms remains incompletely elucidated. This updated systematic analysis aims to assess the extant research correlating the gut microbial community with IBS.\n\n**Methods:** A systematic search was performed in major electronic databases including PubMed, EMBASE and Web of Science, spanning from their inception to December 2024. The objective was to identify case-control studies that examined and compared the composition of the fecal or colonic microbiota in individuals diagnosed with IBS against healthy controls.\n\n**Results:** Our systematic search included 44 articles, which collectively revealed that IBS patients exhibit lower intestinal microbiome diversity compared to healthy controls. Fecal microbiome analysis demonstrated an imbalance in the phyla Firmicutes and Bacteroidetes among IBS patients. Specifically, IBS with diarrhea (IBS-D) patients showed reduced levels of Butyricimonas and Proteobacteria, while IBS with constipation (IBS-C) patients exhibited decreased Firmicutes and Actinobacteria, along with increased Verrucomicrobiota and Proteobacteria. Additionally, disruptions in the gut microbiome were noted, particularly in the duodenum and jejunum, as well as changes in key bacterial populations within the colon and rectum.\n\n**Conclusion:** Our review confirms significant gut microbiota dysbiosis in IBS patients, characterized by reduced microbial diversity and altered abundances of Firmicutes and Bacteroidetes. These findings support the potential for microbiota-targeted therapies in IBS management, though further research is needed to establish causal mechanisms and clinical applications.", "abstract_zh": "**Background and aimsï¼š** è‚ æ˜“æ¿€ç»¼åˆç—‡ï¼ˆIBSï¼‰æ˜¯ä¸€ç§å¸¸è§çš„åŠŸèƒ½æ€§èƒƒè‚ é“ç–¾ç—…ï¼Œç»™æ‚£è€…å’ŒåŒ»ç”Ÿå¸¦æ¥äº†å·¨å¤§çš„æŒ‘æˆ˜ã€‚æœ€è¿‘çš„ç ”ç©¶è¡¨æ˜è‚ é“å¾®ç”Ÿç‰©ç»„æ˜¯ IBS çš„æ½œåœ¨æ²»ç–—é¶ç‚¹ã€‚ç„¶è€Œï¼Œè¿™äº›å¾®ç”Ÿç‰©ä¸ IBS ç—‡çŠ¶ä¹‹é—´çš„ç¡®åˆ‡å…³è”ä»æœªå®Œå…¨é˜æ˜ã€‚è¿™é¡¹æ›´æ–°çš„ç³»ç»Ÿåˆ†ææ—¨åœ¨è¯„ä¼°ç°æœ‰çš„è‚ é“å¾®ç”Ÿç‰©ç¾¤è½ä¸è‚ æ˜“æ¿€ç»¼åˆç—‡ç›¸å…³çš„ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬åœ¨åŒ…æ‹¬ PubMedã€EMBASE å’Œ Web of Science åœ¨å†…çš„ä¸»è¦ç”µå­æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œæ£€ç´¢æ—¶é—´ä»æ•°æ®åº“æˆç«‹åˆ° 2024 å¹´ 12 æœˆã€‚ç›®çš„æ˜¯ç¡®å®šç—…ä¾‹å¯¹ç…§ç ”ç©¶ï¼Œè¿™äº›ç ”ç©¶æ£€æŸ¥å¹¶æ¯”è¾ƒäº†è¯Šæ–­ä¸º IBS çš„ä¸ªä½“ä¸å¥åº·å¯¹ç…§è€…çš„ç²ªä¾¿æˆ–ç»“è‚ å¾®ç”Ÿç‰©ç¾¤çš„ç»„æˆã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬çš„ç³»ç»Ÿæœç´¢åŒ…æ‹¬ 44 ç¯‡æ–‡ç« ï¼Œè¿™äº›æ–‡ç« å…±åŒæ­ç¤ºäº†ä¸å¥åº·å¯¹ç…§ç›¸æ¯”ï¼ŒIBS æ‚£è€…çš„è‚ é“å¾®ç”Ÿç‰©ç»„å¤šæ ·æ€§è¾ƒä½ã€‚ç²ªä¾¿å¾®ç”Ÿç‰©ç»„åˆ†æè¡¨æ˜ IBS æ‚£è€…çš„åšå£èŒé—¨å’Œæ‹Ÿæ†èŒé—¨ä¸å¹³è¡¡ã€‚å…·ä½“è€Œè¨€ï¼Œè…¹æ³»å‹IBSï¼ˆIBS-Dï¼‰æ‚£è€…çš„ä¸é…¸å•èƒèŒå’Œå˜å½¢èŒæ°´å¹³é™ä½ï¼Œè€Œä¾¿ç§˜å‹IBSï¼ˆIBS-Cï¼‰æ‚£è€…çš„åšå£èŒé—¨å’Œæ”¾çº¿èŒå‡å°‘ï¼Œç–£å¾®ç”Ÿç‰©ç¾¤å’Œå˜å½¢èŒå¢åŠ ã€‚æ­¤å¤–ï¼Œè¿˜æ³¨æ„åˆ°è‚ é“å¾®ç”Ÿç‰©ç»„çš„ç ´åï¼Œç‰¹åˆ«æ˜¯åœ¨åäºŒæŒ‡è‚ å’Œç©ºè‚ ä¸­ï¼Œä»¥åŠç»“è‚ å’Œç›´è‚ å†…å…³é”®ç»†èŒç§ç¾¤çš„å˜åŒ–ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°è¯å®äº† IBS æ‚£è€…å­˜åœ¨æ˜¾ç€çš„è‚ é“å¾®ç”Ÿç‰©ç¾¤å¤±è°ƒï¼Œå…¶ç‰¹å¾æ˜¯å¾®ç”Ÿç‰©å¤šæ ·æ€§å‡å°‘ä»¥åŠåšå£èŒé—¨å’Œæ‹Ÿæ†èŒé—¨çš„ä¸°åº¦æ”¹å˜ã€‚è¿™äº›å‘ç°æ”¯æŒäº†å¾®ç”Ÿç‰©ç¾¤é¶å‘æ²»ç–—åœ¨ IBS æ²»ç–—ä¸­çš„æ½œåŠ›ï¼Œå°½ç®¡è¿˜éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶æ¥ç¡®å®šå› æœæœºåˆ¶å’Œä¸´åºŠåº”ç”¨ã€‚", "keywords_zh": "IBS è‚ æ˜“æ¿€ç»¼åˆå¾ã€IBS-CÂ IBS ä¾¿ç§˜ã€IBS-DÂ IBS è…¹æ³»ã€èŒç¾¤å¤±è°ƒã€è‚ é“å¾®ç”Ÿç‰©ç¾¤ã€è‚ æ˜“æ¿€ç»¼åˆå¾ã€å¾®ç”Ÿç‰©ç»„ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "IBS irritable bowel syndrome, IBS-CÂ IBS with constipation, IBS-DÂ IBS with diarrhea, Dysbiosis, Gut microbiota, Irritable bowel syndrome, Microbiome, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/41413743/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 18 Dec 2025"}, {"id": "41399305", "title_en": "Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis", "title_zh": "å›¾åƒå¼•å¯¼ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€ä¸ç»ç›´è‚ å‰åˆ—è…ºæ´»æ£€å¯¹æœ‰ä¸´åºŠæ„ä¹‰çš„å‰åˆ—è…ºç™Œçš„è¯Šæ–­å‡†ç¡®æ€§å’Œå®‰å…¨æ€§ï¼šGRADE è¯„ä¼°çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Muhammad Salih", "abstract_en": "**Introduction:** This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies.\n\n**Methods:** Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence.\n\n**Results:** Twenty-nine studies (<i>n</i>â€‰=â€‰90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; <i>p</i>â€‰=â€‰0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; <i>p</i>â€‰=â€‰0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher.\n\n**Conclusion:** TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary.\n\n**Protocol Registration:** https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.", "abstract_zh": "**ä»‹ç»ï¼š** è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¯”è¾ƒäº†å‰åˆ—è…ºç™Œç»ä¼šé˜´æ´»æ£€ (TPBx) ä¸ç»ç›´è‚ æ´»æ£€ (TRBx) çš„è¯Šæ–­æ€§èƒ½å’Œå¹¶å‘ç—‡æƒ…å†µï¼Œçº³å…¥äº†æœ€è¿‘çš„éšæœºå’Œå¤§å‹è§‚å¯Ÿæ€§ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA 2020 æŒ‡å—ï¼Œæ£€ç´¢äº† PubMedã€Scopusã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œç›´è‡³ 2025 å¹´ 4 æœˆã€‚å…¶ä¸­åŒ…æ‹¬ç›´æ¥æ¯”è¾ƒ TPBx å’Œ TRBx çš„ç ”ç©¶ã€‚ä½¿ç”¨ RoB 2.0 è¿›è¡Œéšæœºè¯•éªŒè¯„ä¼°åå€šé£é™©ï¼Œä½¿ç”¨çº½å¡æ–¯å°” - æ¸¥å¤ªåé‡è¡¨è¿›è¡Œè§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è®¡ç®—å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„æ±‡æ€»ç›¸å¯¹é£é™© (RR)ã€‚è¿›è¡Œäºšç»„åˆ†æå’Œ GRADE è¯„ä¼°ä»¥è¯„ä¼°è¯æ®çš„ç¡®å®šæ€§ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 29 é¡¹ç ”ç©¶ (<i>n</i>â€‰=â€‰90,621)ã€‚ TPBx æ˜¾ç¤ºå‡ºè¾ƒé«˜çš„ PCa æ£€å‡ºç‡ï¼ˆRR 1.08ï¼›95% CI 1.01-1.15ï¼›<i>p</i>â€‰=â€‰0.02ï¼‰å’Œ csPCa æ£€å‡ºç‡ï¼ˆRR 1.14ï¼›95% CI 1.05-1.24ï¼›<i>p</i>â€‰=â€‰0.001ï¼‰ï¼Œä½†è¯æ®è´¨é‡ä¸ºä½è‡³ä¸­ç­‰ã€‚å¼‚è´¨æ€§ä¸ºä¸­åº¦è‡³é«˜åº¦ã€‚ TPBx è¿˜è¡¨ç°å‡ºè¾ƒä½çš„æ„ŸæŸ“ç›¸å…³å¹¶å‘ç—‡å’Œå¯æ¯”è¾ƒçš„æ€»ä½“äº‹ä»¶ï¼Œå°½ç®¡æ‰‹æœ¯ç›¸å…³çš„ç–¼ç—›ç•¥é«˜ã€‚\n\n**ç»“è®ºï¼š** ä¸ TRBx ç›¸æ¯”ï¼ŒTPBx å…·æœ‰æ›´é«˜çš„è¯Šæ–­ç‡å’Œæ›´ä½çš„æ„ŸæŸ“é£é™©ï¼Œä¸”å®‰å…¨æ€§ç›¸å½“ã€‚ç„¶è€Œï¼Œé‰´äºä¸­ç­‰å¼‚è´¨æ€§å’Œæœ‰é™çš„é«˜è´¨é‡éšæœºå¯¹ç…§è¯•éªŒï¼Œè¿›ä¸€æ­¥çš„éªŒè¯æ€§è¯•éªŒæ˜¯å¿…è¦çš„ã€‚\n\n**Protocol registrationï¼š** https://www.crd.york.ac.uk/PROSPERO æ ‡è¯†ç¬¦ä¸º CRD420251035763ã€‚", "keywords_zh": "å‰åˆ—è…ºæ´»æ£€ã€æœ‰ä¸´åºŠæ„ä¹‰çš„å‰åˆ—è…ºç™Œã€å‰åˆ—è…ºç™Œã€ç»ä¼šé˜´ã€ç»ç›´è‚ ", "keywords_en": "Prostate biopsy, clinically significant prostate cancer, prostate cancer, transperineal, transrectal", "link": "https://pubmed.ncbi.nlm.nih.gov/41399305/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 16 Dec 2025"}, {"id": "41385931", "title_en": "Transperineal versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "title_zh": "ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€ä¸ç»ç›´è‚ å‰åˆ—è…ºæ´»æ£€ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Leopoldo Alves Ribeiro-Filho", "abstract_en": "To compare the safety and diagnostic performance of transperineal (TP) versus transrectal (TR) ultrasound-guided prostate biopsies using only data from randomized controlled trials (RCTs). A systematic search was performed in multiple databases up to May 2025. We included only RCTs comparing TP and TR approaches in men undergoing MRI-targeted prostate biopsies. Meta-analysis was conducted using odds ratios (OR) and 95% confidence intervals (CI) for categorical outcomes. The primary endpoints were cancer detection rate and postbiopsy infection rate. Secondary outcomes included urinary retention, bleeding, pain, and complications stratified by the Clavien-Dindo system. Study quality and certainty of evidence were assessed using the Cochrane ROB2 and GRADE tools. Four RCTs encompassing 2682 patients (TP: 1323; TR: 1359) were included. No significant differences were observed in overall prostate cancer detection rates (OR 1.03, 95% CI, 0.79-1.36) or detection of anterior lesions (OR 1.01, 95% CI, 0.41-2.45). Similarly, no differences were found in bleeding (OR 1.14, 95% CI, 0.66-1.95), urinary retention (OR 1.01, 95% CI, 0.50-2.04), total infections (OR 1.02, 95% CI, 0.77-1.35), or severe infections (OR 2.17, 95% CI, 0.97-4.88). Mild pain was more frequent in the TP group (OR 1.56, 95% CI, 1.20-2.03), while moderate to severe pain did not differ significantly (OR 0.65, 95% CI, 0.39-1.07). Transperineal and transrectal MRI-fusion-guided biopsy approaches demonstrated equivalent diagnostic accuracy and safety profiles. While the transperineal route was associated with slightly greater mild discomfort, cancer detection and complication rates were comparable. The selection of approach should be guided by principles of antimicrobial stewardship, patient preference, and institutional expertise.", "abstract_zh": "ä»…ä½¿ç”¨éšæœºå¯¹ç…§è¯•éªŒ (RCT) çš„æ•°æ®æ¥æ¯”è¾ƒç»ä¼šé˜´ (TP) ä¸ç»ç›´è‚  (TR) è¶…å£°å¼•å¯¼å‰åˆ—è…ºæ´»æ£€çš„å®‰å…¨æ€§å’Œè¯Šæ–­æ€§èƒ½ã€‚æˆªè‡³ 2025 å¹´ 5 æœˆï¼Œæˆ‘ä»¬åœ¨å¤šä¸ªæ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ€§æ£€ç´¢ã€‚æˆ‘ä»¬ä»…çº³å…¥äº†æ¯”è¾ƒ TP å’Œ TR æ–¹æ³•åœ¨æ¥å— MRI é¶å‘å‰åˆ—è…ºæ´»æ£€çš„ç”·æ€§ä¸­çš„éšæœºå¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨ä¼˜åŠ¿æ¯” (OR) å’Œ 95% ç½®ä¿¡åŒºé—´ (CI) è¿›è¡Œåˆ†ç±»ç»“æœçš„èŸèƒåˆ†æã€‚ä¸»è¦ç»ˆç‚¹æ˜¯ç™Œç—‡æ£€å‡ºç‡å’Œæ´»æ£€åæ„ŸæŸ“ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æŒ‰ Clavien-Dindo ç³»ç»Ÿåˆ†å±‚çš„å°¿æ½´ç•™ã€å‡ºè¡€ã€ç–¼ç—›å’Œå¹¶å‘ç—‡ã€‚ä½¿ç”¨ Cochrane ROB2 å’Œ GRADE å·¥å…·è¯„ä¼°ç ”ç©¶è´¨é‡å’Œè¯æ®çš„ç¡®å®šæ€§ã€‚çº³å…¥äº†å››é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œæ¶‰åŠ 2682 åæ‚£è€…ï¼ˆTPï¼š1323ï¼›TRï¼š1359ï¼‰ã€‚æ€»ä½“å‰åˆ—è…ºç™Œæ£€å‡ºç‡ï¼ˆOR 1.03ï¼Œ95% CIï¼Œ0.79-1.36ï¼‰æˆ–å‰éƒ¨ç—…å˜æ£€å‡ºç‡ï¼ˆOR 1.01ï¼Œ95% CIï¼Œ0.41-2.45ï¼‰æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚åŒæ ·ï¼Œå‡ºè¡€ï¼ˆOR 1.14ï¼Œ95% CIï¼Œ0.66-1.95ï¼‰ã€å°¿æ½´ç•™ï¼ˆOR 1.01ï¼Œ95% CIï¼Œ0.50-2.04ï¼‰ã€æ€»æ„ŸæŸ“ï¼ˆOR 1.02ï¼Œ95% CIï¼Œ0.77-1.35ï¼‰æˆ–ä¸¥é‡æ„ŸæŸ“ï¼ˆOR 2.17ï¼Œ95% CIï¼Œ 0.97-4.88ï¼‰ã€‚ TP ç»„è½»åº¦ç–¼ç—›æ›´ä¸ºå¸¸è§ï¼ˆOR 1.56ï¼Œ95% CIï¼Œ1.20-2.03ï¼‰ï¼Œè€Œä¸­åº¦è‡³é‡åº¦ç–¼ç—›æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼ˆOR 0.65ï¼Œ95% CIï¼Œ0.39-1.07ï¼‰ã€‚ç»ä¼šé˜´å’Œç»ç›´è‚  MRI èåˆå¼•å¯¼æ´»æ£€æ–¹æ³•è¡¨ç°å‡ºç›¸åŒçš„è¯Šæ–­å‡†ç¡®æ€§å’Œå®‰å…¨æ€§ã€‚è™½ç„¶ç»ä¼šé˜´é€”å¾„ä¼šå¸¦æ¥ç¨å¤§çš„è½»å¾®ä¸é€‚ï¼Œä½†ç™Œç—‡æ£€å‡ºç‡å’Œå¹¶å‘ç—‡å‘ç”Ÿç‡ç›¸å½“ã€‚æ–¹æ³•çš„é€‰æ‹©åº”éµå¾ªæŠ—èŒè¯ç‰©ç®¡ç†ã€æ‚£è€…åå¥½å’Œæœºæ„ä¸“ä¸šçŸ¥è¯†çš„åŸåˆ™ã€‚", "keywords_zh": "è¯Šæ–­, å‰åˆ—è…ºç™Œ, éšæœºè¯•éªŒ, ç»ä¼šé˜´æ´»æ£€, ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€", "keywords_en": "Diagnosis, Prostate cancer, Randomized trial, Transperineal Biopsy, Transperineal prostate biopsy", "link": "https://pubmed.ncbi.nlm.nih.gov/41385931/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 12 Dec 2025"}, {"id": "41372917", "title_en": "The impact of primary tumor location of colorectal cancer on the survival outcome of patients with brain metastasis: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ ç™ŒåŸå‘è‚¿ç˜¤éƒ¨ä½å¯¹è„‘è½¬ç§»æ‚£è€…ç”Ÿå­˜ç»“å±€çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Abhishek Kumar", "abstract_en": "**Objectives:** Several prior studies have shown that in metastasized colorectal cancer, the primary cancer's location influences patients' survival rates, with left-sided colorectal cancer being associated with longer survival than right-sided colorectal cancer. This study aimed to explore the influence of the primary location of colorectal cancer on survival following brain metastasis.\n\n**Methods:** To address this clinical question, we conducted a systematic review and meta-analysis. We included studies focused on patients diagnosed with brain metastasis from colorectal cancer. These studies reported survival outcomes based on different primary tumor sites (right versus left and colon versus rectum). The primary outcome was to aggregate the hazard ratio (HR) of left-sided colorectal cancer when metastasized to the brain compared with right-sided colorectal cancer. The secondary outcome was to aggregate the HR of rectal cancer when it metastasized to the brain compared with colon cancer.\n\n**Results:** Ten studies with a total of 1792 patients were included in the meta-analysis, and combined HR was calculated. Left-sided colon cancer showed higher overall survival compared with right-sided colon cancer when metastasized to the brain (HR: 0.71, 95% CI: 0.54-0.94, I<sup>2</sup>â€‰=â€‰0%). Rectal cancer did not show a statistically significant difference in overall survival compared with colon cancer (HR: 0.75, 95% CI: 0.40-1.41, I<sup>2</sup>â€‰=â€‰81%).\n\n**Conclusions:** Concordant with lung and liver metastases, the primary location of colorectal cancer influenced overall survival when metastasized to the brain. Left-sided colon cancer demonstrated higher overall survival than right-sided colon cancer.", "abstract_zh": "**Objectivesï¼š** å…ˆå‰çš„å‡ é¡¹ç ”ç©¶è¡¨æ˜ï¼Œåœ¨è½¬ç§»æ€§ç»“ç›´è‚ ç™Œä¸­ï¼ŒåŸå‘ç™Œç—‡çš„ä½ç½®å½±å“æ‚£è€…çš„ç”Ÿå­˜ç‡ï¼Œå·¦ä¾§ç»“ç›´è‚ ç™Œæ¯”å³ä¾§ç»“ç›´è‚ ç™Œçš„ç”Ÿå­˜æœŸæ›´é•¿ã€‚æœ¬ç ”ç©¶æ—¨åœ¨æ¢è®¨ç»“ç›´è‚ ç™Œçš„åŸå‘éƒ¨ä½å¯¹è„‘è½¬ç§»åç”Ÿå­˜çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** ä¸ºäº†è§£å†³è¿™ä¸ªä¸´åºŠé—®é¢˜ï¼Œæˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚æˆ‘ä»¬çº³å…¥çš„ç ”ç©¶é‡ç‚¹æ˜¯è¯Šæ–­ä¸ºç»“ç›´è‚ ç™Œè„‘è½¬ç§»çš„æ‚£è€…ã€‚è¿™äº›ç ”ç©¶æŠ¥å‘Šäº†åŸºäºä¸åŒåŸå‘è‚¿ç˜¤éƒ¨ä½ï¼ˆå³ä¸å·¦ã€ç»“è‚ ä¸ç›´è‚ ï¼‰çš„ç”Ÿå­˜ç»“æœã€‚ä¸»è¦ç»“æœæ˜¯æ±‡æ€»å·¦ä¾§ç»“ç›´è‚ ç™Œä¸å³ä¾§ç»“ç›´è‚ ç™Œè½¬ç§»è‡³å¤§è„‘æ—¶çš„é£é™©æ¯”ï¼ˆHRï¼‰ã€‚æ¬¡è¦ç»“æœæ˜¯ä¸ç»“è‚ ç™Œç›¸æ¯”ï¼Œæ±‡æ€»ç›´è‚ ç™Œè½¬ç§»è‡³å¤§è„‘æ—¶çš„ HRã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†æçº³å…¥ 10 é¡¹ç ”ç©¶ï¼Œå…± 1792 åæ‚£è€…ï¼Œå¹¶è®¡ç®—äº†åˆå¹¶ HRã€‚å½“è½¬ç§»è‡³è„‘éƒ¨æ—¶ï¼Œå·¦ä¾§ç»“è‚ ç™Œæ¯”å³ä¾§ç»“è‚ ç™Œè¡¨ç°å‡ºæ›´é«˜çš„æ€»ç”Ÿå­˜ç‡ï¼ˆHRï¼š0.71ï¼Œ95% CIï¼š0.54-0.94ï¼ŒI<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚ä¸ç»“è‚ ç™Œç›¸æ¯”ï¼Œç›´è‚ ç™Œçš„æ€»ç”Ÿå­˜ç‡æ²¡æœ‰è¡¨ç°å‡ºç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ï¼ˆHRï¼š0.75ï¼Œ95% CIï¼š0.40-1.41ï¼ŒI<sup>2</sup>â€‰=â€‰81%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ä¸è‚ºå’Œè‚è½¬ç§»ä¸€è‡´ï¼Œç»“ç›´è‚ ç™Œè½¬ç§»åˆ°å¤§è„‘æ—¶çš„ä¸»è¦ä½ç½®ä¼šå½±å“æ€»ä½“ç”Ÿå­˜ç‡ã€‚å·¦ä¾§ç»“è‚ ç™Œçš„æ€»ä½“ç”Ÿå­˜ç‡é«˜äºå³ä¾§ç»“è‚ ç™Œã€‚", "keywords_zh": "è„‘è½¬ç§»ã€ç»“ç›´è‚ ç™Œã€å·¦ç»“è‚ ç™Œã€ç›´è‚ ç™Œã€å³ç»“è‚ ç™Œ", "keywords_en": "Brain metastasis, Colorectal cancer, Left colon cancer, Rectal cancer, Right colon cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/41372917/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 10 Dec 2025"}, {"id": "41359190", "title_en": "Anatomical and functional outcomes of combined ventral rectopexy and sacrocolpo/hysteropexy for multicompartment pelvic organ prolapse: a systematic review and meta-analysis", "title_zh": "è…¹ä¾§ç›´è‚ å›ºå®šæœ¯å’Œéª¶é˜´é“/å­å®«å›ºå®šæœ¯è”åˆæ²»ç–—å¤šå®¤ç›†è…”å™¨å®˜è„±å‚çš„è§£å‰–å’ŒåŠŸèƒ½ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Marine Lallemant", "abstract_en": "**Introduction:** Limited data exists in literature regarding concomitant ventral rectopexy (VRP) and sacrocolpo/hysteropexy (SCP/SHP), with existing studies being predominantly retrospective. The aim of this meta-analysis is to assess the anatomical and functional outcomes of combined VRP and SCP/SHP for the treatment of multicompartmental pelvic organ prolapse (POP).\n\n**Methods:** We performed systematic research and meta-analysis from PubMed/MEDLINE and EMBASE, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, until 15 January 2025. Women submitted to VRP with SCP/SHP were included. Improvement of anorectal symptoms were evaluated. Postoperative anatomical relapse was reported. Re-operation rates were evaluated.\n\n**Results:** Six articles were included. Constipation/obstructed defecation syndrome (ODS) [odds ratio (OR) 0.26, 95% CI 0.10-0.68; pâ€‰=â€‰0.006 (I<sup>2</sup> test 81%, pâ€‰=â€‰0.56)] and of anal/fecal incontinence (AI/FI) rates [OR 0.09, 95% CI 0.03-0.30; pâ€‰<â€‰0.0001 (I<sup>2</sup> test 70%, pâ€‰=â€‰0.04)] significantly improved after combined VRP and SCP/SHP. The proportion metanalysis of four included studies reported a subjective POP recurrence rate of 7% (95% CI 1-13%; I<sup>2</sup> test 82.9%, pâ€‰<â€‰0.001). The proportion metanalysis of five included studies for objective POP recurrence was 5% (95% CI 1-9%; I<sup>2</sup> test 56.9%, pâ€‰=â€‰0.041). No serious adverse events were reported.\n\n**Conclusions:** VRP combined with SCP/SHP has been shown to be safe and effective for women with multicompartment POP, providing optimal anatomical and functional outcomes. Larger, long-term, prospective-controlled studies are needed to confirm these results.", "abstract_zh": "**ä»‹ç»ï¼š** æ–‡çŒ®ä¸­å…³äºä¼´éšè…¹ä¾§ç›´è‚ å›ºå®šæœ¯ï¼ˆVRPï¼‰å’Œéª¶é˜´é“/å­å®«å›ºå®šæœ¯ï¼ˆSCP/SHPï¼‰çš„æ•°æ®æœ‰é™ï¼Œç°æœ‰ç ”ç©¶ä¸»è¦æ˜¯å›é¡¾æ€§çš„ã€‚æœ¬èŸèƒåˆ†æçš„ç›®çš„æ˜¯è¯„ä¼° VRP å’Œ SCP/SHP è”åˆæ²»ç–—å¤šå®¤ç›†è…”å™¨å®˜è„±å‚ (POP) çš„è§£å‰–å­¦å’ŒåŠŸèƒ½ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2025 å¹´ 1 æœˆ 15 æ—¥ï¼Œæˆ‘ä»¬æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) 2020 æŒ‡å—ï¼Œä» PubMed/MEDLINE å’Œ EMBASE è¿›è¡Œäº†ç³»ç»Ÿç ”ç©¶å’ŒèŸèƒåˆ†æã€‚çº³å…¥äº†é€šè¿‡ SCP/SHP æäº¤ VRP çš„å¥³æ€§ã€‚è¯„ä¼°è‚›é—¨ç›´è‚ ç—‡çŠ¶çš„æ”¹å–„æƒ…å†µã€‚æ®æŠ¥é“æœ¯åè§£å‰–å­¦å¤å‘ã€‚è¯„ä¼°äº†å†æ‰‹æœ¯ç‡ã€‚\n\n**ç»“æœï¼š** æ”¶å½•äº†å…­ç¯‡æ–‡ç« ã€‚ä¾¿ç§˜/æ’ä¾¿é˜»å¡ç»¼åˆå¾ (ODS) [æ¯”å€¼æ¯” (OR) 0.26ï¼Œ95% CI 0.10-0.68ï¼› pâ€‰=â€‰0.006ï¼ˆI<sup>2</sup> æµ‹è¯• 81%ï¼Œpâ€‰=â€‰0.56ï¼‰] å’Œè‚›é—¨/å¤§ä¾¿å¤±ç¦ (AI/FI) ç‡ [OR 0.09ï¼Œ95% CI 0.03-0.30ï¼› pâ€‰<â€‰0.0001ï¼ˆI<sup>2</sup>æµ‹è¯•70%ï¼Œpâ€‰=â€‰0.04ï¼‰]åœ¨VRPå’ŒSCP/SHPç»“åˆåæ˜¾ç€æ”¹å–„ã€‚å››é¡¹çº³å…¥ç ”ç©¶çš„æ¯”ä¾‹èŸèƒåˆ†ææŠ¥å‘Šä¸»è§‚ POP å¤å‘ç‡ä¸º 7%ï¼ˆ95% CI 1-13%ï¼›I<sup>2</sup> æ£€éªŒ 82.9%ï¼Œp<0.001ï¼‰ã€‚äº”é¡¹çº³å…¥å®¢è§‚ POP å¤å‘ç ”ç©¶çš„èŸèƒåˆ†ææ¯”ä¾‹ä¸º 5%ï¼ˆ95% CI 1-9%ï¼›I<sup>2</sup> æ£€éªŒ 56.9%ï¼Œpâ€‰=â€‰0.041ï¼‰ã€‚æ²¡æœ‰æŠ¥å‘Šä¸¥é‡ä¸è‰¯äº‹ä»¶ã€‚\n\n**ç»“è®ºï¼š** VRP ä¸ SCP/SHP ç›¸ç»“åˆå·²è¢«è¯æ˜å¯¹æ‚£æœ‰å¤šå®¤ POP çš„å¥³æ€§å®‰å…¨æœ‰æ•ˆï¼Œå¯æä¾›æœ€ä½³çš„è§£å‰–å’ŒåŠŸèƒ½ç»“æœã€‚éœ€è¦æ›´å¤§è§„æ¨¡ã€é•¿æœŸã€å‰ç»æ€§å¯¹ç…§ç ”ç©¶æ¥è¯å®è¿™äº›ç»“æœã€‚", "keywords_zh": "è‚›é—¨å¤±ç¦ã€æ’ä¾¿é˜»å¡ç»¼åˆå¾ã€ç›†è…”å™¨å®˜è„±å‚ã€ç›´è‚ è„±å‚ã€éª¶éª¨é˜´é“å›ºå®šæœ¯ã€éª¶å­å®«å›ºå®šæœ¯ã€è…¹ä¾§ç›´è‚ å›ºå®šæœ¯", "keywords_en": "Anal incontinence, Obstructed defecation syndrome, Pelvic organ prolapse, Rectal prolapse, Sacrocolpopexy, Sacrohysteropexy, Ventral rectopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/41359190/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 08 Dec 2025"}, {"id": "41316735", "title_en": "Colorectal polyp distribution in relation to age: meta-analysis", "title_zh": "ç»“ç›´è‚ æ¯è‚‰åˆ†å¸ƒä¸å¹´é¾„çš„å…³ç³»ï¼šèŸèƒåˆ†æ", "authors": "Frank Frizelle", "abstract_en": "**Background:** An increase in early-onset colorectal cancer has been observed globally, despite a decline in colorectal cancer incidence rates in many Western countries. Screening strategies for younger individuals are particularly challenging, as there are limited data on polyps in young individuals to guide clinicians. This study aimed to systematically review the current evidence surrounding polyp distribution in different age groups.\n\n**Methods:** A literature search was performed in PubMed, Scopus, MEDLINE, Embase (OVID), Web of Science, and Cochrane Review databases using the keywords 'age' and 'polyp', and Medical Subject Heading terms 'age of onset', 'age factors', 'age distribution', and 'age groups', with no restrictions on publication year. Articles published in English that described the distribution of polyps (adenomatous, advanced adenomatous polyps, and sessile serrated lesions) or individuals with polyps according to different age groups were considered for inclusion. Younger patients were defined as those aged < 50 years. The outcomes of interest were the number of patients with polyps in the left and/or right colon, or the number of polyps per side of the colorectum in different age groups.\n\n**Results:** From 12 470 articles, 24 met the eligibility criteria for the systematic review, and 12 were suitable for meta-analysis. Among younger people, 46.5% had right-sided and 75.9% had left-sided polyps. In comparison, 70.8% of the older group had right-sided and 61.9% had left-sided polyps. Meta-analyses of studies showed a greater proportion of younger people than older people with at least one left-sided polyp (mean difference 0.06, 95% confidence interval (c.i.) 0.03 to 0.09; P < 0.001). There was also a greater proportion of left-sided polyps in younger people (odds ratio 0.77, 95% c.i. 0.59 to 1.01; P < 0.001).\n\n**Conclusion:** Patients aged < 50 years have a greater tendency towards having polyps in the left colon, compared with people â‰¥ 50 years of age, similar to the distribution of early-onset colorectal cancer. This has implications for the methodology of screening and investigation of symptoms in those aged < 50 years.", "abstract_zh": "**èƒŒæ™¯ï¼š** å°½ç®¡è®¸å¤šè¥¿æ–¹å›½å®¶çš„ç»“ç›´è‚ ç™Œå‘ç—…ç‡æœ‰æ‰€ä¸‹é™ï¼Œä½†å…¨çƒèŒƒå›´å†…æ—©å‘æ€§ç»“ç›´è‚ ç™Œçš„å‘ç—…ç‡æœ‰æ‰€å¢åŠ ã€‚é’ˆå¯¹å¹´è½»äººçš„ç­›æŸ¥ç­–ç•¥å°¤å…¶å…·æœ‰æŒ‘æˆ˜æ€§ï¼Œå› ä¸ºæŒ‡å¯¼ä¸´åºŠåŒ»ç”Ÿçš„å¹´è½»äººæ¯è‚‰æ•°æ®æœ‰é™ã€‚æœ¬ç ”ç©¶æ—¨åœ¨ç³»ç»Ÿåœ°å›é¡¾æœ‰å…³ä¸åŒå¹´é¾„ç»„æ¯è‚‰åˆ†å¸ƒçš„å½“å‰è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨å…³é”®è¯â€œå¹´é¾„â€å’Œâ€œæ¯è‚‰â€ä»¥åŠåŒ»å­¦ä¸»é¢˜è¯â€œå‘ç—…å¹´é¾„â€ã€â€œå¹´é¾„å› ç´ â€ã€â€œå¹´é¾„åˆ†å¸ƒâ€å’Œâ€œå¹´é¾„ç»„â€åœ¨ PubMedã€Scopusã€MEDLINEã€Embase (OVID)ã€Web of Science å’Œ Cochrane Review æ•°æ®åº“ä¸­è¿›è¡Œæ–‡çŒ®æ£€ç´¢ï¼Œå¯¹å‘è¡¨å¹´ä»½æ²¡æœ‰é™åˆ¶ã€‚ä»¥è‹±æ–‡å‘è¡¨çš„æè¿°æ¯è‚‰ï¼ˆè…ºç˜¤æ€§ã€æ™šæœŸè…ºç˜¤æ€§æ¯è‚‰å’Œæ— è’‚é”¯é½¿çŠ¶ç—…å˜ï¼‰æˆ–æ¯è‚‰ä¸ªä½“æ ¹æ®ä¸åŒå¹´é¾„ç»„çš„åˆ†å¸ƒçš„æ–‡ç« è¢«è€ƒè™‘çº³å…¥ã€‚å¹´è½»æ‚£è€…è¢«å®šä¹‰ä¸ºå¹´é¾„ < 50 å²çš„æ‚£è€…ã€‚æ„Ÿå…´è¶£çš„ç»“æœæ˜¯å·¦å’Œ/æˆ–å³ç»“è‚ æ¯è‚‰æ‚£è€…çš„æ•°é‡ï¼Œæˆ–ä¸åŒå¹´é¾„ç»„ä¸­ç»“è‚ ç›´è‚ æ¯ä¾§æ¯è‚‰çš„æ•°é‡ã€‚\n\n**ç»“æœï¼š** åœ¨ 12 470 ç¯‡æ–‡ç« ä¸­ï¼Œ24 ç¯‡ç¬¦åˆç³»ç»Ÿè¯„ä»·çš„èµ„æ ¼æ ‡å‡†ï¼Œ12 ç¯‡é€‚åˆèŸèƒåˆ†æã€‚åœ¨å¹´è½»äººä¸­ï¼Œ46.5% æ‚£æœ‰å³ä¾§æ¯è‚‰ï¼Œ75.9% æ‚£æœ‰å·¦ä¾§æ¯è‚‰ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œ70.8% çš„è€å¹´äººæ‚£æœ‰å³ä¾§æ¯è‚‰ï¼Œ61.9% çš„è€å¹´äººæ‚£æœ‰å·¦ä¾§æ¯è‚‰ã€‚ç ”ç©¶èŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ‚£æœ‰è‡³å°‘ä¸€é¢—å·¦ä¾§æ¯è‚‰çš„å¹´è½»äººæ¯”ä¾‹é«˜äºè€å¹´äººï¼ˆå¹³å‡å·® 0.06ï¼Œ95% ç½®ä¿¡åŒºé—´ (c.i.) 0.03 è‡³ 0.09ï¼›P < 0.001ï¼‰ã€‚å¹´è½»äººä¸­å·¦ä¾§æ¯è‚‰çš„æ¯”ä¾‹ä¹Ÿè¾ƒé«˜ï¼ˆæ¯”å€¼æ¯” 0.77ï¼Œ95% c.i. 0.59 è‡³ 1.01ï¼›P < 0.001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ä¸å¹´é¾„â‰¥50å²çš„äººç›¸æ¯”ï¼Œå¹´é¾„<50å²çš„æ‚£è€…å·¦åŠç»“è‚ æ¯è‚‰çš„å€¾å‘æ›´å¤§ï¼Œä¸æ—©å‘æ€§ç»“ç›´è‚ ç™Œçš„åˆ†å¸ƒç›¸ä¼¼ã€‚è¿™å¯¹äº 50 å²ä»¥ä¸‹äººç¾¤çš„ç—‡çŠ¶ç­›æŸ¥å’Œè°ƒæŸ¥æ–¹æ³•å…·æœ‰é‡è¦æ„ä¹‰ã€‚", "keywords_zh": "è…ºç˜¤ã€ç»“è‚ ã€ç›´è‚ ã€æ— è’‚é”¯é½¿çŠ¶ç—…å˜", "keywords_en": "adenoma, colon, rectum, sessile serrated lesions", "link": "https://pubmed.ncbi.nlm.nih.gov/41316735/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 29 Nov 2025"}, {"id": "41290553", "title_en": "Preemptive Versus Postoperative Analgesia in Colorectal Surgery: A Systematic Review and Meta-Analysis", "title_zh": "ç»“ç›´è‚ æ‰‹æœ¯ä¸­çš„å…ˆå‘æ€§é•‡ç—›ä¸æœ¯åé•‡ç—›ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Muhammed Elhadi", "abstract_en": "**Background:** Preemptive and preventative methods have been suggested to decrease pain by blocking nociceptive inputs to tissues. Preemptive analgesia has the potential to enhance postoperative recovery in patients undergoing colorectal surgery. This study aimed to evaluate the efficacy and safety of preemptive versus postoperative analgesia in this population.\n\n**Methods:** We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library from inception to December 2024, and updated the search in May 2025, to identify randomized controlled trials (RCTs) comparing preemptive analgesia with postoperative analgesia in adult patients undergoing colorectal surgery. The primary outcomes were opioid consumption within 24Â h, visual analog scale (VAS) pain score at rest at 24 and 48Â h postoperatively. Secondary outcomes included adverse events, length of hospital stay, surgery duration (minutes), and postoperative nausea and vomiting (PONV). The Cochrane Risk of Bias 2.0 tool was used to assess risk of bias, and the strength of evidence was graded using the GRADE approach.\n\n**Results:** We identified a total of 2739 records. Seven studies involving 625 patients (312 preemptive and 313 postoperative) met the inclusion criteria. Preemptive analgesia decreased VAS scores at 24Â h compared to postoperative analgesia (MD -0.45, 95% CI: -0.89 to -0.01, pÂ =Â 0.04). However, significant heterogeneity was observed among included studies. Additionally, there was no difference between the two groups regarding VAS at 48Â h (MD -0.17, 95% CI -0.43 to 0.09, pÂ =Â 0.21) and opioid consumption at 24Â h (MD -21.17, 95% CI 48.18-5.85, pÂ =Â 0.12).\n\n**Conclusion:** The findings indicate that preemptive analgesia did not decrease opioid consumption at 24Â h; however, it decreased VAS score at 24Â h without any difference in VAS at 48Â h, length of hospital stay, incidence of PONV, or other adverse events when compared to postoperative analgesia alone in colorectal surgery.\n\n**Trial Registration:** The study is registered in PROSPERO under the registration number CRD420250636020.", "abstract_zh": "**èƒŒæ™¯ï¼š** å·²æå‡ºå…ˆå‘åˆ¶äººå’Œé¢„é˜²æ€§æ–¹æ³•ï¼Œé€šè¿‡é˜»æ­¢å¯¹ç»„ç»‡çš„ä¼¤å®³æ€§è¾“å…¥æ¥å‡è½»ç–¼ç—›ã€‚è¶…å‰é•‡ç—›æœ‰å¯èƒ½ä¿ƒè¿›ç»“ç›´è‚ æ‰‹æœ¯æ‚£è€…çš„æœ¯åæ¢å¤ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å…ˆå‘æ€§é•‡ç—›ä¸æœ¯åé•‡ç—›åœ¨è¿™ä¸€äººç¾¤ä¸­çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ç³»ç»Ÿåœ°æ£€ç´¢äº† PubMedã€Scopusã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œä»å¼€å§‹åˆ° 2024 å¹´ 12 æœˆï¼Œå¹¶äº 2025 å¹´ 5 æœˆæ›´æ–°äº†æ£€ç´¢ï¼Œä»¥è¯†åˆ«åœ¨æ¥å—ç»“ç›´è‚ æ‰‹æœ¯çš„æˆå¹´æ‚£è€…ä¸­æ¯”è¾ƒè¶…å‰é•‡ç—›ä¸æœ¯åé•‡ç—›çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚ä¸»è¦ç»“æœæ˜¯ 24 å°æ—¶å†…é˜¿ç‰‡ç±»è¯ç‰©çš„æ¶ˆè€—é‡ã€æœ¯å 24 å°æ—¶å’Œ 48 å°æ—¶çš„è§†è§‰æ¨¡æ‹Ÿé‡è¡¨ (VAS) é™æ¯ç–¼ç—›è¯„åˆ†ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ä¸è‰¯äº‹ä»¶ã€ä½é™¢æ—¶é—´ã€æ‰‹æœ¯æŒç»­æ—¶é—´ï¼ˆåˆ†é’Ÿï¼‰å’Œæœ¯åæ¶å¿ƒå’Œå‘•åï¼ˆPONVï¼‰ã€‚ Cochrane åå€šé£é™© 2.0 å·¥å…·ç”¨äºè¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ GRADE æ–¹æ³•å¯¹è¯æ®å¼ºåº¦è¿›è¡Œåˆ†çº§ã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬æ€»å…±è¯†åˆ«å‡º 2739 æ¡è®°å½•ã€‚æ¶‰åŠ 625 åæ‚£è€…ï¼ˆ312 åå…ˆå‘æ€§æ‚£è€…å’Œ 313 åæœ¯åæ‚£è€…ï¼‰çš„ 7 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ä¸æœ¯åé•‡ç—›ç›¸æ¯”ï¼Œè¶…å‰é•‡ç—›åœ¨ 24 å°æ—¶é™ä½äº† VAS è¯„åˆ†ï¼ˆMD -0.45ï¼Œ95% CIï¼š-0.89 è‡³ -0.01ï¼Œp = 0.04ï¼‰ã€‚ç„¶è€Œï¼Œçº³å…¥çš„ç ”ç©¶ä¹‹é—´è§‚å¯Ÿåˆ°æ˜¾ç€çš„å¼‚è´¨æ€§ã€‚æ­¤å¤–ï¼Œä¸¤ç»„ä¹‹é—´ 48 å°æ—¶ VASï¼ˆMD -0.17ï¼Œ95% CI -0.43 è‡³ 0.09ï¼Œp = 0.21ï¼‰å’Œ 24 å°æ—¶é˜¿ç‰‡ç±»è¯ç‰©æ¶ˆè€—é‡ï¼ˆMD -21.17ï¼Œ95% CI 48.18-5.85ï¼Œp = 0.12ï¼‰ä¹‹é—´æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œè¶…å‰é•‡ç—›å¹¶æ²¡æœ‰å‡å°‘ 24 å°æ—¶é˜¿ç‰‡ç±»è¯ç‰©çš„æ¶ˆè€—ï¼›ç„¶è€Œï¼Œä¸ç»“ç›´è‚ æ‰‹æœ¯ä¸­å•ç‹¬ä½¿ç”¨æœ¯åé•‡ç—›ç›¸æ¯”ï¼Œå®ƒé™ä½äº† 24 å°æ—¶ VAS è¯„åˆ†ï¼Œä½† 48 å°æ—¶ VASã€ä½é™¢æ—¶é—´ã€PONV å‘ç”Ÿç‡æˆ–å…¶ä»–ä¸è‰¯äº‹ä»¶æ²¡æœ‰ä»»ä½•å·®å¼‚ã€‚\n\n**Trial registrationï¼š** è¯¥ç ”ç©¶å·²åœ¨ PROSPERO ä¸­æ³¨å†Œï¼Œæ³¨å†Œå·ä¸º CRD420250636020ã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€æœ¯åé•‡ç—›ã€è¶…å‰é•‡ç—›", "keywords_en": "colorectal surgery, postoperative analgesia, preemptive analgesia", "link": "https://pubmed.ncbi.nlm.nih.gov/41290553/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 25 Nov 2025"}, {"id": "41263625", "title_en": "Regarding: \"Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: a systematic review and meta-analysis\"", "title_zh": "å…³äºï¼šâ€œäºšç”²è“æ²»ç–—ç—”ç–®æœ¯åç–¼ç—›çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€", "authors": "Fahmi H Kakamad", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/41263625/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 20 Nov 2025"}, {"id": "41223393", "title_en": "Systematic Review of Hyperbaric Oxygen for Late Radiation Tissue Injury (Bowel, Bladder)", "title_zh": "é«˜å‹æ°§æ²»ç–—æ™šæœŸæ”¾å°„æ€§ç»„ç»‡æŸä¼¤ï¼ˆè‚ ã€è†€èƒ±ï¼‰çš„ç³»ç»Ÿè¯„ä»·", "authors": "Marissa Janine Carter", "abstract_en": "**Background:** This systematic review evaluated comparative studies to determine if hyperbaric oxygen therapy (HBOâ‚‚) is beneficial to late radiation tissue injury (LRTI) of the bowel/bladder.\n\n**Methods:** We included adequately powered, comparative studies evaluating the effect of HBOâ‚‚ on patients with LRTI (â‰¥3 months duration and/or â‰¥6 months after radiation therapy) to the bowel/bladder compared to no HBOâ‚‚ or placebo/sham; complete outcomes data must have corresponded to the tools used to measure change in LRTI symptoms. Medline was searched through May 4, 2023, Embase through May 29, 2023, and Google Scholar through May 5, 2023. The Cochrane risk-of-bias tool and GRADE approach were used with a certainty of outcomes assessment.\n\n**Results:** Three RCTs were included with 273 subjects. Two double-blinded studies evaluated rectal symptoms; one open study evaluated cystitis. One study had a low risk of bias; two had some concerns. All had moderate certainty of outcomes. There is moderate certainty with a weak recommendation for using HBOâ‚‚ for rectal complications or cystitis, which (in context of GRADE terminology) means the decision to treat depends on a case-by-case basis.\n\n**Discussion:** The highly heterogeneous design of the trials made meta-analysis impossible, but moderate certainty of the beneficial effect of HBOâ‚‚ on LRTI to the rectum and bladder was confirmed. With the weak recommendation, a discussion should take place between the patient and their physician as to whether or not the patient is likely to benefit from HBOâ‚‚.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ¬ç³»ç»Ÿç»¼è¿°è¯„ä¼°äº†æ¯”è¾ƒç ”ç©¶ï¼Œä»¥ç¡®å®šé«˜å‹æ°§æ²»ç–— (HBO 2) æ˜¯å¦æœ‰ç›Šäºè‚ /è†€èƒ±çš„æ™šæœŸæ”¾å°„æ€§ç»„ç»‡æŸä¼¤ (LRTI)ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬çº³å…¥äº†å……åˆ†æœ‰åŠ›çš„æ¯”è¾ƒç ”ç©¶ï¼Œè¯„ä¼°ä¸ä¸ä½¿ç”¨ HBO æˆ–å®‰æ…°å‰‚/å‡æ‰‹æœ¯ç›¸æ¯”ï¼ŒHBO 2 å¯¹ LRTIï¼ˆæŒç»­æ—¶é—´â‰¥3 ä¸ªæœˆå’Œ/æˆ–æ”¾å°„æ²»ç–—åâ‰¥6 ä¸ªæœˆï¼‰æ‚£è€…å¯¹è‚ /è†€èƒ±çš„å½±å“ï¼›å®Œæ•´çš„ç»“æœæ•°æ®å¿…é¡»ä¸ç”¨äºæµ‹é‡ LRTI ç—‡çŠ¶å˜åŒ–çš„å·¥å…·ç›¸å¯¹åº”ã€‚ Medline çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 4 æ—¥ï¼ŒEmbase çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 29 æ—¥ï¼ŒGoogle Scholar çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 5 æ—¥ã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·å’Œ GRADE æ–¹æ³•å¯¹ç»“æœè¿›è¡Œç¡®å®šæ€§è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒçº³å…¥äº† 273 åå—è¯•è€…ã€‚ä¸¤é¡¹åŒç›²ç ”ç©¶è¯„ä¼°äº†ç›´è‚ ç—‡çŠ¶ï¼›ä¸€é¡¹å¼€æ”¾ç ”ç©¶è¯„ä¼°äº†è†€èƒ±ç‚ã€‚ä¸€é¡¹ç ”ç©¶çš„åå€šé£é™©è¾ƒä½ï¼›ä¸¤ä¸ªäººæœ‰ä¸€äº›æ‹…å¿§ã€‚æ‰€æœ‰ç»“æœçš„ç¡®å®šæ€§å‡ä¸ºä¸­ç­‰ã€‚å¯¹äºä½¿ç”¨ HBO æ¥æ²»ç–—ç›´è‚ å¹¶å‘ç—‡æˆ–è†€èƒ±ç‚æœ‰ä¸­ç­‰ç¨‹åº¦çš„ç¡®å®šæ€§å’Œå¼±æ¨èï¼Œè¿™ï¼ˆåœ¨ GRADE æœ¯è¯­çš„èƒŒæ™¯ä¸‹ï¼‰æ„å‘³ç€æ²»ç–—å†³å®šå–å†³äºå…·ä½“æƒ…å†µã€‚\n\n**è®¨è®ºï¼š** è¯•éªŒè®¾è®¡çš„é«˜åº¦å¼‚è´¨æ€§ä½¿å¾—èŸèƒåˆ†æå˜å¾—ä¸å¯èƒ½ï¼Œä½† HBO2 å¯¹ç›´è‚ å’Œè†€èƒ± LRTI çš„æœ‰ç›Šä½œç”¨çš„ä¸­ç­‰ç¡®å®šæ€§å¾—åˆ°äº†è¯å®ã€‚å¯¹äºå¼±å»ºè®®ï¼Œæ‚£è€…å’ŒåŒ»ç”Ÿåº”å°±æ‚£è€…æ˜¯å¦å¯èƒ½ä» HBO2 ä¸­å—ç›Šè¿›è¡Œè®¨è®ºã€‚", "keywords_zh": "LRTIã€ç™Œç—‡ã€æ…¢æ€§ä¼¤å£ã€æ¯”è¾ƒç ”ç©¶ã€è†€èƒ±ç‚ã€é«˜å‹æ°§æ²»ç–—ã€ç›´è‚ ç‚", "keywords_en": "LRTI, cancer, chronic wounds, comparative studies, cystitis, hyperbaric oxygen therapy, proctitis", "link": "https://pubmed.ncbi.nlm.nih.gov/41223393/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 12 Nov 2025"}, {"id": "41075390", "title_en": "Quality of Life and Functional Outcomes After Watch-and-Wait for Locally Advanced Rectal Cancer: A Meta-analysis", "title_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œè§‚å¯Ÿç­‰å¾…åçš„ç”Ÿæ´»è´¨é‡å’ŒåŠŸèƒ½ç»“æœï¼šèŸèƒåˆ†æ", "authors": "Jonathan S Abelson", "abstract_en": "**Introduction:** Watch-and-wait (W&W), which involves total neoadjuvant therapy followed by close observation, has emerged as an alternative to total mesorectal excision for patients with locally advanced rectal cancer who achieve a clinical or near-complete response. This approach aims to preserve bowel function and avoid the morbidity associated with radical surgery.\n\n**Methods:** This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines. Eligible studies included randomized trials and observational studies of patients with locally advanced rectal cancer treated with total neoadjuvant therapy, followed by either W&W or total mesorectal excision. The primary outcome was quality of life (QoL), assessed using validated instruments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, Quality of Life Questionnaire-CR29, Fecal Incontinence Quality of Life). Secondary outcomes included bowel function among patients without an ostomy, using validated measures such as Cleveland Clinic Florida Fecal Incontinence Scores, Vaizey, Memorial Sloan Kettering Cancer Center, and low anterior resection syndrome scores. A comprehensive search of PubMed, EMBASE, Medline, and Web of Science (Sept 2023-May 2025) was performed without language or date restrictions. Abstract/full-text screening, data extraction, and risk of bias assessments were conducted independently by two reviewers. Meta-analyses used inverse-variance weighting under a random-effects model. Data unsuitable for meta-analysis were synthesized narratively.\n\n**Results:** Of 617 screened studies, 28 were reviewed in full and 9 met inclusion criteria (total 923 patients). Meta-analysis of five studies (n = 601) with no statistically significant difference in overall QoL between groups (pooled mean difference = 0.10, 95% confidence interval: -0.19 to 0.39, P = 0.49). However, pooled analysis of fecal incontinence scores from four studies (n = 384) showed a significant advantage for W&W (pooled mean difference = -1.10, 95% confidence interval: -1.50 to -0.73, P < 0.001). Qualitative synthesis of low anterior resections syndrome scores outcomes favored W&W.\n\n**Conclusions:** W&W, offers a functional advantage without compromising QoL. The decision to pursue W&W should be individualized, considering both the potential functional benefits and the oncological risks.", "abstract_zh": "**ä»‹ç»ï¼š** è§‚å¯Ÿç­‰å¾…ï¼ˆWï¼†Wï¼‰æ¶‰åŠå…¨é¢æ–°è¾…åŠ©æ²»ç–—ï¼Œç„¶åè¿›è¡Œå¯†åˆ‡è§‚å¯Ÿï¼Œå·²æˆä¸ºå±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…è¾¾åˆ°ä¸´åºŠæˆ–æ¥è¿‘å®Œå…¨ç¼“è§£çš„å…¨ç›´è‚ ç³»è†œåˆ‡é™¤çš„æ›¿ä»£æ–¹æ¡ˆã€‚è¿™ç§æ–¹æ³•æ—¨åœ¨ä¿æŠ¤è‚ é“åŠŸèƒ½å¹¶é¿å…ä¸æ ¹æ²»æ€§æ‰‹æœ¯ç›¸å…³çš„å‘ç—…ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æéµå¾ªç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ä»¥åŠ Cochrane æŒ‡å—ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬å¯¹æ¥å—å…¨æ–°è¾…åŠ©æ²»ç–—ã€éšåè¿›è¡Œ W&W æˆ–å…¨ç›´è‚ ç³»è†œåˆ‡é™¤çš„å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…è¿›è¡Œçš„éšæœºè¯•éªŒå’Œè§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯ç”Ÿæ´»è´¨é‡ï¼ˆQoLï¼‰ï¼Œä½¿ç”¨ç»è¿‡éªŒè¯çš„ä»ªå™¨ï¼ˆæ¬§æ´²ç™Œç—‡ç ”ç©¶å’Œæ²»ç–—ç»„ç»‡ç”Ÿæ´»è´¨é‡é—®å·-C30ã€ç”Ÿæ´»è´¨é‡é—®å·-CR29ã€å¤§ä¾¿å¤±ç¦ç”Ÿæ´»è´¨é‡ï¼‰è¿›è¡Œè¯„ä¼°ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æœªè¿›è¡Œé€ å£æœ¯çš„æ‚£è€…çš„è‚ é“åŠŸèƒ½ï¼Œä½¿ç”¨ç»è¿‡éªŒè¯çš„æªæ–½ï¼Œå¦‚å…‹åˆ©å¤«å…°è¯Šæ‰€ä½›ç½—é‡Œè¾¾å¤§ä¾¿å¤±ç¦è¯„åˆ†ã€Vaizeyã€çºªå¿µæ–¯éš†å‡¯ç‰¹ç³ç™Œç—‡ä¸­å¿ƒå’Œä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†ã€‚å¯¹ PubMedã€EMBASEã€Medline å’Œ Web of Scienceï¼ˆ2023 å¹´ 9 æœˆè‡³ 2025 å¹´ 5 æœˆï¼‰è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œæ²¡æœ‰è¯­è¨€æˆ–æ—¥æœŸé™åˆ¶ã€‚æ‘˜è¦/å…¨æ–‡ç­›é€‰ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ç”±ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¿›è¡Œã€‚èŸèƒåˆ†æåœ¨éšæœºæ•ˆåº”æ¨¡å‹ä¸‹ä½¿ç”¨é€†æ–¹å·®åŠ æƒã€‚ä¸é€‚åˆèŸèƒåˆ†æçš„æ•°æ®ä»¥å™è¿°æ–¹å¼åˆæˆã€‚\n\n**ç»“æœï¼š** åœ¨ 617 é¡¹ç­›é€‰ç ”ç©¶ä¸­ï¼Œ28 é¡¹ç»è¿‡å…¨é¢å®¡æŸ¥ï¼Œ9 é¡¹ç¬¦åˆçº³å…¥æ ‡å‡†ï¼ˆæ€»å…± 923 åæ‚£è€…ï¼‰ã€‚å¯¹äº”é¡¹ç ”ç©¶ (n = 601) è¿›è¡ŒèŸèƒåˆ†æï¼Œç»„é—´æ€»ä½“ç”Ÿæ´»è´¨é‡æ— ç»Ÿè®¡å­¦æ˜¾ç€å·®å¼‚ï¼ˆæ±‡æ€»å¹³å‡å·® = 0.10ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š-0.19 è‡³ 0.39ï¼ŒP = 0.49ï¼‰ã€‚ç„¶è€Œï¼Œå››é¡¹ç ”ç©¶ (n = 384) çš„å¤§ä¾¿å¤±ç¦è¯„åˆ†æ±‡æ€»åˆ†ææ˜¾ç¤º W&W å…·æœ‰æ˜¾ç€ä¼˜åŠ¿ï¼ˆæ±‡æ€»å¹³å‡å·® = -1.10ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š-1.50 è‡³ -0.73ï¼ŒP < 0.001ï¼‰ã€‚ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†ç»“æœçš„å®šæ€§ç»¼åˆæœ‰åˆ©äº W&Wã€‚\n\n**ç»“è®ºï¼š** W&W åœ¨ä¸å½±å“ç”Ÿæ´»è´¨é‡çš„æƒ…å†µä¸‹æä¾›åŠŸèƒ½ä¼˜åŠ¿ã€‚è¿½æ±‚ W&W çš„å†³å®šåº”è¯¥å› äººè€Œå¼‚ï¼ŒåŒæ—¶è€ƒè™‘æ½œåœ¨çš„åŠŸèƒ½ç›Šå¤„å’Œè‚¿ç˜¤é£é™©ã€‚", "keywords_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œï¼ŒèŸèƒåˆ†æï¼Œç”Ÿæ´»è´¨é‡ï¼Œç³»ç»Ÿè¯„ä»·ï¼Œè§‚å¯Ÿç­‰å¾…", "keywords_en": "Locally advanced rectal cancer, Meta-analysis, Quality of life, Systematic review, Watch-and-wait", "link": "https://pubmed.ncbi.nlm.nih.gov/41075390/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 11 Oct 2025"}, {"id": "41023221", "title_en": "Single-incision laparoscopic endorectal pull-through for Hirschsprung disease: a prospective institutional study and systematic review with meta-analysis", "title_zh": "å•åˆ‡å£è…¹è…”é•œç›´è‚ å†…ç‰µå¼•æ²»ç–—å…ˆå¤©æ€§å·¨ç»“è‚ ï¼šå‰ç»æ€§æœºæ„ç ”ç©¶å’ŒèŸèƒåˆ†æç³»ç»Ÿè¯„ä»·", "authors": "Quang Thanh Nguyen", "abstract_en": "**Background:** Single-incision laparoscopic endorectal pull-through (SILEP) has emerged as an alternative to conventional laparoscopic surgery for Hirschsprung disease (HSCR), offering improved cosmetic outcomes with comparable efficacy. However, its adoption remains limited, and evidence supporting its long-term safety and functional outcomes is sparse. This study presents our institutional experience with SILEP, alongside a systematic review and meta-analysis evaluating perioperative outcomes, postoperative complications, bowel function, and cosmesis.\n\n**Patients And Methods:** A prospective study was conducted at our institution involving 93 pediatric patients diagnosed with HSCR, who underwent SILEP between 2020 and 2021. Demographic data, perioperative details, and postoperative outcomes, including bowel function score (Rintala) and cosmetic results (Manchester Scar Scale), were prospectively collected and analyzed. Additionally, a systematic review and meta-analysis were performed following PRISMA guidelines, pooling data from nine studies comprising 420 patients.\n\n**Results:** The mean operative time was 70.0â€‰Â±â€‰30.3Â min, significantly shorter than the pooled estimate from the meta-analysis (166.44Â min; 95% CI 137.74-195.14, pâ€‰<â€‰0.001). No intraoperative complications or conversions were recorded. The mean hospital stay was 5.23â€‰Â±â€‰2.69Â days, consistent with prior reports. Enterocolitis occurred in 16.1% of cases, comparable to the pooled estimate (12%; 95% CI 7-21%). Among patients agedâ€‰â‰¥â€‰4Â years (nâ€‰=â€‰64), 84% achieved good to excellent bowel function scores. The mean Manchester Scar Score was 5.73â€‰Â±â€‰1.38.\n\n**Conclusion:** SILEP is a safe, effective, and cosmetically superior approach for HSCR, with favorable perioperative outcomes and functional results. Our findings, supported by meta-analysis data, reinforce the feasibility of SILEP as a viable alternative for HSCR management.", "abstract_zh": "**èƒŒæ™¯ï¼š** å•åˆ‡å£è…¹è…”é•œç›´è‚ å†…æ‹‰ç©¿æœ¯ (SILEP) å·²æˆä¸ºæ²»ç–—å…ˆå¤©æ€§å·¨ç»“è‚  (HSCR) çš„ä¼ ç»Ÿè…¹è…”é•œæ‰‹æœ¯çš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¯æä¾›æ”¹å–„çš„ç¾å®¹æ•ˆæœä¸”ç–—æ•ˆç›¸å½“ã€‚ç„¶è€Œï¼Œå®ƒçš„é‡‡ç”¨ä»ç„¶æœ‰é™ï¼Œå¹¶ä¸”æ”¯æŒå…¶é•¿æœŸå®‰å…¨æ€§å’ŒåŠŸèƒ½ç»“æœçš„è¯æ®å¾ˆå°‘ã€‚æœ¬ç ”ç©¶ä»‹ç»äº†æˆ‘ä»¬åœ¨ SILEP æ–¹é¢çš„æœºæ„ç»éªŒï¼Œä»¥åŠè¯„ä¼°å›´æ‰‹æœ¯æœŸç»“æœã€æœ¯åå¹¶å‘ç—‡ã€è‚ é“åŠŸèƒ½å’Œç¾å®¹çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚\n\n**Patients and methodsï¼š** æˆ‘ä»¬çš„æœºæ„è¿›è¡Œäº†ä¸€é¡¹å‰ç»æ€§ç ”ç©¶ï¼Œæ¶‰åŠ 93 åè¯Šæ–­ä¸º HSCR çš„å„¿ç«¥æ‚£è€…ï¼Œè¿™äº›æ‚£è€…åœ¨ 2020 å¹´è‡³ 2021 å¹´é—´æ¥å—äº† SILEPã€‚å‰ç»æ€§æ”¶é›†å’Œåˆ†æäº†äººå£ç»Ÿè®¡æ•°æ®ã€å›´æ‰‹æœ¯æœŸè¯¦ç»†ä¿¡æ¯å’Œæœ¯åç»“æœï¼ŒåŒ…æ‹¬è‚ åŠŸèƒ½è¯„åˆ† (Rintala) å’Œç¾å®¹ç»“æœï¼ˆæ›¼å½»æ–¯ç‰¹ç–¤ç—•é‡è¡¨ï¼‰ã€‚æ­¤å¤–ï¼Œè¿˜æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œæ±‡é›†äº†æ¶‰åŠ 420 åæ‚£è€…çš„ 9 é¡¹ç ”ç©¶çš„æ•°æ®ã€‚\n\n**ç»“æœï¼š** å¹³å‡æ‰‹æœ¯æ—¶é—´ä¸º 70.0Â±30.3 åˆ†é’Ÿï¼Œæ˜æ˜¾çŸ­äºèŸèƒåˆ†æçš„æ±‡æ€»ä¼°è®¡æ—¶é—´ï¼ˆ166.44 åˆ†é’Ÿï¼›95% CI 137.74-195.14ï¼Œp<0.001ï¼‰ã€‚æ²¡æœ‰è®°å½•æœ¯ä¸­å¹¶å‘ç—‡æˆ–è½¬åŒ–ã€‚å¹³å‡ä½é™¢æ—¶é—´ä¸º 5.23Â±2.69 å¤©ï¼Œä¸ä¹‹å‰çš„æŠ¥å‘Šä¸€è‡´ã€‚ 16.1% çš„ç—…ä¾‹å‘ç”Ÿå°è‚ ç»“è‚ ç‚ï¼Œä¸æ±‡æ€»ä¼°è®¡å€¼ç›¸å½“ï¼ˆ12%ï¼›95% CI 7-21%ï¼‰ã€‚åœ¨å¹´é¾„â€‰â‰¥â€‰4å²çš„æ‚£è€…ä¸­ï¼ˆnâ€‰=â€‰64ï¼‰ï¼Œ84%çš„äººå–å¾—äº†è‰¯å¥½è‡³ä¼˜ç§€çš„è‚ é“åŠŸèƒ½è¯„åˆ†ã€‚å¹³å‡æ›¼å½»æ–¯ç‰¹ç–¤ç—•è¯„åˆ†ä¸º 5.73Â±1.38ã€‚\n\n**ç»“è®ºï¼š** SILEP æ˜¯ä¸€ç§å®‰å…¨ã€æœ‰æ•ˆä¸”ç¾è§‚çš„ HSCR æ–¹æ³•ï¼Œå…·æœ‰è‰¯å¥½çš„å›´æ‰‹æœ¯æœŸç»“æœå’ŒåŠŸèƒ½ç»“æœã€‚æˆ‘ä»¬çš„ç ”ç©¶ç»“æœå¾—åˆ°èŸèƒåˆ†ææ•°æ®çš„æ”¯æŒï¼Œå¼ºåŒ–äº† SILEP ä½œä¸º HSCR ç®¡ç†çš„å¯è¡Œæ›¿ä»£æ–¹æ¡ˆçš„å¯è¡Œæ€§ã€‚", "keywords_zh": "è‚ é“åŠŸèƒ½ï¼Œå…ˆå¤©æ€§å·¨ç»“è‚ ï¼Œè…¹è…”é•œï¼ŒèŸèƒåˆ†æï¼Œå•åˆ‡å£ï¼ŒSoave æ‰‹æœ¯", "keywords_en": "Bowel function, Hirschsprungâ€™s disease, Laparoscopic, Meta-analysis, Single-incision, Soave procedure", "link": "https://pubmed.ncbi.nlm.nih.gov/41023221/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 29 Sep 2025"}, {"id": "40972340", "title_en": "Postoperative physiotherapy in enhanced recovery pathways: A general surgery evidence update, dominated by colorectal studies", "title_zh": "åŠ é€Ÿåº·å¤è·¯å¾„ä¸­çš„æœ¯åç‰©ç†æ²»ç–—ï¼šä»¥ç»“ç›´è‚ ç ”ç©¶ä¸ºä¸»çš„æ™®å¤–ç§‘è¯æ®æ›´æ–°", "authors": "Thomas W Wainwright", "abstract_en": "**Introduction:** Physiotherapy is a pivotal component of enhanced recovery protocols, particularly in initiating early mobilisation and supporting the return to functional independence. Despite this, there is a lack of guidance on optimal post-mobilisation physiotherapy strategies. This systematic review aims to synthesise and critically appraise the most recent evidence on postoperative physiotherapy interventions within enhanced recovery pathways for general surgical patients. This review seeks to advance scientific understanding and provide guidance for the optimisation of physiotherapy practice within enhanced recovery pathways.\n\n**Materials And Methods:** A systematic review of the literature between 2000 and 2024 was conducted to identify studies of physiotherapy interventions in general surgical populations following an enhanced recovery protocol.\n\n**Results:** Ten studies met the inclusion criteria. Six studies were conducted in colorectal patients, one study (plus a secondary analysis) was conducted in radical cystectomy patients, one in head and neck patients undergoing oncologic resection, and one included a mixed patient sample (colon, rectum, stomach, pancreas and liver surgery). Interventions involving early physiotherapy were found to benefit postoperative walking distance, achievement of activities of daily living and length of stay in hospital. There was mixed evidence for influence on readiness for discharge, quality of recovery measures and health-related quality of life. No consistent effects were observed for inpatient satisfaction or functional outcome.\n\n**Conclusion:** This review supports the feasibility and potential benefits of a structured physiotherapy interventions within enhanced recovery protocols. These results highlight the potential for structured mobilisation interventions to enhance recovery, particularly when supported by education and technology-based strategies.", "abstract_zh": "**ä»‹ç»ï¼š** ç‰©ç†æ²»ç–—æ˜¯åŠ é€Ÿåº·å¤æ–¹æ¡ˆçš„å…³é”®ç»„æˆéƒ¨åˆ†ï¼Œç‰¹åˆ«æ˜¯åœ¨å¯åŠ¨æ—©æœŸæ´»åŠ¨å’Œæ”¯æŒæ¢å¤åŠŸèƒ½ç‹¬ç«‹æ–¹é¢ã€‚å°½ç®¡å¦‚æ­¤ï¼Œä»ç¼ºä¹å…³äºæœ€ä½³åŠ¨å‘˜åç‰©ç†æ²»ç–—ç­–ç•¥çš„æŒ‡å¯¼ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨ç»¼åˆå¹¶ä¸¥æ ¼è¯„ä¼°æ™®é€šå¤–ç§‘æ‚£è€…åŠ é€Ÿåº·å¤é€”å¾„æœ¯åç‰©ç†æ²»ç–—å¹²é¢„çš„æœ€æ–°è¯æ®ã€‚æœ¬ç»¼è¿°æ—¨åœ¨å¢è¿›ç§‘å­¦ç†è§£ï¼Œå¹¶ä¸ºåŠ é€Ÿåº·å¤é€”å¾„ä¸­ç‰©ç†æ²»ç–—å®è·µçš„ä¼˜åŒ–æä¾›æŒ‡å¯¼ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** å¯¹ 2000 å¹´è‡³ 2024 å¹´æœŸé—´çš„æ–‡çŒ®è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥ç¡®å®šåœ¨åŠ é€Ÿåº·å¤æ–¹æ¡ˆåå¯¹æ™®é€šæ‰‹æœ¯äººç¾¤è¿›è¡Œç‰©ç†æ²»ç–—å¹²é¢„çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** åé¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚å…­é¡¹ç ”ç©¶åœ¨ç»“ç›´è‚ æ‚£è€…ä¸­è¿›è¡Œï¼Œä¸€é¡¹ç ”ç©¶ï¼ˆåŠ ä¸ŠäºŒæ¬¡åˆ†æï¼‰æ˜¯åœ¨æ ¹æ²»æ€§è†€èƒ±åˆ‡é™¤æœ¯æ‚£è€…ä¸­è¿›è¡Œçš„ï¼Œä¸€é¡¹ç ”ç©¶æ˜¯åœ¨æ¥å—è‚¿ç˜¤åˆ‡é™¤æœ¯çš„å¤´é¢ˆéƒ¨æ‚£è€…ä¸­è¿›è¡Œçš„ï¼Œä¸€é¡¹ç ”ç©¶åŒ…æ‹¬æ··åˆæ‚£è€…æ ·æœ¬ï¼ˆç»“è‚ ã€ç›´è‚ ã€èƒƒã€èƒ°è…ºå’Œè‚è„æ‰‹æœ¯ï¼‰ã€‚ç ”ç©¶å‘ç°ï¼Œæ¶‰åŠæ—©æœŸç‰©ç†æ²»ç–—çš„å¹²é¢„æªæ–½æœ‰åˆ©äºæœ¯åæ­¥è¡Œè·ç¦»ã€æ—¥å¸¸ç”Ÿæ´»æ´»åŠ¨çš„å®Œæˆåº¦å’Œä½é™¢æ—¶é—´ã€‚å¯¹äºå‡ºé™¢å‡†å¤‡ã€åº·å¤æªæ–½è´¨é‡å’Œå¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡çš„å½±å“ï¼Œè¯æ®ä¸ä¸€ã€‚å¯¹äºä½é™¢æ‚£è€…æ»¡æ„åº¦æˆ–åŠŸèƒ½ç»“æœæ²¡æœ‰è§‚å¯Ÿåˆ°ä¸€è‡´çš„æ•ˆæœã€‚\n\n**ç»“è®ºï¼š** è¿™ç¯‡ç»¼è¿°æ”¯æŒäº†å¼ºåŒ–åº·å¤æ–¹æ¡ˆä¸­ç»“æ„åŒ–ç‰©ç†æ²»ç–—å¹²é¢„æªæ–½çš„å¯è¡Œæ€§å’Œæ½œåœ¨ç›Šå¤„ã€‚è¿™äº›ç»“æœå‡¸æ˜¾äº†ç»“æ„åŒ–åŠ¨å‘˜å¹²é¢„æªæ–½åœ¨ä¿ƒè¿›åº·å¤æ–¹é¢çš„æ½œåŠ›ï¼Œç‰¹åˆ«æ˜¯åœ¨æ•™è‚²å’ŒæŠ€æœ¯æˆ˜ç•¥çš„æ”¯æŒä¸‹ã€‚", "keywords_zh": "åŠ é€Ÿåº·å¤å¤–ç§‘ (ERAS)ã€æ´»åŠ¨ã€ç‰©ç†æ²»ç–—ã€æ¢å¤ã€åº·å¤ã€æ‰‹æœ¯", "keywords_en": "Enhanced recovery after surgery (ERAS), Mobilisation, Physiotherapy, Recovery, Rehabilitation, Surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40972340/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 19 Sep 2025"}, {"id": "40968352", "title_en": "Stroke risk in cancer survivors: A meta-analysis and meta regression", "title_zh": "ç™Œç—‡å¹¸å­˜è€…çš„ä¸­é£é£é™©ï¼šèŸèƒåˆ†æå’ŒèŸèƒå›å½’", "authors": "Rommel Mario RodrÃ­guez Burbano", "abstract_en": "**Introduction:** It is suggested that survivors of different types of cancer may have an increased risk of stroke. Our study aims to evaluate cancer patients and non-cancer controls by analyzing stroke events in each group. Previous studies concluded that certain types of cancer increased stroke risk, however, their results had significant heterogeneity and statistical concerns.\n\n**Methods:** Medline, Embase, and Cochrane databases were systematically searched until February 18th, 2024, assessing stroke in cancer survivor patients compared to the global population. Data were examined using the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed using IÂ² statistics. Rstudio software, version 4.2.3., was used for statistical analysis.\n\n**Results:** A total of 18 studies were included, and stroke was reported in both cancer and non-cancer groups. Breast cancer (HR 1.09; 95% CI 1.02-1.17; pâ€‰=â€‰0.01; IÂ²= 0%), Central Nervous System cancers (HR 2.47; 95% CI 1.01-6.01; pâ€‰=â€‰0.047; IÂ²= 78%), cervical cancers (HR 1.58; 95% CI 1.19-2.09; pâ€‰=â€‰0.001; IÂ²= 0%), head and neck cancers (HR 1.4439; 95% CI 1.3095-1.5922; pâ€‰<â€‰0.001; IÂ²=31.5%), lung cancers (HR 1.60; 95% CI 1.40-1.83; pâ€‰<â€‰0.001; IÂ²=67%), multiple myeloma (HR 1.58; 95% CI 1.32-1.89; pâ€‰<â€‰0.001; IÂ²= 49%), nasopharyngeal cancers (HR 1.9178; 95% CI 1.3358-2.7533; pâ€‰<â€‰0.001; IÂ²=89.7%), oesophageal cancers (HR 1.33; 95% CI 1.07-1.65; pâ€‰=â€‰0.009; IÂ²= 0%), ovarian cancers (HR 1.33; 95% CI 1.07-1.65; pâ€‰=â€‰0.01; IÂ²= 38%), pancreatic cancers (HR 2,70; 95% CI 2.34-3.11; pâ€‰<â€‰0.001; IÂ²= 0%) and rectum cancers (HR 1.29; 95% CI 1.01-1.63; pâ€‰=â€‰0.04; IÂ²= 0%) showed statistically significant differences between groups in favor of non-cancer controls.\n\n**Conclusions:** In this meta-analysis, the stroke risk was increased in all cancers that reached statistical significance. Furthermore, our study brings relevant data to the body of literature concerning this long-term clinical uncertainty.", "abstract_zh": "**ä»‹ç»ï¼š** ç ”ç©¶è¡¨æ˜ï¼Œä¸åŒç±»å‹ç™Œç—‡çš„å¹¸å­˜è€…æ‚£ä¸­é£çš„é£é™©å¯èƒ½ä¼šå¢åŠ ã€‚æˆ‘ä»¬çš„ç ”ç©¶æ—¨åœ¨é€šè¿‡åˆ†ææ¯ç»„çš„ä¸­é£äº‹ä»¶æ¥è¯„ä¼°ç™Œç—‡æ‚£è€…å’Œéç™Œç—‡å¯¹ç…§ã€‚å…ˆå‰çš„ç ”ç©¶å¾—å‡ºçš„ç»“è®ºæ˜¯ï¼ŒæŸäº›ç±»å‹çš„ç™Œç—‡ä¼šå¢åŠ ä¸­é£é£é™©ï¼Œç„¶è€Œï¼Œä»–ä»¬çš„ç»“æœå­˜åœ¨æ˜¾ç€çš„å¼‚è´¨æ€§å’Œç»Ÿè®¡é—®é¢˜ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2024 å¹´ 2 æœˆ 18 æ—¥ï¼Œå¯¹ Medlineã€Embase å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œè¯„ä¼°äº†ç™Œç—‡å¹¸å­˜è€…æ‚£è€…ä¸­é£ä¸å…¨çƒäººå£çš„æƒ…å†µã€‚ä½¿ç”¨ Mantel-Haenszel æ–¹æ³•å’Œ 95% CI æ£€æŸ¥æ•°æ®ã€‚ä½¿ç”¨ IÂ² ç»Ÿè®¡æ•°æ®è¯„ä¼°å¼‚è´¨æ€§ã€‚ä½¿ç”¨Rstudioè½¯ä»¶4.2.3ç‰ˆè¿›è¡Œç»Ÿè®¡åˆ†æã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥äº† 18 é¡¹ç ”ç©¶ï¼Œç™Œç—‡ç»„å’Œéç™Œç—‡ç»„å‡æŠ¥å‘Šäº†ä¸­é£ã€‚ä¹³è…ºç™Œï¼ˆHR 1.09ï¼›95% CI 1.02-1.17ï¼›pâ€‰=â€‰0.01ï¼›IÂ²= 0%ï¼‰ã€ä¸­æ¢ç¥ç»ç³»ç»Ÿç™Œç—‡ï¼ˆHR 2.47ï¼›95% CI 1.01-6.01ï¼›pâ€‰=â€‰0.047ï¼›IÂ²= 78%ï¼‰ã€å®«é¢ˆç™Œï¼ˆHR 1.58ï¼›95% CI 1.19-2.09ï¼›pâ€‰=â€‰0.001ï¼›IÂ²= 0%ï¼‰ã€å¤´é¢ˆç™Œï¼ˆHR 1.4439ï¼›95% CI 1.3095-1.5922ï¼›pâ€‰<â€‰0.001ï¼›IÂ²=31.5%ï¼‰ã€è‚ºç™Œï¼ˆHR 1.60ï¼›95% CI 1.40-1.83ï¼›p<â€‰0.001ï¼›IÂ²=67%ï¼‰ã€å¤šå‘æ€§éª¨é«“ç˜¤ï¼ˆHR 1.58ï¼›95% CI 1.32-1.89ï¼›p<â€‰0.001ï¼›IÂ²= 49%ï¼‰ã€é¼»å’½ç™Œï¼ˆHR 1.9178ï¼›95% CI 1.3358-2.7533ï¼›pâ€‰<â€‰0.001ï¼›IÂ²=89.7%ï¼‰ã€é£Ÿé“ç™Œï¼ˆHR 1.33ï¼›95% CI 1.07-1.65ï¼›pâ€‰=â€‰0.009ï¼›IÂ²= 0%ï¼‰ã€åµå·¢ç™Œï¼ˆHR 1.33ï¼›95% CI 1.07-1.65ï¼›pâ€‰=â€‰0.01ï¼›IÂ²= 38%ï¼‰ã€èƒ°è…ºç™Œï¼ˆHR 2.70ï¼›95% CI 2.34-3.11ï¼›pâ€‰<â€‰0.001ï¼›IÂ²= 0%ï¼‰å’Œç›´è‚ ç™Œï¼ˆHR 1.29ï¼›95% CI 1.01-1.63ï¼› pâ€‰=â€‰0.04ï¼›IÂ²= 0%ï¼‰æ˜¾ç¤ºç»„é—´å­˜åœ¨ç»Ÿè®¡å­¦æ˜¾ç€å·®å¼‚ï¼Œæœ‰åˆ©äºéç™Œç—‡å¯¹ç…§ã€‚\n\n**ç»“è®ºï¼š** åœ¨è¿™é¡¹èŸèƒåˆ†æä¸­ï¼Œæ‰€æœ‰ç™Œç—‡çš„ä¸­é£é£é™©å‡å¢åŠ ï¼Œå¹¶è¾¾åˆ°ç»Ÿè®¡å­¦æ˜¾ç€æ€§ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬çš„ç ”ç©¶ä¸ºæœ‰å…³è¿™ç§é•¿æœŸä¸´åºŠä¸ç¡®å®šæ€§çš„æ–‡çŒ®æä¾›äº†ç›¸å…³æ•°æ®ã€‚", "keywords_zh": "ç™Œç—‡å¹¸å­˜è€…ã€èŸèƒåˆ†æã€ä¸­é£é£é™©", "keywords_en": "Cancer survivors, Meta-Analysis, Stroke risk", "link": "https://pubmed.ncbi.nlm.nih.gov/40968352/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 19 Sep 2025"}, {"id": "40956186", "title_en": "Clinicopathological characteristics and biomarker alterations in early-onset vs. late-onset colorectal cancer: a systematic review and meta-analysis", "title_zh": "æ—©å‘æ€§ç»“ç›´è‚ ç™Œä¸æ™šå‘æ€§ç»“ç›´è‚ ç™Œçš„ä¸´åºŠç—…ç†å­¦ç‰¹å¾å’Œç”Ÿç‰©æ ‡å¿—ç‰©å˜åŒ–ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Lie Yang", "abstract_en": "**Background:** The clinicopathological and molecular characteristics of early-onset colorectal cancer (EOCRC) are unclear. In this study, we compared the clinicopathological features, biomarkers, and prognoses between EOCRC and late-onset colorectal cancer (LOCRC).\n\n**Methods:** A search was conducted on PubMed, Web of Science, Embase, and Cochrane Library from inception to May 2024. The key outcomes were clinicopathological features, prevalence of molecular biomarker alterations, and 5-year overall survival (OS), with pooled odds ratios (ORs) and hazard ratios (HRs), along with their corresponding 95% confidence intervals (CIs), calculated for each outcome.\n\n**Results:** Forty studies were included in the final analysis. EOCRC exhibited distal colon and rectum localization (OR: 0.59; 95% CI: 0.55-0.62; P < 0.001), was poorly differentiated (OR: 0.56; 95% CI: 0.52-0.60; P = 0.01), tended to be more mucinous or signet-ring cell carcinoma (OR: 0.56; 95% CI: 0.52-0.60; P < 0.001), and was associated with advanced stages (OR: 1.49; 95% CI: 1.30-1.71; P < 0.001), lymph node metastasis (LNM) (OR: 0.56; 95% CI: 0.53-0.60; P < 0.001), and distant metastasis (OR: 1.29; 95% CI: 1.04-1.60; P = 0.02). EOCRC exhibited higher TP53 mutation rates (OR: 1.33; 95% CI: 1.13-1.58; P < 0.001), MSI-H status (OR: 1.45; 95% CI: 1.10-1.92; P = 0.01), but lower PIK3CA mutation rates (OR: 0.93; 95% CI: 0.88-0.99; P = 0.03). EOCRC and LOCRC had similar 5-year OS rates (HR: 1.01; 95% CI: 0.79-1.30; P = 0.92). Although no significant difference was observed in the APC, BRAF, KRAS, NRAS, SM4D4, and MMR, subgroup analyses revealed that BRAF ( P = 0.01), KRAS mutations ( P < 0.001), and DNA hypermethylation ( P = 0.01) were less prevalent among westerners.\n\n**Conclusion:** EOCRC often presents with more aggressive and metastatic features due to its frequent diagnosis at advanced stages. TP53 mutations and the MSI-H status are prevalent in EOCRC. EOCRC's prognosis is often comparable to LOCRC. Radical and tailored treatment strategies should be developed to improve the survival outcomes in advanced and metastatic EOCRC.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ˆEOCRCï¼‰çš„ä¸´åºŠç—…ç†å­¦å’Œåˆ†å­ç‰¹å¾å°šä¸æ¸…æ¥šã€‚åœ¨è¿™é¡¹ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬æ¯”è¾ƒäº† EOCRC å’Œæ™šå‘ç»“ç›´è‚ ç™Œ (LOCRC) çš„ä¸´åºŠç—…ç†ç‰¹å¾ã€ç”Ÿç‰©æ ‡å¿—ç‰©å’Œé¢„åã€‚\n\n**æ–¹æ³•ï¼š** ä»å¼€å§‹åˆ° 2024 å¹´ 5 æœˆï¼Œæˆ‘ä»¬åœ¨ PubMedã€Web of Scienceã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ä¸Šè¿›è¡Œäº†æ£€ç´¢ã€‚ä¸»è¦ç»“æœæ˜¯ä¸´åºŠç—…ç†å­¦ç‰¹å¾ã€åˆ†å­ç”Ÿç‰©æ ‡è®°ç‰©æ”¹å˜çš„å‘ç”Ÿç‡å’Œ 5 å¹´æ€»ç”Ÿå­˜ç‡ (OS)ï¼Œä»¥åŠé’ˆå¯¹æ¯ä¸ªç»“æœè®¡ç®—çš„æ±‡æ€»æ¯”å€¼æ¯” (OR) å’Œé£é™©æ¯” (HR) åŠå…¶ç›¸åº”çš„ 95% ç½®ä¿¡åŒºé—´ (CI)ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆåˆ†æä¸­çº³å…¥äº†å››åé¡¹ç ”ç©¶ã€‚ EOCRC è¡¨ç°å‡ºè¿œç«¯ç»“è‚ å’Œç›´è‚ å®šä½ï¼ˆORï¼š0.59ï¼›95% CIï¼š0.55-0.62ï¼›P < 0.001ï¼‰ï¼Œåˆ†åŒ–ä¸è‰¯ï¼ˆORï¼š0.56ï¼›95% CIï¼š0.52-0.60ï¼›P = 0.01ï¼‰ï¼Œå€¾å‘äºæ›´å¤šç²˜æ¶²æ€§æˆ–å°æˆ’ç»†èƒç™Œï¼ˆORï¼š0.56ï¼›95% CIï¼š 0.52-0.60ï¼›P < 0.001ï¼‰ï¼Œå¹¶ä¸”ä¸æ™šæœŸï¼ˆORï¼š1.49ï¼›95% CIï¼š1.30-1.71ï¼›P < 0.001ï¼‰ã€æ·‹å·´ç»“è½¬ç§»ï¼ˆLNMï¼‰ï¼ˆORï¼š0.56ï¼›95% CIï¼š0.53-0.60ï¼›P < 0.001ï¼‰å’Œè¿œå¤„è½¬ç§»ï¼ˆORï¼š 1.29ï¼›95% CIï¼š1.04-1.60ï¼›P = 0.02ï¼‰ã€‚ EOCRC è¡¨ç°å‡ºè¾ƒé«˜çš„ TP53 çªå˜ç‡ï¼ˆORï¼š1.33ï¼›95% CIï¼š1.13-1.58ï¼›P < 0.001ï¼‰ã€MSI-H çŠ¶æ€ï¼ˆORï¼š1.45ï¼›95% CIï¼š1.10-1.92ï¼›P = 0.01ï¼‰ï¼Œä½† PIK3CA çªå˜ç‡è¾ƒä½ï¼ˆORï¼š0.93ï¼›95% CIï¼š 0.88-0.99ï¼›P = 0.03ï¼‰ã€‚ EOCRC å’Œ LOCRC çš„ 5 å¹´ OS ç‡ç›¸ä¼¼ï¼ˆHRï¼š1.01ï¼›95% CIï¼š0.79-1.30ï¼›P = 0.92ï¼‰ã€‚å°½ç®¡APCã€BRAFã€KRASã€NRASã€SM4D4å’ŒMMRæ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ï¼Œä½†äºšç»„åˆ†ææ˜¾ç¤ºBRAFï¼ˆP=0.01ï¼‰ã€KRASçªå˜ï¼ˆP<0.001ï¼‰å’ŒDNAé«˜ç”²åŸºåŒ–ï¼ˆP=0.01ï¼‰åœ¨è¥¿æ–¹äººä¸­è¾ƒå°‘è§ã€‚\n\n**ç»“è®ºï¼š** ç”±äº EOCRC ç»å¸¸åœ¨æ™šæœŸè¯Šæ–­ï¼Œå› æ­¤é€šå¸¸è¡¨ç°å‡ºæ›´å…·ä¾µè¢­æ€§å’Œè½¬ç§»æ€§çš„ç‰¹å¾ã€‚ TP53 çªå˜å’Œ MSI-H çŠ¶æ€åœ¨ EOCRC ä¸­æ™®éå­˜åœ¨ã€‚ EOCRC çš„é¢„åé€šå¸¸ä¸ LOCRC ç›¸å½“ã€‚åº”åˆ¶å®šæ ¹æ²»æ€§å’Œé‡èº«å®šåˆ¶çš„æ²»ç–—ç­–ç•¥ï¼Œä»¥æ”¹å–„æ™šæœŸå’Œè½¬ç§»æ€§ EOCRC çš„ç”Ÿå­˜ç»“æœã€‚", "keywords_zh": "ä¸´åºŠç—…ç†ç‰¹å¾, ç»“ç›´è‚ ç™Œ, æ—©å‘å‹, åˆ†å­ç”Ÿç‰©æ ‡å¿—ç‰©, ç”Ÿå­˜", "keywords_en": "clinicopathological features, colorectal cancer, early-onset, molecular biomarker, survival", "link": "https://pubmed.ncbi.nlm.nih.gov/40956186/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 16 Sep 2025"}, {"id": "40944330", "title_en": "Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: a systematic review and meta-analysis", "title_zh": "äºšç”²è“æ²»ç–—ç—”ç–®æœ¯åç–¼ç—›çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Li Xu", "abstract_en": "**Objectives:** Pain is a common complication after haemorrhoid surgery. In addition to anaesthetic methods, surgical techniques and postoperative interventions, surgeons also use intraoperative adjuncts to alleviate postoperative pain. This study aims to evaluate the effectiveness and safety of methylene blue in reducing postoperative pain in haemorrhoid patients.\n\n**Methods:** A search was conducted in PubMed, Embase, Cochrane Library and Web of Science for randomized controlled trials (RCTs) up until 9 December 2024, involving methylene blue use for pain relief after haemorrhoid surgery. Two reviewers independently assessed the study eligibility, extracted data and evaluated the risk of bias. Data analysis was performed using Stata 18 software. The primary outcome was the visual analogue scale (VAS) pain scores at different time points within 14â€‰days postoperatively. Secondary outcomes included the number of patients requiring analgesics and the occurrence of complications.\n\n**Results:** 358 articles were retrieved and six studies involving 598 patients were included after screening. Compared with the control group, the use of methylene blue reduced pain within 12â€‰h postoperatively(WMD -1.582, 95% CI -2.834 to -0.330, <i>p</i>â€‰=â€‰.013), as well as on day 2 (WMD -1.441, 95% CI - 1.874 to -1.008, <i>p</i>â€‰<â€‰.0001), day 3 (WMD -0.975, 95% CI -1.309 to -0.641, <i>p</i>â€‰<â€‰.0001), day 5(WMD -0.786, 95% CI -1.094 to -0.478, <i>p</i>â€‰=â€‰.028) and day 7 (WMD -0.679, 95% CI -1.257 to -0.101, <i>p</i>â€‰=â€‰.021), decreased the number of patients using analgesics(RR 0.293, 95% CI 0.203 to 0.422, <i>p</i>â€‰<â€‰.0001) and did not increase the incidence of complications(RR 0.65, 95% CI 0.39-1.10, <i>p</i>â€‰=â€‰.111) such as urinary retention, secondary haemorrhage, pruritus, temporary incontinence, wound infection, or local skin reactions.\n\n**Conclusions:** This study shows that methylene blue can reduce postoperative pain, decrease analgesic use and does not increase complications after haemorrhoid surgery.", "abstract_zh": "**Objectivesï¼š** ç–¼ç—›æ˜¯ç—”ç–®æ‰‹æœ¯åå¸¸è§çš„å¹¶å‘ç—‡ã€‚é™¤äº†éº»é†‰æ–¹æ³•ã€æ‰‹æœ¯æŠ€æœ¯å’Œæœ¯åå¹²é¢„å¤–ï¼Œå¤–ç§‘åŒ»ç”Ÿè¿˜ä½¿ç”¨æœ¯ä¸­è¾…åŠ©æ‰‹æ®µæ¥å‡è½»æœ¯åç–¼ç—›ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°äºšç”²è“å‡è½»ç—”ç–®æ‚£è€…æœ¯åç–¼ç—›çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ PubMedã€Embaseã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä¸­æ£€ç´¢äº†æˆªè‡³ 2024 å¹´ 12 æœˆ 9 æ—¥çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œæ¶‰åŠäºšç”²è“ç”¨äºç¼“è§£ç—”ç–®æ‰‹æœ¯åçš„ç–¼ç—›ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¯„ä¼°ç ”ç©¶èµ„æ ¼ã€æå–æ•°æ®å¹¶è¯„ä¼°åå€šé£é™©ã€‚ä½¿ç”¨Stata 18è½¯ä»¶è¿›è¡Œæ•°æ®åˆ†æã€‚ä¸»è¦ç»“æœæ˜¯æœ¯å14å¤©å†…ä¸åŒæ—¶é—´ç‚¹çš„è§†è§‰æ¨¡æ‹Ÿè¯„åˆ†ï¼ˆVASï¼‰ç–¼ç—›è¯„åˆ†ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬éœ€è¦é•‡ç—›è¯çš„æ‚£è€…æ•°é‡å’Œå¹¶å‘ç—‡çš„å‘ç”Ÿç‡ã€‚\n\n**ç»“æœï¼š** ç­›é€‰åå…±æ£€ç´¢åˆ° 358 ç¯‡æ–‡ç« ï¼Œçº³å…¥ 6 é¡¹æ¶‰åŠ 598 åæ‚£è€…çš„ç ”ç©¶ã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œä½¿ç”¨äºšç”²åŸºè“å¯å‡è½»æœ¯å 12 å°æ—¶å†…çš„ç–¼ç—›ï¼ˆWMD -1.582ï¼Œ95% CI -2.834 è‡³ -0.330ï¼Œ<i>p</i>â€‰=â€‰.013ï¼‰ä»¥åŠç¬¬ 2 å¤©ï¼ˆWMD -1.441ï¼Œ95% CI -1.874 è‡³ -1.008ï¼Œ <i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œç¬¬ 3 å¤©ï¼ˆWMD -0.975ï¼Œ95% CI -1.309 è‡³ -0.641ï¼Œ<i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œç¬¬ 5 å¤©ï¼ˆWMD -0.786ï¼Œ95% CI -1.094 è‡³ -0.478ï¼Œ <i>p</i>â€‰=â€‰.028ï¼‰å’Œç¬¬7å¤©ï¼ˆWMD -0.679ï¼Œ95% CI -1.257è‡³-0.101ï¼Œ<i>p</i>â€‰=â€‰.021ï¼‰ï¼Œä½¿ç”¨é•‡ç—›è¯çš„æ‚£è€…æ•°é‡å‡å°‘ï¼ˆRR 0.293ï¼Œ95% CI 0.203è‡³0.422ï¼Œ <i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œå¹¶ä¸”ä¸ä¼šå¢åŠ å°¿æ½´ç•™ã€ç»§å‘æ€§å‡ºè¡€ã€ç˜™ç—’ã€æš‚æ—¶å¤±ç¦ã€ä¼¤å£æ„ŸæŸ“æˆ–å±€éƒ¨çš®è‚¤ååº”ç­‰å¹¶å‘ç—‡çš„å‘ç”Ÿç‡ï¼ˆRR 0.65ï¼Œ95% CI 0.39-1.10ï¼Œ<i>p</i>â€‰=â€‰.111ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼Œäºšç”²è“å¯ä»¥å‡è½»æœ¯åç–¼ç—›ï¼Œå‡å°‘é•‡ç—›è¯çš„ä½¿ç”¨ï¼Œå¹¶ä¸”ä¸ä¼šå¢åŠ ç—”ç–®æ‰‹æœ¯åçš„å¹¶å‘ç—‡ã€‚", "keywords_zh": "é•‡ç—›ï¼Œç—”ç–®åˆ‡é™¤æœ¯ï¼Œäºšç”²è“ï¼Œæœ¯åç–¼ç—›", "keywords_en": "Analgesia, haemorrhoidectomy, methylene blue, postoperative pain", "link": "https://pubmed.ncbi.nlm.nih.gov/40944330/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 13 Sep 2025"}, {"id": "40914745", "title_en": "Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis of oncological, perioperative, and survival-related outcomes", "title_zh": "æ–°è¾…åŠ©æ”¾åŒ–ç–—åæœºå™¨äººä¸è…¹è…”é•œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯æ²»ç–—ä¸­ä½ä½ç›´è‚ ç™Œï¼šè‚¿ç˜¤å­¦ã€å›´æ‰‹æœ¯æœŸå’Œç”Ÿå­˜ç›¸å…³ç»“æœçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Shukai Wang", "abstract_en": "A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT. A PRISMA-compliant systematic review and meta-analysis included 20 non-randomized studies (13,212 patients) from Web of Science, PubMed, and Embase up to July 2025. Outcomes encompassed pathological completeness (circumferential resection margin, TME quality), perioperative metrics (operative duration, conversion rates), complications, and survival (5-year OS/DFS). Risk of bias was assessed via ROBINS-I; statistical synthesis utilized RevMan5.4 and hazard ratios derived from Kaplan-Meier curves. This meta-analysis of 20 non-randomized studies (13,212 patients) found no significant differences in 5-year overall survival (HR: 1.07, 95% CI 0.20-5.66, pâ€‰=â€‰0.94, I<sup>2</sup>â€‰=â€‰98%) or disease-free survival (HR: 1.16, 95% CI 0.72-1.89, pâ€‰=â€‰0.54, I<sup>2</sup>â€‰=â€‰0%) between robotic and laparoscopic TME after nCRT. Robotic surgery demonstrated superior technical outcomes, including higher rates of complete TME (OR: 1.97, pâ€‰=â€‰0.02) and reduced conversion to open surgery (OR: 0.46, pâ€‰<â€‰0.001), but required significantly longer operative time (WMD:â€‰+â€‰42.09Â min, pâ€‰<â€‰0.001). Perioperative metrics showed equivalence in intraoperative blood loss (pâ€‰=â€‰0.20), hospitalization duration (pâ€‰=â€‰0.78), and postoperative complications, including anastomotic leakage (5.4% vs. 6.5%, pâ€‰=â€‰0.28) and Clavien-Dindo III-IV events (OR: 1.11, pâ€‰=â€‰0.54). Pathological outcomes were comparable, with no differences in circumferential resection margin positivity (OR: 1.0, pâ€‰=â€‰1), distal margin length (pâ€‰=â€‰0.92), or lymph-node yield (pâ€‰=â€‰0.55). Local (OR: 0.85, pâ€‰=â€‰0.34) and distant recurrence rates (pâ€‰=â€‰0.99) were statistically indistinguishable. Risk-of-bias assessment revealed confounding risks in non-randomized designs, underscoring the need for RCT validation. Robotic and laparoscopic TME achieve equivalent long-term survival and oncological control after nCRT, with robotic advantages in technical precision counterbalanced by prolonged operative duration. The equivalence underscores nCRT's dominant role in tumor control, while procedural differences highlight context-dependent surgical feasibility. High heterogeneity in survival data and reliance on non-randomized evidence necessitate validation through rigorously designed RCTs incorporating standardized protocols and patient-reported functional outcomes.", "abstract_zh": "ä½œä¸ºç™Œç—‡æ­»äº¡çš„ä¸»è¦åŸå› ï¼Œç»“ç›´è‚ ç™Œåœ¨å¹´è½»äººä¸­å˜å¾—è¶Šæ¥è¶Šå¸¸è§ã€‚æœºå™¨äººä¸è…¹è…”é•œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆTMEï¼‰ä½œä¸ºæ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼ˆnCRTï¼‰åä¸­ä½ä½ç›´è‚ ç™Œæ‰‹æœ¯å¹²é¢„çš„æ•ˆæœä»ä¸ç¡®å®šã€‚ç³»ç»Ÿè¯„ä¼° nCRT åæœºå™¨äººä¸è…¹è…”é•œæ‰‹æœ¯æ²»ç–—ä¸­ä½ä½ç›´è‚ ç™Œçš„è‚¿ç˜¤å­¦ã€å›´æ‰‹æœ¯æœŸå’Œç”Ÿå­˜ç»“æœã€‚ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æåŒ…æ‹¬æˆªè‡³ 2025 å¹´ 7 æœˆæ¥è‡ª Web of Scienceã€PubMed å’Œ Embase çš„ 20 é¡¹ééšæœºç ”ç©¶ï¼ˆ13,212 åæ‚£è€…ï¼‰ã€‚ç»“æœåŒ…æ‹¬ç—…ç†å®Œæ•´æ€§ï¼ˆåœ†å‘¨åˆ‡é™¤è¾¹ç¼˜ã€TME è´¨é‡ï¼‰ã€å›´æ‰‹æœ¯æœŸæŒ‡æ ‡ï¼ˆæ‰‹æœ¯æŒç»­æ—¶é—´ã€è½¬æ¢ç‡ï¼‰ã€å¹¶å‘ç—‡å’Œç”Ÿå­˜ç‡ï¼ˆ5 å¹´ OS/DFSï¼‰ã€‚é€šè¿‡ ROBINS-I è¯„ä¼°åå€šé£é™©ï¼›ç»Ÿè®¡ç»¼åˆåˆ©ç”¨ RevMan5.4 å’Œæºè‡ª Kaplan-Meier æ›²çº¿çš„é£é™©æ¯”ã€‚è¿™é¡¹å¯¹ 20 é¡¹ééšæœºç ”ç©¶ï¼ˆ13,212 åæ‚£è€…ï¼‰çš„èŸèƒåˆ†æå‘ç°ï¼Œ5 å¹´æ€»ç”Ÿå­˜ç‡ï¼ˆHRï¼š1.07ï¼Œ95% CI 0.20-5.66ï¼Œpâ€‰=â€‰0.94ï¼ŒI<sup>2</sup>â€‰=â€‰98%ï¼‰æˆ–æ— ç—…ç”Ÿå­˜ç‡ï¼ˆHRï¼š1.16ï¼Œ95% CIï¼‰æ²¡æœ‰æ˜¾ç€å·®å¼‚nCRT åæœºå™¨äºº TME ä¸è…¹è…”é•œ TME ä¹‹é—´çš„å·®å¼‚ä¸º 0.72-1.89ï¼Œpâ€‰=â€‰0.54ï¼ŒI<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚æœºå™¨äººæ‰‹æœ¯è¡¨ç°å‡ºä¼˜è¶Šçš„æŠ€æœ¯æˆæœï¼ŒåŒ…æ‹¬æ›´é«˜çš„å®Œå…¨ TME ç‡ï¼ˆORï¼š1.97ï¼Œpâ€‰=â€‰0.02ï¼‰å’Œå‡å°‘ä¸­è½¬å¼€æ”¾æ‰‹æœ¯ï¼ˆORï¼š0.46ï¼Œpâ€‰<â€‰0.001ï¼‰ï¼Œä½†éœ€è¦æ˜æ˜¾æ›´é•¿çš„æ‰‹æœ¯æ—¶é—´ï¼ˆWMDï¼šâ€‰+â€‰42.09 åˆ†é’Ÿï¼Œpâ€‰<â€‰0.001ï¼‰ã€‚å›´æ‰‹æœ¯æœŸæŒ‡æ ‡æ˜¾ç¤ºæœ¯ä¸­å¤±è¡€é‡ (pâ€‰=â€‰0.20)ã€ä½é™¢æ—¶é—´ (pâ€‰=â€‰0.78) å’Œæœ¯åå¹¶å‘ç—‡ï¼ŒåŒ…æ‹¬å»åˆå£ç˜˜ï¼ˆ5.4% vs. 6.5%ï¼Œpâ€‰=â€‰0.28ï¼‰å’Œ Clavien-Dindo III-IV äº‹ä»¶ï¼ˆORï¼š1.11ï¼Œpâ€‰=â€‰0.54ï¼‰ç­‰æ–¹é¢çš„ç­‰æ•ˆæ€§ã€‚ç—…ç†ç»“æœå…·æœ‰å¯æ¯”æ€§ï¼Œç¯å‘¨åˆ‡ç¼˜é˜³æ€§ç‡ï¼ˆORï¼š1.0ï¼Œpâ€‰=â€‰1ï¼‰ã€è¿œç«¯åˆ‡ç¼˜é•¿åº¦ï¼ˆpâ€‰=â€‰0.92ï¼‰æˆ–æ·‹å·´ç»“äº§é‡ï¼ˆpâ€‰=â€‰0.55ï¼‰æ²¡æœ‰å·®å¼‚ã€‚å±€éƒ¨å¤å‘ç‡ï¼ˆORï¼š0.85ï¼Œpâ€‰=â€‰0.34ï¼‰å’Œè¿œå¤„å¤å‘ç‡ï¼ˆpâ€‰=â€‰0.99ï¼‰åœ¨ç»Ÿè®¡å­¦ä¸Šæ— æ³•åŒºåˆ†ã€‚åå€šé£é™©è¯„ä¼°æ­ç¤ºäº†ééšæœºè®¾è®¡ä¸­çš„æ··æ‚é£é™©ï¼Œå¼ºè°ƒäº† RCT éªŒè¯çš„å¿…è¦æ€§ã€‚æœºå™¨äººå’Œè…¹è…”é•œ TME åœ¨ nCRT åå®ç°äº†åŒç­‰çš„é•¿æœŸç”Ÿå­˜å’Œè‚¿ç˜¤æ§åˆ¶ï¼Œæœºå™¨äººåœ¨æŠ€æœ¯ç²¾åº¦æ–¹é¢çš„ä¼˜åŠ¿è¢«å»¶é•¿çš„æ‰‹æœ¯æ—¶é—´æ‰€æŠµæ¶ˆã€‚è¿™ç§ç­‰åŒæ€§å¼ºè°ƒäº† nCRT åœ¨è‚¿ç˜¤æ§åˆ¶ä¸­çš„ä¸»å¯¼ä½œç”¨ï¼Œè€Œç¨‹åºå·®å¼‚åˆ™å¼ºè°ƒäº†æ‰‹æœ¯å¯è¡Œæ€§ã€‚ç”Ÿå­˜æ•°æ®çš„é«˜åº¦å¼‚è´¨æ€§å’Œå¯¹ééšæœºè¯æ®çš„ä¾èµ–éœ€è¦é€šè¿‡ä¸¥æ ¼è®¾è®¡çš„éšæœºå¯¹ç…§è¯•éªŒï¼ˆç»“åˆæ ‡å‡†åŒ–æ–¹æ¡ˆå’Œæ‚£è€…æŠ¥å‘Šçš„åŠŸèƒ½ç»“æœï¼‰è¿›è¡ŒéªŒè¯ã€‚", "keywords_zh": "è…¹è…”é•œæ‰‹æœ¯ã€Metaåˆ†æã€ä¸­ä½ä½ç›´è‚ ç™Œã€æ–°è¾…åŠ©æ”¾åŒ–ç–—ã€æœºå™¨äººæ‰‹æœ¯ã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯", "keywords_en": "Laparoscopic surgery, Meta-analysis, Midâ€“low rectal cancer, Neoadjuvant chemoradiotherapy, Robotic surgery, Total mesorectal excision", "link": "https://pubmed.ncbi.nlm.nih.gov/40914745/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 06 Sep 2025"}, {"id": "40907429", "title_en": "ICG-FA for Anastomotic Leak Prevention During Minimally Invasive Colorectal Surgery: A Meta-analysis", "title_zh": "ICG-FA åœ¨å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´é¢„é˜²å»åˆå£æ¼ï¼šèŸèƒåˆ†æ", "authors": "Muhammad Shehryar Hussain", "abstract_en": "**Introduction:** Anastomotic leakage is a serious complication after colorectal surgery. Indocyanine green fluorescence angiography (ICG-FA) allows real-time perfusion assessment and may reduce leak rates; however, recent larger randomized clinical trials reported conflicting results. This meta-analysis aimed to clarify the effectiveness of ICG-FA in reducing anastomotic leakage and related complications following minimally invasive colorectal surgery.\n\n**Methods:** We conducted a comprehensive search across the databases to identify relevant studies. The search results were imported into Covidence for article eligibility screening, and all relevant outcomes data were synthesized using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs) in meta-analysis models using RevMan 5.4. CRD420251031138.\n\n**Results:** Six randomized clinical trials involving 3264 participants were included. ICG-FA significantly reduced the risk of overall anastomotic leakage (RR: 0.66, 95% CI [0.53-0.83], P = 0.0005) and complications (RR: 0.88, 95% CI [0.78-0.99], P = 0.03). Subgroup analysis showed a significant reduction in leakage for left-sided anastomoses (RR: 0.57, 95% CI [0.44-0.75], P < 0.0001) but not for right-sided ones (RR: 0.90, 95% CI [0.53-1.51], P = 0.68). No significant differences were found in Clavien-Dindo â‰¥3 complications, reoperation rates, or hospital stay. However, the ICG-FA group had a longer operation time (mean difference: 5.57, 95% CI [1.56-9.58], P = 0.006).\n\n**Conclusions:** ICG-FA significantly reduces anastomotic leakage and overall complications in minimally invasive colorectal surgery, especially for left-sided anastomoses. However, its use is associated with a slightly longer operative time. Further research is needed to confirm its role in right-sided procedures and long-term outcomes.", "abstract_zh": "**ä»‹ç»ï¼š** å»åˆå£æ¼æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ã€‚å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±ï¼ˆICG-FAï¼‰å¯è¿›è¡Œå®æ—¶çŒæ³¨è¯„ä¼°ï¼Œå¹¶å¯é™ä½æ¸—æ¼ç‡ï¼›ç„¶è€Œï¼Œæœ€è¿‘æ›´å¤§è§„æ¨¡çš„éšæœºä¸´åºŠè¯•éªŒæŠ¥å‘Šäº†ç›¸äº’çŸ›ç›¾çš„ç»“æœã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨é˜æ˜ ICG-FA åœ¨å‡å°‘å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯åå»åˆå£ç˜˜å’Œç›¸å…³å¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹æ•°æ®åº“è¿›è¡Œäº†å…¨é¢æœç´¢ï¼Œä»¥ç¡®å®šç›¸å…³ç ”ç©¶ã€‚å°†æœç´¢ç»“æœå¯¼å…¥ Covidence è¿›è¡Œæ–‡ç« èµ„æ ¼ç­›é€‰ï¼Œå¹¶ä½¿ç”¨ RevMan 5.4 åœ¨èŸèƒåˆ†ææ¨¡å‹ä¸­ä½¿ç”¨é£é™©æ¯” (RR) æˆ–å¹³å‡å·®ä¸ 95% ç½®ä¿¡åŒºé—´ (CI) åˆæˆæ‰€æœ‰ç›¸å…³ç»“æœæ•°æ®ã€‚ CRD420251031138ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 6 é¡¹éšæœºä¸´åºŠè¯•éªŒï¼Œæ¶‰åŠ 3264 åå‚ä¸è€…ã€‚ ICG-FA æ˜¾ç€é™ä½äº†æ€»ä½“å»åˆå£ç˜˜ï¼ˆRRï¼š0.66ï¼Œ95% CI [0.53-0.83]ï¼ŒP = 0.0005ï¼‰å’Œå¹¶å‘ç—‡ï¼ˆRRï¼š0.88ï¼Œ95% CI [0.78-0.99]ï¼ŒP = 0.03ï¼‰çš„é£é™©ã€‚äºšç»„åˆ†ææ˜¾ç¤ºå·¦ä¾§å»åˆæœ¯çš„æ¸—æ¼æ˜¾ç€å‡å°‘ï¼ˆRRï¼š0.57ï¼Œ95% CI [0.44-0.75]ï¼ŒP < 0.0001ï¼‰ï¼Œä½†å³ä¾§å»åˆæœ¯çš„æ¸—æ¼æ²¡æœ‰æ˜¾ç€å‡å°‘ï¼ˆRRï¼š0.90ï¼Œ95% CI [0.53-1.51]ï¼ŒP = 0.68ï¼‰ã€‚ Clavien-Dindo â‰¥3 ç§å¹¶å‘ç—‡ã€å†æ‰‹æœ¯ç‡æˆ–ä½é™¢æ—¶é—´æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼ŒICG-FAç»„çš„æ‰‹æœ¯æ—¶é—´è¾ƒé•¿ï¼ˆå¹³å‡å·®ï¼š5.57ï¼Œ95% CI [1.56-9.58]ï¼ŒP = 0.006ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICG-FA æ˜¾ç€å‡å°‘å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯ä¸­çš„å»åˆå£ç˜˜å’Œæ€»ä½“å¹¶å‘ç—‡ï¼Œå°¤å…¶æ˜¯å·¦ä¾§å»åˆæœ¯ã€‚ç„¶è€Œï¼Œå…¶ä½¿ç”¨ä¼šå¯¼è‡´æ‰‹æœ¯æ—¶é—´ç¨é•¿ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥ç¡®è®¤å…¶åœ¨æ­£ç¡®ç¨‹åºå’Œé•¿æœŸç»“æœä¸­çš„ä½œç”¨ã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ æ‰‹æœ¯ã€è§å…‰è¡€ç®¡é€ å½±ã€ICGã€å²å“šèç»¿ã€Metaåˆ†æã€å¾®åˆ›æ‰‹æœ¯", "keywords_en": "Anastomotic leakage, Colorectal surgery, Fluorescence angiography, ICG, Indocyanine green, Meta-analysis, Minimally invasive surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40907429/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 04 Sep 2025"}, {"id": "40905480", "title_en": "Neoadjuvant Chemotherapy Without Radiation for Locally Advanced Rectal Cancer: A Meta-analysis of Surgical Outcomes After Total Mesorectal Excision", "title_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ— æ”¾å°„æ–°è¾…åŠ©åŒ–ç–—ï¼šå…¨ç›´è‚ ç³»è†œåˆ‡é™¤åæ‰‹æœ¯ç»“æœçš„èŸèƒåˆ†æ", "authors": "Dean A Fergusson", "abstract_en": "**Background:** Neoadjuvant chemotherapy alone (with radiation omission) for locally advanced rectal cancer has been evaluated in several randomized controlled trials. Although oncologic outcomes have been well described, the impact of this treatment strategy on surgical outcomes is unknown.\n\n**Objective:** To evaluate how important surgical outcomes were reported in previous trials comparing neoadjuvant chemotherapy to chemoradiation therapy for locally advanced rectal cancer and to perform a meta-analysis of available data.\n\n**Data Sources:** A systematic review was conducted using MEDLINE, Embase, and the Cochrane Library Databases.\n\n**Study Selection:** All published randomized controlled trials that compared neoadjuvant chemotherapy to chemoradiation for MRI-staged rectal adenocarcinoma.\n\n**Interventions:** Neoadjuvant chemotherapy alone (with radiation omission).\n\n**Main Outcome Measures:** Postoperative surgical outcomes, including anastomotic leak, diverting ostomy use, ostomy nonreversal, 30-day postoperative morbidity, and postoperative bowel function.\n\n**Results:** Four randomized controlled trials met eligibility criteria and were included for data analysis. Oncologic outcomes demonstrated that neoadjuvant chemotherapy was equivalent or noninferior to chemoradiation therapy. Anastomotic leak and use of diverting ostomy were reported in 3 of the 4 trials, whereas 30-day postoperative morbidity and ostomy nonreversal were reported in only 2 trials. Bowel function was measured in 3 trials but was measured and reported differently in each trial. On meta-analysis, neoadjuvant chemotherapy was associated with a significant reduction in anastomotic leak (relative risk [RR] 0.54; 95% CI, 0.35-0.81), use of diverting ostomy (RR 0.79; 95% CI, 0.70-0.88), and ostomy nonreversal (RR 0.37; 95% CI, 0.15-0.93). There was no association between neoadjuvant chemotherapy and 30-day postoperative morbidity (RR 0.88; 95% CI, 0.53-1.45).\n\n**Limitations:** A small number of included trials with heterogeneity in outcome definitions was the limitation.\n\n**Conclusions:** Important surgical outcomes were not reported in trials comparing neoadjuvant chemotherapy alone to chemoradiation therapy for locally advanced rectal cancer. Based on the limited data available, chemotherapy alone was associated with reduced risk of anastomotic leak, diverting ostomy use, and ostomy nonreversal. See Video Abstract .", "abstract_zh": "**èƒŒæ™¯ï¼š** å¤šé¡¹éšæœºå¯¹ç…§è¯•éªŒå·²å¯¹å•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ï¼ˆçœç•¥æ”¾ç–—ï¼‰æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œè¿›è¡Œäº†è¯„ä¼°ã€‚å°½ç®¡è‚¿ç˜¤å­¦ç»“æœå·²å¾—åˆ°å¾ˆå¥½çš„æè¿°ï¼Œä½†è¿™ç§æ²»ç–—ç­–ç•¥å¯¹æ‰‹æœ¯ç»“æœçš„å½±å“å°šä¸æ¸…æ¥šã€‚\n\n**ç›®çš„ï¼š** è¯„ä¼°å…ˆå‰æ¯”è¾ƒæ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è¯•éªŒä¸­æŠ¥å‘Šçš„æ‰‹æœ¯ç»“æœçš„é‡è¦æ€§ï¼Œå¹¶å¯¹ç°æœ‰æ•°æ®è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**Data sourcesï¼š** ä½¿ç”¨ MEDLINEã€Embase å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚\n\n**Study selectionï¼š** æ‰€æœ‰å·²å‘è¡¨çš„éšæœºå¯¹ç…§è¯•éªŒéƒ½å¯¹ MRI åˆ†æœŸç›´è‚ è…ºç™Œçš„æ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—è¿›è¡Œäº†æ¯”è¾ƒã€‚\n\n**Interventionsï¼š** å•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ï¼ˆçœç•¥æ”¾å°„æ²»ç–—ï¼‰ã€‚\n\n**Main outcome measuresï¼š** æœ¯åæ‰‹æœ¯ç»“æœï¼ŒåŒ…æ‹¬å»åˆå£ç˜˜ã€åˆ†æµé€ å£æœ¯çš„ä½¿ç”¨ã€é€ å£æœ¯ä¸å¯é€†è½¬ã€æœ¯å 30 å¤©çš„å‘ç—…ç‡å’Œæœ¯åè‚ åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** å››é¡¹éšæœºå¯¹ç…§è¯•éªŒç¬¦åˆèµ„æ ¼æ ‡å‡†å¹¶è¢«çº³å…¥æ•°æ®åˆ†æã€‚è‚¿ç˜¤å­¦ç»“æœè¡¨æ˜ï¼Œæ–°è¾…åŠ©åŒ–ç–—ç›¸å½“äºæˆ–ä¸åŠ£äºæ”¾åŒ–ç–—ã€‚ 4 é¡¹è¯•éªŒä¸­æœ‰ 3 é¡¹æŠ¥å‘Šäº†å»åˆå£ç˜˜å’Œæ”¹é“é€ å£æœ¯çš„ä½¿ç”¨ï¼Œè€Œä»… 2 é¡¹è¯•éªŒæŠ¥å‘Šäº†æœ¯å 30 å¤©çš„å‘ç—…ç‡å’Œé€ å£æœ¯ä¸å¯é€†è½¬ã€‚åœ¨ 3 é¡¹è¯•éªŒä¸­æµ‹é‡äº†è‚ åŠŸèƒ½ï¼Œä½†æ¯é¡¹è¯•éªŒçš„æµ‹é‡å’ŒæŠ¥å‘Šéƒ½ä¸åŒã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ–°è¾…åŠ©åŒ–ç–—ä¸å»åˆå£ç˜˜æ˜¾ç€å‡å°‘ï¼ˆç›¸å¯¹é£é™© [RR] 0.54ï¼›95% CIï¼Œ0.35-0.81ï¼‰ã€æ”¹é“é€ å£æœ¯çš„ä½¿ç”¨ï¼ˆRR 0.79ï¼›95% CIï¼Œ0.70-0.88ï¼‰å’Œé€ å£éé€†è½¬ï¼ˆRR 0.37ï¼›95% CIï¼Œ 0.15-0.93ï¼‰ã€‚æ–°è¾…åŠ©åŒ–ç–—ä¸æœ¯å 30 å¤©å‘ç—…ç‡ä¹‹é—´æ²¡æœ‰å…³è”ï¼ˆRR 0.88ï¼›95% CIï¼Œ0.53-1.45ï¼‰ã€‚\n\n**Limitationsï¼š** å°‘æ•°çº³å…¥çš„è¯•éªŒåœ¨ç»“æœå®šä¹‰ä¸Šå…·æœ‰å¼‚è´¨æ€§æ˜¯é™åˆ¶ã€‚\n\n**ç»“è®ºï¼š** åœ¨æ¯”è¾ƒå•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è¯•éªŒä¸­ï¼Œæ²¡æœ‰æŠ¥å‘Šé‡è¦çš„æ‰‹æœ¯ç»“æœã€‚æ ¹æ®ç°æœ‰çš„æœ‰é™æ•°æ®ï¼Œå•ç‹¬åŒ–ç–—ä¸é™ä½å»åˆå£ç˜˜ã€è½¬ç§»é€ å£æœ¯ä½¿ç”¨å’Œé€ å£æœ¯ä¸å¯é€†è½¬çš„é£é™©ç›¸å…³ã€‚å‚è§è§†é¢‘æ‘˜è¦ã€‚", "keywords_zh": "åŒ–ç–—ã€æ–°è¾…åŠ©æ²»ç–—ã€é—æ¼æ”¾å°„æ²»ç–—ã€ç›´è‚ ç™Œã€æ‰‹æœ¯ç»“æœ", "keywords_en": "Chemotherapy, Neoadjuvant therapy, Radiation omission, Rectal cancer, Surgical outcomes", "link": "https://pubmed.ncbi.nlm.nih.gov/40905480/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 04 Sep 2025"}, {"id": "40894328", "title_en": "Systematic meta-review: diagnostic accuracy of colon capsule endoscopy for colonic neoplasia with umbrella meta-analysis", "title_zh": "ç³»ç»ŸèŸèƒå›é¡¾ï¼šç»“è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥å¯¹ç»“è‚ è‚¿ç˜¤çš„ä¼å½¢èŸèƒåˆ†æè¯Šæ–­å‡†ç¡®æ€§", "authors": "Anastasios Koulaouzidis", "abstract_en": "**Background:** Colorectal cancer (CRC) incidence is rising globally, intensifying pressure on endoscopy services. Colon capsule endoscopy (CCE) offers a non-invasive alternative. Despite several systematic reviews showing reasonable polyp detection rates, clinical scepticism remains.\n\n**Objectives:** This meta-review and umbrella meta-analysis aim to synthesise evidence on CCE's diagnostic accuracy in polyp and CRC detection, using CT colonography or colonoscopy as the reference standard.\n\n**Methods:** We conducted a systematic search of EMBASE, MEDLINE and PubMed for systematic reviews evaluating the diagnostic accuracy of CCE in detecting polyps and CRC. A qualitative thematic review and synthesis were conducted following PRISMA guidelines. A bivariate generalised linear mixed model with random effects was used for pooled diagnostic accuracy estimates, and meta-regression was performed using restricted maximum likelihood estimation.\n\n**Results:** Nine systematic reviews encompassing 28 unique studies (3472 participants) were included. For polyps of any size, the pooled per-patient sensitivity was 0.79 (95% CI: 0.69-0.86), specificity was 0.77 (95% CI: 0.71-0.82), and the area under the curve (AUC) was 0.81. For polyps â©¾6â€‰mm, sensitivity and specificity were 0.80 and 0.87 (AUC 0.81), and for polyps â©¾10â€‰mm, 0.88 and 0.95 (AUC 0.95), respectively. Second-generation CCE (CCE2) improved diagnostic accuracy across all polyp sizes. For polyps of any size, CCE2 achieved a sensitivity of 0.90, specificity of 0.81 and AUC of 0.82. For polypsâ€‰â©¾â€‰6â€‰mm and â©¾10â€‰mm, AUCs were 0.92 and 0.94, respectively. CCE2 showed high sensitivity for detecting any polyp size and polyps â©¾6â€‰mm, with low heterogeneity (<i>p</i>â€‰>â€‰0.05, <i>I</i> <sup>2</sup>â€‰<â€‰25%). CRC detection sensitivity was 0.96 (95% CI: 0.73-1.00) after excluding cases where the capsule failed to reach the rectum due to battery exhaustion.\n\n**Conclusion:** CCE2 has high diagnostic accuracy for polyps and colorectal cancer detection. While technical challenges persist, CCE2 shows promise as a complementary diagnostic tool to help address the increasing demands for endoscopy services.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨çƒç»“ç›´è‚ ç™Œï¼ˆCRCï¼‰å‘ç—…ç‡ä¸æ–­ä¸Šå‡ï¼ŒåŠ å¤§äº†å†…çª¥é•œæ£€æŸ¥æœåŠ¡çš„å‹åŠ›ã€‚ç»“è‚ èƒ¶å›Šå†…çª¥é•œæ£€æŸ¥ (CCE) æä¾›äº†ä¸€ç§éä¾µå…¥æ€§æ›¿ä»£æ–¹æ¡ˆã€‚å°½ç®¡å¤šé¡¹ç³»ç»Ÿè¯„ä»·æ˜¾ç¤ºæ¯è‚‰æ£€å‡ºç‡åˆç†ï¼Œä½†ä¸´åºŠä»æŒæ€€ç–‘æ€åº¦ã€‚\n\n**Objectivesï¼š** è¿™é¡¹èŸèƒå®¡æŸ¥å’Œä¼å¼èŸèƒåˆ†ææ—¨åœ¨ä»¥ CT ç»“è‚ æˆåƒæˆ–ç»“è‚ é•œæ£€æŸ¥ä½œä¸ºå‚è€ƒæ ‡å‡†ï¼Œç»¼åˆè¯æ˜ CCE åœ¨æ¯è‚‰å’Œ CRC æ£€æµ‹ä¸­è¯Šæ–­å‡†ç¡®æ€§çš„è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ EMBASEã€MEDLINE å’Œ PubMed è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œä»¥è¿›è¡Œç³»ç»Ÿè¯„ä»·ï¼Œè¯„ä¼° CCE åœ¨æ£€æµ‹æ¯è‚‰å’Œ CRC æ–¹é¢çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†å®šæ€§ä¸»é¢˜å®¡æŸ¥å’Œç»¼åˆã€‚å…·æœ‰éšæœºæ•ˆåº”çš„äºŒå…ƒå¹¿ä¹‰çº¿æ€§æ··åˆæ¨¡å‹ç”¨äºæ±‡æ€»è¯Šæ–­å‡†ç¡®æ€§ä¼°è®¡ï¼Œå¹¶ä½¿ç”¨é™åˆ¶æœ€å¤§ä¼¼ç„¶ä¼°è®¡è¿›è¡Œå…ƒå›å½’ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 9 é¡¹ç³»ç»Ÿè¯„ä»·ï¼Œæ¶µç›– 28 é¡¹ç‹¬ç‰¹ç ”ç©¶ï¼ˆ3472 åå‚ä¸è€…ï¼‰ã€‚å¯¹äºä»»ä½•å¤§å°çš„æ¯è‚‰ï¼Œæ¯ä½æ‚£è€…çš„æ±‡æ€»æ•æ„Ÿæ€§ä¸º 0.79ï¼ˆ95% CIï¼š0.69-0.86ï¼‰ï¼Œç‰¹å¼‚æ€§ä¸º 0.77ï¼ˆ95% CIï¼š0.71-0.82ï¼‰ï¼Œæ›²çº¿ä¸‹é¢ç§¯ (AUC) ä¸º 0.81ã€‚å¯¹äºâ‰¥6mmçš„æ¯è‚‰ï¼Œæ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§åˆ†åˆ«ä¸º0.80å’Œ0.87ï¼ˆAUC 0.81ï¼‰ï¼Œå¯¹äºâ‰¥10mmçš„æ¯è‚‰ï¼Œæ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§åˆ†åˆ«ä¸º0.88å’Œ0.95ï¼ˆAUC 0.95ï¼‰ã€‚ç¬¬äºŒä»£ CCE (CCE2) æé«˜äº†æ‰€æœ‰æ¯è‚‰å°ºå¯¸çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚å¯¹äºä»»ä½•å¤§å°çš„æ¯è‚‰ï¼ŒCCE2 çš„æ•æ„Ÿæ€§ä¸º 0.90ï¼Œç‰¹å¼‚æ€§ä¸º 0.81ï¼ŒAUC ä¸º 0.82ã€‚å¯¹äºâ€‰â©¾â€‰6â€‰mmå’Œâ©¾10â€‰mmçš„æ¯è‚‰ï¼ŒAUCåˆ†åˆ«ä¸º0.92å’Œ0.94ã€‚ CCE2 å¯¹æ£€æµ‹ä»»ä½•æ¯è‚‰å¤§å°å’Œæ¯è‚‰ â©¾6â€‰mm è¡¨ç°å‡ºé«˜çµæ•åº¦ï¼Œå¼‚è´¨æ€§ä½ï¼ˆ<i>p</i>â€‰>â€‰0.05ï¼Œ<i>I</i> <sup>2</sup>â€‰<â€‰25%ï¼‰ã€‚æ’é™¤èƒ¶å›Šå› ç”µæ± è€—å°½è€Œæœªèƒ½åˆ°è¾¾ç›´è‚ çš„æƒ…å†µåï¼ŒCRC æ£€æµ‹çµæ•åº¦ä¸º 0.96ï¼ˆ95% CIï¼š0.73-1.00ï¼‰ã€‚\n\n**ç»“è®ºï¼š** CCE2å¯¹äºæ¯è‚‰å’Œç»“ç›´è‚ ç™Œæ£€æµ‹å…·æœ‰è¾ƒé«˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚å°½ç®¡æŠ€æœ¯æŒ‘æˆ˜ä»ç„¶å­˜åœ¨ï¼Œä½† CCE2 ä½œä¸ºä¸€ç§è¡¥å……è¯Šæ–­å·¥å…·æœ‰æœ›å¸®åŠ©æ»¡è¶³æ—¥ç›Šå¢é•¿çš„å†…çª¥é•œæœåŠ¡éœ€æ±‚ã€‚", "keywords_zh": "CCEã€CRCæ£€æµ‹ã€CTç»“è‚ é•œæ£€æŸ¥ã€èƒ¶å›Šå†…é•œæ£€æŸ¥ã€ç»“è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥ã€ç»“è‚ é•œæ£€æŸ¥ã€å…¨è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥ã€æ¯è‚‰ã€æ¯è‚‰æ£€æµ‹ã€æ¯è‚‰æ ·ç—…å˜", "keywords_en": "CCE, CRC detection, CT colonoscopy, capsule endoscopy, colon capsule endoscopy, colonoscopy, panenteric capsule endoscopy, polyp, polyp detection, polypoidal lesion", "link": "https://pubmed.ncbi.nlm.nih.gov/40894328/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 02 Sep 2025"}, {"id": "40877526", "title_en": "Outcomes of embolization therapy of superior rectal arteries for the management of grade 1 to 3 internal hemorrhoids: a systematic Review of clinical studies", "title_zh": "ç›´è‚ ä¸ŠåŠ¨è„‰æ “å¡æ²»ç–— 1 è‡³ 3 çº§å†…ç—”çš„ç»“æœï¼šä¸´åºŠç ”ç©¶çš„ç³»ç»Ÿè¯„ä»·", "authors": "Jana Al Jnainati", "abstract_en": "**Background:** Superior rectal artery embolization (\"Emborrhoid\") offers a catheter-based alternative for grade I-III internal hemorrhoids when office therapies fail or surgery is undesirable.\n\n**Methods:** Following PRISMA 2020, PubMed and Embase were searched (Jan 2014-Jan 2024). Two reviewers independently screened records, extracted data, and applied RoB 2, ROBINS-I, or an adapted Newcastle-Ottawa Scale. Prespecified outcomes were technical success, clinical success (â‰¥â€‰2-point fall in bleeding score or equivalent), adverse events, and recurrence. Substantial heterogeneity blocked meta-analysis; results were narratively synthesized.\n\n**Results:** Twenty-two studies encompassing 810 procedures qualified. Technical success reached 93-100%. Clinical success ranged from 63 to 94%, yielding marked bleeding control and symptom relief. Reported complications were mild and self-limited (pelvic discomfort, nausea, and low-grade fever); no ischemic injury, continence disturbance, or mortality occurred. Recurrence necessitating repeat treatment affected 8-20% of patients, usually when collateral arterial supply persisted. Patient-reported satisfaction exceeded 80% in every series. Only two small, heterogeneous comparative studies versus rubber-band ligation or sclerotherapy were available, precluding a pooled analysis.\n\n**Conclusions:** Current evidence suggests Emborrhoid is a safe, effective bridge between office procedures and surgery-particularly valuable for frail or anticoagulated patients. Yet small single-center cohorts, disparate techniques, and scarce head-to-head trials limit external validity. Multicenter randomized studies with harmonized outcomes andâ€‰â‰¥â€‰24-month follow-up are required to confirm long-term efficacy, cost-effectiveness, and optimal patient selection.", "abstract_zh": "**èƒŒæ™¯ï¼š** å½“åŠå…¬å®¤æ²»ç–—å¤±è´¥æˆ–ä¸å®œè¿›è¡Œæ‰‹æœ¯æ—¶ï¼Œç›´è‚ ä¸ŠåŠ¨è„‰æ “å¡æœ¯ï¼ˆâ€œæ “å¡æœ¯â€ï¼‰ä¸º I-III çº§å†…ç—”æä¾›äº†ä¸€ç§åŸºäºå¯¼ç®¡çš„æ›¿ä»£æ–¹æ¡ˆã€‚\n\n**æ–¹æ³•ï¼š** ç»§ PRISMA 2020 ä¹‹åï¼Œå¯¹ PubMed å’Œ Embase è¿›è¡Œäº†æ£€ç´¢ï¼ˆ2014 å¹´ 1 æœˆ-2024 å¹´ 1 æœˆï¼‰ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹ç­›é€‰è®°å½•ã€æå–æ•°æ®å¹¶åº”ç”¨ RoB 2ã€ROBINS-I æˆ–æ”¹ç¼–çš„çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ã€‚é¢„å…ˆè®¾å®šçš„ç»“æœæ˜¯æŠ€æœ¯æˆåŠŸã€ä¸´åºŠæˆåŠŸï¼ˆå‡ºè¡€è¯„åˆ†ä¸‹é™â‰¥2åˆ†æˆ–åŒç­‰æ°´å¹³ï¼‰ã€ä¸è‰¯äº‹ä»¶å’Œå¤å‘ã€‚æ˜¾ç€çš„å¼‚è´¨æ€§é˜»ç¢äº†èŸèƒåˆ†æï¼›ç»“æœæ˜¯å™è¿°æ€§ç»¼åˆçš„ã€‚\n\n**ç»“æœï¼š** æ¶µç›– 810 é¡¹ç¨‹åºçš„ 22 é¡¹ç ”ç©¶åˆæ ¼ã€‚æŠ€æœ¯æˆåŠŸç‡è¾¾åˆ°93-100%ã€‚ä¸´åºŠæˆåŠŸç‡ä¸º 63% è‡³ 94%ï¼Œæ˜¾ç€æ§åˆ¶å‡ºè¡€å¹¶ç¼“è§£ç—‡çŠ¶ã€‚æŠ¥å‘Šçš„å¹¶å‘ç—‡è½»å¾®ä¸”å…·æœ‰è‡ªé™æ€§ï¼ˆéª¨ç›†ä¸é€‚ã€æ¶å¿ƒå’Œä½çƒ§ï¼‰ï¼›æ²¡æœ‰å‘ç”Ÿç¼ºè¡€æ€§æŸä¼¤ã€å¤±ç¦éšœç¢æˆ–æ­»äº¡ã€‚éœ€è¦é‡å¤æ²»ç–—çš„å¤å‘å½±å“äº† 8-20% çš„æ‚£è€…ï¼Œé€šå¸¸æ˜¯åœ¨ä¾§æ”¯åŠ¨è„‰ä¾›åº”æŒç»­å­˜åœ¨çš„æƒ…å†µä¸‹ã€‚æ¯ä¸ªç³»åˆ—ä¸­æ‚£è€…æŠ¥å‘Šçš„æ»¡æ„åº¦å‡è¶…è¿‡ 80%ã€‚åªæœ‰ä¸¤é¡¹å°å‹ã€å¼‚è´¨æ€§ä¸æ©¡çš®ç­‹ç»“æ‰æˆ–ç¡¬åŒ–ç–—æ³•çš„æ¯”è¾ƒç ”ç©¶å¯ç”¨ï¼Œæ’é™¤äº†æ±‡æ€»åˆ†æã€‚\n\n**ç»“è®ºï¼š** ç›®å‰çš„è¯æ®è¡¨æ˜ï¼ŒEmborroid æ˜¯åŠå…¬å®¤ç¨‹åºå’Œæ‰‹æœ¯ä¹‹é—´çš„å®‰å…¨ã€æœ‰æ•ˆçš„æ¡¥æ¢ï¼Œå¯¹äºä½“å¼±æˆ–æ¥å—æŠ—å‡æ²»ç–—çš„æ‚£è€…å°¤å…¶æœ‰ä»·å€¼ã€‚ç„¶è€Œï¼Œå°å‹å•ä¸­å¿ƒé˜Ÿåˆ—ã€ä¸åŒçš„æŠ€æœ¯å’Œç¨€ç¼ºçš„å¤´å¯¹å¤´è¯•éªŒé™åˆ¶äº†å¤–éƒ¨æœ‰æ•ˆæ€§ã€‚éœ€è¦å…·æœ‰ä¸€è‡´ç»“æœçš„å¤šä¸­å¿ƒéšæœºç ”ç©¶å’Œâ‰¥24ä¸ªæœˆçš„éšè®¿æ¥ç¡®è®¤é•¿æœŸç–—æ•ˆã€æˆæœ¬æ•ˆç›Šå’Œæœ€ä½³æ‚£è€…é€‰æ‹©ã€‚", "keywords_zh": "æ “å¡ææ–™ã€ç—”ç–®æ “å¡ã€å¾®åˆ›æ²»ç–—ã€æ‚£è€…æ»¡æ„åº¦ã€å¤å‘ç‡ã€ç›´è‚ ä¸ŠåŠ¨è„‰ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "Embolic materials, Hemorrhoidal embolization, Minimally invasive therapy, Patient satisfaction, Recurrence rates, Superior rectal artery, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40877526/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 28 Aug 2025"}, {"id": "40876363", "title_en": "Local excision versus total mesorectal excision following neoadjuvant chemoradiotherapy for rectal cancer: A systematic review and meta-analysis", "title_zh": "ç›´è‚ ç™Œæ–°è¾…åŠ©æ”¾åŒ–ç–—åå±€éƒ¨åˆ‡é™¤ä¸å…¨ç›´è‚ ç³»è†œåˆ‡é™¤ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Neary Peter", "abstract_en": "**Background:** Total mesorectal excision (TME) with or without neoadjuvant chemoradiotherapy remains the gold standard treatment for rectal cancer. However, newer organ sparing methods, including Local Excision (LE) have been introduced in conjunction with neoadjuvant therapy to improve morbidity and functional outcomes while not impacting on oncological outcomes.\n\n**Methods:** A systematic review and meta-analysis was performed using the PRISMA guidelines. All studies comparing neoadjuvant chemoradiotherapy and local excision versus TME were included from 2000 to 2024. Primary endpoint included local recurrence rates. Secondary outcomes included distant recurrence, disease free survival (DFS), overall survival (OS), and morbidity. Subgroup analysis was performed on randomised control trials (RCT).\n\n**Results:** Sixteen studies (nÂ =Â 2121; LEÂ =Â 616, TMEÂ =Â 1505) were included. LE was associated with higher local recurrence (8.3Â % vs 5.5Â %; OR 1.82, 95Â % CI 1.19-2.77, pÂ =Â 0.006). However, in RCTs (nÂ =Â 245), this difference was not significant (7.3Â % vs 6.6Â %; OR 1.10, 95Â % CI 0.41-2.97, pÂ =Â 0.84). No significant differences were observed in distant recurrence, DFS, or OS. LE was associated with significantly reduced morbidity (OR 0.30, 95Â % CI 0.18-0.50, pÂ <Â 0.0001).\n\n**Conclusion:** Local recurrence was not statistically significant in the RCT subgroup analysis. Despite, higher local recurrence rates in the overall pooled analysis, no significant differences were observed for secondary outcomes. Neoadjuvant chemoradiotherapy and local excision appears oncologically safe, defined by DFS and OS, in select patient cohorts with a clinical complete or near-complete response to neoadjuvant therapy.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆTMEï¼‰è”åˆæˆ–ä¸è”åˆæ–°è¾…åŠ©æ”¾åŒ–ç–—ä»ç„¶æ˜¯ç›´è‚ ç™Œçš„é‡‘æ ‡å‡†æ²»ç–—ã€‚ç„¶è€Œï¼Œæ–°çš„å™¨å®˜ä¿ç•™æ–¹æ³•ï¼ŒåŒ…æ‹¬å±€éƒ¨åˆ‡é™¤ï¼ˆLEï¼‰ï¼Œå·²ä¸æ–°è¾…åŠ©æ²»ç–—ç»“åˆä½¿ç”¨ï¼Œä»¥æ”¹å–„å‘ç—…ç‡å’ŒåŠŸèƒ½ç»“æœï¼ŒåŒæ—¶ä¸å½±å“è‚¿ç˜¤ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨ PRISMA æŒ‡å—è¿›è¡Œç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ 2000 å¹´è‡³ 2024 å¹´æœŸé—´æ‰€æœ‰æ¯”è¾ƒæ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œå±€éƒ¨åˆ‡é™¤ä¸ TME çš„ç ”ç©¶å‡çº³å…¥å…¶ä¸­ã€‚ä¸»è¦ç»ˆç‚¹åŒ…æ‹¬å±€éƒ¨å¤å‘ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬è¿œå¤„å¤å‘ã€æ— ç—…ç”Ÿå­˜æœŸï¼ˆDFSï¼‰ã€æ€»ç”Ÿå­˜æœŸï¼ˆOSï¼‰å’Œå‘ç—…ç‡ã€‚åœ¨éšæœºå¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰ä¸­è¿›è¡Œäºšç»„åˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 16 é¡¹ç ”ç©¶ï¼ˆn = 2121ï¼›LE = 616ï¼ŒTME = 1505ï¼‰ã€‚ LE ä¸è¾ƒé«˜çš„å±€éƒ¨å¤å‘ç‡ç›¸å…³ï¼ˆ8.3% vs 5.5%ï¼›OR 1.82ï¼Œ95% CI 1.19-2.77ï¼Œp = 0.006ï¼‰ã€‚ç„¶è€Œï¼Œåœ¨éšæœºå¯¹ç…§è¯•éªŒ (n = 245) ä¸­ï¼Œè¿™ç§å·®å¼‚å¹¶ä¸æ˜¾ç€ï¼ˆ7.3% vs 6.6%ï¼›OR 1.10ï¼Œ95% CI 0.41-2.97ï¼Œp = 0.84ï¼‰ã€‚åœ¨è¿œå¤„å¤å‘ã€DFS æˆ– OS æ–¹é¢æœªè§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚ LE ä¸å‘ç—…ç‡æ˜¾ç€é™ä½ç›¸å…³ï¼ˆOR 0.30ï¼Œ95% CI 0.18-0.50ï¼Œp < 0.0001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** åœ¨ RCT äºšç»„åˆ†æä¸­ï¼Œå±€éƒ¨å¤å‘æ²¡æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚å°½ç®¡åœ¨æ€»ä½“æ±‡æ€»åˆ†æä¸­å±€éƒ¨å¤å‘ç‡è¾ƒé«˜ï¼Œä½†æ¬¡è¦ç»“å±€æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚åœ¨å¯¹æ–°è¾…åŠ©æ²»ç–—å…·æœ‰ä¸´åºŠå®Œå…¨æˆ–æ¥è¿‘å®Œå…¨ååº”çš„é€‰å®šæ‚£è€…é˜Ÿåˆ—ä¸­ï¼Œæ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œå±€éƒ¨åˆ‡é™¤ä¼¼ä¹åœ¨è‚¿ç˜¤å­¦ä¸Šæ˜¯å®‰å…¨çš„ï¼ˆç”± DFS å’Œ OS å®šä¹‰ï¼‰ã€‚", "keywords_zh": "å±€éƒ¨åˆ‡é™¤ã€æ ¹æ²»æ€§æ‰‹æœ¯ã€ç›´è‚ ç™Œã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤", "keywords_en": "Local excision, Radical surgery, Rectal cancer, Total mesorectal excision", "link": "https://pubmed.ncbi.nlm.nih.gov/40876363/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 28 Aug 2025"}, {"id": "40845608", "title_en": "Transparency in Externally Validated Models: A systematic review of machine learning vs. logistic regression for predicting colorectal anastomotic leakage", "title_zh": "å¤–éƒ¨éªŒè¯æ¨¡å‹çš„é€æ˜åº¦ï¼šå¯¹æœºå™¨å­¦ä¹ ä¸é€»è¾‘å›å½’é¢„æµ‹ç»“ç›´è‚ å»åˆå£æ¼çš„ç³»ç»Ÿè¯„ä»·", "authors": "Freek Daams", "abstract_en": "**Introduction:** Colorectal resection carries a 2.8Â %-30Â % risk of anastomotic leakage. Machine learning can estimate risks and guide decisions, but clinical implementation remains inadequate due to transparency issues. This review assesses the performance and transparency of machine learning models compared to logistic regression.\n\n**Methods:** A systematic review followed PRISMA guidelines. Medline, Embase, Web of Science, and Cochrane databases were searched for studies using Logistic Regression or Machine Learning with external validation for colorectal anastomotic leakage prediction. Data were extracted using CHARMS, risk of bias assessed with PROBAST, and transparency with TRIPODÂ +Â AI.\n\n**Results:** Ten studies were included. Machine learning models were validated on smaller cohorts than logistic regression. Transparency scores ranged from 29Â % to 63Â %, averaging 45Â % for logistic regression and 43Â % for machine learning. Reporting of missing data was inconsistent, and external validation was limited. Most studies had a high risk of bias due to small sample sizes and low event counts.\n\n**Conclusion:** In comparison to Logistic regression studies, machine learning studies are limited by small cohorts, low outcome numbers, and a lower level of transparency. Future research should prioritise transparency, adhere to TRIPODÂ +Â AI standards, and develop LR and ML models in parallel using the same datasets while ensuring separate models for colon and rectal surgery. Currently, these models are not yet suitable for clinical implementation; more robust and transparent models must be developed based on these recommendations before they can be applied in clinical practice.", "abstract_zh": "**ä»‹ç»ï¼š** ç»“ç›´è‚ åˆ‡é™¤æœ¯æœ‰ 2.8%-30% çš„å»åˆå£ç˜˜é£é™©ã€‚æœºå™¨å­¦ä¹ å¯ä»¥ä¼°è®¡é£é™©å¹¶æŒ‡å¯¼å†³ç­–ï¼Œä½†ç”±äºé€æ˜åº¦é—®é¢˜ï¼Œä¸´åºŠå®æ–½ä»ç„¶ä¸è¶³ã€‚è¿™ç¯‡ç»¼è¿°è¯„ä¼°äº†æœºå™¨å­¦ä¹ æ¨¡å‹ä¸é€»è¾‘å›å½’ç›¸æ¯”çš„æ€§èƒ½å’Œé€æ˜åº¦ã€‚\n\n**æ–¹æ³•ï¼š** ç³»ç»Ÿè¯„ä»·éµå¾ª PRISMA æŒ‡å—ã€‚åœ¨ Medlineã€Embaseã€Web of Science å’Œ Cochrane æ•°æ®åº“ä¸­æœç´¢äº†ä½¿ç”¨ Logistic å›å½’æˆ–æœºå™¨å­¦ä¹ å¹¶è¿›è¡Œç»“ç›´è‚ å»åˆå£æ¼é¢„æµ‹å¤–éƒ¨éªŒè¯çš„ç ”ç©¶ã€‚ä½¿ç”¨ CHARMS æå–æ•°æ®ï¼Œä½¿ç”¨ PROBAST è¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ TRIPOD + AI è¯„ä¼°é€æ˜åº¦ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬åé¡¹ç ”ç©¶ã€‚æœºå™¨å­¦ä¹ æ¨¡å‹åœ¨æ¯”é€»è¾‘å›å½’æ›´å°çš„é˜Ÿåˆ—ä¸Šè¿›è¡Œäº†éªŒè¯ã€‚é€æ˜åº¦åˆ†æ•°èŒƒå›´ä¸º 29% åˆ° 63%ï¼Œé€»è¾‘å›å½’å¹³å‡ä¸º 45%ï¼Œæœºå™¨å­¦ä¹ å¹³å‡ä¸º 43%ã€‚ç¼ºå¤±æ•°æ®çš„æŠ¥å‘Šä¸ä¸€è‡´ï¼Œå¤–éƒ¨éªŒè¯ä¹Ÿæœ‰é™ã€‚ç”±äºæ ·æœ¬é‡å°å’Œäº‹ä»¶è®¡æ•°ä½ï¼Œå¤§å¤šæ•°ç ”ç©¶å­˜åœ¨è¾ƒé«˜çš„åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** ä¸é€»è¾‘å›å½’ç ”ç©¶ç›¸æ¯”ï¼Œæœºå™¨å­¦ä¹ ç ”ç©¶å—åˆ°å°ç¾¤ä½“ã€ä½ç»“æœæ•°é‡å’Œè¾ƒä½é€æ˜åº¦çš„é™åˆ¶ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¼˜å…ˆè€ƒè™‘é€æ˜åº¦ï¼Œéµå®ˆ TRIPOD + AI æ ‡å‡†ï¼Œå¹¶ä½¿ç”¨ç›¸åŒçš„æ•°æ®é›†å¹¶è¡Œå¼€å‘ LR å’Œ ML æ¨¡å‹ï¼ŒåŒæ—¶ç¡®ä¿ç»“è‚ å’Œç›´è‚ æ‰‹æœ¯çš„æ¨¡å‹ä¸åŒã€‚ç›®å‰ï¼Œè¿™äº›æ¨¡å‹å°šä¸é€‚åˆä¸´åºŠå®æ–½ï¼›å¿…é¡»æ ¹æ®è¿™äº›å»ºè®®å¼€å‘æ›´ç¨³å¥å’Œé€æ˜çš„æ¨¡å‹ï¼Œç„¶åæ‰èƒ½åº”ç”¨äºä¸´åºŠå®è·µã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ æ‰‹æœ¯ã€Logistic å›å½’ã€æœºå™¨å­¦ä¹ ã€é¢„æµ‹", "keywords_en": "Anastomotic leakage, Colorectal surgery, Logistic regression, Machine learning, Prediction", "link": "https://pubmed.ncbi.nlm.nih.gov/40845608/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 22 Aug 2025"}, {"id": "40824311", "title_en": "Abdominoperineal pull-through with delayed coloanal anastomosis for pelvic anastomotic failure-a systematic review", "title_zh": "è…¹ä¼šé˜´ç‰µå¼•å»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ²»ç–—ç›†è…”å»åˆå¤±è´¥çš„ç³»ç»Ÿè¯„ä»·", "authors": "I Seow-En", "abstract_en": "**Aim:** Despite theÂ potential benefits of abdominoperineal pull-through with delayed coloanal anastomosis (DCAA), it is still infrequently performed as a salvage procedure for pelvic anastomotic failure. We aimed to perform a systematic review on the subject to guide practice.\n\n**Method:** PubMed, Embase and Cochrane were used to identify studies evaluating DCAA for salvage after pelvic surgery from inception to August 2024. Risk of bias assessment was performed using the Newcastle-Ottawa scale. The primary outcome was overall stoma-free survival. Secondary outcomes included hospital length of stay, high-grade postoperative complication rates, 30-day postoperative mortality rates, incidence of redo surgical intervention after DCAA, and postoperative anorectal function.\n\n**Results:** Five retrospective cohort studies evaluating a total of 97 patientsÂ who underwent salvage abdominoperineal pull-through and DCAA were included in this review. All patients had previous pelvic surgery, predominantly proctectomy (nâ€‰=â€‰84, 86.6%). The most common indication forÂ redo surgery was chronic fistula (nâ€‰=â€‰62, 63.9%) followed by anastomotic leak or chronic pelvic sepsis (nâ€‰=â€‰34, 35.1%). The pooled overall stoma-free survival rate across all five studies was 81.4% over a mean 24-month postoperative follow-up duration. The overall incidence of high-grade complicationsÂ after DCAA was 39.1% (nâ€‰=â€‰38). Pooled mean length of stay was 17 days. There were no cases of early postoperative death. Pooled rate of repeat surgery across four studies was 11.6% (nâ€‰=â€‰8). Pooled mean functional scores across three studies indicated minor low anterior resection syndrome at 26 months.\n\n**Conclusion:** Abdominoperineal pull-through with delayed coloanal anastomosis is a viable option for salvage surgery following pelvic anastomotic complications, with low rates of permanent stoma and acceptable long-term anorectal function.", "abstract_zh": "**Aimï¼š** å°½ç®¡è…¹ä¼šé˜´æ‹‰ç©¿å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ (DCAA) å…·æœ‰æ½œåœ¨ç›Šå¤„ï¼Œä½†å®ƒä»ç„¶å¾ˆå°‘ä½œä¸ºéª¨ç›†å»åˆå¤±è´¥çš„æŒ½æ•‘æ‰‹æœ¯è¿›è¡Œã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯å¯¹è¯¥ä¸»é¢˜è¿›è¡Œç³»ç»Ÿå›é¡¾ä»¥æŒ‡å¯¼å®è·µã€‚\n\n**Methodï¼š** PubMedã€Embase å’Œ Cochrane è¢«ç”¨æ¥è¯†åˆ«ä»å¼€å§‹åˆ° 2024 å¹´ 8 æœˆè¯„ä¼° DCAA åœ¨ç›†è…”æ‰‹æœ¯åæŒ½æ•‘æ•ˆæœçš„ç ”ç©¶ã€‚ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨è¿›è¡Œåå€šé£é™©è¯„ä¼°ã€‚ä¸»è¦ç»“æœæ˜¯æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ä½é™¢æ—¶é—´ã€æœ¯åé«˜çº§å¹¶å‘ç—‡å‘ç”Ÿç‡ã€æœ¯å 30 å¤©æ­»äº¡ç‡ã€DCAA åé‡åšæ‰‹æœ¯å¹²é¢„çš„å‘ç”Ÿç‡ä»¥åŠæœ¯åè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** æœ¬ç»¼è¿°çº³å…¥äº†äº”é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œè¯„ä¼°äº†æ€»å…± 97 åæ¥å—æŒ½æ•‘æ€§è…¹ä¼šé˜´ç‰µå¼•æœ¯å’Œ DCAA çš„æ‚£è€…ã€‚æ‰€æœ‰æ‚£è€…å‡æ›¾æ¥å—è¿‡ç›†è…”æ‰‹æœ¯ï¼Œä¸»è¦æ˜¯ç›´è‚ åˆ‡é™¤æœ¯ï¼ˆnâ€‰=â€‰84ï¼Œ86.6%ï¼‰ã€‚é‡åšæ‰‹æœ¯æœ€å¸¸è§çš„é€‚åº”ç—‡æ˜¯æ…¢æ€§ç˜˜ï¼ˆnâ€‰=â€‰62ï¼Œ63.9%ï¼‰ï¼Œå…¶æ¬¡æ˜¯å»åˆå£ç˜˜æˆ–æ…¢æ€§ç›†è…”è„“æ¯’ç—‡ï¼ˆnâ€‰=â€‰34ï¼Œ35.1%ï¼‰ã€‚åœ¨å¹³å‡ 24 ä¸ªæœˆçš„æœ¯åéšè®¿æœŸé—´ï¼Œæ‰€æœ‰äº”é¡¹ç ”ç©¶çš„æ±‡æ€»æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ä¸º 81.4%ã€‚ DCAA åé«˜çº§å¹¶å‘ç—‡çš„æ€»ä½“å‘ç”Ÿç‡ä¸º 39.1% (nâ€‰=â€‰38)ã€‚åˆå¹¶å¹³å‡ä½é™¢æ—¶é—´ä¸º 17 å¤©ã€‚æ— æœ¯åæ—©æœŸæ­»äº¡ç—…ä¾‹ã€‚å››é¡¹ç ”ç©¶çš„é‡å¤æ‰‹æœ¯æ±‡æ€»ç‡ä¸º 11.6% (nâ€‰=â€‰8)ã€‚ä¸‰é¡¹ç ”ç©¶çš„æ±‡æ€»å¹³å‡åŠŸèƒ½è¯„åˆ†è¡¨æ˜ 26 ä¸ªæœˆæ—¶æœ‰è½»å¾®çš„ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ã€‚\n\n**ç»“è®ºï¼š** è…¹ä¼šé˜´ç‰µå¼•è”åˆå»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ˜¯ç›†è…”å»åˆå¹¶å‘ç—‡åæŒ½æ•‘æ‰‹æœ¯çš„å¯è¡Œé€‰æ‹©ï¼Œå…·æœ‰è¾ƒä½çš„æ°¸ä¹…æ€§é€ å£ç‡å’Œå¯æ¥å—çš„é•¿æœŸè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚", "keywords_zh": "è…¹ä¼šé˜´ç‰µå¼•ã€ç»“ç›´è‚ æ‰‹æœ¯ã€å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ã€é‡åšæ‰‹æœ¯", "keywords_en": "Abdominoperineal pull-through, Colorectal surgery, Delayed coloanal anastomosis, Redo surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40824311/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 18 Aug 2025"}, {"id": "40819153", "title_en": "Comprehensive evaluation of reinforcement strategies for anastomotic leak prevention in rectal cancer surgery: an umbrella review of meta-analyses", "title_zh": "ç›´è‚ ç™Œæ‰‹æœ¯ä¸­é¢„é˜²å»åˆå£ç˜˜çš„å¼ºåŒ–ç­–ç•¥çš„ç»¼åˆè¯„ä»·ï¼šèŸèƒåˆ†æçš„æ€»ä½“ç»¼è¿°", "authors": "Leonardo Vincenti", "abstract_en": "Anastomotic leakage remains a serious complication following colorectal surgery. Various reinforcement techniques have been explored in literature, with multiple systematic reviews and meta-analyses addressing their effectiveness. However, no umbrella review has yet comprehensively synthesized this evidence. We aimed to summarize and critically appraise the available systematic reviews and meta-analyses investigating the effectiveness of anastomotic reinforcement techniques in colorectal surgery. A comprehensive literature search was conducted in PubMed, Embase, Scopus, and Cochrane Library up to June 2025. Eligible studies were systematic reviews or meta-analyses evaluating any reinforcement technique (biological, mechanical, or chemical) in colorectal anastomoses. Data extraction included review characteristics, reinforcement strategies, primary outcomes (anastomotic leak), and methodological quality assessed using AMSTAR 2. Twenty-one systematic reviews and meta-analyses were included. The reinforcement strategies evaluated comprised transanal tube (TAT) placement, suture reinforcement, and omentoplasty. Most reviews showed a reduction in anastomotic leak rates, particularly with TAT (43-70%) and sutures (59-75%), with the most pronounced effect observed in patients without a diverting stoma. TAT was also associated with a reduction in reintervention rates (62-84%). Findings on hospital stay were inconsistent, while no significant effects were reported for anastomotic bleeding, infections, stenosis, or mortality. The overall methodological quality of the included studies was rated as critically low. TAT and reinforcement sutures show potential in reducing anastomotic leakage in colorectal surgery. However, significant heterogeneity and variable methodological quality across reviews limit definitive conclusions. High-quality, targeted studies and standardized outcome definitions are warranted.", "abstract_zh": "å»åˆå£æ¼ä»ç„¶æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ã€‚æ–‡çŒ®ä¸­å·²ç»æ¢è®¨äº†å„ç§å¼ºåŒ–æŠ€æœ¯ï¼Œå¹¶è¿›è¡Œäº†å¤šé¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ¥æ¢è®¨å…¶æœ‰æ•ˆæ€§ã€‚ç„¶è€Œï¼Œè¿˜æ²¡æœ‰æ€»ä½“å®¡æŸ¥å…¨é¢ç»¼åˆè¿™äº›è¯æ®ã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯æ€»ç»“å’Œæ‰¹åˆ¤æ€§è¯„ä»·ç°æœ‰çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æï¼Œç ”ç©¶ç»“ç›´è‚ æ‰‹æœ¯ä¸­å»åˆåŠ å›ºæŠ€æœ¯çš„æœ‰æ•ˆæ€§ã€‚æˆªè‡³ 2025 å¹´ 6 æœˆï¼Œåœ¨ PubMedã€Embaseã€Scopus å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶æ˜¯è¯„ä¼°ç»“ç›´è‚ å»åˆæœ¯ä¸­ä»»ä½•å¼ºåŒ–æŠ€æœ¯ï¼ˆç”Ÿç‰©ã€æœºæ¢°æˆ–åŒ–å­¦ï¼‰çš„ç³»ç»Ÿè¯„ä»·æˆ–èŸèƒåˆ†æã€‚æ•°æ®æå–åŒ…æ‹¬ç»¼è¿°ç‰¹å¾ã€å¼ºåŒ–ç­–ç•¥ã€ä¸»è¦ç»“å±€ï¼ˆå»åˆå£ç˜˜ï¼‰ä»¥åŠä½¿ç”¨ AMSTAR 2 è¯„ä¼°çš„æ–¹æ³•å­¦è´¨é‡ã€‚å…¶ä¸­åŒ…æ‹¬ 21 é¡¹ç³»ç»Ÿç»¼è¿°å’ŒèŸèƒåˆ†æã€‚è¯„ä¼°çš„åŠ å›ºç­–ç•¥åŒ…æ‹¬ç»è‚›ç®¡ï¼ˆTATï¼‰æ”¾ç½®ã€ç¼åˆåŠ å›ºå’Œç½‘è†œæˆå½¢æœ¯ã€‚å¤§å¤šæ•°è¯„è®ºæ˜¾ç¤ºå»åˆå£æ¼ç‡é™ä½ï¼Œç‰¹åˆ«æ˜¯ TATï¼ˆ43-70%ï¼‰å’Œç¼åˆï¼ˆ59-75%ï¼‰ï¼Œåœ¨æ²¡æœ‰åˆ†æµé€ å£çš„æ‚£è€…ä¸­è§‚å¯Ÿåˆ°æœ€æ˜æ˜¾çš„æ•ˆæœã€‚ TAT è¿˜ä¸å†å¹²é¢„ç‡çš„é™ä½æœ‰å…³ (62-84%)ã€‚å…³äºä½é™¢æ—¶é—´çš„ç ”ç©¶ç»“æœä¸ä¸€è‡´ï¼Œè€Œå¯¹äºå»åˆå£å‡ºè¡€ã€æ„ŸæŸ“ã€ç‹­çª„æˆ–æ­»äº¡ç‡æ²¡æœ‰æ˜¾ç€å½±å“ã€‚çº³å…¥ç ”ç©¶çš„æ€»ä½“æ–¹æ³•å­¦è´¨é‡è¢«è¯„ä¸ºæä½ã€‚ TAT å’ŒåŠ å›ºç¼åˆçº¿æ˜¾ç¤ºå‡ºå‡å°‘ç»“ç›´è‚ æ‰‹æœ¯ä¸­å»åˆå£æ¸—æ¼çš„æ½œåŠ›ã€‚ç„¶è€Œï¼Œä¸åŒè¯„è®ºé—´æ˜¾ç€çš„å¼‚è´¨æ€§å’Œå¯å˜çš„æ–¹æ³•å­¦è´¨é‡é™åˆ¶äº†æ˜ç¡®çš„ç»“è®ºã€‚é«˜è´¨é‡ã€æœ‰é’ˆå¯¹æ€§çš„ç ”ç©¶å’Œæ ‡å‡†åŒ–çš„ç»“æœå®šä¹‰æ˜¯å¿…è¦çš„ã€‚", "keywords_zh": "å»åˆå£æ¼ã€å»åˆå£åŠ å›ºã€ç›´è‚ ç™Œã€ç»è‚›ç®¡", "keywords_en": "Anastomotic leak, Anastomotic reinforcement, Rectal cancer, Transanal tube", "link": "https://pubmed.ncbi.nlm.nih.gov/40819153/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 16 Aug 2025"}, {"id": "40808658", "title_en": "Association between anastomotic leak after rectal resection and bowel dysfunction, a systematic review, meta-analysis and meta-regression", "title_zh": "ç›´è‚ åˆ‡é™¤æœ¯åå»åˆå£ç˜˜ä¸è‚ åŠŸèƒ½éšœç¢ä¹‹é—´çš„å…³è”ã€ç³»ç»Ÿè¯„ä»·ã€èŸèƒåˆ†æå’ŒèŸèƒå›å½’", "authors": "Marylise Boutros", "abstract_en": "**Background:** Anastomotic leak (AL) after colorectal anastomosis can be a risk factor for bowel dysfunction, namely low anterior resection syndrome (LARS). The present study aimed to assess bowel dysfunction in patients who developed AL after anterior resection compared to patients without AL.\n\n**Methods:** We conducted a PRISMA-compliant systematic review of PubMed, Scopus and Cochrane Library for randomized and observational studies investigating the association between AL after anterior resection and bowel dysfunction. The main outcomes were LARS, faecal incontinence and urgency. Pairwise meta-analyses were conducted to calculate the relative risk (RR) of the study outcomes and their 95% confidence intervals (CI).\n\n**Results:** This review included 20 retrospective studies comprising 4764 patients (61.6% male, median age 63â€‰years). AL was detected in 14% of patients and those who experienced AL had a higher risk of LARS (six studies; 1329 patients, RR: 1.27 95%CI: 1.02, 1.58, pâ€‰=â€‰0.035), major LARS (seven studies; 1395 patients, RR: 1.38, 95%CI: 1.07, 1.79, pâ€‰=â€‰0.012), urgency (five studies; 955 patients, RR: 1.15, 95%CI: 1.04, 1.27, pâ€‰=â€‰0.005) and had higher LARS scores (seven studies; 1450 patients, WMD: 6.64, 95%CI: 3.76, 9.52, pâ€‰<â€‰0.001) and Wexner incontinence scores (seven studies; 1045 patients, WMD: 1.72, 95%CI: 0.16, 3.28, pâ€‰=â€‰0.031).\n\n**Conclusion:** Based on low to moderate certainty evidence, AL after colorectal and coloanal anastomoses was significantly associated with an increased risk of LARS, particularly major LARS, urgency and higher LARS and Wexner/Cleveland Clinic Florida-Fecal Incontinence Scores.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ å»åˆæœ¯åå»åˆå£æ¼ï¼ˆALï¼‰å¯èƒ½æ˜¯è‚ åŠŸèƒ½éšœç¢çš„å±é™©å› ç´ ï¼Œå³ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å‰åˆ‡é™¤æœ¯åå‘ç”Ÿ AL çš„æ‚£è€…ä¸æœªå‘ç”Ÿ AL çš„æ‚£è€…ç›¸æ¯”çš„è‚ åŠŸèƒ½éšœç¢ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ PubMedã€Scopus å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¿›è¡Œéšæœºå’Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œè°ƒæŸ¥å‰åˆ‡é™¤æœ¯å AL ä¸è‚ åŠŸèƒ½éšœç¢ä¹‹é—´çš„å…³è”ã€‚ä¸»è¦ç»“å±€æ˜¯ LARSã€å¤§ä¾¿å¤±ç¦å’Œå°¿æ€¥ã€‚è¿›è¡Œé…å¯¹èŸèƒåˆ†æä»¥è®¡ç®—ç ”ç©¶ç»“æœçš„ç›¸å¯¹é£é™©ï¼ˆRRï¼‰åŠå…¶95%ç½®ä¿¡åŒºé—´ï¼ˆCIï¼‰ã€‚\n\n**ç»“æœï¼š** è¯¥ç»¼è¿°åŒ…æ‹¬ 20 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œæ¶‰åŠ 4764 åæ‚£è€…ï¼ˆ61.6% ä¸ºç”·æ€§ï¼Œä¸­ä½å¹´é¾„ 63 å²ï¼‰ã€‚ 14% çš„æ‚£è€…æ£€æµ‹åˆ° ALï¼Œç»å†è¿‡ AL çš„æ‚£è€…å‘ç”Ÿ LARS çš„é£é™©è¾ƒé«˜ï¼ˆå…­é¡¹ç ”ç©¶ï¼›1329 åæ‚£è€…ï¼ŒRRï¼š1.27 95%CIï¼š1.02ã€1.58ï¼Œpâ€‰=â€‰0.035ï¼‰ã€ä¸»è¦ LARSï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1395 åæ‚£è€…ï¼ŒRRï¼š1.38ï¼Œ95%CIï¼š1.07ï¼Œ 1.79ï¼Œpâ€‰=â€‰0.012ï¼‰ï¼Œç´§è¿«æ€§ï¼ˆäº”é¡¹ç ”ç©¶ï¼›955 åæ‚£è€…ï¼ŒRRï¼š1.15ï¼Œ95%CIï¼š1.04ï¼Œ1.27ï¼Œpâ€‰=â€‰0.005ï¼‰å¹¶ä¸”å…·æœ‰è¾ƒé«˜çš„ LARS è¯„åˆ†ï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1450 åæ‚£è€…ï¼ŒWMDï¼š6.64ï¼Œ95%CIï¼š3.76ï¼Œ 9.52ï¼Œp<â€‰0.001ï¼‰å’Œ Wexner å¤±ç¦è¯„åˆ†ï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1045 åæ‚£è€…ï¼ŒWMDï¼š1.72ï¼Œ95%CIï¼š0.16ã€3.28ï¼Œp=â€‰0.031ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®ä½è‡³ä¸­åº¦ç¡®å®šæ€§è¯æ®ï¼Œç»“ç›´è‚ å’Œç»“è‚ è‚›ç®¡å»åˆæœ¯åçš„ AL ä¸ LARS é£é™©å¢åŠ æ˜¾ç€ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯ä¸»è¦ LARSã€å°¿æ€¥å’Œè¾ƒé«˜çš„ LARS ä»¥åŠ Wexner/Cleveland Clinic ä½›ç½—é‡Œè¾¾å¤§ä¾¿å¤±ç¦è¯„åˆ†ã€‚", "keywords_zh": "LARSï¼Œå»åˆå£ç˜˜ï¼Œå‰åˆ‡é™¤ï¼Œè‚ åŠŸèƒ½éšœç¢ï¼Œç»“ç›´è‚ ï¼Œç³»ç»Ÿè¯„ä»·", "keywords_en": "LARS, anastomotic leak, anterior resection, bowel dysfunction, colorectal, systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40808658/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 14 Aug 2025"}, {"id": "40793873", "title_en": "Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies", "title_zh": "ç³»ç»Ÿç»¼è¿°ï¼šé¸Ÿæªæ³•å®åŸºå› ç»„ç ”ç©¶ä¸­ç²ªä¾¿å¾®ç”Ÿç‰©ç»„ä¸ç»“ç›´è‚ è‚¿ç˜¤ä¹‹é—´çš„å…³ç³»", "authors": "Colin Rees", "abstract_en": "**Background:** The human gut microbiome is of academic and clinical interest. Associations between certain organisms and colorectal neoplasia have been reported, but findings have limited reproducibility in different populations.\n\n**Methods:** We performed a systematic review of whole metagenome shotgun sequencing studies using faecal samples from patients with colorectal neoplasia and control populations. Searches were performed on 30th June 2023. We identified 26 studies, reporting on 22 study populations (13 from Asia, five from Europe and four from North America). Study size ranged from 14 to 971 individuals (mean 170).\n\n**Results:** Some reproducible data were identified, such as the significant enrichment of Fusobacterium nucleatum and Parvimonas micra in colorectal cancer patients compared to controls (in 10 and nine studies, respectively). However, 21 out of 26 studies scored poorly on quality appraisal, specifically surrounding selection of cases and controls. Definitions of controls varied; some studies used individuals with normal endoscopic investigations, some used 'healthy' individuals where no colonoscopy was performed, and one used those with non-neoplastic findings (haemorrhoids). There was even less reproducibility of data in studies where individuals with colorectal polyps were compared to controls, possibly because of heterogeneity in these patient groupings as a variety of definitions for 'polyp cases' were used.\n\n**Conclusions:** Heterogeneity and potential for bias indicates that findings should be interpreted with caution. Standardised protocols to ensure robust methodology and allow pooling of large-scale data are required before these findings can be used in clinical practice (PROSPERO: CRD42023431977).", "abstract_zh": "**èƒŒæ™¯ï¼š** äººç±»è‚ é“å¾®ç”Ÿç‰©ç»„å…·æœ‰å­¦æœ¯å’Œä¸´åºŠæ„ä¹‰ã€‚æŸäº›å¾®ç”Ÿç‰©ä¸ç»“ç›´è‚ è‚¿ç˜¤ä¹‹é—´çš„å…³è”å·²æœ‰æŠ¥é“ï¼Œä½†ç ”ç©¶ç»“æœåœ¨ä¸åŒäººç¾¤ä¸­çš„é‡å¤æ€§æœ‰é™ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ä½¿ç”¨ç»“ç›´è‚ è‚¿ç˜¤æ‚£è€…å’Œå¯¹ç…§äººç¾¤çš„ç²ªä¾¿æ ·æœ¬å¯¹æ•´ä¸ªå®åŸºå› ç»„é¸Ÿæªæ³•æµ‹åºç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚æ£€ç´¢äº 2023 å¹´ 6 æœˆ 30 æ—¥è¿›è¡Œã€‚æˆ‘ä»¬ç¡®å®šäº† 26 é¡¹ç ”ç©¶ï¼ŒæŠ¥å‘Šäº† 22 ä¸ªç ”ç©¶äººç¾¤ï¼ˆ13 é¡¹æ¥è‡ªäºšæ´²ï¼Œ5 é¡¹æ¥è‡ªæ¬§æ´²ï¼Œ4 é¡¹æ¥è‡ªåŒ—ç¾ï¼‰ã€‚ç ”ç©¶è§„æ¨¡ä» 14 äººåˆ° 971 äººä¸ç­‰ï¼ˆå¹³å‡ 170 äººï¼‰ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº†ä¸€äº›å¯é‡å¤çš„æ•°æ®ï¼Œä¾‹å¦‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œç»“ç›´è‚ ç™Œæ‚£è€…ä¸­å…·æ ¸æ¢­æ†èŒå’Œå¾®å°å•èƒèŒæ˜¾ç€å¯Œé›†ï¼ˆåˆ†åˆ«åœ¨ 10 é¡¹å’Œ 9 é¡¹ç ”ç©¶ä¸­ï¼‰ã€‚ç„¶è€Œï¼Œ26 é¡¹ç ”ç©¶ä¸­æœ‰ 21 é¡¹åœ¨è´¨é‡è¯„ä¼°æ–¹é¢å¾—åˆ†è¾ƒä½ï¼Œç‰¹åˆ«æ˜¯åœ¨ç—…ä¾‹å’Œå¯¹ç…§çš„é€‰æ‹©æ–¹é¢ã€‚æ§åˆ¶çš„å®šä¹‰å„ä¸ç›¸åŒï¼›ä¸€äº›ç ”ç©¶ä½¿ç”¨äº†æ­£å¸¸å†…çª¥é•œæ£€æŸ¥çš„ä¸ªä½“ï¼Œä¸€äº›ç ”ç©¶ä½¿ç”¨äº†æœªè¿›è¡Œç»“è‚ é•œæ£€æŸ¥çš„â€œå¥åº·â€ä¸ªä½“ï¼Œè¿˜æœ‰ä¸€é¡¹ç ”ç©¶ä½¿ç”¨äº†éè‚¿ç˜¤å‘ç°ï¼ˆç—”ç–®ï¼‰çš„ä¸ªä½“ã€‚åœ¨å°†ç»“ç›´è‚ æ¯è‚‰æ‚£è€…ä¸å¯¹ç…§ç»„è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶ä¸­ï¼Œæ•°æ®çš„é‡å¤æ€§ç”šè‡³æ›´ä½ï¼Œè¿™å¯èƒ½æ˜¯å› ä¸ºè¿™äº›æ‚£è€…åˆ†ç»„çš„å¼‚è´¨æ€§ï¼Œå› ä¸ºä½¿ç”¨äº†å¤šç§â€œæ¯è‚‰ç—…ä¾‹â€å®šä¹‰ã€‚\n\n**ç»“è®ºï¼š** å¼‚è´¨æ€§å’Œæ½œåœ¨åå·®è¡¨æ˜åº”è°¨æ…è§£é‡Šç ”ç©¶ç»“æœã€‚åœ¨å°†è¿™äº›å‘ç°ç”¨äºä¸´åºŠå®è·µä¹‹å‰ï¼Œéœ€è¦åˆ¶å®šæ ‡å‡†åŒ–æ–¹æ¡ˆä»¥ç¡®ä¿ç¨³å¥çš„æ–¹æ³•å¹¶å…è®¸æ±‡é›†å¤§è§„æ¨¡æ•°æ®ï¼ˆPROSPEROï¼šCRD42023431977ï¼‰ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40793873/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 12 Aug 2025"}, {"id": "40788642", "title_en": "Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies", "title_zh": "æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸­çš„ä½œç”¨ï¼šå¯¹ç°æœ‰ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾", "authors": "Alexander G Heriot", "abstract_en": "**Background:** During the past few decades, the standard of care for locally advanced rectal cancer, involving neoadjuvant chemoradiation followed by surgery, has been associated with a pathological complete response rate of only 10% to 20%. Combination therapy with immune checkpoint inhibitors may improve treatment response.\n\n**Objective:** This systematic review examines the current evidence regarding neoadjuvant immune checkpoint inhibitors in locally advanced rectal cancer in terms of treatment efficacy, impact on surgical outcomes, and potential adverse events.\n\n**Data Sources:** A literature search was conducted using the Ovid MEDLINE, Embase, Web of Science, and Cochrane Library databases from the start of database records to October 31, 2024.\n\n**Study Selection:** All studies that reported outcomes in patients with locally advanced rectal cancer who received immune checkpoint inhibitors as part of their neoadjuvant treatment were included for examination.\n\n**Main Outcome Measures:** Primary outcome was pathological complete response rate. Secondary outcomes were major pathological response rate, clinical complete response rate, complete response rate, R0 resection rate, and sphincter preservation rate. Safety data were included where available. Potential biomarkers of treatment response were identified.\n\n**Results:** Twelve studies were reviewed. All were prospective phase I/II clinical trials. The overall pathological complete response rate ranged from 25% to 62.5% (50% for deficient mismatch repair/high microsatellite instability; 25%-62.5% for proficient mismatch repair/microsatellite stable). The clinical complete response rate ranged from 10.9% to 100% (56%-100% for deficient mismatch repair/high microsatellite instability; 16.4%-48% for proficient mismatch repair/microsatellite stable). The complete response rate ranged from 44% to 75% (75% for deficient mismatch repair/high microsatellite instability; 44%-56.5% for proficient mismatch repair/microsatellite stable). The R0 resection rate ranged from 94% to 100% and the sphincter preservation rate ranged from 59.4% to 100%. The majority of adverse events were of grades 1 and 2.\n\n**Limitations:** Our review was limited by a small number of mostly single-arm studies with a lack of long-term survival outcomes, as well as marked clinical and methodological heterogeneity among included studies.\n\n**Conclusions:** Combination therapy with immune checkpoint inhibitors in locally advanced rectal cancer appears to improve treatment response, but high-level evidence and long-term data are still lacking.", "abstract_zh": "**èƒŒæ™¯ï¼š** åœ¨è¿‡å»çš„å‡ åå¹´é‡Œï¼Œå±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„æŠ¤ç†æ ‡å‡†ï¼ˆåŒ…æ‹¬æ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œæ‰‹æœ¯ï¼‰çš„ç—…ç†å®Œå…¨ç¼“è§£ç‡ä»…ä¸º 10% è‡³ 20%ã€‚ä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„è”åˆæ²»ç–—å¯èƒ½ä¼šæ”¹å–„æ²»ç–—ååº”ã€‚\n\n**ç›®çš„ï¼š** æœ¬ç³»ç»Ÿç»¼è¿°ä»æ²»ç–—æ•ˆæœã€å¯¹æ‰‹æœ¯ç»“æœçš„å½±å“å’Œæ½œåœ¨ä¸è‰¯äº‹ä»¶æ–¹é¢æ¢è®¨äº†æœ‰å…³æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„å½“å‰è¯æ®ã€‚\n\n**Data sourcesï¼š** ä½¿ç”¨ Ovid MEDLINEã€Embaseã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†ä»æ•°æ®åº“è®°å½•å¼€å§‹åˆ° 2024 å¹´ 10 æœˆ 31 æ—¥çš„æ–‡çŒ®æ£€ç´¢ã€‚\n\n**Study selectionï¼š** æ‰€æœ‰æŠ¥å‘Šæ¥å—å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ä½œä¸ºæ–°è¾…åŠ©æ²»ç–—ä¸€éƒ¨åˆ†çš„å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…ç»“å±€çš„ç ”ç©¶å‡è¢«çº³å…¥æ£€æŸ¥ã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“æœæ˜¯ç—…ç†å®Œå…¨ç¼“è§£ç‡ã€‚æ¬¡è¦ç»“å±€ä¸ºä¸»è¦ç—…ç†ç¼“è§£ç‡ã€ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ã€å®Œå…¨ç¼“è§£ç‡ã€R0åˆ‡é™¤ç‡å’Œæ‹¬çº¦è‚Œä¿ç•™ç‡ã€‚å¦‚æœ‰å¯ç”¨çš„å®‰å…¨æ•°æ®ä¹ŸåŒ…æ‹¬åœ¨å†…ã€‚ç¡®å®šäº†æ²»ç–—ååº”çš„æ½œåœ¨ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚\n\n**ç»“æœï¼š** å®¡æŸ¥äº†åäºŒé¡¹ç ”ç©¶ã€‚æ‰€æœ‰å‡ä¸ºå‰ç»æ€§ I/II æœŸä¸´åºŠè¯•éªŒã€‚æ€»ä½“ç—…ç†å®Œå…¨ç¼“è§£ç‡èŒƒå›´ä¸º 25% è‡³ 62.5%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿé«˜åº¦ä¸ç¨³å®šä¸º 50%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º 25%-62.5%ï¼‰ã€‚ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ä¸º10.9%è‡³100%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿé«˜åº¦ä¸ç¨³å®šæ€§ä¸º56%-100%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º16.4%-48%ï¼‰ã€‚å®Œå…¨ç¼“è§£ç‡èŒƒå›´ä¸º 44% è‡³ 75%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿä¸ç¨³å®šæ€§é«˜ä¸º 75%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º 44%-56.5%ï¼‰ã€‚ R0åˆ‡é™¤ç‡ä¸º94%ï½100%ï¼Œæ‹¬çº¦è‚Œä¿ç•™ç‡ä¸º59.4%ï½100%ã€‚å¤§å¤šæ•°ä¸è‰¯äº‹ä»¶ä¸º 1 çº§å’Œ 2 çº§ã€‚\n\n**Limitationsï¼š** æˆ‘ä»¬çš„ç»¼è¿°å—åˆ°å°‘æ•°ä¸»è¦æ˜¯å•è‡‚ç ”ç©¶çš„é™åˆ¶ï¼Œç¼ºä¹é•¿æœŸç”Ÿå­˜ç»“æœï¼Œä»¥åŠçº³å…¥çš„ç ”ç©¶ä¹‹é—´å­˜åœ¨æ˜æ˜¾çš„ä¸´åºŠå’Œæ–¹æ³•å­¦å¼‚è´¨æ€§ã€‚\n\n**ç»“è®ºï¼š** å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„è”åˆæ²»ç–—ä¼¼ä¹å¯ä»¥æ”¹å–„æ²»ç–—ååº”ï¼Œä½†ä»ç¼ºä¹é«˜æ°´å¹³çš„è¯æ®å’Œé•¿æœŸæ•°æ®ã€‚", "keywords_zh": "å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ã€å…ç–«æ²»ç–—ã€ç—…ç†å®Œå…¨ç¼“è§£ã€ç›´è‚ ç™Œ", "keywords_en": "Immune checkpoint inhibitors, Immunotherapy, Pathologic complete response, Rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/40788642/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 11 Aug 2025"}, {"id": "40788606", "title_en": "Research Perspective on Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies", "title_zh": "æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸­ä½œç”¨çš„ç ”ç©¶è§†è§’ï¼šå¯¹ç°æœ‰ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾", "authors": "William C Chapman", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40788606/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 11 Aug 2025"}, {"id": "40760310", "title_en": "Correction: Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "çº æ­£ï¼šèšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Gianpiero Gravante", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40760310/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 05 Aug 2025"}, {"id": "40723194", "title_en": "Quality of Life in Rectal Cancer Treatments: An Updated Systematic Review of Randomized Controlled Trials (2013-2023)", "title_zh": "ç›´è‚ ç™Œæ²»ç–—çš„ç”Ÿæ´»è´¨é‡ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·ï¼ˆ2013-2023ï¼‰", "authors": "Emanuele Damiano Luca Urso", "abstract_en": "**Background:** Rectal cancer management involves surgery, chemotherapy (CT), radiotherapy (RT), and patient care strategies, all of which significantly affect health-related quality of life (HRQoL). Understanding these effects is critical for optimizing treatment protocols. This review aimed to systematically analyze the impact of rectal cancer treatment on HRQoL.\n\n**Methods:** Four databases, Scopus, EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials, were searched for randomized controlled trials (RCTs) published between January 2013 and December 2023. RCTs specifically focusing on rectal cancer treatments (surgical interventions, pre- and/or post-CT and/or RT, and patient care strategies) were included. An abstract review, data extraction, and a risk-of-bias assessment were independently conducted by two reviewers.\n\n**Results:** The 41 included studies comprised 9240 patients: 16 evaluated surgical interventions (3507 patients), 15 evaluated pre- and/or post-CT and/or RT protocols (5114 patients), and 10 focused on patient-care strategies (619 patients). Sphincter-sparing procedures were associated with better HRQoL than abdominoperineal resection, and rectal-sparing techniques were associated with better overall HRQoL than rectal resection. RT was associated with a poorer HRQoL. Continuity-of-care interventions improved HRQoL in ostomy patients, whereas transanal irrigation improved HRQoL after ostomy closure.\n\n**Conclusions:** This systematic review of RCTs underscores the importance of organ-sparing strategies, such as rectum-sparing approaches and continuity-of-care packages, in improving HRQoL in patients with rectal cancer. Although RT negatively affects HRQoL, treatment regimens should be individualized. Tailored organ-preservation approaches and structured follow-up care are essential for optimizing HRQoL in patients with rectal cancer.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ ç™Œç®¡ç†æ¶‰åŠæ‰‹æœ¯ã€åŒ–ç–— (CT)ã€æ”¾ç–— (RT) å’Œæ‚£è€…æŠ¤ç†ç­–ç•¥ï¼Œæ‰€æœ‰è¿™äº›éƒ½ä¼šæ˜¾ç€å½±å“å¥åº·ç›¸å…³çš„ç”Ÿæ´»è´¨é‡ (HRQoL)ã€‚äº†è§£è¿™äº›å½±å“å¯¹äºä¼˜åŒ–æ²»ç–—æ–¹æ¡ˆè‡³å…³é‡è¦ã€‚æœ¬ç»¼è¿°æ—¨åœ¨ç³»ç»Ÿåˆ†æç›´è‚ ç™Œæ²»ç–—å¯¹ HRQoL çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† Scopusã€EMBASEã€MEDLINE å’Œ Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“è¿™å››ä¸ªæ•°æ®åº“ï¼Œä»¥æŸ¥æ‰¾ 2013 å¹´ 1 æœˆè‡³ 2023 å¹´ 12 æœˆæœŸé—´å‘è¡¨çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚å…¶ä¸­åŒ…æ‹¬ä¸“é—¨é’ˆå¯¹ç›´è‚ ç™Œæ²»ç–—ï¼ˆæ‰‹æœ¯å¹²é¢„ã€CT å’Œ/æˆ– RT å‰åå’Œ/æˆ–æœ¯åä»¥åŠæ‚£è€…æŠ¤ç†ç­–ç•¥ï¼‰çš„ RCTã€‚æ‘˜è¦å®¡æŸ¥ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ç”±ä¸¤åå®¡æŸ¥å‘˜ç‹¬ç«‹è¿›è¡Œã€‚\n\n**ç»“æœï¼š** è¿™ 41 é¡¹ç ”ç©¶æ¶‰åŠ 9240 åæ‚£è€…ï¼š16 é¡¹è¯„ä¼°æ‰‹æœ¯å¹²é¢„ï¼ˆ3507 åæ‚£è€…ï¼‰ï¼Œ15 é¡¹è¯„ä¼° CT å’Œ/æˆ– RT æ–¹æ¡ˆä¹‹å‰å’Œ/æˆ–ä¹‹åï¼ˆ5114 åæ‚£è€…ï¼‰ï¼Œ10 é¡¹é‡ç‚¹å…³æ³¨æ‚£è€…æŠ¤ç†ç­–ç•¥ï¼ˆ619 åæ‚£è€…ï¼‰ã€‚ä¸è…¹ä¼šé˜´åˆ‡é™¤æœ¯ç›¸æ¯”ï¼Œä¿ç•™æ‹¬çº¦è‚Œçš„æ‰‹æœ¯ä¸æ›´å¥½çš„ HRQoL ç›¸å…³ï¼Œè€Œä¸ç›´è‚ åˆ‡é™¤æœ¯ç›¸æ¯”ï¼Œç›´è‚ ä¿ç•™æŠ€æœ¯ä¸æ›´å¥½çš„æ€»ä½“ HRQoL ç›¸å…³ã€‚ RT ä¸è¾ƒå·®çš„ HRQoL ç›¸å…³ã€‚è¿ç»­æŠ¤ç†å¹²é¢„æªæ–½æ”¹å–„äº†é€ å£æ‚£è€…çš„ HRQoLï¼Œè€Œç»è‚›é—¨å†²æ´—åˆ™æ”¹å–„äº†é€ å£é—­åˆåçš„ HRQoLã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹éšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å¼ºè°ƒäº†å™¨å®˜ä¿ç•™ç­–ç•¥ï¼ˆä¾‹å¦‚ä¿ç•™ç›´è‚ æ–¹æ³•å’Œè¿ç»­æ€§æŠ¤ç†åŒ…ï¼‰åœ¨æ”¹å–„ç›´è‚ ç™Œæ‚£è€… HRQoL æ–¹é¢çš„é‡è¦æ€§ã€‚å°½ç®¡æ”¾ç–—ä¼šå¯¹ HRQoL äº§ç”Ÿè´Ÿé¢å½±å“ï¼Œä½†æ²»ç–—æ–¹æ¡ˆåº”ä¸ªä½“åŒ–ã€‚å®šåˆ¶çš„å™¨å®˜ä¿å­˜æ–¹æ³•å’Œç»“æ„åŒ–çš„åç»­æŠ¤ç†å¯¹äºä¼˜åŒ–ç›´è‚ ç™Œæ‚£è€…çš„ HRQoL è‡³å…³é‡è¦ã€‚", "keywords_zh": "å¥åº·ç›¸å…³çš„ç”Ÿæ´»è´¨é‡ã€å™¨å®˜ä¿å­˜ç­–ç•¥ã€æ”¾å°„æ²»ç–—ã€ç›´è‚ ç™Œ", "keywords_en": "health-related quality of life, organ-preserving strategies, radiotherapy, rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/40723194/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 29 Jul 2025"}, {"id": "40719429", "title_en": "Mechanical bowel preparation to prevent infective complications after colon and rectal surgery: a systematic review and meta-analysis of randomized controlled trials", "title_zh": "æœºæ¢°è‚ é“å‡†å¤‡é¢„é˜²ç»“è‚ å’Œç›´è‚ æ‰‹æœ¯åæ„ŸæŸ“å¹¶å‘ç—‡ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Eloy EspÃ­n-Basany", "abstract_en": "**Introduction:** Surgical site infections (SSI) represent a global health challenge, particularly in colorectal surgery, when rates can reach up to 20%. The role of mechanical bowel preparation (MBP) is still debated. A systematic review is proposed to evaluate MBP effectiveness in reducing SSI and complications after colorectal surgery.\n\n**Evidence Acquisition:** This systematic review and meta-analysis was conducted following the PRISMA guidelines. Only randomized studies comparing two or more methods for preventing infectious complications in patients undergoing colorectal surgery were included. The primary endpoint was the occurrence of SSIs, while secondary endpoints included anastomotic leak (AL) and intra-abdominal septic complications (IASC) other than AL.\n\n**Evidence Synthesis:** Eighteen studies met the inclusion criteria, including a total of 6,302 patients in the analysis. The meta-analysis showed similar SSI rates between the MBP and no-treatment groups (OR 1.015, 95% CI 0.855-1.206, I<sup>2</sup>=22.33%, P=0.863) as well as between the MBP and enema groups (OR 1.100, 95% CI 0.616-1.965, I<sup>2</sup>=35.96%, P=0.748). The risk of anastomotic leak (AL) was also similar when comparing no treatment to MBP (OR 0.904, 95% CI 0.661-1.237, I<sup>2</sup>=0%, P=0.528), and MBP to enema (OR 0.727, 95% CI 0.286-1.845, I<sup>2</sup>=25.98%, P=0.502). IASC rates were lower with MBP compared to no treatment (OR 0.526, 95% CI 0.326-0.848, I<sup>2</sup>=3.50%, P=0.008).\n\n**Conclusions:** This meta-analysis found no significant reduction in SSI or AL rates with MBP alone compared to no preparation or enema use. However, MBP significantly lowered IASC. Further research is warranted to evaluate the effectiveness of MBP combined with antibiotics in reducing postoperative complications.", "abstract_zh": "**ä»‹ç»ï¼š** æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) æ˜¯ä¸€é¡¹å…¨çƒå¥åº·æŒ‘æˆ˜ï¼Œç‰¹åˆ«æ˜¯åœ¨ç»“ç›´è‚ æ‰‹æœ¯ä¸­ï¼Œæ„ŸæŸ“ç‡é«˜è¾¾ 20%ã€‚æœºæ¢°è‚ é“å‡†å¤‡ï¼ˆMBPï¼‰çš„ä½œç”¨ä»ç„¶å­˜åœ¨äº‰è®®ã€‚å»ºè®®è¿›è¡Œç³»ç»Ÿè¯„ä»·æ¥è¯„ä¼° MBP åœ¨å‡å°‘ç»“ç›´è‚ æ‰‹æœ¯å SSI å’Œå¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚\n\n**Evidence acquisitionï¼š** æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ˜¯æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œçš„ã€‚ä»…çº³å…¥æ¯”è¾ƒä¸¤ç§æˆ–å¤šç§é¢„é˜²ç»“ç›´è‚ æ‰‹æœ¯æ‚£è€…æ„ŸæŸ“å¹¶å‘ç—‡çš„æ–¹æ³•çš„éšæœºç ”ç©¶ã€‚ä¸»è¦ç»ˆç‚¹æ˜¯ SSI çš„å‘ç”Ÿï¼Œæ¬¡è¦ç»ˆç‚¹åŒ…æ‹¬ AL ä»¥å¤–çš„å»åˆå£ç˜˜ (AL) å’Œè…¹è…”å†…è„“æ¯’ç—‡å¹¶å‘ç—‡ (IASC)ã€‚\n\n**Evidence synthesisï¼š** 18 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œåˆ†æä¸­å…±æœ‰ 6,302 åæ‚£è€…ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼ŒMBP ç»„å’Œæœªæ²»ç–—ç»„ä¹‹é—´ï¼ˆOR 1.015ï¼Œ95% CI 0.855-1.206ï¼ŒI<sup>2</sup>=22.33%ï¼ŒP=0.863ï¼‰ä»¥åŠ MBP å’ŒçŒè‚ ç»„ä¹‹é—´ï¼ˆOR 1.100ï¼Œ95% CI 0.616-1.965ï¼Œ I<sup>2</sup>=35.96%ï¼ŒP=0.748ï¼‰ã€‚å°†ä¸æ²»ç–—ä¸ MBP è¿›è¡Œæ¯”è¾ƒï¼ˆOR 0.904ï¼Œ95% CI 0.661-1.237ï¼ŒI<sup>2</sup>=0%ï¼ŒP=0.528ï¼‰ï¼Œä»¥åŠå°† MBP ä¸çŒè‚ è¿›è¡Œæ¯”è¾ƒï¼ˆOR 0.727ï¼Œ95% CI 0.286-1.845ï¼Œ I<sup>2</sup>=25.98%ï¼ŒP=0.502ï¼‰ã€‚ä¸æœªæ²»ç–—ç›¸æ¯”ï¼ŒMBP æ²»ç–—ç»„çš„ IASC ç‡è¾ƒä½ï¼ˆOR 0.526ï¼Œ95% CI 0.326-0.848ï¼ŒI<sup>2</sup>=3.50%ï¼ŒP=0.008ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹èŸèƒåˆ†æå‘ç°ï¼Œä¸ä¸ä½¿ç”¨åˆ¶å‰‚æˆ–çŒè‚ å‰‚ç›¸æ¯”ï¼Œå•ç‹¬ä½¿ç”¨ MBP çš„ SSI æˆ– AL ç‡æ²¡æœ‰æ˜¾ç€é™ä½ã€‚ç„¶è€Œï¼ŒMBP æ˜¾ç€é™ä½äº† IASCã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥è¯„ä¼° MBP è”åˆæŠ—ç”Ÿç´ åœ¨å‡å°‘æœ¯åå¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40719429/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 28 Jul 2025"}, {"id": "40714623", "title_en": "Closing the gap: addressing delayed healthcare-seeking and improving quality of life for Ethiopian women with pelvic organ prolapse", "title_zh": "ç¼©å°å·®è·ï¼šè§£å†³æ‚£æœ‰ç›†è…”å™¨å®˜è„±å‚çš„åŸƒå¡ä¿„æ¯”äºšå¦‡å¥³å»¶è¿Ÿå°±åŒ»çš„é—®é¢˜å¹¶æé«˜ç”Ÿæ´»è´¨é‡", "authors": "Lencho Kajela", "abstract_en": "**Background:** Pelvic organs prolapse (POP) involves the herniation of pelvic organs, such as the uterus, cervix, vaginal wall, bladder, and rectum, into the vagina. While it is a common gynecologic problem, its impact on quality of life and timely healthcare-seeking remains poorly understood in developing countries. This systematic review and meta-analysis aimed to assess the quality of life, delays in healthcare-seeking, and associated factors among women diagnosed with POP in Ethiopia.\n\n**Methods:** A systematic review and meta-analysis were conducted following PRISMA guidelines. Extensive literature searches were performed in PubMed, CINAHL, Google Scholar, ScienceDirect, and Scopus. A restricted maximum likelihood random-effects model was used to estimate pooled proportions. Heterogeneity among studies was assessed using the Cochrane Q-test and I2 statistics. Publication bias was evaluated using funnel plots and Egger's test. Stata 17 software was used for all analyses.\n\n**Results:** From an initial pool of 421 articles, 10 met the inclusion criteria, encompassing data from 1489 women diagnosed with POP. The pooled proportion of poor quality of life among women with POP in Ethiopia was 52.07Â % [95Â % C.I.: 48.04Â %, 56.09Â %]. Moderate heterogeneity was observed across studies. The mean delay between symptom onset and seeking medical care was 50.64Â months [95Â % C.I: 32.50, 68.79], with an estimated 78.22Â % [95Â % C.I.: 70.72Â %, 85.72Â %] of women experiencing delays in seeking healthcare. Postmenopausal status (OR = 2.05, 95Â % CI: 1.22-3.45), living with POP for more than 2Â years (OR = 4.17, 95Â % CI: 1.23-14.10), and having Stage III/IV POP (OR = 4.48, 95Â % CI: 1.61-12.44) associated with poor quality of life. In addition, factors associated with delayed healthcare seeking include: fear of disclosure (OR = 4.60, 95Â % CI: 4.65-45.71), lack of social support (OR = 4.09, 95Â % CI: 1.91-8.74), low income (OR = 4.80, 95Â % CI: 2.12-10.86), and experiencing stigma (OR = 5.78, 95Â % CI: 1.07-31.36).\n\n**Conclusion:** This review highlights a high prevalence of poor quality of life and significant delays in healthcare-seeking among Ethiopian women with POP, with an average delay of over four years after symptom onset. Stigma, fear of disclosure, low income, and lack of social support were significantly associated with delays in seeking health care. Additionally, longer prolapse duration, menopause, and stage III or IV pelvic organ prolapse (POP) were significantly associated with a reduced quality of life.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›†è…”å™¨å®˜è„±å‚ï¼ˆPOPï¼‰æ¶‰åŠç›†è…”å™¨å®˜ï¼ˆå¦‚å­å®«ã€å­å®«é¢ˆã€é˜´é“å£ã€è†€èƒ±å’Œç›´è‚ ï¼‰ç–å…¥é˜´é“ã€‚è™½ç„¶è¿™æ˜¯ä¸€ä¸ªå¸¸è§çš„å¦‡ç§‘é—®é¢˜ï¼Œä½†åœ¨å‘å±•ä¸­å›½å®¶ï¼Œå®ƒå¯¹ç”Ÿæ´»è´¨é‡å’ŒåŠæ—¶å°±åŒ»çš„å½±å“ä»ç„¶çŸ¥ä¹‹ç”šå°‘ã€‚è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°åŸƒå¡ä¿„æ¯”äºšè¯Šæ–­æ‚£æœ‰ POP çš„å¥³æ€§çš„ç”Ÿæ´»è´¨é‡ã€å°±åŒ»å»¶è¿Ÿä»¥åŠç›¸å…³å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚åœ¨ PubMedã€CINAHLã€Google Scholarã€ScienceDirect å’Œ Scopus ä¸­è¿›è¡Œäº†å¹¿æ³›çš„æ–‡çŒ®æ£€ç´¢ã€‚ä½¿ç”¨é™åˆ¶æœ€å¤§ä¼¼ç„¶éšæœºæ•ˆåº”æ¨¡å‹æ¥ä¼°è®¡åˆå¹¶æ¯”ä¾‹ã€‚ä½¿ç”¨ Cochrane Q æ£€éªŒå’Œ I2 ç»Ÿè®¡æ¥è¯„ä¼°ç ”ç©¶ä¹‹é—´çš„å¼‚è´¨æ€§ã€‚ä½¿ç”¨æ¼æ–—å›¾å’Œè‰¾æ ¼æ£€éªŒè¯„ä¼°å‘è¡¨åå€šã€‚ Stata 17 è½¯ä»¶ç”¨äºæ‰€æœ‰åˆ†æã€‚\n\n**ç»“æœï¼š** ä»æœ€åˆçš„ 421 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 10 ç¯‡ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œæ¶µç›–äº† 1489 åè¢«è¯Šæ–­æ‚£æœ‰ POP çš„å¥³æ€§çš„æ•°æ®ã€‚åŸƒå¡ä¿„æ¯”äºš POP å¥³æ€§ä¸­ç”Ÿæ´»è´¨é‡è¾ƒå·®çš„æ€»ä½“æ¯”ä¾‹ä¸º 52.07% [95% C.I.: 48.04%, 56.09%]ã€‚å„é¡¹ç ”ç©¶ä¸­è§‚å¯Ÿåˆ°ä¸­ç­‰ç¨‹åº¦çš„å¼‚è´¨æ€§ã€‚ç—‡çŠ¶å‡ºç°å’Œå°±åŒ»ä¹‹é—´çš„å¹³å‡å»¶è¿Ÿæ—¶é—´ä¸º 50.64 ä¸ªæœˆ [95% C.I.: 32.50, 68.79]ï¼Œä¼°è®¡æœ‰ 78.22% [95% C.I.: 70.72%, 85.72%] çš„å¥³æ€§åœ¨å¯»æ±‚åŒ»ç–—ä¿å¥æ–¹é¢å‡ºç°å»¶è¿Ÿã€‚ç»ç»åçŠ¶æ€ï¼ˆOR = 2.05ï¼Œ95% CIï¼š1.22-3.45ï¼‰ã€æ‚£æœ‰ POP è¶…è¿‡ 2 å¹´ï¼ˆOR = 4.17ï¼Œ95% CIï¼š1.23-14.10ï¼‰ä»¥åŠæ‚£æœ‰ III/IV æœŸ POPï¼ˆOR = 4.48ï¼Œ95% CIï¼š1.61-12.44ï¼‰ä¸ä¸è‰¯è´¨é‡ç›¸å…³ç”Ÿæ´»ã€‚æ­¤å¤–ï¼Œä¸å»¶è¿Ÿå°±åŒ»ç›¸å…³çš„å› ç´ åŒ…æ‹¬ï¼šå®³æ€•æŠ«éœ²ï¼ˆOR = 4.60ï¼Œ95% CIï¼š4.65-45.71ï¼‰ã€ç¼ºä¹ç¤¾ä¼šæ”¯æŒï¼ˆOR = 4.09ï¼Œ95% CIï¼š1.91-8.74ï¼‰ã€ä½æ”¶å…¥ï¼ˆOR = 4.80ï¼Œ95% CIï¼š2.12-10.86ï¼‰å’Œç»å†è€»è¾±ï¼ˆOR = 5.78ï¼Œ95% CIï¼š1.07-31.36ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™ç¯‡ç»¼è¿°å¼ºè°ƒäº†æ‚£æœ‰ POP çš„åŸƒå¡ä¿„æ¯”äºšå¥³æ€§æ™®éå­˜åœ¨ç”Ÿæ´»è´¨é‡å·®å’Œå°±åŒ»ä¸¥é‡å»¶è¿Ÿçš„æƒ…å†µï¼Œç—‡çŠ¶å‡ºç°åå¹³å‡å»¶è¿Ÿå››å¹´ä»¥ä¸Šã€‚è€»è¾±ã€å®³æ€•æŠ«éœ²ã€ä½æ”¶å…¥å’Œç¼ºä¹ç¤¾ä¼šæ”¯æŒä¸å»¶è¿Ÿå¯»æ±‚åŒ»ç–—ä¿å¥å¯†åˆ‡ç›¸å…³ã€‚æ­¤å¤–ï¼Œè¾ƒé•¿çš„è„±å‚æŒç»­æ—¶é—´ã€æ›´å¹´æœŸå’Œ III æœŸæˆ– IV æœŸç›†è…”å™¨å®˜è„±å‚ (POP) ä¸ç”Ÿæ´»è´¨é‡ä¸‹é™æ˜¾ç€ç›¸å…³ã€‚", "keywords_zh": "åŸƒå¡ä¿„æ¯”äºš, å¯»æ±‚åŒ»ç–—ä¿å¥, ç›†åº•åŠŸèƒ½éšœç¢, ç›†è…”å™¨å®˜è„±å‚, ç”Ÿæ´»è´¨é‡", "keywords_en": "Ethiopia, Healthcare-seeking, Pelvic floor dysfunction, Pelvic organs prolapse, Quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/40714623/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sun, 27 Jul 2025"}, {"id": "40703667", "title_en": "Radiotherapy boost to the primary tumour in locally advanced rectal cancer: Systematic review of practices and meta-analysis", "title_zh": "æ”¾å°„æ²»ç–—å¯¹å±€éƒ¨æ™šæœŸç›´è‚ ç™ŒåŸå‘è‚¿ç˜¤çš„å¢å¼ºä½œç”¨ï¼šå®è·µå’ŒèŸèƒåˆ†æçš„ç³»ç»Ÿå›é¡¾", "authors": "GeneviÃ¨ve Van Ooteghem", "abstract_en": "**Introduction:** In locally advanced rectal cancer (LARC), increasing the complete response (CR) rate after total neo-adjuvant treatment may increase the patient eligibility for non-operative management (\"watch and wait\", W&W). Although a radiotherapy (RT) boost to the primary tumour may enhance CR rates, clear guidelines are currently lacking. This systematic review and <i>meta</i>-analysis investigate the technical parameters used for rectal boost RT and assess their impact on oncological outcomes.\n\n**Methods:** Following PRISMA guidelines, the terms \"rectum,\" \"radiotherapy,\" and \"boost\" were searched in PubMed and EMBASE (PROSPERO: CRD42023444685). Studies reporting on external beam RT boost to the primary tumour in LARC and meeting quality criteria were included. Descriptive analyses extracted data on RT technique, preparation, boost delineation, dose, chemotherapy, and follow-up. A mixed-effects <i>meta</i>-analysis model evaluated the impact of selected parameters on CR and local recurrence rate (LRR). Studies were analysed separately based on treatment intent: planned surgery or W&W.\n\n**Results:** Out of 3904 references, 83 were included in the descriptive analysis and 78 in the <i>meta</i>-analysis. Substantial variability in RT parameters was observed across studies. Pathologic CR rates were significantly higher with intensity-modulated/volumetric-modulated arc RT (IMRT/VMAT, pÂ =Â 0.007), simultaneous boost (pÂ =Â 0.020), dose escalation (Biological equivalent doseÂ >Â 74Â Gy, pÂ =Â 0.035), and the combination of induction and consolidation chemotherapy (pÂ =Â 0.023). No significant associations were found for clinical CR or LRR.\n\n**Conclusion:** While rectal RT boost is already part of real-world practices, the wide heterogeneity in techniques highlights the urgent need for standardisation. Our <i>meta</i>-analysis suggests that IMRT/VMAT, simultaneous boost, and dose escalation are associated with higher pathological CR rates and should be considered in future rectal boost guidelines. These findings, however, warrant careful interpretation due to the absence of adjustments for clinical, tumoral, or patient-related parameters that may also influence response rate and oncological outcomes.", "abstract_zh": "**ä»‹ç»ï¼š** åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œ (LARC) ä¸­ï¼Œæé«˜æ–°è¾…åŠ©æ²»ç–—åçš„å®Œå…¨ç¼“è§£ (CR) ç‡å¯èƒ½ä¼šå¢åŠ æ‚£è€…æ¥å—éæ‰‹æœ¯æ²»ç–—çš„èµ„æ ¼ï¼ˆâ€œè§‚å¯Ÿå¹¶ç­‰å¾…â€ï¼ŒW&Wï¼‰ã€‚å°½ç®¡å¯¹åŸå‘è‚¿ç˜¤è¿›è¡Œæ”¾å°„æ²»ç–—ï¼ˆRTï¼‰å¯èƒ½ä¼šæé«˜ CR ç‡ï¼Œä½†ç›®å‰ç¼ºä¹æ˜ç¡®çš„æŒ‡å—ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æè°ƒæŸ¥äº†ç›´è‚ å¢å¼ºæ”¾ç–—æ‰€ç”¨çš„æŠ€æœ¯å‚æ•°ï¼Œå¹¶è¯„ä¼°äº†å®ƒä»¬å¯¹è‚¿ç˜¤å­¦ç»“æœçš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œåœ¨ PubMed å’Œ EMBASE ä¸­æ£€ç´¢äº†æœ¯è¯­â€œç›´è‚ â€ã€â€œæ”¾å°„æ²»ç–—â€å’Œâ€œå¢å¼ºâ€ï¼ˆPROSPEROï¼šCRD42023444685ï¼‰ã€‚æŠ¥å‘Šäº†å¤–ç…§å°„æ”¾ç–—å¯¹ LARC åŸå‘è‚¿ç˜¤çš„å¢å¼ºä½œç”¨å¹¶ç¬¦åˆè´¨é‡æ ‡å‡†çš„ç ”ç©¶ä¹Ÿè¢«çº³å…¥å…¶ä¸­ã€‚æè¿°æ€§åˆ†ææå–äº†æœ‰å…³ RT æŠ€æœ¯ã€å‡†å¤‡ã€åŠ å¼ºèŒƒå›´ã€å‰‚é‡ã€åŒ–ç–—å’Œéšè®¿çš„æ•°æ®ã€‚æ··åˆæ•ˆåº”å…ƒåˆ†ææ¨¡å‹è¯„ä¼°äº†æ‰€é€‰å‚æ•°å¯¹ CR å’Œå±€éƒ¨å¤å‘ç‡ (LRR) çš„å½±å“ã€‚æ ¹æ®æ²»ç–—ç›®çš„åˆ†åˆ«åˆ†æç ”ç©¶ï¼šè®¡åˆ’æ‰‹æœ¯æˆ– W&Wã€‚\n\n**ç»“æœï¼š** åœ¨ 3904 ç¯‡å‚è€ƒæ–‡çŒ®ä¸­ï¼Œ83 ç¯‡çº³å…¥æè¿°æ€§åˆ†æï¼Œ78 ç¯‡çº³å…¥å…ƒåˆ†æã€‚ä¸åŒç ”ç©¶ä¸­è§‚å¯Ÿåˆ° RT å‚æ•°å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚å¼ºåº¦è°ƒåˆ¶/ä½“ç§¯è°ƒåˆ¶å¼§å½¢æ”¾ç–—ï¼ˆIMRT/VMATï¼Œp = 0.007ï¼‰ã€åŒæ—¶åŠ å¼ºåŒ–ç–—ï¼ˆp = 0.020ï¼‰ã€å‰‚é‡é€’å¢ï¼ˆç”Ÿç‰©ç­‰æ•ˆå‰‚é‡> 74 Gyï¼Œp = 0.035ï¼‰ä»¥åŠè¯±å¯¼å’Œå·©å›ºåŒ–ç–—ç›¸ç»“åˆï¼ˆp = 0.023ï¼‰çš„ç—…ç† CR ç‡æ˜¾ç€æ›´é«˜ã€‚æœªå‘ç°ä¸ä¸´åºŠ CR æˆ– LRR æ˜¾ç€ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** è™½ç„¶ç›´è‚ æ”¾ç–—å¢å¼ºå·²ç»æˆä¸ºç°å®ä¸–ç•Œå®è·µçš„ä¸€éƒ¨åˆ†ï¼Œä½†æŠ€æœ¯ä¸Šçš„å¹¿æ³›å¼‚è´¨æ€§å‡¸æ˜¾äº†æ ‡å‡†åŒ–çš„è¿«åˆ‡éœ€è¦ã€‚æˆ‘ä»¬çš„èŸèƒåˆ†æè¡¨æ˜ï¼ŒIMRT/VMATã€åŒæ­¥åŠ å¼ºå’Œå‰‚é‡é€’å¢ä¸è¾ƒé«˜çš„ç—…ç† CR ç‡ç›¸å…³ï¼Œåº”åœ¨æœªæ¥çš„ç›´è‚ åŠ å¼ºæŒ‡å—ä¸­äºˆä»¥è€ƒè™‘ã€‚ç„¶è€Œï¼Œç”±äºæ²¡æœ‰å¯¹ä¹Ÿå¯èƒ½å½±å“ç¼“è§£ç‡å’Œè‚¿ç˜¤å­¦ç»“æœçš„ä¸´åºŠã€è‚¿ç˜¤æˆ–æ‚£è€…ç›¸å…³å‚æ•°è¿›è¡Œè°ƒæ•´ï¼Œè¿™äº›å‘ç°éœ€è¦ä»”ç»†è§£é‡Šã€‚", "keywords_zh": "å®Œå…¨ç¼“è§£ã€å‰‚é‡é€’å¢ã€å±€éƒ¨æ™šæœŸç›´è‚ ç™Œã€èŸèƒåˆ†æã€æ–°è¾…åŠ©æ²»ç–—ã€ç›´è‚ åŠ å¼ºæ²»ç–—", "keywords_en": "Complete response, Dose escalation, Locally advanced rectal cancer, Meta-analysis, Neo-adjuvant therapy, Rectal boost", "link": "https://pubmed.ncbi.nlm.nih.gov/40703667/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 24 Jul 2025"}, {"id": "40697442", "title_en": "Early-onset colorectal cancer in patients younger than 50 years: a systematic review of the literature", "title_zh": "50 å²ä»¥ä¸‹æ‚£è€…çš„æ—©å‘ç»“ç›´è‚ ç™Œï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Konstantinos Vlachos", "abstract_en": "Early-onset colorectal cancer (EO-CRC) refers to CRC diagnosed before the age of 50. Its incidence has risen in recent years, turning researchers' attention to its oncologic behavior and potentially modifiable risk factors. In this review, PubMed/MEDLINE database was searched for all original research articles concerning EO-CRC. The inclusion criteria were CRC patients under 50, without a known predisposing factor for malignancy or an inherited CRC syndrome, presenting oncological characteristics and outcomes. All studies were assessed for bias, based on the ROBINS-E 2022 tool, and were synthesized in a qualitative analysis. Twenty-nine articles, reporting on 64,376 EO-CRC patients, were included in the qualitative synthesis. Results were classified into 3 categories: a) demographics; b) histopathologic characteristics; and c) treatment outcomes. Of these publications, 21 studies agreed that rectum (45%) and left-sided (47.1%) cancers are most common in younger patients, and 5 indicated that the highest prevalence of CRC concerns the 40-49 years age group. Seventeen of 29 studies reported a higher stage (III and IV) on diagnosis, with lymphovascular and perineural invasion. Our review has some limitations: as it was based on a single database, not all studies provided information on the variables; and patients were not categorized in all studies in the same age groups, although all were under 50 years. As EO-CRC is on the rise, the need for closer monitoring and possibly earlier screening becomes apparent. Further research should focus on finding novel screening biomarkers and modifiable risk factors that would decrease mortality and improve patient outcomes.", "abstract_zh": "æ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ˆEO-CRCï¼‰æ˜¯æŒ‡50å²ä¹‹å‰è¯Šæ–­å‡ºçš„ç»“ç›´è‚ ç™Œã€‚è¿‘å¹´æ¥å…¶å‘ç—…ç‡æœ‰æ‰€ä¸Šå‡ï¼Œè¿™ä½¿å¾—ç ”ç©¶äººå‘˜å¼€å§‹å…³æ³¨å…¶è‚¿ç˜¤è¡Œä¸ºå’Œæ½œåœ¨å¯æ”¹å˜çš„å±é™©å› ç´ ã€‚åœ¨è¿™ç¯‡ç»¼è¿°ä¸­ï¼Œæ£€ç´¢äº† PubMed/MEDLINE æ•°æ®åº“ä¸­æœ‰å…³ EO-CRC çš„æ‰€æœ‰åŸå§‹ç ”ç©¶æ–‡ç« ã€‚çº³å…¥æ ‡å‡†æ˜¯ 50 å²ä»¥ä¸‹çš„ CRC æ‚£è€…ï¼Œæ²¡æœ‰å·²çŸ¥çš„æ¶æ€§è‚¿ç˜¤è¯±å‘å› ç´ æˆ–é—ä¼ æ€§ CRC ç»¼åˆå¾ï¼Œä¸”å…·æœ‰è‚¿ç˜¤å­¦ç‰¹å¾å’Œç»“æœã€‚æ‰€æœ‰ç ”ç©¶å‡æ ¹æ® ROBINS-E 2022 å·¥å…·è¿›è¡Œåå€šè¯„ä¼°ï¼Œå¹¶è¿›è¡Œå®šæ€§åˆ†æç»¼åˆã€‚å®šæ€§ç»¼åˆä¸­çº³å…¥äº† 29 ç¯‡æ–‡ç« ï¼ŒæŠ¥å‘Šäº† 64,376 å EO-CRC æ‚£è€…ã€‚ç»“æœåˆ†ä¸º 3 ç±»ï¼ša) äººå£ç»Ÿè®¡ï¼› b) ç»„ç»‡ç—…ç†å­¦ç‰¹å¾ï¼› c) æ²»ç–—ç»“æœã€‚åœ¨è¿™äº›å‡ºç‰ˆç‰©ä¸­ï¼Œ21 é¡¹ç ”ç©¶ä¸€è‡´è®¤ä¸ºç›´è‚ ç™Œ (45%) å’Œå·¦ä¾§ç™Œç—‡ (47.1%) åœ¨å¹´è½»æ‚£è€…ä¸­æœ€å¸¸è§ï¼Œ5 é¡¹ç ”ç©¶è¡¨æ˜ CRC æ‚£ç—…ç‡æœ€é«˜çš„æ˜¯ 40-49 å²å¹´é¾„ç»„ã€‚ 29 é¡¹ç ”ç©¶ä¸­æœ‰ 17 é¡¹æŠ¥å‘Šäº†è¾ƒé«˜çš„è¯Šæ–­é˜¶æ®µï¼ˆIII å’Œ IVï¼‰ï¼Œä¼´æœ‰æ·‹å·´è¡€ç®¡å’Œç¥ç»å‘¨å›´ä¾µçŠ¯ã€‚æˆ‘ä»¬çš„å®¡æŸ¥æœ‰ä¸€äº›å±€é™æ€§ï¼šç”±äºå®ƒåŸºäºå•ä¸€æ•°æ®åº“ï¼Œå¹¶éæ‰€æœ‰ç ”ç©¶éƒ½æä¾›æœ‰å…³å˜é‡çš„ä¿¡æ¯ï¼›å°½ç®¡æ‰€æœ‰ç ”ç©¶çš„æ‚£è€…å¹´é¾„éƒ½åœ¨ 50 å²ä»¥ä¸‹ï¼Œä½†å¹¶éæ‰€æœ‰ç ”ç©¶ä¸­çš„æ‚£è€…éƒ½è¢«å½’ä¸ºåŒä¸€å¹´é¾„ç»„ã€‚éšç€ EO-CRC çš„å¢åŠ ï¼Œæ›´å¯†åˆ‡çš„ç›‘æµ‹ä»¥åŠå¯èƒ½æ›´æ—©çš„ç­›æŸ¥çš„å¿…è¦æ€§å˜å¾—æ˜¾è€Œæ˜“è§ã€‚è¿›ä¸€æ­¥çš„ç ”ç©¶åº”é›†ä¸­äºå¯»æ‰¾æ–°çš„ç­›æŸ¥ç”Ÿç‰©æ ‡å¿—ç‰©å’Œå¯æ”¹å˜çš„é£é™©å› ç´ ï¼Œä»¥é™ä½æ­»äº¡ç‡å¹¶æ”¹å–„æ‚£è€…çš„æ²»ç–—ç»“æœã€‚", "keywords_zh": "50å²ï¼Œæ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ŒæŒ‡å—ï¼Œå¹´è½»äºº", "keywords_en": "50 years old, Early-onset colorectal cancer, guidelines, young adults", "link": "https://pubmed.ncbi.nlm.nih.gov/40697442/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 23 Jul 2025"}, {"id": "40672439", "title_en": "Diagnosis and treatment for anal fistula: a systematic review of clinical practice guidelines and consensus statements", "title_zh": "è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—ï¼šä¸´åºŠå®è·µæŒ‡å—å’Œå…±è¯†å£°æ˜çš„ç³»ç»Ÿå›é¡¾", "authors": "Rong Shi", "abstract_en": "**Background:** Anal fistula constitutes a pathological channel originating either from the anal canal or rectum to the skin surrounding the anus, primarily characterized by recurrent pain, purulent discharge, and pruritus. This study aims to compare and standardize the recommendations for the diagnosis and treatment of anal fistula, drawing on contemporary clinical practice guidelines.\n\n**Methods:** A comprehensive search was conducted across multiple databases including PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biological Medicine Database, from their inception through April 1, 2024. The objective was to collate all published guidelines on anal fistula. The quality of the eligible guidelines was appraised by two reviewers using the Appraisal of Guidelines for Research and Evaluation II instrument.\n\n**Results:** The search yielded fifteen guidance documents -comprising nine guidelines and six consensus statements -each offering specific recommendations. Twelve of these documents address screening and diagnosis of anal fistula, while all fifteen discuss various treatment and management strategies. Document analysis highlighted MRI as the predominant diagnostic recommendation. Treatment and management strategies were categorized into four categories: preoperative management, surgical method selection, pharmacological interventions, and postoperative management. Regarding surgical interventions, all guidelines address incision and drainage of fistulas. Most guidelines offer a low recommendation for cutting setons, mainly attributed to the presence of incontinence. For high-positioned anal fistula, a push-pull flap procedure is recommended, whereas the LIFT procedure is advocated for newly identified, high, and sphincter-penetrating fistulas. Among the 15 guidelines and consensus statements evaluated in this study, more than half demonstrated methodological limitations, with particularly deficient performance in the applicability domain. As a critical determinant of implementation effectiveness, these deficiencies may undermine guidelines' capacity to optimize health outcomes.\n\n**Conclusion:** There is a pressing need for an updated search of potential evidence on the diagnosis and treatment of anal fistula. Effective diagnoses and therapeutic approaches, whether conventional or complementary and alternative medicine, should be thoroughly evaluated and incorporated based on robust evidence.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›ç˜˜æ˜¯ä»è‚›ç®¡æˆ–ç›´è‚ åˆ°è‚›é—¨å‘¨å›´çš®è‚¤çš„ç—…ç†é€šé“ï¼Œä¸»è¦è¡¨ç°ä¸ºåå¤ç–¼ç—›ã€è„“æ€§åˆ†æ³Œç‰©å’Œç˜™ç—’ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å€Ÿé‰´å½“ä»£ä¸´åºŠå®è·µæŒ‡å—ï¼Œå¯¹è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—å»ºè®®è¿›è¡Œæ¯”è¾ƒå’Œæ ‡å‡†åŒ–ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹PubMedã€EMBASEã€ä¸­å›½å›½å®¶çŸ¥è¯†åŸºç¡€è®¾æ–½ã€ä¸‡æ–¹æ•°æ®åº“ã€ä¸­å›½ç§‘æŠ€æœŸåˆŠæ•°æ®åº“å’Œä¸­å›½ç”Ÿç‰©åŒ»å­¦æ•°æ®åº“ç­‰å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œä»å»ºåº“åˆ°2024å¹´4æœˆ1æ—¥ã€‚ç›®çš„æ˜¯æ•´ç†æ‰€æœ‰å·²å‘å¸ƒçš„è‚›ç˜˜æŒ‡å—ã€‚åˆæ ¼æŒ‡å—çš„è´¨é‡ç”±ä¸¤åè¯„å®¡å‘˜ä½¿ç”¨â€œç ”ç©¶å’Œè¯„ä¼°æŒ‡å— II è¯„ä¼°â€å·¥å…·è¿›è¡Œè¯„ä¼°ã€‚\n\n**ç»“æœï¼š** æœç´¢äº§ç”Ÿäº†åäº”ä»½æŒ‡å¯¼æ–‡ä»¶ï¼Œå…¶ä¸­åŒ…æ‹¬ä¹ä»½æŒ‡å—å’Œå…­ä»½å…±è¯†å£°æ˜ï¼Œæ¯ä»½æ–‡ä»¶éƒ½æä¾›äº†å…·ä½“å»ºè®®ã€‚å…¶ä¸­åäºŒä»½æ–‡ä»¶æ¶‰åŠè‚›ç˜˜çš„ç­›æŸ¥å’Œè¯Šæ–­ï¼Œæ‰€æœ‰åäº”ä»½æ–‡ä»¶éƒ½è®¨è®ºäº†å„ç§æ²»ç–—å’Œç®¡ç†ç­–ç•¥ã€‚æ–‡æ¡£åˆ†æå¼ºè°ƒ MRI æ˜¯ä¸»è¦çš„è¯Šæ–­å»ºè®®ã€‚æ²»ç–—å’Œç®¡ç†ç­–ç•¥åˆ†ä¸ºå››ç±»ï¼šæœ¯å‰ç®¡ç†ã€æ‰‹æœ¯æ–¹æ³•é€‰æ‹©ã€è¯ç‰©å¹²é¢„å’Œæœ¯åç®¡ç†ã€‚å…³äºæ‰‹æœ¯å¹²é¢„ï¼Œæ‰€æœ‰æŒ‡å—å‡æ¶‰åŠç˜˜ç®¡åˆ‡å¼€å’Œå¼•æµã€‚å¤§å¤šæ•°æŒ‡å—å¯¹åˆ‡æŒ‚çº¿çš„å»ºè®®è¾ƒä½ï¼Œè¿™ä¸»è¦æ˜¯ç”±äºå­˜åœ¨å¤±ç¦ã€‚å¯¹äºé«˜ä½è‚›ç˜˜ï¼Œå»ºè®®é‡‡ç”¨æ¨æ‹‰çš®ç“£æ‰‹æœ¯ï¼Œè€Œå¯¹äºæ–°å‘ç°çš„é«˜ä½è‚›ç˜˜å’Œæ‹¬çº¦è‚Œç©¿é€æ€§è‚›ç˜˜åˆ™æå€¡é‡‡ç”¨ LIFT æ‰‹æœ¯ã€‚åœ¨æœ¬ç ”ç©¶è¯„ä¼°çš„ 15 æ¡æŒ‡å—å’Œå…±è¯†å£°æ˜ä¸­ï¼Œè¶…è¿‡ä¸€åŠè¡¨ç°å‡ºæ–¹æ³•å­¦å±€é™æ€§ï¼Œå°¤å…¶æ˜¯åœ¨é€‚ç”¨æ€§é¢†åŸŸè¡¨ç°ä¸è¶³ã€‚ä½œä¸ºå®æ–½æœ‰æ•ˆæ€§çš„å…³é”®å†³å®šå› ç´ ï¼Œè¿™äº›ç¼ºé™·å¯èƒ½ä¼šå‰Šå¼±æŒ‡å—ä¼˜åŒ–å¥åº·ç»“æœçš„èƒ½åŠ›ã€‚\n\n**ç»“è®ºï¼š** è¿«åˆ‡éœ€è¦æ›´æ–°æœ‰å…³è‚›ç˜˜è¯Šæ–­å’Œæ²»ç–—çš„æ½œåœ¨è¯æ®ã€‚æœ‰æ•ˆçš„è¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ï¼Œæ— è®ºæ˜¯ä¼ ç»ŸåŒ»å­¦è¿˜æ˜¯è¡¥å……å’Œæ›¿ä»£åŒ»å­¦ï¼Œéƒ½åº”åŸºäºå¼ºæœ‰åŠ›çš„è¯æ®è¿›è¡Œå½»åº•è¯„ä¼°å’Œæ•´åˆã€‚", "keywords_zh": "è‚›ç˜˜, è¯Šæ–­, æŒ‡å—, ç³»ç»Ÿè¯„ä»·, æ²»ç–—", "keywords_en": "anal fistula, diagnosis, guidelines, systematic review, therapeutic", "link": "https://pubmed.ncbi.nlm.nih.gov/40672439/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 17 Jul 2025"}, {"id": "40670732", "title_en": "Robotic Beyond Total Mesorectal Excision (bTME) for locally advanced and recurrent anorectal cancer: a systematic review", "title_zh": "æœºå™¨äººè¶…è¶Šå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆbTMEï¼‰æ²»ç–—å±€éƒ¨æ™šæœŸå’Œå¤å‘æ€§è‚›é—¨ç›´è‚ ç™Œï¼šç³»ç»Ÿè¯„ä»·", "authors": "Muhammad Rafaih Iqbal", "abstract_en": "Robotic surgery is increasingly utilized for rectal cancer resection, particularly in cases requiring beyond total mesorectal excision (bTME) to achieve oncological clearance. Despite longer operative times, robotic bTME has been associated with reduced morbidity and blood loss, making it an emerging approach in specialized centers. A systematic review following PRISMA guidelines was conducted in Web of Science, PubMed, and Scopus. Studies reporting robotic bTME for recurrent or locally advanced anorectal cancer were included. Outcomes assessed included study characteristics, demographics, operative outcomes, oncological data, and follow-up. Nineteen studies comprising 1027 patients met the inclusion criteria (13 case series-68% and 6 cohort studies-32%). The median patient age ranged from 51 to 68Â years with 73.7% males. Most patients had an ASA score of 2 (53.1%), and BMI ranged from 21.1 to 28.6. Tumor locations were predominantly near the anal verge (median: 3-6Â cm), and the most common clinical staging was cT3, cN1, and cM0. Surgical complications included urinary issues (22.6%), anastomotic leakage (11.4%), ileus (10.4%), and bleeding (5.3%). Follow-up data indicated a recurrence rate of 24.9%, and the 1-year survival rate was >â€‰90%. These studies reported an overall complication rate of 49.7%, with a median follow-up of 12-36Â months. Oncological outcomes were favorable, although there was significant variability in survival data between studies. The heterogenicity of the studies makes it challenging to conclusively establish robotic bTME as a feasible alternative to the gold standard. Further prospective studies, with measurable outcomes and consistent terminology, are needed to ensure homogeneity.", "abstract_zh": "æœºå™¨äººæ‰‹æœ¯è¶Šæ¥è¶Šå¤šåœ°ç”¨äºç›´è‚ ç™Œåˆ‡é™¤ï¼Œç‰¹åˆ«æ˜¯åœ¨éœ€è¦å®Œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤ï¼ˆbTMEï¼‰ä¹‹å¤–æ‰èƒ½å®ç°è‚¿ç˜¤æ¸…é™¤çš„ç—…ä¾‹ã€‚å°½ç®¡æ‰‹æœ¯æ—¶é—´è¾ƒé•¿ï¼Œä½†æœºå™¨äºº bTME ä¸é™ä½å‘ç—…ç‡å’Œå¤±è¡€é‡æœ‰å…³ï¼Œä½¿å…¶æˆä¸ºä¸“ä¸šä¸­å¿ƒçš„æ–°å…´æ–¹æ³•ã€‚ Web of Scienceã€PubMed å’Œ Scopus éµå¾ª PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚æŠ¥å‘Šæœºå™¨äºº bTME ç”¨äºæ²»ç–—å¤å‘æ€§æˆ–å±€éƒ¨æ™šæœŸè‚›é—¨ç›´è‚ ç™Œçš„ç ”ç©¶ä¹Ÿè¢«çº³å…¥å…¶ä¸­ã€‚è¯„ä¼°çš„ç»“æœåŒ…æ‹¬ç ”ç©¶ç‰¹å¾ã€äººå£ç»Ÿè®¡ã€æ‰‹æœ¯ç»“æœã€è‚¿ç˜¤æ•°æ®å’Œéšè®¿ã€‚åŒ…å« 1027 åæ‚£è€…çš„ 19 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼ˆ13 é¡¹ç—…ä¾‹ç³»åˆ—ç ”ç©¶ - 68% å’Œ 6 é¡¹é˜Ÿåˆ—ç ”ç©¶ - 32%ï¼‰ã€‚æ‚£è€…ä¸­ä½å¹´é¾„èŒƒå›´ä¸º 51 å²è‡³ 68 å²ï¼Œå…¶ä¸­ 73.7% ä¸ºç”·æ€§ã€‚å¤§å¤šæ•°æ‚£è€…çš„ ASA è¯„åˆ†ä¸º 2 åˆ†ï¼ˆ53.1%ï¼‰ï¼ŒBMI èŒƒå›´ä¸º 21.1 è‡³ 28.6ã€‚è‚¿ç˜¤ä½ç½®ä¸»è¦ä½äºè‚›ç¼˜é™„è¿‘ï¼ˆä¸­ä½ï¼š3-6 cmï¼‰ï¼Œæœ€å¸¸è§çš„ä¸´åºŠåˆ†æœŸæ˜¯ cT3ã€cN1 å’Œ cM0ã€‚æ‰‹æœ¯å¹¶å‘ç—‡åŒ…æ‹¬æ³Œå°¿é—®é¢˜ï¼ˆ22.6%ï¼‰ã€å»åˆå£æ¼ï¼ˆ11.4%ï¼‰ã€è‚ æ¢—é˜»ï¼ˆ10.4%ï¼‰å’Œå‡ºè¡€ï¼ˆ5.3%ï¼‰ã€‚éšè®¿æ•°æ®æ˜¾ç¤ºå¤å‘ç‡ä¸º24.9%ï¼Œ1å¹´ç”Ÿå­˜ç‡>90%ã€‚è¿™äº›ç ”ç©¶æŠ¥å‘Šçš„æ€»ä½“å¹¶å‘ç—‡ç‡ä¸º 49.7%ï¼Œä¸­ä½éšè®¿æ—¶é—´ä¸º 12-36 ä¸ªæœˆã€‚å°½ç®¡ç ”ç©¶ä¹‹é—´çš„ç”Ÿå­˜æ•°æ®å­˜åœ¨æ˜¾ç€å·®å¼‚ï¼Œä½†è‚¿ç˜¤å­¦ç»“æœè‰¯å¥½ã€‚ç ”ç©¶çš„å¼‚è´¨æ€§ä½¿å¾—æœ€ç»ˆç¡®å®šæœºå™¨äºº bTME ä½œä¸ºé»„é‡‘æ ‡å‡†çš„å¯è¡Œæ›¿ä»£æ–¹æ¡ˆå…·æœ‰æŒ‘æˆ˜æ€§ã€‚éœ€è¦è¿›ä¸€æ­¥çš„å‰ç»æ€§ç ”ç©¶ï¼Œå…·æœ‰å¯æµ‹é‡çš„ç»“æœå’Œä¸€è‡´çš„æœ¯è¯­ï¼Œä»¥ç¡®ä¿åŒè´¨æ€§ã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç™Œã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤ä¹‹å¤–ã€å¾®åˆ›æ‰‹æœ¯ã€ç›†è…”å»“æ¸…æœ¯ã€æœºå™¨äººæ‰‹æœ¯", "keywords_en": "Anorectal cancer, Beyond total mesorectal excision, Minimally invasive surgery, Pelvic exenteration, Robotic surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40670732/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 16 Jul 2025"}, {"id": "40665575", "title_en": "Haemorrhoidal artery ligation: Is Doppler guidance useful? A systematic review and meta-analysis of randomized controlled trials", "title_zh": "ç—”åŠ¨è„‰ç»“æ‰ï¼šå¤šæ™®å‹’å¼•å¯¼æœ‰ç”¨å—ï¼Ÿéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Gaetano Gallo", "abstract_en": "**Aim:** Haemorrhoidal arterial ligation (HAL) with or without mucopexy (recto-anal repair, RAR) is a minimally invasive technique for the treatment of haemorrhoidal disease. It is still debated if it should be performed with Doppler guidance (DG-HAL) or without. The primary aim of this study was to find evidence that the use of Doppler guidance reduces the risk of recurrence. The secondary aim was to evaluate the benefit of Doppler guidance on postoperative complications.\n\n**Methods:** A comprehensive literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (2020). The population, intervention, comparison, outcomes and study design (PICOS) framework was used for eligibility criteria. Data were extracted independently by two reviewers for initial screening and for eligibility to be included in the meta-analysis of randomized controlled trials. Random effects meta-analysis, leave-one-out meta-analysis and meta-regression were performed to assess the main outcomes.\n\n**Results:** Seven randomized controlled trials, published between 2008 and 2023, were selected. They included 514 patients (mean age 49.13â€‰years, 46% men) with different haemorrhoidal degrees. The HAL technique was performed in 255 patients and DG-HAL in 259 patients. The meta-analysis revealed that the DG-HAL procedure was associated with a significant risk of recurrence (Pâ€‰=â€‰0.007) and similar postoperative pain (Pâ€‰=â€‰0.623) compared to the HAL procedure. In a subgroup analysis of patients treated with a combined RAR procedure, no differences were found between the DG-HAL-RAR and HAL-RAR regarding the risk of recurrence (Pâ€‰=â€‰0.36) and postoperative pain (Pâ€‰=â€‰0.31).\n\n**Conclusion:** In conclusion, this meta-analysis did not find superiority of DG-HAL over HAL with or without RAR in reducing postoperative complications and recurrence.", "abstract_zh": "**Aimï¼š** ç—”åŠ¨è„‰ç»“æ‰ (HAL) è”åˆæˆ–ä¸è”åˆç²˜æ¶²å›ºå®šæœ¯ï¼ˆç›´è‚ è‚›é—¨ä¿®å¤æœ¯ï¼ŒRARï¼‰æ˜¯ä¸€ç§æ²»ç–—ç—”ç–®ç–¾ç—…çš„å¾®åˆ›æŠ€æœ¯ã€‚æ˜¯å¦åº”è¯¥ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼ (DG-HAL) æˆ–ä¸ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼è¿›è¡Œä»æœ‰äº‰è®®ã€‚æœ¬ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯å¯»æ‰¾è¯æ®è¯æ˜ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼å¯é™ä½å¤å‘é£é™©ã€‚ç¬¬äºŒä¸ªç›®çš„æ˜¯è¯„ä¼°å¤šæ™®å‹’å¼•å¯¼å¯¹æœ¯åå¹¶å‘ç—‡çš„ç›Šå¤„ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å— (2020) è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚äººå£ã€å¹²é¢„ã€æ¯”è¾ƒã€ç»“æœå’Œç ”ç©¶è®¾è®¡ï¼ˆPICOSï¼‰æ¡†æ¶ç”¨äºèµ„æ ¼æ ‡å‡†ã€‚æ•°æ®ç”±ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹æå–ï¼Œç”¨äºåˆæ­¥ç­›é€‰å’Œçº³å…¥éšæœºå¯¹ç…§è¯•éªŒèŸèƒåˆ†æçš„èµ„æ ¼ã€‚è¿›è¡Œéšæœºæ•ˆåº”èŸèƒåˆ†æã€ç•™ä¸€èŸèƒåˆ†æå’ŒèŸèƒå›å½’æ¥è¯„ä¼°ä¸»è¦ç»“æœã€‚\n\n**ç»“æœï¼š** é€‰æ‹©äº† 2008 å¹´è‡³ 2023 å¹´é—´å‘è¡¨çš„ä¸ƒé¡¹éšæœºå¯¹ç…§è¯•éªŒã€‚ä»–ä»¬åŒ…æ‹¬ 514 åæ‚£æœ‰ä¸åŒç—”ç–®ç¨‹åº¦çš„æ‚£è€…ï¼ˆå¹³å‡å¹´é¾„ 49.13 å²ï¼Œ46% ä¸ºç”·æ€§ï¼‰ã€‚ 255 åæ‚£è€…æ¥å—äº† HAL æŠ€æœ¯ï¼Œ259 åæ‚£è€…æ¥å—äº† DG-HAL æŠ€æœ¯ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œä¸ HAL æ‰‹æœ¯ç›¸æ¯”ï¼ŒDG-HAL æ‰‹æœ¯å…·æœ‰æ˜¾ç€çš„å¤å‘é£é™© (Pâ€‰=â€‰0.007) å’Œç›¸ä¼¼çš„æœ¯åç–¼ç—› (Pâ€‰=â€‰0.623)ã€‚åœ¨å¯¹è”åˆ RAR æ‰‹æœ¯æ²»ç–—çš„æ‚£è€…è¿›è¡Œçš„äºšç»„åˆ†æä¸­ï¼ŒDG-HAL-RAR å’Œ HAL-RAR åœ¨å¤å‘é£é™© (Pâ€‰=â€‰0.36) å’Œæœ¯åç–¼ç—› (Pâ€‰=â€‰0.31) æ–¹é¢æ²¡æœ‰å‘ç°å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ€»ä¹‹ï¼Œè¿™é¡¹èŸèƒåˆ†ææ²¡æœ‰å‘ç° DG-HAL åœ¨å‡å°‘æœ¯åå¹¶å‘ç—‡å’Œå¤å‘æ–¹é¢æ¯”æœ‰æˆ–æ²¡æœ‰ RAR çš„ HAL å…·æœ‰ä¼˜è¶Šæ€§ã€‚", "keywords_zh": "å¤šæ™®å‹’ã€ç—”ç–®ã€ç—”åŠ¨è„‰ç»“æ‰ã€ç—”è¡€ç®¡åŒ–ã€ç²˜æ¶²å›ºå®šæœ¯", "keywords_en": "Doppler, haemorrhoid, haemorrhoidal artery ligation, haemorrhoidal vascularization, mucopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/40665575/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 16 Jul 2025"}, {"id": "40632066", "title_en": "Negative pressure wound therapy for colorectal incisions: a systematic review and meta-analysis of controlled trials", "title_zh": "ç»“ç›´è‚ åˆ‡å£è´Ÿå‹ä¼¤å£æ²»ç–—ï¼šå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Chiehfeng Chen", "abstract_en": "**Objective:** Negative pressure wound therapy (NPWT) has demonstrated promising results in reducing surgical site infection (SSI) rates following orthopaedic, vascular, cardiothoracic, plastic and abdominal surgery. The literature on use of NPWT on colorectal incisions is growing, with several randomised controlled trials (RCTs); however, findings have been inconsistent. This review evaluated the effectiveness and safety of NPWT for colorectal incisions in elective and emergency surgery.\n\n**Method:** The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, and ClinicalTrials.gov databases were searched for RCTs and non-RCTs comparing NPWT with standard of care.\n\n**Results:** A total of five RCTs and six non-RCTs were included (with a total number of patients 2193). NPWT significantly reduced the rate of infection in colorectal incisions (odds ratio (OR): 0.57; 95% confidence interval (CI): 0.41, 0.78; I<sup>2</sup>=14%; p<0.0005) and wound complications of the colorectal surgical incisions (OR: 0.33; 95% CI: 0.13, 0.88; I<sup>2</sup>=59%; p=0.03). NPWT also shortened the wound healing time by three days (mean difference: -2.98; 95% CI: -4.99, -0.97; I<sup>2</sup>=0%; p=0.004). Subgroup analysis revealed that NPWT conferred greater benefits on wounds resulting from life-threatening emergency surgery, and contaminated or dirty-infected wounds.\n\n**Conclusion:** The findings of this review showed that NPWT is an effective intervention for the closure of wounds in patients following colorectal surgery, and lead to a significant reduction in SSIs, overall wound complications, and mean complete wound healing time. It was particularly effective in emergency cases and in contaminated to dirty-infected wounds. Treatment options should be considered in terms of cost-benefits and adequate patient selection during shared decision-making.", "abstract_zh": "**ç›®çš„ï¼š** è´Ÿå‹ä¼¤å£æ²»ç–— (NPWT) åœ¨é™ä½éª¨ç§‘ã€è¡€ç®¡ã€å¿ƒèƒ¸ã€æ•´å½¢å’Œè…¹éƒ¨æ‰‹æœ¯åæ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) ç‡æ–¹é¢å·²æ˜¾ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœã€‚å…³äºåœ¨ç»“ç›´è‚ åˆ‡å£ä¸Šä½¿ç”¨ NPWT çš„æ–‡çŒ®è¶Šæ¥è¶Šå¤šï¼Œå…¶ä¸­æœ‰å‡ é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼›ç„¶è€Œï¼Œè°ƒæŸ¥ç»“æœå¹¶ä¸ä¸€è‡´ã€‚æœ¬ç»¼è¿°è¯„ä¼°äº† NPWT åœ¨æ‹©æœŸå’Œæ€¥è¯Šæ‰‹æœ¯ä¸­ç»“ç›´è‚ åˆ‡å£çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**Methodï¼š** æ£€ç´¢äº† Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“ã€PubMedã€EMBASEã€æŠ¤ç†å’Œè”åˆå¥åº·æ–‡çŒ®ç´¯ç§¯ç´¢å¼•ä»¥åŠ ClinicalTrials.gov æ•°æ®åº“ï¼Œä»¥æŸ¥æ‰¾æ¯”è¾ƒ NPWT ä¸æ ‡å‡†æŠ¤ç†çš„éšæœºå¯¹ç…§è¯•éªŒå’Œééšæœºå¯¹ç…§è¯•éªŒã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 5 é¡¹éšæœºå¯¹ç…§è¯•éªŒå’Œ 6 é¡¹ééšæœºå¯¹ç…§è¯•éªŒï¼ˆæ‚£è€…æ€»æ•° 2193 ä¾‹ï¼‰ã€‚ NPWTæ˜¾ç€é™ä½ç»“ç›´è‚ åˆ‡å£æ„ŸæŸ“ç‡ï¼ˆæ¯”å€¼æ¯”ï¼ˆORï¼‰ï¼š0.57ï¼›95%ç½®ä¿¡åŒºé—´ï¼ˆCIï¼‰ï¼š0.41ï¼Œ0.78ï¼›I<sup>2</sup>=14%ï¼›p<0.0005ï¼‰å’Œç»“ç›´è‚ æ‰‹æœ¯åˆ‡å£ä¼¤å£å¹¶å‘ç—‡ï¼ˆORï¼š0.33ï¼›95% CIï¼š0.13ï¼Œ0.88ï¼›95% CIï¼š0.13ï¼Œ0.88ï¼›p<0.0005ï¼‰ã€‚ I<sup>2</sup>=59%ï¼›p=0.03ï¼‰ã€‚ NPWT è¿˜å°†ä¼¤å£æ„ˆåˆæ—¶é—´ç¼©çŸ­äº†ä¸‰å¤©ï¼ˆå¹³å‡å·®ï¼š-2.98ï¼›95% CIï¼š-4.99ï¼Œ-0.97ï¼›I<sup>2</sup>=0%ï¼›p=0.004ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºï¼ŒNPWT å¯¹å±åŠç”Ÿå‘½çš„ç´§æ€¥æ‰‹æœ¯é€ æˆçš„ä¼¤å£ä»¥åŠæ±¡æŸ“æˆ–è„æ„ŸæŸ“çš„ä¼¤å£å…·æœ‰æ›´å¤§çš„ç›Šå¤„ã€‚\n\n**ç»“è®ºï¼š** æœ¬æ¬¡ç»¼è¿°çš„ç»“æœè¡¨æ˜ï¼ŒNPWT æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åæ‚£è€…ä¼¤å£é—­åˆçš„æœ‰æ•ˆå¹²é¢„æªæ–½ï¼Œå¯æ˜¾ç€å‡å°‘ SSIã€æ€»ä½“ä¼¤å£å¹¶å‘ç—‡å’Œå¹³å‡ä¼¤å£å®Œå…¨æ„ˆåˆæ—¶é—´ã€‚å®ƒåœ¨ç´§æ€¥æƒ…å†µå’Œæ±¡æŸ“åˆ°è„æ„ŸæŸ“çš„ä¼¤å£ä¸­ç‰¹åˆ«æœ‰æ•ˆã€‚åœ¨å…±åŒå†³ç­–è¿‡ç¨‹ä¸­ï¼Œåº”æ ¹æ®æˆæœ¬æ•ˆç›Šå’Œå……åˆ†çš„æ‚£è€…é€‰æ‹©æ¥è€ƒè™‘æ²»ç–—æ–¹æ¡ˆã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€èŸèƒåˆ†æã€è´Ÿå‹ä¼¤å£æ²»ç–—ã€æ‰‹æœ¯åˆ‡å£ã€æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ã€ç³»ç»Ÿè¯„ä»·ã€ä¼¤å£ã€ä¼¤å£æŠ¤ç†ã€ä¼¤å£æ•·æ–™ã€ä¼¤å£æ„ˆåˆ", "keywords_en": "colorectal surgery, meta-analysis, negative pressure wound therapy, surgical incision, surgical site infection, systematic review, wound, wound care, wound dressing, wound healing", "link": "https://pubmed.ncbi.nlm.nih.gov/40632066/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 09 Jul 2025"}, {"id": "40624403", "title_en": "Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Azka Mustaan", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40624403/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 07 Jul 2025"}, {"id": "40596934", "title_en": "Comparison of efficacy and safety between surgical and conservative treatments for hemorrhoids: a meta-analysis", "title_zh": "æ‰‹æœ¯æ²»ç–—å’Œä¿å®ˆæ²»ç–—ç—”ç–®çš„ç–—æ•ˆå’Œå®‰å…¨æ€§æ¯”è¾ƒï¼šä¸€é¡¹èŸèƒåˆ†æ", "authors": "Xiaoqiang Jia", "abstract_en": "**Objectives:** Hemorrhoids, a common anorectal condition, can be managed through surgical or conservative treatments. The aim of this meta-analysis is to compare the efficacy and safety of surgical and conservative treatments for hemorrhoids.\n\n**Methods:** A systematic search was conducted from of PubMed, Embase, the Cochrane Library, and Web of Science from their inception to September 25, 2024. Eligible studies compared surgical treatments with non-invasive conservative treatments in hemorrhoids. Statistical analyses included pooled odds ratios (ORs) and mean differences (MDs)/standard mean differences (SMDs) with 95% confidence intervals (CIs).\n\n**Results:** Seven studies, including 760 patients, were analyzed. Surgery achieved higher rates of complete symptom resolution than conservative therapy (ORâ€‰=â€‰2.96, 95% CI: 1.66-5.28, pâ€‰<â€‰0.001). Overall pain scores favored surgery (SMD = -0.93, 95% CI: 1.73 to -0.13, pâ€‰=â€‰0.02). Subgroup analysis showed clear superiority within four days (SMD = -1.26, 95% CI -1.84 to -0.68) but parity beyond ten days (SMDâ€‰=â€‰0.00, 95% CI -0.44 to 0.44; pâ€‰=â€‰0.99). Comparable patterns were observed in pregnant women with thrombosed external hemorrhoids. Rates of postoperative bleeding (OR: 1.09; 95% CI: 0.42 to 2.82, pâ€‰=â€‰0.86; I2â€‰=â€‰41%, pâ€‰=â€‰0.15) and urinary retention (OR: 1.75; 95% CI: 0.30 to 10.31, pâ€‰=â€‰0.54; I2â€‰=â€‰45%, pâ€‰=â€‰0.18) did not differ significantly between groups. Surgical-specific adverse events were infrequent (incontinence 3%, persistent pain 5%, watery discharge 6%). Surgery shortened recovery in pregnant thrombosed cases by approximately seven days (MD: -6.80; 95% CI: -7.64 to -5.96, pâ€‰<â€‰0.001; I2â€‰=â€‰55%, pâ€‰=â€‰0.14) and reduced overall recurrence (95% CI: 0.10 to 0.37, pâ€‰<â€‰0.001; I2â€‰=â€‰0%, pâ€‰=â€‰0.97).\n\n**Conclusion:** Surgical treatments provide superior symptom relief, faster recovery, and lower recurrence but with some specific post-treatment complications, while conservative treatments are safer and less invasive but with provides slower symptom relief and higher recurrence rates. Individualized treatment should consider symptom severity, patient preferences, and risk tolerance.", "abstract_zh": "**Objectivesï¼š** ç—”ç–®æ˜¯ä¸€ç§å¸¸è§çš„è‚›é—¨ç›´è‚ ç–¾ç—…ï¼Œå¯ä»¥é€šè¿‡æ‰‹æœ¯æˆ–ä¿å®ˆæ²»ç–—æ¥æ²»ç–—ã€‚è¿™é¡¹èŸèƒåˆ†æçš„ç›®çš„æ˜¯æ¯”è¾ƒæ‰‹æœ¯æ²»ç–—å’Œä¿å®ˆæ²»ç–—ç—”ç–®çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ PubMedã€Embaseã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä»æˆç«‹åˆ° 2024 å¹´ 9 æœˆ 25 æ—¥æœŸé—´è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶æ¯”è¾ƒäº†ç—”ç–®çš„æ‰‹æœ¯æ²»ç–—ä¸éä¾µå…¥æ€§ä¿å®ˆæ²»ç–—ã€‚ç»Ÿè®¡åˆ†æåŒ…æ‹¬åˆå¹¶ä¼˜åŠ¿æ¯” (OR) å’Œå¹³å‡å·® (MD)/æ ‡å‡†å¹³å‡å·® (SMD)ï¼Œç½®ä¿¡åŒºé—´ (CI) ä¸º 95%ã€‚\n\n**ç»“æœï¼š** å¯¹ä¸ƒé¡¹ç ”ç©¶ï¼ˆåŒ…æ‹¬ 760 åæ‚£è€…ï¼‰è¿›è¡Œäº†åˆ†æã€‚æ‰‹æœ¯çš„ç—‡çŠ¶å®Œå…¨ç¼“è§£ç‡é«˜äºä¿å®ˆæ²»ç–—ï¼ˆORâ€‰=â€‰2.96ï¼Œ95% CIï¼š1.66-5.28ï¼Œpâ€‰<â€‰0.001ï¼‰ã€‚æ€»ä½“ç–¼ç—›è¯„åˆ†å€¾å‘äºæ‰‹æœ¯ï¼ˆSMD = -0.93ï¼Œ95% CIï¼š1.73 è‡³ -0.13ï¼Œpâ€‰=â€‰0.02ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºå››å¤©å†…å…·æœ‰æ˜æ˜¾ä¼˜åŠ¿ï¼ˆSMD = -1.26ï¼Œ95% CI -1.84 è‡³ -0.68ï¼‰ï¼Œä½†åå¤©ååˆ™å…·æœ‰åŒç­‰æ€§ï¼ˆSMDâ€‰=â€‰0.00ï¼Œ95% CI -0.44 è‡³ 0.44ï¼›pâ€‰=â€‰0.99ï¼‰ã€‚åœ¨æ‚£æœ‰è¡€æ “æ€§å¤–ç—”çš„å­•å¦‡ä¸­è§‚å¯Ÿåˆ°äº†ç±»ä¼¼çš„æ¨¡å¼ã€‚æœ¯åå‡ºè¡€ç‡ï¼ˆORï¼š1.09ï¼›95% CIï¼š0.42è‡³2.82ï¼Œpâ€‰=â€‰0.86ï¼›I2â€‰=â€‰41%ï¼Œpâ€‰=â€‰0.15ï¼‰å’Œå°¿æ½´ç•™ç‡ï¼ˆORï¼š1.75ï¼›95% CIï¼š0.30è‡³10.31ï¼Œpâ€‰=â€‰0.54ï¼› I2â€‰=â€‰45%ï¼Œpâ€‰=â€‰0.18ï¼‰ç»„é—´æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚æ‰‹æœ¯ç‰¹å¼‚æ€§ä¸è‰¯äº‹ä»¶å¹¶ä¸å¸¸è§ï¼ˆå¤±ç¦ 3%ã€æŒç»­æ€§ç–¼ç—› 5%ã€æ°´æ ·åˆ†æ³Œç‰© 6%ï¼‰ã€‚æ‰‹æœ¯ä½¿å¦Šå¨ è¡€æ “ç—…ä¾‹çš„æ¢å¤æ—¶é—´ç¼©çŸ­çº¦ 7 å¤©ï¼ˆMDï¼š-6.80ï¼›95% CIï¼š-7.64 è‡³ -5.96ï¼Œp<â€‰0.001ï¼›I2â€‰=â€‰55%ï¼Œpâ€‰=â€‰0.14ï¼‰ï¼Œå¹¶å‡å°‘æ€»ä½“å¤å‘ï¼ˆ95% CIï¼š0.10 è‡³ 0.37ï¼Œp<â€‰0.001ï¼›I2=â€‰55%ï¼Œpâ€‰=â€‰0.14ï¼‰ã€‚ I2â€‰=â€‰0%ï¼Œpâ€‰=â€‰0.97ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ‰‹æœ¯æ²»ç–—å¯æ˜¾ç€ç¼“è§£ç—‡çŠ¶ã€åŠ å¿«æ¢å¤é€Ÿåº¦å¹¶é™ä½å¤å‘ç‡ï¼Œä½†ä¼šå‡ºç°ä¸€äº›ç‰¹å®šçš„æ²»ç–—åå¹¶å‘ç—‡ï¼Œè€Œä¿å®ˆæ²»ç–—æ›´å®‰å…¨ä¸”ä¾µå…¥æ€§è¾ƒå°ï¼Œä½†ç—‡çŠ¶ç¼“è§£è¾ƒæ…¢ä¸”å¤å‘ç‡è¾ƒé«˜ã€‚ä¸ªä½“åŒ–æ²»ç–—åº”è€ƒè™‘ç—‡çŠ¶ä¸¥é‡ç¨‹åº¦ã€æ‚£è€…åå¥½å’Œé£é™©æ‰¿å—èƒ½åŠ›ã€‚", "keywords_zh": "ä¿å®ˆæ²»ç–—ã€ç—”ç–®ã€èŸèƒåˆ†æã€æ‰‹æœ¯æ²»ç–—", "keywords_en": "Conservative treatment, Hemorrhoids, Meta-Analysis, Surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40596934/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 02 Jul 2025"}, {"id": "40590873", "title_en": "Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery in the Treatment of Rectal Neuroendocrine Tumors: Systematic Review and Meta-Analysis of the Observational Studies", "title_zh": "å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯å’Œç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯æ²»ç–—ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼šè§‚å¯Ÿæ€§ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Andrzej BiaÅ‚ek", "abstract_en": "**Introduction:** Rectal neuroendocrine tumors (rNETs) are subepithelial lesions with potential of malignancy. Despite the guidelines recommending that rNETs measuring 10-20 mm should be removed either endoscopic submucosal dissection (ESD) or transanal endoscopic microsurgery (TEM), the management with these entities is still a clinical dilemma. We performed a meta-analysis to compare ESD and TEM regarding method effectiveness and safety in the treatment of rNETs.\n\n**Methods:** PubMed/MEDLINE/Embase/EBSCO/CINAHL was searched up for observational studies analyzing the efficacy and safety of both methods in the treatment of rNETs.\n\n**Results:** A total of 59 observational studies with a total of n = 2,804 participants were included. In a subgroup analysis, we demonstrated that the R0 resection rate was significantly ( P = 0.002) lower for ESD (rate: 0.854) than for TEM (0.924). The recurrence rate differed significantly ( P = 0.008); the lowest (event rate [ER] = 0.015) was found for ESD and the highest for TEM (ER = 0.035). The overall bleeding rate was 0.046 and perforation rate was 0.023 and no significant differences ( P = 0.274 for bleeding, P = 0.808 for perforation) were found by intervention type. The rate of other complications (wound dehiscence, soilage, incontinence, rectovaginal fistula, pelvic pain, retroperitoneal emphysema, coagulation syndrome) was significantly ( P = 0.000) higher for TEM (ER = 0.107) than ESD (ER = 0.013). We also included 4 comparative studies with 490 patients. Using random-effects analysis, we found that the risk ratio for R0 resection was approximately 10% lower for ESD. Our analysis showed significantly greater size ( P = 0.01) and follow-up ( P = 0.03) in the group treated with TEM.\n\n**Discussion:** The efficacy of TEM is higher than ESD with a higher risk of complications in this method. Lesions with a greater size are treated with TEM, and recurrence rate is greater for this procedure. Long follow-up is needed after the treatment of rNETs to detect the recurrence early.", "abstract_zh": "**ä»‹ç»ï¼š** ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼ˆrNETï¼‰æ˜¯å…·æœ‰æ¶æ€§æ½œåŠ›çš„ä¸Šçš®ä¸‹ç—…å˜ã€‚å°½ç®¡æŒ‡å—å»ºè®®åº”é€šè¿‡å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯ (ESD) æˆ–ç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯ (TEM) åˆ‡é™¤ 10-20 æ¯«ç±³çš„ rNETï¼Œä½†è¿™äº›å®ä½“çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªä¸´åºŠå›°å¢ƒã€‚æˆ‘ä»¬è¿›è¡Œäº†ä¸€é¡¹èŸèƒåˆ†æï¼Œä»¥æ¯”è¾ƒ ESD å’Œ TEM æ²»ç–— rNET çš„æ–¹æ³•æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† PubMed/MEDLINE/Embase/EBSCO/CINAHL çš„è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œåˆ†æè¿™ä¸¤ç§æ–¹æ³•æ²»ç–— rNET çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 59 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œå…±æœ‰ 2,804 åå‚ä¸è€…ã€‚åœ¨äºšç»„åˆ†æä¸­ï¼Œæˆ‘ä»¬è¯æ˜ ESD çš„ R0 åˆ‡é™¤ç‡ï¼ˆæ¯”ç‡ï¼š0.854ï¼‰æ˜¾ç€ä½äº TEMï¼ˆ0.924ï¼‰ï¼ˆP = 0.002ï¼‰ã€‚å¤å‘ç‡å·®å¼‚æ˜¾ç€ï¼ˆP=0.008ï¼‰ï¼› ESD æœ€ä½ï¼ˆäº‹ä»¶ç‡ [ER] = 0.015ï¼‰ï¼ŒTEM æœ€é«˜ï¼ˆER = 0.035ï¼‰ã€‚æ€»å‡ºè¡€ç‡ä¸º0.046ï¼Œç©¿å­”ç‡ä¸º0.023ï¼Œä¸åŒå¹²é¢„ç±»å‹å·®å¼‚æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆå‡ºè¡€P=0.274ï¼Œç©¿å­”P=0.808ï¼‰ã€‚ TEM (ER = 0.107) çš„å…¶ä»–å¹¶å‘ç—‡ï¼ˆä¼¤å£è£‚å¼€ã€æ±¡æ¸ã€å¤±ç¦ã€ç›´è‚ é˜´é“ç˜˜ã€éª¨ç›†ç–¼ç—›ã€è…¹è†œåæ°”è‚¿ã€å‡è¡€ç»¼åˆå¾ï¼‰å‘ç”Ÿç‡æ˜¾ç€é«˜äº ESD (ER = 0.013) (P = 0.000)ã€‚æˆ‘ä»¬è¿˜çº³å…¥äº† 4 é¡¹æ¯”è¾ƒç ”ç©¶ï¼Œæ¶‰åŠ 490 åæ‚£è€…ã€‚é€šè¿‡éšæœºæ•ˆåº”åˆ†æï¼Œæˆ‘ä»¬å‘ç° R0 åˆ‡é™¤çš„é£é™©æ¯” ESD å¤§çº¦ä½ 10%ã€‚æˆ‘ä»¬çš„åˆ†ææ˜¾ç¤ºï¼ŒTEM æ²»ç–—ç»„çš„ä½“å‹æ˜¾ç€å¢å¤§ (P = 0.01)ï¼Œéšè®¿æ—¶é—´ä¹Ÿæ˜æ˜¾å¢å¤§ (P = 0.03)ã€‚\n\n**è®¨è®ºï¼š** TEM çš„ç–—æ•ˆé«˜äº ESDï¼Œä½†è¯¥æ–¹æ³•å‡ºç°å¹¶å‘ç—‡çš„é£é™©è¾ƒé«˜ã€‚ç—…å˜å°ºå¯¸è¶Šå¤§ï¼Œåˆ™é‡‡ç”¨ TEM æ²»ç–—ï¼Œå¤å‘ç‡è¶Šé«˜ã€‚ rNET æ²»ç–—åéœ€è¦é•¿æœŸéšè®¿ï¼Œä»¥ä¾¿åŠæ—©å‘ç°å¤å‘æƒ…å†µã€‚", "keywords_zh": "ESDã€TEMã€rNETã€ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ã€æ²»ç–—", "keywords_en": "ESD, TEM, rNETs, rectal neuroendocrine tumors, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40590873/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 01 Jul 2025"}, {"id": "40576944", "title_en": "Operative versus nonoperative treatment of thrombosed external hemorrhoids: a systematic review and meta-analysis", "title_zh": "è¡€æ “æ€§å¤–ç—”çš„æ‰‹æœ¯ä¸éæ‰‹æœ¯æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Rachid Eduardo Noleto da Nobrega Oliveira", "abstract_en": "Thrombosed external hemorrhoids are a complication of hemorrhoids characterized by severe pain, swelling, and lump formation due to acute venous engorgement. Treatment options remain controversial, with limited evidence guiding the choice between surgical and conservative approaches. PubMed, Embase, and Cochrane Library databases were searched from inception to December 2024 to identify clinical trials comparing surgery with conservative treatment in thrombosed external hemorrhoids. Statistical analyses were performed using Review Manager 5.4.1 with a random-effects model. Heterogeneity was assessed using the I<sup>2</sup> test. We included six studies with a total of 851 patients, of whom 390 (45.8%) underwent surgical treatment. Surgical treatment was associated with a lower risk of recurrence compared to conservative management (RR 0.49; 95% CI 0.26-0.91; Pâ€‰<â€‰0.05; I<sup>2</sup>â€‰=â€‰54%). However, there were no significant differences in the risk of bleeding between the groups (RR 0.96; 95% CI 0.27-3.44; Pâ€‰=â€‰0.95; I<sup>2</sup>â€‰=â€‰60%). Subgroup analyses of the excision surgery group revealed no differences between approaches. Our main findings indicated no significant difference in bleeding between surgery and conservative treatment groups. However, operative management is associated with significantly lower recurrences, which should be the preferred choice.", "abstract_zh": "è¡€æ “æ€§å¤–ç—”æ˜¯ç—”ç–®çš„ä¸€ç§å¹¶å‘ç—‡ï¼Œå…¶ç‰¹å¾æ˜¯ç”±äºæ€¥æ€§é™è„‰å……è¡€è€Œå¯¼è‡´å‰§çƒˆç–¼ç—›ã€è‚¿èƒ€å’Œè‚¿å—å½¢æˆã€‚æ²»ç–—é€‰æ‹©ä»ç„¶å­˜åœ¨äº‰è®®ï¼ŒæŒ‡å¯¼æ‰‹æœ¯å’Œä¿å®ˆæ²»ç–—ä¹‹é—´é€‰æ‹©çš„è¯æ®æœ‰é™ã€‚å¯¹ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†æ£€ç´¢ï¼Œä»æœ€åˆåˆ° 2024 å¹´ 12 æœˆï¼Œä»¥è¯†åˆ«æ¯”è¾ƒæ‰‹æœ¯ä¸ä¿å®ˆæ²»ç–—è¡€æ “æ€§å¤–ç—”çš„ä¸´åºŠè¯•éªŒã€‚ä½¿ç”¨ Review Manager 5.4.1 å’Œéšæœºæ•ˆåº”æ¨¡å‹è¿›è¡Œç»Ÿè®¡åˆ†æã€‚ä½¿ç”¨ I<sup>2</sup> æ£€éªŒè¯„ä¼°å¼‚è´¨æ€§ã€‚æˆ‘ä»¬çº³å…¥äº† 6 é¡¹ç ”ç©¶ï¼Œå…± 851 åæ‚£è€…ï¼Œå…¶ä¸­ 390 å (45.8%) æ¥å—äº†æ‰‹æœ¯æ²»ç–—ã€‚ä¸ä¿å®ˆæ²»ç–—ç›¸æ¯”ï¼Œæ‰‹æœ¯æ²»ç–—çš„å¤å‘é£é™©è¾ƒä½ï¼ˆRR 0.49ï¼›95% CI 0.26-0.91ï¼›Pâ€‰<â€‰0.05ï¼›I<sup>2</sup>â€‰=â€‰54%ï¼‰ã€‚ç„¶è€Œï¼Œå„ç»„ä¹‹é—´çš„å‡ºè¡€é£é™©æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼ˆRR 0.96ï¼›95% CI 0.27-3.44ï¼›Pâ€‰=â€‰0.95ï¼›I<sup>2</sup>â€‰=â€‰60%ï¼‰ã€‚åˆ‡é™¤æ‰‹æœ¯ç»„çš„äºšç»„åˆ†ææ˜¾ç¤ºæ–¹æ³•ä¹‹é—´æ²¡æœ‰å·®å¼‚ã€‚æˆ‘ä»¬çš„ä¸»è¦å‘ç°è¡¨æ˜æ‰‹æœ¯æ²»ç–—ç»„å’Œä¿å®ˆæ²»ç–—ç»„ä¹‹é—´çš„å‡ºè¡€æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼Œæ‰‹æœ¯æ²»ç–—å¯æ˜¾ç€é™ä½å¤å‘ç‡ï¼Œè¿™åº”è¯¥æ˜¯é¦–é€‰ã€‚", "keywords_zh": "ç—”ç–®ï¼Œéæ‰‹æœ¯æ€§ï¼Œæ‰‹æœ¯æ€§ï¼Œå¤å‘", "keywords_en": "Hemorrhoids, Nonoperative, Operative, Recurrence", "link": "https://pubmed.ncbi.nlm.nih.gov/40576944/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 27 Jun 2025"}, {"id": "40548987", "title_en": "Robotic surgery in anorectal malformations: Where are we? A systematic review", "title_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢çš„æœºå™¨äººæ‰‹æœ¯ï¼šæˆ‘ä»¬åœ¨å“ªé‡Œï¼Ÿç³»ç»Ÿå›é¡¾", "authors": "Giovanna Riccipetitoni", "abstract_en": "Robotic surgery has emerged as a promising technique in pediatric colorectal surgery, offering enhanced precision, superior ergonomics, and potentially improved outcomes compared to conventional laparoscopic and open approaches. This systematic review aimed to evaluate the current literature on robotic-assisted surgery for anorectal malformations (ARMs) in pediatric patients. A comprehensive search of PubMed, Web of Science, and the Cochrane Library was conducted for studies published between 2000 and 2025, focusing on robotic procedures in infants with ARMs. Eight studies met the inclusion criteria, reporting on a total of 39 patients (male-to-female ratio 15:0.5), with a median age at surgery of 6.9Â months. The most frequent ARM types were recto-prostatic, recto-bulbar, and recto-vesical fistulas. Median operative time was 226.3Â min, and median length of hospital stay was 5.5Â days. No intraoperative or early postoperative complications were observed, while late complications occurred in 18% of cases. Only one study included a comparative analysis with laparoscopic-assisted PSARP, precluding meta-analysis. Robotic-assisted anorectoplasty appears to be a safe and feasible approach, particularly advantageous for nerve-sparing pelvic dissection. However, further high-quality studies are necessary to define indications, evaluate long-term functional outcomes, and compare this technique with conventional surgical approaches.", "abstract_zh": "æœºå™¨äººæ‰‹æœ¯å·²æˆä¸ºå„¿ç§‘ç»“ç›´è‚ æ‰‹æœ¯ä¸­ä¸€é¡¹æœ‰å‰æ™¯çš„æŠ€æœ¯ï¼Œä¸ä¼ ç»Ÿçš„è…¹è…”é•œå’Œå¼€æ”¾æ‰‹æœ¯ç›¸æ¯”ï¼Œå®ƒå…·æœ‰æ›´é«˜çš„ç²¾ç¡®åº¦ã€å“è¶Šçš„äººä½“å·¥ç¨‹å­¦è®¾è®¡ä»¥åŠæ½œåœ¨çš„æ”¹å–„ç»“æœã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨è¯„ä¼°ç›®å‰å…³äºå„¿ç«¥æ‚£è€…è‚›é—¨ç›´è‚ ç•¸å½¢ (ARM) æœºå™¨äººè¾…åŠ©æ‰‹æœ¯çš„æ–‡çŒ®ã€‚å¯¹ PubMedã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†å¯¹ 2000 å¹´è‡³ 2025 å¹´é—´å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œé‡ç‚¹å…³æ³¨ ARM å©´å„¿çš„æœºå™¨äººæ‰‹æœ¯ã€‚å…«é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œå…±æŠ¥å‘Šäº† 39 åæ‚£è€…ï¼ˆç”·å¥³æ¯”ä¾‹ 15:0.5ï¼‰ï¼Œæ‰‹æœ¯æ—¶çš„ä¸­ä½å¹´é¾„ä¸º 6.9 ä¸ªæœˆã€‚æœ€å¸¸è§çš„ ARM ç±»å‹æ˜¯ç›´è‚ å‰åˆ—è…ºç˜˜ã€ç›´è‚ çƒç˜˜å’Œç›´è‚ è†€èƒ±ç˜˜ã€‚ä¸­ä½æ‰‹æœ¯æ—¶é—´ä¸º 226.3 åˆ†é’Ÿï¼Œä¸­ä½ä½é™¢æ—¶é—´ä¸º 5.5 å¤©ã€‚æœªè§‚å¯Ÿåˆ°æœ¯ä¸­æˆ–æœ¯åæ—©æœŸå¹¶å‘ç—‡ï¼Œè€Œ18%çš„ç—…ä¾‹å‡ºç°æ™šæœŸå¹¶å‘ç—‡ã€‚åªæœ‰ä¸€é¡¹ç ”ç©¶åŒ…æ‹¬ä¸è…¹è…”é•œè¾…åŠ© PSARP çš„æ¯”è¾ƒåˆ†æï¼Œæ’é™¤äº†èŸèƒåˆ†æã€‚æœºå™¨äººè¾…åŠ©è‚›é—¨ç›´è‚ æˆå½¢æœ¯ä¼¼ä¹æ˜¯ä¸€ç§å®‰å…¨å¯è¡Œçš„æ–¹æ³•ï¼Œç‰¹åˆ«æœ‰åˆ©äºä¿ç•™ç¥ç»çš„ç›†è…”è§£å‰–ã€‚ç„¶è€Œï¼Œéœ€è¦è¿›ä¸€æ­¥çš„é«˜è´¨é‡ç ”ç©¶æ¥å®šä¹‰é€‚åº”ç—‡ã€è¯„ä¼°é•¿æœŸåŠŸèƒ½ç»“æœå¹¶å°†è¯¥æŠ€æœ¯ä¸ä¼ ç»Ÿæ‰‹æœ¯æ–¹æ³•è¿›è¡Œæ¯”è¾ƒã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢ã€è‚›é—¨ç›´è‚ æˆå½¢æœ¯ã€æœºå™¨äººè¾…åŠ©æ‰‹æœ¯", "keywords_en": "Anorectal malformation, Anorectoplasty, Robotic-assisted surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40548987/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 23 Jun 2025"}, {"id": "40508850", "title_en": "Biopsychosocial Strategies for Alleviating Low Back Pain in Late Mothers: A Systematic Review", "title_zh": "ç¼“è§£å·²æ•…æ¯äº²è…°ç—›çš„ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šç­–ç•¥ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mariola Bidzan", "abstract_en": "<b>Background:</b> Low back pain (LBP) in older mothers is a prevalent and multifaceted condition influenced by a range of biopsychosocial factors. As the trend of late motherhood increases globally, it is essential to understand how LBP affects this population from a biopsychosocial perspective. <b>Objective:</b> This systematic review aims to examine the biopsychosocial determinants of LBP in older mothers by synthesizing findings from quantitative studies published between January 2010 and May 2024. Specifically, it explores the biological, psychological, and social factors contributing to LBP in this population and how it affects their daily lives and well-being. <b>Methods:</b> A comprehensive literature search was conducted across PubMed, PsychInfo, Web of Science, EMBASE, DARE, and the Cochrane Library. Studies were screened for eligibility based on predefined criteria. Five quantitative studies with a combined sample of 118,964 participants were included. The methodological quality was assessed, and data were extracted for analysis. <b>Results:</b> All five studies addressed biological aspects of LBP, including pelvic girdle pain, hemorrhoids, and varicose veins. Three studies also explored psychological factors such as depression and stress. Two studies incorporated social dimensions, including inadequate support systems, occupational burdens, and healthcare access barriers. Age and parity were consistently reported as exacerbating physical and psychological symptoms. <b>Conclusions:</b> This review highlights the importance of considering biopsychosocial factors when managing LBP in older mothers. Tailored interventions, such as exercise programs, family support, and workplace accommodations, are essential for improving outcomes. Further research using longitudinal studies is needed to explore these factors in greater depth.", "abstract_zh": "<b>èƒŒæ™¯ï¼š</b>é«˜é¾„æ¯äº²çš„è…°ç—› (LBP) æ˜¯ä¸€ç§æ™®éå­˜åœ¨çš„å¤šæ–¹é¢ç–¾ç—…ï¼Œå—ä¸€ç³»åˆ—ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ çš„å½±å“ã€‚éšç€å…¨çƒæ™šå­•è¶‹åŠ¿çš„å¢åŠ ï¼Œæœ‰å¿…è¦ä»ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šè§’åº¦äº†è§£å…‰ä½“ç—›å¦‚ä½•å½±å“è¿™ä¸€äººç¾¤ã€‚ <b>ç›®çš„ï¼š</b>æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨é€šè¿‡ç»¼åˆ 2010 å¹´ 1 æœˆè‡³ 2024 å¹´ 5 æœˆæœŸé—´å‘è¡¨çš„å®šé‡ç ”ç©¶ç»“æœï¼Œæ¢è®¨è€å¹´æ¯äº² LBP çš„ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå†³å®šå› ç´ ã€‚å…·ä½“è€Œè¨€ï¼Œå®ƒæ¢è®¨äº†å¯¼è‡´è¯¥äººç¾¤ LBP çš„ç”Ÿç‰©ã€å¿ƒç†å’Œç¤¾ä¼šå› ç´ ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±å“å¥¹ä»¬çš„æ—¥å¸¸ç”Ÿæ´»å’Œç¦ç¥‰ã€‚ <b>æ–¹æ³•ï¼š</b>åœ¨ PubMedã€PsychInfoã€Web of Scienceã€EMBASEã€DARE å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚æ ¹æ®é¢„å…ˆå®šä¹‰çš„æ ‡å‡†ç­›é€‰ç ”ç©¶èµ„æ ¼ã€‚å…¶ä¸­åŒ…æ‹¬äº”é¡¹å®šé‡ç ”ç©¶ï¼Œåˆå¹¶æ ·æœ¬ä¸º 118,964 åå‚ä¸è€…ã€‚è¯„ä¼°æ–¹æ³•å­¦è´¨é‡ï¼Œå¹¶æå–æ•°æ®è¿›è¡Œåˆ†æã€‚ <b>ç»“æœï¼š</b>æ‰€æœ‰äº”é¡¹ç ”ç©¶éƒ½æ¶‰åŠ LBP çš„ç”Ÿç‰©å­¦æ–¹é¢ï¼ŒåŒ…æ‹¬éª¨ç›†å¸¦ç–¼ç—›ã€ç—”ç–®å’Œé™è„‰æ›²å¼ ã€‚ä¸‰é¡¹ç ”ç©¶è¿˜æ¢è®¨äº†æŠ‘éƒå’Œå‹åŠ›ç­‰å¿ƒç†å› ç´ ã€‚ä¸¤é¡¹ç ”ç©¶çº³å…¥äº†ç¤¾ä¼šå±‚é¢ï¼ŒåŒ…æ‹¬æ”¯æŒç³»ç»Ÿä¸è¶³ã€èŒä¸šè´Ÿæ‹…å’ŒåŒ»ç–—ä¿å¥è·å–éšœç¢ã€‚æ®ä¸€è‡´æŠ¥é“ï¼Œå¹´é¾„å’Œèƒæ¬¡ä¼šåŠ å‰§èº«ä½“å’Œå¿ƒç†ç—‡çŠ¶ã€‚ <b>ç»“è®ºï¼š</b>æœ¬ç»¼è¿°å¼ºè°ƒäº†åœ¨ç®¡ç†é«˜é¾„æ¯äº²è…°ç—›æ—¶è€ƒè™‘ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ çš„é‡è¦æ€§ã€‚é‡èº«å®šåˆ¶çš„å¹²é¢„æªæ–½ï¼Œä¾‹å¦‚é”»ç‚¼è®¡åˆ’ã€å®¶åº­æ”¯æŒå’Œå·¥ä½œåœºæ‰€ä½å®¿ï¼Œå¯¹äºæ”¹å–„ç»“æœè‡³å…³é‡è¦ã€‚éœ€è¦ä½¿ç”¨çºµå‘ç ”ç©¶è¿›è¡Œè¿›ä¸€æ­¥ç ”ç©¶ï¼Œä»¥æ›´æ·±å…¥åœ°æ¢è®¨è¿™äº›å› ç´ ã€‚", "keywords_zh": "ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ ã€ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šæ¨¡å‹ã€è…°ç—›ã€é«˜é¾„æ¯äº²", "keywords_en": "biopsychosocial factors, biopsychosocial model, low back pain, older mothers", "link": "https://pubmed.ncbi.nlm.nih.gov/40508850/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 13 Jun 2025"}, {"id": "40501157", "title_en": "The median sacral artery and its surgical anatomy in pelvic and spinal surgery: a systematic review and meta-analysis", "title_zh": "éª¶æ­£ä¸­åŠ¨è„‰åŠå…¶åœ¨ç›†è…”å’Œè„ŠæŸ±æ‰‹æœ¯ä¸­çš„æ‰‹æœ¯è§£å‰–ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "PrzemysÅ‚aw PÄ™kala", "abstract_en": "**Background:** The median sacral artery (MSA) is a small but clinically significant artery arising from the aortic bifurcation and traveling along the anterior sacrum. It supplies the lumbar and sacral vertebrae and, in some cases, parts of the rectum. Despite its size, the MSA is crucial in regional circulation and is particularly relevant in spinal, pelvic, and vascular surgeries. This meta-analysis aims to provide a comprehensive synthesis of anatomical evidence regarding the MSA's origin, variations, and surgical relevance.\n\n**Materials And Methods:** A systematic search was conducted in major databases (PubMed, Embase, ScienceDirect, Scopus, Web of Science, and SciELO) until January 2025. Studies reporting anatomical data on the MSA, including its origin, variations, and clinical significance, were included. A total of 13 studies (n = 1,007 arteries) met the criteria.\n\n**Results:** The MSA originated directly from the aorta in 89.98% (95% CI: 84.05%-95.92%) of cases. In 8.27% (95% CI: 3.29%-13.25%), it shared a common origin with a lumbar artery, typically the 4th lumbar artery (97.86%). The 5th lumbar artery variation was rare (0.66%). Regarding its position relative to the sacral midline, the MSA was found on the left (48.80%), right (31.32%), or directly along the midline (13.35%). The mean distance from the midline was 3.54 mm.\n\n**Conclusions:** Recognizing MSA variations is essential for surgical planning to prevent vascular injury during spinal and gynecological procedures. Further cadaveric and imaging studies are needed to enhance procedural safety.", "abstract_zh": "**èƒŒæ™¯ï¼š** éª¶æ­£ä¸­åŠ¨è„‰ (MSA) æ˜¯ä¸€æ¡å°ä½†å…·æœ‰ä¸´åºŠæ„ä¹‰çš„åŠ¨è„‰ï¼Œèµ·æºäºä¸»åŠ¨è„‰åˆ†å‰å¹¶æ²¿éª¶å‰éƒ¨è¡Œè¿›ã€‚å®ƒä¾›åº”è…°æ¤å’Œéª¶æ¤ï¼Œåœ¨æŸäº›æƒ…å†µä¸‹ï¼Œä¾›åº”éƒ¨åˆ†ç›´è‚ ã€‚å°½ç®¡ MSA å¾ˆå¤§ï¼Œä½†å®ƒå¯¹å±€éƒ¨å¾ªç¯è‡³å…³é‡è¦ï¼Œå°¤å…¶ä¸è„ŠæŸ±ã€éª¨ç›†å’Œè¡€ç®¡æ‰‹æœ¯ç›¸å…³ã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨æä¾›æœ‰å…³ MSA èµ·æºã€å˜å¼‚å’Œæ‰‹æœ¯ç›¸å…³æ€§çš„è§£å‰–å­¦è¯æ®çš„å…¨é¢ç»¼åˆã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** æˆªè‡³ 2025 å¹´ 1 æœˆï¼Œæˆ‘ä»¬åœ¨ä¸»è¦æ•°æ®åº“ï¼ˆPubMedã€Embaseã€ScienceDirectã€Scopusã€Web of Science å’Œ SciELOï¼‰ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚æŠ¥å‘Šäº† MSA è§£å‰–æ•°æ®çš„ç ”ç©¶ï¼ŒåŒ…æ‹¬å…¶èµ·æºã€å˜å¼‚å’Œä¸´åºŠæ„ä¹‰ã€‚å…±æœ‰ 13 é¡¹ç ”ç©¶ï¼ˆn = 1,007 æ¡åŠ¨è„‰ï¼‰ç¬¦åˆæ ‡å‡†ã€‚\n\n**ç»“æœï¼š** 89.98% (95% CI: 84.05%-95.92%) çš„ç—…ä¾‹ä¸­ MSA ç›´æ¥èµ·æºäºä¸»åŠ¨è„‰ã€‚ 8.27%ï¼ˆ95% CIï¼š3.29%-13.25%ï¼‰çš„æ‚£è€…ä¸è…°åŠ¨è„‰æœ‰å…±åŒèµ·æºï¼Œé€šå¸¸æ˜¯ç¬¬å››è…°åŠ¨è„‰ï¼ˆ97.86%ï¼‰ã€‚ç¬¬5è…°åŠ¨è„‰å˜å¼‚ç½•è§ï¼ˆ0.66%ï¼‰ã€‚å°±å…¶ç›¸å¯¹äºéª¶éª¨ä¸­çº¿çš„ä½ç½®è€Œè¨€ï¼ŒMSAä½äºå·¦ä¾§ï¼ˆ48.80%ï¼‰ã€å³ä¾§ï¼ˆ31.32%ï¼‰æˆ–ç›´æ¥æ²¿ç€ä¸­çº¿ï¼ˆ13.35%ï¼‰ã€‚è·ä¸­çº¿çš„å¹³å‡è·ç¦»ä¸º 3.54 æ¯«ç±³ã€‚\n\n**ç»“è®ºï¼š** è®¤è¯† MSA å˜åŒ–å¯¹äºæ‰‹æœ¯è§„åˆ’è‡³å…³é‡è¦ï¼Œä»¥é˜²æ­¢è„ŠæŸ±å’Œå¦‡ç§‘æ‰‹æœ¯æœŸé—´å‘ç”Ÿè¡€ç®¡æŸä¼¤ã€‚éœ€è¦è¿›ä¸€æ­¥çš„å°¸ä½“å’Œæˆåƒç ”ç©¶ä»¥æé«˜æ‰‹æœ¯å®‰å…¨æ€§ã€‚", "keywords_zh": "è§£å‰–å˜å¼‚ã€ä¸´åºŠè§£å‰–å­¦ã€éª¶æ­£ä¸­åŠ¨è„‰ã€èŸèƒåˆ†æã€ç›†è…”è¡€ç®¡åŒ–ã€éª¶éª¨", "keywords_en": "anatomic variations, clinical anatomy, median sacral artery, meta-analysis, pelvic vascularization, sacrum", "link": "https://pubmed.ncbi.nlm.nih.gov/40501157/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 12 Jun 2025"}, {"id": "40500490", "title_en": "Indocyanine green and height of anastomosis in colorectal surgery- a network meta-analysis", "title_zh": "å²å“šèç»¿ä¸ç»“ç›´è‚ æ‰‹æœ¯å»åˆé«˜åº¦çš„ç½‘ç»œèŸèƒåˆ†æ", "authors": "James Wei-Tatt Toh", "abstract_en": "**Purpose:** Anastomotic leak is a potentially life-threatening complication of colorectal surgery, with perfusion and height of anastomoses considered important risk factors. Indocyanine green (ICG) is commonly used in fluorescence angiography (FA) for perfusion assessment though techniques vary. This is a network meta-analysis comparing use of ICG-FA and height of anastomosis for left sided colorectal anastomoses and rates of anastomotic leak.\n\n**Methods:** A systematic review was performed including all adult clinical studies using ICG-FA in colorectal anastomoses. A network meta-analysis was performed to compare high and low anterior resections and the use of ICG for the outcome of anastomotic leak.\n\n**Results:** Of some 333 studies retrieved during review, 31 studies were included, totalling 6431 patients. In a meta-analysis to compare high and low anterior resection, with and without ICG, odds of anastomotic leak were greater in low compared to high anastomoses, and ICG is protective in both, OR of 0.38 (0.20-0.73) for high and OR of 0.41 (0.30-0.54) in low anastomoses, with ICG compared to without.\n\n**Conclusion:** There is benefit of ICG for both HAR and LAR in reducing anastomotic leak. While there is no consensus on the application, dosage and timing of ICG during anterior resection, pooled results and most studies have shown that the use of ICG to check for tissue perfusion of anastomosis reduces leak. ICG should be considered as part of a surgeon's armamentarium for intraoperative anastomotic check to reduce the risk of postoperative anastomotic leak.", "abstract_zh": "**Purposeï¼š** å»åˆå£ç˜˜æ˜¯ç»“ç›´è‚ æ‰‹æœ¯çš„ä¸€ç§æ½œåœ¨å±åŠç”Ÿå‘½çš„å¹¶å‘ç—‡ï¼ŒçŒæ³¨å’Œå»åˆå£é«˜åº¦è¢«è®¤ä¸ºæ˜¯é‡è¦çš„å±é™©å› ç´ ã€‚å°½ç®¡æŠ€æœ¯å„å¼‚ï¼Œå²å“šèç»¿ (ICG) é€šå¸¸ç”¨äºè§å…‰è¡€ç®¡é€ å½± (FA) ä¸­è¿›è¡ŒçŒæ³¨è¯„ä¼°ã€‚è¿™æ˜¯ä¸€é¡¹ç½‘ç»œèŸèƒåˆ†æï¼Œæ¯”è¾ƒäº†å·¦ä¾§ç»“ç›´è‚ å»åˆæœ¯ä¸­ ICG-FA çš„ä½¿ç”¨å’Œå»åˆé«˜åº¦ä»¥åŠå»åˆå£æ¼ç‡ã€‚\n\n**æ–¹æ³•ï¼š** è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼ŒåŒ…æ‹¬åœ¨ç»“ç›´è‚ å»åˆæœ¯ä¸­ä½¿ç”¨ ICG-FA çš„æ‰€æœ‰æˆäººä¸´åºŠç ”ç©¶ã€‚è¿›è¡Œäº†ç½‘ç»œèŸèƒåˆ†ææ¥æ¯”è¾ƒé«˜ä½å’Œä½ä½å‰åˆ‡é™¤æœ¯ä»¥åŠ ICG å¯¹å»åˆå£ç˜˜ç»“æœçš„ä½¿ç”¨ã€‚\n\n**ç»“æœï¼š** åœ¨å®¡æŸ¥è¿‡ç¨‹ä¸­æ£€ç´¢åˆ°çš„çº¦ 333 é¡¹ç ”ç©¶ä¸­ï¼Œçº³å…¥äº† 31 é¡¹ç ”ç©¶ï¼Œå…±è®¡ 6431 åæ‚£è€…ã€‚åœ¨ä¸€é¡¹æ¯”è¾ƒé«˜ä½å’Œä½ä½å‰åˆ‡é™¤æœ¯ï¼ˆæœ‰å’Œæ²¡æœ‰ ICGï¼‰çš„èŸèƒåˆ†æä¸­ï¼Œä¸é«˜ä½å»åˆç›¸æ¯”ï¼Œä½ä½å»åˆæœ¯å‘ç”Ÿå»åˆå£æ¼çš„å‡ ç‡æ›´å¤§ï¼Œå¹¶ä¸” ICG å¯¹ä¸¤ç§æƒ…å†µéƒ½æœ‰ä¿æŠ¤ä½œç”¨ï¼Œæœ‰ ICG ä¸æ—  ICG ç›¸æ¯”ï¼Œé«˜ä½å»åˆçš„ OR ä¸º 0.38ï¼ˆ0.20-0.73ï¼‰ï¼Œä½ä½å»åˆçš„ OR ä¸º 0.41ï¼ˆ0.30-0.54ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICG å¯¹äº HAR å’Œ LAR éƒ½æœ‰åˆ©äºå‡å°‘å»åˆå£ç˜˜ã€‚è™½ç„¶å¯¹äºå‰åˆ‡é™¤æœ¯ä¸­ ICG çš„åº”ç”¨ã€å‰‚é‡å’Œæ—¶æœºå°šæœªè¾¾æˆå…±è¯†ï¼Œä½†æ±‡æ€»ç»“æœå’Œå¤§å¤šæ•°ç ”ç©¶è¡¨æ˜ï¼Œä½¿ç”¨ ICG æ£€æŸ¥å»åˆå£çš„ç»„ç»‡çŒæ³¨å¯å‡å°‘æ¸—æ¼ã€‚ ICG åº”è¢«è§†ä¸ºå¤–ç§‘åŒ»ç”Ÿæœ¯ä¸­å»åˆå£æ£€æŸ¥è£…å¤‡çš„ä¸€éƒ¨åˆ†ï¼Œä»¥é™ä½æœ¯åå»åˆå£ç˜˜çš„é£é™©ã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ å»åˆæœ¯ã€é«˜ä½å‰åˆ‡é™¤æœ¯ã€å²å“šé’ç»¿ã€ä½ä½å‰åˆ‡é™¤æœ¯", "keywords_en": "Anastomotic leak, Colorectal anastomosis, High anterior resection, Indocyanine green, Low anterior resection", "link": "https://pubmed.ncbi.nlm.nih.gov/40500490/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 11 Jun 2025"}, {"id": "40493094", "title_en": "Limitations of the Goligher classification in randomized trials for hemorrhoidal disease: a qualitative systematic review of selection criteria", "title_zh": "ç—”ç–®ç–¾ç—…éšæœºè¯•éªŒä¸­ Goligher åˆ†ç±»çš„å±€é™æ€§ï¼šé€‰æ‹©æ ‡å‡†çš„å®šæ€§ç³»ç»Ÿè¯„ä»·", "authors": "G Gallo", "abstract_en": "**Background:** The diverse range of therapeutic options for hemorrhoidal disease (HD) highlights the need for precise classification systems to guide treatment. Although the Goligher classification remains the most widely used, it has been criticized for its simplicity and limited ability to capture symptom severity or guide treatment decisions. This study aims to evaluate the patient selection criteria and classification systems employed in randomized controlled trials (RCTs) for HD.\n\n**Methods:** A systematic review was conducted following the 2020 PRISMA guidelines. A comprehensive search of databases identified randomized controlled trials (RCTs) comparing treatments for HD, focusing on classification systems used for patient enrollment. Eligible studies included adult patients and at least one arm involving surgical treatment.\n\n**Results:** Out of 6692 records, 162 studies met the inclusion criteria, with a median cohort size of 84 patients and 55.4% male. Most studies (86.4%) used the Goligher system, though the majority did not fully describe or cite the system. Only 13.6% of studies employed more recent alternative classification systems. The most common outcome measures across studies were postoperative pain (147 studies) and complications (133 studies). Recurrence rates were reported in 42% of studies, yet 70% of these did not provide adequate inclusion criteria or references to Goligher's classification.\n\n**Conclusions:** The inconsistent application of the Goligher classification and the variability in patient selection criteria across RCTs highlight the need for more nuanced and standardized systems. Future research should focus on refining classification methods and incorporating patient-reported outcomes to improve the reliability and relevance of HD trials.\n\n**Prospero Registration:** CRD42023387339.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®ç–¾ç—… (HD) çš„æ²»ç–—é€‰æ‹©å¤šç§å¤šæ ·ï¼Œå‡¸æ˜¾äº†éœ€è¦ç²¾ç¡®çš„åˆ†ç±»ç³»ç»Ÿæ¥æŒ‡å¯¼æ²»ç–—ã€‚å°½ç®¡ Goligher åˆ†ç±»ä»ç„¶æ˜¯ä½¿ç”¨æœ€å¹¿æ³›çš„åˆ†ç±»ï¼Œä½†å®ƒå› å…¶ç®€å•æ€§å’Œæ•æ‰ç—‡çŠ¶ä¸¥é‡ç¨‹åº¦æˆ–æŒ‡å¯¼æ²»ç–—å†³ç­–çš„èƒ½åŠ›æœ‰é™è€Œå—åˆ°æ‰¹è¯„ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼° HD éšæœºå¯¹ç…§è¯•éªŒ (RCT) ä¸­é‡‡ç”¨çš„æ‚£è€…é€‰æ‹©æ ‡å‡†å’Œåˆ†ç±»ç³»ç»Ÿã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® 2020 å¹´ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿå®¡æŸ¥ã€‚å¯¹æ•°æ®åº“è¿›è¡Œå…¨é¢æ£€ç´¢ï¼Œç¡®å®šäº†æ¯”è¾ƒ HD æ²»ç–—æ–¹æ³•çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œé‡ç‚¹å…³æ³¨ç”¨äºæ‚£è€…å…¥ç»„çš„åˆ†ç±»ç³»ç»Ÿã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬æˆå¹´æ‚£è€…å’Œè‡³å°‘ä¸€åªæ¶‰åŠæ‰‹æœ¯æ²»ç–—çš„æ‰‹è‡‚ã€‚\n\n**ç»“æœï¼š** åœ¨ 6692 é¡¹è®°å½•ä¸­ï¼Œæœ‰ 162 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œé˜Ÿåˆ—è§„æ¨¡ä¸­ä½æ•°ä¸º 84 åæ‚£è€…ï¼Œå…¶ä¸­ 55.4% ä¸ºç”·æ€§ã€‚å¤§å¤šæ•°ç ”ç©¶ (86.4%) ä½¿ç”¨ Goligher ç³»ç»Ÿï¼Œå°½ç®¡å¤§å¤šæ•°ç ”ç©¶æ²¡æœ‰å®Œå…¨æè¿°æˆ–å¼•ç”¨è¯¥ç³»ç»Ÿã€‚åªæœ‰ 13.6% çš„ç ”ç©¶é‡‡ç”¨äº†æ›´æ–°çš„æ›¿ä»£åˆ†ç±»ç³»ç»Ÿã€‚ç ”ç©¶ä¸­æœ€å¸¸è§çš„ç»“æœæŒ‡æ ‡æ˜¯æœ¯åç–¼ç—›ï¼ˆ147 é¡¹ç ”ç©¶ï¼‰å’Œå¹¶å‘ç—‡ï¼ˆ133 é¡¹ç ”ç©¶ï¼‰ã€‚ 42% çš„ç ”ç©¶æŠ¥å‘Šäº†å¤å‘ç‡ï¼Œä½†å…¶ä¸­ 70% çš„ç ”ç©¶æ²¡æœ‰æä¾›è¶³å¤Ÿçš„çº³å…¥æ ‡å‡†æˆ–å¯¹ Goligher åˆ†ç±»çš„å‚è€ƒã€‚\n\n**ç»“è®ºï¼š** Goligher åˆ†ç±»çš„åº”ç”¨ä¸ä¸€è‡´ä»¥åŠéšæœºå¯¹ç…§è¯•éªŒä¸­æ‚£è€…é€‰æ‹©æ ‡å‡†çš„å¯å˜æ€§çªå‡ºè¡¨æ˜éœ€è¦æ›´ç»†è‡´å’Œæ ‡å‡†åŒ–çš„ç³»ç»Ÿã€‚æœªæ¥çš„ç ”ç©¶åº”ä¾§é‡äºå®Œå–„åˆ†ç±»æ–¹æ³•å¹¶çº³å…¥æ‚£è€…æŠ¥å‘Šçš„ç»“æœï¼Œä»¥æé«˜ HD è¯•éªŒçš„å¯é æ€§å’Œç›¸å…³æ€§ã€‚\n\n**Prospero registrationï¼š** CRD42023387339ã€‚", "keywords_zh": "åˆ†ç±»ç³»ç»Ÿã€Goligher åˆ†ç±»ã€ç—”ç–®ç–¾ç—…ã€ç—”ç–®ã€æ‚£è€…é€‰æ‹©ã€éšæœºå¯¹ç…§è¯•éªŒ", "keywords_en": "Classification systems, Goligher classification, Hemorrhoidal disease, Hemorrhoids, Patient selection, Randomized controlled trials", "link": "https://pubmed.ncbi.nlm.nih.gov/40493094/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 10 Jun 2025"}, {"id": "40481245", "title_en": "Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Gianpiero Gravante", "abstract_en": "Polidocanol foam sclerotherapy has gained increasing attention as a minimally invasive treatment for hemorrhoidal disease (HD). However, significant variability exists in its clinical application regarding patient selection, procedural techniques, and postoperative management. This study aimed to assess real-world practice patterns among international experts, summarize existing evidence through a systematic literature review, and develop evidence-based clinical practice recommendations. A systematic review was conducted in MEDLINE, EMBASE, and CENTRAL to identify studies evaluating polidocanol foam sclerotherapy for HD. A total of 20 studies met the inclusion criteria. Additionally, an international survey was distributed to 30 experts in proctology and colorectal surgery to explore variations in indications, perioperative management, technique, and follow-up. Survey responses were analyzed descriptively to identify common trends and areas of divergence. Subsequently, based on both the experts' opinions and the results of the survey, a Delphi method was employed to produce clinical practice recommendations. The questions for the Delphi process were developed by the authors leading the project, followed by a detailed discussion with the whole panel of experts. Most experts (90%) reported using polidocanol foam sclerotherapy primarily for Goligher grade II HD, with 67% extending its use to grade III cases. Preoperative bowel preparation and anesthesia use varied widely. The preferred concentration was 3% polidocanol, with 2Â mL injected per hemorrhoidal pile in most cases. Post-procedural care lacked standardization, though stool softeners and flavonoids were commonly recommended. Compared to rubber band ligation, polidocanol foam was perceived as having higher success rates (88.3% vs. 66.7%) and lower recurrence rates (16.1% vs. 41.2%). Adverse events were infrequent. The present article offers a comprehensive suite of clinical practice expert-based recommendations concerning the use of polidocanol foam sclerotherapy for HD. However, there is still significant variation in its application. These findings highlight the need for standardized guidelines and further research to optimize procedural strategies and long-term outcomes.", "abstract_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•ä½œä¸ºç—”ç–®ç–¾ç—…ï¼ˆHDï¼‰çš„å¾®åˆ›æ²»ç–—æ–¹æ³•è¶Šæ¥è¶Šå—åˆ°å…³æ³¨ã€‚ç„¶è€Œï¼Œå…¶ä¸´åºŠåº”ç”¨åœ¨æ‚£è€…é€‰æ‹©ã€æ‰‹æœ¯æŠ€æœ¯å’Œæœ¯åç®¡ç†æ–¹é¢å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å›½é™…ä¸“å®¶çš„çœŸå®å®è·µæ¨¡å¼ï¼Œé€šè¿‡ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ€»ç»“ç°æœ‰è¯æ®ï¼Œå¹¶åˆ¶å®šåŸºäºè¯æ®çš„ä¸´åºŠå®è·µå»ºè®®ã€‚ MEDLINEã€EMBASE å’Œ CENTRAL è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥ç¡®å®šè¯„ä¼°èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— HD çš„ç ”ç©¶ã€‚å…±æœ‰ 20 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚æ­¤å¤–ï¼Œè¿˜å‘ 30 åç›´è‚ ç—…å­¦å’Œç»“ç›´è‚ å¤–ç§‘ä¸“å®¶è¿›è¡Œäº†ä¸€é¡¹å›½é™…è°ƒæŸ¥ï¼Œä»¥æ¢è®¨é€‚åº”ç—‡ã€å›´æ‰‹æœ¯æœŸç®¡ç†ã€æŠ€æœ¯å’Œéšè®¿æ–¹é¢çš„å·®å¼‚ã€‚å¯¹è°ƒæŸ¥å›å¤è¿›è¡Œæè¿°æ€§åˆ†æï¼Œä»¥ç¡®å®šå…±åŒè¶‹åŠ¿å’Œåˆ†æ­§é¢†åŸŸã€‚éšåï¼Œæ ¹æ®ä¸“å®¶æ„è§å’Œè°ƒæŸ¥ç»“æœï¼Œé‡‡ç”¨å¾·å°”è²æ³•æå‡ºä¸´åºŠå®è·µå»ºè®®ã€‚å¾·å°”è²æµç¨‹çš„é—®é¢˜æ˜¯ç”±é¢†å¯¼è¯¥é¡¹ç›®çš„ä½œè€…æå‡ºçš„ï¼Œç„¶åä¸æ•´ä¸ªä¸“å®¶å°ç»„è¿›è¡Œäº†è¯¦ç»†è®¨è®ºã€‚å¤§å¤šæ•°ä¸“å®¶ (90%) æŠ¥å‘Šä¸»è¦ä½¿ç”¨èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— Goligher II çº§ HDï¼Œå…¶ä¸­ 67% å°†å…¶ä½¿ç”¨èŒƒå›´æ‰©å¤§åˆ° III çº§ç—…ä¾‹ã€‚æœ¯å‰è‚ é“å‡†å¤‡å’Œéº»é†‰ä½¿ç”¨å·®å¼‚å¾ˆå¤§ã€‚é¦–é€‰æµ“åº¦æ˜¯ 3% èšå¤šå¡é†‡ï¼Œå¤§å¤šæ•°æƒ…å†µä¸‹æ¯ä¸ªç—”ç–®æ³¨å°„ 2 mLã€‚å°½ç®¡é€šå¸¸æ¨èä½¿ç”¨å¤§ä¾¿è½¯åŒ–å‰‚å’Œç±»é»„é…®ï¼Œä½†æœ¯åæŠ¤ç†ç¼ºä¹æ ‡å‡†åŒ–ã€‚ä¸æ©¡çš®ç­‹ç»“æ‰ç›¸æ¯”ï¼Œèšå¤šå¡é†‡æ³¡æ²«è¢«è®¤ä¸ºå…·æœ‰æ›´é«˜çš„æˆåŠŸç‡ï¼ˆ88.3% vs. 66.7%ï¼‰å’Œè¾ƒä½çš„å¤å‘ç‡ï¼ˆ16.1% vs. 41.2%ï¼‰ã€‚ä¸è‰¯äº‹ä»¶å¾ˆå°‘å‘ç”Ÿã€‚æœ¬æ–‡æä¾›äº†ä¸€å¥—åŸºäºä¸´åºŠå®è·µä¸“å®¶çš„å…¨é¢å»ºè®®ï¼Œæ¶‰åŠä½¿ç”¨èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— HDã€‚ç„¶è€Œï¼Œå…¶åº”ç”¨ä»ç„¶å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚è¿™äº›å‘ç°å¼ºè°ƒéœ€è¦æ ‡å‡†åŒ–æŒ‡å—å’Œè¿›ä¸€æ­¥ç ”ç©¶æ¥ä¼˜åŒ–ç¨‹åºç­–ç•¥å’Œé•¿æœŸç»“æœã€‚", "keywords_zh": "ä¸“å®¶è°ƒæŸ¥ã€ç—”ç–®ç–¾ç—…ã€èšå¤šå¡é†‡æ³¡æ²«ã€ç¡¬åŒ–ç–—æ³•ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "Expert survey, Hemorrhoidal disease, Polidocanol foam, Sclerotherapy, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40481245/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 06 Jun 2025"}, {"id": "40461025", "title_en": "Comparison of endoscopic vacuum therapy with standard care for colorectal anastomotic leakage: a systematic review and meta-analysis", "title_zh": "å†…é•œè´Ÿå‹æ²»ç–—ä¸ç»“ç›´è‚ å»åˆå£ç˜˜æ ‡å‡†æŠ¤ç†çš„æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Yunhong Tian", "abstract_en": "This systematic review and meta-analysis aimed to evaluate the effectiveness of endoscopic vacuum therapy (EVT) compared with standard care in managing colorectal anastomotic leakage, a serious complication following colorectal surgery.We conducted a literature search across PubMed, Embase, and the Cochrane Library for clinical studies published before October 2024 that compared the outcomes of EVT and standard care for anastomotic leakage, including leakage resolution rates, treatment duration, hospital stay duration, or postoperative complications. The pooled estimates of risk ratio (RR) or mean difference were primarily derived using a fixed-effects model, with a random-effects model used when high heterogeneity was detected.The analysis included six observational studies (273 patients). EVT was associated with a significantly higher resolution rate compared with standard care (RR 1.18, 95%CI 1.03 to 1.35; <i>P</i> = 0.02). Treatment duration was significantly shorter in the EVT group (mean difference -30.6 days, 95%CI -43.5 to -17.7; <i>P</i> < 0.001), while hospital stay duration showed no significant difference between EVT and standard care (mean difference 1.7 days, 95%CI -4.2 to 7.7; <i>P</i> = 0.57). No statistically significant difference was found in the rate of treatment-related complications between EVT and standard care (RR 1.17, 95%CI 0.52 to 2.80; <i>P</i> = 0.71).This meta-analysis suggests that EVT has superior effectiveness in terms of leakage resolution rates, as well as a shorter treatment duration compared with standard care for colorectal anastomotic leakage. This study is however constrained by the lack of prospective data, the risk of selection bias, and heterogeneity, requiring cautious interpretation of the findings.PROSPERO registration: CRD 4873455814.", "abstract_zh": "è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°å†…é•œçœŸç©ºæ²»ç–— (EVT) ä¸æ ‡å‡†æŠ¤ç†ç›¸æ¯”åœ¨å¤„ç†ç»“ç›´è‚ å»åˆå£ç˜˜ï¼ˆç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ï¼‰æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚æˆ‘ä»¬å¯¹ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ï¼ŒæŸ¥æ‰¾ 2024 å¹´ 10 æœˆä¹‹å‰å‘è¡¨çš„ä¸´åºŠç ”ç©¶ï¼Œæ¯”è¾ƒ EVT å’Œæ ‡å‡†æŠ¤ç†å¯¹å»åˆå£ç˜˜çš„ç»“æœï¼ŒåŒ…æ‹¬æ³„æ¼è§£å†³ç‡ã€æ²»ç–—æŒç»­æ—¶é—´ã€ä½é™¢æ—¶é—´æˆ–æœ¯åå¹¶å‘ç—‡ã€‚é£é™©æ¯” (RR) æˆ–å¹³å‡å·®çš„æ±‡æ€»ä¼°è®¡å€¼ä¸»è¦ä½¿ç”¨å›ºå®šæ•ˆåº”æ¨¡å‹å¾—å‡ºï¼Œå½“æ£€æµ‹åˆ°é«˜åº¦å¼‚è´¨æ€§æ—¶ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹ã€‚è¯¥åˆ†æåŒ…æ‹¬å…­é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼ˆ273 åæ‚£è€…ï¼‰ã€‚ä¸æ ‡å‡†æŠ¤ç†ç›¸æ¯”ï¼ŒEVT çš„ç¼“è§£ç‡æ˜æ˜¾æ›´é«˜ï¼ˆRR 1.18ï¼Œ95% CI 1.03 è‡³ 1.35ï¼›<i>P</i> = 0.02ï¼‰ã€‚ EVT ç»„çš„æ²»ç–—æ—¶é—´æ˜¾ç€ç¼©çŸ­ï¼ˆå¹³å‡å·® -30.6 å¤©ï¼Œ95%CI -43.5 è‡³ -17.7ï¼›<i>P</i> < 0.001ï¼‰ï¼Œè€Œ EVT å’Œæ ‡å‡†æ²»ç–—ä¹‹é—´çš„ä½é™¢æ—¶é—´æ— æ˜¾ç€å·®å¼‚ï¼ˆå¹³å‡å·® 1.7 å¤©ï¼Œ95%CI -4.2 è‡³ -17.7ï¼›<i>P</i> = 0.57ï¼‰ã€‚ EVT å’Œæ ‡å‡†æŠ¤ç†ä¹‹é—´çš„æ²»ç–—ç›¸å…³å¹¶å‘ç—‡å‘ç”Ÿç‡æ²¡æœ‰å‘ç°ç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ï¼ˆRR 1.17ï¼Œ95%CI 0.52 è‡³ 2.80ï¼›<i>P</i> = 0.71ï¼‰ã€‚è¯¥èŸèƒåˆ†æè¡¨æ˜ï¼Œä¸ç»“ç›´è‚ å»åˆå£ç˜˜æ ‡å‡†æŠ¤ç†ç›¸æ¯”ï¼ŒEVT åœ¨æ¸—æ¼è§£å†³ç‡æ–¹é¢å…·æœ‰æ›´é«˜çš„æœ‰æ•ˆæ€§ï¼Œå¹¶ä¸”æ²»ç–—æŒç»­æ—¶é—´æ›´çŸ­ã€‚ç„¶è€Œï¼Œè¿™é¡¹ç ”ç©¶å—åˆ°ç¼ºä¹å‰ç»æ€§æ•°æ®ã€é€‰æ‹©åå€šé£é™©å’Œå¼‚è´¨æ€§çš„é™åˆ¶ï¼Œéœ€è¦å¯¹ç ”ç©¶ç»“æœè¿›è¡Œè°¨æ…è§£é‡Šã€‚PROSPERO æ³¨å†Œï¼šCRD 4873455814ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40461025/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 03 Jun 2025"}, {"id": "40456210", "title_en": "Transmission of gonorrhea from the oral cavity to the rectal tract: A systematic review", "title_zh": "æ·‹ç—…ä»å£è…”ä¼ æ’­åˆ°ç›´è‚ ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mabel Miluska Suca Salas", "abstract_en": "BackgroundThe antimicrobial resistance of Neisseria gonorrhoeae and the high prevalence of asymptomatic extragenital infections are a worldwide concern. This research investigated whether gonorrhea can be transmitted from the oral cavity to the anorectal tract among men who have sex with men.<b>Purpose</b>The aim of this research is to find plausible relationships regarding the probability of gonococcal transmission from the oral cavity to the anorectal tract among MSM.<b>Research Design</b>A research question was defined using the P.I.C.O. strategy (population, intervention or exposure, comparison and outcome), where the target population is MSM, the intervention is exposure to contaminated oral cavity/saliva, the control is the absence of exposure, and the outcome is the acquisition of GC. The eligibility criteria included observational studies involving men who have sex with men, regardless of sexual orientation, aged 16 or older, screened for oropharyngeal and rectal gonorrhea, and examining the role of oral fluids in transmission. Studies involving partners previously diagnosed with urogenital gonorrhea or reporting consistent condom use during receptive penoanal sex were excluded to avoid urethral-to-anorectal transmission bias.<b>Study Sample</b>The databases employed were PubMed, Scopus, Web of Science, EBSCO, SciELO, and the Virtual Health Library (VHL). A total of 383 studies were identified, however, only 6 were included.<b>Data Collection and/or Analysis</b>According to the Newcastle-Ottawa Scale (NOS), two studies were \"very good,\" two \"good,\" and two \"satisfactory\". Most studies described a complete methodology according to Strengthening the Reporting of Observational studies in Epidemiology (STROBE).<b>Results</b>Differences in diagnostic methods, methodologies, and variables limited the findings. While the results do not confirm transmission from the oral cavity to the anorectal tract, they suggest its possibility. Further research is needed to better understand this transmission route.<b>Conclusions</b>Transmissibility of gonorrhea from oropharyngeal via to the anorectal tract cannot be totally establish. However, evidence suggested the existence of this gonorrhea transmission. The fact that men with rectal gonorrhea continue to appear, even in contexts of condom use or the absence of receptive penoanal sex, brings the importance of cases monitoring and the establishment of preventive strategies.", "abstract_zh": "èƒŒæ™¯æ·‹ç—…å¥ˆç‘ŸèŒçš„æŠ—èŒè¯ç‰©è€è¯æ€§å’Œæ— ç—‡çŠ¶ç”Ÿæ®–å™¨å¤–æ„ŸæŸ“çš„é«˜æ‚£ç—…ç‡æ˜¯å…¨ä¸–ç•Œå…³æ³¨çš„é—®é¢˜ã€‚æœ¬ç ”ç©¶è°ƒæŸ¥äº†ç”·ç”·æ€§è¡Œä¸ºè€…ä¸­æ·‹ç—…æ˜¯å¦å¯ä»¥ä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ ã€‚<b>ç›®çš„</b>æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯å¯»æ‰¾ MSM ä¸­æ·‹çƒèŒä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ çš„æ¦‚ç‡ä¹‹é—´çš„åˆç†å…³ç³»ã€‚<b>ç ”ç©¶è®¾è®¡</b>ä½¿ç”¨ P.I.C.O. å®šä¹‰äº†ä¸€ä¸ªç ”ç©¶é—®é¢˜ã€‚ç­–ç•¥ï¼ˆäººç¾¤ã€å¹²é¢„æˆ–æš´éœ²ã€æ¯”è¾ƒå’Œç»“æœï¼‰ï¼Œå…¶ä¸­ç›®æ ‡äººç¾¤æ˜¯ MSMï¼Œå¹²é¢„æ˜¯æš´éœ²äºå—æ±¡æŸ“çš„å£è…”/å”¾æ¶²ï¼Œå¯¹ç…§æ˜¯ä¸å­˜åœ¨æš´éœ²ï¼Œç»“æœæ˜¯ GC çš„è·å¾—ã€‚èµ„æ ¼æ ‡å‡†åŒ…æ‹¬å¯¹å¹´é¾„åœ¨ 16 å²æˆ–ä»¥ä¸Šçš„ç”·ç”·æ€§è¡Œä¸ºè€…ï¼ˆæ— è®ºæ€§å–å‘å¦‚ä½•ï¼‰è¿›è¡Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œç­›æŸ¥å£å’½å’Œç›´è‚ æ·‹ç—…ï¼Œå¹¶æ£€æŸ¥å£è…”æ¶²ä½“åœ¨ä¼ æ’­ä¸­çš„ä½œç”¨ã€‚æ¶‰åŠå…ˆå‰è¯Šæ–­ä¸ºæ³Œå°¿ç”Ÿæ®–æ·‹ç—…æˆ–æŠ¥å‘Šåœ¨æ¥å—æ€§è‚›äº¤æœŸé—´æŒç»­ä½¿ç”¨å®‰å…¨å¥—çš„ç ”ç©¶è¢«æ’é™¤ï¼Œä»¥é¿å…å°¿é“åˆ°è‚›é—¨ç›´è‚ ä¼ æ’­åå·®ã€‚<b>ç ”ç©¶æ ·æœ¬</b>ä½¿ç”¨çš„æ•°æ®åº“åŒ…æ‹¬ PubMedã€Scopusã€Web of Scienceã€EBSCOã€SciELO å’Œè™šæ‹Ÿå¥åº·å›¾ä¹¦é¦† (VHL)ã€‚æ€»å…±ç¡®å®šäº† 383 é¡¹ç ”ç©¶ï¼Œä½†ä»…çº³å…¥ 6 é¡¹ã€‚<b>æ•°æ®æ”¶é›†å’Œ/æˆ–åˆ†æ</b>æ ¹æ®çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ (NOS)ï¼Œä¸¤é¡¹ç ”ç©¶ä¸ºâ€œéå¸¸å¥½â€ï¼Œä¸¤é¡¹ä¸ºâ€œè‰¯å¥½â€ï¼Œä¸¤é¡¹ä¸ºâ€œä»¤äººæ»¡æ„â€ã€‚å¤§å¤šæ•°ç ”ç©¶æ ¹æ®åŠ å¼ºæµè¡Œç—…å­¦è§‚å¯Ÿç ”ç©¶æŠ¥å‘Š (STROBE) æè¿°äº†å®Œæ•´çš„æ–¹æ³•ã€‚<b>ç»“æœ</b>è¯Šæ–­æ–¹æ³•ã€æ–¹æ³•å’Œå˜é‡çš„å·®å¼‚é™åˆ¶äº†ç ”ç©¶ç»“æœã€‚è™½ç„¶ç»“æœå¹¶æœªè¯å®ä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ ï¼Œä½†è¡¨æ˜äº†å…¶å¯èƒ½æ€§ã€‚éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ä»¥æ›´å¥½åœ°äº†è§£è¿™ç§ä¼ æ’­é€”å¾„ã€‚<b>ç»“è®º</b>æ·‹ç—…ä»å£å’½åˆ°è‚›é—¨ç›´è‚ çš„ä¼ æ’­èƒ½åŠ›å°šä¸èƒ½å®Œå…¨ç¡®å®šã€‚ç„¶è€Œï¼Œæœ‰è¯æ®è¡¨æ˜å­˜åœ¨è¿™ç§æ·‹ç—…ä¼ æ’­ã€‚å³ä½¿åœ¨ä½¿ç”¨å®‰å…¨å¥—æˆ–ç¼ºä¹æ¥å—æ€§äº¤çš„æƒ…å†µä¸‹ï¼Œæ‚£æœ‰ç›´è‚ æ·‹ç—…çš„ç”·æ€§ä»ç„¶ä¸æ–­å‡ºç°ï¼Œè¿™ä¸€äº‹å®å‡¸æ˜¾äº†ç—…ä¾‹ç›‘æµ‹å’Œåˆ¶å®šé¢„é˜²ç­–ç•¥çš„é‡è¦æ€§ã€‚", "keywords_zh": "å£è…”ã€æ·‹ç—…ã€ç›´è‚ ã€æ€§å°‘æ•°å’Œæ€§åˆ«å°‘æ•°ã€æ€§ä¼ æ’­ç–¾ç—…", "keywords_en": "Mouth, gonorrhoea, rectum, sexual and gender minorities, sexually transmitted diseases", "link": "https://pubmed.ncbi.nlm.nih.gov/40456210/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 02 Jun 2025"}, {"id": "40434549", "title_en": "A rare combination of hypogonadotropic hypogonadism, GH deficiency and rectal atresia in a female with an FGFR1 variant: a case report and systematic review of the literature", "title_zh": "FGFR1 å˜å¼‚å¥³æ€§ç½•è§æ€§è…ºæ¿€ç´ å‡é€€ç—‡ã€ç”Ÿé•¿æ¿€ç´ ç¼ºä¹ç—‡å’Œç›´è‚ é—­é”çš„ç»„åˆï¼šç—…ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "George Mastorakos", "abstract_en": "**Purpose:** To report a case with combined pituitary hormone deficiency (CPHD) and Fibroblast growth factor receptor 1 (FGFR1) gene defect, and summarize the clinical characteristics of similar cases by reviewing the current reports from the literature.\n\n**Methods:** A 24-year-old woman was admitted to the outpatient endocrinology unit with a diagnosis of primary amenorrhea, history of Growth Hormone deficiency and multiple congenital anomalies including rectal atresia. The subsequent hormonal investigation led to the diagnosis of hypogonadotropic hypogonadism and persistent GH deficiency. Abdominal and pelvic ultrasounds were normal whereas the brain MRI revealed a hypoplastic sella turcica with a hypoplastic anterior pituitary lobe, an ectopic posterior pituitary lobe and a thin pituitary stalk. The genetic analysis revealed a novel pathogenic missense heterozygous variant (c.1958Gâ€‰>â€‰A, p.Agr635Gln) in exon 15 of FGFR1 gene. PubMed, Scopus, and Web of Science were searched for the identification of studies reporting cases of CPHD with FGFR1 gene defects.\n\n**Results:** Of the 648 records retrieved, 10 were included in this review. A comprehensive overview of the cases was summarized, and their clinical and genetic characteristics were presented.\n\n**Conclusion:** Although FGFR1 variants have been associated with Kallmann syndrome and isolated hypogonadotropic hypogonadism and recently with CPHD, the patient's phenotype includes phenotypic alterations not previously described, to the best of our knowledge, within the spectrum of non-reproductive features of either of these entities. Isolated GH deficiency combined with other non-common abnormalities exerts a great possibility for subsequent CPHD manifestation.", "abstract_zh": "**Purposeï¼š** æŠ¥å‘Š1ä¾‹åˆå¹¶å‚ä½“æ¿€ç´ ç¼ºä¹ç—‡ï¼ˆCPHDï¼‰å’Œæˆçº¤ç»´ç»†èƒç”Ÿé•¿å› å­å—ä½“1ï¼ˆFGFR1ï¼‰åŸºå› ç¼ºé™·çš„ç—…ä¾‹ï¼Œé€šè¿‡å›é¡¾ç°æœ‰æ–‡çŒ®æŠ¥é“ï¼Œæ€»ç»“åŒç±»ç—…ä¾‹çš„ä¸´åºŠç‰¹ç‚¹ã€‚\n\n**æ–¹æ³•ï¼š** ä¸€å 24 å²å¥³æ€§è¢«é€å¾€å†…åˆ†æ³Œç§‘é—¨è¯Šï¼Œè¯Šæ–­ä¸ºåŸå‘æ€§é—­ç»ã€ç”Ÿé•¿æ¿€ç´ ç¼ºä¹ç—…å²ä»¥åŠåŒ…æ‹¬ç›´è‚ é—­é”åœ¨å†…çš„å¤šç§å…ˆå¤©æ€§å¼‚å¸¸ã€‚éšåçš„æ¿€ç´ æ£€æŸ¥è¯Šæ–­ä¸ºä½ä¿ƒæ€§è…ºæ¿€ç´ æ€§æ€§è…ºåŠŸèƒ½å‡é€€ç—‡å’ŒæŒç»­æ€§ GH ç¼ºä¹ã€‚è…¹éƒ¨å’Œç›†è…”è¶…å£°æ£€æŸ¥æ­£å¸¸ï¼Œè€Œè„‘éƒ¨ MRI æ˜¾ç¤ºè¶éå‘è‚²ä¸è‰¯ï¼Œå‚ä½“å‰å¶å‘è‚²ä¸è‰¯ã€å¼‚ä½å‚ä½“åå¶å’Œç»†å‚ä½“æŸ„ã€‚é—ä¼ åˆ†ææ­ç¤ºäº† FGFR1 åŸºå› ç¬¬ 15 å·å¤–æ˜¾å­ä¸­å­˜åœ¨ä¸€ç§æ–°çš„è‡´ç—…æ€§é”™ä¹‰æ‚åˆå˜å¼‚ä½“ï¼ˆc.1958Gâ€‰>â€‰Aï¼Œp.Agr635Glnï¼‰ã€‚å¯¹ PubMedã€Scopus å’Œ Web of Science è¿›è¡Œäº†æœç´¢ï¼Œä»¥ç¡®å®šæŠ¥å‘Š FGFR1 åŸºå› ç¼ºé™·çš„ CPHD ç—…ä¾‹çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** åœ¨æ£€ç´¢åˆ°çš„ 648 æ¡è®°å½•ä¸­ï¼Œæœ¬æ¬¡å®¡æŸ¥çº³å…¥äº† 10 æ¡è®°å½•ã€‚å¯¹ç—…ä¾‹è¿›è¡Œäº†å…¨é¢çš„æ¦‚è¿°ï¼Œå¹¶ä»‹ç»äº†å®ƒä»¬çš„ä¸´åºŠå’Œé—ä¼ ç‰¹å¾ã€‚\n\n**ç»“è®ºï¼š** å°½ç®¡ FGFR1 å˜å¼‚ä¸å¡å°”æ›¼ç»¼åˆå¾å’Œå­¤ç«‹æ€§ä½ä¿ƒæ€§è…ºæ¿€ç´ æ€§æ€§è…ºåŠŸèƒ½å‡é€€ç—‡ä»¥åŠæœ€è¿‘çš„ CPHD ç›¸å…³ï¼Œä½†æ®æˆ‘ä»¬æ‰€çŸ¥ï¼Œæ‚£è€…çš„è¡¨å‹åŒ…æ‹¬ä»¥å‰æœªæè¿°è¿‡çš„è¡¨å‹æ”¹å˜ï¼Œå±äºè¿™äº›å®ä½“çš„éç”Ÿæ®–ç‰¹å¾èŒƒå›´ã€‚å­¤ç«‹çš„ GH ç¼ºä¹åˆå¹¶å…¶ä»–ä¸å¸¸è§çš„å¼‚å¸¸å¾ˆå¯èƒ½å¯¼è‡´éšåçš„ CPHD è¡¨ç°ã€‚", "keywords_zh": "CPHDã€FGFR1ã€GHDã€å‚ä½“åŠŸèƒ½å‡é€€ç—‡ã€è¯„è®º", "keywords_en": "CPHD, FGFR1, GHD, Hypopituitarism, Review", "link": "https://pubmed.ncbi.nlm.nih.gov/40434549/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 28 May 2025"}, {"id": "40413456", "title_en": "MicroRNAs involved in colorectal cancer, a rapid mini-systematic review", "title_zh": "ä¸ç»“ç›´è‚ ç™Œæœ‰å…³çš„ MicroRNAï¼Œå¿«é€Ÿå°å‹ç³»ç»Ÿè¯„ä»·", "authors": "Mahdi Barazesh", "abstract_en": "**Introduction:** Colorectal cancer (CRC) involves the uncontrolled proliferation of glandular epithelial cells in the colon or rectum. The high mortality rate associated with CRC has driven extensive research into innovative diagnostic and therapeutic strategies. Among these, microRNAs (miRNA) have gained attention for their crucial role in regulating various cellular processes that contribute to the initiation, progression, and metastasis of CRC.\n\n**Method:** This systematic review aimed to assess the roles of various miRNAs in CRC by analyzing multiple studies. The PICO framework was followed to structure the study regarding miRNA involved in CRC development and progression compared to normal cases. The outcomes were measured according miRNAs impact on CRC progression, survival rates, and treatment response. Systematic review of studies published from 2000 to November 2023 were included. Data were collected from prominent databases, including Google Scholar, PubMed, ScienceDirect, Irandoc, SID, and Magiran, covering studies from 2000 to November 2023. Studies were managed using EndNote for citation management, and duplicates were removed. The remaining studies were evaluated based on predefined inclusion and exclusion criteria.\n\n**Results:** In our review, we categorized 28 miRNAs based on their potential tumor suppressor or oncogenic effects in CRC progression. Among them, 14 miRNAs were highlighted as important based on the assessment using TCGA data, with miR-200a also showing a significant effect on patient survival.\n\n**Conclusion:** This study compiled and analyzed validated miRNAs associated with CRC progression. The findings suggest the potential of these miRNAs as non-invasive biomarkers, which may be used alone or in combination with traditional tumor markers for improved diagnostic and prognostic applications in CRC. This review contributes novel insights by updating the current understanding and offering a comprehensive evaluation of miRNAs in CRC.", "abstract_zh": "**ä»‹ç»ï¼š** ç»“ç›´è‚ ç™Œ (CRC) æ¶‰åŠç»“è‚ æˆ–ç›´è‚ ä¸­è…ºä¸Šçš®ç»†èƒä¸å—æ§åˆ¶çš„å¢æ®–ã€‚ç»“ç›´è‚ ç™Œç›¸å…³çš„é«˜æ­»äº¡ç‡æ¨åŠ¨äº†å¯¹åˆ›æ–°è¯Šæ–­å’Œæ²»ç–—ç­–ç•¥çš„å¹¿æ³›ç ”ç©¶ã€‚å…¶ä¸­ï¼ŒmicroRNA (miRNA) å› å…¶åœ¨è°ƒèŠ‚å„ç§ç»†èƒè¿‡ç¨‹ä¸­çš„å…³é”®ä½œç”¨è€Œå—åˆ°å…³æ³¨ï¼Œè¿™äº›ç»†èƒè¿‡ç¨‹æœ‰åŠ©äº CRC çš„èµ·å§‹ã€è¿›å±•å’Œè½¬ç§»ã€‚\n\n**Methodï¼š** æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨é€šè¿‡åˆ†æå¤šé¡¹ç ”ç©¶æ¥è¯„ä¼°å„ç§ miRNA åœ¨ CRC ä¸­çš„ä½œç”¨ã€‚éµå¾ª PICO æ¡†æ¶æ¥æ„å»ºä¸æ­£å¸¸ç—…ä¾‹ç›¸æ¯”å‚ä¸ CRC å‘ç”Ÿå’Œè¿›å±•çš„ miRNA çš„ç ”ç©¶ã€‚ç»“æœæ˜¯æ ¹æ® miRNA å¯¹ CRC è¿›å±•ã€ç”Ÿå­˜ç‡å’Œæ²»ç–—ååº”çš„å½±å“æ¥è¡¡é‡çš„ã€‚å¯¹ 2000 å¹´è‡³ 2023 å¹´ 11 æœˆå‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚æ•°æ®æ”¶é›†è‡ªè‘—åæ•°æ®åº“ï¼ŒåŒ…æ‹¬ Google Scholarã€PubMedã€ScienceDirectã€Irandocã€SID å’Œ Magiranï¼Œæ¶µç›– 2000 å¹´è‡³ 2023 å¹´ 11 æœˆçš„ç ”ç©¶ã€‚ç ”ç©¶ä½¿ç”¨ EndNote è¿›è¡Œå¼•æ–‡ç®¡ç†ï¼Œå¹¶åˆ é™¤é‡å¤é¡¹ã€‚å…¶ä½™ç ”ç©¶æ ¹æ®é¢„å…ˆç¡®å®šçš„çº³å…¥å’Œæ’é™¤æ ‡å‡†è¿›è¡Œè¯„ä¼°ã€‚\n\n**ç»“æœï¼š** åœ¨æˆ‘ä»¬çš„ç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬æ ¹æ® 28 ç§ miRNA åœ¨ CRC è¿›å±•ä¸­çš„æ½œåœ¨æŠ‘ç™Œæˆ–è‡´ç™Œä½œç”¨å¯¹å…¶è¿›è¡Œäº†åˆ†ç±»ã€‚å…¶ä¸­ï¼Œæ ¹æ® TCGA æ•°æ®çš„è¯„ä¼°ï¼Œ14 ä¸ª miRNA è¢«å¼ºè°ƒä¸ºé‡è¦ï¼Œå…¶ä¸­ miR-200a ä¹Ÿæ˜¾ç¤ºå‡ºå¯¹æ‚£è€…ç”Ÿå­˜çš„æ˜¾ç€å½±å“ã€‚\n\n**ç»“è®ºï¼š** æœ¬ç ”ç©¶ç¼–è¯‘å¹¶åˆ†æäº†ä¸ CRC è¿›å±•ç›¸å…³çš„ç»è¿‡éªŒè¯çš„ miRNAã€‚è¿™äº›å‘ç°è¡¨æ˜è¿™äº› miRNA ä½œä¸ºéä¾µå…¥æ€§ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ½œåŠ›ï¼Œå¯ä»¥å•ç‹¬ä½¿ç”¨æˆ–ä¸ä¼ ç»Ÿè‚¿ç˜¤æ ‡å¿—ç‰©ç»“åˆä½¿ç”¨ï¼Œä»¥æ”¹å–„ CRC çš„è¯Šæ–­å’Œé¢„ååº”ç”¨ã€‚è¿™ç¯‡ç»¼è¿°é€šè¿‡æ›´æ–°å½“å‰çš„ç†è§£å¹¶å¯¹ CRC ä¸­çš„ miRNA è¿›è¡Œå…¨é¢è¯„ä¼°ï¼Œæä¾›äº†æ–°é¢–çš„è§è§£ã€‚", "keywords_zh": "ç”Ÿç‰©æ ‡å¿—ç‰©ã€ç»“ç›´è‚ ç™Œã€MicroRNA", "keywords_en": "Biomarker, Colorectal cancer, MicroRNAs", "link": "https://pubmed.ncbi.nlm.nih.gov/40413456/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 24 May 2025"}, {"id": "40410673", "title_en": "The efficacy of retrograde and antegrade enemas in the management of low anterior resection syndrome in patients undergoing rectal resection: a systematic review and meta-analysis", "title_zh": "é€†è¡Œå’Œé¡ºè¡ŒçŒè‚ æ²»ç–—ç›´è‚ åˆ‡é™¤æœ¯æ‚£è€…ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾çš„ç–—æ•ˆï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Hui Yang", "abstract_en": "**Background:** Rectal resection could potentially cause low anterior resection syndrome (LARS). Although recent studies have reported the efficacy of enema against LARS, no systematic review and meta-analysis has been conducted.\n\n**Methods:** A systematic search was conducted in PubMed, EMBASE, MEDLINE, CINAHL Complete, Cochrane library and Web of Science. Eligible studies that quantified the effect of enema vs. other approaches on LARS following rectal resection were selected. Meta-analysis was conducted by using RevMan 5.4 software and StataMP 17. Where meta-analysis was not possible, vote counting was performed.\n\n**Results:** This study comprised five RCTs with 159 participants and meta-analysis was performed in 4 studies. Compared with the control group, enema reduced LARS score with mean differences of -10.84 (95% CI: -16.71 to -4.98, Pâ€‰=â€‰0.0003). Subgroup analysis based on the type of enema were performed, with three European studies using retrograde enema and one Asian study using antegrade enema, with mean differences of -13.77 (95% CI: -17.97 to -9.57, Pâ€‰<â€‰0.00001) and -4.86 (95% CI: -9.26 to -0.46, Pâ€‰=â€‰0.03), respectively. According to follow-up period, two trials reported short-term effects and the other two investigated medium/long-term effects with mean differences of -14.22 (95% CI: -20.05 to -8.38, Pâ€‰=â€‰0.23) and -7.59 (95% CI: -14.47 to -0.71, Pâ€‰=â€‰0.13), respectively. One study that used antegrade enema was key contributor to the substantial interstudy heterogeneity by the leave-one-out sensitivity analysis. After exclusion of this study, no heterogeneity was found (t<sup>2</sup>â€‰=â€‰0.00; Ï‡<sup>2</sup>â€‰=â€‰1.63, dfâ€‰=â€‰2, pâ€‰=â€‰0.44; I<sup>2</sup>â€‰=â€‰0%). Vote counting also showed positive effects of enema on LARS.\n\n**Conclusions:** Enema, particularly retrograde enema, is effective in managing LARS. However, the effectiveness of antegrade enema deserves further investigation. The short-term effects of enema are more pronounced compared to long-term outcomes. Due to the limited number of included studies, these findings should be taken cautiously. More RCTs on other continents are needed to validate the impact of enema on LARS, as well as to develop standardised protocols to facilitate clinical practice.\n\n**Prospero Registration:** CRD42024539973.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ åˆ‡é™¤æœ¯å¯èƒ½ä¼šå¯¼è‡´ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ã€‚å°½ç®¡æœ€è¿‘çš„ç ”ç©¶æŠ¥å‘Šäº†çŒè‚ å¯¹ LARS çš„åŠŸæ•ˆï¼Œä½†å°šæœªè¿›è¡Œç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ PubMedã€EMBASEã€MEDLINEã€CINAHL Completeã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚é€‰æ‹©äº†é‡åŒ–çŒè‚ ä¸å…¶ä»–æ–¹æ³•å¯¹ç›´è‚ åˆ‡é™¤æœ¯å LARS æ•ˆæœçš„åˆæ ¼ç ”ç©¶ã€‚ä½¿ç”¨ RevMan 5.4 è½¯ä»¶å’Œ StataMP 17 è¿›è¡ŒèŸèƒåˆ†æã€‚åœ¨æ— æ³•è¿›è¡ŒèŸèƒåˆ†æçš„æƒ…å†µä¸‹ï¼Œè¿›è¡Œè®¡ç¥¨ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹ç ”ç©¶åŒ…æ‹¬ 5 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œå…±æœ‰ 159 åå‚ä¸è€…ï¼Œå¹¶å¯¹ 4 é¡¹ç ”ç©¶è¿›è¡Œäº†èŸèƒåˆ†æã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼ŒçŒè‚ é™ä½LARSè¯„åˆ†ï¼Œå¹³å‡å·®å¼‚ä¸º-10.84ï¼ˆ95% CIï¼š-16.71è‡³-4.98ï¼ŒPâ€‰=â€‰0.0003ï¼‰ã€‚æ ¹æ®çŒè‚ ç±»å‹è¿›è¡Œäºšç»„åˆ†æï¼Œå…¶ä¸­ä¸‰é¡¹æ¬§æ´²ç ”ç©¶ä½¿ç”¨é€†è¡ŒçŒè‚ ï¼Œä¸€é¡¹äºšæ´²ç ”ç©¶ä½¿ç”¨é¡ºè¡ŒçŒè‚ ï¼Œå¹³å‡å·®å¼‚ä¸º-13.77ï¼ˆ95ï¼…CIï¼š-17.97è‡³-9.57ï¼ŒPâ€‰<â€‰0.00001ï¼‰å’Œ-4.86ï¼ˆ95ï¼…CIï¼š-9.26è‡³-0.46ï¼ŒPâ€‰=â€‰0.03ï¼‰ï¼Œåˆ†åˆ«ã€‚æ ¹æ®éšè®¿æ—¶é—´ï¼Œä¸¤é¡¹è¯•éªŒæŠ¥å‘Šäº†çŸ­æœŸæ•ˆåº”ï¼Œå¦å¤–ä¸¤é¡¹ç ”ç©¶äº†ä¸­/é•¿æœŸæ•ˆåº”ï¼Œå¹³å‡å·®å¼‚åˆ†åˆ«ä¸º-14.22ï¼ˆ95% CIï¼š-20.05è‡³-8.38ï¼ŒPâ€‰=â€‰0.23ï¼‰å’Œ-7.59ï¼ˆ95% CIï¼š-14.47è‡³-0.71ï¼ŒPâ€‰=â€‰0.13ï¼‰ã€‚ä¸€é¡¹ä½¿ç”¨é¡ºè¡ŒçŒè‚ çš„ç ”ç©¶æ˜¯ç•™ä¸€æ•æ„Ÿæ€§åˆ†æå¯¼è‡´ç ”ç©¶é—´æ˜¾ç€å¼‚è´¨æ€§çš„å…³é”®å› ç´ ã€‚æ’é™¤æœ¬ç ”ç©¶åï¼Œæœªå‘ç°å¼‚è´¨æ€§ï¼ˆt<sup>2</sup>â€‰=â€‰0.00ï¼›Ï‡<sup>2</sup>â€‰=â€‰1.63ï¼Œdfâ€‰=â€‰2ï¼Œpâ€‰=â€‰0.44ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚è®¡ç¥¨ä¹Ÿæ˜¾ç¤ºçŒè‚ å¯¹ LARS å…·æœ‰ç§¯æä½œç”¨ã€‚\n\n**ç»“è®ºï¼š** çŒè‚ ï¼Œç‰¹åˆ«æ˜¯é€†è¡ŒçŒè‚ ï¼Œå¯¹äºæ²»ç–— LARS æ˜¯æœ‰æ•ˆçš„ã€‚ç„¶è€Œï¼Œé¡ºè¡ŒçŒè‚ çš„æœ‰æ•ˆæ€§å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚ä¸é•¿æœŸç»“æœç›¸æ¯”ï¼ŒçŒè‚ çš„çŸ­æœŸæ•ˆæœæ›´ä¸ºæ˜æ˜¾ã€‚ç”±äºçº³å…¥çš„ç ”ç©¶æ•°é‡æœ‰é™ï¼Œè¿™äº›ç ”ç©¶ç»“æœåº”è°¨æ…å¯¹å¾…ã€‚éœ€è¦åœ¨å…¶ä»–å¤§é™†è¿›è¡Œæ›´å¤šéšæœºå¯¹ç…§è¯•éªŒæ¥éªŒè¯çŒè‚ å¯¹ LARS çš„å½±å“ï¼Œå¹¶åˆ¶å®šæ ‡å‡†åŒ–æ–¹æ¡ˆä»¥ä¿ƒè¿›ä¸´åºŠå®è·µã€‚\n\n**Prospero registrationï¼š** CRD42024539973ã€‚", "keywords_zh": "çŒè‚ ï¼Œä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ŒèŸèƒåˆ†æï¼Œç›´è‚ åˆ‡é™¤æœ¯", "keywords_en": "Enema, Low anterior resection syndrome, Meta-analysis, Rectal resection", "link": "https://pubmed.ncbi.nlm.nih.gov/40410673/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 23 May 2025"}, {"id": "40407946", "title_en": "Simultaneous robotic-assisted prostatectomy and rectal resection: a systematic review", "title_zh": "æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯åŒæ—¶è¿›è¡Œï¼šç³»ç»Ÿè¯„ä»·", "authors": "Matthew J Roberts", "abstract_en": "Prostate cancer (PC) and rectal cancer (RC) are common and can require complex management, especially when presenting synchronously or with invasive characteristics. Robotic surgery has emerged as a viable option for managing these challenging cases; however, the outcomes are yet to be summarised or compared to traditional approaches. This systematic review aims to evaluate the feasibility, oncological outcomes, and functional results of simultaneous robotic-assisted resections of the prostate and rectum. Following prior protocol registration (PROSPERO: CRD42023449872) and according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, we conducted a systematic search across multiple databases, selecting studies that involved simultaneous bladder-sparing robotic-assisted prostatectomy and rectal resection. The Joanna Briggs Institute tool was used for risk of bias assessment. Data on patient demographics, treatment details, post-operative course, and functional and oncological outcomes were extracted and analysed. From 1357 identified records, 25 studies met our inclusion criteria resulting in 45 cases/patients. The median patient age was 62Â years. Diverse treatment backgrounds and outcome definitions were recorded. Median operative time was 548Â min and median estimated blood loss was 450Â mL. The overall complication rate was 44.4%, with major complications (Clavien-Dindo III) occurring in 17.8% of cases. Surgical margins were negative in 92.6% of cases. Continence recovery occurred for most (78.6%) of the cases reporting on urinary function. Simultaneous robotic-assisted prostatectomy and rectal resection appears to be a feasible, safe and oncologically effective approach with satisfactory oncological and functional outcomes for managing patients with synchronous or invasive PC and RC.", "abstract_zh": "å‰åˆ—è…ºç™Œ (PC) å’Œç›´è‚ ç™Œ (RC) å¾ˆå¸¸è§ï¼Œå¯èƒ½éœ€è¦å¤æ‚çš„æ²»ç–—ï¼Œç‰¹åˆ«æ˜¯åœ¨åŒæ—¶å‡ºç°æˆ–å…·æœ‰ä¾µè¢­æ€§ç‰¹å¾æ—¶ã€‚æœºå™¨äººæ‰‹æœ¯å·²æˆä¸ºå¤„ç†è¿™äº›å…·æœ‰æŒ‘æˆ˜æ€§çš„ç—…ä¾‹çš„å¯è¡Œé€‰æ‹©ï¼›ç„¶è€Œï¼Œç»“æœå°šæœªæ€»ç»“æˆ–ä¸ä¼ ç»Ÿæ–¹æ³•è¿›è¡Œæ¯”è¾ƒã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨è¯„ä¼°æœºå™¨äººè¾…åŠ©åŒæ­¥å‰åˆ—è…ºå’Œç›´è‚ åˆ‡é™¤æœ¯çš„å¯è¡Œæ€§ã€è‚¿ç˜¤å­¦ç»“æœå’ŒåŠŸèƒ½ç»“æœã€‚åœ¨å…ˆå‰çš„æ–¹æ¡ˆæ³¨å†Œï¼ˆPROSPEROï¼šCRD42023449872ï¼‰ä¹‹åå¹¶æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼ˆPRISMAï¼‰æŒ‡å—ï¼Œæˆ‘ä»¬åœ¨å¤šä¸ªæ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæœç´¢ï¼Œé€‰æ‹©æ¶‰åŠåŒæ—¶ä¿ç•™è†€èƒ±çš„æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯çš„ç ”ç©¶ã€‚ä¹”å®‰å¨œÂ·å¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€å·¥å…·ç”¨äºè¯„ä¼°åå·®é£é™©ã€‚æå–å¹¶åˆ†æäº†æ‚£è€…äººå£ç»Ÿè®¡ã€æ²»ç–—ç»†èŠ‚ã€æœ¯åç—…ç¨‹ä»¥åŠåŠŸèƒ½å’Œè‚¿ç˜¤ç»“æœçš„æ•°æ®ã€‚ä» 1357 ä»½å·²ç¡®å®šçš„è®°å½•ä¸­ï¼Œæœ‰ 25 é¡¹ç ”ç©¶ç¬¦åˆæˆ‘ä»¬çš„çº³å…¥æ ‡å‡†ï¼Œå…± 45 ä¾‹/æ‚£è€…ã€‚æ‚£è€…å¹´é¾„ä¸­ä½æ•°ä¸º 62 å²ã€‚è®°å½•äº†ä¸åŒçš„æ²»ç–—èƒŒæ™¯å’Œç»“æœå®šä¹‰ã€‚ä¸­ä½æ‰‹æœ¯æ—¶é—´ä¸º 548 åˆ†é’Ÿï¼Œä¸­ä½ä¼°è®¡å¤±è¡€é‡ä¸º 450 mLã€‚æ€»ä½“å¹¶å‘ç—‡å‘ç”Ÿç‡ä¸º44.4%ï¼Œå…¶ä¸­ä¸»è¦å¹¶å‘ç—‡ï¼ˆClavien-Dindo IIIï¼‰å‘ç”Ÿç‡ä¸º17.8%ã€‚ 92.6% çš„ç—…ä¾‹æ‰‹æœ¯åˆ‡ç¼˜å‘ˆé˜´æ€§ã€‚å¤§å¤šæ•°ï¼ˆ78.6%ï¼‰æŠ¥å‘Šæ³Œå°¿åŠŸèƒ½çš„ç—…ä¾‹å‡æ¢å¤äº†å¤±ç¦ã€‚åŒæ­¥æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯ä¼¼ä¹æ˜¯ä¸€ç§å¯è¡Œã€å®‰å…¨ä¸”è‚¿ç˜¤å­¦æœ‰æ•ˆçš„æ–¹æ³•ï¼Œå¯¹äºæ²»ç–—åŒæ­¥æˆ–ä¾µå…¥æ€§ PC å’Œ RC æ‚£è€…å…·æœ‰ä»¤äººæ»¡æ„çš„è‚¿ç˜¤å­¦å’ŒåŠŸèƒ½ç»“æœã€‚", "keywords_zh": "è…¹ä¼šé˜´åˆ‡é™¤æœ¯ï¼ˆAPRï¼‰ã€å‰åˆ‡é™¤æœ¯ï¼ˆARï¼‰ã€å‰åˆ—è…ºç™Œã€å‰åˆ—è…ºåˆ‡é™¤æœ¯ã€ç›´è‚ ç™Œã€æœºå™¨äººæ‰‹æœ¯", "keywords_en": "Abdominoperineal resection (APR), Anterior resection (AR), Prostate cancer, Prostatectomy, Rectal cancer, Robotic surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40407946/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 23 May 2025"}, {"id": "40371426", "title_en": "Prostate biopsy in patients without rectal access: a systematic review and proportional meta-analysis", "title_zh": "æ— ç›´è‚ å…¥è·¯æ‚£è€…çš„å‰åˆ—è…ºæ´»æ£€ï¼šç³»ç»Ÿè¯„ä»·å’Œæ¯”ä¾‹èŸèƒåˆ†æ", "authors": "Dionysios Mitropoulos", "abstract_en": "**Introduction:** Historically, the anal canal plays a substantial role in both screening and diagnosis of pro-state cancer with digital rectal examination (DRE) and transrectal ultrasound (TRUS) guided biopsy, respectively. However, in patients with a prior history of abdominoperineal resection the transrectal route towards the prostate capsule cannot be utilized and thus alternative approaches have to be employed. The aim of this systematic review and proportional meta-analysis is to evaluate the available alternative prostate biopsy techniques in patients without rectal access.\n\n**Material And Methods:** The systematic literature review was performed using MEDLINE, Scopus, EMBASE, and the CENTRAL register for randomized controlled trials (RCTs). The following search algorithm was used: \"resection of rectum\" OR \"abdominoperineal resection\" OR \"without rectal access\" AND \"prostate biopsy\" (PROSPERO 2023 CRD42023459080).\n\n**Results:** A total of 21 studies and 203 patients were included in this systematic review and meta-analysis, while 6 different prostate biopsy techniques were detected in the current literature. The transperineal approach under transperineal US (TPUS) and the transgluteal approach guided by computed tomography (CT) were associated with 0.74 [0.48; 0.94] and 0.70 [0.49; 0.89] pooled diagnostic yield estimates as well as 0.01 [0.00; 0.01] and 0 [0.00; 0.01] pooled complication rate estimates. The performance of multiparametric magnetic resonance imaging (mpMRI) prior to transgluteal CT-guided prostate biopsy seemed to significantly affect the biopsy result (p = 0.0002).\n\n**Conclusions:** Based on current data, the TPUS-guided prostate biopsy has the highest pooled diagnostic yield estimate. However, this conclusion is based on poor evidence and more reliable and well-organized studies are needed to thoroughly explore this problem.", "abstract_zh": "**ä»‹ç»ï¼š** ä»å†å²ä¸Šçœ‹ï¼Œè‚›ç®¡åˆ†åˆ«åœ¨ç›´è‚ æŒ‡æ£€ï¼ˆDREï¼‰å’Œç»ç›´è‚ è¶…å£°ï¼ˆTRUSï¼‰å¼•å¯¼æ´»æ£€çš„å‰åˆ—è…ºç™Œç­›æŸ¥å’Œè¯Šæ–­ä¸­å‘æŒ¥ç€é‡è¦ä½œç”¨ã€‚ç„¶è€Œï¼Œå¯¹äºæ—¢å¾€æœ‰è…¹ä¼šé˜´åˆ‡é™¤å²çš„æ‚£è€…ï¼Œæ— æ³•åˆ©ç”¨ç»ç›´è‚ é€”å¾„åˆ°è¾¾å‰åˆ—è…ºå›Šï¼Œå› æ­¤å¿…é¡»é‡‡ç”¨æ›¿ä»£æ–¹æ³•ã€‚æœ¬ç³»ç»Ÿè¯„ä»·å’Œæ¯”ä¾‹èŸèƒåˆ†æçš„ç›®çš„æ˜¯è¯„ä¼°å¯¹äºæ²¡æœ‰ç›´è‚ é€šè·¯çš„æ‚£è€…å¯ç”¨çš„æ›¿ä»£å‰åˆ—è…ºæ´»æ£€æŠ€æœ¯ã€‚\n\n**Material and methodsï¼š** ä½¿ç”¨ MEDLINEã€Scopusã€EMBASE å’Œ CENTRAL æ³¨å†Œåº“è¿›è¡Œç³»ç»Ÿæ–‡çŒ®ç»¼è¿°ä»¥è¿›è¡Œéšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚ä½¿ç”¨ä»¥ä¸‹æœç´¢ç®—æ³•ï¼šâ€œç›´è‚ åˆ‡é™¤æœ¯â€æˆ–â€œè…¹ä¼šé˜´åˆ‡é™¤æœ¯â€æˆ–â€œæ— ç›´è‚ é€šè·¯â€å’Œâ€œå‰åˆ—è…ºæ´»æ£€â€(PROSPERO 2023 CRD42023459080)ã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æå…±çº³å…¥ 21 é¡¹ç ”ç©¶å’Œ 203 åæ‚£è€…ï¼ŒåŒæ—¶åœ¨å½“å‰æ–‡çŒ®ä¸­æ£€æµ‹åˆ° 6 ç§ä¸åŒçš„å‰åˆ—è…ºæ´»æ£€æŠ€æœ¯ã€‚ç»ä¼šé˜´è¶…å£° (TPUS) ä¸‹çš„ç»ä¼šé˜´å…¥è·¯å’Œè®¡ç®—æœºæ–­å±‚æ‰«æ (CT) å¼•å¯¼ä¸‹çš„ç»è‡€å…¥è·¯ä¸ 0.74 [0.48ï¼›0.74] ç›¸å…³ã€‚ 0.94]å’Œ0.70[0.49ï¼› 0.89] æ±‡æ€»è¯Šæ–­äº§é‡ä¼°è®¡å€¼ä»¥åŠ 0.01 [0.00ï¼›0.00ï¼› 0.01] å’Œ 0 [0.00ï¼› 0.01]åˆå¹¶å¹¶å‘ç—‡å‘ç”Ÿç‡ä¼°è®¡å€¼ã€‚ç»è‡€ CT å¼•å¯¼çš„å‰åˆ—è…ºæ´»æ£€ä¹‹å‰çš„å¤šå‚æ•°ç£å…±æŒ¯æˆåƒ (mpMRI) çš„è¡¨ç°ä¼¼ä¹æ˜¾ç€å½±å“æ´»æ£€ç»“æœ (p = 0.0002)ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®å½“å‰æ•°æ®ï¼ŒTPUS å¼•å¯¼çš„å‰åˆ—è…ºæ´»æ£€å…·æœ‰æœ€é«˜çš„æ±‡æ€»è¯Šæ–­ç‡ä¼°è®¡ã€‚ç„¶è€Œï¼Œè¿™ä¸€ç»“è®ºçš„è¯æ®ä¸è¶³ï¼Œéœ€è¦æ›´å¯é å’Œç»„ç»‡è‰¯å¥½çš„ç ”ç©¶æ¥å½»åº•æ¢è®¨è¿™ä¸ªé—®é¢˜ã€‚", "keywords_zh": "æ´»æ£€, å‰åˆ—è…º, å‰åˆ—è…ºç™Œ, ç»ä¼šé˜´, è¶…å£°æ³¢", "keywords_en": "biopsy, prostate, prostate cancer, transperineal, ultrasound", "link": "https://pubmed.ncbi.nlm.nih.gov/40371426/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 15 May 2025"}, {"id": "40347378", "title_en": "Effects of low anterior resection syndrome after colorectal cancer resections on health-related quality of life: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ ç™Œåˆ‡é™¤æœ¯åä½ä½å‰åˆ‡é™¤ç»¼åˆå¾å¯¹å¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S V Hosseini", "abstract_en": "**Background:** Low anterior resection syndrome (LARS) is a term that encompasses multidimensional bowel dysfunction that typically occurs following resections of rectum and distal parts of the colon. We aimed to systematically assess the available literature on the effects of bowel dysfunction after colorectal cancer (CRC) surgeries on health-related quality of life (HRQOL) and conduct a meta-analysis.\n\n**Methods:** Studies were included if they assessed patients who had undergone sphincter-preservation surgeries for CRC. Studies were eligible if they assessed bowel dysfunction using the LARS score and HRQOL using the European Organization for Research and Treatment Core Quality-of-Life Questionnaire (EORTC QLQ-C30).\n\n**Results:** Of 1410 reports, 28 studies were included. According to the analyses, patients with major LARS had lower global health status [weighted mean differences (WMD)â€‰=â€‰-â€‰10.98; 95% confidence interval (CI) -â€‰13.18, -â€‰8.79], physical functioning (WMDâ€‰=â€‰- 5.96; 95%Â CI - 7.40, - 4.52), role functioning (WMDâ€‰=â€‰- 10.59; 95%Â CI - 12.54, - 8.63), emotional functioning (WMDâ€‰=â€‰- 11.09; 95%Â CI - 14.34, 7.84), cognitive functioning (WMDâ€‰=â€‰- 9.27; 95%Â CI - 12.22, - 6.32), and social functioning (WMDâ€‰=â€‰- 15.73; 95%Â CI - 18.82, - 12.63) and higher scores of symptoms compared to patients with minor/no LARS.\n\n**Conclusions:** The study findings suggest that patients with major LARS experience worse HRQOL compared to those with minor/no LARS.\n\n**Registration:** PROSPERO, CRD42023479657.", "abstract_zh": "**èƒŒæ™¯ï¼š** ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰æ˜¯ä¸€ä¸ªæ¶µç›–å¤šç»´è‚ åŠŸèƒ½éšœç¢çš„æœ¯è¯­ï¼Œé€šå¸¸å‘ç”Ÿåœ¨ç›´è‚ å’Œç»“è‚ è¿œç«¯åˆ‡é™¤æœ¯åã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯ç³»ç»Ÿè¯„ä¼°å…³äºç»“ç›´è‚ ç™Œï¼ˆCRCï¼‰æ‰‹æœ¯åè‚ åŠŸèƒ½éšœç¢å¯¹å¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡ï¼ˆHRQOLï¼‰å½±å“çš„ç°æœ‰æ–‡çŒ®ï¼Œå¹¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** å¦‚æœä»–ä»¬è¯„ä¼°å› ç»“ç›´è‚ ç™Œæ¥å—æ‹¬çº¦è‚Œä¿ç•™æ‰‹æœ¯çš„æ‚£è€…ï¼Œåˆ™çº³å…¥ç ”ç©¶ã€‚å¦‚æœç ”ç©¶ä½¿ç”¨ LARS è¯„åˆ†å’Œ HRQOL ä½¿ç”¨æ¬§æ´²ç ”ç©¶å’Œæ²»ç–—ç»„ç»‡æ ¸å¿ƒç”Ÿæ´»è´¨é‡é—®å· (EORTC QLQ-C30) è¯„ä¼°è‚ é“åŠŸèƒ½éšœç¢ï¼Œåˆ™ç ”ç©¶åˆæ ¼ã€‚\n\n**ç»“æœï¼š** 1410 ä»½æŠ¥å‘Šä¸­çº³å…¥äº† 28 é¡¹ç ”ç©¶ã€‚æ ¹æ®åˆ†æï¼Œé‡åº¦ LARS æ‚£è€…çš„æ•´ä½“å¥åº·çŠ¶å†µè¾ƒä½[åŠ æƒå¹³å‡å·® (WMD)â€‰=â€‰-â€‰10.98ï¼› 95% ç½®ä¿¡åŒºé—´ (CI) -â€‰13.18, -â€‰8.79]ã€èº«ä½“åŠŸèƒ½ (WMDâ€‰=â€‰- 5.96; 95% CI - 7.40, - 4.52)ã€è§’è‰²åŠŸèƒ½ (WMDâ€‰=â€‰- 10.59; 95% CI - 12.54, - 8.63)ã€æƒ…ç»ªåŠŸèƒ½(WMDâ€‰=â€‰- 11.09; 95% CI - 14.34, 7.84)ã€è®¤çŸ¥åŠŸèƒ½ (WMDâ€‰=â€‰- 9.27; 95% CI - 12.22, - 6.32) å’Œç¤¾äº¤åŠŸèƒ½ (WMDâ€‰=â€‰- 15.73; 95% CI - 18.82, - 12.63ï¼‰ï¼Œä¸è½»å¾®/æ—  LARS çš„æ‚£è€…ç›¸æ¯”ï¼Œç—‡çŠ¶å¾—åˆ†æ›´é«˜ã€‚\n\n**ç»“è®ºï¼š** ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œä¸æ‚£æœ‰è½»å¾®/æ—  LARS çš„æ‚£è€…ç›¸æ¯”ï¼Œæ‚£æœ‰ä¸¥é‡ LARS çš„æ‚£è€…çš„ HRQOL è¾ƒå·®ã€‚\n\n**Registrationï¼š** æ™®æ´›æ–¯å½¼ç½—ï¼ŒCRD42023479657ã€‚", "keywords_zh": "ç»“ç›´è‚ è‚¿ç˜¤, ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾, èŸèƒåˆ†æ, ç”Ÿæ´»è´¨é‡, ç³»ç»Ÿè¯„ä»·", "keywords_en": "Colorectal neoplasms, Low anterior resection syndrome, Meta-analysis, Quality of life, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40347378/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 10 May 2025"}, {"id": "40330445", "title_en": "Perirectal spacers in radiotherapy for prostate cancer - a systematic review and meta-analysis", "title_zh": "ç›´è‚ å‘¨å›´é—´éš”ç‰©åœ¨å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¸­çš„åº”ç”¨â€”â€”ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Shahrokh F Shariat", "abstract_en": "**Introduction:** Perirectal spacers reduce the radiotherapy (RT) dose delivered to the rectum, but their impact on treatment toxicity remains debated. We conducted a systematic review and meta-analysis to synthesise emerging data (PROSPERO: CRD42024506380).\n\n**Material And Methods:** MEDLINE, Embase, Scopus, and Google Scholar were searched through 2024/08/18 for prospective randomised (RCT) and non-randomised trials evaluating the clinical outcomes of perirectal spacing in prostate cancer (PCa) patients. Random effects generalised linear mixed models were used to pool odds ratios (OR) for rectal adverse events (AEs) from RCTs. Non-randomised trials were summarised qualitatively. The risk of bias was assessed using the RoB2 and ROBINS-I tools.\n\n**Results:** Three RCTs (<i>n</i> = 645) were identified. The rates of grade â‰¥ 2 (G â‰¥ 2) rectal AEs in control groups were low, ranging 4.2-13.8% for early AEs and 0-1.4% for late AEs. Perirectal spacers were associated with decreased incidence of early G â‰¥ 2 rectal AEs (OR: 0.43; 95% CI: 0.19-0.96), but not of late G â‰¥ 2 rectal AEs (OR: 0.26; 95% CI: 0.02-2.91). Assuming a comparator risk of 7.1% and 1%, this corresponded to a number needed to treat of 26 patients to avoid one early AE, and 135 pa- tients to avoid one late G â‰¥ 2 AE, respectively. Randomised clinical trial were at moderate risk of bias due to concerns regarding the concealment of allocation.\n\n**Conclusions:** There is evidence that perirectal spacers result in a small decrease in acute rectal toxicity. However, modern RT for clinically localised PCa is generally well-tolerated, and severe AEs are rare. Greater scrutiny of the risks and benefits associated with perirectal spacers is necessary.", "abstract_zh": "**ä»‹ç»ï¼š** ç›´è‚ å‘¨å›´é—´éš”å™¨å¯å‡å°‘ç›´è‚ çš„æ”¾å°„æ²»ç–— (RT) å‰‚é‡ï¼Œä½†å…¶å¯¹æ²»ç–—æ¯’æ€§çš„å½±å“ä»å­˜åœ¨äº‰è®®ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¥ç»¼åˆæ–°å…´æ•°æ®ï¼ˆPROSPEROï¼šCRD42024506380ï¼‰ã€‚\n\n**Material and methodsï¼š** æˆªè‡³ 2024 å¹´ 8 æœˆ 18 æ—¥ï¼ŒMEDLINEã€Embaseã€Scopus å’Œ Google Scholar å‡æœç´¢äº†è¯„ä¼°å‰åˆ—è…ºç™Œ (PCa) æ‚£è€…ç›´è‚ å‘¨å›´é—´éš”ä¸´åºŠç»“æœçš„å‰ç»æ€§éšæœº (RCT) å’Œééšæœºè¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”å¹¿ä¹‰çº¿æ€§æ··åˆæ¨¡å‹æ¥æ±‡æ€»éšæœºå¯¹ç…§è¯•éªŒä¸­ç›´è‚ ä¸è‰¯äº‹ä»¶ (AE) çš„æ¯”å€¼æ¯” (OR)ã€‚å¯¹ééšæœºè¯•éªŒè¿›è¡Œäº†å®šæ€§æ€»ç»“ã€‚ä½¿ç”¨ RoB2 å’Œ ROBINS-I å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº†ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒ (<i>n</i> = 645)ã€‚å¯¹ç…§ç»„ä¸­ â‰¥ 2 çº§ (G â‰¥ 2) ç›´è‚  AE å‘ç”Ÿç‡è¾ƒä½ï¼Œæ—©æœŸ AE ä¸º 4.2-13.8%ï¼Œæ™šæœŸ AE ä¸º 0-1.4%ã€‚ç›´è‚ å‘¨å›´é—´éš”ç‰©ä¸æ—©æœŸ G â‰¥ 2 ç›´è‚  AE å‘ç”Ÿç‡é™ä½ç›¸å…³ï¼ˆORï¼š0.43ï¼›95% CIï¼š0.19-0.96ï¼‰ï¼Œä½†ä¸æ™šæœŸ G â‰¥ 2 ç›´è‚  AE å‘ç”Ÿç‡é™ä½æ— å…³ï¼ˆORï¼š0.26ï¼›95% CIï¼š0.02-2.91ï¼‰ã€‚å‡è®¾æ¯”è¾ƒé£é™©ä¸º 7.1% å’Œ 1%ï¼Œè¿™åˆ†åˆ«ç›¸å½“äºéœ€è¦æ²»ç–— 26 åæ‚£è€…ä»¥é¿å…ä¸€ç§æ—©æœŸ AE å’Œ 135 åæ‚£è€…ä»¥é¿å…ä¸€ç§æ™šæœŸ G â‰¥ 2 AEã€‚ç”±äºæ‹…å¿ƒåˆ†é…çš„éšè—ï¼Œéšæœºä¸´åºŠè¯•éªŒå­˜åœ¨ä¸­ç­‰åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** æœ‰è¯æ®è¡¨æ˜ï¼Œç›´è‚ å‘¨å›´å«ç‰‡å¯ä½¿æ€¥æ€§ç›´è‚ æ¯’æ€§å°å¹…é™ä½ã€‚ç„¶è€Œï¼Œç°ä»£æ”¾ç–—æ²»ç–—ä¸´åºŠå±€é™æ€§å‰åˆ—è…ºç™Œé€šå¸¸è€å—æ€§è‰¯å¥½ï¼Œä¸¥é‡çš„ AE å¾ˆå°‘è§ã€‚æœ‰å¿…è¦å¯¹ç›´è‚ å‘¨å›´é—´éš”ç‰©ç›¸å…³çš„é£é™©å’Œç›Šå¤„è¿›è¡Œæ›´ä¸¥æ ¼çš„å®¡æŸ¥ã€‚", "keywords_zh": "Barrigelã€ProSpaceã€SpaceOARã€æ€¥æ€§æ¯’æ€§ã€æ…¢æ€§æ¯’æ€§ã€èƒƒè‚ é“æ¯’æ€§", "keywords_en": "Barrigel, ProSpace, SpaceOAR, acute toxicity, chronic toxicity, gastrointestinal toxicity", "link": "https://pubmed.ncbi.nlm.nih.gov/40330445/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 07 May 2025"}, {"id": "40327435", "title_en": "Research Perspective on \"Social Determinants of Health in Diverticulitis: A Systematic Review\"", "title_zh": "â€œæ†©å®¤ç‚å¥åº·çš„ç¤¾ä¼šå†³å®šå› ç´ ï¼šç³»ç»Ÿå›é¡¾â€çš„ç ”ç©¶è§†è§’", "authors": "Ira L Leeds", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40327435/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 06 May 2025"}, {"id": "40269754", "title_en": "Risk factors for unplanned 31-day readmission after surgery for colorectal cancer patients: a meta-analysis", "title_zh": "ç»“ç›´è‚ ç™Œæ‚£è€…æœ¯å 31 å¤©éè®¡åˆ’å†å…¥é™¢çš„å±é™©å› ç´ ï¼šä¸€é¡¹èŸèƒåˆ†æ", "authors": "Liping Cui", "abstract_en": "**Background:** The high incidence of unplanned readmissions within 31Â days after colorectal cancer surgery remains a significant challenge. However, the identified risk factors for these readmissions are inconsistent across the literature. This study aims to perform a comprehensive meta-analysis to estimate the incidence of unplanned readmissions and systematically identify the factors associated with this risk, providing robust evidence for targeted interventions to reduce readmission rates.\n\n**Methods:** This study was conducted in accordance with the PRISMA guidelines. All study steps, including study selection, data extraction, and quality assessment, were independently performed by two authors, with any disagreements resolved through consultation with a third author. A comprehensive search for published studies was conducted across the following databases up to January 2025: VIP Journal Database, Wanfang Data, CNKI, SinoMed, PubMed, Embase, Web of Science, and the Cochrane Library. Statistical analyses were performed using RevMan 5.4 and Stata 17.0, with a p-value of less than 0.05 considered statistically significant.\n\n**Results:** This meta-analysis identified several significant risk factors associated with unplanned readmission during this period (Pâ€‰<â€‰0.05), including age (ORâ€‰=â€‰1.13), postoperative complications (ORâ€‰=â€‰1.87), tumor stage (TNMâ€‰â‰¥â€‰III) (ORâ€‰=â€‰2.01), tumor site in the rectum (ORâ€‰=â€‰1.64), stoma creation (ORâ€‰=â€‰1.70), Complicated diabetes (ORâ€‰=â€‰1.56), Charlson Comorbidity Index (CCI) (ORâ€‰=â€‰1.27), blood transfusion (BT) (ORâ€‰=â€‰1.24), Length of hospital stay (LOS) (ORâ€‰=â€‰1.65), and surgical approach (ORâ€‰=â€‰1.22). Notably, female (ORâ€‰=â€‰0.85) was identified as a protective factor against unplanned readmission.\n\n**Conclusion:** The unplanned readmission rate within 31Â days after colorectal cancer surgery was 11.73%. Current evidence suggests that age, postoperative complications, TNMâ€‰â‰¥â€‰III, tumor site in the rectum, stoma creation, complicated diabetes, Charlson Comorbidity Index (CCI), blood transfusion (BT), length of hospital stay (LOS), and surgical approach are significant risk factors for unplanned readmission. Conversely, female has been identified as a protective factor. To mitigate these risks and reduce readmission rates, healthcare professionals should implement targeted educational and clinical interventions.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ ç™Œæ‰‹æœ¯å 31 å¤©å†…æ„å¤–å†å…¥é™¢çš„é«˜å‘ç”Ÿç‡ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ã€‚ç„¶è€Œï¼Œæ–‡çŒ®ä¸­ç¡®å®šçš„è¿™äº›å†å…¥é™¢çš„é£é™©å› ç´ å¹¶ä¸ä¸€è‡´ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¿›è¡Œå…¨é¢çš„èŸèƒåˆ†æï¼Œä»¥ä¼°è®¡éè®¡åˆ’å†å…¥é™¢çš„å‘ç”Ÿç‡ï¼Œå¹¶ç³»ç»Ÿåœ°è¯†åˆ«ä¸è¯¥é£é™©ç›¸å…³çš„å› ç´ ï¼Œä¸ºé™ä½å†å…¥é™¢ç‡çš„é’ˆå¯¹æ€§å¹²é¢„æªæ–½æä¾›æœ‰åŠ›çš„è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç ”ç©¶æ˜¯æ ¹æ® PRISMA æŒ‡å—è¿›è¡Œçš„ã€‚æ‰€æœ‰ç ”ç©¶æ­¥éª¤ï¼ŒåŒ…æ‹¬ç ”ç©¶é€‰æ‹©ã€æ•°æ®æå–å’Œè´¨é‡è¯„ä¼°ï¼Œå‡ç”±ä¸¤ä½ä½œè€…ç‹¬ç«‹æ‰§è¡Œï¼Œä»»ä½•åˆ†æ­§å‡é€šè¿‡ä¸ç¬¬ä¸‰ä½ä½œè€…åå•†è§£å†³ã€‚å¯¹æˆªè‡³ 2025 å¹´ 1 æœˆçš„ä»¥ä¸‹æ•°æ®åº“ä¸­å·²å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼šVIP æœŸåˆŠæ•°æ®åº“ã€ä¸‡æ–¹æ•°æ®ã€CNKIã€SinoMedã€PubMedã€Embaseã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ã€‚ä½¿ç”¨ RevMan 5.4 å’Œ Stata 17.0 è¿›è¡Œç»Ÿè®¡åˆ†æï¼Œp å€¼å°äº 0.05 è¢«è®¤ä¸ºå…·æœ‰ç»Ÿè®¡æ˜¾ç€æ€§ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹èŸèƒåˆ†æç¡®å®šäº†åœ¨æ­¤æœŸé—´ä¸éè®¡åˆ’å†å…¥é™¢ç›¸å…³çš„å‡ ä¸ªé‡è¦å±é™©å› ç´ ï¼ˆPâ€‰<â€‰0.05ï¼‰ï¼ŒåŒ…æ‹¬å¹´é¾„ï¼ˆORâ€‰=â€‰1.13ï¼‰ã€æœ¯åå¹¶å‘ç—‡ï¼ˆORâ€‰=â€‰1.87ï¼‰ã€è‚¿ç˜¤åˆ†æœŸï¼ˆTNMâ€‰â‰¥â€‰IIIï¼‰ï¼ˆORâ€‰=â€‰2.01ï¼‰ã€ç›´è‚ è‚¿ç˜¤éƒ¨ä½(ORâ€‰=â€‰1.64)ã€é€ å£æœ¯ (ORâ€‰=â€‰1.70)ã€å¤æ‚æ€§ç³–å°¿ç—… (ORâ€‰=â€‰1.56)ã€æŸ¥å°”æ£®åˆå¹¶ç—‡æŒ‡æ•° (CCI) (ORâ€‰=â€‰1.27)ã€è¾“è¡€ (BT) (ORâ€‰=â€‰1.24)ã€ä½é™¢æ—¶é—´ (LOS) ï¼ˆORâ€‰=â€‰1.65ï¼‰å’Œæ‰‹æœ¯æ–¹æ³•ï¼ˆORâ€‰=â€‰1.22ï¼‰ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œå¥³æ€§ï¼ˆORâ€‰=â€‰0.85ï¼‰è¢«è®¤ä¸ºæ˜¯é˜²æ­¢æ„å¤–å†å…¥é™¢çš„ä¿æŠ¤å› ç´ ã€‚\n\n**ç»“è®ºï¼š** ç»“ç›´è‚ ç™Œæœ¯å31å¤©å†…éè®¡åˆ’å†å…¥é™¢ç‡ä¸º11.73%ã€‚ç›®å‰çš„è¯æ®è¡¨æ˜ï¼Œå¹´é¾„ã€æœ¯åå¹¶å‘ç—‡ã€TNMâ€‰â‰¥â€‰IIIã€ç›´è‚ è‚¿ç˜¤éƒ¨ä½ã€é€ å£åˆ›å»ºã€å¹¶å‘ç³–å°¿ç—…ã€æŸ¥å°”æ£®åˆå¹¶ç—‡æŒ‡æ•°ï¼ˆCCIï¼‰ã€è¾“è¡€ï¼ˆBTï¼‰ã€ä½é™¢æ—¶é—´ï¼ˆLOSï¼‰å’Œæ‰‹æœ¯æ–¹å¼æ˜¯éè®¡åˆ’å†å…¥é™¢çš„é‡è¦å±é™©å› ç´ ã€‚ç›¸åï¼Œå¥³æ€§è¢«è®¤ä¸ºæ˜¯ä¸€ä¸ªä¿æŠ¤å› ç´ ã€‚ä¸ºäº†å‡è½»è¿™äº›é£é™©å¹¶é™ä½å†å…¥é™¢ç‡ï¼ŒåŒ»ç–—ä¿å¥ä¸“ä¸šäººå‘˜åº”å®æ–½æœ‰é’ˆå¯¹æ€§çš„æ•™è‚²å’Œä¸´åºŠå¹²é¢„æªæ–½ã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œã€èŸèƒåˆ†æã€å±é™©å› ç´ ã€éè®¡åˆ’å†å…¥é™¢", "keywords_en": "Colorectal cancer, Meta-analysis, Risk factors, Unplanned readmission", "link": "https://pubmed.ncbi.nlm.nih.gov/40269754/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 24 Apr 2025"}, {"id": "40260850", "title_en": "Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer", "title_zh": "åœ¨å®¶ä¸­ä¸åœ¨åŒ»é™¢æˆ–ç¤¾åŒºç¯å¢ƒä¸­ä¸ºæˆäººç™Œç—‡æ‚£è€…æä¾›é™è„‰æŠ—ç™Œæ²»ç–—", "authors": "Rachelle Buchbinder", "abstract_en": "**Background:** Intravenous (IV) chemotherapy and immunotherapy are administered at frequent, regular intervals (weekly to four-weekly) for 4 to 24 months, with treatment sessions lasting between 20 minutes and several hours for adults with cancer. These treatments are usually given in chemotherapy day units in hospitals as same-day treatments. However, less complex anti-cancer therapy regimens may be administered in the participant's home.\n\n**Objectives:** To assess the safety, patient preference for, and cost of IV (including subcutaneous) anti-cancer therapy (chemotherapy or immunotherapy) delivered at home as an alternative to the same IV anti-cancer therapy regimen delivered in a hospital or community setting in adults with cancer.\n\n**Search Methods:** We searched CENTRAL, Cochrane Database of Systematic Reviews, MEDLINE, Embase, CINAHL, NHS Economic Evaluation Database, Cost-Effectiveness Analysis Registry and trial registries (ClinicalTrials.gov and WHO-ICTRP) from inception until 16 October 2024. We also searched PDQ Evidence and Epistemonikos for related systematic reviews. We screened reference lists of included studies and relevant systematic reviews.\n\n**Selection Criteria:** We included randomised parallel and cross-over trials, conducted in adults (aged 18 years and over) diagnosed with any type and stage of cancer requiring IV anti-cancer chemotherapy or immunotherapy. Eligible studies compared delivery of IV anti-cancer therapy at home with delivery of the same therapy in a hospital setting (as an inpatient or outpatient), or in the community setting (e.g. GP practice, community clinic). We included economic evaluation studies (i.e. cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses) conducted alongside eligible effectiveness studies. Primary outcomes were adverse events, hospital inpatient admission and additional hospital attendance (e.g. emergency department visit) within 48 hours of administration of anti-cancer therapy, IV line complications, participant preference, and cost of delivering IV anti-cancer therapy from a healthcare system perspective.\n\n**Data Collection And Analysis:** Two review authors selected studies for inclusion, extracted trial characteristics and numerical data, assessed risk of bias, and judged the certainty of evidence using the GRADE approach. The main comparison was delivery of IV anti-cancer therapy at home versus in a hospital outpatient clinic. The primary time points of interest for outcomes related to serious adverse events, complications and cost were those collected at the longest follow-up postintervention. For outcomes such as participant preference, participant quality of life, participant and caregiver satisfaction, and non-adherence to the treatment regimen, data collected at time points as soon as possible after the intervention were of primary interest.\n\n**Main Results:** We identified seven eligible trials (three parallel RCTs, four randomised cross-over trials; 401 randomised participants, with 272 participants included in the final analyses) and five ongoing trials. Five included trials were performed prior to the 2000s and two were performed between 2007 and 2011. Trial participants' mean age ranged from 60 to 70 years. Four trials recruited a mix of cancer patients, including breast, colon, rectum, pancreatic, pancreaticobiliary, non-Hodgkin's lymphoma, lung, and head and neck cancer. Three trials focused on specific cancers (i.e. colorectal cancer, breast cancer, colon cancer). Seven trials compared delivery of IV anti-cancer therapy at home versus in a hospital outpatient clinic. One trial compared delivery of IV anti-cancer therapy in the participant's home, in the hospital outpatient clinic, and in local general practice surgery. All participants were assessed either by a physician or trained chemotherapy nurse prior to receiving each treatment cycle, and trained chemotherapy nurses administered the therapy, as per standard clinical practice, in all settings in all trials. We judged three trials as having low overall risk of bias. In four trials, the overall risk of bias was unclear due to poorly reported study methods, failing to report assessed data points and inaccessible study protocols. Due to the very low certainty of the evidence, we are uncertain of the effect of delivering IV anti-cancer therapy at home versus in the hospital outpatient clinic on the response to and management of adverse events, on both hospital inpatient admission and additional hospital attendance within 48 hours of administration of anti-cancer therapy, and on IV line complications (including infection and thrombosis). Based on low-certainty evidence, participants receiving therapy at home may be more likely to prefer future treatments at home, after receiving treatment in this setting (35 more per 100, 10 to 70 more; data from 1 RCT with 65 participants). Based on low-certainty evidence, delivering IV anti-cancer therapy at home may make little or no difference to the cost of the treatment from the healthcare system perspective in comparison to delivering it in the hospital outpatient clinic (mean cost (in 2022 Australian dollars (AUD)) per treatment at home: 126 AUD less; 1798 AUD less to 1546 AUD more; data from 2 RCTs with 80 participants). We are uncertain of the effect of delivering IV anti-cancer therapy at home, versus a local GP surgery, on the response to and management of adverse events. No studies reported on hospital inpatient admission. Evidence on additional hospital attendance within 48 hours of administration of anti-cancer therapy is of very low certainty. Low-certainty evidence suggests that compared to receiving treatment in a local GP surgery, participants may or may not be more likely to prefer future treatments at home, and delivering anti-cancer therapy at home may make little or no difference to the cost of the treatment.\n\n**Authors' Conclusions:** Evidence on the safety and cost-effectiveness of IV anti-cancer therapy at home is scarce and outdated. IV anti-cancer regimens have evolved; the findings of studies performed more than a decade ago may lack applicability to current practice. However, key considerations when considering suitability for home treatment remain unchanged: safety, duration of treatment and geographic catchment area. The finding that patients may prefer future treatments at home after receiving treatment in this setting, albeit based upon low-certainty evidence, is consistent with the widespread current practice of delivering IV anti-cancer therapy, including immunotherapies, at home when judged safe and preferred by the patient. Appropriate selection of patients and regimens is a key consideration for ensuring the safety of delivering IV anti-cancer therapy at home.", "abstract_zh": "**èƒŒæ™¯ï¼š** é™è„‰ (IV) åŒ–ç–—å’Œå…ç–«ç–—æ³•ä»¥é¢‘ç¹ã€æœ‰è§„å¾‹çš„é—´éš”ï¼ˆæ¯å‘¨è‡³æ¯å››å‘¨ï¼‰è¿›è¡Œï¼ŒæŒç»­ 4 è‡³ 24 ä¸ªæœˆï¼Œå¯¹äºæˆäººç™Œç—‡æ‚£è€…ï¼Œæ²»ç–—æŒç»­ 20 åˆ†é’Ÿè‡³å‡ ä¸ªå°æ—¶ã€‚è¿™äº›æ²»ç–—é€šå¸¸åœ¨åŒ»é™¢çš„åŒ–ç–—æ—¥é—´å•ä½ä½œä¸ºå½“å¤©æ²»ç–—è¿›è¡Œã€‚ç„¶è€Œï¼Œä¸å¤ªå¤æ‚çš„æŠ—ç™Œæ²»ç–—æ–¹æ¡ˆå¯ä»¥åœ¨å‚ä¸è€…çš„å®¶ä¸­è¿›è¡Œã€‚\n\n**Objectivesï¼š** è¯„ä¼°åœ¨å®¶ä¸­è¿›è¡Œçš„é™è„‰æ³¨å°„ï¼ˆåŒ…æ‹¬çš®ä¸‹ï¼‰æŠ—ç™Œæ²»ç–—ï¼ˆåŒ–ç–—æˆ–å…ç–«æ²»ç–—ï¼‰çš„å®‰å…¨æ€§ã€æ‚£è€…åå¥½å’Œè´¹ç”¨ï¼Œä½œä¸ºæˆäººç™Œç—‡æ‚£è€…åœ¨åŒ»é™¢æˆ–ç¤¾åŒºç¯å¢ƒä¸­è¿›è¡Œçš„ç›¸åŒé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—æ–¹æ¡ˆçš„æ›¿ä»£æ–¹æ¡ˆã€‚\n\n**Search methodsï¼š** æˆ‘ä»¬æ£€ç´¢äº† CENTRALã€Cochrane ç³»ç»Ÿè¯„ä»·æ•°æ®åº“ã€MEDLINEã€Embaseã€CINAHLã€NHS ç»æµè¯„ä¼°æ•°æ®åº“ã€æˆæœ¬æ•ˆç›Šåˆ†ææ³¨å†Œä¸­å¿ƒå’Œè¯•éªŒæ³¨å†Œä¸­å¿ƒï¼ˆClinicalTrials.gov å’Œ WHO-ICTRPï¼‰ï¼Œä»å¼€å§‹åˆ° 2024 å¹´ 10 æœˆ 16 æ—¥ã€‚æˆ‘ä»¬è¿˜æ£€ç´¢äº† PDQ Evidence å’Œ Epistemonikos ä»¥è·å–ç›¸å…³çš„ç³»ç»Ÿè¯„ä»·ã€‚æˆ‘ä»¬ç­›é€‰äº†çº³å…¥ç ”ç©¶çš„å‚è€ƒæ–‡çŒ®åˆ—è¡¨å’Œç›¸å…³çš„ç³»ç»Ÿè¯„ä»·ã€‚\n\n**Selection criteriaï¼š** æˆ‘ä»¬çº³å…¥äº†éšæœºå¹³è¡Œå’Œäº¤å‰è¯•éªŒï¼Œè¿™äº›è¯•éªŒåœ¨è¯Šæ–­ä¸ºä»»ä½•ç±»å‹å’Œé˜¶æ®µçš„ç™Œç—‡ä¸”éœ€è¦é™è„‰æ³¨å°„æŠ—ç™ŒåŒ–ç–—æˆ–å…ç–«æ²»ç–—çš„æˆäººï¼ˆ18 å²åŠä»¥ä¸Šï¼‰ä¸­è¿›è¡Œã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶å°†åœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸åœ¨åŒ»é™¢ç¯å¢ƒï¼ˆä½é™¢æ‚£è€…æˆ–é—¨è¯Šæ‚£è€…ï¼‰æˆ–ç¤¾åŒºç¯å¢ƒï¼ˆä¾‹å¦‚å…¨ç§‘åŒ»ç”Ÿè¯Šæ‰€ã€ç¤¾åŒºè¯Šæ‰€ï¼‰ä¸­è¿›è¡Œç›¸åŒçš„æ²»ç–—è¿›è¡Œäº†æ¯”è¾ƒã€‚æˆ‘ä»¬çº³å…¥äº†ä¸åˆæ ¼çš„æœ‰æ•ˆæ€§ç ”ç©¶ä¸€èµ·è¿›è¡Œçš„ç»æµè¯„ä¼°ç ”ç©¶ï¼ˆå³æˆæœ¬æ•ˆç›Šåˆ†æã€æˆæœ¬æ•ˆç”¨åˆ†æã€æˆæœ¬æ•ˆç›Šåˆ†æï¼‰ã€‚ä¸»è¦ç»“å±€æ˜¯æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…çš„ä¸è‰¯äº‹ä»¶ã€ä½é™¢æ‚£è€…å…¥é™¢å’Œé¢å¤–å°±è¯Šï¼ˆä¾‹å¦‚æ€¥è¯Šç§‘å°±è¯Šï¼‰ã€IV çº¿å¹¶å‘ç—‡ã€å‚ä¸è€…åå¥½ä»¥åŠä»åŒ»ç–—ä¿å¥ç³»ç»Ÿè§’åº¦æä¾› IV æŠ—ç™Œæ²»ç–—çš„æˆæœ¬ã€‚\n\n**Data collection and analysisï¼š** ä¸¤ä½ç»¼è¿°ä½œè€…é€‰æ‹©çº³å…¥ç ”ç©¶ï¼Œæå–è¯•éªŒç‰¹å¾å’Œæ•°å€¼æ•°æ®ï¼Œè¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ GRADE æ–¹æ³•åˆ¤æ–­è¯æ®çš„ç¡®å®šæ€§ã€‚ä¸»è¦æ¯”è¾ƒæ˜¯åœ¨å®¶ä¸­ä¸åœ¨åŒ»é™¢é—¨è¯Šè¯Šæ‰€è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ã€‚ä¸ä¸¥é‡ä¸è‰¯äº‹ä»¶ã€å¹¶å‘ç—‡å’Œè´¹ç”¨ç›¸å…³çš„ç»“æœçš„ä¸»è¦å…³æ³¨æ—¶é—´ç‚¹æ˜¯åœ¨å¹²é¢„åæœ€é•¿çš„éšè®¿ä¸­æ”¶é›†çš„æ—¶é—´ç‚¹ã€‚å¯¹äºå‚ä¸è€…åå¥½ã€å‚ä¸è€…ç”Ÿæ´»è´¨é‡ã€å‚ä¸è€…å’ŒæŠ¤ç†äººå‘˜æ»¡æ„åº¦ä»¥åŠä¸éµå®ˆæ²»ç–—æ–¹æ¡ˆç­‰ç»“æœï¼Œå¹²é¢„åå°½å¿«åœ¨æ—¶é—´ç‚¹æ”¶é›†çš„æ•°æ®æ˜¯ä¸»è¦å…³æ³¨ç‚¹ã€‚\n\n**Main resultsï¼š** æˆ‘ä»¬ç¡®å®šäº† 7 é¡¹ç¬¦åˆæ¡ä»¶çš„è¯•éªŒï¼ˆ3 é¡¹å¹³è¡Œéšæœºå¯¹ç…§è¯•éªŒã€4 é¡¹éšæœºäº¤å‰è¯•éªŒï¼›401 åéšæœºå—è¯•è€…ï¼Œå…¶ä¸­ 272 åå—è¯•è€…çº³å…¥æœ€ç»ˆåˆ†æï¼‰å’Œ 5 é¡¹æ­£åœ¨è¿›è¡Œçš„è¯•éªŒã€‚å…¶ä¸­äº”é¡¹è¯•éªŒæ˜¯åœ¨ 2000 å¹´ä»£ä¹‹å‰è¿›è¡Œçš„ï¼Œä¸¤é¡¹è¯•éªŒæ˜¯åœ¨ 2007 å¹´è‡³ 2011 å¹´ä¹‹é—´è¿›è¡Œçš„ã€‚è¯•éªŒå‚ä¸è€…çš„å¹³å‡å¹´é¾„ä¸º 60 å²è‡³ 70 å²ã€‚å››é¡¹è¯•éªŒæ‹›å‹Ÿäº†å¤šç§ç™Œç—‡æ‚£è€…ï¼ŒåŒ…æ‹¬ä¹³è…ºç™Œã€ç»“è‚ ç™Œã€ç›´è‚ ç™Œã€èƒ°è…ºç™Œã€èƒ°èƒ†ç™Œã€ééœå¥‡é‡‘æ·‹å·´ç˜¤ã€è‚ºç™Œå’Œå¤´é¢ˆç™Œã€‚ä¸‰é¡¹è¯•éªŒä¾§é‡äºç‰¹å®šç™Œç—‡ï¼ˆå³ç»“ç›´è‚ ç™Œã€ä¹³è…ºç™Œã€ç»“è‚ ç™Œï¼‰ã€‚ä¸ƒé¡¹è¯•éªŒæ¯”è¾ƒäº†åœ¨å®¶å’ŒåŒ»é™¢é—¨è¯Šè¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ã€‚ä¸€é¡¹è¯•éªŒæ¯”è¾ƒäº†åœ¨å‚ä¸è€…å®¶ä¸­ã€åŒ»é™¢é—¨è¯Šè¯Šæ‰€å’Œå½“åœ°å…¨ç§‘æ‰‹æœ¯ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—çš„æƒ…å†µã€‚åœ¨æ¥å—æ¯ä¸ªæ²»ç–—å‘¨æœŸä¹‹å‰ï¼Œæ‰€æœ‰å‚ä¸è€…å‡ç”±åŒ»ç”Ÿæˆ–ç»è¿‡åŸ¹è®­çš„åŒ–ç–—æŠ¤å£«è¿›è¡Œè¯„ä¼°ï¼Œå¹¶ç”±ç»è¿‡åŸ¹è®­çš„åŒ–ç–—æŠ¤å£«æŒ‰ç…§æ ‡å‡†ä¸´åºŠå®è·µåœ¨æ‰€æœ‰è¯•éªŒçš„æ‰€æœ‰ç¯å¢ƒä¸­è¿›è¡Œæ²»ç–—ã€‚æˆ‘ä»¬åˆ¤æ–­ä¸‰é¡¹è¯•éªŒæ€»ä½“åå€šé£é™©è¾ƒä½ã€‚åœ¨å››é¡¹è¯•éªŒä¸­ï¼Œç”±äºç ”ç©¶æ–¹æ³•æŠ¥å‘Šä¸å……åˆ†ã€æœªèƒ½æŠ¥å‘Šè¯„ä¼°çš„æ•°æ®ç‚¹ä»¥åŠæ— æ³•è·å–çš„ç ”ç©¶æ–¹æ¡ˆï¼Œæ€»ä½“åå€šé£é™©å°šä¸æ¸…æ¥šã€‚ç”±äºè¯æ®çš„è´¨é‡éå¸¸ä½ï¼Œæˆ‘ä»¬ä¸ç¡®å®šåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸åœ¨åŒ»é™¢é—¨è¯Šè¿›è¡Œæ²»ç–—ç›¸æ¯”ï¼Œå¯¹ä¸è‰¯äº‹ä»¶çš„ååº”å’Œç®¡ç†ã€æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…ä½é™¢æ‚£è€…å…¥é™¢å’Œé¢å¤–å°±è¯Šä»¥åŠé™è„‰æ³¨å°„å¹¶å‘ç—‡ï¼ˆåŒ…æ‹¬æ„ŸæŸ“å’Œè¡€æ “å½¢æˆï¼‰çš„å½±å“ã€‚æ ¹æ®ä½ç¡®å®šæ€§è¯æ®ï¼Œåœ¨å®¶æ¥å—æ²»ç–—çš„å‚ä¸è€…åœ¨è¿™ç§ç¯å¢ƒä¸‹æ¥å—æ²»ç–—åï¼Œå¯èƒ½æ›´å–œæ¬¢æœªæ¥åœ¨å®¶æ¥å—æ²»ç–—ï¼ˆæ¯ 100 äººä¸­å¤šå‡º 35 äººï¼Œå¤šå‡º 10 åˆ° 70 äººï¼›æ•°æ®æ¥è‡ª 1 é¡¹åŒ…å« 65 åå‚ä¸è€…çš„éšæœºå¯¹ç…§è¯•éªŒï¼‰ã€‚æ ¹æ®ä½ç¡®å®šæ€§è¯æ®ï¼Œä»åŒ»ç–—ä¿å¥ç³»ç»Ÿçš„è§’åº¦æ¥çœ‹ï¼Œä¸åœ¨åŒ»é™¢é—¨è¯Šè¿›è¡Œæ²»ç–—ç›¸æ¯”ï¼Œåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—å¯èƒ½å¯¹æ²»ç–—æˆæœ¬å‡ ä¹æ²¡æœ‰å½±å“æˆ–æ²¡æœ‰å½±å“ï¼ˆåœ¨å®¶æ¯æ¬¡æ²»ç–—çš„å¹³å‡æˆæœ¬ï¼ˆä»¥ 2022 å¹´æ¾³å…ƒ (AUD) è®¡ç®—ï¼‰ï¼šå°‘ 126 æ¾³å…ƒï¼›å°‘ 1798 æ¾³å…ƒè‡³å¤š 1546 æ¾³å…ƒï¼›æ•°æ®æ¥è‡ª 80 åå—è¯•è€…çš„ 2 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼‰ã€‚æˆ‘ä»¬ä¸ç¡®å®šåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸å½“åœ°å…¨ç§‘åŒ»ç”Ÿæ‰‹æœ¯ç›¸æ¯”ï¼Œå¯¹ä¸è‰¯äº‹ä»¶çš„ååº”å’Œç®¡ç†çš„å½±å“ã€‚æ²¡æœ‰ç ”ç©¶æŠ¥å‘Šä½é™¢æ‚£è€…çš„å…¥é™¢æƒ…å†µã€‚æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…é¢å¤–ä½é™¢çš„è¯æ®çš„ç¡®å®šæ€§éå¸¸ä½ã€‚ä½è´¨é‡è¯æ®è¡¨æ˜ï¼Œä¸åœ¨å½“åœ°å…¨ç§‘åŒ»ç”Ÿæ‰‹æœ¯ä¸­æ¥å—æ²»ç–—ç›¸æ¯”ï¼Œå‚ä¸è€…å¯èƒ½ä¼šæˆ–å¯èƒ½ä¸ä¼šæ›´å–œæ¬¢æœªæ¥åœ¨å®¶ä¸­çš„æ²»ç–—ï¼Œå¹¶ä¸”åœ¨å®¶æä¾›æŠ—ç™Œæ²»ç–—å¯èƒ½å¯¹æ‚£è€…æ¥è¯´å‡ ä¹æ²¡æœ‰å½±å“æˆ–æ²¡æœ‰å½±å“ã€‚\n\n**Authors' conclusionsï¼š** å…³äºå®¶åº­é™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—çš„å®‰å…¨æ€§å’Œæˆæœ¬æ•ˆç›Šçš„è¯æ®å¾ˆå°‘ä¸”å·²ç»è¿‡æ—¶ã€‚é™è„‰æ³¨å°„æŠ—ç™Œç–—æ³•å·²ç»å‘å±•ï¼›åå¤šå¹´å‰è¿›è¡Œçš„ç ”ç©¶ç»“æœå¯èƒ½ä¸é€‚ç”¨äºå½“å‰çš„å®è·µã€‚ç„¶è€Œï¼Œåœ¨è€ƒè™‘æ˜¯å¦é€‚åˆå®¶åº­æ²»ç–—æ—¶ï¼Œå…³é”®è€ƒè™‘å› ç´ ä¿æŒä¸å˜ï¼šå®‰å…¨æ€§ã€æ²»ç–—æŒç»­æ—¶é—´å’Œåœ°ç†è¦†ç›–åŒºåŸŸã€‚å°½ç®¡åŸºäºä½ç¡®å®šæ€§è¯æ®ï¼Œä½†æ‚£è€…åœ¨è¿™ç§æƒ…å†µä¸‹æ¥å—æ²»ç–—åå¯èƒ½æ›´å–œæ¬¢æœªæ¥åœ¨å®¶æ¥å—æ²»ç–—çš„å‘ç°ä¸å½“å‰å¹¿æ³›çš„åœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ï¼ˆåŒ…æ‹¬å…ç–«æ²»ç–—ï¼‰çš„åšæ³•æ˜¯ä¸€è‡´çš„ï¼Œå½“æ‚£è€…è®¤ä¸ºå®‰å…¨ä¸”é¦–é€‰æ—¶ï¼Œåœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ï¼ˆåŒ…æ‹¬å…ç–«æ²»ç–—ï¼‰ã€‚é€‚å½“é€‰æ‹©æ‚£è€…å’Œæ–¹æ¡ˆæ˜¯ç¡®ä¿åœ¨å®¶è¿›è¡Œé™è„‰æŠ—ç™Œæ²»ç–—å®‰å…¨çš„å…³é”®è€ƒè™‘å› ç´ ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40260850/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 22 Apr 2025"}, {"id": "40246613", "title_en": "Carbon Ion Radiotherapy Reirradiation for Recurrent Malignancy: A Systematic Assessment", "title_zh": "ç¢³ç¦»å­æ”¾å°„æ²»ç–—å†ç…§å°„æ²»ç–—å¤å‘æ€§æ¶æ€§è‚¿ç˜¤ï¼šç³»ç»Ÿè¯„ä¼°", "authors": "S Chen", "abstract_en": "Reirradiation presents a significant challenge despite recent advances in modern radiation therapy. Carbon ion radiotherapy has garnered increasing attention among radiation oncologists due to its potentially superior physical dosimetric distribution and radiobiological advantages. This systematic review comprehensively evaluated clinical outcomes from 27 original studies on the use of carbon ion reirradiation for locoregional recurrent malignancies, including those affecting the central nervous system, lung, head and neck, pancreas, liver, rectum, and gynecological sites. The findings suggest that carbon ion reirradiation for locoregional recurrent malignancies yields favorable clinical outcomes with a relatively low incidence of high-grade toxicities. For recurrent nasopharyngeal carcinoma, the reported 2-year overall survival, local control, regional control, and metastasis-free survival rates were 83.7%, 58.0%, 87.3%, and 94.7%, respectively. Grade â‰¥3 late nasopharyngeal necrosis occurred in 16% (33/206) of cases. In the case of recurrent glioblastoma, median overall survival and local control survival were reported at 13 and 7 months, respectively, with minimal high-grade complications; observed low-grade toxicities included acute involuntary movements, incomplete hemiparesis, and late-onset dysphasia. For recurrent lung cancer, 2-year local control and overall survival rates were reported as 54.0% and 61.9%, respectively. Grade â‰¥3 toxicities included two cases of radiation pneumonitis and one case of bronchopleural fistula. In recurrent pancreatic cancer, 1-year local control, progression-free survival, and overall survival rates were 53.5%, 24.5%, and 48.7%, respectively. A high-grade complication of Grade 3 acute duodenal stenosis was observed in one patient. Additionally, concurrent chemotherapy with carbon ion reirradiation was associated with minimal high-grade additive toxicities. Overall, carbon ion reirradiation appears to be a potentially safe and effective reirradiation modality for treating locoregional recurrent malignancies, though data remains limited.", "abstract_zh": "å°½ç®¡ç°ä»£æ”¾å°„æ²»ç–—æœ€è¿‘å–å¾—äº†è¿›å±•ï¼Œä½†å†æ”¾å°„ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ã€‚ç¢³ç¦»å­æ”¾å°„æ²»ç–—ç”±äºå…¶æ½œåœ¨çš„ä¼˜è¶Šçš„ç‰©ç†å‰‚é‡åˆ†å¸ƒå’Œæ”¾å°„ç”Ÿç‰©å­¦ä¼˜åŠ¿è€Œè¶Šæ¥è¶Šå—åˆ°æ”¾å°„è‚¿ç˜¤å­¦å®¶çš„å…³æ³¨ã€‚æœ¬ç³»ç»Ÿç»¼è¿°å…¨é¢è¯„ä¼°äº† 27 é¡¹å…³äºä½¿ç”¨ç¢³ç¦»å­å†ç…§å°„æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤çš„åŸå§‹ç ”ç©¶çš„ä¸´åºŠç»“æœï¼ŒåŒ…æ‹¬å½±å“ä¸­æ¢ç¥ç»ç³»ç»Ÿã€è‚ºã€å¤´é¢ˆã€èƒ°è…ºã€è‚è„ã€ç›´è‚ å’Œå¦‡ç§‘éƒ¨ä½çš„æ¶æ€§è‚¿ç˜¤ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œç¢³ç¦»å­å†ç…§å°„æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤å¯äº§ç”Ÿè‰¯å¥½çš„ä¸´åºŠç»“æœï¼Œä¸”é«˜çº§åˆ«æ¯’æ€§çš„å‘ç”Ÿç‡ç›¸å¯¹è¾ƒä½ã€‚å¯¹äºå¤å‘é¼»å’½ç™Œï¼ŒæŠ¥å‘Šçš„2å¹´æ€»ç”Ÿå­˜ç‡ã€å±€éƒ¨æ§åˆ¶ç‡ã€åŒºåŸŸæ§åˆ¶ç‡å’Œæ— è½¬ç§»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º83.7%ã€58.0%ã€87.3%å’Œ94.7%ã€‚ 16%ï¼ˆ33/206ï¼‰çš„ç—…ä¾‹å‘ç”Ÿâ‰¥3çº§æ™šæœŸé¼»å’½åæ­»ã€‚å¯¹äºå¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼Œä¸­ä½æ€»ç”Ÿå­˜æœŸå’Œå±€éƒ¨å¯¹ç…§ç”Ÿå­˜æœŸåˆ†åˆ«æŠ¥å‘Šä¸º 13 ä¸ªæœˆå’Œ 7 ä¸ªæœˆï¼Œä¸”é«˜åº¦å¹¶å‘ç—‡æå°‘ï¼›è§‚å¯Ÿåˆ°çš„ä½åº¦æ¯’æ€§åŒ…æ‹¬æ€¥æ€§ä¸è‡ªä¸»è¿åŠ¨ã€ä¸å®Œå…¨æ€§åç˜«å’Œè¿Ÿå‘æ€§è¯­è¨€éšœç¢ã€‚å¯¹äºå¤å‘æ€§è‚ºç™Œï¼Œ2 å¹´å±€éƒ¨æ§åˆ¶ç‡å’Œæ€»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º 54.0% å’Œ 61.9%ã€‚ â‰¥3çº§æ¯’æ€§åŒ…æ‹¬2ä¾‹æ”¾å°„æ€§è‚ºç‚å’Œ1ä¾‹æ”¯æ°”ç®¡èƒ¸è†œç˜˜ã€‚åœ¨å¤å‘æ€§èƒ°è…ºç™Œä¸­ï¼Œ1 å¹´å±€éƒ¨æ§åˆ¶ç‡ã€æ— è¿›å±•ç”Ÿå­˜ç‡å’Œæ€»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º 53.5%ã€24.5% å’Œ 48.7%ã€‚åœ¨ä¸€åæ‚£è€…ä¸­è§‚å¯Ÿåˆ° 3 çº§æ€¥æ€§åäºŒæŒ‡è‚ ç‹­çª„çš„é«˜çº§å¹¶å‘ç—‡ã€‚æ­¤å¤–ï¼ŒåŒæ­¥åŒ–ç–—ä¸ç¢³ç¦»å­å†ç…§å°„ä¸æœ€å°çš„é«˜çº§é™„åŠ æ¯’æ€§ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œç¢³ç¦»å­å†ç…§å°„ä¼¼ä¹æ˜¯æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤çš„ä¸€ç§æ½œåœ¨å®‰å…¨æœ‰æ•ˆçš„å†ç…§å°„æ–¹å¼ï¼Œå°½ç®¡æ•°æ®ä»ç„¶æœ‰é™ã€‚", "keywords_zh": "ç¢³ç¦»å­ã€ä¸´åºŠç»“æœã€å±€éƒ¨å¤å‘ã€æ¶æ€§è‚¿ç˜¤ã€å†ç…§å°„ã€æ¯’æ€§", "keywords_en": "Carbon ion, Clinical outcomes, Locoregional recurrence, Malignancy, Reirradiation, Toxicities", "link": "https://pubmed.ncbi.nlm.nih.gov/40246613/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 17 Apr 2025"}, {"id": "40246071", "title_en": "Implantable Rectal Spacers in Prostate Cancer Radiation Therapy: A Systematic Review", "title_zh": "å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¸­æ¤å…¥å¼ç›´è‚ é—´éš”å™¨ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Ben G L Vanneste", "abstract_en": "**Purpose:** This systematic review provides an overview of the available literature regarding the efficacy and safety of implantable rectal spacers (IRSs) in reducing rectal dose and gastrointestinal toxicity during prostate cancer radiation therapy.\n\n**Methods And Materials:** A comprehensive literature search was conducted in December 2024. Results included prospective research in humans and were limited to the English language. The 30 included studies, all published between 2007 and 2024, were randomized controlled trials or clinical trials that focused on adverse events, rectal dose reduction, gastrointestinal toxicity, or bowel quality of life. Next, IRS implantation technique, safety, and spacing distance were assessed.\n\n**Results:** Randomized controlled trial data were available for hydrogel, hyaluronic acid, and rectal balloon implant spacers, whereas only one pilot study is available for human collagen. Prospective clinical research on IRS in brachytherapy is limited. One centimeter of spacing between the rectum and prostate sufficed to spare the rectum, the primary dose-limiting organ. Findings indicate a favorable safety profile, with an overall complication rate of 0,96% when using hydrogel spacers. There was no grade 4 to 5 gastrointestinal toxicity reported in clinical trials. The use of an IRS was associated with improved long-term bowel quality of life.\n\n**Conclusions:** The integration of IRS into clinical practice offers the potential to enhance the therapeutic landscape for patients with prostate cancer. However, its use should be guided by careful consideration of individual patient needs to determine those who benefit most from the IRS because not all patients may benefit equally.", "abstract_zh": "**Purposeï¼š** æœ¬ç³»ç»Ÿç»¼è¿°æ¦‚è¿°äº†æœ‰å…³æ¤å…¥å¼ç›´è‚ é—´éš”å™¨ (IRS) åœ¨å‡å°‘å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—æœŸé—´ç›´è‚ å‰‚é‡å’Œèƒƒè‚ é“æ¯’æ€§æ–¹é¢çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§çš„ç°æœ‰æ–‡çŒ®ã€‚\n\n**Methods and materialsï¼š** 2024 å¹´ 12 æœˆè¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚ç»“æœåŒ…æ‹¬é’ˆå¯¹äººç±»çš„å‰ç»æ€§ç ”ç©¶ï¼Œä¸”ä»…é™äºè‹±è¯­ã€‚è¿™ 30 é¡¹çº³å…¥ç ”ç©¶å‡äº 2007 å¹´è‡³ 2024 å¹´æœŸé—´å‘è¡¨ï¼Œå‡ä¸ºéšæœºå¯¹ç…§è¯•éªŒæˆ–ä¸´åºŠè¯•éªŒï¼Œé‡ç‚¹å…³æ³¨ä¸è‰¯äº‹ä»¶ã€ç›´è‚ å‰‚é‡å‡å°‘ã€èƒƒè‚ é“æ¯’æ€§æˆ–è‚ é“ç”Ÿæ´»è´¨é‡ã€‚æ¥ä¸‹æ¥ï¼Œè¯„ä¼°äº† IRS æ¤å…¥æŠ€æœ¯ã€å®‰å…¨æ€§å’Œé—´è·ã€‚\n\n**ç»“æœï¼š** æ°´å‡èƒ¶ã€é€æ˜è´¨é…¸å’Œç›´è‚ çƒå›Šæ¤å…¥å«ç‰‡æœ‰éšæœºå¯¹ç…§è¯•éªŒæ•°æ®ï¼Œè€Œäººç±»èƒ¶åŸè›‹ç™½åªæœ‰ä¸€é¡¹åˆæ­¥ç ”ç©¶ã€‚ IRS åœ¨è¿‘è·ç¦»æ”¾å°„æ²»ç–—ä¸­çš„å‰ç»æ€§ä¸´åºŠç ”ç©¶æœ‰é™ã€‚ç›´è‚ å’Œå‰åˆ—è…ºä¹‹é—´ä¸€å˜ç±³çš„é—´è·è¶³ä»¥ä¿æŠ¤ç›´è‚ ï¼Œå³ä¸»è¦çš„å‰‚é‡é™åˆ¶å™¨å®˜ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œä½¿ç”¨æ°´å‡èƒ¶å«ç‰‡æ—¶çš„æ€»ä½“å¹¶å‘ç—‡ç‡ä¸º 0.96%ï¼Œå…·æœ‰è‰¯å¥½çš„å®‰å…¨æ€§ã€‚ä¸´åºŠè¯•éªŒä¸­æœªæŠ¥å‘Š4è‡³5çº§èƒƒè‚ é“æ¯’æ€§ã€‚ IRS çš„ä½¿ç”¨ä¸é•¿æœŸè‚ é“ç”Ÿæ´»è´¨é‡çš„æ”¹å–„ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** IRS èå…¥ä¸´åºŠå®è·µæœ‰å¯èƒ½æ”¹å–„å‰åˆ—è…ºç™Œæ‚£è€…çš„æ²»ç–—å‰æ™¯ã€‚ç„¶è€Œï¼Œå…¶ä½¿ç”¨åº”ä»”ç»†è€ƒè™‘ä¸ªä½“æ‚£è€…çš„éœ€æ±‚ï¼Œä»¥ç¡®å®šå“ªäº›äººä» IRS ä¸­å—ç›Šæœ€å¤§ï¼Œå› ä¸ºå¹¶éæ‰€æœ‰æ‚£è€…éƒ½å¯ä»¥å¹³ç­‰å—ç›Šã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40246071/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 17 Apr 2025"}, {"id": "40234278", "title_en": "Inflammatory myofibroblastic tumors of the colon in pediatrics: clinical presentation, management, and outcomes-A case report and systematic review of literature", "title_zh": "å„¿ç§‘ç»“è‚ ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒè‚¿ç˜¤ï¼šä¸´åºŠè¡¨ç°ã€æ²»ç–—å’Œç»“æœâ€”â€”ç—…ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Essam Elhalaby", "abstract_en": "**Purpose:** Inflammatory myofibroblastic tumors (IMTs) of the colon represent an exceptionally rare entity in the pediatric population. This systematic review aims to comprehensively analyze the clinical presentation, diagnostic workup, management strategies, and outcomes of colorectal IMTs in children.\n\n**Methods:** A systematic literature review was conducted across multiple electronic databases (inception to January 2025), including MEDLINE (via PubMed), Embase, Cochrane, Web of Science, and Google Scholar. Two independent reviewers screened abstracts, reviewed studies, and extracted data on all reported cases of colorectal IMTs in the pediatric population, including one previously unreported case from our institution.\n\n**Results:** Including our case, 53 pediatric patients with colorectal IMTs were identified from 39 studies. The mean age at diagnosis was 7 years (range: 5 months-17 years) with a slight female preponderance. The IMTs comprised a wide range of anatomic locations with rectum (27%) and ascending colon (24%) being the most common. Abdominal pain (54%), gastrointestinal bleeding (29%), and fever (21%) were the predominant symptoms. Anemia was the most common laboratory abnormality (62%). Surgical resection was the primary treatment modality in 98% of cases. After a mean follow-up of 38 months ( range: 3-181 months), the local recurrence rate was 11%, with no distant metastases reported.\n\n**Conclusion:** Colorectal IMTs in children present diagnostic and therapeutic challenges. While complete surgical resection remains the gold standard treatment, emerging therapies such as ALK inhibitors and NSAIDs warrant further investigation. The potential for late recurrence mandates long term follow-up.", "abstract_zh": "**Purposeï¼š** ç»“è‚ ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒè‚¿ç˜¤ï¼ˆIMTï¼‰åœ¨å„¿ç§‘äººç¾¤ä¸­æ˜¯ä¸€ç§æå…¶ç½•è§çš„å®ä½“ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨å…¨é¢åˆ†æå„¿ç«¥ç»“ç›´è‚  IMT çš„ä¸´åºŠè¡¨ç°ã€è¯Šæ–­æ£€æŸ¥ã€ç®¡ç†ç­–ç•¥å’Œç»“æœã€‚\n\n**æ–¹æ³•ï¼š** å¯¹å¤šä¸ªç”µå­æ•°æ®åº“ï¼ˆæˆç«‹è‡³ 2025 å¹´ 1 æœˆï¼‰è¿›è¡Œäº†ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°ï¼ŒåŒ…æ‹¬ MEDLINEï¼ˆé€šè¿‡ PubMedï¼‰ã€Embaseã€Cochraneã€Web of Science å’Œ Google Scholarã€‚ä¸¤åç‹¬ç«‹è¯„å®¡å‘˜ç­›é€‰äº†æ‘˜è¦ã€è¯„å®¡äº†ç ”ç©¶å¹¶æå–äº†å„¿ç§‘äººç¾¤ä¸­æ‰€æœ‰æŠ¥å‘Šçš„ç»“ç›´è‚  IMT ç—…ä¾‹çš„æ•°æ®ï¼Œå…¶ä¸­åŒ…æ‹¬æˆ‘ä»¬æœºæ„ä»¥å‰æœªæŠ¥å‘Šçš„ä¸€ä¾‹ç—…ä¾‹ã€‚\n\n**ç»“æœï¼š** åŒ…æ‹¬æˆ‘ä»¬çš„ç—…ä¾‹åœ¨å†…ï¼Œæˆ‘ä»¬ä» 39 é¡¹ç ”ç©¶ä¸­é‰´å®šå‡º 53 åæ‚£æœ‰ç»“ç›´è‚  IMT çš„å„¿ç«¥æ‚£è€…ã€‚è¯Šæ–­æ—¶çš„å¹³å‡å¹´é¾„ä¸º 7 å²ï¼ˆèŒƒå›´ï¼š5 ä¸ªæœˆè‡³ 17 å²ï¼‰ï¼Œå…¶ä¸­å¥³æ€§ç•¥å¤šã€‚ IMT åŒ…æ‹¬å¹¿æ³›çš„è§£å‰–ä½ç½®ï¼Œå…¶ä¸­æœ€å¸¸è§çš„æ˜¯ç›´è‚  (27%) å’Œå‡ç»“è‚  (24%)ã€‚è…¹ç—›ï¼ˆ54%ï¼‰ã€èƒƒè‚ é“å‡ºè¡€ï¼ˆ29%ï¼‰å’Œå‘çƒ§ï¼ˆ21%ï¼‰æ˜¯ä¸»è¦ç—‡çŠ¶ã€‚è´«è¡€æ˜¯æœ€å¸¸è§çš„å®éªŒå®¤å¼‚å¸¸ï¼ˆ62%ï¼‰ã€‚æ‰‹æœ¯åˆ‡é™¤æ˜¯ 98% ç—…ä¾‹çš„ä¸»è¦æ²»ç–—æ–¹å¼ã€‚å¹³å‡éšè®¿38ä¸ªæœˆï¼ˆèŒƒå›´ï¼š3-181ä¸ªæœˆï¼‰åï¼Œå±€éƒ¨å¤å‘ç‡ä¸º11%ï¼Œæ— è¿œå¤„è½¬ç§»æŠ¥é“ã€‚\n\n**ç»“è®ºï¼š** å„¿ç«¥ç»“ç›´è‚  IMT æå‡ºäº†è¯Šæ–­å’Œæ²»ç–—æŒ‘æˆ˜ã€‚è™½ç„¶å®Œå…¨æ‰‹æœ¯åˆ‡é™¤ä»ç„¶æ˜¯é‡‘æ ‡å‡†æ²»ç–—ï¼Œä½† ALK æŠ‘åˆ¶å‰‚å’Œ NSAID ç­‰æ–°å…´ç–—æ³•å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚æ™šæœŸå¤å‘çš„å¯èƒ½æ€§éœ€è¦é•¿æœŸéšè®¿ã€‚", "keywords_zh": "ç—…ä¾‹æŠ¥å‘Šã€ç»“ç›´è‚ ã€IMTã€ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒè‚¿ç˜¤ã€è‚¿ç˜¤ã€å„¿ç§‘", "keywords_en": "Case report, Colorectal, IMT, Inflammatory myofibroblastic tumor, Neoplasm, Pediatric", "link": "https://pubmed.ncbi.nlm.nih.gov/40234278/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Tue, 15 Apr 2025"}, {"id": "40229635", "title_en": "Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a systematic review", "title_zh": "è†€èƒ±ç™Œä¸­è†€èƒ±ã€è‚ é“å’Œé˜´é“çš„å¾®ç”Ÿç‰©ç»„æ™¯è§‚ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Uwe Bieri", "abstract_en": "**Background:** Microbiomes have been linked to oncogenesis, e.g. the intestinal microbiome and colon cancer or HPV-associated cervical cancer. A connection between microbiomes of different body cavities and tumor oncogenesis was shown. The gut microbiome's influence on bladder cancer was established, raising the question whether nearby microbiomes (rectum, vagina) also influence bladder cancer due to their proximity.\n\n**Objective:** Considering the influence of various body cavities and the broader microbial components, this systematic review aims to investigate differences in the bladder, vaginal, and intestinal microbiota-including bacterial, viral, fungal and archaea-between patients with bladder cancer and healthy controls.\n\n**Methods:** Databases (PubMed, Scopus, Embase) were searched until April 2022. Three types of studies were included: \"(1) studies using bladder cancer and control groups (case-controlled studies) (2) studies that provided information on the presence or abundance of microbial taxa (3) studies that provided information on increased or decreased taxa in bladder cancer and/or control groups.\". Risk of bias was assessed using the Newcastle Ottawa Scale.\n\n**Results:** Fourteen studies (695 samples: 403 bladder cancer, 292 controls) were analyzed. Bacterial taxa that have been detected in at least two studies, the genera Geobacillus and Rubrobacter were more frequently in bladder cancer patients; while Streptococcus and Roseomonas were more prevalent in controls. No consistent taxa were identified across stool or bladder tissue samples.\n\n**Conclusion:** The microbiota in bladder cancer patients show significant variation across studies. Standardized methods and expanded investigations into viral and fungal components are needed to clarify the role of microbiota in bladder cancer.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¾®ç”Ÿç‰©ç»„ä¸è‚¿ç˜¤å‘ç”Ÿæœ‰å…³ï¼Œä¾‹å¦‚è‚ é“å¾®ç”Ÿç‰©ç¾¤ä¸ç»“è‚ ç™Œæˆ– HPV ç›¸å…³å®«é¢ˆç™Œã€‚æ˜¾ç¤ºäº†ä¸åŒä½“è…”çš„å¾®ç”Ÿç‰©ç»„ä¸è‚¿ç˜¤å‘ç”Ÿä¹‹é—´çš„è”ç³»ã€‚è‚ é“å¾®ç”Ÿç‰©ç»„å¯¹è†€èƒ±ç™Œçš„å½±å“å·²ç»ç¡®å®šï¼Œè¿™å°±æå‡ºäº†ä¸€ä¸ªé—®é¢˜ï¼šé™„è¿‘çš„å¾®ç”Ÿç‰©ç»„ï¼ˆç›´è‚ ã€é˜´é“ï¼‰æ˜¯å¦ä¹Ÿä¼šå› ä¸ºè·ç¦»è¾ƒè¿‘è€Œå½±å“è†€èƒ±ç™Œã€‚\n\n**ç›®çš„ï¼š** è€ƒè™‘åˆ°å„ç§ä½“è…”å’Œæ›´å¹¿æ³›çš„å¾®ç”Ÿç‰©æˆåˆ†çš„å½±å“ï¼Œæœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨ç ”ç©¶è†€èƒ±ç™Œæ‚£è€…å’Œå¥åº·å¯¹ç…§è€…ä¹‹é—´è†€èƒ±ã€é˜´é“å’Œè‚ é“å¾®ç”Ÿç‰©ç¾¤ï¼ˆåŒ…æ‹¬ç»†èŒã€ç—…æ¯’ã€çœŸèŒå’Œå¤ç»†èŒï¼‰çš„å·®å¼‚ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢æ•°æ®åº“ï¼ˆPubMedã€Scopusã€Embaseï¼‰ç›´è‡³ 2022 å¹´ 4 æœˆã€‚å…¶ä¸­åŒ…æ‹¬ä¸‰ç§ç±»å‹çš„ç ”ç©¶ï¼šâ€œ(1) ä½¿ç”¨è†€èƒ±ç™Œå’Œå¯¹ç…§ç»„çš„ç ”ç©¶ï¼ˆç—…ä¾‹å¯¹ç…§ç ”ç©¶ï¼‰(2) æä¾›æœ‰å…³å¾®ç”Ÿç‰©ç±»ç¾¤å­˜åœ¨æˆ–ä¸°åº¦çš„ä¿¡æ¯çš„ç ”ç©¶ (3) æä¾›æœ‰å…³è†€èƒ±ç™Œå’Œ/æˆ–å¯¹ç…§ç»„ä¸­ç±»ç¾¤å¢åŠ æˆ–å‡å°‘çš„ä¿¡æ¯çš„ç ”ç©¶ã€‚â€ã€‚ä½¿ç”¨çº½å¡æ–¯å°”æ¸¥å¤ªåé‡è¡¨è¯„ä¼°åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 14 é¡¹ç ”ç©¶ï¼ˆ695 ä¸ªæ ·æœ¬ï¼š403 ä¸ªè†€èƒ±ç™Œï¼Œ292 ä¸ªå¯¹ç…§ï¼‰ã€‚è‡³å°‘åœ¨ä¸¤é¡¹ç ”ç©¶ä¸­æ£€æµ‹åˆ°çš„ç»†èŒç±»ç¾¤ï¼ŒåœŸèŠ½å­¢æ†èŒå±å’Œçº¢æ†èŒå±åœ¨è†€èƒ±ç™Œæ‚£è€…ä¸­æ›´ä¸ºå¸¸è§ï¼›è€Œé“¾çƒèŒå’Œç«ç‘°å•èƒèŒåœ¨å¯¹ç…§ç»„ä¸­æ›´ä¸ºæ™®éã€‚åœ¨ç²ªä¾¿æˆ–è†€èƒ±ç»„ç»‡æ ·æœ¬ä¸­æ²¡æœ‰å‘ç°ä¸€è‡´çš„åˆ†ç±»ç¾¤ã€‚\n\n**ç»“è®ºï¼š** è†€èƒ±ç™Œæ‚£è€…çš„å¾®ç”Ÿç‰©ç¾¤åœ¨ä¸åŒç ”ç©¶ä¸­æ˜¾â€‹â€‹ç¤ºå‡ºæ˜¾ç€å·®å¼‚ã€‚éœ€è¦æ ‡å‡†åŒ–æ–¹æ³•å’Œå¯¹ç—…æ¯’å’ŒçœŸèŒæˆåˆ†çš„æ‰©å±•ç ”ç©¶æ¥é˜æ˜å¾®ç”Ÿç‰©ç¾¤åœ¨è†€èƒ±ç™Œä¸­çš„ä½œç”¨ã€‚", "keywords_zh": "ç»†èŒã€è†€èƒ±ç™Œã€è†€èƒ±å¾®ç”Ÿç‰©ç¾¤ã€çœŸèŒã€è‚ é“å¾®ç”Ÿç‰©ç¾¤ã€å¾®ç”Ÿç‰©ç¾¤ã€é˜´é“å¾®ç”Ÿç‰©ç¾¤ã€ç—…æ¯’", "keywords_en": "Bacteria, Bladder cancer, Bladder microbiota, Fungi, Intestinal microbiota, Microbiome, Vaginal microbiota, Viruses", "link": "https://pubmed.ncbi.nlm.nih.gov/40229635/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 14 Apr 2025"}, {"id": "40225020", "title_en": "Gastrointestinal Tract Perineuriomas and Benign Fibroblastic Polyps: Case Report and Comprehensive Systematic Review", "title_zh": "èƒƒè‚ é“ç¥ç»æŸè†œç˜¤å’Œè‰¯æ€§çº¤ç»´æ¯ç»†èƒæ¯è‚‰ï¼šç—…ä¾‹æŠ¥å‘Šå’Œç»¼åˆç³»ç»Ÿè¯„ä»·", "authors": "Talat Bessissow", "abstract_en": "<b>Background:</b> Perineurioma is a rare benign peripheral nerve sheath tumor that can arise in various body locations. In the gastrointestinal (GI) tract, perineuriomas are uncommon and have only been reported in case reports and case series. In addition, a new classification suggests reclassifying benign fibroblastic polyps as perineurioma when they show positive markers of perineurial differentiation. <b>Objective:</b> This study aims to enhance understanding of GI tract perineuriomas by presenting a new case and conducting a systematic literature review. <b>Methods:</b> We described a new case of colonic perineurioma and systematically reviewed all case reports and case series on GI perineuriomas and benign fibroblastic polyps with perineurial markers. We searched ScienceDirect, PubMed/MEDLINE, and Web of Science up to May 2024. <b>Results:</b> A total of 148 cases were analyzed, and most of the cases were published in the last decade (2014-2024). The majority were females (59.46%), with a mean age of 51â€‰years (standard deviation [SD] Â±14.87). Most GI perineuriomas (87.5%) were in the distal colon, predominantly in the sigmoid/rectosigmoid (56%) and rectum (14%). Outside the colon, the stomach was the most affected site (7 of 10 cases), with fewer cases in the small intestine and esophagus. The two most commonly performed stains were for epithelial membrane antigen (EMA) and glucose transporter 1 (GLUT-1), at 75% and 56% of cases, respectively. Noncolonic perineuriomas were generally larger and more symptomatic than colonic ones. Submucosal polyps were more likely symptomatic than mucosal polyps. <b>Conclusion:</b> Perineurioma in the GI tract is a rare benign polyp mainly identified in the distal colon. Its rarity and limited follow-up data restrict our understanding of recurrence rates. We recommend reporting uncommon polyp locations, detailing polyp morphologies, and using at least two markers for classification.", "abstract_zh": "<b>èƒŒæ™¯ï¼š</b>ç¥ç»æŸè†œç˜¤æ˜¯ä¸€ç§ç½•è§çš„è‰¯æ€§å‘¨å›´ç¥ç»é˜è‚¿ç˜¤ï¼Œå¯å‘ç”Ÿåœ¨èº«ä½“çš„å„ä¸ªéƒ¨ä½ã€‚åœ¨èƒƒè‚ é“ï¼ˆGIï¼‰ä¸­ï¼Œç¥ç»æŸè†œç˜¤å¹¶ä¸å¸¸è§ï¼Œä»…åœ¨ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—ä¸­æŠ¥é“è¿‡ã€‚æ­¤å¤–ï¼Œä¸€ç§æ–°çš„åˆ†ç±»å»ºè®®ï¼Œå½“è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰æ˜¾ç¤ºå‡ºç¥ç»æŸè†œåˆ†åŒ–çš„é˜³æ€§æ ‡è®°æ—¶ï¼Œå°†å…¶é‡æ–°åˆ†ç±»ä¸ºç¥ç»æŸè†œç˜¤ã€‚ <b>ç›®çš„ï¼š</b>æœ¬ç ”ç©¶æ—¨åœ¨é€šè¿‡æå‡ºæ–°ç—…ä¾‹å¹¶è¿›è¡Œç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ¥å¢å¼ºå¯¹èƒƒè‚ é“ç¥ç»æŸè†œç˜¤çš„äº†è§£ã€‚ <b>æ–¹æ³•ï¼š</b>æˆ‘ä»¬æè¿°äº†ä¸€ä¸ªæ–°çš„ç»“è‚ ç¥ç»æŸè†œç—…ä¾‹ï¼Œå¹¶ç³»ç»Ÿåœ°å›é¡¾äº†æœ‰å…³èƒƒè‚ é“ç¥ç»æŸè†œç˜¤å’Œå…·æœ‰ç¥ç»æŸè†œæ ‡è®°çš„è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰çš„æ‰€æœ‰ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—ã€‚æˆ‘ä»¬æ£€ç´¢äº†æˆªè‡³ 2024 å¹´ 5 æœˆçš„ ScienceDirectã€PubMed/MEDLINE å’Œ Web of Scienceã€‚<b>ç»“æœï¼š</b>å…±åˆ†æäº† 148 ä¸ªç—…ä¾‹ï¼Œå¤§å¤šæ•°ç—…ä¾‹å‘è¡¨äºè¿‡å»åå¹´ï¼ˆ2014-2024 å¹´ï¼‰ã€‚å¤§å¤šæ•°ä¸ºå¥³æ€§ (59.46%)ï¼Œå¹³å‡å¹´é¾„ä¸º 51 å²ï¼ˆæ ‡å‡†å·® [SD] Â±14.87ï¼‰ã€‚å¤§å¤šæ•°èƒƒè‚ é“ç¥ç»æŸè†œç˜¤ï¼ˆ87.5%ï¼‰ä½äºè¿œç«¯ç»“è‚ ï¼Œä¸»è¦ä½äºä¹™çŠ¶ç»“è‚ /ç›´è‚ ä¹™çŠ¶ç»“è‚ ï¼ˆ56%ï¼‰å’Œç›´è‚ ï¼ˆ14%ï¼‰ã€‚åœ¨ç»“è‚ ä»¥å¤–ï¼Œèƒƒæ˜¯å—å½±å“æœ€ä¸¥é‡çš„éƒ¨ä½ï¼ˆ10ä¾‹ä¸­æœ‰7ä¾‹ï¼‰ï¼Œå°è‚ å’Œé£Ÿé“çš„ç—…ä¾‹è¾ƒå°‘ã€‚æœ€å¸¸è¿›è¡Œçš„ä¸¤ç§æŸ“è‰²æ˜¯ä¸Šçš®è†œæŠ—åŸ (EMA) å’Œè‘¡è„ç³–è½¬è¿è›‹ç™½ 1 (GLUT-1)ï¼Œåˆ†åˆ«å  75% å’Œ 56% çš„ç—…ä¾‹ã€‚éç»“è‚ ç¥ç»æŸè†œç˜¤é€šå¸¸æ¯”ç»“è‚ ç¥ç»æŸè†œç˜¤æ›´å¤§ä¸”ç—‡çŠ¶æ›´ä¸¥é‡ã€‚ç²˜è†œä¸‹æ¯è‚‰æ¯”ç²˜è†œæ¯è‚‰æ›´æœ‰å¯èƒ½å‡ºç°ç—‡çŠ¶ã€‚ <b>ç»“è®ºï¼š</b> èƒƒè‚ é“ç¥ç»æŸè†œç˜¤æ˜¯ä¸€ç§ç½•è§çš„è‰¯æ€§æ¯è‚‰ï¼Œä¸»è¦å‘ç”Ÿåœ¨è¿œç«¯ç»“è‚ ã€‚å®ƒçš„ç¨€æœ‰æ€§å’Œæœ‰é™çš„éšè®¿æ•°æ®é™åˆ¶äº†æˆ‘ä»¬å¯¹å¤å‘ç‡çš„ç†è§£ã€‚æˆ‘ä»¬å»ºè®®æŠ¥å‘Šä¸å¸¸è§çš„æ¯è‚‰ä½ç½®ï¼Œè¯¦ç»†è¯´æ˜æ¯è‚‰å½¢æ€ï¼Œå¹¶ä½¿ç”¨è‡³å°‘ä¸¤ä¸ªæ ‡è®°è¿›è¡Œåˆ†ç±»ã€‚", "keywords_zh": "è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰, ç—…ä¾‹æŠ¥å‘Š, ç—…ä¾‹ç³»åˆ—, èƒƒè‚ é“, ç¥ç»æŸè†œç˜¤, ç³»ç»Ÿè¯„ä»·", "keywords_en": "benign fibroblastic polyps, case report, case series, gastrointestinal tract, perineurioma, systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40225020/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 14 Apr 2025"}, {"id": "40192825", "title_en": "Botulinum toxin injection for management of post-haemorrhoidectomy pain: an updated systematic review and meta-analysis of randomised clinical trials", "title_zh": "è‚‰æ¯’æ¯’ç´ æ³¨å°„æ²»ç–—ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›ï¼šéšæœºä¸´åºŠè¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S Albayati", "abstract_en": "**Introduction:** Excisional haemorrhoidectomy remains the gold-standard treatment for grade III-IV haemorrhoids owing to the high success rate. However, post-operative pain management is an ongoing challenge. Botulinum toxin injection is thought to improve pain by targeting the internal anal sphincter spasm which occurs following haemorrhoidectomy. This systematic review and meta-analysis examines the effects of concurrent botulinum toxin injection on post-haemorrhoidectomy pain.\n\n**Methods:** A search of MEDLINE, EMBASE and Cochrane Databases for randomised controlled trials (RCTs) of botulinum toxin injection compared with placebo for management of post-haemorrhoidectomy pain was conducted following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Outcomes assessed included daily post-operative pain scores assessed using an analogue scale (0-10), pain at first defecation, analgesia use, complication rates and time to return to work.\n\n**Results:** A total of seven RCTs assessing 340 patients who underwent an excisional haemorrhoidectomy were included. In total, seven studies (nâ€‰=â€‰340) found significant reduction in pain post-procedure with botulinum toxin use on day 1 (mean difference, MD -1.53; 95% confidence intervals, CI -2.12, -0.94; pâ€‰<â€‰0.00001), with similar findings on day 2 and 4 (MD -1.84, 95% CI -3.28, -0.41; pâ€‰=â€‰0.01 and MD -1.63, 95% CI -2.15, -1.09; pâ€‰<â€‰0.00001, respectively). However, the analgesic effects were not seen on subsequent analyses up to day 14. Botulinum toxin was seen to be safe, with no significant difference in faecal incontinence (MD 1.05, 95% CI 0.40, 2.75; pâ€‰=â€‰0.93) or urinary retention (MD 0.37, 95% CI 0.09, 1.53; pâ€‰=â€‰0.17).\n\n**Conclusions:** Botulinum toxin use for pain relief post-excisional haemorrhoidectomy is safe and effective in the initial peri-operative period; however, the results were short-lived. Further, more robust randomised controlled trials are needed to strengthen these findings and determine the utility of botulinum toxin in this setting.\n\n**Trial Registration:** PROSPERO Register for Systematic Reviews Registration Number - CRD42024541351 on April 29 2024.", "abstract_zh": "**ä»‹ç»ï¼š** ç”±äºæˆåŠŸç‡é«˜ï¼Œç—”åˆ‡é™¤æœ¯ä»ç„¶æ˜¯æ²»ç–— III-IV çº§ç—”ç–®çš„é‡‘æ ‡å‡†ã€‚ç„¶è€Œï¼Œæœ¯åç–¼ç—›ç®¡ç†æ˜¯ä¸€ä¸ªæŒç»­çš„æŒ‘æˆ˜ã€‚è‚‰æ¯’æ†èŒæ¯’ç´ æ³¨å°„è¢«è®¤ä¸ºå¯ä»¥é€šè¿‡é’ˆå¯¹ç—”ç–®åˆ‡é™¤æœ¯åå‘ç”Ÿçš„è‚›é—¨å†…æ‹¬çº¦è‚Œç—‰æŒ›æ¥æ”¹å–„ç–¼ç—›ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æç ”ç©¶äº†åŒæ—¶æ³¨å°„è‚‰æ¯’æ¯’ç´ å¯¹ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ï¼Œåœ¨ MEDLINEã€EMBASE å’Œ Cochrane æ•°æ®åº“ä¸­æ£€ç´¢äº†è‚‰æ¯’æ¯’ç´ æ³¨å°„ä¸å®‰æ…°å‰‚æ²»ç–—ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚è¯„ä¼°çš„ç»“æœåŒ…æ‹¬ä½¿ç”¨æ¨¡æ‹Ÿé‡è¡¨ï¼ˆ0-10ï¼‰è¯„ä¼°çš„æ¯æ—¥æœ¯åç–¼ç—›è¯„åˆ†ã€ç¬¬ä¸€æ¬¡æ’ä¾¿æ—¶çš„ç–¼ç—›ã€é•‡ç—›å‰‚çš„ä½¿ç”¨ã€å¹¶å‘ç—‡å‘ç”Ÿç‡å’Œé‡è¿”å·¥ä½œå²—ä½çš„æ—¶é—´ã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥äº† 7 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œè¯„ä¼°äº† 340 åæ¥å—ç—”åˆ‡é™¤æœ¯çš„æ‚£è€…ã€‚æ€»å…±æœ‰ä¸ƒé¡¹ç ”ç©¶ (nâ€‰=â€‰340) å‘ç°ï¼Œåœ¨ç¬¬ 1 å¤©ä½¿ç”¨è‚‰æ¯’æ†èŒæ¯’ç´ å¯æ˜¾ç€å‡è½»æœ¯åç–¼ç—›ï¼ˆå¹³å‡å·®ï¼ŒMD -1.53ï¼›95% ç½®ä¿¡åŒºé—´ï¼ŒCI -2.12, -0.94ï¼›p<â€‰0.00001ï¼‰ï¼Œç¬¬ 2 å¤©å’Œç¬¬ 4 å¤©ä¹Ÿæœ‰ç±»ä¼¼çš„ç»“æœï¼ˆMD -1.84ï¼Œ95% CI -3.28ï¼Œ -0.41ï¼›pâ€‰=â€‰0.01ï¼ŒMD -1.63ï¼Œ95% CI -2.15ï¼Œ-1.09ï¼›pâ€‰<â€‰0.00001ï¼‰ã€‚ç„¶è€Œï¼Œåœ¨éšåçš„ç¬¬ 14 å¤©åˆ†æä¸­å¹¶æœªå‘ç°é•‡ç—›ä½œç”¨ã€‚è‚‰æ¯’æ†èŒæ¯’ç´ è¢«è®¤ä¸ºæ˜¯å®‰å…¨çš„ï¼Œåœ¨å¤§ä¾¿å¤±ç¦ï¼ˆMD 1.05ï¼Œ95% CI 0.40ï¼Œ2.75ï¼›pâ€‰=â€‰0.93ï¼‰æˆ–å°¿æ½´ç•™ï¼ˆMD 0.37ï¼Œ95% CI 0.09ï¼Œ1.53ï¼›pâ€‰=â€‰0.93ï¼‰æ–¹é¢æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ pâ€‰=â€‰0.17ï¼‰ã€‚\n\n**ç»“è®ºï¼š** åœ¨å›´æ‰‹æœ¯æœŸåˆæœŸï¼Œä½¿ç”¨è‚‰æ¯’æ†èŒæ¯’ç´ ç¼“è§£ç—”ç–®åˆ‡é™¤æœ¯åçš„ç–¼ç—›æ˜¯å®‰å…¨æœ‰æ•ˆçš„ï¼›ç„¶è€Œï¼Œç»“æœæ˜¯çŸ­æš‚çš„ã€‚æ­¤å¤–ï¼Œéœ€è¦æ›´å¼ºæœ‰åŠ›çš„éšæœºå¯¹ç…§è¯•éªŒæ¥åŠ å¼ºè¿™äº›å‘ç°å¹¶ç¡®å®šè‚‰æ¯’æ†èŒæ¯’ç´ åœ¨è¿™ç§æƒ…å†µä¸‹çš„æ•ˆç”¨ã€‚\n\n**Trial registrationï¼š** PROSPERO äº 2024 å¹´ 4 æœˆ 29 æ—¥æ³¨å†Œç³»ç»Ÿè¯„ä»·æ³¨å†Œå· - CRD42024541351ã€‚", "keywords_zh": "é•‡ç—›ã€è‚‰æ¯’æ†èŒæ¯’ç´ ã€ç—”ç–®åˆ‡é™¤æœ¯ã€ç–¼ç—›ã€æœ¯å", "keywords_en": "Analgesia, Botulinum Toxins, Hemorrhoidectomy, Pain, Post-operative", "link": "https://pubmed.ncbi.nlm.nih.gov/40192825/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 07 Apr 2025"}, {"id": "40186734", "title_en": "A systematic review of preoperative radiological factors associated with the development of low anterior resection syndrome (LARS)", "title_zh": "ä¸ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰å‘ç”Ÿç›¸å…³çš„æœ¯å‰æ”¾å°„å­¦å› ç´ çš„ç³»ç»Ÿè¯„ä»·", "authors": "Giuseppe CurrÃ²", "abstract_en": "The aim of this systematic review is to summarise the available evidence for radiological changes associated with postoperative low anterior resection syndrome (LARS). A literature search was undertaken for all studies focusing on preoperative radiological predictors of postoperative LARS. Articles were selected from MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases up to October 2024. Eighty-four articles were screened: eighty-one were excluded and three were included in the analysis. All included studies focused on preoperative Magnetic Resonance Imaging (MRI) already performed as part of the oncological assessments, no study examined ultrasound or defecography. Authors retrospectively selected patients that underwent LAR, screened them with the LARS score, and reviewed preoperative MRI images with specific softwares in order to find radiological characteristics associated with LARS. Results showed that particular anatomical characteristics were present in patients that subsequently developed major LARS: the volume of the pubococcygealâ€‰+â€‰iliococcygeus muscles in 27 LARS patients out of 46 LAR (odds ratio-OR 14.7, 95% CI 1.7-128.3; pâ€‰=â€‰0.02), the thickness of the anorectal joint in 136 LARS out of 255 LAR preceded by neoadjuvant chemoradiotherapy (OR 0.653, 95% CI 0.565-0.756; pâ€‰=â€‰0.001) and the mesorectal/pelvic volumes in 135 LARS out of 236 LAR (Cox Regression analysis, pâ€‰=â€‰0.0017 and pâ€‰=â€‰0.0001 respectively). Pelvic floor musculature is a factor, among the others, that contributes to LARS. Future prospective studies need to validate these retrospective results, further delineate its influence, and investigate the potential contribution of other radiologic investigations (ultrasound and defecography) in this setting.", "abstract_zh": "æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯æ€»ç»“ä¸æœ¯åä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ç›¸å…³çš„æ”¾å°„å­¦å˜åŒ–çš„ç°æœ‰è¯æ®ã€‚å¯¹æ‰€æœ‰å…³æ³¨æœ¯å LARS æœ¯å‰æ”¾å°„å­¦é¢„æµ‹å› ç´ çš„ç ”ç©¶è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚æˆªè‡³ 2024 å¹´ 10 æœˆï¼Œæ–‡ç« é€‰è‡ª MEDLINEã€EMBASE å’Œ Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“ (CENTRAL) æ•°æ®åº“ã€‚ç­›é€‰äº† 84 ç¯‡æ–‡ç« ï¼š81 ç¯‡è¢«æ’é™¤ï¼Œ3 ç¯‡çº³å…¥åˆ†æã€‚æ‰€æœ‰çº³å…¥çš„ç ”ç©¶éƒ½é›†ä¸­åœ¨ä½œä¸ºè‚¿ç˜¤å­¦è¯„ä¼°ä¸€éƒ¨åˆ†è¿›è¡Œçš„æœ¯å‰ç£å…±æŒ¯æˆåƒ (MRI)ï¼Œæ²¡æœ‰ç ”ç©¶æ£€æŸ¥è¶…å£°æˆ–æ’ç²ªé€ å½±ã€‚ä½œè€…å›é¡¾æ€§é€‰æ‹©æ¥å— LAR çš„æ‚£è€…ï¼Œé€šè¿‡ LARS è¯„åˆ†å¯¹å…¶è¿›è¡Œç­›æŸ¥ï¼Œå¹¶ä½¿ç”¨ç‰¹å®šè½¯ä»¶æŸ¥çœ‹æœ¯å‰ MRI å›¾åƒï¼Œä»¥å‘ç°ä¸ LARS ç›¸å…³çš„æ”¾å°„å­¦ç‰¹å¾ã€‚ç»“æœæ˜¾ç¤ºï¼Œéšåå‘ç”Ÿä¸¥é‡ LARS çš„æ‚£è€…å­˜åœ¨ç‰¹å®šçš„è§£å‰–å­¦ç‰¹å¾ï¼š46 ä¾‹ LAR æ‚£è€…ä¸­ï¼Œ27 ä¾‹æ‚£è€…çš„è€»éª¨å°¾éª¨â€‰+â€‰é«‚å°¾éª¨è‚Œè‚‰ä½“ç§¯ï¼ˆæ¯”å€¼æ¯” OR 14.7ï¼Œ95% CI 1.7-128.3ï¼›pâ€‰=â€‰0.02ï¼‰ï¼Œ136 ä¾‹ LARS ä¸­è‚›é—¨ç›´è‚ å…³èŠ‚çš„åšåº¦255 ä¾‹ LAR ä¸­å…ˆè¡Œæ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼ˆOR 0.653ï¼Œ95% CI 0.565-0.756ï¼›pâ€‰=â€‰0.001ï¼‰ï¼Œ236 ä¾‹ LAR ä¸­ 135 ä¾‹ LARS çš„ç›´è‚ ç³»è†œ/ç›†è…”ä½“ç§¯ï¼ˆCox å›å½’åˆ†æï¼Œpâ€‰=â€‰0.0017 å’Œpâ€‰=â€‰0.0001ï¼‰ã€‚ç›†åº•è‚Œè‚‰ç»„ç»‡æ˜¯å¯¼è‡´ LARS çš„ä¸€ä¸ªå› ç´ ã€‚æœªæ¥çš„å‰ç»æ€§ç ”ç©¶éœ€è¦éªŒè¯è¿™äº›å›é¡¾æ€§ç»“æœï¼Œè¿›ä¸€æ­¥æè¿°å…¶å½±å“ï¼Œå¹¶è°ƒæŸ¥å…¶ä»–æ”¾å°„å­¦æ£€æŸ¥ï¼ˆè¶…å£°å’Œæ’ç²ªé€ å½±ï¼‰åœ¨æ­¤æƒ…å†µä¸‹çš„æ½œåœ¨è´¡çŒ®ã€‚", "keywords_zh": "ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ã€ç£å…±æŒ¯æˆåƒã€ç›†åº•ç–¾ç—…ã€æ”¾å°„å­¦ã€è¶…å£°", "keywords_en": "Low anterior resection syndrome, Magnetic resonance imaging, Pelvic floor diseases, Radiology, Ultrasound", "link": "https://pubmed.ncbi.nlm.nih.gov/40186734/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 05 Apr 2025"}, {"id": "40171091", "title_en": "Treatment of Hemorrhoidal Disease in Patients with Liver Cirrhosis: A Systematic Review", "title_zh": "è‚ç¡¬åŒ–æ‚£è€…ç—”ç–®çš„æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Paulo Salgueiro", "abstract_en": "**Introduction:** The incidence of hemorrhoidal disease (HD) in cirrhotic patients is similar to that of general population, varying between 21% and 79%. Managing this clinical condition in these patients is challenging, due to the need to differentiate between bleeding originating from hemorrhoids or anorectal varices, and the unique hemostatic balance of each patient, which can lead to a decompensation of liver function and subsequently increase the anesthetic risk. To date, there are no systematic reviews specifically addressing this topic.\n\n**Methods:** This was a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were retrieved from three electronic databases. Efficacy (symptomatic improvement, patient satisfaction, quality of life improvement, disease recurrence/need for surgery and/or hemorrhoidal prolapse reduction in anoscopy) and safety (reported adverse events) outcomes were evaluated. Data from each study were initially described individually, followed by a comparative analysis for procedures applied in multiple studies.\n\n**Results:** Six studies were included - 1 randomized clinical trial (RCT), 2 prospective cohort studies, 1 retrospective cohort study, and 2 case series. The considered techniques encompassed rubber band ligation (RBL), injection sclerotherapy (IS) using 3 agents - aluminum potassium sulfate and tannic acid (ALTA), ethanolamine oleate 5% (EAO), or N-butyl-cyanoacrylate, hemorrhoidopexy, and emborrhoid technique. RBL showed great symptomatic improvement and patient satisfaction in 63% and 73% of patients, respectively, and in 90% was associated with one-grade prolapse reduction after only one session. The most frequently reported adverse events included pain (16%) and ulceration/fissure (1-17%). Concerning IS, symptomatic improvement was observed in all patients. Recurrence rates varied with the agent used (EAO: 13% at 12 months; N-butyl-cyanoacrylate: 40% at 12 months; ALTA: 18% at 5 years), and 86.7% of patients exhibited more than one-grade reduction after the initial session. The most frequent adverse event was pain (EAO: 63%; N-butyl-cyanoacrylate: 60%). Stapled hemorrhoidopexy resulted in symptomatic improvement in all patients, although associated with a recurrence rate of 25% within 4 months. With an emborrhoid technique, 80% of the patients showed clinical improvement at a 3-month follow-up, without significant adverse events, at the cost of a 40% recurrence rate.\n\n**Conclusions:** All the treatment methods assessed in the included studies appear to be effective and safe in cirrhotic patients. This assumption challenges previous concerns regarding significant bleeding after office-based procedures like RBL in this population. Future research should prioritize RCT to thoroughly assess the management of HD in these patients, particularly addressing polidocanol foam sclerotherapy, a minimally invasive technique that has previously been shown to be more effective than RBL in the general population and in patients with bleeding disorders.", "abstract_zh": "**ä»‹ç»ï¼š** è‚ç¡¬åŒ–æ‚£è€…ä¸­ç—”ç–®ç–¾ç—… (HD) çš„å‘ç—…ç‡ä¸ä¸€èˆ¬äººç¾¤ç›¸ä¼¼ï¼Œåœ¨ 21% è‡³ 79% ä¹‹é—´å˜åŒ–ã€‚å¤„ç†è¿™äº›æ‚£è€…çš„è¿™ç§ä¸´åºŠçŠ¶å†µå…·æœ‰æŒ‘æˆ˜æ€§ï¼Œå› ä¸ºéœ€è¦åŒºåˆ†æºè‡ªç—”ç–®æˆ–è‚›é—¨ç›´è‚ é™è„‰æ›²å¼ çš„å‡ºè¡€ï¼Œä»¥åŠæ¯ä¸ªæ‚£è€…ç‹¬ç‰¹çš„æ­¢è¡€å¹³è¡¡ï¼Œè¿™å¯èƒ½å¯¼è‡´è‚åŠŸèƒ½å¤±ä»£å¿ï¼Œä»è€Œå¢åŠ éº»é†‰é£é™©ã€‚è¿„ä»Šä¸ºæ­¢ï¼Œè¿˜æ²¡æœ‰ä¸“é—¨é’ˆå¯¹è¯¥ä¸»é¢˜çš„ç³»ç»Ÿç»¼è¿°ã€‚\n\n**æ–¹æ³•ï¼š** è¿™æ˜¯éµå¾ªç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æé¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—çš„ç³»ç»Ÿè¯„ä»·ã€‚ç ”ç©¶æ˜¯ä»ä¸‰ä¸ªç”µå­æ•°æ®åº“ä¸­æ£€ç´¢çš„ã€‚è¯„ä¼°ç–—æ•ˆï¼ˆç—‡çŠ¶æ”¹å–„ã€æ‚£è€…æ»¡æ„åº¦ã€ç”Ÿæ´»è´¨é‡æ”¹å–„ã€ç–¾ç—…å¤å‘/æ‰‹æœ¯éœ€è¦å’Œ/æˆ–è‚›é—¨é•œæ£€æŸ¥ä¸­ç—”è„±å‚å‡å°‘ï¼‰å’Œå®‰å…¨æ€§ï¼ˆæŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶ï¼‰ç»“æœã€‚æ¯é¡¹ç ”ç©¶çš„æ•°æ®æœ€åˆéƒ½æ˜¯å•ç‹¬æè¿°çš„ï¼Œç„¶åå¯¹å¤šé¡¹ç ”ç©¶ä¸­åº”ç”¨çš„ç¨‹åºè¿›è¡Œæ¯”è¾ƒåˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥å…­é¡¹ç ”ç©¶ - 1 é¡¹éšæœºä¸´åºŠè¯•éªŒ (RCT)ã€2 é¡¹å‰ç»æ€§é˜Ÿåˆ—ç ”ç©¶ã€1 é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶å’Œ 2 é¡¹ç—…ä¾‹ç³»åˆ—ç ”ç©¶ã€‚è€ƒè™‘çš„æŠ€æœ¯åŒ…æ‹¬æ©¡çš®ç­‹ç»“æ‰ (RBL)ã€ä½¿ç”¨ 3 ç§è¯ç‰©çš„æ³¨å°„ç¡¬åŒ–ç–—æ³• (IS) - ç¡«é…¸é“é’¾å’Œå•å®é…¸ (ALTA)ã€æ²¹é…¸ä¹™é†‡èƒº 5% (EAO) æˆ–æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ã€ç—”ç–®å›ºå®šæœ¯å’Œç—”ç–®æŠ€æœ¯ã€‚ RBL åˆ†åˆ«åœ¨ 63% å’Œ 73% çš„æ‚£è€…ä¸­æ˜¾ç¤ºå‡ºæå¤§çš„ç—‡çŠ¶æ”¹å–„å’Œæ‚£è€…æ»¡æ„åº¦ï¼Œå¹¶ä¸” 90% çš„æ‚£è€…ä»…åœ¨ä¸€æ¬¡ç–—ç¨‹åå°±å®ç°äº†ä¸€çº§è„±å‚å‡å°‘ã€‚æœ€å¸¸æŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶åŒ…æ‹¬ç–¼ç—›ï¼ˆ16%ï¼‰å’Œæºƒç–¡/è£‚éš™ï¼ˆ1-17%ï¼‰ã€‚å…³äº ISï¼Œæ‰€æœ‰æ‚£è€…å‡è§‚å¯Ÿåˆ°ç—‡çŠ¶æ”¹å–„ã€‚å¤å‘ç‡éšæ‰€ç”¨è¯ç‰©çš„ä¸åŒè€Œå˜åŒ–ï¼ˆEAOï¼š12 ä¸ªæœˆæ—¶ä¸º 13%ï¼›æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ï¼š12 ä¸ªæœˆæ—¶ä¸º 40%ï¼›ALTAï¼š5 å¹´æ—¶ä¸º 18%ï¼‰ï¼Œ86.7% çš„æ‚£è€…åœ¨åˆæ¬¡æ²»ç–—åè¡¨ç°å‡ºè¶…è¿‡ä¸€çº§çš„å¤å‘ç‡ã€‚æœ€å¸¸è§çš„ä¸è‰¯äº‹ä»¶æ˜¯ç–¼ç—›ï¼ˆEAOï¼š63%ï¼›æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ï¼š60%ï¼‰ã€‚å»åˆå™¨ç—”ç–®å›ºå®šæœ¯ä½¿æ‰€æœ‰æ‚£è€…çš„ç—‡çŠ¶å¾—åˆ°æ”¹å–„ï¼Œä½† 4 ä¸ªæœˆå†…å¤å‘ç‡é«˜è¾¾ 25%ã€‚ä½¿ç”¨ç—”ç–®æŠ€æœ¯ï¼Œ80% çš„æ‚£è€…åœ¨ 3 ä¸ªæœˆçš„éšè®¿ä¸­è¡¨ç°å‡ºä¸´åºŠæ”¹å–„ï¼Œæ²¡æœ‰æ˜æ˜¾çš„ä¸è‰¯äº‹ä»¶ï¼Œä½†ä»£ä»·æ˜¯ 40% çš„å¤å‘ç‡ã€‚\n\n**ç»“è®ºï¼š** çº³å…¥ç ”ç©¶ä¸­è¯„ä¼°çš„æ‰€æœ‰æ²»ç–—æ–¹æ³•ä¼¼ä¹å¯¹è‚ç¡¬åŒ–æ‚£è€…æœ‰æ•ˆä¸”å®‰å…¨ã€‚è¿™ä¸€å‡è®¾æŒ‘æˆ˜äº†ä¹‹å‰å¯¹è¯¥äººç¾¤è¿›è¡Œ RBL ç­‰åŠå…¬å®¤æ‰‹æœ¯åå‡ºç°å¤§é‡å‡ºè¡€çš„æ‹…å¿§ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¼˜å…ˆè€ƒè™‘éšæœºå¯¹ç…§è¯•éªŒï¼Œä»¥å½»åº•è¯„ä¼°è¿™äº›æ‚£è€…çš„ HD æ²»ç–—ï¼Œç‰¹åˆ«æ˜¯è§£å†³èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•ï¼Œè¿™æ˜¯ä¸€ç§å¾®åˆ›æŠ€æœ¯ï¼Œæ­¤å‰å·²è¢«è¯æ˜åœ¨æ™®é€šäººç¾¤å’Œå‡ºè¡€æ€§ç–¾ç—…æ‚£è€…ä¸­æ¯” RBL æ›´æœ‰æ•ˆã€‚", "keywords_zh": "ç—”ç–®ç–¾ç—…ï¼Œè‚ç¡¬åŒ–ï¼Œç³»ç»Ÿè¯„ä»·", "keywords_en": "Hemorrhoidal disease, Liver cirrhosis, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40171091/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 02 Apr 2025"}, {"id": "40161159", "title_en": "Hemorrhoidal Artery Ligation (HAL) vs. Rubber Band Ligation (RBL) for Second- and Third-Degree Hemorrhoids: A Systematic Review and Meta-Analysis", "title_zh": "äºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç—”åŠ¨è„‰ç»“æ‰ (HAL) ä¸æ©¡çš®ç­‹ç»“æ‰ (RBL)ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Ali Yasen Mohamedahmed", "abstract_en": "This systematic review investigates the outcomes of rubber band ligation (RBL) vs. hemorrhoidal artery ligation (HAL) for second and third-degree hemorrhoids. This review was designed, performed, and reported as per the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Literature databases, including PubMed, Cochrane, Science Direct, and Google Scholar, were searched for studies comparing rubber band ligation vs. hemorrhoidal artery ligation for second- and third-degree hemorrhoids. The primary outcome was the recurrence of hemorrhoids, while post-operative bleeding, post-operative pain, surgical site infection, and success rate were the secondary outcomes. The literature search and inclusion criteria identified five studies (n=953) comparing HAL (n=548) vs. RBL (n=405). The recurrence rate was higher in the RBL group (28.4%) compared to the HAL group (19.3%) (odds ratio {OR}: 0.57, p=0.001). The two groups showed comparable results regarding post-operative pain (OR: 0.77, p=0.77), post-operative bleeding (OR: 1.48, p=0.44), and surgical site infection (risk difference: 0.00, p=0.67). Moreover, the short-term success rate was 85% in HAL compared to 86% in RBL (p=0.71). Rubber band ligation and hemorrhoidal artery ligation showed comparable short-term outcomes regarding symptom treatment, post-operative bleeding, and pain. However, HAL was superior in terms of recurrence rate.", "abstract_zh": "æœ¬ç³»ç»Ÿç»¼è¿°ç ”ç©¶äº†æ©¡çš®ç­‹ç»“æ‰ (RBL) ä¸ç—”åŠ¨è„‰ç»“æ‰ (HAL) å¯¹äºäºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç–—æ•ˆã€‚æœ¬æ¬¡è¯„ä»·æ˜¯æ ¹æ®å¹²é¢„ç³»ç»Ÿè¯„ä»· Cochrane æ‰‹å†Œä»¥åŠç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æé¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—çš„å»ºè®®è¿›è¡Œè®¾è®¡ã€æ‰§è¡Œå’ŒæŠ¥å‘Šçš„ã€‚æ£€ç´¢äº†åŒ…æ‹¬ PubMedã€Cochraneã€Science Direct å’Œ Google Scholar åœ¨å†…çš„æ–‡çŒ®æ•°æ®åº“ï¼ŒæŸ¥æ‰¾æ¯”è¾ƒæ©¡çš®ç­‹ç»“æ‰ä¸ç—”åŠ¨è„‰ç»“æ‰æ²»ç–—äºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯ç—”ç–®å¤å‘ï¼Œæ¬¡è¦ç»“å±€æ˜¯æœ¯åå‡ºè¡€ã€æœ¯åç–¼ç—›ã€æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“å’ŒæˆåŠŸç‡ã€‚æ–‡çŒ®æ£€ç´¢å’Œçº³å…¥æ ‡å‡†ç¡®å®šäº†äº”é¡¹ç ”ç©¶ (n=953)ï¼Œæ¯”è¾ƒ HAL (n=548) ä¸ RBL (n=405)ã€‚ RBL ç»„çš„å¤å‘ç‡ (28.4%) é«˜äº HAL ç»„ (19.3%)ï¼ˆæ¯”å€¼æ¯” {OR}ï¼š0.57ï¼Œp=0.001ï¼‰ã€‚ä¸¤ç»„åœ¨æœ¯åç–¼ç—›ï¼ˆORï¼š0.77ï¼Œp=0.77ï¼‰ã€æœ¯åå‡ºè¡€ï¼ˆORï¼š1.48ï¼Œp=0.44ï¼‰å’Œæ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ï¼ˆé£é™©å·®å¼‚ï¼š0.00ï¼Œp=0.67ï¼‰æ–¹é¢æ˜¾ç¤ºå‡ºå¯æ¯”çš„ç»“æœã€‚æ­¤å¤–ï¼ŒHAL çš„çŸ­æœŸæˆåŠŸç‡ä¸º 85%ï¼Œè€Œ RBL çš„çŸ­æœŸæˆåŠŸç‡ä¸º 86% (p=0.71)ã€‚æ©¡çš®ç­‹ç»“æ‰å’Œç—”åŠ¨è„‰ç»“æ‰åœ¨ç—‡çŠ¶æ²»ç–—ã€æœ¯åå‡ºè¡€å’Œç–¼ç—›æ–¹é¢æ˜¾ç¤ºå‡ºç›¸å½“çš„çŸ­æœŸç»“æœã€‚ç„¶è€Œï¼ŒHAL åœ¨å¤å‘ç‡æ–¹é¢æ›´èƒœä¸€ç­¹ã€‚", "keywords_zh": "äºŒåº¦ã€ä¸‰åº¦ç—”ç–®ï¼ŒäºŒåº¦ï¼Œä¸‰åº¦ç—”ç–®ï¼Œç—”åŠ¨è„‰ç»“æ‰æ‰‹æœ¯ï¼ˆæ™•ï¼‰ï¼Œç—”ç–®æ‰‹æœ¯ï¼Œç›´è‚ ç§‘ï¼Œæ©¡çš®ç­‹ç»“æ‰æ‰‹æœ¯", "keywords_en": "2nd and 3rd degree hemorrhoids, 2nd degree and 3rd degree haemorrhoids, hemorrhoidal artery ligation operation (halo), hemorrhoids surgery, proctology, rubber band ligation procedure", "link": "https://pubmed.ncbi.nlm.nih.gov/40161159/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 31 Mar 2025"}, {"id": "40148836", "title_en": "Rectal prolapse as an initial presentation of colorectal cancer: a systematic review", "title_zh": "ç›´è‚ è„±å‚ä½œä¸ºç»“ç›´è‚ ç™Œçš„é¦–å‘è¡¨ç°ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Esmat Davoudi-Monfared", "abstract_en": "**Background:** Colorectal cancer rising incidence still pose a public health challenge. In the present systematic review, we aimed to study the colorectal cancer patients with initial presentation of rectal prolapse.\n\n**Method:** The study protocol was developed (PROSPERO CRD42017060473). We searched Web of Science, PubMed and Scopus to identify case reports of rectal Prolapse as a chief compliant of colorectal cancer. The Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) guidelines were used for screening and data extraction.\n\n**Results:** Thirty-one case reports were included in this review. More than half of the patients were females over 65 years old and meanâ€‰Â±â€‰SD age of the cases were 64â€‰Â±â€‰17.9 years and, the female gender were mentioned in 17 (56%) case reports. The majority (64.5%) of the identified cancer belong to rectum and recto-sigmoid origin's location. In the history retained from the cases, rectal bleeding and constipation were the most frequent reported accompanied symptoms in colorectal cancer cases with initial presentation of rectal prolapse. 67.7% of all identified cases in this review published at 2015 and later.\n\n**Conclusion:** Rectal prolapse can be an initial presentation of colorectal cancer, which is more prevalent in female more than 65 years old. The most common symptoms accompanied rectal prolapse were rectal bleeding and constipation. According to rising published case reports on colorectal cancer patients with initial presentation of rectal prolapse in recent years, further work-up is recommended for patients without predisposing factors for a concomitant tumor.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ ç™Œå‘ç—…ç‡ä¸Šå‡ä»ç„¶æ„æˆå…¬å…±å«ç”ŸæŒ‘æˆ˜ã€‚åœ¨æœ¬ç³»ç»Ÿè¯„ä»·ä¸­ï¼Œæˆ‘ä»¬æ—¨åœ¨ç ”ç©¶ä»¥ç›´è‚ è„±å‚ä¸ºé¦–å‘ç—‡çŠ¶çš„ç»“ç›´è‚ ç™Œæ‚£è€…ã€‚\n\n**Methodï¼š** åˆ¶å®šäº†ç ”ç©¶æ–¹æ¡ˆï¼ˆPROSPERO CRD42017060473ï¼‰ã€‚æˆ‘ä»¬æœç´¢äº† Web of Scienceã€PubMed å’Œ Scopusï¼Œä»¥ç¡®å®šç›´è‚ è„±å‚ä½œä¸ºç»“ç›´è‚ ç™Œä¸»è¦ç—‡çŠ¶çš„ç—…ä¾‹æŠ¥å‘Šã€‚ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ç”¨äºç­›é€‰å’Œæ•°æ®æå–ã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡å®¡æŸ¥çº³å…¥äº† 31 ä»½ç—…ä¾‹æŠ¥å‘Šã€‚è¶…è¿‡ä¸€åŠçš„æ‚£è€…ä¸º65å²ä»¥ä¸Šçš„å¥³æ€§ï¼Œç—…ä¾‹çš„å¹³å‡Â±SDå¹´é¾„ä¸º64Â±17.9å²ï¼Œ17ä¾‹ï¼ˆ56%ï¼‰ç—…ä¾‹æŠ¥å‘Šä¸­æåˆ°äº†å¥³æ€§ã€‚å¤§å¤šæ•°ï¼ˆ64.5%ï¼‰å·²å‘ç°çš„ç™Œç—‡å±äºç›´è‚ å’Œç›´è‚ ä¹™çŠ¶ç»“è‚ èµ·æºä½ç½®ã€‚åœ¨ç—…ä¾‹ä¿ç•™çš„ç—…å²ä¸­ï¼Œç›´è‚ å‡ºè¡€å’Œä¾¿ç§˜æ˜¯æœ€åˆè¡¨ç°ä¸ºç›´è‚ è„±å‚çš„ç»“ç›´è‚ ç™Œç—…ä¾‹ä¸­æœ€å¸¸è§çš„ä¼´éšç—‡çŠ¶ã€‚æœ¬æ¬¡å®¡æŸ¥ä¸­å‘ç°çš„æ‰€æœ‰æ¡ˆä¾‹ä¸­ï¼Œ67.7% æ˜¯åœ¨ 2015 å¹´åŠä¹‹åå‘å¸ƒçš„ã€‚\n\n**ç»“è®ºï¼š** ç›´è‚ è„±å‚å¯èƒ½æ˜¯ç»“ç›´è‚ ç™Œçš„é¦–å‘è¡¨ç°ï¼Œç»“ç›´è‚ ç™Œåœ¨ 65 å²ä»¥ä¸Šçš„å¥³æ€§ä¸­æ›´ä¸ºå¸¸è§ã€‚ç›´è‚ è„±å‚æœ€å¸¸è§çš„ç—‡çŠ¶æ˜¯ç›´è‚ å‡ºè¡€å’Œä¾¿ç§˜ã€‚è¿‘å¹´æ¥ï¼Œå…³äºåˆæ¬¡å‡ºç°ç›´è‚ è„±å‚çš„ç»“ç›´è‚ ç™Œæ‚£è€…çš„ç—…ä¾‹æŠ¥å‘Šä¸æ–­å¢åŠ ï¼Œå»ºè®®å¯¹æ²¡æœ‰ä¼´éšè‚¿ç˜¤è¯±å‘å› ç´ çš„æ‚£è€…è¿›è¡Œè¿›ä¸€æ­¥æ£€æŸ¥ã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œ, åˆæ¬¡è¡¨ç°, ç›´è‚ è„±å‚, ç³»ç»Ÿè¯„ä»·", "keywords_en": "Colorectal cancer, Initial presentation, Rectal prolapse, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40148836/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 28 Mar 2025"}, {"id": "40148672", "title_en": "Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer-a systematic review and meta-analysis", "title_zh": "å¯ç”Ÿç‰©é™è§£çš„ç›´è‚ å‘¨å›´é—´éš”ç‰©æ˜¯å¦å¯ä»¥å‡è½»å±€é™æ€§å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—çš„æ²»ç–—æ¯’æ€§â€”â€”ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jeremy Yuen-Chun Teoh", "abstract_en": "**Introduction:** There is an increasing use of biodegradable peri-rectal spacer prior to radiation therapy for prostate cancer to reduce treatment-associated rectal toxicity. While data from individual trials and cohorts is maturing, there is a lack of an updated quantitative analysis that includes outcomes following peri-rectal spacer. We aim to delineate the clinical impact of peri-rectal spacer in localised prostate cancer patients treated with radiotherapy.\n\n**Methods:** In March 2024, a systematic search was performed on MEDLINE, Embase, and Cochrane Central Register of controlled trials for publications since the year 2010. Prospective and retrospective studies reporting comparative outcomes of patients with and without peri-rectal spacer prior to radiotherapy were considered. Outcomes are reported in binary fashion. Random effect meta-analysis with the use of weighted mean difference was adopted. Early (â‰¤3 months) and late rectal toxicity stratified according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria, early and late genitourinary toxicity, quality of life in bowel, sexual and urinary domains (in terms of minimal clinically important difference) were assessed.\n\n**Results:** The systematic review included 17 studies. There are 3 RCTs, 3 prospective cohorts, and 11 retrospective cohorts. Three thousand two hundred patients were included, with 1471 patients who received peri-rectal spacer and 1729 without. The use of spacer is associated with lower likelihood of late (1.62% vs. 9.35%, RRâ€‰=â€‰0.25, 95% CIâ€‰=â€‰0.15-0.42, Pâ€‰<â€‰0.001) and early grade 2 or above late rectal toxicity (3.07% vs. 6.05%, RRâ€‰=â€‰0.53, 95% CIâ€‰=â€‰0.33-0.86, Pâ€‰<â€‰0.001). No difference is observed in significant grade 3 or above GI (acute or late) events. There is no statistical difference in bowel-related bowel QoL (risk differenceâ€‰=â€‰-0.16, 95% CIâ€‰=â€‰-0.38-0.06, Pâ€‰=â€‰0.15). The perirectal spacer is not associated with negative impact to urinary or sexual domains of QoL either.\n\n**Conclusion:** In localised prostate cancer patients treated with radiation therapy, the use of peri-rectal spacer is associated with reduced rectal toxicities.", "abstract_zh": "**ä»‹ç»ï¼š** åœ¨å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¹‹å‰ï¼Œè¶Šæ¥è¶Šå¤šåœ°ä½¿ç”¨å¯ç”Ÿç‰©é™è§£çš„ç›´è‚ å‘¨å›´é—´éš”ç‰©ï¼Œä»¥å‡å°‘æ²»ç–—ç›¸å…³çš„ç›´è‚ æ¯’æ€§ã€‚è™½ç„¶æ¥è‡ªä¸ªåˆ«è¯•éªŒå’Œé˜Ÿåˆ—çš„æ•°æ®æ­£åœ¨æˆç†Ÿï¼Œä½†ç¼ºä¹åŒ…æ‹¬ç›´è‚ å‘¨å›´é—´éš”å™¨åç»“æœçš„æ›´æ–°çš„å®šé‡åˆ†æã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯æè¿°ç›´è‚ å‘¨å›´é—´éš”ç‰©å¯¹æ¥å—æ”¾å°„æ²»ç–—çš„å±€é™æ€§å‰åˆ—è…ºç™Œæ‚£è€…çš„ä¸´åºŠå½±å“ã€‚\n\n**æ–¹æ³•ï¼š** 2024 å¹´ 3 æœˆï¼Œå¯¹ MEDLINEã€Embase å’Œ Cochrane Central Register ä¸Šè‡ª 2010 å¹´ä»¥æ¥å‘è¡¨çš„å¯¹ç…§è¯•éªŒè¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚è€ƒè™‘äº†æŠ¥å‘Šæ”¾ç–—å‰ä½¿ç”¨å’Œä¸ä½¿ç”¨ç›´è‚ å‘¨å›´é—´éš”ç‰©çš„æ‚£è€…çš„æ¯”è¾ƒç»“æœçš„å‰ç»æ€§å’Œå›é¡¾æ€§ç ”ç©¶ã€‚ç»“æœä»¥äºŒè¿›åˆ¶æ–¹å¼æŠ¥å‘Šã€‚é‡‡ç”¨åŠ æƒå¹³å‡å·®çš„éšæœºæ•ˆåº”èŸèƒåˆ†æã€‚æ ¹æ®ä¸è‰¯äº‹ä»¶é€šç”¨æœ¯è¯­æ ‡å‡† (CTCAE) æ ‡å‡†åˆ†å±‚çš„æ—©æœŸï¼ˆâ‰¤3 ä¸ªæœˆï¼‰å’Œæ™šæœŸç›´è‚ æ¯’æ€§ã€æ—©æœŸå’Œæ™šæœŸæ³Œå°¿ç”Ÿæ®–æ¯’æ€§ã€è‚ é“ã€æ€§å’Œæ³Œå°¿é¢†åŸŸçš„ç”Ÿæ´»è´¨é‡ï¼ˆå°±æœ€å°ä¸´åºŠé‡è¦å·®å¼‚è€Œè¨€ï¼‰è¿›è¡Œäº†è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·åŒ…æ‹¬ 17 é¡¹ç ”ç©¶ã€‚æœ‰ 3 ä¸ªéšæœºå¯¹ç…§è¯•éªŒã€3 ä¸ªå‰ç»æ€§é˜Ÿåˆ—å’Œ 11 ä¸ªå›é¡¾æ€§é˜Ÿåˆ—ã€‚ç ”ç©¶çº³å…¥äº† 3200 åæ‚£è€…ï¼Œå…¶ä¸­ 1471 åæ‚£è€…æ¥å—äº†ç›´è‚ å‘¨å›´é—´éš”å™¨ï¼Œ1729 åæ‚£è€…æœªæ¥å—ç›´è‚ å‘¨å›´é—´éš”å™¨ã€‚ä½¿ç”¨å«ç‰‡ä¸æ™šæœŸï¼ˆ1.62% vs. 9.35%ï¼ŒRRâ€‰=â€‰0.25ï¼Œ95% CIâ€‰=â€‰0.15-0.42ï¼ŒPâ€‰<â€‰0.001ï¼‰å’Œæ—©æœŸ2çº§æˆ–ä»¥ä¸Šæ™šæœŸç›´è‚ æ¯’æ€§çš„å¯èƒ½æ€§è¾ƒä½ï¼ˆ3.07% vs. 6.05%ï¼ŒRRâ€‰=â€‰0.53ï¼Œ 95% CIâ€‰=â€‰0.33-0.86ï¼ŒPâ€‰<â€‰0.001ï¼‰ã€‚åœ¨æ˜¾ç€çš„ 3 çº§æˆ–ä»¥ä¸Š GIï¼ˆæ€¥æ€§æˆ–æ™šæœŸï¼‰äº‹ä»¶ä¸­æ²¡æœ‰è§‚å¯Ÿåˆ°å·®å¼‚ã€‚è‚ é“ç›¸å…³çš„è‚ é“QoLæ²¡æœ‰ç»Ÿè®¡å­¦å·®å¼‚ï¼ˆé£é™©å·®â€‰=â€‰-0.16ï¼Œ95% CIâ€‰=â€‰-0.38-0.06ï¼ŒPâ€‰=â€‰0.15ï¼‰ã€‚ç›´è‚ å‘¨å›´é—´éš”ç‰©ä¹Ÿä¸ä¼šå¯¹æ³Œå°¿æˆ–æ€§é¢†åŸŸçš„ç”Ÿæ´»è´¨é‡äº§ç”Ÿè´Ÿé¢å½±å“ã€‚\n\n**ç»“è®ºï¼š** åœ¨æ¥å—æ”¾å°„æ²»ç–—çš„å±€é™æ€§å‰åˆ—è…ºç™Œæ‚£è€…ä¸­ï¼Œä½¿ç”¨ç›´è‚ å‘¨å›´é—´éš”ç‰©å¯å‡å°‘ç›´è‚ æ¯’æ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40148672/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 28 Mar 2025"}, {"id": "40135757", "title_en": "Author's Reply to Letter About: How to Write a Systematic Review and Meta-Analysis", "title_zh": "ä½œè€…å¯¹å…³äºä»¥ä¸‹å†…å®¹çš„ä¿¡çš„å›å¤ï¼šå¦‚ä½•æ’°å†™ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Richard L Nelson", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40135757/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 26 Mar 2025"}, {"id": "40135742", "title_en": "Striking A Balance: The Risks of Oversimplifying Systematic Review Methodology", "title_zh": "å–å¾—å¹³è¡¡ï¼šè¿‡åº¦ç®€åŒ–ç³»ç»Ÿå®¡æŸ¥æ–¹æ³•çš„é£é™©", "authors": "Rachel Riera", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40135742/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 26 Mar 2025"}, {"id": "40102483", "title_en": "Comparative pregnancy rate after colorectal resection versus other surgical procedures for deep infiltrating rectal endometriosis: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸å…¶ä»–æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯åå¦Šå¨ ç‡çš„æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jean-Marc Ayoubi", "abstract_en": "The debate around colorectal surgery for endometriosis has been ongoing, but to date no meta-analysis has investigated the impact of the different surgical approaches on the pregnancy rate. The aim of this meta-analysis study was to determine in women with deep infiltrating rectal endometriosis, how does colorectal resection surgery compare to other surgical techniques (e.g., rectal shaving, disc excision) in terms of pregnancy rates. We searched PubMed, Web of Science, Cochrane library and Clinical Trials for relevant studies published from inception to December 2024. We performed a systematic review and meta-analysis of all English language full-text articles addressing colorectal resection compared with other management of deep infiltrating rectal endometriosis and presenting pregnancy outcomes. We included a study when it (i) provided data on surgical management (shaving, disc excision, and/or colorectal resection) and (ii) detailed the pregnancy outcomes in each subgroup. Four authors independently performed the initial search to evaluate the eligibility criteria. Four authors extracted the data and a fifth author checked this extraction. Of the 113 full-text articles assessed for eligibility, we included 13 in the meta-analysis. These studies represented a total of 3,248 patients. Pregnancy information was available for 2,131 patients: 1073 colorectal resection, 502 shaving, 172 disc excisions, and 384 other practices (expectant management). Colorectal resection was associated with a lower pregnancy rate compared with the other techniques (Nâ€‰=â€‰2,131, odds ratio [OR]â€‰=â€‰0.64 [95% confidence interval 0.52-0.79], pâ€‰<â€‰0.001, I2â€‰=â€‰35%). There were similar results when comparing colorectal resection with rectal shaving (Nâ€‰=â€‰952, ORâ€‰=â€‰0.51 [95% confidence interval 0.36-0.73], pâ€‰<â€‰0.001, I2â€‰=â€‰0%), but not when comparing colorectal resection with disc excision (Nâ€‰=â€‰432, ORâ€‰=â€‰0.65 [95% confidence interval 0.37-1.13], pâ€‰=â€‰0.13). Conclusions Rectal resection for endometriosis is associated with a lower pregnancy rate compared with other type of surgery, such as shaving. Trial registration: PROSPERO registration number CRD42024512328.", "abstract_zh": "å…³äºå­å®«å†…è†œå¼‚ä½ç—‡çš„ç»“ç›´è‚ æ‰‹æœ¯çš„äº‰è®ºä¸€ç›´åœ¨æŒç»­ï¼Œä½†è¿„ä»Šä¸ºæ­¢è¿˜æ²¡æœ‰èŸèƒåˆ†æè°ƒæŸ¥ä¸åŒæ‰‹æœ¯æ–¹æ³•å¯¹å¦Šå¨ ç‡çš„å½±å“ã€‚è¿™é¡¹èŸèƒåˆ†æç ”ç©¶çš„ç›®çš„æ˜¯ç¡®å®šå¯¹äºæ‚£æœ‰æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡çš„å¥³æ€§ï¼Œç»“ç›´è‚ åˆ‡é™¤æ‰‹æœ¯ä¸å…¶ä»–æ‰‹æœ¯æŠ€æœ¯ï¼ˆä¾‹å¦‚ç›´è‚ å‰ƒé™¤æœ¯ã€æ¤é—´ç›˜åˆ‡é™¤æœ¯ï¼‰ç›¸æ¯”ï¼Œå…¶å¦Šå¨ ç‡å¦‚ä½•ã€‚æˆ‘ä»¬æ£€ç´¢äº† PubMedã€Web of Scienceã€Cochrane å›¾ä¹¦é¦†å’Œä¸´åºŠè¯•éªŒï¼ŒæŸ¥æ‰¾ä»å¼€å§‹åˆ° 2024 å¹´ 12 æœˆå‘è¡¨çš„ç›¸å…³ç ”ç©¶ã€‚æˆ‘ä»¬å¯¹æ‰€æœ‰æ¶‰åŠç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡çš„å…¶ä»–æ²»ç–—æ–¹æ³•å’Œå¦Šå¨ ç»“å±€çš„è‹±æ–‡å…¨æ–‡æ–‡ç« è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚æˆ‘ä»¬çº³å…¥äº†ä¸€é¡¹ç ”ç©¶ï¼Œå®ƒï¼ˆiï¼‰æä¾›äº†æ‰‹æœ¯æ²»ç–—ï¼ˆå‰ƒæ¯›ã€æ¤é—´ç›˜åˆ‡é™¤å’Œ/æˆ–ç»“ç›´è‚ åˆ‡é™¤ï¼‰çš„æ•°æ®ï¼Œå¹¶ä¸”ï¼ˆiiï¼‰è¯¦ç»†è¯´æ˜äº†æ¯ä¸ªäºšç»„çš„å¦Šå¨ ç»“å±€ã€‚å››ä½ä½œè€…ç‹¬ç«‹è¿›è¡Œäº†åˆæ­¥æ£€ç´¢ä»¥è¯„ä¼°èµ„æ ¼æ ‡å‡†ã€‚å››ä½ä½œè€…æå–äº†æ•°æ®ï¼Œç¬¬äº”ä½ä½œè€…æ£€æŸ¥äº†æ­¤æå–ã€‚åœ¨è¯„ä¼°èµ„æ ¼çš„ 113 ç¯‡å…¨æ–‡æ–‡ç« ä¸­ï¼Œæˆ‘ä»¬å°† 13 ç¯‡çº³å…¥èŸèƒåˆ†æã€‚è¿™äº›ç ”ç©¶æ€»å…±æ¶‰åŠ 3,248 åæ‚£è€…ã€‚æä¾›äº† 2,131 åæ‚£è€…çš„æ€€å­•ä¿¡æ¯ï¼š1073 ä¾‹ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€502 ä¾‹å‰ƒæ¯›æœ¯ã€172 ä¾‹æ¤é—´ç›˜åˆ‡é™¤æœ¯å’Œ 384 ä¾‹å…¶ä»–æ‰‹æœ¯ï¼ˆæœŸå¾…æ²»ç–—ï¼‰ã€‚ä¸å…¶ä»–æŠ€æœ¯ç›¸æ¯”ï¼Œç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸è¾ƒä½çš„å¦Šå¨ ç‡ç›¸å…³ï¼ˆNâ€‰=â€‰2,131ï¼Œæ¯”å€¼æ¯”[OR]â€‰=â€‰0.64 [95%ç½®ä¿¡åŒºé—´0.52-0.79]ï¼Œpâ€‰<â€‰0.001ï¼ŒI2â€‰=â€‰35%ï¼‰ã€‚æ¯”è¾ƒç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸ç›´è‚ å‰ƒé™¤æœ¯æ—¶æœ‰ç›¸ä¼¼çš„ç»“æœï¼ˆNâ€‰=â€‰952ï¼ŒORâ€‰=â€‰0.51 [95%ç½®ä¿¡åŒºé—´0.36-0.73]ï¼Œpâ€‰<â€‰0.001ï¼ŒI2â€‰=â€‰0%ï¼‰ï¼Œä½†æ¯”è¾ƒç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸æ¤é—´ç›˜åˆ‡é™¤æœ¯æ—¶åˆ™ä¸ç„¶ï¼ˆNâ€‰=â€‰432ï¼Œ ORâ€‰=â€‰0.65 [95% ç½®ä¿¡åŒºé—´ 0.37-1.13]ï¼Œpâ€‰=â€‰0.13ï¼‰ã€‚ç»“è®º ä¸å…¶ä»–ç±»å‹çš„æ‰‹æœ¯ï¼ˆä¾‹å¦‚å‰ƒæ¯›ï¼‰ç›¸æ¯”ï¼Œç›´è‚ åˆ‡é™¤æœ¯æ²»ç–—å­å®«å†…è†œå¼‚ä½ç—‡çš„å¦Šå¨ ç‡è¾ƒä½ã€‚è¯•ç”¨æ³¨å†Œï¼šPROSPEROæ³¨å†Œå·CRD42024512328ã€‚", "keywords_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€æ¤é—´ç›˜åˆ‡é™¤æœ¯ã€å­å®«å†…è†œå¼‚ä½ç—‡ã€æ€€å­•ã€å‰ƒæ¯›", "keywords_en": "Colorectal resection, Disc excision, Endometriosis, Pregnancy, Shaving", "link": "https://pubmed.ncbi.nlm.nih.gov/40102483/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 19 Mar 2025"}, {"id": "40072118", "title_en": "Key Factors to Consider for Candida auris Screening in Healthcare Settings: A Systematic Review", "title_zh": "åŒ»ç–—æœºæ„ä¸­è€³å¿µç èŒç­›æŸ¥è¦è€ƒè™‘çš„å…³é”®å› ç´ ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mari Molvik", "abstract_en": "**Background:** Candida auris is an emerging fungal pathogen that is often multidrug-resistant. It can persist on skin and in hospital environments, leading to outbreaks and severe infections for patients at risk. Several countries and institutions are working on establishing guidelines and recommendations for prevention. This review aims to assess the evidence on factors associated with C. auris colonisation or infection, the duration of such colonisation, possible colonisation sites, and the risk of secondary cases to inform screening recommendations.\n\n**Methods:** We systematically searched five databases for primary studies and systematic reviews of our four outcomes. We excluded studies on treatment, management, laboratory methods, drug resistance, and environmental screening. From each paper, we extracted relevant data and summarised them in tables. Main findings were described narratively.\n\n**Findings:** We selected 117 studies for inclusion. Most of the studies were observational studies. Without taking the method of testing into account, the duration of C. auris colonisation varied, with up to and beyond a year being common. The predominant sites of colonisation were the axillae and groin, with the nares and rectum being less common sites. The risk of secondary cases saw considerable variation across the studies, and the secondary cases primarily involved patients and not healthcare workers. Critical care settings, invasive medical devices, recent antimicrobial use, and comorbidities were often associated with C. auris colonisation and infection.\n\n**Conclusion:** Our review highlights that, despite relevant findings on factors influencing C. auris colonisation and infection, substantial gaps remain in the evidence supporting screening practices. Most studies were conducted reactively, in outbreak settings, and lack systematic protocols. Given these limitations, screening guidelines are likely to be more successful if grounded in medical theory and yeast microbiology rather than relying solely on current studies. Rigorous, well-designed research is urgently needed to inform future C. auris screening and control efforts.", "abstract_zh": "**èƒŒæ™¯ï¼š** è€³å¿µç èŒæ˜¯ä¸€ç§æ–°å…´çš„çœŸèŒç—…åŸä½“ï¼Œé€šå¸¸å…·æœ‰å¤šé‡è€è¯æ€§ã€‚å®ƒå¯ä»¥æŒç»­å­˜åœ¨äºçš®è‚¤å’ŒåŒ»é™¢ç¯å¢ƒä¸­ï¼Œå¯¼è‡´é«˜å±æ‚£è€…çˆ†å‘å’Œä¸¥é‡æ„ŸæŸ“ã€‚ä¸€äº›å›½å®¶å’Œæœºæ„æ­£åœ¨åŠªåŠ›åˆ¶å®šé¢„é˜²æŒ‡å—å’Œå»ºè®®ã€‚æœ¬ç»¼è¿°æ—¨åœ¨è¯„ä¼°ä¸è€³å¿µç èŒå®šæ¤æˆ–æ„ŸæŸ“ç›¸å…³çš„å› ç´ ã€å®šæ¤æŒç»­æ—¶é—´ã€å¯èƒ½çš„å®šæ¤ä½ç‚¹ä»¥åŠç»§å‘ç—…ä¾‹çš„é£é™©çš„è¯æ®ï¼Œä»¥æä¾›ç­›æŸ¥å»ºè®®ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ç³»ç»Ÿåœ°æ£€ç´¢äº†äº”ä¸ªæ•°æ®åº“è¿›è¡Œåˆæ­¥ç ”ç©¶å¹¶å¯¹æˆ‘ä»¬çš„å››ä¸ªç»“æœè¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚æˆ‘ä»¬æ’é™¤äº†æœ‰å…³æ²»ç–—ã€ç®¡ç†ã€å®éªŒå®¤æ–¹æ³•ã€è€è¯æ€§å’Œç¯å¢ƒç­›æŸ¥çš„ç ”ç©¶ã€‚æˆ‘ä»¬ä»æ¯ç¯‡è®ºæ–‡ä¸­æå–äº†ç›¸å…³æ•°æ®å¹¶å°†å…¶æ€»ç»“åœ¨è¡¨æ ¼ä¸­ã€‚å¯¹ä¸»è¦å‘ç°è¿›è¡Œäº†å™è¿°æ€§æè¿°ã€‚\n\n**Findingsï¼š** æˆ‘ä»¬é€‰æ‹©äº† 117 é¡¹ç ”ç©¶çº³å…¥å…¶ä¸­ã€‚å¤§å¤šæ•°ç ”ç©¶éƒ½æ˜¯è§‚å¯Ÿæ€§ç ”ç©¶ã€‚å¦‚æœä¸è€ƒè™‘æµ‹è¯•æ–¹æ³•ï¼Œè€³å¿µç èŒå®šæ®–çš„æŒç»­æ—¶é—´å„ä¸ç›¸åŒï¼Œæœ€é•¿æˆ–è¶…è¿‡ä¸€å¹´çš„æƒ…å†µå¾ˆå¸¸è§ã€‚å®šæ¤çš„ä¸»è¦éƒ¨ä½æ˜¯è…‹çªå’Œè…¹è‚¡æ²Ÿï¼Œé¼»å­”å’Œç›´è‚ æ˜¯ä¸å¤ªå¸¸è§çš„éƒ¨ä½ã€‚å„ä¸ªç ”ç©¶ä¸­ç»§å‘ç—…ä¾‹çš„é£é™©å­˜åœ¨å¾ˆå¤§å·®å¼‚ï¼Œå¹¶ä¸”ç»§å‘ç—…ä¾‹ä¸»è¦æ¶‰åŠæ‚£è€…è€Œä¸æ˜¯åŒ»æŠ¤äººå‘˜ã€‚é‡ç—‡ç›‘æŠ¤ç¯å¢ƒã€ä¾µå…¥æ€§åŒ»ç–—è®¾å¤‡ã€è¿‘æœŸæŠ—èŒè¯ç‰©çš„ä½¿ç”¨ä»¥åŠåˆå¹¶ç—‡é€šå¸¸ä¸è€³å¿µç èŒå®šæ¤å’Œæ„ŸæŸ“æœ‰å…³ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°å¼ºè°ƒï¼Œå°½ç®¡å¯¹å½±å“è€³å¿µç èŒå®šæ¤å’Œæ„ŸæŸ“çš„å› ç´ æœ‰ç›¸å…³å‘ç°ï¼Œä½†æ”¯æŒç­›æŸ¥å®è·µçš„è¯æ®ä»ç„¶å­˜åœ¨å¾ˆå¤§å·®è·ã€‚å¤§å¤šæ•°ç ”ç©¶éƒ½æ˜¯åœ¨ç–«æƒ…çˆ†å‘çš„æƒ…å†µä¸‹è¢«åŠ¨è¿›è¡Œçš„ï¼Œç¼ºä¹ç³»ç»Ÿçš„æ–¹æ¡ˆã€‚é‰´äºè¿™äº›é™åˆ¶ï¼Œå¦‚æœåŸºäºåŒ»å­¦ç†è®ºå’Œé…µæ¯å¾®ç”Ÿç‰©å­¦è€Œä¸æ˜¯ä»…ä»…ä¾èµ–å½“å‰çš„ç ”ç©¶ï¼Œç­›æŸ¥æŒ‡å—å¯èƒ½ä¼šæ›´æˆåŠŸã€‚è¿«åˆ‡éœ€è¦ä¸¥è°¨ã€ç²¾å¿ƒè®¾è®¡çš„ç ”ç©¶æ¥ä¸ºæœªæ¥çš„è€³å¿µç èŒç­›æŸ¥å’Œæ§åˆ¶å·¥ä½œæä¾›ä¿¡æ¯ã€‚", "keywords_zh": "è€³å¿µç èŒã€çœŸèŒæ„ŸæŸ“ã€åŒ»ç–—ä¿å¥ç›¸å…³æ„ŸæŸ“ã€æ„ŸæŸ“æ§åˆ¶ã€ç­›æŸ¥", "keywords_en": "Candida auris, fungal infections, healthcareâ€associated infections, infection control, screening", "link": "https://pubmed.ncbi.nlm.nih.gov/40072118/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 12 Mar 2025"}, {"id": "40063683", "title_en": "Evaluating the Impact of Induction and Consolidation Total Neoadjuvant Therapies Compared to Conventional Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Network Meta-analysis", "title_zh": "è¯„ä¼°è¯±å¯¼å’Œå·©å›ºæ€»ä½“æ–°è¾…åŠ©æ²»ç–—ä¸ä¼ ç»Ÿæ”¾åŒ–ç–—å¯¹å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æ", "authors": "Jeonghyun Kang", "abstract_en": "**Background:** Total neoadjuvant therapy has been introduced to enhance oncological outcomes and minimize toxicity in locally advanced rectal cancer, but the superiority between the induction and consolidation of therapy remain unclear.\n\n**Objective:** To evaluate oncological and postoperative outcomes by comparing induction chemotherapy and consolidation chemotherapy with conventional chemoradiotherapy in patients with locally advanced rectal cancer.\n\n**Data Sources:** Systematic searches of PubMed, Embase, and Cochrane databases wereperformed for studies published from the database's inception until June 2023.\n\n**Study Selection:** The inclusion criteria were patients diagnosed with rectal cancer. Interventions included induction chemotherapy and consolidation chemotherapy, and comparisons were specified as conventional neoadjuvant chemoradiotherapy.\n\n**Main Outcome Measures:** Primary outcomes were the rates of pathologic or clinical complete response, postoperative results, chemoradiotherapy-related toxicity, and survival outcomes.\n\n**Results:** Thirty-three studies, encompassing patients from 1991 to 2021, were eligible for analysis. In network meta-analysis, a significantly increased OR for a pathologic complete response was observed in both the induction therapy group at 1.65 (95% credible interval, 1.18-2.30) and the consolidation therapy group at 1.87 (95% credible interval, 1.40-2.47) compared to conventional chemoradiotherapy. However, no difference was observed in complete response rates, postoperative results, or chemoradiotherapy-related toxicity grade 3 or higher between the groups. There were no differences among the groups in local recurrence, distant metastasis, or disease-free survival, whereas the induction group showed a nonsignificant improvement in overall survival.\n\n**Limitations:** There was significant heterogeneity among the studies, and the short follow-up period in most studies limited the assessment of long-term survival outcomes.\n\n**Conclusions:** Both induction and consolidation total neoadjuvant therapy increase the pathologic complete response rate in locally advanced rectal cancer without compromising safety or postoperative outcomes. However, total neoadjuvant therapy was not associated with a significant improvement in survival outcomes. Although total neoadjuvant therapy strategies for locally advanced rectal cancer are considered safe, additional long-term studies are needed.\n\n**Trial Registration No:** CRD42023445348.", "abstract_zh": "**èƒŒæ™¯ï¼š** å·²å¼•å…¥å…¨æ–°è¾…åŠ©æ²»ç–—æ¥å¢å¼ºå±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è‚¿ç˜¤å­¦ç»“æœå¹¶æœ€å¤§ç¨‹åº¦åœ°å‡å°‘æ¯’æ€§ï¼Œä½†è¯±å¯¼æ²»ç–—å’Œå·©å›ºæ²»ç–—ä¹‹é—´çš„ä¼˜è¶Šæ€§ä»ä¸æ¸…æ¥šã€‚\n\n**ç›®çš„ï¼š** é€šè¿‡æ¯”è¾ƒå±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…çš„è¯±å¯¼åŒ–ç–—å’Œå·©å›ºåŒ–ç–—ä¸å¸¸è§„æ”¾åŒ–ç–—ï¼Œè¯„ä¼°è‚¿ç˜¤å­¦å’Œæœ¯åç»“æœã€‚\n\n**Data sourcesï¼š** å¯¹ PubMedã€Embase å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼ŒæŸ¥æ‰¾ä»æ•°æ®åº“æˆç«‹åˆ° 2023 å¹´ 6 æœˆæœŸé—´å‘è¡¨çš„ç ”ç©¶ã€‚\n\n**Study selectionï¼š** çº³å…¥æ ‡å‡†æ˜¯è¯Šæ–­æ‚£æœ‰ç›´è‚ ç™Œçš„æ‚£è€…ã€‚å¹²é¢„æªæ–½åŒ…æ‹¬è¯±å¯¼åŒ–ç–—å’Œå·©å›ºåŒ–ç–—ï¼Œæ¯”è¾ƒæŒ‡å®šä¸ºå¸¸è§„æ–°è¾…åŠ©æ”¾åŒ–ç–—ã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“å±€æ˜¯ç—…ç†æˆ–ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ã€æœ¯åç»“æœã€æ”¾åŒ–ç–—ç›¸å…³æ¯’æ€§å’Œç”Ÿå­˜ç»“å±€ã€‚\n\n**ç»“æœï¼š** æ¶µç›– 1991 å¹´è‡³ 2021 å¹´æ‚£è€…çš„ 33 é¡¹ç ”ç©¶ç¬¦åˆåˆ†ææ¡ä»¶ã€‚åœ¨ç½‘ç»œèŸèƒåˆ†æä¸­ï¼Œä¸ä¼ ç»Ÿæ”¾åŒ–ç–—ç›¸æ¯”ï¼Œè¯±å¯¼æ²»ç–—ç»„çš„ç—…ç†å®Œå…¨ç¼“è§£ OR æ˜¾ç€å¢åŠ ä¸º 1.65ï¼ˆ95% å¯ä¿¡åŒºé—´ï¼Œ1.18-2.30ï¼‰ï¼Œå·©å›ºæ²»ç–—ç»„ä¸º 1.87ï¼ˆ95% å¯ä¿¡åŒºé—´ï¼Œ1.40-2.47ï¼‰ã€‚ç„¶è€Œï¼Œä¸¤ç»„é—´åœ¨å®Œå…¨ç¼“è§£ç‡ã€æœ¯åç»“æœæˆ–æ”¾åŒ–ç–—ç›¸å…³æ¯’æ€§ 3 çº§æˆ–ä»¥ä¸Šæ–¹é¢æ²¡æœ‰è§‚å¯Ÿåˆ°å·®å¼‚ã€‚å„ç»„ä¹‹é—´çš„å±€éƒ¨å¤å‘ã€è¿œå¤„è½¬ç§»æˆ–æ— ç—…ç”Ÿå­˜ç‡æ²¡â€‹â€‹æœ‰å·®å¼‚ï¼Œè€Œè¯±å¯¼ç»„çš„æ€»ç”Ÿå­˜ç‡æ²¡æœ‰æ˜¾ç€æ”¹å–„ã€‚\n\n**Limitationsï¼š** ç ”ç©¶ä¹‹é—´å­˜åœ¨æ˜¾ç€çš„å¼‚è´¨æ€§ï¼Œå¹¶ä¸”å¤§å¤šæ•°ç ”ç©¶çš„çŸ­æœŸéšè®¿é™åˆ¶äº†é•¿æœŸç”Ÿå­˜ç»“æœçš„è¯„ä¼°ã€‚\n\n**ç»“è®ºï¼š** è¯±å¯¼å’Œå·©å›ºå…¨æ–°è¾…åŠ©æ²»ç–—å‡å¯æé«˜å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„ç—…ç†å®Œå…¨ç¼“è§£ç‡ï¼Œä¸”ä¸å½±å“å®‰å…¨æ€§æˆ–æœ¯åç»“æœã€‚ç„¶è€Œï¼Œæ€»ä½“æ–°è¾…åŠ©æ²»ç–—ä¸ç”Ÿå­˜ç»“æœçš„æ˜¾ç€æ”¹å–„æ— å…³ã€‚å°½ç®¡å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„æ€»ä½“æ–°è¾…åŠ©æ²»ç–—ç­–ç•¥è¢«è®¤ä¸ºæ˜¯å®‰å…¨çš„ï¼Œä½†ä»éœ€è¦é¢å¤–çš„é•¿æœŸç ”ç©¶ã€‚\n\n**Trial registration noï¼š** CRD42023445348ã€‚", "keywords_zh": "å·©å›ºåŒ–ç–—ã€è¯±å¯¼åŒ–ç–—ã€ç›´è‚ ç™Œã€å…¨é¢æ–°è¾…åŠ©æ²»ç–—", "keywords_en": "Consolidation chemotherapy, Induction chemotherapy, Rectal cancer, Total neoadjuvant therapy", "link": "https://pubmed.ncbi.nlm.nih.gov/40063683/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 10 Mar 2025"}, {"id": "40019566", "title_en": "Quantification of indocyanine green fluorescence angiography in colorectal surgery: a systematic review of the literature", "title_zh": "ç»“ç›´è‚ æ‰‹æœ¯ä¸­å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±çš„é‡åŒ–ï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Ronan A Cahill", "abstract_en": "**Background:** Indocyanine green fluorescence angiography (ICGFA) during colorectal surgery associates with reduced post-operative anastomotic complication rates. Because its interpretation is subjective, quantification has been proposed to address inter-user variability. This study reviews the published literature regarding ICGFA quantification during colorectal surgery with a focus on impactful clinical deployment.\n\n**Methods:** A systematic review was performed of English language publications regarding clinical studies of ICGFA quantification in colorectal surgery in PubMed, Scopus, Web of Science and Cochrane Library on 29th August 2024, updated to 18th November 2024, following PRISMA guidelines. Newcastle Ottawa scale (NOS) was used to assess quality.\n\n**Results:** A total of 1428 studies were screened with 22 studies (1469 patients) selected. There was significant heterogeneity of ICGFA methodology, quantification methods and parameter selection and only three studies were NOS \"high\" quality. Extracorporeal application was most common. Four studies (154 patients) conducted real-time ICGFA analyses (others were post hoc) and four utilised artificial intelligence methods. Eleven studies only included patients undergoing left-sided resection (six focusing specifically on rectal resections). Only one study employed the quantification method to guide intra-operative decision-making regarding colonic transection. Twenty-six different perfusion parameters were assessed, with time from injection to visible fluorescence and maximum intensity the most commonly (but not only) correlated parameters regarding anastomotic complication (nâ€‰=â€‰18). Other grounding correlates were tissue oxygenation (nâ€‰=â€‰3, two with hyperspectral imagery), metabolites (nâ€‰=â€‰2) and surgeon interpretation (nâ€‰=â€‰5).\n\n**Conclusion:** Quantification of the ICGFA signal for colorectal surgery is feasible but has so far seen limited academic advancement beyond feasibility.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´çš„å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±ï¼ˆICGFAï¼‰ä¸é™ä½æœ¯åå»åˆå£å¹¶å‘ç—‡å‘ç”Ÿç‡ç›¸å…³ã€‚ç”±äºå…¶è§£é‡Šæ˜¯ä¸»è§‚çš„ï¼Œå› æ­¤æå‡ºäº†é‡åŒ–æ¥è§£å†³ç”¨æˆ·é—´çš„å¯å˜æ€§ã€‚æœ¬ç ”ç©¶å›é¡¾äº†æœ‰å…³ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´ ICGFA å®šé‡çš„å·²å‘è¡¨æ–‡çŒ®ï¼Œé‡ç‚¹å…³æ³¨æœ‰å½±å“åŠ›çš„ä¸´åºŠéƒ¨ç½²ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œäº 2024 å¹´ 8 æœˆ 29 æ—¥å¯¹ PubMedã€Scopusã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ä¸­æœ‰å…³ç»“ç›´è‚ æ‰‹æœ¯ä¸­ ICGFA å®šé‡ä¸´åºŠç ”ç©¶çš„è‹±æ–‡å‡ºç‰ˆç‰©è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œæ›´æ–°è‡³ 2024 å¹´ 11 æœˆ 18 æ—¥ã€‚çº½å¡æ–¯å°”æ¸¥å¤ªåé‡è¡¨ï¼ˆNOSï¼‰ç”¨äºè¯„ä¼°è´¨é‡ã€‚\n\n**ç»“æœï¼š** æ€»å…±ç­›é€‰äº† 1428 é¡¹ç ”ç©¶ï¼Œé€‰å‡ºäº† 22 é¡¹ç ”ç©¶ï¼ˆ1469 åæ‚£è€…ï¼‰ã€‚ ICGFA æ–¹æ³•ã€é‡åŒ–æ–¹æ³•å’Œå‚æ•°é€‰æ‹©å­˜åœ¨æ˜¾ç€å¼‚è´¨æ€§ï¼Œåªæœ‰ä¸‰é¡¹ç ”ç©¶è¾¾åˆ° NOSâ€œé«˜â€è´¨é‡ã€‚ä½“å¤–åº”ç”¨æœ€ä¸ºå¸¸è§ã€‚å››é¡¹ç ”ç©¶ï¼ˆ154 åæ‚£è€…ï¼‰è¿›è¡Œäº†å®æ—¶ ICGFA åˆ†æï¼ˆå…¶ä»–ç ”ç©¶æ˜¯äº‹ååˆ†æï¼‰ï¼Œå››é¡¹ç ”ç©¶åˆ©ç”¨äº†äººå·¥æ™ºèƒ½æ–¹æ³•ã€‚åä¸€é¡¹ç ”ç©¶ä»…çº³å…¥æ¥å—å·¦ä¾§åˆ‡é™¤æœ¯çš„æ‚£è€…ï¼ˆå…¶ä¸­å…­é¡¹ç ”ç©¶ä¸“é—¨é’ˆå¯¹ç›´è‚ åˆ‡é™¤æœ¯ï¼‰ã€‚åªæœ‰ä¸€é¡¹ç ”ç©¶é‡‡ç”¨é‡åŒ–æ–¹æ³•æ¥æŒ‡å¯¼ç»“è‚ æ¨ªæ–­æœ¯çš„æœ¯ä¸­å†³ç­–ã€‚è¯„ä¼°äº†äºŒåå…­ä¸ªä¸åŒçš„çŒæ³¨å‚æ•°ï¼Œä»æ³¨å°„åˆ°å¯è§è§å…‰çš„æ—¶é—´å’Œæœ€å¤§å¼ºåº¦æ˜¯ä¸å»åˆå¹¶å‘ç—‡æœ€å¸¸è§ï¼ˆä½†ä¸ä»…ä»…æ˜¯ï¼‰ç›¸å…³çš„å‚æ•°ï¼ˆnâ€‰=â€‰18ï¼‰ã€‚å…¶ä»–åŸºç¡€ç›¸å…³å› ç´ åŒ…æ‹¬ç»„ç»‡æ°§åˆï¼ˆnâ€‰=â€‰3ï¼Œå…¶ä¸­ä¸¤ä¸ªå…·æœ‰é«˜å…‰è°±å›¾åƒï¼‰ã€ä»£è°¢ç‰©ï¼ˆnâ€‰=â€‰2ï¼‰å’Œå¤–ç§‘åŒ»ç”Ÿè§£é‡Šï¼ˆnâ€‰=â€‰5ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ç»“ç›´è‚ æ‰‹æœ¯ä¸­ ICGFA ä¿¡å·çš„é‡åŒ–æ˜¯å¯è¡Œçš„ï¼Œä½†è¿„ä»Šä¸ºæ­¢å­¦æœ¯è¿›å±•æœ‰é™ï¼Œè¶…å‡ºäº†å¯è¡Œæ€§ã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€è§å…‰è¡€ç®¡é€ å½±ã€å²å“šèç»¿ã€è¿‘çº¢å¤–è…¹è…”é•œæ£€æŸ¥ã€å®šé‡", "keywords_en": "Colorectal surgery, Fluorescence angiography, Indocyanine green, Near infrared laparoscopy, Quantification", "link": "https://pubmed.ncbi.nlm.nih.gov/40019566/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 28 Feb 2025"}, {"id": "39982791", "title_en": "Research Perspective on Outcome Following Surgical Treatment for Chronic Pilonidal Sinus Disease: A Systematic Review of Common Surgical Techniques", "title_zh": "æ…¢æ€§è—æ¯›çª¦ç–¾ç—…æ‰‹æœ¯æ²»ç–—ç»“æœçš„ç ”ç©¶è§†è§’ï¼šå¸¸ç”¨æ‰‹æœ¯æŠ€æœ¯çš„ç³»ç»Ÿå›é¡¾", "authors": "Arielle E Kanters", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39982791/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39982788", "title_en": "Outcome After Surgical Treatment for Chronic Pilonidal Sinus Disease: A Systematic Review of Common Surgical Techniques", "title_zh": "æ…¢æ€§è—æ¯›çª¦ç—…æ‰‹æœ¯æ²»ç–—åçš„ç»“æœï¼šå¸¸è§æ‰‹æœ¯æŠ€æœ¯çš„ç³»ç»Ÿå›é¡¾", "authors": "Birgitte Brandstrup", "abstract_en": "**Background:** The choice of operation for chronic pilonidal sinus disease remains controversial.\n\n**Objective:** To compare the outcomes of common operations for chronic pilonidal disease.\n\n**Data Sources:** We searched PubMed, Embase, and the Cochrane Library.\n\n**Study Selection:** We included randomized trials in English or Danish language, published 2002 to 2024 that compared outcomes of operations to treat chronic pilonidal disease in adults and teenagers.\n\n**Interventions:** We compared the outcomes of secondary healing, primary midline closure, Bascom, Limberg, and Karydakis flap operations.\n\n**Main Outcome Measures:** The primary outcome was recurrence; secondary outcomes were infection, healing time, and length of stay. We compared recurrence and infection rates in meta-analyses for all techniques. We assessed the risk of bias and the quality of all trials.\n\n**Results:** Fifty trials included a total of 5762 participants. In a meta-analysis, the flap operations had fewer recurrences than primary midline closure (OR 0.31; 95% CI, 0.19-0.51; p < 0.01). The trials comparing flap operations with secondary healing were heterogeneous and did not reach significance (OR 0.38; 95% CI, 0.13-1.13; p = 0.08). Recurrence was similar between Limberg and Karydakis operations. Infection rates were lower for the flap operations compared with primary closure (OR 0.33; 95% CI, 0.23-0.48; p < 0.01) and with secondary healing (OR 0.48; 95% CI, 0.30-0.77; p < 0.01). Two trials tested Bascom procedure against Limberg operation without significant differences. All trials found secondary healing to have significantly longer healing times than any other operation.\n\n**Limitations:** Most studies had a high or medium risk of bias, resulting in very low to low certainty of evidence. The trials generally had small numbers, short follow-ups, and no reported primary outcomes or power calculations.\n\n**Conclusions:** Primary closure and secondary healing performed poorly compared with the flap techniques. Most trials tested Limberg operation; only 2 tested Bascom operation. The literature suggests the surgeon's expertise determines the choice of flap technique.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ…¢æ€§è—æ¯›çª¦ç–¾ç—…çš„æ‰‹æœ¯é€‰æ‹©ä»å­˜åœ¨äº‰è®®ã€‚\n\n**ç›®çš„ï¼š** æ¯”è¾ƒæ…¢æ€§è—æ¯›ç—…å¸¸è§æ‰‹æœ¯çš„ç»“æœã€‚\n\n**Data sourcesï¼š** æˆ‘ä»¬æ£€ç´¢äº† PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ã€‚\n\n**Study selectionï¼š** æˆ‘ä»¬çº³å…¥äº† 2002 å¹´è‡³ 2024 å¹´å‘è¡¨çš„è‹±è¯­æˆ–ä¸¹éº¦è¯­éšæœºè¯•éªŒï¼Œæ¯”è¾ƒäº†æ²»ç–—æˆäººå’Œé’å°‘å¹´æ…¢æ€§è—æ¯›ç—…çš„æ‰‹æœ¯ç»“æœã€‚\n\n**Interventionsï¼š** æˆ‘ä»¬æ¯”è¾ƒäº†äºŒæ¬¡æ„ˆåˆã€åˆæ¬¡ä¸­çº¿é—­åˆã€Bascomã€Limberg å’Œ Karydakis çš®ç“£æ‰‹æœ¯çš„ç»“æœã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“å±€æ˜¯å¤å‘ï¼›æ¬¡è¦ç»“å±€æ˜¯æ„ŸæŸ“ã€æ„ˆåˆæ—¶é—´å’Œä½é™¢æ—¶é—´ã€‚æˆ‘ä»¬åœ¨èŸèƒåˆ†æä¸­æ¯”è¾ƒäº†æ‰€æœ‰æŠ€æœ¯çš„å¤å‘ç‡å’Œæ„ŸæŸ“ç‡ã€‚æˆ‘ä»¬è¯„ä¼°äº†æ‰€æœ‰è¯•éªŒçš„åå€šé£é™©å’Œè´¨é‡ã€‚\n\n**ç»“æœï¼š** 50 é¡¹è¯•éªŒå…±æœ‰ 5762 åå‚ä¸è€…ã€‚åœ¨èŸèƒåˆ†æä¸­ï¼Œçš®ç“£æ‰‹æœ¯çš„å¤å‘ç‡ä½äºåˆæ¬¡ä¸­çº¿é—­åˆæœ¯ï¼ˆOR 0.31ï¼›95% CIï¼Œ0.19-0.51ï¼›p < 0.01ï¼‰ã€‚æ¯”è¾ƒçš®ç“£æ‰‹æœ¯ä¸äºŒæ¬¡æ„ˆåˆçš„è¯•éªŒå­˜åœ¨å¼‚è´¨æ€§ï¼Œæœªè¾¾åˆ°æ˜¾ç€æ€§ï¼ˆOR 0.38ï¼›95% CIï¼Œ0.13-1.13ï¼›p = 0.08ï¼‰ã€‚ Limberg å’Œ Karydakis æ‰‹æœ¯çš„å¤å‘ç‡ç›¸ä¼¼ã€‚ä¸åˆæ¬¡é—­åˆï¼ˆOR 0.33ï¼›95% CIï¼Œ0.23-0.48ï¼›p < 0.01ï¼‰å’ŒäºŒæ¬¡æ„ˆåˆï¼ˆOR 0.48ï¼›95% CIï¼Œ0.30-0.77ï¼›p < 0.01ï¼‰ç›¸æ¯”ï¼Œçš®ç“£æ‰‹æœ¯çš„æ„ŸæŸ“ç‡è¾ƒä½ã€‚ä¸¤é¡¹è¯•éªŒé’ˆå¯¹ Limberg æ‰‹æœ¯æµ‹è¯•äº† Bascom ç¨‹åºï¼Œæ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚æ‰€æœ‰è¯•éªŒéƒ½å‘ç°äºŒæ¬¡æ„ˆåˆçš„æ„ˆåˆæ—¶é—´æ¯”ä»»ä½•å…¶ä»–æ‰‹æœ¯éƒ½è¦é•¿å¾—å¤šã€‚\n\n**Limitationsï¼š** å¤§å¤šæ•°ç ”ç©¶éƒ½å­˜åœ¨é«˜æˆ–ä¸­ç­‰åå€šé£é™©ï¼Œå¯¼è‡´è¯æ®è´¨é‡æä½è‡³ä½ã€‚è¿™äº›è¯•éªŒé€šå¸¸æ•°é‡å°‘ï¼Œéšè®¿æ—¶é—´çŸ­ï¼Œå¹¶ä¸”æ²¡æœ‰æŠ¥å‘Šä¸»è¦ç»“æœæˆ–åŠŸæ•ˆè®¡ç®—ã€‚\n\n**ç»“è®ºï¼š** ä¸çš®ç“£æŠ€æœ¯ç›¸æ¯”ï¼Œåˆæ¬¡é—­åˆå’ŒäºŒæ¬¡æ„ˆåˆæ•ˆæœè¾ƒå·®ã€‚å¤§å¤šæ•°è¯•éªŒæµ‹è¯•äº†æ—ä¼¯æ ¼æ“ä½œï¼›ä»… 2 ä¸ªæµ‹è¯•äº† Bascom æ“ä½œã€‚æ–‡çŒ®è¡¨æ˜å¤–ç§‘åŒ»ç”Ÿçš„ä¸“ä¸šçŸ¥è¯†å†³å®šäº†çš®ç“£æŠ€æœ¯çš„é€‰æ‹©ã€‚", "keywords_zh": "Bascom è£‚å£æå‡æ‰‹æœ¯ã€æ…¢æ€§è—æ¯›çª¦ç–¾ç—…ã€è—æ¯›ç–¾ç—…å¹¶å‘ç—‡ã€æ—ä¼¯æ ¼æ‰‹æœ¯ã€è—æ¯›ç–¾ç—…å¤å‘ã€æ‰‹æœ¯æ²»ç–—è—æ¯›ç–¾ç—…", "keywords_en": "Bascom cleft-lift operation, Chronic pilonidal sinus disease, Complications pilonidal disease, Limberg operation, Pilonidal disease recurrence, Surgical treatment pilonidal disease", "link": "https://pubmed.ncbi.nlm.nih.gov/39982788/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39980238", "title_en": "A quality-of-life meta-analysis comparing pre- and postoperative symptoms in women undergoing colorectal resection for deep infiltrating endometriosis", "title_zh": "æ¯”è¾ƒå› æ·±éƒ¨æµ¸æ¶¦å­å®«å†…è†œå¼‚ä½ç—‡æ¥å—ç»“ç›´è‚ åˆ‡é™¤æœ¯çš„å¥³æ€§æœ¯å‰å’Œæœ¯åç—‡çŠ¶çš„ç”Ÿæ´»è´¨é‡èŸèƒåˆ†æ", "authors": "Cillian Clancy", "abstract_en": "**Aim:** Deep infiltrating endometriosis (DIE) may involve the rectum or colon and is associated with pain, gastrointestinal dysfunction and reduced quality of life (QoL). While hormonal treatment may be effective, surgical intervention including colorectal resection can be required. Colorectal resection can result in functional changes and complications, which can also impair QoL. The aim of this study is to examine all available comparative pre- and postoperative data on QoL and symptom outcomes following colorectal resection for DIE.\n\n**Method:** An electronic database search was conducted for studies reporting pre- and postoperative QoL and symptom outcomes following colorectal resection for DIE. The study was registered with PROSPERO and followed PRISMA (Preferred Reporting Items in Systematic Reviews and Meta-analyses) guidelines. Data were combined using random-effects models.\n\n**Results:** Fourteen studies including 1142 patients were included. Colorectal resection was associated with improved outcomes for all items in the SF-36 QoL questionnaire as well as symptom outcomes including dysmenorrhoea, chronic pelvic pain and deep dyspareunia. Importantly, the gastrointestinal QoL index was significantly improved (mean difference 24.50, 95% CI 15.93-33.08, pâ€‰<â€‰0.0001) as was dyschezia (mean difference -4.1, 95% CI -4.77 to -3.42, pâ€‰<â€‰0.0001). There was no change in low anterior resection syndrome scores (mean difference -5.28, 95% CI -11.65 to 1.10, pâ€‰=â€‰0.1046).\n\n**Conclusion:** This study demonstrates a significant postoperative improvement in patient-reported QoL, pain symptoms and gastrointestinal function following colorectal resection for endometriosis.", "abstract_zh": "**Aimï¼š** æ·±éƒ¨æµ¸æ¶¦æ€§å­å®«å†…è†œå¼‚ä½ç—‡ (DIE) å¯èƒ½ç´¯åŠç›´è‚ æˆ–ç»“è‚ ï¼Œå¹¶ä¸ç–¼ç—›ã€èƒƒè‚ åŠŸèƒ½éšœç¢å’Œç”Ÿæ´»è´¨é‡ (QoL) ä¸‹é™æœ‰å…³ã€‚è™½ç„¶æ¿€ç´ æ²»ç–—å¯èƒ½æœ‰æ•ˆï¼Œä½†å¯èƒ½éœ€è¦æ‰‹æœ¯å¹²é¢„ï¼ŒåŒ…æ‹¬ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€‚ç»“ç›´è‚ åˆ‡é™¤æœ¯å¯èƒ½å¯¼è‡´åŠŸèƒ½æ”¹å˜å’Œå¹¶å‘ç—‡ï¼Œè¿™ä¹Ÿä¼šæŸå®³ç”Ÿæ´»è´¨é‡ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯æ£€æŸ¥æ‰€æœ‰å¯ç”¨çš„ DIE ç»“ç›´è‚ åˆ‡é™¤æœ¯åç”Ÿæ´»è´¨é‡å’Œç—‡çŠ¶ç»“æœçš„æœ¯å‰å’Œæœ¯åæ¯”è¾ƒæ•°æ®ã€‚\n\n**Methodï¼š** å¯¹æŠ¥å‘Š DIE ç»“ç›´è‚ åˆ‡é™¤æœ¯åæœ¯å‰å’Œæœ¯å QoL ä»¥åŠç—‡çŠ¶ç»“æœçš„ç ”ç©¶è¿›è¡Œäº†ç”µå­æ•°æ®åº“æœç´¢ã€‚è¯¥ç ”ç©¶å·²åœ¨ PROSPERO æ³¨å†Œå¹¶éµå¾ª PRISMAï¼ˆç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æä¸­çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼‰æŒ‡å—ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹ç»„åˆæ•°æ®ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 14 é¡¹ç ”ç©¶ï¼ŒåŒ…æ‹¬ 1142 åæ‚£è€…ã€‚ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸ SF-36 ç”Ÿæ´»è´¨é‡é—®å·ä¸­æ‰€æœ‰é¡¹ç›®çš„æ”¹å–„ç»“æœä»¥åŠç—›ç»ã€æ…¢æ€§ç›†è…”ç–¼ç—›å’Œæ·±åº¦æ€§äº¤ç–¼ç—›ç­‰ç—‡çŠ¶ç»“æœç›¸å…³ã€‚é‡è¦çš„æ˜¯ï¼Œèƒƒè‚ é“ QoL æŒ‡æ•°æ˜¾ç€æ”¹å–„ï¼ˆå¹³å‡å·® 24.50ï¼Œ95% CI 15.93-33.08ï¼Œp<â€‰0.0001ï¼‰ï¼Œæ’ä¾¿å›°éš¾ä¹Ÿæ˜¾ç€æ”¹å–„ï¼ˆå¹³å‡å·® -4.1ï¼Œ95% CI -4.77 è‡³ -3.42ï¼Œp<â€‰0.0001ï¼‰ã€‚ä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†æ²¡æœ‰å˜åŒ–ï¼ˆå¹³å‡å·® -5.28ï¼Œ95% CI -11.65 è‡³ 1.10ï¼Œpâ€‰=â€‰0.1046ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼Œå­å®«å†…è†œå¼‚ä½ç—‡ç»“ç›´è‚ åˆ‡é™¤æœ¯åæ‚£è€…æŠ¥å‘Šçš„ç”Ÿæ´»è´¨é‡ã€ç–¼ç—›ç—‡çŠ¶å’Œèƒƒè‚ åŠŸèƒ½æ˜¾ç€æ”¹å–„ã€‚", "keywords_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯, å­å®«å†…è†œå¼‚ä½ç—‡, ç”Ÿæ´»è´¨é‡", "keywords_en": "colorectal resection, endometriosis, quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/39980238/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39974280", "title_en": "Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis", "title_zh": "äºŒè‚½åŸºè‚½é…¶ 4 æŠ‘åˆ¶å‰‚å¯¹ 2 å‹ç³–å°¿ç—…æ‚£è€…ç»“ç›´è‚ ç™Œå‘ç—…ç‡çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Zhiyan Wang", "abstract_en": "**Background:** The association between dipeptidyl peptidase-4 inhibitors (DPP-4i) exposure and the risk of colorectal cancer (CRC) in patients with type 2 diabetes mellitus (T2DM) is unclear.\n\n**Objectives:** This meta-analysis aims to investigate the relationship between DPP-4i exposure and the incidence of CRC in patients with T2DM.\n\n**Design:** A systematic review and meta-analysis.\n\n**Methods:** A comprehensive search of electronic databases, including PubMed, Web of Science, EMBASE, and ScienceDirect, was conducted up to March 2024. The studies including randomized clinical trials (RCTs), cohort studies, and case-control studies were retrieved. The odds ratio (OR) was calculated using Stata 12.0 statistical software. The primary outcome assessed was the incidence of CRC.\n\n**Results:** This meta-analysis incorporated six retrospective cohort studies and two case-control studies. The findings indicate that the incidence of CRC in the DPP-4i exposure group was significantly higher than that in the control group (ORâ€‰=â€‰1.11, 95% CI: 1.02-1.21, <i>p</i>â€‰=â€‰0.013). Subgroup analysis revealed that both male (ORâ€‰=â€‰2.07, <i>p</i>â€‰<â€‰0.001) and female participants (ORâ€‰=â€‰1.49, <i>p</i>â€‰=â€‰0.05) in the DPP-4i exposure group exhibited a significantly higher incidence of CRC compared to the control group. Among participants younger than 65 years, the incidence of CRC was markedly elevated in the exposure group (ORâ€‰=â€‰2.81, <i>p</i>â€‰<â€‰0.001). Furthermore, when the exposure duration was less than 1â€‰year, the CRC incidence in the exposure group surpassed that of the control group (ORâ€‰=â€‰1.24, <i>p</i>â€‰=â€‰0.005). When sulfonylureas (SU) were used as control drugs, the incidence of CRC was higher in the exposure group (ORâ€‰=â€‰1.10, <i>p</i>â€‰=â€‰0.017).\n\n**Conclusion:** There is a potential correlation between DPP-4i exposure and increased incidence of CRC in T2DM patients. This association appears to be influenced by gender, age, duration of exposure, and the choice of control medications. Therefore, attention should be paid to colorectal diseases when DPP-4i is employed in the clinic.\n\n**Trial Registration:** The meta-analysis has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). The registration number is CRD42024535292.", "abstract_zh": "**èƒŒæ™¯ï¼š** äºŒè‚½åŸºè‚½é…¶ 4 æŠ‘åˆ¶å‰‚ (DPP-4i) æš´éœ²ä¸ 2 å‹ç³–å°¿ç—… (T2DM) æ‚£è€…æ‚£ç»“ç›´è‚ ç™Œ (CRC) é£é™©ä¹‹é—´çš„å…³ç³»å°šä¸æ¸…æ¥šã€‚\n\n**Objectivesï¼š** æœ¬èŸèƒåˆ†ææ—¨åœ¨æ¢è®¨ T2DM æ‚£è€… DPP-4i æš´éœ²ä¸ CRC å‘ç—…ç‡ä¹‹é—´çš„å…³ç³»ã€‚\n\n**Designï¼š** ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³2024å¹´3æœˆï¼Œå¯¹PubMedã€Web of Scienceã€EMBASEå’ŒScienceDirectç­‰ç”µå­æ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œæ£€ç´¢äº†åŒ…æ‹¬éšæœºä¸´åºŠè¯•éªŒï¼ˆRCTï¼‰ã€é˜Ÿåˆ—ç ”ç©¶å’Œç—…ä¾‹å¯¹ç…§ç ”ç©¶åœ¨å†…çš„ç ”ç©¶ã€‚ä½¿ç”¨Stata 12.0ç»Ÿè®¡è½¯ä»¶è®¡ç®—ä¼˜åŠ¿æ¯”ï¼ˆORï¼‰ã€‚è¯„ä¼°çš„ä¸»è¦ç»“æœæ˜¯ CRC çš„å‘ç”Ÿç‡ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹èŸèƒåˆ†æçº³å…¥äº†å…­é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶å’Œä¸¤é¡¹ç—…ä¾‹å¯¹ç…§ç ”ç©¶ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼ŒDPP-4iæš´éœ²ç»„CRCçš„å‘ç”Ÿç‡æ˜¾ç€é«˜äºå¯¹ç…§ç»„ï¼ˆORâ€‰=â€‰1.11ï¼Œ95% CIï¼š1.02-1.21ï¼Œ<i>p</i>â€‰=â€‰0.013ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼ŒDPP-4iæš´éœ²ç»„ä¸­ç”·æ€§ï¼ˆORâ€‰=â€‰2.07ï¼Œ<i>p</i>â€‰<â€‰0.001ï¼‰å’Œå¥³æ€§å‚ä¸è€…ï¼ˆORâ€‰=â€‰1.49ï¼Œ<i>p</i>â€‰=â€‰0.05ï¼‰çš„CRCå‘ç—…ç‡å‡æ˜¾ç€é«˜äºå¯¹ç…§ç»„ã€‚åœ¨65å²ä»¥ä¸‹çš„å‚ä¸è€…ä¸­ï¼Œæš´éœ²ç»„çš„CRCå‘ç—…ç‡æ˜¾ç€å‡é«˜ï¼ˆORâ€‰=â€‰2.81ï¼Œ<i>p</i>â€‰<â€‰0.001ï¼‰ã€‚æ­¤å¤–ï¼Œå½“æš´éœ²æ—¶é—´å°äº1å¹´æ—¶ï¼Œæš´éœ²ç»„çš„CRCå‘ç—…ç‡è¶…è¿‡å¯¹ç…§ç»„ï¼ˆORâ€‰=â€‰1.24ï¼Œ<i>p</i>â€‰=â€‰0.005ï¼‰ã€‚å½“ä½¿ç”¨ç£ºè„²ç±»è¯ç‰©ï¼ˆSUï¼‰ä½œä¸ºå¯¹ç…§è¯ç‰©æ—¶ï¼Œæš´éœ²ç»„CRCçš„å‘ç”Ÿç‡è¾ƒé«˜ï¼ˆORâ€‰=â€‰1.10ï¼Œ<i>p</i>â€‰=â€‰0.017ï¼‰ã€‚\n\n**ç»“è®ºï¼š** T2DM æ‚£è€…ä¸­ DPP-4i æš´éœ²ä¸ CRC å‘ç—…ç‡å¢åŠ ä¹‹é—´å­˜åœ¨æ½œåœ¨ç›¸å…³æ€§ã€‚è¿™ç§å…³è”ä¼¼ä¹å—åˆ°æ€§åˆ«ã€å¹´é¾„ã€æš´éœ²æ—¶é—´å’Œå¯¹ç…§è¯ç‰©é€‰æ‹©çš„å½±å“ã€‚å› æ­¤ï¼Œä¸´åºŠåº”ç”¨DPP-4iæ—¶åº”æ³¨æ„ç»“ç›´è‚ ç–¾ç—…ã€‚\n\n**Trial registrationï¼š** è¯¥èŸèƒåˆ†æå·²åœ¨å›½é™…å‰ç»æ€§ç³»ç»Ÿè¯„ä»·ç™»è®°å†Œï¼ˆPROSPEROï¼‰æ³¨å†Œã€‚æ³¨å†Œå·ä¸ºCRD42024535292ã€‚", "keywords_zh": "DPP-4iã€ç»“ç›´è‚ ç™Œã€å‘ç—…ç‡ã€èŸèƒåˆ†æã€é£é™©ã€2 å‹ç³–å°¿ç—…", "keywords_en": "DPP-4i, colorectal cancer, incidence, meta-analysis, risk, type 2 diabetes mellitus", "link": "https://pubmed.ncbi.nlm.nih.gov/39974280/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Thu, 20 Feb 2025"}, {"id": "39960767", "title_en": "Is colonic J-pouch superior to other reconstructive techniques after total mesorectal excision? A systematic review with meta-analysis", "title_zh": "å…¨ç›´è‚ ç³»è†œåˆ‡é™¤åç»“è‚  J è¢‹æ˜¯å¦ä¼˜äºå…¶ä»–é‡å»ºæŠ€æœ¯ï¼ŸèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·", "authors": "Mario Morino", "abstract_en": "**Background:** Different reconstruction techniques after total mesorectal excision have been described, such as straight coloanal anastomosis, colonic J-pouch, side-to-end anastomosis and transverse coloplasty pouch. Establishing which technique is the best in functional terms is essential to improving a patient's quality of life.\n\n**Methods:** We compared benefits and harms of different reconstructive techniques. The primary outcome was to compare functional results at 18â€‰months after surgery (long-term). Secondary outcomes were the same as primary but at different time intervals (short-term and medium-term) and perioperative morbidity and mortality.\n\n**Results:** Forty-one reports of 36 trials were included in the analysis. According to primary outcome, no significant difference was observed in terms of bowel frequency, while colonic J-pouch resulted in a lower incidence of faecal urgency only compared to side-to-end. Only up to 18â€‰months after bowel restoration bowel frequency, fecal urgency and the number of individuals using anti-diarrheal medications were reduced in the colonic J-pouch group. No difference in mortality/morbidity could be assessed among the techniques, but a lower rate of anastomotic leak after side-to-end compared to straight coloanal anastomosis was observed.\n\n**Conclusions:** Evidence suggests that reconstruction with colonic J-pouch offers similar long-term benefits to straight coloanal anastomosis and Transverse coloplasty pouch, while superior to side-to-end.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨ç›´è‚ ç³»è†œåˆ‡é™¤åçš„ä¸åŒé‡å»ºæŠ€æœ¯å·²æœ‰æè¿°ï¼Œå¦‚ç»“è‚ ç›´è‚ å»åˆæœ¯ã€ç»“è‚ Jå½¢è¢‹ã€ä¾§ç«¯å»åˆæœ¯å’Œæ¨ªå‘ç»“è‚ æˆå½¢æœ¯è¢‹ã€‚ç¡®å®šå“ªç§æŠ€æœ¯åœ¨åŠŸèƒ½ä¸Šæ˜¯æœ€å¥½çš„å¯¹äºæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»è´¨é‡è‡³å…³é‡è¦ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ¯”è¾ƒäº†ä¸åŒé‡å»ºæŠ€æœ¯çš„å¥½å¤„å’Œåå¤„ã€‚ä¸»è¦ç»“æœæ˜¯æ¯”è¾ƒæœ¯å 18 ä¸ªæœˆï¼ˆé•¿æœŸï¼‰çš„åŠŸèƒ½ç»“æœã€‚æ¬¡è¦ç»“å±€ä¸ä¸»è¦ç»“å±€ç›¸åŒï¼Œä½†æ—¶é—´é—´éš”ï¼ˆçŸ­æœŸå’Œä¸­æœŸï¼‰ä»¥åŠå›´æ‰‹æœ¯æœŸå‘ç—…ç‡å’Œæ­»äº¡ç‡ä¸åŒã€‚\n\n**ç»“æœï¼š** åˆ†æä¸­çº³å…¥äº† 36 é¡¹è¯•éªŒçš„ 41 ä»½æŠ¥å‘Šã€‚æ ¹æ®ä¸»è¦ç»“æœï¼Œåœ¨æ’ä¾¿é¢‘ç‡æ–¹é¢æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ï¼Œè€Œç»“è‚  J å‹è¢‹ä»…ä¸ä¾§å¯¹ç«¯ç›¸æ¯”å¯¼è‡´æ’ä¾¿ç´§è¿«æ„Ÿçš„å‘ç”Ÿç‡è¾ƒä½ã€‚ä»…åœ¨è‚ é“æ¢å¤å 18 ä¸ªæœˆå†…ï¼Œç»“è‚  J è¢‹ç»„çš„æ’ä¾¿é¢‘ç‡ã€æ’ä¾¿ç´§è¿«æ„Ÿå’Œä½¿ç”¨æ­¢æ³»è¯ç‰©çš„äººæ•°å‡æœ‰æ‰€å‡å°‘ã€‚æ— æ³•è¯„ä¼°è¿™äº›æŠ€æœ¯ä¹‹é—´æ­»äº¡ç‡/å‘ç—…ç‡çš„å·®å¼‚ï¼Œä½†ä¸ç›´æ¥ç»“è‚ è‚›é—¨å»åˆç›¸æ¯”ï¼Œè§‚å¯Ÿåˆ°ä¾§ç«¯å»åˆæœ¯åå»åˆå£ç˜˜çš„å‘ç”Ÿç‡è¾ƒä½ã€‚\n\n**ç»“è®ºï¼š** æœ‰è¯æ®è¡¨æ˜ï¼Œç»“è‚  J å½¢è¢‹é‡å»ºä¸ç›´è‚ ç»“è‚ å»åˆæœ¯å’Œæ¨ªå‘ç»“è‚ æˆå½¢æœ¯è¢‹å…·æœ‰ç›¸ä¼¼çš„é•¿æœŸç›Šå¤„ï¼ŒåŒæ—¶ä¼˜äºä¾§ç«¯ç»“è‚ æˆå½¢æœ¯ã€‚", "keywords_zh": "ç›´è‚ ç™Œã€åŠŸèƒ½ç»“æœã€èŸèƒåˆ†æã€é‡å»ºæŠ€æœ¯ã€ç›´è‚ æ‰‹æœ¯", "keywords_en": "Rectal cancer, functional outcomes, meta-analysis, reconstructive techniques, rectal surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/39960767/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 17 Feb 2025"}, {"id": "39920437", "title_en": "Voiding dysfunction after surgery for colorectal deep infiltrating endometriosis: an updated systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ æ·±éƒ¨æµ¸æ¶¦å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯åæ’å°¿åŠŸèƒ½éšœç¢ï¼šæ›´æ–°çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Sofiane Bendifallah", "abstract_en": "To define the risk factors of post-operative voiding dysfunction according to the type of surgical procedure performed. A systematic review through PubMed, the Cochrane Library, and Web of Science databases was performed. The Medical Subject Headings terms aimed for English articles about colorectal endometriosis surgery and voiding dysfunction published until December 26, 2022 were used. The primary outcome was the occurrence of post-operative voiding dysfunction. Secondary outcome was the presence of a persistent voiding dysfunction at 1Â month. MeSH terms included ''deep endometriosis'', ''surgery'', or ''voiding dysfunction''. Two reviewers (AM, PE) assessed the quality of each article independently. A Study Quality Assessment Tool was used to provide rating of the quality of the included studies. 22 studies were included in the final analysis. Rectal shaving was associated with less voiding dysfunction than segmental resection (OR 0.33; 95%CI [0.20: 0.54]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰<â€‰10<sup>-3</sup>). No difference was found between rectal shaving and discoid excision (OR 0.44; 95%CI [0.07: 2.84]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39), nor between discoid excision and segmental resection (OR 0.44; 95%CI [0.18: 1.09]; I<sup>2</sup>â€‰=â€‰49%; pâ€‰=â€‰0.08). Conservative surgery (i.e., shaving and discoid) was associated with less voiding dysfunction than radical surgery (i.e., segmental resection) (OR 0.37; 95%CI [0.25: 0.55]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰<â€‰10<sup>-3</sup>). Regarding persistent voiding dysfunction, rectal shaving and discoid excision were less associated with voiding dysfunction than segmental resection (respectively, OR 0.30; 95%CI [0.14: 0.66]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰=â€‰0.003 and OR 0.13; 95%CI [0.03: 0.57]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰=â€‰0.007). Conservative bowel procedures are associated with lower rates of persistent post-operative voiding dysfunction and should be considered first when possible.Trial registration: Our meta-analysis was registered under the PROSPERO number: CRD42023395356.", "abstract_zh": "æ ¹æ®æ‰€è¿›è¡Œçš„æ‰‹æœ¯ç±»å‹ç¡®å®šæœ¯åæ’å°¿åŠŸèƒ½éšœç¢çš„å±é™©å› ç´ ã€‚é€šè¿‡ PubMedã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚ä½¿ç”¨çš„åŒ»å­¦ä¸»é¢˜æ ‡é¢˜æœ¯è¯­é’ˆå¯¹çš„æ˜¯æˆªè‡³ 2022 å¹´ 12 æœˆ 26 æ—¥å‘è¡¨çš„æœ‰å…³ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯å’Œæ’å°¿åŠŸèƒ½éšœç¢çš„è‹±æ–‡æ–‡ç« ã€‚ä¸»è¦ç»“å±€æ˜¯æœ¯åæ’å°¿åŠŸèƒ½éšœç¢çš„å‘ç”Ÿã€‚æ¬¡è¦ç»“æœæ˜¯ 1 ä¸ªæœˆæ—¶å‡ºç°æŒç»­æ€§æ’å°¿åŠŸèƒ½éšœç¢ã€‚ MeSH æœ¯è¯­åŒ…æ‹¬â€œæ·±éƒ¨å­å®«å†…è†œå¼‚ä½ç—‡â€ã€â€œæ‰‹æœ¯â€æˆ–â€œæ’å°¿åŠŸèƒ½éšœç¢â€ã€‚ä¸¤ä½å®¡ç¨¿äººï¼ˆAMã€PEï¼‰ç‹¬ç«‹è¯„ä¼°æ¯ç¯‡æ–‡ç« çš„è´¨é‡ã€‚ç ”ç©¶è´¨é‡è¯„ä¼°å·¥å…·ç”¨äºå¯¹çº³å…¥ç ”ç©¶çš„è´¨é‡è¿›è¡Œè¯„çº§ã€‚æœ€ç»ˆåˆ†æçº³å…¥22é¡¹ç ”ç©¶ã€‚ç›´è‚ å‰ƒæ¯›ä¸èŠ‚æ®µåˆ‡é™¤ç›¸æ¯”ï¼Œæ’å°¿åŠŸèƒ½éšœç¢è¾ƒå°‘ï¼ˆOR 0.33ï¼›95%CI [0.20: 0.54]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰<â€‰10<sup>-3</sup>ï¼‰ã€‚ç›´è‚ å‰ƒé™¤å’Œç›˜çŠ¶åˆ‡é™¤ä¹‹é—´æ²¡æœ‰å‘ç°å·®å¼‚ï¼ˆOR 0.44; 95%CI [0.07: 2.84]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39ï¼‰ï¼Œç›˜çŠ¶åˆ‡é™¤å’ŒèŠ‚æ®µåˆ‡é™¤ä¹‹é—´ä¹Ÿæ²¡æœ‰å‘ç°å·®å¼‚ï¼ˆOR 0.44; 95%CI [0.18: 1.09]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39ï¼‰ã€‚ I<sup>2</sup>â€‰=â€‰49%ï¼›pâ€‰=â€‰0.08)ã€‚ä¸æ ¹æ²»æ€§æ‰‹æœ¯ï¼ˆå³èŠ‚æ®µåˆ‡é™¤ï¼‰ç›¸æ¯”ï¼Œä¿å®ˆæ‰‹æœ¯ï¼ˆå³å‰ƒæ¯›å’Œç›˜çŠ¶æ‰‹æœ¯ï¼‰ä¸è¾ƒå°‘çš„æ’å°¿åŠŸèƒ½éšœç¢ç›¸å…³ï¼ˆOR 0.37ï¼›95%CI [0.25: 0.55]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰<â€‰10<sup>-3</sup>ï¼‰ã€‚å…³äºæŒç»­æ€§æ’å°¿åŠŸèƒ½éšœç¢ï¼Œç›´è‚ å‰ƒé™¤å’Œç›˜çŠ¶åˆ‡é™¤ä¸èŠ‚æ®µæ€§åˆ‡é™¤ç›¸æ¯”ï¼Œä¸æ’å°¿åŠŸèƒ½éšœç¢çš„ç›¸å…³æ€§è¾ƒå°ï¼ˆåˆ†åˆ«ä¸º OR 0.30ï¼›95%CI [0.14: 0.66]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰=â€‰0.003 å’Œ OR 0.13ï¼›95%CI [0.03: 0.57]ï¼› I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰=â€‰0.007)ã€‚ä¿å®ˆæ€§è‚ é“æ‰‹æœ¯ä¸æœ¯åæŒç»­æ’å°¿åŠŸèƒ½éšœç¢çš„å‘ç”Ÿç‡è¾ƒä½æœ‰å…³ï¼Œå¦‚æœ‰å¯èƒ½ï¼Œåº”é¦–å…ˆè€ƒè™‘ã€‚è¯•éªŒæ³¨å†Œï¼šæˆ‘ä»¬çš„èŸèƒåˆ†æå·²åœ¨ PROSPERO ç¼–å·ä¸‹æ³¨å†Œï¼šCRD42023395356ã€‚", "keywords_zh": "ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡ã€ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€ç›˜çŠ¶åˆ‡é™¤æœ¯ã€å‰ƒæ¯›ã€æ‰‹æœ¯ã€æ’å°¿åŠŸèƒ½éšœç¢", "keywords_en": "Colorectal endometriosis, Colorectal resection, Discoid excision, Shaving, Surgery, Voiding dysfunction", "link": "https://pubmed.ncbi.nlm.nih.gov/39920437/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 07 Feb 2025"}, {"id": "39908072", "title_en": "Endovascular rectal artery embolisation (RAE) for symptomatic haemorrhoids", "title_zh": "è¡€ç®¡å†…ç›´è‚ åŠ¨è„‰æ “å¡æœ¯ï¼ˆRAEï¼‰æ²»ç–—æœ‰ç—‡çŠ¶çš„ç—”ç–®", "authors": "Ian Chetter", "abstract_en": "This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the safety and clinical effectiveness of endovascular rectal artery embolisation (RAE) for symptomatic haemorrhoids.", "abstract_zh": "è¿™æ˜¯ Cochrane ç»¼è¿°ï¼ˆå¹²é¢„ï¼‰çš„æ–¹æ¡ˆã€‚ç›®æ ‡å¦‚ä¸‹ï¼šè¯„ä¼°è¡€ç®¡å†…ç›´è‚ åŠ¨è„‰æ “å¡æœ¯ï¼ˆRAEï¼‰æ²»ç–—æœ‰ç—‡çŠ¶çš„ç—”ç–®çš„å®‰å…¨æ€§å’Œä¸´åºŠæœ‰æ•ˆæ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39908072/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 05 Feb 2025"}, {"id": "39907263", "title_en": "How to Write a Systematic Review and Meta-analysis", "title_zh": "å¦‚ä½•æ’°å†™ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Richard L Nelson", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39907263/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Wed, 05 Feb 2025"}, {"id": "39900861", "title_en": "Impact of indocyanine green fluorescence angiography on surgeon action and anastomotic leak in colorectal resections. A systematic review and meta-analysis", "title_zh": "å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±å¯¹ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸­å¤–ç§‘åŒ»ç”Ÿè¡ŒåŠ¨å’Œå»åˆå£ç˜˜çš„å½±å“ã€‚ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Ronan A Cahill", "abstract_en": "**Background:** Indocyanine green fluorescence angiography (ICGFA) during colorectal surgery either reassures surgeons regarding intestinal perfusion sufficiency or prompts changed surgical strategy by indicating unsuspected insufficiency. This study describes existing evidence supporting ICGFA use in colorectal surgery, particularly regarding impact on intraoperative decisions.\n\n**Methods:** Searches were performed on PubMed, ScienceDirect, Scopus, Web of Science, Cochrane Collaboration databases on 5th December 2023, updated to 19th August 2024. Full English language publications of clinical studies in human patients undergoing colorectal resection with primary anastomosis with the use of ICGFA to assess bowel perfusion intraoperatively, with a control group, were included. Pooling of anastomotic leak (AL) rates was performed for primary outcome analysis with odds ratio (OR) and number-needed-to-treat (NNT) calculated regarding leak reduction.\n\n**Results:** 45 studies comprising 14,333 patients were included, with 7 randomised controlled trials (2911 patients). Overall, AL rate was 6.8%, 4.5% with ICGFA and 8.5% without (OR:0.47, pâ€‰<â€‰0.001, NNT 23), increasing to 9.5%, 7.5% and 11.6%, respectively, in randomised controlled trials (OR:0.62, pâ€‰<â€‰0.01, NNT 25). In rectal resections, AL rate was 4.7% with ICGFA vs 11.5% without (OR: 0.38, pâ€‰<â€‰0.0001). 26 studies performed ICGFA before and after anastomosis formation and 19 used ICGFA only prior to bowel transection, with no significant difference of AL rate reduction on subgroup testing. ICGFA prompted a change in surgical plan in 8.4% of thirty-four studies reporting this. Interestingly, in these studies, leak rates overall were 3.7% when ICGFA matched surgeon judgement versus 5.7% when it prompted change (OR 0.51, pâ€‰<â€‰0.0025), versus 7.7% without (OR 0.45, pâ€‰<â€‰0.0001). In rectal resections, these figures were 5%, 8.8% (OR 0.42, pâ€‰=â€‰0.01) and 12.0% (OR0.39, pâ€‰<â€‰0.0001), respectively.\n\n**Conclusions:** ICGFA colorectal perfusion assessment is associated with lower anastomotic leak rates, especially when confirming surgeons' judgement, and may so stratify patients post-operatively regarding subsequent anastomotic leak rate.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´çš„å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½± (ICGFA) è¦ä¹ˆå¯ä»¥è®©å¤–ç§‘åŒ»ç”Ÿæ”¾å¿ƒè‚ é“çŒæ³¨å……è¶³ï¼Œè¦ä¹ˆé€šè¿‡æŒ‡ç¤ºæ„å¤–çš„ä¸è¶³æ¥æç¤ºæ”¹å˜æ‰‹æœ¯ç­–ç•¥ã€‚æœ¬ç ”ç©¶æè¿°äº†æ”¯æŒ ICGFA åœ¨ç»“ç›´è‚ æ‰‹æœ¯ä¸­ä½¿ç”¨çš„ç°æœ‰è¯æ®ï¼Œç‰¹åˆ«æ˜¯å…³äºå¯¹æœ¯ä¸­å†³ç­–çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº 2023 å¹´ 12 æœˆ 5 æ—¥åœ¨ PubMedã€ScienceDirectã€Scopusã€Web of Scienceã€Cochrane Collaboration æ•°æ®åº“ä¸­è¿›è¡Œï¼Œæ›´æ–°è‡³ 2024 å¹´ 8 æœˆ 19 æ—¥ã€‚çº³å…¥äº†å¯¹æ¥å—ä¸€æœŸç»“ç›´è‚ åˆ‡é™¤æœ¯çš„äººç±»æ‚£è€…è¿›è¡Œä¸´åºŠç ”ç©¶çš„å®Œæ•´è‹±æ–‡å‡ºç‰ˆç‰©ï¼Œå…¶ä¸­ä½¿ç”¨ ICGFA è¯„ä¼°æœ¯ä¸­è‚ é“çŒæ³¨ï¼Œå¹¶æœ‰å¯¹ç…§ç»„ã€‚æ±‡æ€»å»åˆå£æ¼ (AL) ç‡ä»¥è¿›è¡Œä¸»è¦ç»“æœåˆ†æï¼Œå¹¶è®¡ç®—å‡ºæœ‰å…³å‡å°‘æ¼çš„æ¯”å€¼æ¯” (OR) å’Œéœ€è¦æ²»ç–—çš„äººæ•° (NNT)ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 45 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 14,333 åæ‚£è€…ï¼Œå…¶ä¸­ 7 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ˆ2911 åæ‚£è€…ï¼‰ã€‚æ€»ä½“è€Œè¨€ï¼Œæ¥å— ICGFA çš„ AL å‘ç”Ÿç‡ä¸º 6.8%ã€4.5%ï¼Œä¸æ¥å— ICGFA çš„ AL ç‡ä¸º 8.5%ï¼ˆORï¼š0.47ï¼Œp<0.001ï¼ŒNNT 23ï¼‰ï¼Œåœ¨éšæœºå¯¹ç…§è¯•éªŒä¸­åˆ†åˆ«å¢åŠ è‡³ 9.5%ã€7.5% å’Œ 11.6%ï¼ˆORï¼š0.62ï¼Œp<0.01ï¼ŒNNT 25ï¼‰ã€‚åœ¨ç›´è‚ åˆ‡é™¤æœ¯ä¸­ï¼Œä½¿ç”¨ ICGFA çš„ AL ç‡ä¸º 4.7%ï¼Œè€Œæœªä½¿ç”¨ ICGFA çš„ AL ç‡ä¸º 11.5%ï¼ˆORï¼š0.38ï¼Œp<â€‰0.0001ï¼‰ã€‚ 26 é¡¹ç ”ç©¶åœ¨å»åˆå½¢æˆä¹‹å‰å’Œä¹‹åè¿›è¡Œäº† ICGFAï¼Œ19 é¡¹ç ”ç©¶ä»…åœ¨è‚ æ¨ªæ–­ä¹‹å‰ä½¿ç”¨ ICGFAï¼Œäºšç»„æµ‹è¯•ä¸­ AL ç‡é™ä½æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚åœ¨æŠ¥å‘Šè¿™ä¸€æƒ…å†µçš„ 34 é¡¹ç ”ç©¶ä¸­ï¼ŒICGFA ä¿ƒä½¿ 8.4% çš„äººæ”¹å˜äº†æ‰‹æœ¯è®¡åˆ’ã€‚æœ‰è¶£çš„æ˜¯ï¼Œåœ¨è¿™äº›ç ”ç©¶ä¸­ï¼Œå½“ ICGFA ä¸å¤–ç§‘åŒ»ç”Ÿåˆ¤æ–­ç›¸åŒ¹é…æ—¶ï¼Œæ³„æ¼ç‡ä¸º 3.7%ï¼Œè€Œå½“ ICGFA ä¿ƒä½¿æ”¹å˜æ—¶ï¼Œæ³„æ¼ç‡ä¸º 5.7%ï¼ˆOR 0.51ï¼Œp<â€‰0.0025ï¼‰ï¼Œè€Œå½“ ICGFA ä¸åŒ¹é…å¤–ç§‘åŒ»ç”Ÿåˆ¤æ–­æ—¶ï¼Œæ³„æ¼ç‡ä¸º 7.7%ï¼ˆOR 0.45ï¼Œp<â€‰0.0001ï¼‰ã€‚åœ¨ç›´è‚ åˆ‡é™¤æœ¯ä¸­ï¼Œè¿™äº›æ•°å­—åˆ†åˆ«ä¸º 5%ã€8.8%ï¼ˆOR 0.42ï¼Œpâ€‰=â€‰0.01ï¼‰å’Œ 12.0%ï¼ˆOR0.39ï¼Œpâ€‰<â€‰0.0001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICGFAç»“ç›´è‚ çŒæ³¨è¯„ä¼°ä¸è¾ƒä½çš„å»åˆå£æ¼ç‡ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯åœ¨ç¡®è®¤å¤–ç§‘åŒ»ç”Ÿçš„åˆ¤æ–­æ—¶ï¼Œå¹¶ä¸”å¯èƒ½å› æ­¤åœ¨æœ¯åå¯¹æ‚£è€…éšåçš„å»åˆå£æ¼ç‡è¿›è¡Œåˆ†å±‚ã€‚", "keywords_zh": "å»åˆå£ç˜˜ï¼Œç»“ç›´è‚ æ‰‹æœ¯ï¼Œå²å“šèç»¿ï¼Œè¿‘çº¢å¤–è…¹è…”é•œï¼Œç›´è‚ ç™Œ", "keywords_en": "Anastomotic leak, Colorectal surgery, Indocyanine green, Near-infrared laparoscopy, Rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39900861/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Mon, 03 Feb 2025"}, {"id": "39859149", "title_en": "Comprehensive Overview of Molecular, Imaging, and Therapeutic Challenges in Rectal Mucinous Adenocarcinoma", "title_zh": "ç›´è‚ ç²˜æ¶²è…ºç™Œçš„åˆ†å­ã€å½±åƒå­¦å’Œæ²»ç–—æŒ‘æˆ˜çš„å…¨é¢æ¦‚è¿°", "authors": "Florin Graur", "abstract_en": "Rectal cancer is one of the most frequent malignancies worldwide. The most common histological type is adenocarcinoma, followed by mucinous adenocarcinoma. The outcome is less favorable for the mucinous type, yet the treatment course is the same. The aim of this systematic literature review is to assess existing information in order to improve survival in rectal mucinous adenocarcinoma (RMA) and establish a starting point for future research. A systematic search of PubMed, Google Scholar, and Web of Science online libraries was performed in October 2024, evaluating studies regarding clinicopathological and genetic features in connection with targeted treatment and survival outcomes in RMA, using the terms \"rectal cancer\", \"rectum\", \"mucinous adenocarcinoma\", or a combination of the terms. We selected 23 studies, 10 of them regarding the diagnostic implications and 13 discussing the treatment strategies and prognosis of this histological subtype. There were six studies addressing the imaging aspects, highlighting the distinct features of mucinous histology in MRI. The molecular specifics were detailed in four studies, outlining the molecular footprint. The prognosis and treatment course were addressed in 12 studies. The inflammation index prognosis, complete response to neoadjuvant chemotherapy, and surgical aspects were addressed individually in each study. We encapsulated the molecular and clinicopathological characteristics of RMA, as well as diagnostic and treatment approaches, to establish a baseline of references for the benefit of daily practice and further research.", "abstract_zh": "ç›´è‚ ç™Œæ˜¯å…¨ä¸–ç•Œæœ€å¸¸è§çš„æ¶æ€§è‚¿ç˜¤ä¹‹ä¸€ã€‚æœ€å¸¸è§çš„ç»„ç»‡å­¦ç±»å‹æ˜¯è…ºç™Œï¼Œå…¶æ¬¡æ˜¯ç²˜æ¶²æ€§è…ºç™Œã€‚ç²˜æ¶²å‹çš„ç»“æœè¾ƒå·®ï¼Œä½†æ²»ç–—è¿‡ç¨‹æ˜¯ç›¸åŒçš„ã€‚æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°çš„ç›®çš„æ˜¯è¯„ä¼°ç°æœ‰ä¿¡æ¯ï¼Œä»¥æé«˜ç›´è‚ ç²˜æ¶²è…ºç™Œ (RMA) çš„ç”Ÿå­˜ç‡ï¼Œå¹¶ä¸ºæœªæ¥çš„ç ”ç©¶å¥ å®šèµ·ç‚¹ã€‚ 2024 å¹´ 10 æœˆå¯¹ PubMedã€Google Scholar å’Œ Web of Science åœ¨çº¿å›¾ä¹¦é¦†è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œä½¿ç”¨æœ¯è¯­â€œç›´è‚ ç™Œâ€ã€â€œç›´è‚ â€ã€â€œç²˜æ¶²è…ºç™Œâ€æˆ–è¿™äº›æœ¯è¯­çš„ç»„åˆï¼Œè¯„ä¼°äº†ä¸ RMA é¶å‘æ²»ç–—å’Œç”Ÿå­˜ç»“æœç›¸å…³çš„ä¸´åºŠç—…ç†å­¦å’Œé—ä¼ ç‰¹å¾çš„ç ”ç©¶ã€‚æˆ‘ä»¬é€‰æ‹©äº† 23 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­ 10 é¡¹æ¶‰åŠè¯Šæ–­æ„ä¹‰ï¼Œ13 é¡¹è®¨è®ºè¯¥ç»„ç»‡å­¦äºšå‹çš„æ²»ç–—ç­–ç•¥å’Œé¢„åã€‚æœ‰å…­é¡¹ç ”ç©¶æ¶‰åŠæˆåƒæ–¹é¢ï¼Œçªå‡ºäº† MRI ä¸­ç²˜æ¶²ç»„ç»‡å­¦çš„ç‹¬ç‰¹ç‰¹å¾ã€‚å››é¡¹ç ”ç©¶è¯¦ç»†ä»‹ç»äº†åˆ†å­ç»†èŠ‚ï¼Œæ¦‚è¿°äº†åˆ†å­è¶³è¿¹ã€‚ 12 é¡¹ç ”ç©¶æ¢è®¨äº†é¢„åå’Œæ²»ç–—è¿‡ç¨‹ã€‚æ¯é¡¹ç ”ç©¶å‡å•ç‹¬è®¨è®ºäº†ç‚ç—‡æŒ‡æ•°é¢„åã€å¯¹æ–°è¾…åŠ©åŒ–ç–—çš„å®Œå…¨ååº”ä»¥åŠæ‰‹æœ¯æ–¹é¢çš„é—®é¢˜ã€‚æˆ‘ä»¬æ¦‚æ‹¬äº† RMA çš„åˆ†å­å’Œä¸´åºŠç—…ç†å­¦ç‰¹å¾ä»¥åŠè¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ï¼Œä»¥å»ºç«‹å‚è€ƒåŸºçº¿ï¼Œä»¥åˆ©äºæ—¥å¸¸å®è·µå’Œè¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "åˆ†å­é€”å¾„, ç²˜æ¶²è…ºç™Œ, æ–°è¾…åŠ©æ²»ç–—, ç›´è‚ ç™Œ", "keywords_en": "molecular pathways, mucinous adenocarcinoma, neoadjuvant treatment, rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39859149/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Sat, 25 Jan 2025"}, {"id": "39855400", "title_en": "The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic \"Microboost\"", "title_zh": "å±€éƒ¨å‰åˆ—è…ºå†…â€œå¾®å¢å¼ºâ€æ²»ç–—å‰åˆ—è…ºç™Œçš„æ¯’æ€§å†³å®šå› ç´ ", "authors": "Jeffrey M Ryckman", "abstract_en": "**Purpose:** A single-phase 3 trial has demonstrated that prostate radiation therapy with a focal, intraprostatic \"microboost\" can improve disease control without an overall increase in toxicity. It is unclear how these results generalize to other treatment schedules and protocols.\n\n**Methods And Materials:** A systematic search of PubMed and the Cochrane review was performed for studies published on or before September 1, 2023. A random-effects meta-analysis was used to pool the cumulative incidence of grade â‰¥2 (â‰¥G2) acute and late genitourinary (GU) and gastrointestinal (GI) toxicity. Heterogeneity was assessed, and the association of trial-level covariates with toxicity was examined via the subgroup analyses and meta-regression. Odds ratios (ORs) for dose metrics were reported per Gy equivalent dose in 2Gy per fraction (EQD2).\n\n**Results:** Thirty-eight patient cohorts were included. The pooled estimate of the cumulative incidence of â‰¥G2 acute and late GU toxicity was 25.3% (95% CI, 19.1%-32.8%) and 21.1% (95% CI, 16.7%-26.3%), respectively. Late â‰¥G2 GI toxicity was less frequent, estimated at 5.6% (95% CI, 3.5%-8.7%) and 6.9% (95% CI, 4.6%-10.1%), respectively. Subgroup factors associated with at least one â‰¥G2 toxicity category were treatment technique, imaging used for boost volume definition, intrafraction motion management, trial phase, and toxicity grading. Rectal D<sub>Max</sub> was associated with acute â‰¥G2 GI toxicity (OR, 1.05; 95% CI, 1.02-1.08; P < .001). Additionally, urethral D<sub>Max</sub> was associated with late â‰¥G2 GU toxicity (OR, 1.02; 95% CI, 1.01-1.03; P < .001), and a stronger relationship was observed with the average plan urethral D<sub>Max</sub> (OR, 1.05; 95% CI, 1.03-1.07; P < .001). No association of toxicity with any bladder dose metric examined was observed.\n\n**Conclusions:** The utilization of a microboost seems tolerable across treatment protocols; however, subgroup factors, including the use of intrafraction motion management and the type of imaging modality used, may influence the probability of toxicity. Attention to rectal D<sub>Max</sub> constraints and urethral D<sub>Max</sub> dose constraints may help to mitigate GI and GU toxicity, respectively. No association between toxicity and bladder dose constraints was observed.", "abstract_zh": "**Purposeï¼š** ä¸€é¡¹å•æœŸ 3 æœŸè¯•éªŒè¡¨æ˜ï¼Œé‡‡ç”¨å±€ç¶æ€§å‰åˆ—è…ºå†…â€œå¾®å¢å¼ºâ€çš„å‰åˆ—è…ºæ”¾å°„æ²»ç–—å¯ä»¥æ”¹å–„ç–¾ç—…æ§åˆ¶ï¼Œè€Œä¸ä¼šæ€»ä½“å¢åŠ æ¯’æ€§ã€‚ç›®å‰å°šä¸æ¸…æ¥šè¿™äº›ç»“æœå¦‚ä½•æ¨å¹¿åˆ°å…¶ä»–æ²»ç–—æ–¹æ¡ˆå’Œæ–¹æ¡ˆã€‚\n\n**Methods and materialsï¼š** å¯¹ 2023 å¹´ 9 æœˆ 1 æ—¥æˆ–ä¹‹å‰å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº† PubMed å’Œ Cochrane ç»¼è¿°çš„ç³»ç»Ÿæ£€ç´¢ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†ææ¥æ±‡æ€» â‰¥2 çº§ (â‰¥G2) æ€¥æ€§å’Œæ™šæœŸæ³Œå°¿ç”Ÿæ®– (GU) å’Œèƒƒè‚ é“ (GI) æ¯’æ€§çš„ç´¯ç§¯å‘ç”Ÿç‡ã€‚è¯„ä¼°å¼‚è´¨æ€§ï¼Œå¹¶é€šè¿‡äºšç»„åˆ†æå’ŒèŸèƒå›å½’æ£€æŸ¥è¯•éªŒæ°´å¹³åå˜é‡ä¸æ¯’æ€§çš„å…³è”ã€‚å‰‚é‡æŒ‡æ ‡çš„æ¯”å€¼æ¯” (OR) ä»¥æ¯ Gy ç­‰æ•ˆå‰‚é‡æŠ¥å‘Šï¼Œä»¥æ¯åˆ†æ•° 2Gy (EQD2) è¡¨ç¤ºã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 38 åæ‚£è€…é˜Ÿåˆ—ã€‚ â‰¥G2 æ€¥æ€§å’Œæ™šæœŸ GU æ¯’æ€§ç´¯ç§¯å‘ç”Ÿç‡çš„æ±‡æ€»ä¼°è®¡å€¼åˆ†åˆ«ä¸º 25.3%ï¼ˆ95% CIï¼Œ19.1%-32.8%ï¼‰å’Œ 21.1%ï¼ˆ95% CIï¼Œ16.7%-26.3%ï¼‰ã€‚æ™šæœŸâ‰¥G2èƒƒè‚ é“æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½ï¼Œä¼°è®¡åˆ†åˆ«ä¸º5.6%ï¼ˆ95% CIï¼Œ3.5%-8.7%ï¼‰å’Œ6.9%ï¼ˆ95% CIï¼Œ4.6%-10.1%ï¼‰ã€‚ä¸è‡³å°‘ä¸€ç§ â‰¥G2 æ¯’æ€§ç±»åˆ«ç›¸å…³çš„äºšç»„å› ç´ åŒ…æ‹¬æ²»ç–—æŠ€æœ¯ã€ç”¨äºå®šä¹‰å‡å‹é‡çš„æˆåƒã€åˆ†æ¬¡å†…è¿åŠ¨ç®¡ç†ã€è¯•éªŒé˜¶æ®µå’Œæ¯’æ€§åˆ†çº§ã€‚ç›´è‚  D<sub>Max</sub> ä¸æ€¥æ€§ â‰¥G2 èƒƒè‚ é“æ¯’æ€§ç›¸å…³ï¼ˆORï¼Œ1.05ï¼›95% CIï¼Œ1.02-1.08ï¼›P < .001ï¼‰ã€‚æ­¤å¤–ï¼Œå°¿é“ D<sub>Max</sub> ä¸æ™šæœŸ â‰¥G2 GU æ¯’æ€§ç›¸å…³ï¼ˆORï¼Œ1.02ï¼›95% CIï¼Œ1.01-1.03ï¼›P < .001ï¼‰ï¼Œå¹¶ä¸”ä¸å¹³å‡è®¡åˆ’å°¿é“ D<sub>Max</sub> ä¹‹é—´çš„å…³ç³»æ›´å¼ºï¼ˆORï¼Œ1.05ï¼›95% CIï¼Œ1.03-1.07ï¼›P < .001ï¼‰ã€‚æ²¡æœ‰è§‚å¯Ÿåˆ°æ¯’æ€§ä¸ä»»ä½•æ£€æŸ¥çš„è†€èƒ±å‰‚é‡æŒ‡æ ‡ä¹‹é—´çš„å…³è”ã€‚\n\n**ç»“è®ºï¼š** åœ¨ä¸åŒçš„æ²»ç–—æ–¹æ¡ˆä¸­ï¼Œå¾®å¢å¼ºçš„ä½¿ç”¨ä¼¼ä¹æ˜¯å¯ä»¥æ¥å—çš„ã€‚ç„¶è€Œï¼Œäºšç»„å› ç´ ï¼ŒåŒ…æ‹¬åˆ†æ¬¡å†…è¿åŠ¨ç®¡ç†çš„ä½¿ç”¨å’Œæ‰€ä½¿ç”¨çš„æˆåƒæ–¹å¼çš„ç±»å‹ï¼Œå¯èƒ½ä¼šå½±å“æ¯’æ€§çš„å¯èƒ½æ€§ã€‚æ³¨æ„ç›´è‚  D<sub>Max</sub> é™åˆ¶å’Œå°¿é“ D<sub>Max</sub> å‰‚é‡é™åˆ¶å¯èƒ½æœ‰åŠ©äºåˆ†åˆ«å‡è½» GI å’Œ GU æ¯’æ€§ã€‚æ²¡æœ‰è§‚å¯Ÿåˆ°æ¯’æ€§å’Œè†€èƒ±å‰‚é‡é™åˆ¶ä¹‹é—´çš„å…³è”ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39855400/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 24 Jan 2025"}, {"id": "39854786", "title_en": "The prevalence of incontinence after excisional hemorrhoidectomy and stapled hemorrhoidopexy: A systematic review and meta-analysis", "title_zh": "ç—”åˆ‡é™¤æœ¯å’Œå»åˆå™¨ç—”å›ºå®šæœ¯åå¤±ç¦çš„å‘ç”Ÿç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Andrew G Hill", "abstract_en": "**Background:** Excisional hemorrhoidectomy and stapled hemorrhoidopexy are 2 common procedures for treating symptomatic hemorrhoids. However, concerns persist regarding the risk of postoperative complications and their unclear prevalence in the literature. This systematic review aims to evaluate andÂ compare the prevalence of incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy.\n\n**Methods:** A systematic search of Medline, EMBASE, and CENTRAL identified studies published in the past 25Â years that reported incontinence after excisional treatments for hemorrhoids. Primary outcomes included early (<3Â months) and late (â‰¥3Â months) fecal incontinence. Secondary outcomes included postoperative bleeding, urinary retention, and recurrence. Single-arm meta-analyses of proportions were performed using R with meta-regression.\n\n**Results:** In total, 139 studies were included in the meta-analysis, including 68 randomized controlled trials with 8,445 participants and 71 observational studies with 22,687 participants. Early incontinence rates were 5.32% in randomized controlled trials (95% confidence interval, 2.74-8.51%) and 1.03% in nonrandomized controlled trials (95% confidence interval, 0.28-2.09%). Late incontinence rates were 2.48% in randomized controlled trials (95% confidence interval, 1.09-4.25%) and 1.44% in nonrandomized controlled trials (95% confidence interval, 0.71-2.37%). There was no significant difference in the risk of incontinence or other postoperative complications between stapled hemorrhoidopexy and excisional hemorrhoidectomy, both in randomized controlled trials and nonrandomized controlled trials.\n\n**Conclusion:** Incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy is uncommon, and there appears to be no significant difference in risk between the 2 procedures. However, considerable heterogeneity was observed, likely the result of differences in assessment and reporting methods across studies. Future research should standardize definitions and methods for assessing incontinence and include preoperative assessments to more accurately define the risks of complications associated with hemorrhoid surgery.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”åˆ‡é™¤æœ¯å’Œå»åˆå™¨ç—”å›ºå®šæœ¯æ˜¯æ²»ç–—ç—‡çŠ¶æ€§ç—”ç–®çš„ä¸¤ç§å¸¸è§æ‰‹æœ¯ã€‚ç„¶è€Œï¼Œäººä»¬ä»ç„¶å¯¹æœ¯åå¹¶å‘ç—‡çš„é£é™©åŠå…¶æ–‡çŒ®ä¸­ä¸æ¸…æ¥šçš„å‘ç”Ÿç‡è¡¨ç¤ºæ‹…å¿§ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼°å’Œæ¯”è¾ƒå»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯åå¤±ç¦çš„å‘ç”Ÿç‡ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ Medlineã€EMBASE å’Œ CENTRAL çš„ç³»ç»Ÿæ£€ç´¢å‘ç°äº†è¿‡å» 25 å¹´å‘è¡¨çš„ç ”ç©¶ï¼Œè¿™äº›ç ”ç©¶æŠ¥å‘Šäº†ç—”ç–®åˆ‡é™¤æ²»ç–—åçš„å¤±ç¦æƒ…å†µã€‚ä¸»è¦ç»“å±€åŒ…æ‹¬æ—©æœŸï¼ˆ<3 ä¸ªæœˆï¼‰å’Œæ™šæœŸï¼ˆâ‰¥3 ä¸ªæœˆï¼‰å¤§ä¾¿å¤±ç¦ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æœ¯åå‡ºè¡€ã€å°¿æ½´ç•™å’Œå¤å‘ã€‚ä½¿ç”¨ R å’ŒèŸèƒå›å½’å¯¹æ¯”ä¾‹è¿›è¡Œå•è‡‚èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†ææ€»å…±çº³å…¥äº† 139 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­åŒ…æ‹¬ 68 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ˆ8,445 åå—è¯•è€…ï¼‰å’Œ 71 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼ˆ22,687 åå—è¯•è€…ï¼‰ã€‚éšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ—©æœŸå¤±ç¦ç‡ä¸º 5.32%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ2.74-8.51%ï¼‰ï¼Œééšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ—©æœŸå¤±ç¦ç‡ä¸º 1.03%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ0.28-2.09%ï¼‰ã€‚éšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ™šæœŸå¤±ç¦ç‡ä¸º 2.48%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ1.09-4.25%ï¼‰ï¼Œééšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ™šæœŸå¤±ç¦ç‡ä¸º 1.44%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ0.71-2.37%ï¼‰ã€‚åœ¨éšæœºå¯¹ç…§è¯•éªŒå’Œééšæœºå¯¹ç…§è¯•éªŒä¸­ï¼Œå»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯ä¹‹é—´çš„å¤±ç¦æˆ–å…¶ä»–æœ¯åå¹¶å‘ç—‡çš„é£é™©æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** å»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯æœ¯åå¤±ç¦å¹¶ä¸å¸¸è§ï¼Œä¸¤ç§æ‰‹æœ¯ä¹‹é—´çš„é£é™©ä¼¼ä¹æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼Œè§‚å¯Ÿåˆ°ç›¸å½“å¤§çš„å¼‚è´¨æ€§ï¼Œè¿™å¯èƒ½æ˜¯å„ä¸ªç ”ç©¶çš„è¯„ä¼°å’ŒæŠ¥å‘Šæ–¹æ³•å­˜åœ¨å·®å¼‚çš„ç»“æœã€‚æœªæ¥çš„ç ”ç©¶åº”è¯¥æ ‡å‡†åŒ–è¯„ä¼°å¤±ç¦çš„å®šä¹‰å’Œæ–¹æ³•ï¼Œå¹¶åŒ…æ‹¬æœ¯å‰è¯„ä¼°ï¼Œä»¥æ›´å‡†ç¡®åœ°ç¡®å®šä¸ç—”ç–®æ‰‹æœ¯ç›¸å…³çš„å¹¶å‘ç—‡çš„é£é™©ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39854786/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260213213008&v=2.18.0.post22+67771e2", "date": "Fri, 24 Jan 2025"}]}, currentFeed: '', currentPapers: [], currentPaper: null,
                    init() { const ks = Object.keys(this.feeds); if(ks.length > 0) { this.currentFeed = ks[0]; this.selectFeed(); } },
                    selectFeed() { this.currentPapers = this.feeds[this.currentFeed]; this.currentPaper = this.currentPapers.length > 0 ? this.currentPapers[0] : null; document.querySelector('aside').scrollTop = 0; }
                }
            }
        </script>
    </body>
    </html>
    